sent0 All O
sent0 live O
sent0 births O
sent0 > O
sent0 or O
sent0 = O
sent0 23 O
sent0 weeks O
sent0 at O
sent0 the O
sent0 University O
sent0 of O
sent0 Vermont O
sent0 in O
sent0 1995 O
sent0 ( O
sent0 n O
sent0 = O
sent0 2395 O
sent0 ) O
sent0 were O
sent0 retrospectively O
sent0 analyzed O
sent0 for O
sent0 delivery O
sent0 route O
sent0 , O
sent0 indication O
sent0 for O
sent0 cesarean O
sent0 , O
sent0 gestational O
sent0 age O
sent0 , O
sent0 parity O
sent0 , O
sent0 and O
sent0 practice O
sent0 group O
sent0 ( O
sent0 to O
sent0 reflect O
sent0 risk O
sent0 status O
sent0 ) O
sent1 The O
sent1 total O
sent1 cesarean O
sent1 rate O
sent1 was O
sent1 14.4 O
sent1 % O
sent1 ( O
sent1 344 O
sent1 of O
sent1 2395 O
sent1 ) O
sent1 , O
sent1 and O
sent1 the O
sent1 primary O
sent1 rate O
sent1 was O
sent1 11.4 O
sent1 % O
sent1 ( O
sent1 244 O
sent1 of O
sent1 2144 O
sent1 ) O
sent2 Abnormal O
sent2 presentation O
sent2 was O
sent2 the O
sent2 most O
sent2 common O
sent2 indication O
sent2 ( O
sent2 25.6 O
sent2 % O
sent2 , O
sent2 88 O
sent2 of O
sent2 344 O
sent2 ) O
sent3 The O
sent3 `` O
sent3 corrected O
sent3 '' O
sent3 cesarean O
sent3 rate O
sent3 ( O
sent3 maternal-fetal O
sent3 medicine O
sent3 and O
sent3 transported O
sent3 patients O
sent3 excluded O
sent3 ) O
sent3 was O
sent3 12.4 O
sent3 % O
sent3 ( O
sent3 273 O
sent3 of O
sent3 2194 O
sent3 ) O
sent3 , O
sent3 and O
sent3 the O
sent3 `` O
sent3 corrected O
sent3 '' O
sent3 primary O
sent3 rate O
sent3 was O
sent3 9.6 O
sent3 % O
sent3 ( O
sent3 190 O
sent3 of O
sent3 1975 O
sent3 ) O
sent4 Furthermore O
sent4 , O
sent4 when O
sent4 all O
sent4 deliveries O
sent4 were O
sent4 analyzed O
sent4 , O
sent4 regardless O
sent4 of O
sent4 risk O
sent4 status O
sent4 but O
sent4 limited O
sent4 to O
sent4 gestational O
sent4 age O
sent4 > O
sent4 or O
sent4 = O
sent4 36 O
sent4 weeks O
sent4 , O
sent4 the O
sent4 rates O
sent4 did O
sent4 not O
sent4 change O
sent4 ( O
sent4 12.6 O
sent4 % O
sent4 , O
sent4 280 O
sent4 of O
sent4 2214 O
sent4 ; O
sent4 primary O
sent4 9.2 O
sent4 % O
sent4 , O
sent4 183 O
sent4 of O
sent4 1994 O
sent4 ) O
sent5 Arrest O
sent5 of O
sent5 dilation O
sent5 was O
sent5 the O
sent5 most O
sent5 common O
sent5 indication O
sent5 in O
sent5 both O
sent5 `` O
sent5 corrected O
sent5 '' O
sent5 subgroups O
sent5 ( O
sent5 23.4 O
sent5 and O
sent5 24.6 O
sent5 % O
sent5 , O
sent5 respectively O
sent5 ) O
sent6 Cesarean O
sent6 rates O
sent6 at O
sent6 tertiary O
sent6 care O
sent6 hospitals O
sent6 should O
sent6 be O
sent6 compared O
sent6 with O
sent6 rates O
sent6 at O
sent6 community O
sent6 hospitals O
sent6 only O
sent6 after O
sent6 correcting O
sent6 for O
sent6 dissimilar O
sent6 patient O
sent6 groups O
sent6 or O
sent6 gestational O
sent6 age O
sent7 In O
sent7 the O
sent7 third O
sent7 trimester O
sent7 , O
sent7 the O
sent7 amniotic O
sent7 fluid O
sent7 index O
sent7 ( O
sent7 AFI O
sent7 ) O
sent7 may O
sent7 be O
sent7 affected O
sent7 by O
sent7 maternal O
sent7 fluid O
sent7 status O
sent8 As O
sent8 the O
sent8 ambient O
sent8 temperature O
sent8 increases O
sent8 , O
sent8 there O
sent8 is O
sent8 an O
sent8 increase O
sent8 in O
sent8 insensible O
sent8 fluid O
sent8 loss O
sent8 and O
sent8 the O
sent8 potential O
sent8 for O
sent8 dehydration O
sent9 We O
sent9 hypothesize O
sent9 that O
sent9 as O
sent9 temperature O
sent9 increases O
sent9 there O
sent9 would O
sent9 be O
sent9 a O
sent9 concomitant O
sent9 decrease O
sent9 in O
sent9 AFI O
sent10 From O
sent10 June O
sent10 11 O
sent10 to O
sent10 August O
sent10 16 O
sent10 , O
sent10 1993 O
sent10 , O
sent10 during O
sent10 a O
sent10 period O
sent10 of O
sent10 unusual O
sent10 high O
sent10 heat O
sent10 , O
sent10 42 O
sent10 women O
sent10 with O
sent10 singleton O
sent10 pregnancies O
sent10 between O
sent10 27 O
sent10 and O
sent10 40 O
sent10 weeks O
sent10 ' O
sent10 gestation O
sent10 undergoing O
sent10 serial O
sent10 antenatal O
sent10 testing O
sent10 had O
sent10 AFI O
sent10 determinations O
sent10 recorded O
sent10 at O
sent10 least O
sent10 weekly O
sent11 The O
sent11 daily O
sent11 high O
sent11 ambient O
sent11 temperature O
sent11 in O
sent11 our O
sent11 urban O
sent11 area O
sent11 was O
sent11 subsequently O
sent11 obtained O
sent12 A O
sent12 2- O
sent12 , O
sent12 3- O
sent12 , O
sent12 and O
sent12 4-day O
sent12 mean O
sent12 temperature O
sent12 prior O
sent12 to O
sent12 the O
sent12 test O
sent12 date O
sent12 was O
sent12 compared O
sent12 to O
sent12 AFI O
sent12 using O
sent12 a O
sent12 Spearman-rank O
sent12 Correlation O
sent13 The O
sent13 daily O
sent13 high O
sent13 temperature O
sent13 ranged O
sent13 from O
sent13 71 O
sent13 to O
sent13 104 O
sent13 degrees O
sent13 F O
sent13 and O
sent13 AFI O
sent13 values O
sent13 ranged O
sent13 from O
sent13 1.7 O
sent13 to O
sent13 24.7 O
sent13 cm O
sent13 during O
sent13 the O
sent13 study O
sent13 period O
sent14 There O
sent14 was O
sent14 a O
sent14 significant O
sent14 correlation O
sent14 between O
sent14 the O
sent14 2- O
sent14 , O
sent14 3- O
sent14 , O
sent14 and O
sent14 4-day O
sent14 mean O
sent14 temperature O
sent14 and O
sent14 AFI O
sent14 , O
sent14 with O
sent14 the O
sent14 4-day O
sent14 mean O
sent14 being O
sent14 the O
sent14 most O
sent14 significant O
sent14 ( O
sent14 r O
sent14 = O
sent14 0.31 O
sent14 , O
sent14 p O
sent14 & O
sent14 # O
sent14 60 O
sent14 ; O
sent14 0.001 O
sent14 ) O
sent15 Fluctuations O
sent15 in O
sent15 ambient O
sent15 temperature O
sent15 are O
sent15 inversely O
sent15 correlated O
sent15 to O
sent15 changes O
sent15 in O
sent15 AFI O
sent16 This O
sent16 relationship O
sent16 should O
sent16 be O
sent16 taken O
sent16 into O
sent16 account O
sent16 when O
sent16 interpreting O
sent16 the O
sent16 AFI O
sent16 as O
sent16 a O
sent16 measure O
sent16 of O
sent16 fetal O
sent16 well-being O
sent17 This O
sent17 study O
sent17 tested O
sent17 the O
sent17 hypothesis O
sent17 that O
sent17 to O
sent17 reduce O
sent17 the O
sent17 rate O
sent17 of O
sent17 macrosomic O
sent17 infants O
sent17 in O
sent17 gestational O
sent17 diabetes O
sent17 cases O
sent17 , O
sent17 good O
sent17 glycemic O
sent17 control O
sent17 should O
sent17 be O
sent17 initiated O
sent17 before O
sent17 34 O
sent17 completed O
sent17 gestational O
sent17 weeks O
sent18 The O
sent18 study O
sent18 population O
sent18 included O
sent18 84 O
sent18 women O
sent18 with O
sent18 gestational D
sent18 diabetes D
sent18 , O
sent18 ascertained O
sent18 by O
sent18 universal O
sent18 screening O
sent18 of O
sent18 all O
sent18 women O
sent18 attending O
sent18 the O
sent18 antenatal O
sent18 clinic O
sent18 of O
sent18 the O
sent18 Hadassah O
sent18 Medical O
sent18 Center O
sent18 , O
sent18 over O
sent18 a O
sent18 2-year O
sent18 period O
sent19 The O
sent19 60 O
sent19 women O
sent19 ( O
sent19 71 O
sent19 % O
sent19 ) O
sent19 , O
sent19 who O
sent19 initiated O
sent19 treatment O
sent19 before O
sent19 34 O
sent19 completed O
sent19 weeks O
sent19 , O
sent19 composed O
sent19 the O
sent19 `` O
sent19 early O
sent19 '' O
sent19 group O
sent20 The O
sent20 24 O
sent20 women O
sent20 ( O
sent20 29 O
sent20 % O
sent20 ) O
sent20 , O
sent20 who O
sent20 initiated O
sent20 treatment O
sent20 after O
sent20 the O
sent20 34th O
sent20 week O
sent20 , O
sent20 composed O
sent20 the O
sent20 `` O
sent20 late O
sent20 '' O
sent20 group O
sent21 All O
sent21 patients O
sent21 were O
sent21 managed O
sent21 by O
sent21 an O
sent21 intensified O
sent21 protocol O
sent21 , O
sent21 including O
sent21 stringent O
sent21 glycemic T
sent21 control T
sent22 In O
sent22 the O
sent22 `` O
sent22 early O
sent22 '' O
sent22 and O
sent22 `` O
sent22 late O
sent22 '' O
sent22 groups O
sent22 , O
sent22 mean O
sent22 gestational O
sent22 age O
sent22 at O
sent22 the O
sent22 beginning O
sent22 of O
sent22 treatment O
sent22 was O
sent22 30.0 O
sent22 +/- O
sent22 3.8 O
sent22 and O
sent22 36.2 O
sent22 +/- O
sent22 1.2 O
sent22 weeks O
sent22 , O
sent22 and O
sent22 duration O
sent22 of O
sent22 treatment O
sent22 was O
sent22 9.6 O
sent22 +/- O
sent22 4.1 O
sent22 and O
sent22 3.7 O
sent22 +/- O
sent22 1.8 O
sent22 weeks O
sent22 , O
sent22 respectively O
sent23 Maternal O
sent23 characteristics O
sent23 were O
sent23 similar O
sent23 in O
sent23 the O
sent23 two O
sent23 groups O
sent24 The O
sent24 rate O
sent24 of O
sent24 macrosomic O
sent24 and O
sent24 large-for-gestational-age O
sent24 infants O
sent24 were O
sent24 5 O
sent24 and O
sent24 11 O
sent24 % O
sent24 , O
sent24 respectively O
sent24 , O
sent24 in O
sent24 the O
sent24 early O
sent24 group O
sent24 as O
sent24 compared O
sent24 to O
sent24 25 O
sent24 and O
sent24 29 O
sent24 % O
sent24 in O
sent24 the O
sent24 `` O
sent24 late O
sent24 '' O
sent24 group O
sent24 ( O
sent24 p O
sent24 & O
sent24 # O
sent24 60 O
sent24 ; O
sent24 0.05 O
sent24 ) O
sent25 No O
sent25 significant O
sent25 differences O
sent25 were O
sent25 found O
sent25 between O
sent25 the O
sent25 two O
sent25 groups O
sent25 in O
sent25 the O
sent25 mode O
sent25 of O
sent25 delivery O
sent25 or O
sent25 Apgar O
sent25 scores O
sent26 We O
sent26 conclude O
sent26 that O
sent26 to O
sent26 reduce O
sent26 the O
sent26 rate O
sent26 of O
sent26 macrosomic D
sent26 infants D
sent26 in D
sent26 gestational D
sent26 diabetes D
sent26 cases D
sent26 , O
sent26 good T
sent26 glycemic T
sent26 control T
sent26 should O
sent26 be O
sent26 initiated O
sent26 before O
sent26 34 O
sent26 completed O
sent26 gestational O
sent26 weeks O
sent27 Our O
sent27 aim O
sent27 was O
sent27 to O
sent27 investigate O
sent27 the O
sent27 contribution O
sent27 of O
sent27 certain O
sent27 antenatally O
sent27 detectable O
sent27 markers O
sent27 leading O
sent27 to O
sent27 the O
sent27 diagnosis O
sent27 of O
sent27 trisomic O
sent27 fetuses O
sent27 we O
sent27 observed O
sent27 over O
sent27 a O
sent27 period O
sent27 of O
sent27 6 O
sent27 years O
sent28 In O
sent28 our O
sent28 study O
sent28 , O
sent28 we O
sent28 specifically O
sent28 analyzed O
sent28 the O
sent28 role O
sent28 played O
sent28 by O
sent28 advanced O
sent28 maternal O
sent28 age O
sent28 and O
sent28 sonographically O
sent28 discovered O
sent28 abnormalities O
sent28 in O
sent28 the O
sent28 detection O
sent28 of O
sent28 autosomal D
sent28 trisomies D
sent29 All O
sent29 together O
sent29 , O
sent29 27 O
sent29 fetuses O
sent29 had O
sent29 this O
sent29 disorder O
sent29 , O
sent29 representing O
sent29 28.7 O
sent29 % O
sent29 ( O
sent29 27 O
sent29 of O
sent29 94 O
sent29 ) O
sent29 of O
sent29 all O
sent29 cytogenetic D
sent29 aberrations D
sent29 detected O
sent29 at O
sent29 our O
sent29 center O
sent29 over O
sent29 the O
sent29 same O
sent29 period O
sent30 Down D
sent30 syndrome D
sent30 ( O
sent30 12 O
sent30 cases O
sent30 ) O
sent30 and O
sent30 Edward D
sent30 syndrome D
sent30 ( O
sent30 11 O
sent30 cases O
sent30 ) O
sent30 were O
sent30 the O
sent30 most O
sent30 common O
sent30 trisomies D
sent30 , O
sent30 while O
sent30 4 O
sent30 cases O
sent30 of O
sent30 Patau D
sent30 syndrome D
sent30 were O
sent30 also O
sent30 diagnosed O
sent31 The O
sent31 most O
sent31 common O
sent31 indication O
sent31 leading O
sent31 to O
sent31 diagnosis O
sent31 was O
sent31 abnormal O
sent31 ultrasound O
sent31 finding O
sent31 ( O
sent31 48.2 O
sent31 % O
sent31 ) O
sent31 , O
sent31 followed O
sent31 by O
sent31 advanced O
sent31 maternal O
sent31 age O
sent31 ( O
sent31 44.4 O
sent31 % O
sent31 ) O
sent32 However O
sent32 , O
sent32 63 O
sent32 % O
sent32 of O
sent32 the O
sent32 trisomic O
sent32 fetuses O
sent32 belonged O
sent32 to O
sent32 mothers O
sent32 aged O
sent32 35 O
sent32 years O
sent32 and O
sent32 above O
sent33 Down D
sent33 syndrome D
sent33 fetuses O
sent33 ( O
sent33 41.7 O
sent33 % O
sent33 ) O
sent33 had O
sent33 prenatally O
sent33 detected O
sent33 sonographic O
sent33 anomalies O
sent33 , O
sent33 63.6 O
sent33 % O
sent33 for O
sent33 Edward D
sent33 syndrome D
sent33 , O
sent33 and O
sent33 all O
sent33 fetuses O
sent33 with O
sent33 Patau D
sent33 syndrome D
sent33 ( O
sent33 4 O
sent33 of O
sent33 4 O
sent33 ) O
sent33 showed O
sent33 abnormal O
sent33 sonographic O
sent33 signs O
sent34 Trisomy D
sent34 21 D
sent34 presented O
sent34 with O
sent34 the O
sent34 following O
sent34 features O
sent34 : O
sent34 hydramnios O
sent34 , O
sent34 complex O
sent34 malformations O
sent34 , O
sent34 pyelectasis D
sent34 , O
sent34 and O
sent34 duodenal D
sent34 atresia D
sent35 Trisomy D
sent35 18 D
sent35 fetuses O
sent35 showed O
sent35 hydramnios O
sent35 , O
sent35 intrauterine O
sent35 growth O
sent35 retardation O
sent35 , O
sent35 microcephaly D
sent35 , O
sent35 spina D
sent35 bifida D
sent35 , O
sent35 and O
sent35 nonimmune D
sent35 hydrops D
sent35 fetalis D
sent36 Signs O
sent36 observed O
sent36 in O
sent36 fetuses O
sent36 with O
sent36 trisomy D
sent36 13 D
sent36 were O
sent36 : O
sent36 hydrocephalus O
sent36 , O
sent36 intrauterine O
sent36 growth O
sent36 retardation O
sent36 , O
sent36 oligoanhydramnios O
sent36 , O
sent36 complex O
sent36 malformations O
sent36 , O
sent36 severe O
sent36 fetal O
sent36 bradycardia D
sent36 and O
sent36 hydronephrosis D
sent37 The O
sent37 objective O
sent37 of O
sent37 this O
sent37 study O
sent37 was O
sent37 to O
sent37 determine O
sent37 if O
sent37 the O
sent37 rate O
sent37 of O
sent37 preeclampsia D
sent37 is O
sent37 increased O
sent37 in O
sent37 triplet O
sent37 as O
sent37 compared O
sent37 to O
sent37 twin O
sent37 gestations O
sent38 Fifty-three O
sent38 triplet O
sent38 pregnancies O
sent38 between O
sent38 1986 O
sent38 and O
sent38 1993 O
sent38 at O
sent38 The O
sent38 New O
sent38 York O
sent38 Hospital-Cornell O
sent38 Medical O
sent38 Center O
sent38 were O
sent38 reviewed O
sent39 These O
sent39 were O
sent39 matched O
sent39 for O
sent39 maternal O
sent39 age O
sent39 , O
sent39 parity O
sent39 , O
sent39 and O
sent39 race O
sent39 to O
sent39 twin O
sent39 gestations O
sent39 ( O
sent39 N O
sent39 = O
sent39 53 O
sent39 ) O
sent39 from O
sent39 the O
sent39 same O
sent39 population O
sent40 Severe O
sent40 preeclampsia D
sent40 was O
sent40 defined O
sent40 by O
sent40 standard O
sent40 criteria O
sent41 Student O
sent41 's O
sent41 t-test O
sent41 , O
sent41 Fisher O
sent41 exact O
sent41 test O
sent41 , O
sent41 and O
sent41 Chi-square O
sent41 were O
sent41 used O
sent41 for O
sent41 statistical O
sent41 analysis O
sent42 The O
sent42 rate O
sent42 of O
sent42 severe O
sent42 preeclampsia D
sent42 was O
sent42 increased O
sent42 significantly O
sent42 in O
sent42 the O
sent42 triplet O
sent42 group O
sent42 12 O
sent42 of O
sent42 53 O
sent42 ( O
sent42 22.6 O
sent42 % O
sent42 ) O
sent42 as O
sent42 compared O
sent42 with O
sent42 the O
sent42 twin O
sent42 group O
sent42 3 O
sent42 of O
sent42 53 O
sent42 ( O
sent42 5.7 O
sent42 % O
sent42 ) O
sent42 ( O
sent42 OR O
sent42 = O
sent42 4.9 O
sent42 , O
sent42 95 O
sent42 % O
sent42 CI O
sent42 1.2-23.5 O
sent42 , O
sent42 p O
sent42 = O
sent42 0.02 O
sent42 ) O
sent43 The O
sent43 rate O
sent43 of O
sent43 overall O
sent43 preeclampsia D
sent43 was O
sent43 not O
sent43 significantly O
sent43 different O
sent43 in O
sent43 the O
sent43 triplet O
sent43 18 O
sent43 of O
sent43 53 O
sent43 ( O
sent43 33.96 O
sent43 % O
sent43 ) O
sent43 or O
sent43 twin O
sent43 12 O
sent43 of O
sent43 53 O
sent43 ( O
sent43 22.6 O
sent43 % O
sent43 ) O
sent43 groups O
sent44 In O
sent44 this O
sent44 retrospective O
sent44 , O
sent44 case-controlled O
sent44 study O
sent44 , O
sent44 the O
sent44 rate O
sent44 of O
sent44 severe O
sent44 pre-eclampsia D
sent44 was O
sent44 significantly O
sent44 increased O
sent44 in O
sent44 triplet O
sent44 gestations O
sent44 as O
sent44 compared O
sent44 to O
sent44 twins O
sent44 although O
sent44 the O
sent44 overall O
sent44 rate O
sent44 of O
sent44 preeclampsia D
sent44 was O
sent44 not O
sent45 This O
sent45 information O
sent45 may O
sent45 be O
sent45 useful O
sent45 in O
sent45 counseling O
sent45 patients O
sent45 with O
sent45 high O
sent45 order O
sent45 multifetal O
sent45 gestations O
sent46 We O
sent46 conducted O
sent46 a O
sent46 survey O
sent46 and O
sent46 audit O
sent46 of O
sent46 thermal O
sent46 equipment O
sent46 use O
sent46 in O
sent46 very O
sent46 low-birth-weight O
sent46 infants O
sent46 in O
sent46 five O
sent46 Ohio O
sent46 neonatal O
sent46 intensive O
sent46 care O
sent46 units O
sent46 ( O
sent46 NICUs O
sent46 ) O
sent46 to O
sent46 document O
sent46 regional O
sent46 practice O
sent47 The O
sent47 survey O
sent47 indicated O
sent47 a O
sent47 variety O
sent47 of O
sent47 thermal O
sent47 care O
sent47 styles O
sent48 Two O
sent48 NICUs O
sent48 preferred O
sent48 to O
sent48 admit O
sent48 infants O
sent48 to O
sent48 incubators O
sent48 , O
sent48 the O
sent48 other O
sent48 three O
sent48 favoring O
sent48 radiant O
sent48 warmers O
sent49 These O
sent49 three O
sent49 NICUs O
sent49 moved O
sent49 infants O
sent49 from O
sent49 radiant O
sent49 warmers O
sent49 into O
sent49 incubators O
sent49 at O
sent49 significantly O
sent49 different O
sent49 mean O
sent49 ages O
sent50 The O
sent50 audit O
sent50 demonstrated O
sent50 inconsistent O
sent50 use O
sent50 of O
sent50 plastic O
sent50 covers O
sent50 , O
sent50 warming O
sent50 mattresses O
sent50 , O
sent50 and O
sent50 added O
sent50 humidity O
sent50 under O
sent50 radiant O
sent50 warmers O
sent50 , O
sent50 and O
sent50 discrepancies O
sent50 between O
sent50 survey O
sent50 responses O
sent50 and O
sent50 actual O
sent50 use O
sent50 within O
sent50 NICUs O
sent51 Inter-NICU O
sent51 variability O
sent51 of O
sent51 thermal O
sent51 equipment O
sent51 use O
sent51 may O
sent51 complicate O
sent51 fluid O
sent51 management O
sent52 This O
sent52 report O
sent52 describes O
sent52 a O
sent52 full-term O
sent52 newborn O
sent52 with O
sent52 massive D
sent52 fetomaternal D
sent52 hemorrhage D
sent53 Fetal O
sent53 movements O
sent53 were O
sent53 decreased O
sent53 48 O
sent53 hr O
sent53 prior O
sent53 to O
sent53 delivery O
sent54 On O
sent54 the O
sent54 day O
sent54 of O
sent54 delivery O
sent54 , O
sent54 they O
sent54 were O
sent54 absent O
sent55 The O
sent55 nonstress O
sent55 test O
sent55 was O
sent55 abnormal O
sent55 with O
sent55 low O
sent55 biophysical O
sent55 profile O
sent55 and O
sent55 decreased O
sent55 beat-to-beat O
sent55 variability O
sent56 The O
sent56 infant O
sent56 presented O
sent56 with O
sent56 extreme O
sent56 pallor O
sent56 , O
sent56 hypotonia D
sent56 , O
sent56 hepatosplenomegaly D
sent56 , O
sent56 and O
sent56 ascites D
sent57 The O
sent57 initial O
sent57 hemoglobin O
sent57 was O
sent57 2.2 O
sent57 g/dL O
sent57 , O
sent57 the O
sent57 Kleihauer-Betke O
sent57 stain O
sent57 was O
sent57 27.6 O
sent57 % O
sent57 ( O
sent57 highest O
sent57 level O
sent57 ever O
sent57 reported O
sent57 ) O
sent58 Right O
sent58 temporal O
sent58 and O
sent58 cerebellar O
sent58 hemorrhages O
sent58 were O
sent58 present O
sent59 Sequelae O
sent59 include O
sent59 severe O
sent59 developmental O
sent59 delay O
sent59 and O
sent59 asymmetric O
sent59 double O
sent59 hemiplegia D
sent60 Omphalocele-Exstrophy-Imperforate D
sent60 anus-Spinal D
sent60 defects D
sent60 ( D
sent60 OEIS D
sent60 complex D
sent60 ) D
sent60 , O
sent60 a O
sent60 combination O
sent60 of O
sent60 omphalocele D
sent60 , O
sent60 exstrophy D
sent60 of D
sent60 the D
sent60 bladder D
sent60 , O
sent60 an O
sent60 imperforate O
sent60 anus O
sent60 and O
sent60 spinal D
sent60 defects D
sent60 , O
sent60 arises O
sent60 from O
sent60 a O
sent60 single O
sent60 localized O
sent60 defect O
sent60 in O
sent60 the O
sent60 early O
sent60 development O
sent60 of O
sent60 the O
sent60 mesoderm O
sent60 that O
sent60 will O
sent60 later O
sent60 contribute O
sent60 to O
sent60 infraumbilical O
sent60 mesenchyme O
sent60 , O
sent60 cloacal O
sent60 septum O
sent60 , O
sent60 and O
sent60 caudal O
sent60 vertebrae O
sent61 In O
sent61 this O
sent61 report O
sent61 , O
sent61 we O
sent61 document O
sent61 the O
sent61 perinatal O
sent61 features O
sent61 of O
sent61 two O
sent61 cases O
sent61 of O
sent61 OEIS D
sent61 complex D
sent61 associated O
sent61 with O
sent61 meningomyeloceles D
sent61 and O
sent61 severe O
sent61 lower O
sent61 limb O
sent61 defects O
sent61 , O
sent61 and O
sent61 discuss O
sent61 the O
sent61 prenatal O
sent61 diagnosis O
sent61 , O
sent61 inheritance O
sent61 , O
sent61 and O
sent61 differential O
sent61 diagnosis O
sent61 of O
sent61 this O
sent61 association O
sent61 of O
sent61 malformations O
sent62 Although O
sent62 long-term O
sent62 survival O
sent62 can O
sent62 be O
sent62 achieved O
sent62 by O
sent62 successful O
sent62 corrective T
sent62 surgery T
sent62 , O
sent62 the O
sent62 associated O
sent62 structural O
sent62 defects O
sent62 such O
sent62 as O
sent62 large D
sent62 meningomyelocele D
sent62 and O
sent62 severe O
sent62 limb D
sent62 aplasia D
sent62 or O
sent62 hypoplasia D
sent62 , O
sent62 as O
sent62 seen O
sent62 in O
sent62 our O
sent62 patient O
sent62 , O
sent62 can O
sent62 influence O
sent62 the O
sent62 patient O
sent62 's O
sent62 quality O
sent62 of O
sent62 life O
sent62 . O
sent63 We O
sent63 would O
sent63 like O
sent63 to O
sent63 emphasize O
sent63 that O
sent63 an O
sent63 accurate O
sent63 prenatal O
sent63 diagnosis O
sent63 of O
sent63 OEIS D
sent63 complex D
sent63 and O
sent63 associated O
sent63 malformations O
sent63 is O
sent63 important O
sent63 for O
sent63 the O
sent63 detailed O
sent63 counseling O
sent63 of O
sent63 the O
sent63 family O
sent63 as O
sent63 well O
sent63 as O
sent63 appropriate O
sent63 perinatal O
sent63 management O
sent63 by O
sent63 the O
sent63 obstetricians O
sent63 , O
sent63 pediatric O
sent63 surgeons O
sent63 , O
sent63 urologists O
sent63 , O
sent63 neurosurgeons O
sent63 , O
sent63 and O
sent63 neonatologists O
sent64 Nonimmune D
sent64 hydrops D
sent64 fetails D
sent64 diagnosed O
sent64 at O
sent64 21 O
sent64 weeks O
sent64 ' O
sent64 gestation O
sent64 with O
sent64 profound O
sent64 ascites D
sent64 , O
sent64 hydrothorax D
sent64 , O
sent64 and O
sent64 pericardial D
sent64 effusion D
sent64 receded O
sent64 gradually O
sent64 with O
sent64 regression O
sent64 of O
sent64 a O
sent64 subchorial O
sent64 placental O
sent64 lucencies O
sent64 immediately O
sent64 below O
sent64 the O
sent64 umbilical O
sent64 cord O
sent64 insertion O
sent65 Careful O
sent65 inspection O
sent65 of O
sent65 the O
sent65 delivered O
sent65 placenta O
sent65 revealed O
sent65 that O
sent65 there O
sent65 was O
sent65 a O
sent65 yellowish O
sent65 lesion O
sent65 of O
sent65 fibrin O
sent65 deposits O
sent65 below O
sent65 the O
sent65 cord O
sent65 insertion O
sent65 site O
sent65 , O
sent65 which O
sent65 resulted O
sent65 from O
sent65 the O
sent65 absorption O
sent65 of O
sent65 hematoma O
sent66 A O
sent66 subchorial O
sent66 placental O
sent66 hematoma D
sent66 , O
sent66 which O
sent66 detected O
sent66 as O
sent66 a O
sent66 subchorial O
sent66 placental O
sent66 lucencies D
sent66 by O
sent66 ultrasonography O
sent66 , O
sent66 can O
sent66 be O
sent66 a O
sent66 cause O
sent66 of O
sent66 reversible O
sent66 nonimmune D
sent66 hydrops D
sent66 fetalis D
sent67 The O
sent67 mitochondrial D
sent67 diseases D
sent67 are O
sent67 uncommon O
sent67 multisystem O
sent67 disorders O
sent67 characterized O
sent67 by O
sent67 the O
sent67 presence O
sent67 of O
sent67 functionally O
sent67 and/or O
sent67 structurally O
sent67 abnormal O
sent67 mitochondria O
sent68 As O
sent68 there O
sent68 have O
sent68 been O
sent68 few O
sent68 reports O
sent68 of O
sent68 the O
sent68 obstetrical O
sent68 care O
sent68 of O
sent68 affected O
sent68 patients O
sent68 , O
sent68 we O
sent68 wish O
sent68 to O
sent68 document O
sent68 two O
sent68 pregnancies O
sent68 in O
sent68 a O
sent68 woman O
sent68 with O
sent68 a O
sent68 Chronic D
sent68 Progressive D
sent68 External D
sent68 Ophthalmoplegia D
sent68 ( D
sent68 Kearns-Sayre-like D
sent68 syndrome D
sent68 ) D
sent69 Both O
sent69 pregnancies O
sent69 were O
sent69 complicated O
sent69 by O
sent69 preterm O
sent69 labor O
sent69 and O
sent69 hypertension D
sent70 CONTEXT O
sent70 : O
sent70 Four O
sent70 genetic O
sent70 loci O
sent70 have O
sent70 been O
sent70 identified O
sent70 as O
sent70 contributing O
sent70 to O
sent70 Alzheimer D
sent70 disease D
sent70 ( D
sent70 AD D
sent70 ) D
sent70 , O
sent70 including O
sent70 the O
sent70 amyloid O
sent70 precursor O
sent70 protein O
sent70 gene O
sent70 , O
sent70 the O
sent70 presenilin O
sent70 1 O
sent70 gene O
sent70 , O
sent70 the O
sent70 presenilin O
sent70 2 O
sent70 gene O
sent70 , O
sent70 and O
sent70 the O
sent70 apolipoprotein O
sent70 E O
sent70 gene O
sent70 , O
sent70 but O
sent70 do O
sent70 not O
sent70 account O
sent70 for O
sent70 all O
sent70 the O
sent70 genetic O
sent70 risk O
sent70 for O
sent70 AD O
sent71 OBJECTIVE O
sent71 : O
sent71 To O
sent71 identify O
sent71 additional O
sent71 genetic O
sent71 risk O
sent71 factors O
sent71 for O
sent71 late-onset O
sent71 AD O
sent72 DESIGN O
sent72 : O
sent72 A O
sent72 complete O
sent72 genomic O
sent72 screen O
sent72 was O
sent72 performed O
sent72 ( O
sent72 N=280 O
sent72 markers O
sent72 ) O
sent73 Critical O
sent73 values O
sent73 for O
sent73 chromosomal O
sent73 regional O
sent73 follow-up O
sent73 were O
sent73 a O
sent73 P O
sent73 value O
sent73 of O
sent73 .05 O
sent73 or O
sent73 less O
sent73 for O
sent73 affected O
sent73 relative O
sent73 pair O
sent73 analysis O
sent73 or O
sent73 sibpair O
sent73 analysis O
sent73 , O
sent73 a O
sent73 parametric O
sent73 lod O
sent73 score O
sent73 of O
sent73 1.0 O
sent73 or O
sent73 greater O
sent73 , O
sent73 or O
sent73 both O
sent74 Regional O
sent74 follow-up O
sent74 included O
sent74 analysis O
sent74 of O
sent74 additional O
sent74 markers O
sent74 and O
sent74 a O
sent74 second O
sent74 data O
sent74 set O
sent75 SETTING O
sent75 : O
sent75 Clinic O
sent75 populations O
sent75 in O
sent75 the O
sent75 continental O
sent75 United O
sent75 States O
sent76 PATIENTS O
sent76 : O
sent76 > O
sent76 From O
sent76 a O
sent76 series O
sent76 of O
sent76 multiplex O
sent76 families O
sent76 affected O
sent76 with O
sent76 late-onset O
sent76 ( O
sent76 > O
sent76 or O
sent76 =60 O
sent76 years O
sent76 ) O
sent76 AD O
sent76 ascertained O
sent76 during O
sent76 the O
sent76 last O
sent76 14 O
sent76 years O
sent76 ( O
sent76 National O
sent76 Insititute O
sent76 of O
sent76 Neurological O
sent76 Disorders O
sent76 and O
sent76 Stroke-Alzheimer O
sent76 's O
sent76 Disease O
sent76 and O
sent76 Related O
sent76 Disorders O
sent76 Association O
sent76 diagnostic O
sent76 criteria O
sent76 ) O
sent76 and O
sent76 for O
sent76 which O
sent76 DNA O
sent76 has O
sent76 been O
sent76 obtained O
sent76 , O
sent76 a O
sent76 subset O
sent76 of O
sent76 16 O
sent76 families O
sent76 ( O
sent76 135 O
sent76 total O
sent76 family O
sent76 members O
sent76 , O
sent76 52 O
sent76 of O
sent76 whom O
sent76 were O
sent76 patients O
sent76 with O
sent76 AD O
sent76 ) O
sent76 was O
sent76 used O
sent76 for O
sent76 the O
sent76 genomic O
sent76 screen O
sent77 A O
sent77 second O
sent77 subset O
sent77 of O
sent77 38 O
sent77 families O
sent77 ( O
sent77 216 O
sent77 total O
sent77 family O
sent77 members O
sent77 , O
sent77 89 O
sent77 of O
sent77 whom O
sent77 were O
sent77 patients O
sent77 with O
sent77 AD O
sent77 ) O
sent77 was O
sent77 used O
sent77 for O
sent77 the O
sent77 follow-up O
sent77 analysis O
sent78 MAIN O
sent78 OUTCOME O
sent78 MEASURES O
sent78 : O
sent78 Linkage O
sent78 analysis O
sent78 results O
sent78 generated O
sent78 using O
sent78 both O
sent78 genetic O
sent78 model-dependent O
sent78 ( O
sent78 lod O
sent78 score O
sent78 ) O
sent78 and O
sent78 model-independent O
sent78 methods O
sent79 RESULTS O
sent79 : O
sent79 Fifteen O
sent79 chromosomal O
sent79 regions O
sent79 warranted O
sent79 initial O
sent79 follow-up O
sent80 Follow-up O
sent80 analyses O
sent80 revealed O
sent80 4 O
sent80 regions O
sent80 of O
sent80 continued O
sent80 interest O
sent80 on O
sent80 chromosomes O
sent80 4 O
sent80 , O
sent80 6 O
sent80 , O
sent80 12 O
sent80 , O
sent80 and O
sent80 20 O
sent80 , O
sent80 with O
sent80 the O
sent80 strongest O
sent80 results O
sent80 observed O
sent80 forchromosome O
sent80 12 O
sent81 Peak O
sent81 2-point O
sent81 affecteds-only O
sent81 lod O
sent81 scores O
sent81 ( O
sent81 n=54 O
sent81 ) O
sent81 were O
sent81 1.3 O
sent81 , O
sent81 1.6 O
sent81 , O
sent81 2.7 O
sent81 , O
sent81 and O
sent81 2.2 O
sent81 and O
sent81 affected O
sent81 relative O
sent81 pairs O
sent81 P O
sent81 values O
sent81 ( O
sent81 n=54 O
sent81 ) O
sent81 were O
sent81 .04 O
sent81 , O
sent81 .03 O
sent81 , O
sent81 .14 O
sent81 , O
sent81 and O
sent81 .04 O
sent81 for O
sent81 D12S373 O
sent81 , O
sent81 D12S1057 O
sent81 , O
sent81 D12S1042 O
sent81 , O
sent81 and O
sent81 D12S390 O
sent81 , O
sent81 respectively O
sent82 Sibpair O
sent82 analysis O
sent82 ( O
sent82 n=54 O
sent82 ) O
sent82 resulted O
sent82 in O
sent82 maximum O
sent82 lod O
sent82 scores O
sent82 ( O
sent82 MLSs O
sent82 ) O
sent82 of O
sent82 1.5 O
sent82 , O
sent82 2.6 O
sent82 , O
sent82 3.2 O
sent82 , O
sent82 and O
sent82 2.3 O
sent82 for O
sent82 these O
sent82 markers O
sent82 , O
sent82 with O
sent82 a O
sent82 peak O
sent82 multipoint O
sent82 MLS O
sent82 of O
sent82 3.5 O
sent83 A O
sent83 priori O
sent83 stratification O
sent83 by O
sent83 APOE O
sent83 genotype O
sent83 identified O
sent83 27 O
sent83 families O
sent83 that O
sent83 had O
sent83 at O
sent83 least O
sent83 1 O
sent83 member O
sent83 with O
sent83 AD O
sent83 whose O
sent83 genotype O
sent83 did O
sent83 not O
sent83 contain O
sent83 an O
sent83 APOE*4 O
sent83 allele O
sent84 Analysis O
sent84 of O
sent84 these O
sent84 27 O
sent84 families O
sent84 resulted O
sent84 in O
sent84 MLSs O
sent84 of O
sent84 1.0 O
sent84 , O
sent84 2.4 O
sent84 , O
sent84 3.7 O
sent84 , O
sent84 and O
sent84 3.3 O
sent84 and O
sent84 a O
sent84 peak O
sent84 multipoint O
sent84 MLS O
sent84 of O
sent84 3.9 O
sent85 CONCLUSIONS O
sent85 : O
sent85 A O
sent85 complete O
sent85 genomic O
sent85 screen O
sent85 in O
sent85 families O
sent85 affected O
sent85 with O
sent85 late-onset O
sent85 AD O
sent85 identified O
sent85 4 O
sent85 regions O
sent85 of O
sent85 interest O
sent85 after O
sent85 follow-up O
sent86 Chromosome O
sent86 12 O
sent86 gave O
sent86 the O
sent86 strongest O
sent86 and O
sent86 most O
sent86 consistent O
sent86 results O
sent86 with O
sent86 a O
sent86 peak O
sent86 multipoint O
sent86 MLS O
sent86 of O
sent86 3.5 O
sent86 , O
sent86 suggesting O
sent86 that O
sent86 this O
sent86 region O
sent86 contains O
sent86 a O
sent86 new O
sent86 susceptibility O
sent86 gene O
sent86 for O
sent86 AD O
sent87 Additional O
sent87 analyses O
sent87 are O
sent87 necessary O
sent87 to O
sent87 identify O
sent87 the O
sent87 chromosome O
sent87 12 O
sent87 susceptibility O
sent87 gene O
sent87 for O
sent87 AD O
sent87 and O
sent87 to O
sent87 follow O
sent87 up O
sent87 the O
sent87 regions O
sent87 of O
sent87 interest O
sent87 on O
sent87 chromosomes O
sent87 4 O
sent87 , O
sent87 6 O
sent87 , O
sent87 and O
sent87 20 O
sent88 CONTEXT O
sent88 : O
sent88 A O
sent88 mutation O
sent88 in O
sent88 the O
sent88 BRCA1 O
sent88 gene O
sent88 may O
sent88 confer O
sent88 substantial O
sent88 risk O
sent88 for O
sent88 breast O
sent88 and/or O
sent88 ovarian O
sent88 cancer D
sent89 However O
sent89 , O
sent89 knowledge O
sent89 regarding O
sent89 all O
sent89 possible O
sent89 mutations O
sent89 and O
sent89 the O
sent89 relationship O
sent89 between O
sent89 risk O
sent89 factors O
sent89 and O
sent89 mutations O
sent89 is O
sent89 incomplete O
sent90 OBJECTIVES O
sent90 : O
sent90 To O
sent90 identify O
sent90 BRCA1 O
sent90 mutations O
sent90 and O
sent90 to O
sent90 determine O
sent90 factors O
sent90 that O
sent90 best O
sent90 predict O
sent90 presence O
sent90 of O
sent90 a O
sent90 deleterious O
sent90 BRCA1 O
sent90 mutation O
sent90 in O
sent90 patients O
sent90 with O
sent90 breast O
sent90 and/or O
sent90 ovarian O
sent90 cancer D
sent91 DESIGN O
sent91 : O
sent91 A O
sent91 complete O
sent91 sequence O
sent91 analysis O
sent91 of O
sent91 the O
sent91 BRCA1 O
sent91 coding O
sent91 sequence O
sent91 and O
sent91 flanking O
sent91 intronic O
sent91 regions O
sent91 was O
sent91 performed O
sent91 in O
sent91 798 O
sent91 women O
sent91 in O
sent91 a O
sent91 collaborative O
sent91 effort O
sent91 involving O
sent91 institutions O
sent91 from O
sent91 the O
sent91 United O
sent91 States O
sent91 , O
sent91 Italy O
sent91 , O
sent91 Germany O
sent91 , O
sent91 Finland O
sent91 , O
sent91 and O
sent91 Switzerland O
sent92 PARTICIPANTS O
sent92 : O
sent92 Institutions O
sent92 selected O
sent92 798 O
sent92 persons O
sent92 representing O
sent92 families O
sent92 ( O
sent92 1 O
sent92 person O
sent92 for O
sent92 each O
sent92 family O
sent92 ) O
sent92 thought O
sent92 to O
sent92 be O
sent92 at O
sent92 elevated O
sent92 a O
sent92 priori O
sent92 risk O
sent92 of O
sent92 BRCA1 O
sent92 mutation O
sent92 due O
sent92 to O
sent92 potential O
sent92 risk O
sent92 factors O
sent92 , O
sent92 such O
sent92 as O
sent92 multiple O
sent92 cases O
sent92 of O
sent92 breast D
sent92 cancer D
sent92 , O
sent92 early O
sent92 age O
sent92 of O
sent92 breast D
sent92 cancer D
sent92 diagnosis O
sent92 , O
sent92 and O
sent92 cases O
sent92 of O
sent92 ovarian D
sent92 cancer D
sent93 No O
sent93 participant O
sent93 was O
sent93 from O
sent93 a O
sent93 family O
sent93 in O
sent93 which O
sent93 genetic O
sent93 markers O
sent93 showed O
sent93 linkage O
sent93 to O
sent93 the O
sent93 BRCA1 O
sent93 locus O
sent94 MAJOR O
sent94 OUTCOME O
sent94 MEASURES O
sent94 : O
sent94 Sequence O
sent94 variants O
sent94 detected O
sent94 in O
sent94 this O
sent94 sample O
sent94 are O
sent94 presented O
sent94 along O
sent94 with O
sent94 analyses O
sent94 designed O
sent94 to O
sent94 determine O
sent94 predictive O
sent94 characteristics O
sent94 of O
sent94 those O
sent94 testing O
sent94 positive O
sent94 for O
sent94 BRCA1 O
sent94 mutations O
sent95 RESULTS O
sent95 : O
sent95 In O
sent95 102 O
sent95 women O
sent95 ( O
sent95 12.8 O
sent95 % O
sent95 ) O
sent95 , O
sent95 clearly O
sent95 deleterious O
sent95 mutations O
sent95 were O
sent95 detected O
sent96 Fifty O
sent96 new O
sent96 genetic O
sent96 alterations O
sent96 were O
sent96 found O
sent96 including O
sent96 24 O
sent96 deleterious O
sent96 mutations O
sent96 , O
sent96 24 O
sent96 variants O
sent96 of O
sent96 unknown O
sent96 significance O
sent96 , O
sent96 and O
sent96 2 O
sent96 rare O
sent96 polymorphisms O
sent97 In O
sent97 a O
sent97 subset O
sent97 of O
sent97 71 O
sent97 Ashkenazi O
sent97 Jewish O
sent97 women O
sent97 , O
sent97 only O
sent97 2 O
sent97 distinct O
sent97 deleterious O
sent97 mutations O
sent97 were O
sent97 found O
sent97 : O
sent97 185delAG O
sent97 in O
sent97 17 O
sent97 cases O
sent97 and O
sent97 5382insC O
sent97 in O
sent97 7 O
sent97 cases O
sent98 A O
sent98 bias O
sent98 in O
sent98 prior O
sent98 reports O
sent98 for O
sent98 mutations O
sent98 in O
sent98 exon O
sent98 11 O
sent98 was O
sent98 revealed O
sent99 Characteristics O
sent99 of O
sent99 a O
sent99 patient O
sent99 's O
sent99 specific O
sent99 diagnosis O
sent99 ( O
sent99 unilateral O
sent99 or O
sent99 bilateral O
sent99 breast D
sent99 cancer D
sent99 , O
sent99 with O
sent99 or O
sent99 without O
sent99 ovarian D
sent99 cancer D
sent99 ) O
sent99 , O
sent99 early O
sent99 age O
sent99 at O
sent99 diagnosis O
sent99 , O
sent99 Ashkenazi O
sent99 Jewish O
sent99 ethnicity O
sent99 , O
sent99 and O
sent99 family O
sent99 history O
sent99 of O
sent99 cancer O
sent99 were O
sent99 positively O
sent99 associated O
sent99 with O
sent99 the O
sent99 probability O
sent99 of O
sent99 her O
sent99 carrying O
sent99 a O
sent99 deleterious O
sent99 BRCA1 O
sent99 mutation O
sent100 CONCLUSIONS O
sent100 : O
sent100 Using O
sent100 logistic O
sent100 regression O
sent100 analysis O
sent100 , O
sent100 we O
sent100 provide O
sent100 a O
sent100 method O
sent100 for O
sent100 evaluating O
sent100 the O
sent100 probability O
sent100 of O
sent100 a O
sent100 woman O
sent100 's O
sent100 carrying O
sent100 a O
sent100 deleterious O
sent100 BRCA1 O
sent100 mutation O
sent100 for O
sent100 a O
sent100 wide O
sent100 range O
sent100 of O
sent100 cases O
sent100 , O
sent100 which O
sent100 can O
sent100 be O
sent100 an O
sent100 important O
sent100 tool O
sent100 for O
sent100 clinicians O
sent100 as O
sent100 they O
sent100 incorporate O
sent100 genetic O
sent100 susceptibility O
sent100 testing O
sent100 into O
sent100 their O
sent100 medical O
sent100 practice O
sent101 CONTEXT O
sent101 : O
sent101 Approximately O
sent101 9 O
sent101 % O
sent101 of O
sent101 prostate D
sent101 cancer D
sent101 cases O
sent101 have O
sent101 been O
sent101 estimated O
sent101 to O
sent101 result O
sent101 from O
sent101 inheritance O
sent101 of O
sent101 mutated O
sent101 prostate O
sent101 cancer O
sent101 susceptibility O
sent101 genes O
sent102 Few O
sent102 data O
sent102 exist O
sent102 as O
sent102 to O
sent102 whether O
sent102 there O
sent102 are O
sent102 clinical O
sent102 differences O
sent102 between O
sent102 prostate D
sent102 cancers D
sent102 that O
sent102 are O
sent102 inherited O
sent102 and O
sent102 those O
sent102 that O
sent102 occur O
sent102 in O
sent102 the O
sent102 general O
sent102 population O
sent103 OBJECTIVE O
sent103 : O
sent103 To O
sent103 investigate O
sent103 phenotypic O
sent103 characteristics O
sent103 of O
sent103 families O
sent103 potentially O
sent103 linked O
sent103 to O
sent103 the O
sent103 hereditary O
sent103 prostate O
sent103 cancer O
sent103 1 O
sent103 ( O
sent103 HPC1 O
sent103 ) O
sent103 locus O
sent103 on O
sent103 chromosome O
sent103 1q24-25 O
sent104 DESIGN O
sent104 : O
sent104 Retrospective O
sent104 case O
sent104 study O
sent104 in O
sent104 which O
sent104 clinical O
sent104 data O
sent104 were O
sent104 extracted O
sent104 from O
sent104 medical O
sent104 and O
sent104 pathological O
sent104 records O
sent105 FAMILIES O
sent105 : O
sent105 A O
sent105 total O
sent105 of O
sent105 74 O
sent105 North O
sent105 American O
sent105 families O
sent105 with O
sent105 hereditary O
sent105 prostate D
sent105 cancer D
sent106 Prostate O
sent106 cancer O
sent106 cases O
sent106 from O
sent106 the O
sent106 National O
sent106 Cancer O
sent106 Data O
sent106 Base O
sent106 were O
sent106 used O
sent106 as O
sent106 a O
sent106 reference O
sent106 population O
sent106 for O
sent106 comparison O
sent107 MAIN O
sent107 OUTCOME O
sent107 MEASURES O
sent107 : O
sent107 The O
sent107 families O
sent107 were O
sent107 divided O
sent107 into O
sent107 2 O
sent107 groups O
sent107 : O
sent107 either O
sent107 potentially O
sent107 linked O
sent107 ( O
sent107 33 O
sent107 families O
sent107 with O
sent107 133 O
sent107 men O
sent107 with O
sent107 prostate D
sent107 cancer D
sent107 ) O
sent107 , O
sent107 and O
sent107 thus O
sent107 likely O
sent107 to O
sent107 be O
sent107 carrying O
sent107 an O
sent107 altered O
sent107 HPC1 O
sent107 gene O
sent107 , O
sent107 or O
sent107 potentially O
sent107 unlinked O
sent107 ( O
sent107 41 O
sent107 families O
sent107 with O
sent107 172 O
sent107 men O
sent107 with O
sent107 prostate D
sent107 cancer D
sent107 ) O
sent107 , O
sent107 on O
sent107 the O
sent107 basis O
sent107 of O
sent107 haplotype O
sent107 analysis O
sent107 in O
sent107 the O
sent107 region O
sent107 of O
sent107 HPC1 O
sent108 The O
sent108 age O
sent108 at O
sent108 diagnosis O
sent108 of O
sent108 prostate D
sent108 cancer D
sent108 , O
sent108 serum O
sent108 prostate-specific O
sent108 antigen O
sent108 levels O
sent108 , O
sent108 digital O
sent108 rectal O
sent108 examination O
sent108 status O
sent108 , O
sent108 stage O
sent108 , O
sent108 grade O
sent108 , O
sent108 primary O
sent108 treatment O
sent108 of O
sent108 prostate D
sent108 cancers D
sent108 , O
sent108 and O
sent108 occurrence O
sent108 of O
sent108 other O
sent108 cancers D
sent108 were O
sent108 compared O
sent108 between O
sent108 the O
sent108 groups O
sent109 RESULTS O
sent109 : O
sent109 The O
sent109 mean O
sent109 age O
sent109 at O
sent109 diagnosis O
sent109 of O
sent109 prostate D
sent109 cancer D
sent109 for O
sent109 men O
sent109 in O
sent109 potentially O
sent109 linked O
sent109 families O
sent109 was O
sent109 significantly O
sent109 lower O
sent109 than O
sent109 for O
sent109 men O
sent109 in O
sent109 potentially O
sent109 unlinked O
sent109 families O
sent109 ( O
sent109 63.7 O
sent109 vs O
sent109 65.9 O
sent109 years O
sent109 , O
sent109 respectively O
sent109 , O
sent109 P=.01 O
sent109 ; O
sent109 mean O
sent109 age O
sent109 at O
sent109 diagnosis O
sent109 in O
sent109 the O
sent109 reference O
sent109 population O
sent109 was O
sent109 71.6 O
sent109 years O
sent109 ) O
sent110 Higher-grade O
sent110 cancers D
sent110 ( O
sent110 grade O
sent110 3 O
sent110 ) O
sent110 were O
sent110 more O
sent110 common O
sent110 in O
sent110 potentially O
sent110 linked O
sent110 families O
sent110 , O
sent110 and O
sent110 advanced-stage O
sent110 disease O
sent110 was O
sent110 found O
sent110 in O
sent110 41 O
sent110 % O
sent110 of O
sent110 the O
sent110 case O
sent110 patients O
sent110 in O
sent110 potentially O
sent110 linked O
sent110 families O
sent110 compared O
sent110 with O
sent110 31 O
sent110 % O
sent110 in O
sent110 both O
sent110 the O
sent110 potentially O
sent110 unlinked O
sent110 families O
sent110 and O
sent110 the O
sent110 reference O
sent110 groups O
sent110 ( O
sent110 P=.03 O
sent110 for O
sent110 the O
sent110 latter O
sent110 comparison O
sent110 ) O
sent111 In O
sent111 the O
sent111 other O
sent111 clinical O
sent111 parameters O
sent111 , O
sent111 we O
sent111 found O
sent111 no O
sent111 significant O
sent111 differences O
sent111 between O
sent111 the O
sent111 groups O
sent112 A O
sent112 modest O
sent112 excess O
sent112 of O
sent112 breast D
sent112 cancer D
sent112 and O
sent112 colon D
sent112 cancer D
sent112 was O
sent112 found O
sent112 in O
sent112 potentially O
sent112 linked O
sent112 families O
sent112 in O
sent112 comparison O
sent112 with O
sent112 potentially O
sent112 unlinked O
sent112 families O
sent112 , O
sent112 but O
sent112 this O
sent112 difference O
sent112 was O
sent112 not O
sent112 statistically O
sent112 significant O
sent113 CONCLUSIONS O
sent113 : O
sent113 Families O
sent113 that O
sent113 provide O
sent113 evidence O
sent113 for O
sent113 segregation O
sent113 of O
sent113 an O
sent113 altered O
sent113 HPC1 O
sent113 gene O
sent113 are O
sent113 characterized O
sent113 by O
sent113 multiple O
sent113 cases O
sent113 of O
sent113 prostate D
sent113 cancer D
sent113 that O
sent113 , O
sent113 in O
sent113 most O
sent113 respects O
sent113 , O
sent113 are O
sent113 indistinguishable O
sent113 from O
sent113 nonhereditary O
sent113 cases O
sent114 However O
sent114 , O
sent114 3 O
sent114 characteristics O
sent114 were O
sent114 observed O
sent114 : O
sent114 younger O
sent114 age O
sent114 at O
sent114 diagnosis O
sent114 , O
sent114 higher-grade O
sent114 tumors D
sent114 , O
sent114 and O
sent114 more O
sent114 advanced-stage O
sent114 disease O
sent115 Our O
sent115 study O
sent115 shows O
sent115 that O
sent115 a O
sent115 significant O
sent115 fraction O
sent115 of O
sent115 hereditary O
sent115 prostate D
sent115 cancers D
sent115 are O
sent115 diagnosed O
sent115 in O
sent115 advanced O
sent115 stages O
sent115 , O
sent115 emphasizing O
sent115 the O
sent115 clinical O
sent115 importance O
sent115 of O
sent115 early O
sent115 detection O
sent115 in O
sent115 men O
sent115 potentially O
sent115 carrying O
sent115 prostate O
sent115 cancer O
sent115 susceptibility O
sent115 genes O
sent116 These O
sent116 findings O
sent116 support O
sent116 the O
sent116 current O
sent116 recommendations O
sent116 to O
sent116 screen O
sent116 men O
sent116 with O
sent116 a O
sent116 positive O
sent116 family O
sent116 history O
sent116 of O
sent116 prostate D
sent116 cancer D
sent116 beginning O
sent116 at O
sent116 age O
sent116 40 O
sent116 years O
sent117 CONTEXT O
sent117 : O
sent117 Susceptibility O
sent117 to O
sent117 multiple D
sent117 sclerosis D
sent117 ( D
sent117 MS D
sent117 ) D
sent117 involves O
sent117 a O
sent117 genetically O
sent117 complex O
sent117 autoimmune O
sent117 component O
sent118 However O
sent118 , O
sent118 except O
sent118 for O
sent118 genes O
sent118 in O
sent118 the O
sent118 HLA O
sent118 system O
sent118 , O
sent118 specific O
sent118 susceptibility O
sent118 loci O
sent118 are O
sent118 unknown O
sent118 or O
sent118 unconfirmed O
sent119 OBJECTIVE O
sent119 : O
sent119 To O
sent119 investigate O
sent119 several O
sent119 loci O
sent119 spanning O
sent119 3 O
sent119 candidate O
sent119 regions O
sent119 for O
sent119 a O
sent119 role O
sent119 in O
sent119 multiple D
sent119 sclerosis D
sent119 ( D
sent119 MS D
sent119 ) D
sent119 susceptibility O
sent119 in O
sent119 2 O
sent119 ethnic O
sent119 groups O
sent119 using O
sent119 both O
sent119 single-locus O
sent119 and O
sent119 haplotype O
sent119 analyses O
sent120 The O
sent120 3 O
sent120 regions O
sent120 include O
sent120 HLA O
sent120 on O
sent120 chromosome O
sent120 6p21.3 O
sent120 , O
sent120 APOE O
sent120 on O
sent120 chromosome O
sent120 19ql O
sent120 3.2 O
sent120 , O
sent120 and O
sent120 MBP O
sent120 ( O
sent120 myelin O
sent120 basic O
sent120 protein O
sent120 ) O
sent120 on O
sent120 chromosome O
sent120 18q23 O
sent121 DESIGN O
sent121 : O
sent121 Case-control O
sent121 association O
sent121 testing O
sent122 SUBJECTS O
sent122 : O
sent122 A O
sent122 total O
sent122 of O
sent122 120 O
sent122 Caucasian O
sent122 patients O
sent122 with O
sent122 MS O
sent122 and O
sent122 107 O
sent122 unrelated O
sent122 control O
sent122 individuals O
sent122 from O
sent122 California O
sent122 , O
sent122 and O
sent122 32 O
sent122 patients O
sent122 and O
sent122 32 O
sent122 unrelated O
sent122 control O
sent122 individuals O
sent122 from O
sent122 Beijing O
sent122 , O
sent122 China O
sent123 All O
sent123 patients O
sent123 with O
sent123 MS O
sent123 were O
sent123 diagnosed O
sent123 as O
sent123 having O
sent123 clinically O
sent123 definite O
sent123 disease O
sent123 according O
sent123 to O
sent123 published O
sent123 criteria O
sent124 MAIN O
sent124 OUTCOME O
sent124 MEASURES O
sent124 : O
sent124 Chi2 O
sent124 Testing O
sent124 of O
sent124 loci O
sent124 and O
sent124 individual O
sent124 alleles O
sent124 and O
sent124 haplotypes O
sent125 Haplotype O
sent125 frequencies O
sent125 were O
sent125 estimated O
sent125 with O
sent125 standard O
sent125 maximum O
sent125 likelihood O
sent125 methods O
sent126 RESULTS O
sent126 : O
sent126 The O
sent126 HLA O
sent126 effect O
sent126 is O
sent126 due O
sent126 to O
sent126 the O
sent126 class O
sent126 II O
sent126 DR2 O
sent126 haplotype O
sent126 , O
sent126 DRB1*1501-DQA1*0102-DRB1*0602 O
sent126 ; O
sent126 contributions O
sent126 to O
sent126 MS O
sent126 susceptibility O
sent126 from O
sent126 additional O
sent126 DRB1-DQB1 O
sent126 alleles O
sent126 or O
sent126 other O
sent126 HLA O
sent126 region O
sent126 loci O
sent126 were O
sent126 not O
sent126 observed O
sent127 Variation O
sent127 within O
sent127 the O
sent127 MBP O
sent127 locus O
sent127 on O
sent127 chromosome O
sent127 18q23 O
sent127 showed O
sent127 no O
sent127 effect O
sent127 in O
sent127 MS O
sent128 The O
sent128 distribution O
sent128 of O
sent128 haplotypes O
sent128 from O
sent128 5 O
sent128 loci O
sent128 within O
sent128 the O
sent128 chromosome O
sent128 19q13.2 O
sent128 region O
sent128 , O
sent128 including O
sent128 D19S178 O
sent128 , O
sent128 D19S574 O
sent128 , O
sent128 APOE O
sent128 , O
sent128 APOC2 O
sent128 , O
sent128 and O
sent128 D19S219 O
sent128 , O
sent128 differed O
sent128 between O
sent128 patient O
sent128 and O
sent128 control O
sent128 samples O
sent129 D19S574 O
sent129 showed O
sent129 a O
sent129 significant O
sent129 effect O
sent129 ( O
sent129 P=.015 O
sent129 ) O
sent129 in O
sent129 Caucasian O
sent129 patients O
sent129 with O
sent129 MS O
sent129 due O
sent129 to O
sent129 the O
sent129 increased O
sent129 frequency O
sent129 of O
sent129 a O
sent129 single O
sent129 allele O
sent129 ( O
sent129 P=.002 O
sent129 ) O
sent130 The O
sent130 APOE O
sent130 variation O
sent130 , O
sent130 prominent O
sent130 in O
sent130 other O
sent130 neurological O
sent130 diseases O
sent130 , O
sent130 showed O
sent130 no O
sent130 influence O
sent130 on O
sent130 MS O
sent130 susceptibility O
sent130 , O
sent130 despite O
sent130 its O
sent130 location O
sent130 within O
sent130 the O
sent130 chromosome O
sent130 19q13.2 O
sent130 region O
sent131 Interaction O
sent131 effects O
sent131 between O
sent131 DR2 O
sent131 and O
sent131 chromosome O
sent131 19q13.2 O
sent131 or O
sent131 MBP O
sent131 in O
sent131 MS O
sent131 susceptibility O
sent131 were O
sent131 not O
sent131 apparent O
sent132 CONCLUSIONS O
sent132 : O
sent132 The O
sent132 significant O
sent132 chromosome O
sent132 19q13.2 O
sent132 single-locus O
sent132 and O
sent132 multilocus O
sent132 haplotype O
sent132 associations O
sent132 with O
sent132 MS O
sent132 in O
sent132 Caucasian O
sent132 and O
sent132 Chinese O
sent132 patient O
sent132 samples O
sent132 indicate O
sent132 an O
sent132 effect O
sent132 from O
sent132 a O
sent132 nearby O
sent132 disease O
sent132 susceptibility O
sent132 locus O
sent133 These O
sent133 initial O
sent133 observations O
sent133 are O
sent133 an O
sent133 encouraging O
sent133 step O
sent133 toward O
sent133 the O
sent133 description O
sent133 of O
sent133 non-HLA O
sent133 genetic O
sent133 susceptibility O
sent133 to O
sent133 MS O
sent134 < O
sent134 TO_SEE O
sent134 > O
sent134 CONTEXT O
sent134 : O
sent134 There O
sent134 is O
sent134 a O
sent134 substantial O
sent134 risk O
sent134 of O
sent134 a O
sent134 second O
sent134 cancer O
sent134 for O
sent134 persons O
sent134 with O
sent134 hereditary O
sent134 retinoblastoma O
sent134 , O
sent134 which O
sent134 is O
sent134 enhanced O
sent134 by O
sent134 radiotherapy O
sent135 < O
sent135 TO_SEE O
sent135 > O
sent135 OBJECTIVE O
sent135 : O
sent135 To O
sent135 examine O
sent135 long-term O
sent135 risk O
sent135 of O
sent135 new O
sent135 primary O
sent135 cancers O
sent135 in O
sent135 survivors O
sent135 of O
sent135 childhood O
sent135 retinoblastoma O
sent135 and O
sent135 quantify O
sent135 the O
sent135 role O
sent135 of O
sent135 radiotherapy O
sent135 in O
sent135 sarcoma O
sent135 development O
sent136 DESIGN O
sent136 : O
sent136 Cohort O
sent136 incidence O
sent136 study O
sent136 of O
sent136 patients O
sent136 with O
sent136 retinoblastoma O
sent136 followed O
sent136 for O
sent136 a O
sent136 median O
sent136 of O
sent136 20 O
sent136 years O
sent136 , O
sent136 and O
sent136 nested O
sent136 case-control O
sent136 study O
sent136 of O
sent136 a O
sent136 radiation O
sent136 dose-response O
sent136 relationship O
sent136 for O
sent136 bone O
sent136 and O
sent136 soft O
sent136 tissue O
sent136 sarcomas O
sent137 SETTING/PARTICIPANTS O
sent137 : O
sent137 A O
sent137 total O
sent137 of O
sent137 1604 O
sent137 patients O
sent137 with O
sent137 retinoblastoma D
sent137 who O
sent137 survived O
sent137 at O
sent137 least O
sent137 1 O
sent137 year O
sent137 after O
sent137 diagnosis O
sent137 , O
sent137 identified O
sent137 from O
sent137 hospital O
sent137 records O
sent137 in O
sent137 Massachusetts O
sent137 and O
sent137 New O
sent137 York O
sent137 during O
sent137 1914 O
sent137 to O
sent137 1984 O
sent138 RESULTS O
sent138 : O
sent138 Incidence O
sent138 of O
sent138 subsequent O
sent138 cancers D
sent138 was O
sent138 statistically O
sent138 significantly O
sent138 elevated O
sent138 only O
sent138 in O
sent138 the O
sent138 961 O
sent138 patients O
sent138 with O
sent138 hereditary O
sent138 retinoblastoma D
sent138 , O
sent138 in O
sent138 whom O
sent138 190 O
sent138 cancers D
sent138 were O
sent138 diagnosed O
sent138 , O
sent138 vs O
sent138 6.3 O
sent138 expected O
sent138 in O
sent138 the O
sent138 general O
sent138 population O
sent138 ( O
sent138 relative O
sent138 risk O
sent138 ( O
sent138 RR O
sent138 ) O
sent138 , O
sent138 30 O
sent138 ( O
sent138 95 O
sent138 % O
sent138 confidence O
sent138 interval O
sent138 , O
sent138 26-47 O
sent138 ) O
sent138 ) O
sent139 Cumulative O
sent139 incidence O
sent139 ( O
sent139 +/-SE O
sent139 ) O
sent139 of O
sent139 a O
sent139 second O
sent139 cancer D
sent139 at O
sent139 50 O
sent139 years O
sent139 after O
sent139 diagnosis O
sent139 was O
sent139 51.0 O
sent139 % O
sent139 ( O
sent139 +/-6.2 O
sent139 % O
sent139 ) O
sent139 for O
sent139 hereditary O
sent139 retinoblastoma D
sent139 , O
sent139 and O
sent139 5.0 O
sent139 % O
sent139 ( O
sent139 +/-3.0 O
sent139 % O
sent139 ) O
sent139 for O
sent139 nonhereditary O
sent139 retinoblastoma D
sent140 All O
sent140 114 O
sent140 sarcomas D
sent140 of O
sent140 diverse O
sent140 histologic O
sent140 types O
sent140 occurred O
sent140 in O
sent140 patients O
sent140 with O
sent140 hereditary O
sent140 retinoblastoma D
sent141 For O
sent141 soft O
sent141 tissue O
sent141 sarcomas D
sent141 , O
sent141 the O
sent141 RRs O
sent141 showed O
sent141 a O
sent141 stepwise O
sent141 increase O
sent141 at O
sent141 all O
sent141 dose O
sent141 categories O
sent141 , O
sent141 and O
sent141 were O
sent141 statistically O
sent141 significant O
sent141 at O
sent141 10 O
sent141 to O
sent141 29.9 O
sent141 Gy O
sent141 and O
sent141 30 O
sent141 to O
sent141 59.9 O
sent141 Gy O
sent142 A O
sent142 radiation O
sent142 risk O
sent142 for O
sent142 all O
sent142 sarcomas O
sent142 combined O
sent142 was O
sent142 evident O
sent142 at O
sent142 doses O
sent142 above O
sent142 5 O
sent142 Gy O
sent142 , O
sent142 rising O
sent142 to O
sent142 10.7-fold O
sent142 at O
sent142 doses O
sent142 of O
sent142 60 O
sent142 Gy O
sent142 or O
sent142 greater O
sent142 ( O
sent142 P O
sent142 & O
sent142 # O
sent142 60 O
sent142 ; O
sent142 .05 O
sent142 ) O
sent143 < O
sent143 TO_SEE O
sent143 > O
sent143 CONCLUSIONS O
sent143 : O
sent143 Genetic O
sent143 predisposition O
sent143 has O
sent143 a O
sent143 substantial O
sent143 impact O
sent143 on O
sent143 risk O
sent143 of O
sent143 subsequent D
sent143 cancers D
sent143 in O
sent143 retinoblastoma D
sent143 patients O
sent143 , O
sent143 which O
sent143 is O
sent143 further O
sent143 increased O
sent143 by O
sent143 radiation T
sent143 treatment T
sent144 A O
sent144 radiation O
sent144 dose-response O
sent144 relationship O
sent144 is O
sent144 demonstrated O
sent144 for O
sent144 all O
sent144 sarcomas O
sent144 and O
sent144 , O
sent144 for O
sent144 the O
sent144 first O
sent144 time O
sent144 in O
sent144 humans O
sent144 , O
sent144 for O
sent144 soft O
sent144 tissue O
sent144 sarcomas O
sent145 Retinoblastoma D
sent145 patients O
sent145 should O
sent145 be O
sent145 examined O
sent145 for O
sent145 new O
sent145 cancers D
sent145 and O
sent145 followed O
sent145 into O
sent145 later O
sent145 life O
sent145 to O
sent145 determine O
sent145 whether O
sent145 their O
sent145 extraordinary O
sent145 cancer O
sent145 risk O
sent145 extends O
sent145 to O
sent145 common O
sent145 cancers D
sent145 of O
sent145 adulthood O
sent146 The O
sent146 objective O
sent146 of O
sent146 this O
sent146 study O
sent146 was O
sent146 to O
sent146 determine O
sent146 the O
sent146 rate O
sent146 of O
sent146 recent O
sent146 cocaine O
sent146 use O
sent146 among O
sent146 a O
sent146 metropolitan O
sent146 population O
sent146 of O
sent146 predominantly O
sent146 Hispanic O
sent146 and O
sent146 African-American O
sent146 women O
sent146 with O
sent146 preterm O
sent146 premature D
sent146 rupture D
sent146 of D
sent146 the D
sent146 membranes D
sent146 ( D
sent146 PROM D
sent146 ) D
sent146 and O
sent146 to O
sent146 ascertain O
sent146 the O
sent146 impact O
sent146 of O
sent146 cocaine O
sent146 on O
sent146 the O
sent146 latency O
sent146 period O
sent146 between O
sent146 rupture O
sent146 of O
sent146 membranes O
sent146 and O
sent146 delivery O
sent147 Urine O
sent147 toxicology O
sent147 screens O
sent147 were O
sent147 prospectively O
sent147 obtained O
sent147 on O
sent147 147 O
sent147 women O
sent147 with O
sent147 preterm D
sent147 PROM D
sent148 The O
sent148 urine O
sent148 screen O
sent148 did O
sent148 not O
sent148 influence O
sent148 management O
sent148 decisions O
sent149 All O
sent149 women O
sent149 were O
sent149 expectantly O
sent149 managed O
sent149 without O
sent149 tocolytics O
sent149 until O
sent149 37 O
sent149 weeks O
sent149 ' O
sent149 gestation O
sent149 unless O
sent149 they O
sent149 developed O
sent149 clinical O
sent149 chorioamnionitis O
sent149 , O
sent149 or O
sent149 nonreassuring O
sent149 fetal O
sent149 heart O
sent149 rate O
sent149 tracing O
sent149 or O
sent149 biophysical O
sent149 profile O
sent150 Demographic O
sent150 information O
sent150 , O
sent150 hours O
sent150 from O
sent150 rupture O
sent150 of O
sent150 membranes O
sent150 to O
sent150 delivery O
sent150 , O
sent150 gestational O
sent150 age O
sent150 , O
sent150 and O
sent150 birth O
sent150 weight O
sent150 at O
sent150 delivery O
sent150 were O
sent150 compared O
sent150 using O
sent150 Fisher O
sent150 's O
sent150 exact O
sent150 , O
sent150 Mann-Whitney O
sent150 U O
sent150 , O
sent150 and O
sent150 randomization O
sent150 tests O
sent150 where O
sent150 appropriate O
sent151 The O
sent151 rate O
sent151 of O
sent151 positive O
sent151 urine O
sent151 drug O
sent151 screens O
sent151 for O
sent151 cocaine O
sent151 was O
sent151 8.2 O
sent151 % O
sent152 Women O
sent152 in O
sent152 the O
sent152 cocaine O
sent152 positive O
sent152 group O
sent152 were O
sent152 of O
sent152 higher O
sent152 parity O
sent152 ( O
sent152 3 O
sent152 , O
sent152 ( O
sent152 0-7 O
sent152 ) O
sent152 vs. O
sent152 1 O
sent152 , O
sent152 ( O
sent152 0-6 O
sent152 ) O
sent152 , O
sent152 p O
sent152 = O
sent152 0.001 O
sent152 ) O
sent152 and O
sent152 tended O
sent152 to O
sent152 be O
sent152 older O
sent152 ( O
sent152 27 O
sent152 , O
sent152 ( O
sent152 23-42 O
sent152 ) O
sent152 vs. O
sent152 25 O
sent152 , O
sent152 ( O
sent152 14-40 O
sent152 ) O
sent152 ) O
sent153 There O
sent153 was O
sent153 a O
sent153 higher O
sent153 rate O
sent153 of O
sent153 recent O
sent153 cocaine O
sent153 use O
sent153 among O
sent153 African-American O
sent153 women O
sent153 ( O
sent153 20.4 O
sent153 % O
sent153 ) O
sent153 as O
sent153 compared O
sent153 to O
sent153 non-African-Americans O
sent153 ( O
sent153 1.2 O
sent153 % O
sent153 , O
sent153 p O
sent153 = O
sent153 0.0001 O
sent153 ) O
sent154 Cocaine-positive O
sent154 women O
sent154 presented O
sent154 at O
sent154 an O
sent154 earlier O
sent154 gestational O
sent154 age O
sent154 ( O
sent154 32 O
sent154 weeks O
sent154 ' O
sent154 , O
sent154 ( O
sent154 24-34 O
sent154 ) O
sent154 vs. O
sent154 33 O
sent154 weeks O
sent154 ' O
sent154 , O
sent154 ( O
sent154 23-36 O
sent154 ) O
sent154 , O
sent154 p O
sent154 = O
sent154 0.02 O
sent154 ) O
sent154 and O
sent154 had O
sent154 a O
sent154 significantly O
sent154 longer O
sent154 membrane O
sent154 rupture O
sent154 to O
sent154 delivery O
sent154 interval O
sent154 than O
sent154 women O
sent154 with O
sent154 a O
sent154 negative O
sent154 urine O
sent154 drug O
sent154 screen O
sent154 ( O
sent154 174 O
sent154 hr O
sent154 , O
sent154 ( O
sent154 6-475 O
sent154 ) O
sent154 vs. O
sent154 33 O
sent154 hours O
sent154 ( O
sent154 1-833 O
sent154 ) O
sent154 , O
sent154 p O
sent154 = O
sent154 0.01 O
sent154 ) O
sent155 There O
sent155 was O
sent155 no O
sent155 significant O
sent155 difference O
sent155 in O
sent155 the O
sent155 reason O
sent155 for O
sent155 delivery O
sent155 between O
sent155 the O
sent155 two O
sent155 groups O
sent155 of O
sent155 patients O
sent156 Recent O
sent156 cocaine O
sent156 use O
sent156 among O
sent156 women O
sent156 with O
sent156 preterm D
sent156 PROM D
sent156 is O
sent156 common O
sent156 in O
sent156 only O
sent156 some O
sent156 segments O
sent156 of O
sent156 an O
sent156 urban O
sent156 population O
sent157 Women O
sent157 with O
sent157 recent O
sent157 cocaine O
sent157 use O
sent157 present O
sent157 with O
sent157 ruptured O
sent157 membranes O
sent157 at O
sent157 an O
sent157 earlier O
sent157 gestational O
sent157 age O
sent157 and O
sent157 may O
sent157 actually O
sent157 have O
sent157 a O
sent157 longer O
sent157 latency O
sent157 period O
sent157 than O
sent157 women O
sent157 who O
sent157 do O
sent157 not O
sent157 use O
sent157 cocaine O
sent158 The O
sent158 objective O
sent158 of O
sent158 this O
sent158 article O
sent158 is O
sent158 to O
sent158 explore O
sent158 attitudes O
sent158 of O
sent158 an O
sent158 inner-city O
sent158 , O
sent158 pregnant O
sent158 cohort O
sent158 about O
sent158 general O
sent158 and O
sent158 HIV-related O
sent158 prenatal O
sent158 care O
sent159 Responses O
sent159 to O
sent159 an O
sent159 interview O
sent159 at O
sent159 initial O
sent159 prenatal O
sent159 care O
sent159 enrollment O
sent159 were O
sent159 compared O
sent159 using O
sent159 Chi-square O
sent159 and O
sent159 Fisher O
sent159 's O
sent159 exact O
sent159 tests O
sent160 Of O
sent160 75 O
sent160 women O
sent160 , O
sent160 drug O
sent160 users O
sent160 ( O
sent160 51 O
sent160 % O
sent160 ) O
sent160 were O
sent160 more O
sent160 likely O
sent160 to O
sent160 say O
sent160 that O
sent160 they O
sent160 would O
sent160 defer O
sent160 initiating O
sent160 prenatal O
sent160 care O
sent160 ( O
sent160 P O
sent160 = O
sent160 0.03 O
sent160 ) O
sent160 and O
sent160 to O
sent160 minimize O
sent160 the O
sent160 risk O
sent160 of O
sent160 drug O
sent160 or O
sent160 alcohol O
sent160 use O
sent160 to O
sent160 the O
sent160 fetus O
sent160 ( O
sent160 P O
sent160 = O
sent160 0.04 O
sent160 ) O
sent161 Most O
sent161 ( O
sent161 85 O
sent161 % O
sent161 ) O
sent161 viewed O
sent161 pregnancy O
sent161 as O
sent161 inappropriate O
sent161 for O
sent161 HIV D
sent161 infected O
sent161 women O
sent161 and O
sent161 primarily O
sent161 drug O
sent161 users O
sent161 ( O
sent161 P O
sent161 = O
sent161 0.06 O
sent161 ) O
sent161 would O
sent161 abort O
sent161 if O
sent161 HIV D
sent161 infected O
sent162 Over O
sent162 half O
sent162 thought O
sent162 HIV D
sent162 transmission O
sent162 occurred O
sent162 most O
sent162 times O
sent162 or O
sent162 always O
sent163 Only O
sent163 20 O
sent163 % O
sent163 had O
sent163 heard O
sent163 of O
sent163 a O
sent163 drug O
sent163 to O
sent163 reduce O
sent163 this O
sent163 risk O
sent163 , O
sent163 but O
sent163 95 O
sent163 % O
sent163 would O
sent163 take O
sent163 such O
sent163 a O
sent163 therapy O
sent164 These O
sent164 inner-city O
sent164 , O
sent164 pregnant O
sent164 women O
sent164 disapproved O
sent164 of O
sent164 pregnancy O
sent164 if O
sent164 HIV D
sent164 infected O
sent164 and O
sent164 thought O
sent164 the O
sent164 risk O
sent164 of O
sent164 transmission O
sent164 was O
sent164 high O
sent165 They O
sent165 knew O
sent165 little O
sent165 of O
sent165 how O
sent165 to O
sent165 reduce O
sent165 this O
sent165 risk O
sent165 but O
sent165 nearly O
sent165 all O
sent165 would O
sent165 accept O
sent165 a O
sent165 drug O
sent165 to O
sent165 prevent O
sent165 transmission O
sent166 The O
sent166 association O
sent166 of O
sent166 parvovirus D
sent166 B19 D
sent166 infection D
sent166 and O
sent166 hydrops D
sent166 fetalis D
sent166 is O
sent166 well O
sent166 known O
sent167 However O
sent167 , O
sent167 the O
sent167 association O
sent167 of O
sent167 parvovirus D
sent167 and O
sent167 fetal O
sent167 pleural O
sent167 or O
sent167 pericardial D
sent167 effusions D
sent167 has O
sent167 not O
sent167 been O
sent167 reported O
sent168 We O
sent168 present O
sent168 five O
sent168 cases O
sent168 of O
sent168 isolated O
sent168 pleural O
sent168 or O
sent168 pericardial D
sent168 effusion D
sent168 with O
sent168 documented O
sent168 maternal O
sent168 parvovirus D
sent168 infection D
sent168 in O
sent168 four O
sent168 of O
sent168 these O
sent168 pregnancies O
sent169 In O
sent169 the O
sent169 absence O
sent169 of O
sent169 structural O
sent169 or O
sent169 karyotypic O
sent169 abnormalities O
sent169 , O
sent169 spontaneous O
sent169 resolution O
sent169 of O
sent169 the O
sent169 effusion O
sent169 portends O
sent169 for O
sent169 a O
sent169 successful O
sent169 pregnancy O
sent169 outcome O
sent170 BACKGROUND O
sent170 : O
sent170 Cochlear T
sent170 implantation T
sent170 is O
sent170 nowadays O
sent170 a O
sent170 reliable O
sent170 and O
sent170 well-accepted O
sent170 method O
sent170 of O
sent170 auditory O
sent170 rehabilitation O
sent170 in O
sent170 selected O
sent170 adults O
sent170 and O
sent170 children O
sent171 METHODS O
sent171 : O
sent171 We O
sent171 present O
sent171 rehabilitation O
sent171 data O
sent171 on O
sent171 21 O
sent171 adult O
sent171 patients O
sent171 provided O
sent171 with O
sent171 the O
sent171 Nucleus O
sent171 CI22 O
sent171 M O
sent171 cochlear O
sent171 implant O
sent171 using O
sent171 the O
sent171 SPEAK O
sent171 strategy O
sent172 RESULTS O
sent172 : O
sent172 Results O
sent172 of O
sent172 first O
sent172 tune-up O
sent172 show O
sent172 an O
sent172 open O
sent172 set O
sent172 speech O
sent172 understanding O
sent172 in O
sent172 approximately O
sent172 50 O
sent172 % O
sent172 of O
sent172 patients O
sent173 Long-term O
sent173 results O
sent173 also O
sent173 reveal O
sent173 further O
sent173 improvement O
sent173 in O
sent173 patients O
sent173 who O
sent173 had O
sent173 no O
sent173 open O
sent173 set O
sent173 speech O
sent173 understanding O
sent174 Our O
sent174 data O
sent174 seem O
sent174 to O
sent174 indicate O
sent174 similar O
sent174 results O
sent174 in O
sent174 comparison O
sent174 to O
sent174 other O
sent174 groups O
sent174 using O
sent174 the O
sent174 CIS O
sent174 strategy O
sent175 CONCLUSIONS O
sent175 : O
sent175 In O
sent175 adults O
sent175 , O
sent175 open O
sent175 set O
sent175 speech O
sent175 understanding O
sent175 can O
sent175 be O
sent175 achieved O
sent175 even O
sent175 at O
sent175 the O
sent175 first O
sent175 tune-up O
sent176 Results O
sent176 of O
sent176 early O
sent176 rehabilitation O
sent176 seem O
sent176 to O
sent176 be O
sent176 influenced O
sent176 by O
sent176 duration O
sent176 and O
sent176 etiology O
sent176 of O
sent176 deafness D
sent176 , O
sent176 experience O
sent176 with O
sent176 hearing O
sent176 aids O
sent176 , O
sent176 and O
sent176 other O
sent176 factors O
sent177 Adverse O
sent177 drug O
sent177 effects O
sent177 are O
sent177 manifold O
sent177 and O
sent177 heterogenous O
sent178 Many O
sent178 situations O
sent178 may O
sent178 hamper O
sent178 the O
sent178 signalling O
sent178 ( O
sent178 i.e O
sent178 . O
sent178 the O
sent178 detection O
sent178 of O
sent178 early O
sent178 warning O
sent178 signs O
sent178 ) O
sent178 of O
sent178 adverse O
sent178 effects O
sent178 and O
sent178 new O
sent178 signals O
sent178 often O
sent178 differ O
sent178 from O
sent178 previous O
sent178 experiences O
sent179 Signals O
sent179 have O
sent179 qualitative O
sent179 and O
sent179 quantitative O
sent179 aspects O
sent180 Different O
sent180 categories O
sent180 of O
sent180 adverse O
sent180 effects O
sent180 need O
sent180 different O
sent180 methods O
sent180 for O
sent180 detection O
sent181 Current O
sent181 pharmacovigilance O
sent181 is O
sent181 predominantly O
sent181 based O
sent181 on O
sent181 spontaneous O
sent181 reporting O
sent181 and O
sent181 is O
sent181 mainly O
sent181 helpful O
sent181 in O
sent181 detecting O
sent181 type O
sent181 B O
sent181 effects O
sent181 ( O
sent181 those O
sent181 effects O
sent181 that O
sent181 are O
sent181 often O
sent181 allergic O
sent181 or O
sent181 idiosyncratic O
sent181 reactions O
sent181 , O
sent181 characteristically O
sent181 occurring O
sent181 in O
sent181 only O
sent181 a O
sent181 minority O
sent181 of O
sent181 patients O
sent181 and O
sent181 usually O
sent181 unrelated O
sent181 to O
sent181 dosage O
sent181 and O
sent181 that O
sent181 are O
sent181 serious O
sent181 , O
sent181 unexpected O
sent181 and O
sent181 unpredictable O
sent181 ) O
sent181 and O
sent181 unusual O
sent181 type O
sent181 A O
sent181 effects O
sent181 ( O
sent181 those O
sent181 effects O
sent181 that O
sent181 are O
sent181 related O
sent181 to O
sent181 the O
sent181 pharmacological O
sent181 effects O
sent181 of O
sent181 the O
sent181 drug O
sent181 and O
sent181 are O
sent181 dosage-related O
sent181 ) O
sent182 Examples O
sent182 of O
sent182 other O
sent182 sources O
sent182 of O
sent182 signals O
sent182 are O
sent182 prescription O
sent182 event O
sent182 monitoring O
sent182 , O
sent182 large O
sent182 automated O
sent182 data O
sent182 resources O
sent182 on O
sent182 morbidity O
sent182 and O
sent182 drug O
sent182 use O
sent182 ( O
sent182 including O
sent182 record O
sent182 linkage O
sent182 ) O
sent182 , O
sent182 case-control O
sent182 surveillance O
sent182 and O
sent182 follow-up O
sent182 studies O
sent183 Type O
sent183 C O
sent183 effects O
sent183 ( O
sent183 those O
sent183 effects O
sent183 related O
sent183 to O
sent183 an O
sent183 increased O
sent183 frequency O
sent183 of O
sent183 'spontaneous O
sent183 ' O
sent183 disease O
sent183 ) O
sent183 are O
sent183 difficult O
sent183 to O
sent183 study O
sent183 , O
sent183 however O
sent183 , O
sent183 and O
sent183 continue O
sent183 to O
sent183 pose O
sent183 a O
sent183 pharmacoepidemiological O
sent183 challenge O
sent184 Seven O
sent184 basic O
sent184 considerations O
sent184 can O
sent184 be O
sent184 identified O
sent184 that O
sent184 determine O
sent184 the O
sent184 evidence O
sent184 contained O
sent184 in O
sent184 a O
sent184 signal O
sent184 : O
sent184 quantitative O
sent184 strength O
sent184 of O
sent184 the O
sent184 association O
sent184 , O
sent184 consistency O
sent184 of O
sent184 the O
sent184 data O
sent184 , O
sent184 exposure O
sent184 response O
sent184 relationship O
sent184 , O
sent184 biological O
sent184 plausibility O
sent184 , O
sent184 experimental O
sent184 findings O
sent184 , O
sent184 possible O
sent184 analogies O
sent184 and O
sent184 the O
sent184 nature O
sent184 and O
sent184 quality O
sent184 of O
sent184 the O
sent184 data O
sent185 A O
sent185 proposal O
sent185 is O
sent185 made O
sent185 for O
sent185 a O
sent185 standard O
sent185 signal O
sent185 management O
sent185 procedure O
sent185 at O
sent185 pharmacovigilance O
sent185 centres O
sent185 , O
sent185 including O
sent185 the O
sent185 following O
sent185 steps O
sent185 : O
sent185 signal O
sent185 delineation O
sent185 , O
sent185 literature O
sent185 search O
sent185 , O
sent185 preliminary O
sent185 inventory O
sent185 of O
sent185 data O
sent185 , O
sent185 collection O
sent185 of O
sent185 additional O
sent185 information O
sent185 , O
sent185 consultation O
sent185 with O
sent185 the O
sent185 World O
sent185 Health O
sent185 Organization O
sent185 Centre O
sent185 for O
sent185 International O
sent185 Drug O
sent185 Monitoring O
sent185 and O
sent185 the O
sent185 relevant O
sent185 drug O
sent185 companies O
sent185 , O
sent185 aggregated O
sent185 data O
sent185 assessment O
sent185 and O
sent185 a O
sent185 report O
sent185 in O
sent185 writing O
sent186 A O
sent186 better O
sent186 understanding O
sent186 of O
sent186 the O
sent186 conditions O
sent186 and O
sent186 mechanisms O
sent186 involved O
sent186 in O
sent186 the O
sent186 detection O
sent186 of O
sent186 adverse O
sent186 drug O
sent186 effects O
sent186 may O
sent186 further O
sent186 improve O
sent186 strategies O
sent186 for O
sent186 pharmacovigilance O
sent187 OBJECTIVE O
sent187 : O
sent187 To O
sent187 study O
sent187 the O
sent187 safety O
sent187 and O
sent187 efficacy O
sent187 of O
sent187 methylphenidate T
sent187 in O
sent187 children O
sent187 with O
sent187 the O
sent187 dual O
sent187 diagnosis O
sent187 of O
sent187 epilepsy D
sent187 and O
sent187 attention D
sent187 deficit D
sent187 hyperactivity D
sent187 disorder D
sent187 ( D
sent187 ADHD D
sent187 ) D
sent188 STUDY O
sent188 DESIGN O
sent188 : O
sent188 Thirty O
sent188 children O
sent188 , O
sent188 aged O
sent188 6.4 O
sent188 to O
sent188 16.4 O
sent188 years O
sent188 , O
sent188 with O
sent188 epilepsy D
sent188 and O
sent188 ADHD D
sent188 were O
sent188 studied O
sent188 during O
sent188 a O
sent188 4-month O
sent188 period O
sent189 During O
sent189 the O
sent189 initial O
sent189 2 O
sent189 months O
sent189 of O
sent189 the O
sent189 study O
sent189 , O
sent189 the O
sent189 children O
sent189 were O
sent189 treated O
sent189 with O
sent189 antiepileptic T
sent189 drugs T
sent189 ( T
sent189 AEDs T
sent189 ) T
sent189 only O
sent189 , O
sent189 and O
sent189 for O
sent189 the O
sent189 remaining O
sent189 2 O
sent189 months O
sent189 , O
sent189 methylphenidate T
sent189 was O
sent189 added O
sent189 at O
sent189 a O
sent189 morning O
sent189 dose O
sent189 of O
sent189 0.3 O
sent189 mg/kg O
sent190 They O
sent190 underwent O
sent190 neurologic O
sent190 assessment O
sent190 , O
sent190 brain O
sent190 computed O
sent190 tomography O
sent190 , O
sent190 IQ O
sent190 testing O
sent190 , O
sent190 and O
sent190 assessment O
sent190 with O
sent190 the O
sent190 Childhood O
sent190 Behavior O
sent190 Checklist O
sent190 at O
sent190 baseline O
sent190 before O
sent190 methylphenidate T
sent190 therapy T
sent191 Electroencephalography O
sent191 , O
sent191 AED O
sent191 determinations O
sent191 , O
sent191 and O
sent191 the O
sent191 continuous-performance O
sent191 task O
sent191 ( O
sent191 CPT O
sent191 ) O
sent191 test O
sent191 were O
sent191 done O
sent191 at O
sent191 baseline O
sent191 and O
sent191 after O
sent191 2 O
sent191 months O
sent191 of O
sent191 methylphenidate O
sent191 therapy O
sent192 A O
sent192 double-blind O
sent192 , O
sent192 crossover O
sent192 design O
sent192 was O
sent192 used O
sent192 to O
sent192 compare O
sent192 the O
sent192 effects O
sent192 of O
sent192 methylphenidate T
sent192 versus O
sent192 placebo O
sent192 on O
sent192 an O
sent192 electroencephalogram O
sent192 , O
sent192 AED O
sent192 levels O
sent192 , O
sent192 and O
sent192 the O
sent192 CPT O
sent193 On O
sent193 the O
sent193 2 O
sent193 days O
sent193 of O
sent193 testing O
sent193 , O
sent193 the O
sent193 child O
sent193 received O
sent193 AEDs T
sent193 and O
sent193 a O
sent193 capsule O
sent193 containing O
sent193 either O
sent193 placebo O
sent193 or O
sent193 methylphenidate T
sent194 RESULTS O
sent194 : O
sent194 None O
sent194 of O
sent194 the O
sent194 25 O
sent194 children O
sent194 of O
sent194 this O
sent194 sample O
sent194 who O
sent194 were O
sent194 seizure O
sent194 free O
sent194 had O
sent194 attacks O
sent194 while O
sent194 taking O
sent194 methylphenidate O
sent195 Of O
sent195 the O
sent195 5 O
sent195 children O
sent195 with O
sent195 seizures D
sent195 , O
sent195 3 O
sent195 had O
sent195 an O
sent195 increase O
sent195 in O
sent195 attacks O
sent195 , O
sent195 whereas O
sent195 the O
sent195 other O
sent195 2 O
sent195 showed O
sent195 no O
sent195 change O
sent195 or O
sent195 a O
sent195 reduction O
sent196 There O
sent196 were O
sent196 no O
sent196 significant O
sent196 changes O
sent196 in O
sent196 AED O
sent196 levels O
sent196 or O
sent196 electroencephalographic O
sent196 findings O
sent197 Methylphenidate T
sent197 benefited O
sent197 70 O
sent197 % O
sent197 of O
sent197 children O
sent197 according O
sent197 to O
sent197 parental O
sent197 report O
sent197 ; O
sent197 methylphenidate T
sent197 also O
sent197 enhanced O
sent197 performance O
sent197 on O
sent197 the O
sent197 CPT O
sent198 Side O
sent198 effects O
sent198 of O
sent198 methylphenidate T
sent198 were O
sent198 mild O
sent198 and O
sent198 transient O
sent199 CONCLUSION O
sent199 : O
sent199 Methylphenidate T
sent199 is O
sent199 effective O
sent199 in O
sent199 treating O
sent199 children O
sent199 with O
sent199 epilepsy D
sent199 and O
sent199 ADHD D
sent199 and O
sent199 safe O
sent199 in O
sent199 children O
sent199 who O
sent199 are O
sent199 seizure O
sent199 free O
sent200 Caution O
sent200 is O
sent200 warranted O
sent200 for O
sent200 those O
sent200 still O
sent200 having O
sent200 seizures O
sent200 while O
sent200 receiving O
sent200 AED O
sent200 therapy O
sent201 The O
sent201 temporal O
sent201 properties O
sent201 of O
sent201 semantic O
sent201 and O
sent201 phonological O
sent201 processes O
sent201 in O
sent201 speech O
sent201 production O
sent201 were O
sent201 investigated O
sent201 in O
sent201 a O
sent201 new O
sent201 experimental O
sent201 paradigm O
sent201 using O
sent201 movement-related O
sent201 brain O
sent201 potentials O
sent202 The O
sent202 main O
sent202 experimental O
sent202 task O
sent202 was O
sent202 picture O
sent202 naming O
sent203 In O
sent203 addition O
sent203 , O
sent203 a O
sent203 2-choice O
sent203 reaction O
sent203 go/no-go O
sent203 procedure O
sent203 was O
sent203 included O
sent203 , O
sent203 involving O
sent203 a O
sent203 semantic O
sent203 and O
sent203 a O
sent203 phonological O
sent203 categorization O
sent203 of O
sent203 the O
sent203 picture O
sent203 name O
sent204 Lateralized O
sent204 readiness O
sent204 potentials O
sent204 ( O
sent204 LRPs O
sent204 ) O
sent204 were O
sent204 derived O
sent204 to O
sent204 test O
sent204 whether O
sent204 semantic O
sent204 and O
sent204 phonological O
sent204 information O
sent204 activated O
sent204 motor O
sent204 processes O
sent204 at O
sent204 separate O
sent204 moments O
sent204 in O
sent204 time O
sent205 An O
sent205 LRP O
sent205 was O
sent205 only O
sent205 observed O
sent205 on O
sent205 no-go O
sent205 trials O
sent205 when O
sent205 the O
sent205 semantic O
sent205 ( O
sent205 not O
sent205 the O
sent205 phonological O
sent205 ) O
sent205 decision O
sent205 determined O
sent205 the O
sent205 response O
sent205 hand O
sent206 Varying O
sent206 the O
sent206 position O
sent206 of O
sent206 the O
sent206 critical O
sent206 phoneme O
sent206 in O
sent206 the O
sent206 picture O
sent206 name O
sent206 did O
sent206 not O
sent206 affect O
sent206 the O
sent206 onset O
sent206 of O
sent206 the O
sent206 LRP O
sent206 but O
sent206 rather O
sent206 influenced O
sent206 when O
sent206 the O
sent206 LRP O
sent206 began O
sent206 to O
sent206 differ O
sent206 on O
sent206 go O
sent206 and O
sent206 no-go O
sent206 trials O
sent206 and O
sent206 allowed O
sent206 the O
sent206 duration O
sent206 of O
sent206 phonological O
sent206 encoding O
sent206 of O
sent206 a O
sent206 word O
sent206 to O
sent206 be O
sent206 estimated O
sent207 These O
sent207 results O
sent207 provide O
sent207 electrophysiological O
sent207 evidence O
sent207 for O
sent207 early O
sent207 semantic O
sent207 activation O
sent207 and O
sent207 later O
sent207 phonological O
sent207 encoding O
sent208 The O
sent208 effects O
sent208 of O
sent208 alanine O
sent208 and O
sent208 glycine O
sent208 substitution O
sent208 for O
sent208 tryptophan O
sent208 upon O
sent208 the O
sent208 species O
sent208 heterogeneity O
sent208 of O
sent208 gramicidin O
sent208 A O
sent208 analogs O
sent208 incorporated O
sent208 into O
sent208 SDS O
sent208 micelles O
sent208 have O
sent208 been O
sent208 investigated O
sent209 The O
sent209 sequential O
sent209 replacement O
sent209 of O
sent209 the O
sent209 four O
sent209 tryptophan O
sent209 residues O
sent209 in O
sent209 gramicidin O
sent209 A O
sent209 at O
sent209 positions O
sent209 15 O
sent209 , O
sent209 13 O
sent209 , O
sent209 11 O
sent209 , O
sent209 and O
sent209 9 O
sent209 with O
sent209 glycine O
sent209 showed O
sent209 that O
sent209 there O
sent209 was O
sent209 no O
sent209 detectable O
sent209 effect O
sent209 at O
sent209 position O
sent209 15 O
sent209 but O
sent209 increasing O
sent209 heterogeneity O
sent209 of O
sent209 species O
sent209 in O
sent209 the O
sent209 micelles O
sent209 proceeding O
sent209 toward O
sent209 the O
sent209 interior O
sent209 of O
sent209 the O
sent209 micelle O
sent209 at O
sent209 position O
sent209 9 O
sent210 The O
sent210 replacement O
sent210 of O
sent210 tryptophan O
sent210 at O
sent210 positions O
sent210 15 O
sent210 and O
sent210 9 O
sent210 with O
sent210 alanine O
sent210 was O
sent210 found O
sent210 to O
sent210 produce O
sent210 more O
sent210 species O
sent210 heterogeneity O
sent210 than O
sent210 found O
sent210 with O
sent210 glycine O
sent210 substitution O
sent210 at O
sent210 the O
sent210 same O
sent210 positions O
sent211 An O
sent211 increase O
sent211 in O
sent211 the O
sent211 SDS O
sent211 concentration O
sent211 reduces O
sent211 the O
sent211 number O
sent211 of O
sent211 different O
sent211 species O
sent211 present O
sent211 in O
sent211 micelles O
sent212 With O
sent212 the O
sent212 Gly-11 O
sent212 , O
sent212 Gly-13 O
sent212 , O
sent212 and O
sent212 Gly-15 O
sent212 analogs O
sent212 , O
sent212 the O
sent212 increase O
sent212 in O
sent212 SDS O
sent212 concentration O
sent212 results O
sent212 in O
sent212 the O
sent212 formation O
sent212 of O
sent212 a O
sent212 single O
sent212 species O
sent212 ; O
sent212 however O
sent212 , O
sent212 for O
sent212 the O
sent212 Gly-9 O
sent212 , O
sent212 Ala-9 O
sent212 , O
sent212 and O
sent212 Ala-15 O
sent212 analogs O
sent212 , O
sent212 heterogeneity O
sent212 remains O
sent213 Molecular O
sent213 dynamics O
sent213 in O
sent213 torsion-angle O
sent213 space O
sent213 was O
sent213 applied O
sent213 to O
sent213 nuclear O
sent213 magnetic O
sent213 resonance O
sent213 structure O
sent213 calculation O
sent213 using O
sent213 nuclear O
sent213 Overhauser O
sent213 effect-derived O
sent213 distances O
sent213 and O
sent213 J-coupling-constant-derived O
sent213 dihedral O
sent213 angle O
sent213 restraints O
sent214 Compared O
sent214 to O
sent214 two O
sent214 other O
sent214 commonly O
sent214 used O
sent214 algorithms O
sent214 , O
sent214 molecular O
sent214 dynamics O
sent214 in O
sent214 Cartesian O
sent214 space O
sent214 and O
sent214 metric-matrix O
sent214 geometry O
sent214 combined O
sent214 with O
sent214 Cartesian O
sent214 molecular O
sent214 dynamics O
sent214 , O
sent214 the O
sent214 method O
sent214 shows O
sent214 increased O
sent214 computational O
sent214 efficiency O
sent214 and O
sent214 success O
sent214 rate O
sent214 for O
sent214 large O
sent214 proteins O
sent214 , O
sent214 and O
sent214 it O
sent214 shows O
sent214 a O
sent214 dramatically O
sent214 increased O
sent214 radius O
sent214 of O
sent214 convergence O
sent214 for O
sent214 DNA O
sent215 The O
sent215 torsion-angle O
sent215 molecular O
sent215 dynamics O
sent215 algorithm O
sent215 starts O
sent215 from O
sent215 an O
sent215 extended O
sent215 strand O
sent215 conformation O
sent215 and O
sent215 proceeds O
sent215 in O
sent215 four O
sent215 stages O
sent215 : O
sent215 high-temperature O
sent215 torsion-angle O
sent215 molecular O
sent215 dynamics O
sent215 , O
sent215 slow-cooling O
sent215 torsion-angle O
sent215 molecular O
sent215 dynamics O
sent215 , O
sent215 Cartesian O
sent215 molecular O
sent215 dynamics O
sent215 , O
sent215 and O
sent215 minimization O
sent216 Tests O
sent216 were O
sent216 carried O
sent216 out O
sent216 using O
sent216 experimental O
sent216 NMR O
sent216 data O
sent216 for O
sent216 protein O
sent216 G O
sent216 , O
sent216 interleukin-8 O
sent216 , O
sent216 villin O
sent216 14T O
sent216 , O
sent216 and O
sent216 a O
sent216 12 O
sent216 base-pair O
sent216 duplex O
sent216 of O
sent216 DNA O
sent216 , O
sent216 and O
sent216 simulated O
sent216 NMR O
sent216 data O
sent216 for O
sent216 bovine O
sent216 pancreatic O
sent216 trypsin O
sent216 inhibitor O
sent217 For O
sent217 villin O
sent217 14T O
sent217 , O
sent217 a O
sent217 monomer O
sent217 consisting O
sent217 of O
sent217 126 O
sent217 residues O
sent217 , O
sent217 structure O
sent217 determination O
sent217 by O
sent217 torsion-angle O
sent217 molecular O
sent217 dynamics O
sent217 has O
sent217 a O
sent217 success O
sent217 rate O
sent217 of O
sent217 85 O
sent217 % O
sent217 , O
sent217 a O
sent217 more O
sent217 than O
sent217 twofold O
sent217 improvement O
sent217 over O
sent217 other O
sent217 methods O
sent218 In O
sent218 the O
sent218 case O
sent218 of O
sent218 the O
sent218 12 O
sent218 base-pair O
sent218 DNA O
sent218 duplex O
sent218 , O
sent218 torsion-angle O
sent218 molecular O
sent218 dynamics O
sent218 had O
sent218 a O
sent218 success O
sent218 rate O
sent218 of O
sent218 52 O
sent218 % O
sent218 while O
sent218 Cartesian O
sent218 molecular O
sent218 dynamics O
sent218 and O
sent218 metric-matrix O
sent218 distance O
sent218 geometry O
sent218 always O
sent218 failed O
sent219 The O
sent219 wavelet-transform O
sent219 method O
sent219 is O
sent219 used O
sent219 to O
sent219 quantify O
sent219 the O
sent219 magnetic O
sent219 resonance O
sent219 spectroscopy O
sent219 ( O
sent219 MRS O
sent219 ) O
sent219 parameters O
sent219 : O
sent219 chemical O
sent219 shift O
sent219 , O
sent219 apparent O
sent219 relaxation O
sent219 time O
sent219 T2 O
sent219 , O
sent219 resonance O
sent219 amplitude O
sent219 , O
sent219 and O
sent219 phase O
sent220 Wavelet O
sent220 transformation O
sent220 is O
sent220 a O
sent220 time-frequency O
sent220 representation O
sent220 which O
sent220 separates O
sent220 each O
sent220 component O
sent220 from O
sent220 the O
sent220 FID O
sent220 , O
sent220 then O
sent220 successively O
sent220 quantifies O
sent220 it O
sent220 and O
sent220 subtracts O
sent220 it O
sent220 from O
sent220 the O
sent220 raw O
sent220 signal O
sent221 Two O
sent221 iterative O
sent221 procedures O
sent221 have O
sent221 been O
sent221 developed O
sent222 They O
sent222 have O
sent222 been O
sent222 combined O
sent222 with O
sent222 a O
sent222 nonlinear O
sent222 regression O
sent222 analysis O
sent222 method O
sent222 and O
sent222 tested O
sent222 on O
sent222 both O
sent222 simulated O
sent222 and O
sent222 real O
sent222 sets O
sent222 of O
sent222 biomedical O
sent222 MRS O
sent222 data O
sent222 selected O
sent222 with O
sent222 respect O
sent222 to O
sent222 the O
sent222 main O
sent222 problems O
sent222 usually O
sent222 encountered O
sent222 in O
sent222 quantifying O
sent222 biomedical O
sent222 MRS O
sent222 , O
sent222 specifically O
sent222 `` O
sent222 chemical O
sent222 noise O
sent222 , O
sent222 '' O
sent222 resulting O
sent222 from O
sent222 overlapping O
sent222 resonances O
sent222 , O
sent222 and O
sent222 baseline O
sent222 distortion O
sent223 The O
sent223 results O
sent223 indicate O
sent223 that O
sent223 the O
sent223 wavelet-transform O
sent223 method O
sent223 can O
sent223 provide O
sent223 efficient O
sent223 and O
sent223 accurate O
sent223 quantification O
sent223 of O
sent223 MRS O
sent223 data O
sent224 BACKGROUND O
sent224 : O
sent224 Antiplatelet T
sent224 therapy T
sent224 with T
sent224 aspirin T
sent224 and T
sent224 systematic T
sent224 anticoagulation T
sent224 with T
sent224 warfarin T
sent224 reduce O
sent224 cardiovascular D
sent224 morbidity D
sent224 and D
sent224 mortality D
sent224 after D
sent224 myocardial D
sent224 infarction D
sent224 when O
sent224 given O
sent224 alone O
sent225 In O
sent225 the O
sent225 Coumadin O
sent225 Aspirin O
sent225 Reinfarction O
sent225 Study O
sent225 ( O
sent225 CARS O
sent225 ) O
sent225 , O
sent225 we O
sent225 aimed O
sent225 to O
sent225 find O
sent225 out O
sent225 whether O
sent225 a O
sent225 combination O
sent225 of O
sent225 low-dose O
sent225 warfarin T
sent225 and O
sent225 low-dose T
sent225 aspirin T
sent225 would O
sent225 give O
sent225 superior O
sent225 results O
sent225 to O
sent225 standard O
sent225 aspirin T
sent225 monotherapy T
sent225 without O
sent225 excessive O
sent225 bleeding O
sent225 risk O
sent226 METHODS O
sent226 : O
sent226 We O
sent226 used O
sent226 a O
sent226 randomised O
sent226 double-blind O
sent226 study O
sent226 design O
sent227 At O
sent227 293 O
sent227 sites O
sent227 , O
sent227 we O
sent227 randomly O
sent227 assigned O
sent227 8803 O
sent227 patients O
sent227 who O
sent227 had O
sent227 had O
sent227 myocardial D
sent227 infarction D
sent227 , O
sent227 treatment O
sent227 with O
sent227 160 T
sent227 mg T
sent227 aspirin T
sent227 , O
sent227 3 T
sent227 mg T
sent227 warfarin T
sent227 with T
sent227 80 T
sent227 mg T
sent227 aspirin T
sent227 , O
sent227 or O
sent227 1 T
sent227 mg T
sent227 warfarin T
sent227 with T
sent227 80 T
sent227 mg T
sent227 aspirin T
sent228 Patients O
sent228 took O
sent228 a O
sent228 single O
sent228 tablet O
sent228 daily O
sent228 , O
sent228 and O
sent228 attended O
sent228 for O
sent228 prothrombin O
sent228 time O
sent228 ( O
sent228 PT O
sent228 ) O
sent228 measurements O
sent228 at O
sent228 weeks O
sent228 1 O
sent228 , O
sent228 2 O
sent228 , O
sent228 3 O
sent228 , O
sent228 4 O
sent228 , O
sent228 6 O
sent228 , O
sent228 and O
sent228 12 O
sent228 , O
sent228 and O
sent228 then O
sent228 every O
sent228 3 O
sent228 months O
sent229 Patients O
sent229 were O
sent229 followed O
sent229 up O
sent229 for O
sent229 a O
sent229 maximum O
sent229 of O
sent229 33 O
sent229 months O
sent229 ( O
sent229 median O
sent229 14 O
sent229 months O
sent229 ) O
sent230 FINDINGS O
sent230 : O
sent230 The O
sent230 primary O
sent230 event O
sent230 was O
sent230 first O
sent230 occurrence O
sent230 of O
sent230 reinfarction O
sent230 , O
sent230 non-fatal O
sent230 ischaemic D
sent230 stroke D
sent230 , O
sent230 or O
sent230 cardiovascular O
sent230 death O
sent231 1-year O
sent231 life-table O
sent231 estimates O
sent231 for O
sent231 the O
sent231 primary O
sent231 event O
sent231 were O
sent231 8.6 O
sent231 % O
sent231 ( O
sent231 95 O
sent231 % O
sent231 CI O
sent231 7.6-9.6 O
sent231 ) O
sent231 for O
sent231 160 O
sent231 mg O
sent231 aspirin T
sent231 , O
sent231 8.4 O
sent231 % O
sent231 ( O
sent231 7.4-9.4 O
sent231 ) O
sent231 for O
sent231 3 O
sent231 mg O
sent231 warfarin T
sent231 with O
sent231 80 O
sent231 mg O
sent231 aspirin T
sent231 , O
sent231 and O
sent231 8.8 O
sent231 % O
sent231 ( O
sent231 7.6-10 O
sent231 ) O
sent231 for O
sent231 1 O
sent231 mg O
sent231 warfarin T
sent231 with O
sent231 80 O
sent231 mg O
sent231 aspirin T
sent232 Primary O
sent232 comparisons O
sent232 were O
sent232 done O
sent232 with O
sent232 all O
sent232 follow-up O
sent232 data O
sent233 The O
sent233 relative O
sent233 risk O
sent233 of O
sent233 the O
sent233 primary O
sent233 event O
sent233 for O
sent233 the O
sent233 160 O
sent233 mg O
sent233 aspirin O
sent233 group O
sent233 compared O
sent233 with O
sent233 the O
sent233 3 O
sent233 mg O
sent233 warfarin O
sent233 with O
sent233 80 O
sent233 mg O
sent233 aspirin O
sent233 group O
sent233 was O
sent233 0.95 O
sent233 ( O
sent233 0.81-1.12 O
sent233 , O
sent233 p O
sent233 = O
sent233 0.57 O
sent233 ) O
sent234 For O
sent234 spontaneous O
sent234 major O
sent234 haemorrhage O
sent234 ( O
sent234 not O
sent234 procedure O
sent234 related O
sent234 ) O
sent234 , O
sent234 1-year O
sent234 life-table O
sent234 estimates O
sent234 were O
sent234 0.74 O
sent234 % O
sent234 ( O
sent234 0.43-1.1 O
sent234 ) O
sent234 in O
sent234 the O
sent234 160 O
sent234 mg O
sent234 aspirin O
sent234 group O
sent234 and O
sent234 1.4 O
sent234 % O
sent234 ( O
sent234 0.94-1.8 O
sent234 ) O
sent234 in O
sent234 the O
sent234 3 O
sent234 mg O
sent234 warfarin O
sent234 with O
sent234 80 O
sent234 mg O
sent234 aspirin O
sent234 group O
sent234 ( O
sent234 p O
sent234 = O
sent234 0.014 O
sent234 log O
sent234 rank O
sent234 on O
sent234 follow-up O
sent234 ) O
sent235 For O
sent235 the O
sent235 3382 O
sent235 patients O
sent235 assigned O
sent235 3 O
sent235 mg O
sent235 warfarin T
sent235 with O
sent235 80 O
sent235 mg O
sent235 aspirin T
sent235 , O
sent235 the O
sent235 INR O
sent235 results O
sent235 were O
sent235 : O
sent235 at O
sent235 week O
sent235 1 O
sent235 ( O
sent235 n O
sent235 = O
sent235 2985 O
sent235 ) O
sent235 median O
sent235 1.51 O
sent235 ( O
sent235 IQR O
sent235 1.23-2.13 O
sent235 ) O
sent235 ; O
sent235 at O
sent235 week O
sent235 4 O
sent235 ( O
sent235 n O
sent235 = O
sent235 2701 O
sent235 ) O
sent235 1.27 O
sent235 ( O
sent235 1.13-1.64 O
sent235 ) O
sent235 ; O
sent235 at O
sent235 month O
sent235 6 O
sent235 ( O
sent235 n O
sent235 = O
sent235 2145 O
sent235 ) O
sent235 1.19 O
sent235 ( O
sent235 1.08-1.44 O
sent235 ) O
sent236 INTERPRETATION O
sent236 : O
sent236 Low O
sent236 , O
sent236 fixed-dose O
sent236 warfarin T
sent236 ( T
sent236 1 T
sent236 mg T
sent236 or T
sent236 3 T
sent236 mg T
sent236 ) T
sent236 combined T
sent236 with T
sent236 low-dose T
sent236 aspirin T
sent236 ( T
sent236 80 T
sent236 mg T
sent236 ) T
sent236 in O
sent236 patients O
sent236 who O
sent236 have O
sent236 had O
sent236 myocardial D
sent236 infarction D
sent236 does O
sent236 not O
sent236 provide O
sent236 clinical O
sent236 benefit O
sent236 beyond O
sent236 that O
sent236 achievable O
sent236 with O
sent236 160 O
sent236 mg O
sent236 aspirin T
sent236 monotherapy T
sent237 BACKGROUND O
sent237 : O
sent237 There O
sent237 is O
sent237 serological O
sent237 evidence O
sent237 for O
sent237 an O
sent237 association O
sent237 between O
sent237 Chlamydia D
sent237 pneumoniae D
sent237 and O
sent237 coronary D
sent237 heart D
sent237 disease D
sent238 We O
sent238 investigated O
sent238 the O
sent238 hypothesis O
sent238 that O
sent238 an T
sent238 antichlamydial T
sent238 macrolide T
sent238 antibiotic T
sent238 , T
sent238 roxithromycin T
sent238 , O
sent238 can O
sent238 prevent O
sent238 or O
sent238 reduce O
sent238 recurrent O
sent238 major O
sent238 ischaemic O
sent238 events O
sent238 in O
sent238 patients O
sent238 with O
sent238 unstable D
sent238 angina D
sent239 METHODS O
sent239 : O
sent239 The O
sent239 effect O
sent239 of O
sent239 roxithromycin T
sent239 was O
sent239 assessed O
sent239 in O
sent239 a O
sent239 double-blind O
sent239 , O
sent239 randomised O
sent239 , O
sent239 prospective O
sent239 , O
sent239 multicentre O
sent239 , O
sent239 parallel-group O
sent239 , O
sent239 placebo-controlled O
sent239 pilot O
sent239 study O
sent239 of O
sent239 202 O
sent239 patients O
sent239 with O
sent239 unstable D
sent239 angina D
sent239 or O
sent239 non-Q-wave D
sent239 myocardial D
sent239 infarction D
sent240 Patients O
sent240 were O
sent240 randomly O
sent240 assigned O
sent240 either O
sent240 roxithromycin T
sent240 150 O
sent240 mg O
sent240 orally O
sent240 twice O
sent240 a O
sent240 day O
sent240 ( O
sent240 n O
sent240 = O
sent240 102 O
sent240 ) O
sent240 or O
sent240 placebo O
sent240 orally O
sent240 twice O
sent240 a O
sent240 day O
sent240 ( O
sent240 n O
sent240 = O
sent240 100 O
sent240 ) O
sent241 The O
sent241 treatment O
sent241 was O
sent241 for O
sent241 30 O
sent241 days O
sent242 Patients O
sent242 were O
sent242 followed O
sent242 up O
sent242 for O
sent242 6 O
sent242 months O
sent243 We O
sent243 report O
sent243 the O
sent243 primary O
sent243 clinical O
sent243 endpoints O
sent243 ( O
sent243 cardiac D
sent243 ischaemic D
sent243 death D
sent243 , O
sent243 myocardial D
sent243 infarction D
sent243 , O
sent243 and O
sent243 severe O
sent243 recurrent O
sent243 ischaemia D
sent243 ) O
sent243 , O
sent243 assessed O
sent243 at O
sent243 day O
sent243 31 O
sent243 , O
sent243 in O
sent243 202 O
sent243 patients O
sent243 on O
sent243 an O
sent243 intention-to-treat O
sent243 basis O
sent244 FINDINGS O
sent244 : O
sent244 A O
sent244 statistically O
sent244 significant O
sent244 reduction O
sent244 in O
sent244 the O
sent244 primary O
sent244 composite O
sent244 triple O
sent244 endpoint O
sent244 rates O
sent244 was O
sent244 observed O
sent244 in O
sent244 the O
sent244 roxithromycin O
sent244 group O
sent244 : O
sent244 p O
sent244 = O
sent244 0.032 O
sent245 The O
sent245 rate O
sent245 of O
sent245 severe O
sent245 recurrent O
sent245 ischaemia O
sent245 , O
sent245 myocardial O
sent245 infarction O
sent245 , O
sent245 and O
sent245 ischaemic O
sent245 death O
sent245 was O
sent245 5.4 O
sent245 % O
sent245 , O
sent245 2.2 O
sent245 % O
sent245 , O
sent245 and O
sent245 2.2 O
sent245 % O
sent245 in O
sent245 the O
sent245 placebo O
sent245 group O
sent245 and O
sent245 1.1 O
sent245 % O
sent245 , O
sent245 0 O
sent245 % O
sent245 , O
sent245 and O
sent245 0 O
sent245 % O
sent245 , O
sent245 in O
sent245 the O
sent245 roxithromycin O
sent245 group O
sent245 , O
sent245 respectively O
sent246 No O
sent246 major O
sent246 drug-related O
sent246 adverse O
sent246 effects O
sent246 were O
sent246 observed O
sent247 INTERPRETATION O
sent247 : O
sent247 Antichlamydial T
sent247 antibiotics T
sent247 may O
sent247 be O
sent247 useful O
sent247 in O
sent247 therapeutic O
sent247 intervention O
sent247 in O
sent247 addition O
sent247 to O
sent247 standard O
sent247 medication O
sent247 in O
sent247 patients O
sent247 with O
sent247 coronary-artery D
sent247 disease D
sent248 Large-scale O
sent248 trials O
sent248 are O
sent248 needed O
sent248 to O
sent248 confirm O
sent248 these O
sent248 preliminary O
sent248 observations O
sent249 BACKGROUND O
sent249 : O
sent249 Stage D
sent249 Ib D
sent249 and D
sent249 IIa D
sent249 cervical D
sent249 carcinoma D
sent249 can O
sent249 be O
sent249 cured O
sent249 by O
sent249 radical T
sent249 surgery T
sent249 or O
sent249 radiotherapy T
sent250 These O
sent250 two O
sent250 procedures O
sent250 are O
sent250 equally O
sent250 effective O
sent250 , O
sent250 but O
sent250 differ O
sent250 in O
sent250 associated O
sent250 morbidity O
sent250 and O
sent250 type O
sent250 of O
sent250 complications O
sent251 In O
sent251 this O
sent251 prospective O
sent251 randomised O
sent251 trial O
sent251 of O
sent251 radiotherapy T
sent251 versus O
sent251 surgery T
sent251 , O
sent251 our O
sent251 aim O
sent251 was O
sent251 to O
sent251 assess O
sent251 the O
sent251 5-year O
sent251 survival O
sent251 and O
sent251 the O
sent251 rate O
sent251 and O
sent251 pattern O
sent251 of O
sent251 complications O
sent251 and O
sent251 recurrences O
sent251 associated O
sent251 with O
sent251 each O
sent251 treatment O
sent252 METHODS O
sent252 : O
sent252 Between O
sent252 September O
sent252 , O
sent252 1986 O
sent252 , O
sent252 and O
sent252 December O
sent252 , O
sent252 1991 O
sent252 , O
sent252 469 O
sent252 women O
sent252 with O
sent252 newly O
sent252 diagnosed O
sent252 stage O
sent252 Ib O
sent252 and O
sent252 IIa O
sent252 cervical T
sent252 carcinoma T
sent252 were O
sent252 referred O
sent252 to O
sent252 our O
sent252 institute O
sent253 343 O
sent253 eligible O
sent253 patients O
sent253 were O
sent253 randomised O
sent253 : O
sent253 172 O
sent253 to O
sent253 surgery T
sent253 and O
sent253 171 O
sent253 to O
sent253 radical O
sent253 radiotherapy T
sent254 Adjuvant O
sent254 radiotherapy O
sent254 was O
sent254 delivered O
sent254 after O
sent254 surgery O
sent254 for O
sent254 women O
sent254 with O
sent254 surgical O
sent254 stage O
sent254 pT2b O
sent254 or O
sent254 greater O
sent254 , O
sent254 less O
sent254 than O
sent254 3 O
sent254 mm O
sent254 of O
sent254 safe O
sent254 cervical O
sent254 stroma O
sent254 , O
sent254 cut-through O
sent254 , O
sent254 or O
sent254 positive O
sent254 nodes O
sent255 The O
sent255 primary O
sent255 outcome O
sent255 measures O
sent255 were O
sent255 5-year O
sent255 survival O
sent255 and O
sent255 the O
sent255 rate O
sent255 of O
sent255 complications O
sent256 The O
sent256 analysis O
sent256 of O
sent256 survival O
sent256 and O
sent256 recurrence O
sent256 was O
sent256 by O
sent256 intention O
sent256 to O
sent256 treat O
sent256 and O
sent256 analysis O
sent256 of O
sent256 complications O
sent256 was O
sent256 by O
sent256 treatment O
sent256 delivered O
sent257 FINDINGS O
sent257 : O
sent257 170 O
sent257 patients O
sent257 in O
sent257 the O
sent257 surgery O
sent257 group O
sent257 and O
sent257 167 O
sent257 in O
sent257 the O
sent257 radiotherapy O
sent257 group O
sent257 were O
sent257 included O
sent257 in O
sent257 the O
sent257 intention-to-treat O
sent257 analysis O
sent257 ; O
sent257 scheduled O
sent257 treatment O
sent257 was O
sent257 delivered O
sent257 to O
sent257 169 O
sent257 and O
sent257 158 O
sent257 women O
sent257 , O
sent257 respectively O
sent257 , O
sent257 62 O
sent257 of O
sent257 114 O
sent257 women O
sent257 with O
sent257 cervical O
sent257 diameters O
sent257 of O
sent257 4 O
sent257 cm O
sent257 or O
sent257 smaller O
sent257 and O
sent257 46 O
sent257 of O
sent257 55 O
sent257 with O
sent257 diameters O
sent257 larger O
sent257 than O
sent257 4 O
sent257 cm O
sent257 received O
sent257 adjuvant O
sent257 therapy O
sent258 After O
sent258 a O
sent258 median O
sent258 follow-up O
sent258 of O
sent258 87 O
sent258 ( O
sent258 range O
sent258 57-120 O
sent258 ) O
sent258 months O
sent258 , O
sent258 5-year O
sent258 overall O
sent258 and O
sent258 disease-free O
sent258 survival O
sent258 were O
sent258 identical O
sent258 in O
sent258 the O
sent258 surgery O
sent258 and O
sent258 radiotherapy O
sent258 groups O
sent258 ( O
sent258 83 O
sent258 % O
sent258 and O
sent258 74 O
sent258 % O
sent258 , O
sent258 respectively O
sent258 , O
sent258 for O
sent258 both O
sent258 groups O
sent258 ) O
sent258 , O
sent258 86 O
sent258 women O
sent258 developed O
sent258 recurrent O
sent258 disease O
sent258 : O
sent258 42 O
sent258 ( O
sent258 25 O
sent258 % O
sent258 ) O
sent258 in O
sent258 the O
sent258 surgery O
sent258 group O
sent258 and O
sent258 44 O
sent258 ( O
sent258 26 O
sent258 % O
sent258 ) O
sent258 in O
sent258 the O
sent258 radiotherapy O
sent258 group O
sent259 Significant O
sent259 factors O
sent259 for O
sent259 survival O
sent259 in O
sent259 univariate O
sent259 and O
sent259 multivariate O
sent259 analyses O
sent259 were O
sent259 : O
sent259 cervical O
sent259 diameter O
sent259 , O
sent259 positive O
sent259 lymphangiography O
sent259 , O
sent259 and O
sent259 adeno-carcinomatous O
sent259 histotype O
sent260 48 O
sent260 ( O
sent260 28 O
sent260 % O
sent260 ) O
sent260 surgery-group O
sent260 patients O
sent260 had O
sent260 severe O
sent260 morbidity O
sent260 compared O
sent260 with O
sent260 19 O
sent260 ( O
sent260 12 O
sent260 % O
sent260 ) O
sent260 radiotherapy-group O
sent260 patients O
sent260 ( O
sent260 p O
sent260 = O
sent260 0.0004 O
sent260 ) O
sent261 INTERPRETATION O
sent261 : O
sent261 There O
sent261 is O
sent261 no O
sent261 treatment O
sent261 of O
sent261 choice O
sent261 for O
sent261 early-stage O
sent261 cervical D
sent261 carcinoma D
sent261 in O
sent261 terms O
sent261 of O
sent261 overall O
sent261 or O
sent261 disease-free O
sent261 survival O
sent262 The O
sent262 combination O
sent262 of O
sent262 surgery D
sent262 and O
sent262 radiotherapy D
sent262 has O
sent262 the O
sent262 worst O
sent262 morbidity O
sent262 , O
sent262 especially O
sent262 urological O
sent262 complications O
sent263 The O
sent263 optimum O
sent263 therapy O
sent263 for O
sent263 each O
sent263 patient O
sent263 should O
sent263 take O
sent263 account O
sent263 of O
sent263 clinical O
sent263 factors O
sent263 such O
sent263 as O
sent263 menopausal O
sent263 status O
sent263 , O
sent263 age O
sent263 , O
sent263 medical O
sent263 illness O
sent263 , O
sent263 histological O
sent263 type O
sent263 , O
sent263 and O
sent263 cervical O
sent263 diameter O
sent263 to O
sent263 yield O
sent263 the O
sent263 best O
sent263 cure O
sent263 with O
sent263 minimum O
sent263 complications O
sent264 Today O
sent264 's O
sent264 technology O
sent264 links O
sent264 health O
sent264 care O
sent264 providers O
sent264 and O
sent264 patients O
sent264 across O
sent264 town O
sent264 , O
sent264 in O
sent264 the O
sent264 next O
sent264 state O
sent264 or O
sent264 even O
sent264 another O
sent264 country O
sent265 Nursing O
sent265 across O
sent265 state O
sent265 lines O
sent265 poses O
sent265 complications O
sent265 : O
sent265 state-bound O
sent265 regulatory O
sent265 and O
sent265 licensure O
sent265 issues O
sent266 This O
sent266 article O
sent266 discusses O
sent266 many O
sent266 of O
sent266 the O
sent266 nutritional O
sent266 topics O
sent266 important O
sent266 to O
sent266 the O
sent266 intensivist O
sent267 Nutritional O
sent267 assessment O
sent267 , O
sent267 substrate O
sent267 immunonutrition O
sent267 , O
sent267 and O
sent267 disease O
sent267 specific O
sent267 issues O
sent267 are O
sent267 presented O
sent268 Early O
sent268 introduction O
sent268 of O
sent268 enteral O
sent268 feeds O
sent268 and O
sent268 the O
sent268 use O
sent268 of O
sent268 nutritional O
sent268 modulation O
sent268 are O
sent268 emphasized O
sent269 PROBLEM O
sent269 : O
sent269 To O
sent269 compare O
sent269 the O
sent269 expression O
sent269 by O
sent269 T-lymphocytes O
sent269 of O
sent269 an O
sent269 immunomodulatory O
sent269 protein O
sent269 known O
sent269 as O
sent269 progesterone-induced O
sent269 blocking O
sent269 factor O
sent269 ( O
sent269 PIBF O
sent269 ) O
sent269 in O
sent269 conception O
sent269 versus O
sent269 non-conception O
sent269 cycles O
sent269 even O
sent269 when O
sent269 there O
sent269 has O
sent269 been O
sent269 definite O
sent269 fertilization O
sent269 and O
sent269 embryo O
sent269 formation O
sent270 METHOD O
sent270 : O
sent270 PIBF O
sent270 expression O
sent270 on O
sent270 T O
sent270 lymphocytes O
sent270 was O
sent270 measured O
sent270 using O
sent270 an O
sent270 immunohistochemical O
sent270 method O
sent270 with O
sent270 a O
sent270 PIBF-specific O
sent270 polyclonal O
sent270 antibody O
sent271 These O
sent271 levels O
sent271 were O
sent271 determined O
sent271 in O
sent271 patients O
sent271 undergoing O
sent271 three O
sent271 types O
sent271 of O
sent271 therapy O
sent271 : O
sent271 non-in O
sent271 vitro O
sent271 fertilization O
sent271 ( O
sent271 IVF O
sent271 ) O
sent271 , O
sent271 IVF-embryo O
sent271 transfer O
sent271 ( O
sent271 ET O
sent271 ) O
sent271 , O
sent271 and O
sent271 frozen O
sent271 ET O
sent272 Sera O
sent272 were O
sent272 drawn O
sent272 12 O
sent272 days O
sent272 from O
sent272 ovulation O
sent272 in O
sent272 non-IVF O
sent272 cycles O
sent272 or O
sent272 9 O
sent272 days O
sent272 after O
sent272 ET O
sent272 and O
sent272 were O
sent272 assayed O
sent272 for O
sent272 PIBF O
sent272 and O
sent272 beta O
sent272 human O
sent272 chorionic O
sent272 gondotropin O
sent273 Comparison O
sent273 of O
sent273 the O
sent273 frequency O
sent273 of O
sent273 lymphocyte O
sent273 expression O
sent273 of O
sent273 PIBF O
sent273 in O
sent273 pregnant O
sent273 versus O
sent273 non-pregnant O
sent273 women O
sent273 were O
sent273 made O
sent274 RESULTS O
sent274 : O
sent274 PIBF O
sent274 was O
sent274 detected O
sent274 in O
sent274 29.5 O
sent274 % O
sent274 of O
sent274 non-pregnant O
sent274 women O
sent274 and O
sent274 52.5 O
sent274 % O
sent274 of O
sent274 pregnant O
sent274 women O
sent275 There O
sent275 were O
sent275 no O
sent275 differences O
sent275 in O
sent275 PIBF O
sent275 levels O
sent275 by O
sent275 therapy O
sent275 used O
sent275 in O
sent275 non-pregnant O
sent275 cases O
sent275 or O
sent275 in O
sent275 the O
sent275 pregnant O
sent275 group O
sent276 CONCLUSION O
sent276 : O
sent276 These O
sent276 data O
sent276 are O
sent276 consistent O
sent276 with O
sent276 the O
sent276 hypothesis O
sent276 that O
sent276 maternal O
sent276 expression O
sent276 of O
sent276 PIBF O
sent276 in O
sent276 T-lymphocytes O
sent276 soon O
sent276 after O
sent276 trophoblast O
sent276 invasion O
sent276 may O
sent276 depend O
sent276 on O
sent276 successful O
sent276 implantation O
sent277 Many O
sent277 amino O
sent277 acids O
sent277 contain O
sent277 an O
sent277 asymmetric O
sent277 centre O
sent277 , O
sent277 occurring O
sent277 as O
sent277 laevorotatory O
sent277 , O
sent277 L O
sent277 , O
sent277 or O
sent277 dextrorotatory O
sent277 , O
sent277 D O
sent277 , O
sent277 compounds O
sent278 It O
sent278 is O
sent278 generally O
sent278 assumed O
sent278 that O
sent278 abiotic O
sent278 synthesis O
sent278 of O
sent278 amino O
sent278 acids O
sent278 on O
sent278 the O
sent278 early O
sent278 Earth O
sent278 resulted O
sent278 in O
sent278 racemic O
sent278 mixtures O
sent278 ( O
sent278 L- O
sent278 and O
sent278 D-enantiomers O
sent278 in O
sent278 equal O
sent278 abundance O
sent278 ) O
sent279 But O
sent279 the O
sent279 origin O
sent279 of O
sent279 life O
sent279 required O
sent279 , O
sent279 owing O
sent279 to O
sent279 conformational O
sent279 constraints O
sent279 , O
sent279 the O
sent279 almost O
sent279 exclusive O
sent279 selection O
sent279 of O
sent279 either O
sent279 L- O
sent279 or O
sent279 D-enantiomers O
sent279 , O
sent279 and O
sent279 the O
sent279 question O
sent279 of O
sent279 why O
sent279 living O
sent279 systems O
sent279 on O
sent279 the O
sent279 Earth O
sent279 consist O
sent279 of O
sent279 L-enantiomers O
sent279 rather O
sent279 than O
sent279 D-enantiomers O
sent279 is O
sent279 unresolved O
sent280 A O
sent280 substantial O
sent280 fraction O
sent280 of O
sent280 the O
sent280 organic O
sent280 compounds O
sent280 on O
sent280 the O
sent280 early O
sent280 Earth O
sent280 may O
sent280 have O
sent280 been O
sent280 derived O
sent280 from O
sent280 comet O
sent280 and O
sent280 meteorite O
sent280 impacts O
sent281 It O
sent281 has O
sent281 been O
sent281 reported O
sent281 previously O
sent281 that O
sent281 amino O
sent281 acids O
sent281 in O
sent281 the O
sent281 Murchison O
sent281 meteorite O
sent281 exhibit O
sent281 an O
sent281 excess O
sent281 of O
sent281 L-enantiomers O
sent281 , O
sent281 raising O
sent281 the O
sent281 possibility O
sent281 that O
sent281 a O
sent281 similar O
sent281 excess O
sent281 was O
sent281 present O
sent281 in O
sent281 the O
sent281 initial O
sent281 inventory O
sent281 of O
sent281 organic O
sent281 compounds O
sent281 on O
sent281 the O
sent281 Earth O
sent282 The O
sent282 stable O
sent282 carbon O
sent282 isotope O
sent282 compositions O
sent282 of O
sent282 individual O
sent282 amino O
sent282 acids O
sent282 in O
sent282 Murchison O
sent282 support O
sent282 an O
sent282 extraterrestrial O
sent282 origin O
sent282 -- O
sent282 rather O
sent282 than O
sent282 a O
sent282 terrestrial O
sent282 overprint O
sent282 of O
sent282 biological O
sent282 amino O
sent282 acids-although O
sent282 reservations O
sent282 have O
sent282 persisted O
sent283 Here O
sent283 we O
sent283 show O
sent283 that O
sent283 individual O
sent283 amino-acid O
sent283 enantiomers O
sent283 from O
sent283 Murchison O
sent283 are O
sent283 enriched O
sent283 in O
sent283 15N O
sent283 relative O
sent283 to O
sent283 their O
sent283 terrestrial O
sent283 counterparts O
sent283 , O
sent283 so O
sent283 confirming O
sent283 an O
sent283 extraterrestrial O
sent283 source O
sent283 for O
sent283 an O
sent283 L-enantiomer O
sent283 excess O
sent283 in O
sent283 the O
sent283 Solar O
sent283 System O
sent283 that O
sent283 may O
sent283 predate O
sent283 the O
sent283 origin O
sent283 of O
sent283 life O
sent283 on O
sent283 the O
sent283 Earth O
sent284 Home O
sent284 care O
sent284 workers O
sent284 face O
sent284 an O
sent284 increasing O
sent284 risk O
sent284 for O
sent284 workplace O
sent284 violence O
sent285 A O
sent285 proactive O
sent285 preventive O
sent285 approach O
sent285 is O
sent285 presented O
sent285 that O
sent285 suggests O
sent285 strategies O
sent285 to O
sent285 use O
sent285 during O
sent285 the O
sent285 previsit O
sent285 phase O
sent285 , O
sent285 the O
sent285 visit O
sent285 experience O
sent285 , O
sent285 and O
sent285 on O
sent285 an O
sent285 ongoing O
sent285 basis O
sent286 The O
sent286 miracidia O
sent286 of O
sent286 Fasciola O
sent286 hepatica O
sent286 and O
sent286 Trichobilharzia O
sent286 ocellata O
sent286 approach O
sent286 their O
sent286 host O
sent286 snails O
sent286 Lymnaea O
sent286 truncatula O
sent286 and O
sent286 L. O
sent286 stagnalis O
sent286 by O
sent286 increasing O
sent286 their O
sent286 rate O
sent286 of O
sent286 change O
sent286 of O
sent286 direction O
sent286 ( O
sent286 RCD O
sent286 ) O
sent286 in O
sent286 increasing O
sent286 gradients O
sent286 of O
sent286 snail-conditioned O
sent286 water O
sent286 ( O
sent286 SCW O
sent286 ) O
sent286 , O
sent286 and O
sent286 they O
sent286 perform O
sent286 a O
sent286 turnback O
sent286 swimming O
sent286 in O
sent286 decreasing O
sent286 gradients O
sent287 Both O
sent287 hostfinding O
sent287 responses O
sent287 in O
sent287 both O
sent287 species O
sent287 were O
sent287 induced O
sent287 by O
sent287 glycoconjugates O
sent287 with O
sent287 a O
sent287 molecular O
sent287 weight O
sent287 of O
sent287 > O
sent287 30 O
sent287 kDa O
sent287 that O
sent287 were O
sent287 sensitive O
sent287 to O
sent287 hydrolysis O
sent287 with O
sent287 pronase O
sent287 E O
sent287 and O
sent287 oxidation O
sent287 with O
sent287 NaIO4 O
sent288 Alkaline O
sent288 cleavage O
sent288 revealed O
sent288 that O
sent288 they O
sent288 contained O
sent288 carbohydrates O
sent288 linked O
sent288 O-glycosidically O
sent288 via O
sent288 serine O
sent288 and O
sent288 N-acetylgalactosamine O
sent289 Miracidia O
sent289 clearly O
sent289 preferred O
sent289 SCW O
sent289 from O
sent289 their O
sent289 specific O
sent289 host O
sent289 snail O
sent289 versus O
sent289 other O
sent289 sympatric O
sent289 snail O
sent289 species O
sent289 and O
sent289 did O
sent289 not O
sent289 respond O
sent289 to O
sent289 water O
sent289 conditioned O
sent289 with O
sent289 fish O
sent289 , O
sent289 tadpoles O
sent289 , O
sent289 or O
sent289 leeches O
sent290 Differences O
sent290 in O
sent290 the O
sent290 chemical O
sent290 characteristics O
sent290 of O
sent290 SCW O
sent290 from O
sent290 the O
sent290 intermediate O
sent290 hosts O
sent290 L. O
sent290 truncatula O
sent290 and O
sent290 L. O
sent290 stagnalis O
sent290 could O
sent290 be O
sent290 shown O
sent290 by O
sent290 sodium O
sent290 dodecyl O
sent290 sulfate-polyacrylamide O
sent290 gel O
sent290 electrophoresis O
sent290 , O
sent290 blotting O
sent290 , O
sent290 and O
sent290 subsequent O
sent290 carbohydrate O
sent290 detection O
sent291 The O
sent291 first O
sent291 step O
sent291 of O
sent291 purification O
sent291 of O
sent291 the O
sent291 effective O
sent291 signaling O
sent291 SCW O
sent291 components O
sent291 from O
sent291 both O
sent291 snail O
sent291 species O
sent291 was O
sent291 achieved O
sent291 by O
sent291 ion-exchange O
sent291 chromatography O
sent292 Black O
sent292 patients O
sent292 with O
sent292 colon D
sent292 cancer D
sent292 in O
sent292 the O
sent292 Black/White O
sent292 Cancer O
sent292 Survival O
sent292 Study O
sent292 were O
sent292 found O
sent292 to O
sent292 have O
sent292 a O
sent292 poorer O
sent292 survival O
sent292 than O
sent292 white O
sent292 patients O
sent293 More O
sent293 advanced-stage O
sent293 disease O
sent293 at O
sent293 diagnosis O
sent293 was O
sent293 the O
sent293 primary O
sent293 determinant O
sent293 , O
sent293 accounting O
sent293 for O
sent293 60 O
sent293 % O
sent293 of O
sent293 the O
sent293 excess O
sent293 mortality O
sent294 After O
sent294 adjusting O
sent294 for O
sent294 stage O
sent294 , O
sent294 factors O
sent294 such O
sent294 as O
sent294 poverty O
sent294 , O
sent294 other O
sent294 socioeconomic O
sent294 conditions O
sent294 , O
sent294 and O
sent294 treatment O
sent294 did O
sent294 not O
sent294 further O
sent294 explain O
sent294 the O
sent294 remaining O
sent294 survival O
sent294 deficit O
sent295 This O
sent295 study O
sent295 examined O
sent295 the O
sent295 aggressiveness O
sent295 of O
sent295 colon D
sent295 tumors D
sent295 in O
sent295 blacks O
sent295 and O
sent295 whites O
sent295 to O
sent295 explore O
sent295 its O
sent295 role O
sent295 in O
sent295 the O
sent295 racial O
sent295 survival O
sent295 differences O
sent296 Tumor O
sent296 characteristics O
sent296 of O
sent296 703 O
sent296 cases O
sent296 of O
sent296 newly O
sent296 diagnosed O
sent296 invasive O
sent296 colon O
sent296 adenocarcinoma D
sent296 were O
sent296 centrally O
sent296 evaluated O
sent296 by O
sent296 a O
sent296 gastrointestinal O
sent296 pathologist O
sent296 , O
sent296 blinded O
sent296 in O
sent296 regard O
sent296 to O
sent296 the O
sent296 age O
sent296 , O
sent296 race O
sent296 , O
sent296 and O
sent296 sex O
sent296 of O
sent296 the O
sent296 patients O
sent297 Blacks O
sent297 were O
sent297 less O
sent297 likely O
sent297 to O
sent297 have O
sent297 poorly O
sent297 differentiated O
sent297 ( O
sent297 grade O
sent297 3 O
sent297 ) O
sent297 tumors D
sent297 ( O
sent297 odds O
sent297 ratio O
sent297 ( O
sent297 OR O
sent297 ) O
sent297 , O
sent297 0.44 O
sent297 ; O
sent297 95 O
sent297 % O
sent297 confidence O
sent297 interval O
sent297 , O
sent297 0.22-0.88 O
sent297 ) O
sent297 and O
sent297 lymphoid O
sent297 reaction O
sent297 ( O
sent297 OR O
sent297 , O
sent297 0.49 O
sent297 ; O
sent297 95 O
sent297 % O
sent297 confidence O
sent297 interval O
sent297 , O
sent297 0.26-0.90 O
sent297 ) O
sent297 when O
sent297 compared O
sent297 with O
sent297 whites O
sent298 These O
sent298 black/white O
sent298 ( O
sent298 B/W O
sent298 ) O
sent298 differences O
sent298 remained O
sent298 statistically O
sent298 significant O
sent298 after O
sent298 adjusting O
sent298 for O
sent298 age O
sent298 , O
sent298 sex O
sent298 , O
sent298 metropolitan O
sent298 area O
sent298 , O
sent298 summary O
sent298 stage O
sent298 , O
sent298 socioeconomic O
sent298 status O
sent298 , O
sent298 body O
sent298 mass O
sent298 index O
sent298 , O
sent298 and O
sent298 health O
sent298 care O
sent298 access O
sent298 and O
sent298 utilization O
sent299 In O
sent299 addition O
sent299 , O
sent299 blacks O
sent299 were O
sent299 less O
sent299 likely O
sent299 to O
sent299 have O
sent299 high-grade O
sent299 ( O
sent299 grade O
sent299 3 O
sent299 ) O
sent299 nuclear D
sent299 atypia D
sent299 , O
sent299 mitotic O
sent299 activity O
sent299 , O
sent299 and O
sent299 tubule O
sent299 formation O
sent299 , O
sent299 although O
sent299 these O
sent299 ORs O
sent299 did O
sent299 not O
sent299 reach O
sent299 a O
sent299 statistical O
sent299 significance O
sent299 level O
sent299 of O
sent299 0.05 O
sent300 Similar O
sent300 B/W O
sent300 differences O
sent300 were O
sent300 observed O
sent300 for O
sent300 patients O
sent300 with O
sent300 advanced O
sent300 disease O
sent300 but O
sent300 not O
sent300 with O
sent300 early O
sent300 stage O
sent301 Comparison O
sent301 by O
sent301 anatomical O
sent301 subsite O
sent301 showed O
sent301 that O
sent301 blacks O
sent301 had O
sent301 statistically O
sent301 significantly O
sent301 better O
sent301 differentiated O
sent301 tumors D
sent301 for O
sent301 cancers D
sent301 of O
sent301 the O
sent301 proximal O
sent301 and O
sent301 transverse O
sent301 colon O
sent301 but O
sent301 not O
sent301 for O
sent301 the O
sent301 distal O
sent302 No O
sent302 racial O
sent302 differences O
sent302 were O
sent302 found O
sent302 for O
sent302 blood O
sent302 vessel O
sent302 and O
sent302 lymphatic D
sent302 invasion D
sent302 , O
sent302 necrosis D
sent302 , O
sent302 fibrosis D
sent302 , O
sent302 and O
sent302 mucinous O
sent302 type O
sent302 of O
sent302 histology O
sent303 The O
sent303 findings O
sent303 , O
sent303 therefore O
sent303 , O
sent303 are O
sent303 the O
sent303 opposite O
sent303 of O
sent303 those O
sent303 hypothesized O
sent304 After O
sent304 adjusting O
sent304 for O
sent304 stage O
sent304 , O
sent304 more O
sent304 aggressive O
sent304 tumor O
sent304 characteristics O
sent304 do O
sent304 not O
sent304 explain O
sent304 the O
sent304 adverse O
sent304 survival O
sent304 differential O
sent304 in O
sent304 blacks O
sent305 This O
sent305 suggests O
sent305 that O
sent305 there O
sent305 may O
sent305 be O
sent305 racial O
sent305 differences O
sent305 in O
sent305 environmental O
sent305 exposure O
sent305 , O
sent305 and O
sent305 that O
sent305 the O
sent305 intensity O
sent305 and O
sent305 mode O
sent305 of O
sent305 delivery O
sent305 of O
sent305 carcinogen O
sent305 insult O
sent305 as O
sent305 well O
sent305 as O
sent305 host O
sent305 susceptibility O
sent305 may O
sent305 differ O
sent305 by O
sent305 race O
sent305 and O
sent305 anatomical O
sent305 subsite O
sent306 Future O
sent306 studies O
sent306 should O
sent306 explore O
sent306 the O
sent306 B/W O
sent306 differences O
sent306 in O
sent306 tumor O
sent306 biology O
sent306 using O
sent306 molecular O
sent306 markers O
sent306 that O
sent306 precede O
sent306 the O
sent306 conventional O
sent306 histological O
sent306 parameters O
sent306 evaluated O
sent306 here O
sent307 A O
sent307 new O
sent307 method O
sent307 is O
sent307 described O
sent307 for O
sent307 detection O
sent307 of O
sent307 mutations O
sent307 in O
sent307 the O
sent307 lysosomal O
sent307 alpha-glucosidase O
sent307 gene O
sent307 ( O
sent307 GAA O
sent307 ) O
sent307 leading O
sent307 to O
sent307 Glycogen D
sent307 Storage D
sent307 Disease D
sent307 type D
sent307 II D
sent307 ( D
sent307 GSDII D
sent307 ) D
sent308 A O
sent308 key O
sent308 feature O
sent308 of O
sent308 the O
sent308 method O
sent308 is O
sent308 isolation O
sent308 and O
sent308 reverse O
sent308 transcription O
sent308 of O
sent308 mRNA O
sent308 followed O
sent308 by O
sent308 PCR O
sent308 amplification O
sent308 of O
sent308 lysosomal O
sent308 alpha-glucosidase O
sent308 cDNA O
sent308 with O
sent308 M13-extended O
sent308 primers O
sent309 Dye O
sent309 labeled O
sent309 primers O
sent309 are O
sent309 used O
sent309 for O
sent309 cycle O
sent309 sequencing O
sent309 and O
sent309 an O
sent309 ABI O
sent309 PRISM O
sent309 377 O
sent309 DNA O
sent309 sequencing O
sent309 system O
sent309 for O
sent309 analysis O
sent310 The O
sent310 method O
sent310 is O
sent310 rapid O
sent310 and O
sent310 complementary O
sent310 to O
sent310 the O
sent310 automated O
sent310 sequencing O
sent310 of O
sent310 all O
sent310 the O
sent310 19 O
sent310 , O
sent310 PCR O
sent310 amplified O
sent310 , O
sent310 coding O
sent310 exons O
sent310 of O
sent310 the O
sent310 GAA O
sent310 gene O
sent311 The O
sent311 advantages O
sent311 and O
sent311 pitfalls O
sent311 of O
sent311 this O
sent311 new O
sent311 method O
sent311 are O
sent311 discussed O
sent311 in O
sent311 the O
sent311 light O
sent311 of O
sent311 the O
sent311 results O
sent311 obtained O
sent311 with O
sent311 an O
sent311 infantile O
sent311 GSDII O
sent311 patient O
sent312 A O
sent312 new O
sent312 splice O
sent312 site O
sent312 mutation O
sent312 in O
sent312 the O
sent312 GAA O
sent312 gene O
sent312 of O
sent312 this O
sent312 patient O
sent312 was O
sent312 identified O
sent312 , O
sent312 IVS16 O
sent312 ( O
sent312 +2T O
sent312 -- O
sent312 > O
sent312 C O
sent312 ) O
sent312 , O
sent312 resulting O
sent312 in O
sent312 the O
sent312 deletion O
sent312 of O
sent312 16 O
sent312 base O
sent312 pairs O
sent312 of O
sent312 exon O
sent312 16 O
sent313 The O
sent313 presence O
sent313 of O
sent313 clinical O
sent313 autonomic D
sent313 dysfunction D
sent313 in O
sent313 patients O
sent313 with O
sent313 neurologic D
sent313 diseases D
sent313 , O
sent313 such O
sent313 as O
sent313 multiple D
sent313 sclerosis D
sent313 , O
sent313 Parkinson D
sent313 's D
sent313 disease D
sent313 , O
sent313 and O
sent313 cerebrovascular O
sent313 accident O
sent313 , O
sent313 has O
sent313 become O
sent313 increasingly O
sent313 recognized O
sent313 in O
sent313 the O
sent313 past O
sent313 decade O
sent314 Very O
sent314 few O
sent314 autonomic O
sent314 tests O
sent314 have O
sent314 been O
sent314 done O
sent314 on O
sent314 pediatric O
sent314 patients O
sent314 thus O
sent314 far O
sent315 The O
sent315 purpose O
sent315 of O
sent315 this O
sent315 study O
sent315 was O
sent315 to O
sent315 investigate O
sent315 the O
sent315 autonomic O
sent315 function O
sent315 in O
sent315 patients O
sent315 with O
sent315 cerebral D
sent315 palsy D
sent315 using O
sent315 two O
sent315 noninvasive O
sent315 tests O
sent315 : O
sent315 sympathetic O
sent315 skin O
sent315 response O
sent315 ( O
sent315 SSR O
sent315 ) O
sent315 and O
sent315 R-R O
sent315 interval O
sent315 variation O
sent315 ( O
sent315 RRIV O
sent315 ) O
sent316 Twenty-four O
sent316 patients O
sent316 with O
sent316 cerebral D
sent316 palsy D
sent316 and O
sent316 24 O
sent316 control O
sent316 subjects O
sent316 between O
sent316 the O
sent316 ages O
sent316 of O
sent316 4 O
sent316 and O
sent316 12 O
sent316 yr O
sent316 were O
sent316 enrolled O
sent316 in O
sent316 this O
sent316 study O
sent317 There O
sent317 was O
sent317 no O
sent317 significant O
sent317 difference O
sent317 of O
sent317 mean O
sent317 latency O
sent317 , O
sent317 amplitude O
sent317 , O
sent317 or O
sent317 amplitude O
sent317 ratio O
sent317 of O
sent317 SSR O
sent317 between O
sent317 the O
sent317 two O
sent317 groups O
sent317 under O
sent317 electric O
sent317 stimulus O
sent317 , O
sent317 startling O
sent317 stimulus O
sent317 , O
sent317 and O
sent317 deep O
sent317 breathing O
sent317 conditions O
sent318 No O
sent318 significant O
sent318 difference O
sent318 in O
sent318 frequency O
sent318 of O
sent318 absent O
sent318 response O
sent318 and O
sent318 asymmetric O
sent318 response O
sent318 was O
sent318 also O
sent318 noted O
sent319 Mean O
sent319 heart O
sent319 rate O
sent319 under O
sent319 relaxed O
sent319 sitting O
sent319 condition O
sent319 was O
sent319 significantly O
sent319 higher O
sent319 in O
sent319 the O
sent319 study O
sent319 group O
sent320 Significant O
sent320 negative O
sent320 correlation O
sent320 between O
sent320 heart O
sent320 rate O
sent320 and O
sent320 age O
sent320 was O
sent320 noted O
sent320 in O
sent320 the O
sent320 control O
sent320 group O
sent320 but O
sent320 was O
sent320 not O
sent320 present O
sent320 in O
sent320 the O
sent320 study O
sent320 group O
sent321 Also O
sent321 , O
sent321 there O
sent321 was O
sent321 no O
sent321 statistical O
sent321 difference O
sent321 of O
sent321 mean O
sent321 RRIV O
sent321 between O
sent321 the O
sent321 two O
sent321 groups O
sent322 No O
sent322 objective O
sent322 evidence O
sent322 of O
sent322 autonomic O
sent322 disturbance O
sent322 in O
sent322 patients O
sent322 with O
sent322 cerebral D
sent322 palsy D
sent322 was O
sent322 found O
sent322 in O
sent322 this O
sent322 study O
sent323 A O
sent323 two-credits O
sent323 per O
sent323 semester O
sent323 clinical O
sent323 medicine O
sent323 course O
sent323 was O
sent323 established O
sent323 in O
sent323 the O
sent323 Department O
sent323 of O
sent323 Physical O
sent323 Medicine O
sent323 and O
sent323 Rehabilitation O
sent323 ( O
sent323 PM O
sent323 & O
sent323 # O
sent323 38 O
sent323 ; O
sent323 R O
sent323 ) O
sent323 in O
sent323 cooperation O
sent323 with O
sent323 the O
sent323 Johns O
sent323 Hopkins O
sent323 University O
sent323 undergraduate O
sent323 Human O
sent323 Biology O
sent323 faculty O
sent323 to O
sent323 present O
sent323 the O
sent323 variety O
sent323 of O
sent323 inpatient O
sent323 consultation O
sent323 personnel O
sent323 , O
sent323 units O
sent323 , O
sent323 patient O
sent323 diagnostic O
sent323 groups O
sent323 , O
sent323 and O
sent323 functional O
sent323 problems O
sent324 College O
sent324 students O
sent324 spend O
sent324 4 O
sent324 hr O
sent324 weekly O
sent324 on O
sent324 the O
sent324 PM O
sent324 & O
sent324 # O
sent324 38 O
sent324 ; O
sent324 R O
sent324 consultation O
sent324 service O
sent324 as O
sent324 team O
sent324 members O
sent324 under O
sent324 resident O
sent324 supervision O
sent325 The O
sent325 curriculum O
sent325 emphasizes O
sent325 student O
sent325 understanding O
sent325 of O
sent325 the O
sent325 roles O
sent325 of O
sent325 rehabilitation O
sent325 team O
sent325 members O
sent326 Objectives O
sent326 include O
sent326 demonstration O
sent326 of O
sent326 working O
sent326 knowledge O
sent326 of O
sent326 the O
sent326 Biopsychosocial O
sent326 Model O
sent326 , O
sent326 the O
sent326 World O
sent326 Health O
sent326 Organization O
sent326 Model O
sent326 of O
sent326 disablement O
sent326 and O
sent326 interdisciplinary O
sent326 rehabilitation O
sent326 intervention O
sent327 The O
sent327 course O
sent327 includes O
sent327 simulations O
sent327 of O
sent327 physical O
sent327 impairments O
sent327 , O
sent327 demonstrations O
sent327 of O
sent327 adaptive O
sent327 equipment O
sent327 , O
sent327 interactive O
sent327 chart O
sent327 reviews O
sent327 , O
sent327 readings O
sent327 , O
sent327 and O
sent327 audio O
sent327 lectures O
sent328 A O
sent328 retrospective O
sent328 sequential O
sent328 review O
sent328 was O
sent328 made O
sent328 of O
sent328 the O
sent328 last O
sent328 100 O
sent328 physical O
sent328 medicine O
sent328 and O
sent328 rehabilitation O
sent328 consultations O
sent328 with O
sent328 student O
sent328 attendance O
sent329 The O
sent329 results O
sent329 confirm O
sent329 student O
sent329 exposure O
sent329 to O
sent329 many O
sent329 ward O
sent329 settings O
sent329 ( O
sent329 surgery O
sent329 , O
sent329 30 O
sent329 % O
sent329 ; O
sent329 neurology/neurosurgery O
sent329 , O
sent329 28 O
sent329 % O
sent329 ; O
sent329 medicine O
sent329 , O
sent329 24 O
sent329 % O
sent329 ; O
sent329 intensive O
sent329 care O
sent329 , O
sent329 15 O
sent329 % O
sent329 ; O
sent329 oncology O
sent329 , O
sent329 2 O
sent329 % O
sent329 ; O
sent329 and O
sent329 psychiatry O
sent329 , O
sent329 1 O
sent329 % O
sent329 ) O
sent329 , O
sent329 patient O
sent329 complexity O
sent329 ( O
sent329 averaging O
sent329 10 O
sent329 problems O
sent329 ) O
sent329 , O
sent329 and O
sent329 multiple O
sent329 ICD-9 O
sent329 diagnosis O
sent329 categories O
sent329 ( O
sent329 circulatory O
sent329 , O
sent329 36 O
sent329 % O
sent329 ; O
sent329 neurologic O
sent329 , O
sent329 22 O
sent329 % O
sent329 ; O
sent329 musculoskeletal O
sent329 , O
sent329 17 O
sent329 % O
sent329 ; O
sent329 neoplasms O
sent329 , O
sent329 10 O
sent329 % O
sent329 ; O
sent329 injury O
sent329 , O
sent329 5 O
sent329 % O
sent329 ; O
sent329 endocrine O
sent329 , O
sent329 4 O
sent329 % O
sent329 ; O
sent329 infections O
sent329 , O
sent329 3 O
sent329 % O
sent329 ; O
sent329 and O
sent329 others O
sent329 , O
sent329 3 O
sent329 % O
sent329 ) O
sent330 The O
sent330 rehabilitation O
sent330 consultation O
sent330 service O
sent330 is O
sent330 particularly O
sent330 effective O
sent330 as O
sent330 an O
sent330 introduction O
sent330 to O
sent330 hospital-based O
sent330 medical O
sent330 practice O
sent330 due O
sent330 to O
sent330 the O
sent330 diagnostic O
sent330 variety O
sent330 of O
sent330 the O
sent330 patients O
sent330 , O
sent330 the O
sent330 functional O
sent330 approach O
sent330 of O
sent330 rehabilitation O
sent330 , O
sent330 and O
sent330 student O
sent330 exposure O
sent330 to O
sent330 multiple O
sent330 hospital O
sent330 settings O
sent331 The O
sent331 Biopsychosocial O
sent331 Model O
sent331 of O
sent331 medical O
sent331 practice O
sent331 is O
sent331 demonstrated O
sent331 through O
sent331 multiple O
sent331 interdisciplinary O
sent331 perspectives O
sent331 of O
sent331 needs O
sent331 and O
sent331 interventions O
sent331 for O
sent331 patients O
sent331 with O
sent331 obvious O
sent331 functional O
sent331 deficits O
sent332 This O
sent332 process O
sent332 develops O
sent332 a O
sent332 rudimentary O
sent332 understanding O
sent332 of O
sent332 the O
sent332 effect O
sent332 of O
sent332 illness O
sent332 on O
sent332 the O
sent332 person O
sent332 and O
sent332 the O
sent332 variety O
sent332 of O
sent332 medically O
sent332 effective O
sent332 therapeutic O
sent332 modalities O
sent333 This O
sent333 study O
sent333 is O
sent333 designed O
sent333 to O
sent333 investigate O
sent333 the O
sent333 immediate O
sent333 effectiveness O
sent333 of O
sent333 electrotherapy T
sent333 on O
sent333 myofascial D
sent333 trigger D
sent333 points D
sent333 of D
sent333 upper D
sent333 trapezius D
sent333 muscle D
sent334 Sixty O
sent334 patients O
sent334 ( O
sent334 25 O
sent334 males O
sent334 and O
sent334 35 O
sent334 females O
sent334 ) O
sent334 who O
sent334 had O
sent334 myofascial D
sent334 trigger D
sent334 points D
sent334 in O
sent334 one O
sent334 side O
sent334 of O
sent334 the O
sent334 upper O
sent334 trapezius O
sent334 muscles O
sent334 were O
sent334 studied O
sent335 The O
sent335 involved O
sent335 upper O
sent335 trapezius O
sent335 muscles O
sent335 were O
sent335 treated O
sent335 with O
sent335 three O
sent335 different O
sent335 methods O
sent335 according O
sent335 to O
sent335 a O
sent335 random O
sent335 assignment O
sent335 : O
sent335 group O
sent335 A O
sent335 muscles O
sent335 ( O
sent335 n O
sent335 = O
sent335 18 O
sent335 ) O
sent335 were O
sent335 given O
sent335 placebo O
sent335 treatment O
sent335 ( O
sent335 control O
sent335 group O
sent335 ) O
sent335 ; O
sent335 group O
sent335 B O
sent335 muscles O
sent335 ( O
sent335 n O
sent335 = O
sent335 20 O
sent335 ) O
sent335 were O
sent335 treated O
sent335 with O
sent335 electrical T
sent335 nerve T
sent335 stimulation T
sent335 ( T
sent335 ENS T
sent335 ) T
sent335 therapy T
sent335 ; O
sent335 and O
sent335 group O
sent335 C O
sent335 muscles O
sent335 ( O
sent335 n O
sent335 = O
sent335 22 O
sent335 ) O
sent335 were O
sent335 given O
sent335 electrical T
sent335 muscle T
sent335 stimulation T
sent335 ( T
sent335 EMS T
sent335 ) T
sent335 therapy T
sent336 The O
sent336 effectiveness O
sent336 of O
sent336 treatment O
sent336 was O
sent336 assessed O
sent336 by O
sent336 conducting O
sent336 three O
sent336 measurements O
sent336 on O
sent336 each O
sent336 muscle O
sent336 before O
sent336 and O
sent336 immediately O
sent336 after O
sent336 treatment O
sent336 : O
sent336 subjective O
sent336 pain O
sent336 intensity O
sent336 ( O
sent336 ( O
sent336 PI O
sent336 ) O
sent336 with O
sent336 a O
sent336 visual O
sent336 analog O
sent336 scale O
sent336 ) O
sent336 , O
sent336 pressure O
sent336 pain O
sent336 threshold O
sent336 ( O
sent336 ( O
sent336 PT O
sent336 ) O
sent336 with O
sent336 algometry O
sent336 ) O
sent336 , O
sent336 and O
sent336 range O
sent336 of O
sent336 motion O
sent336 ( O
sent336 ( O
sent336 ROM O
sent336 ) O
sent336 with O
sent336 a O
sent336 goniometer O
sent336 ) O
sent336 of O
sent336 upper O
sent336 trapezius O
sent336 muscle O
sent336 ( O
sent336 lateral O
sent336 bending O
sent336 of O
sent336 cervical O
sent336 spine O
sent336 to O
sent336 the O
sent336 opposite O
sent336 side O
sent336 ) O
sent337 When O
sent337 the O
sent337 effectiveness O
sent337 of O
sent337 treatment O
sent337 was O
sent337 compared O
sent337 with O
sent337 that O
sent337 of O
sent337 the O
sent337 placebo O
sent337 group O
sent337 ( O
sent337 group O
sent337 A O
sent337 ) O
sent337 , O
sent337 there O
sent337 was O
sent337 significant O
sent337 improvement O
sent337 in O
sent337 PI O
sent337 and O
sent337 PT O
sent337 in O
sent337 group O
sent337 B O
sent337 ( O
sent337 P O
sent337 & O
sent337 # O
sent337 60 O
sent337 ; O
sent337 0.01 O
sent337 ) O
sent337 but O
sent337 not O
sent337 in O
sent337 group O
sent337 C O
sent337 ( O
sent337 P O
sent337 > O
sent337 0.05 O
sent337 ) O
sent338 The O
sent338 improvement O
sent338 of O
sent338 ROM O
sent338 was O
sent338 significantly O
sent338 more O
sent338 in O
sent338 group O
sent338 C O
sent338 ( O
sent338 P O
sent338 & O
sent338 # O
sent338 60 O
sent338 ; O
sent338 0.01 O
sent338 ) O
sent338 as O
sent338 compared O
sent338 with O
sent338 that O
sent338 in O
sent338 group O
sent338 A O
sent338 or O
sent338 group O
sent338 B O
sent339 When O
sent339 each O
sent339 group O
sent339 was O
sent339 divided O
sent339 into O
sent339 two O
sent339 additional O
sent339 subgroups O
sent339 based O
sent339 on O
sent339 the O
sent339 initial O
sent339 PI O
sent339 , O
sent339 it O
sent339 was O
sent339 found O
sent339 that O
sent339 ENS O
sent339 could O
sent339 reduce O
sent339 PI O
sent339 and O
sent339 increase O
sent339 PT O
sent339 significantly O
sent339 ( O
sent339 P O
sent339 & O
sent339 # O
sent339 60 O
sent339 ; O
sent339 0.05 O
sent339 ) O
sent339 , O
sent339 but O
sent339 did O
sent339 not O
sent339 significantly O
sent339 ( O
sent339 P O
sent339 > O
sent339 0.05 O
sent339 ) O
sent339 improve O
sent339 ROM O
sent339 , O
sent339 as O
sent339 compared O
sent339 with O
sent339 the O
sent339 placebo O
sent339 group O
sent339 for O
sent339 both O
sent339 subgroups O
sent340 EMS O
sent340 could O
sent340 significantly O
sent340 ( O
sent340 P O
sent340 & O
sent340 # O
sent340 60 O
sent340 ; O
sent340 0.05 O
sent340 ) O
sent340 improve O
sent340 ROM O
sent340 , O
sent340 but O
sent340 not O
sent340 PT O
sent340 , O
sent340 better O
sent340 than O
sent340 the O
sent340 placebo O
sent340 groups O
sent340 , O
sent340 for O
sent340 either O
sent340 subgroup O
sent341 It O
sent341 could O
sent341 reduce O
sent341 PI O
sent341 significantly O
sent341 more O
sent341 ( O
sent341 P O
sent341 & O
sent341 # O
sent341 60 O
sent341 ; O
sent341 0.05 O
sent341 ) O
sent341 than O
sent341 placebo O
sent341 controls O
sent341 only O
sent341 for O
sent341 the O
sent341 subgroup O
sent341 with O
sent341 mild O
sent341 to O
sent341 moderate O
sent341 pain O
sent341 , O
sent341 but O
sent341 not O
sent341 with O
sent341 severe O
sent341 pain O
sent342 For O
sent342 pain O
sent342 relief O
sent342 , O
sent342 ENS O
sent342 was O
sent342 significantly O
sent342 better O
sent342 ( O
sent342 P O
sent342 & O
sent342 # O
sent342 60 O
sent342 ; O
sent342 0.05 O
sent342 ) O
sent342 than O
sent342 EMS O
sent342 ; O
sent342 but O
sent342 for O
sent342 the O
sent342 improvement O
sent342 of O
sent342 ROM O
sent342 , O
sent342 EMS O
sent342 was O
sent342 significantly O
sent342 better O
sent342 ( O
sent342 P O
sent342 & O
sent342 # O
sent342 60 O
sent342 ; O
sent342 0.05 O
sent342 ) O
sent342 than O
sent342 ENS O
sent343 It O
sent343 is O
sent343 concluded O
sent343 that O
sent343 ENS T
sent343 is O
sent343 more O
sent343 effective O
sent343 for O
sent343 immediate O
sent343 relief O
sent343 of O
sent343 myofascial D
sent343 trigger D
sent343 point D
sent343 pain D
sent343 than O
sent343 EMS T
sent343 , O
sent343 and O
sent343 EMS T
sent343 has O
sent343 a O
sent343 better O
sent343 effect O
sent343 on O
sent343 immediate O
sent343 release O
sent343 of O
sent343 muscle D
sent343 tightness D
sent343 than O
sent343 ENS T
sent344 Because O
sent344 activity O
sent344 and O
sent344 regular O
sent344 exercise O
sent344 are O
sent344 important O
sent344 factors O
sent344 to O
sent344 maintain O
sent344 general O
sent344 good O
sent344 health O
sent344 in O
sent344 senior O
sent344 citizens O
sent344 , O
sent344 we O
sent344 investigated O
sent344 whether O
sent344 senior O
sent344 dancing O
sent344 has O
sent344 any O
sent344 effect O
sent344 on O
sent344 peripheral O
sent344 or O
sent344 lumbar O
sent344 bone O
sent344 density O
sent345 We O
sent345 performed O
sent345 a O
sent345 prospective O
sent345 study O
sent345 over O
sent345 a12-mo O
sent345 period O
sent345 on O
sent345 bone O
sent345 density O
sent345 at O
sent345 a O
sent345 spinal O
sent345 and O
sent345 peripheral O
sent345 measuring O
sent345 site O
sent345 in O
sent345 28 O
sent345 female O
sent345 senior O
sent345 members O
sent345 ( O
sent345 mean O
sent345 age O
sent345 : O
sent345 67 O
sent345 +/- O
sent345 2 O
sent345 yr O
sent345 ) O
sent345 of O
sent345 a O
sent345 dancing O
sent345 group O
sent345 in O
sent345 Vienna O
sent346 Lumbar O
sent346 bone O
sent346 mineral O
sent346 density O
sent346 was O
sent346 assessed O
sent346 by O
sent346 quantitative O
sent346 computed O
sent346 tomography O
sent346 ( O
sent346 qCT O
sent346 ) O
sent346 and O
sent346 radial O
sent346 bone O
sent346 density O
sent346 by O
sent346 single O
sent346 photon O
sent346 absorptiometry O
sent346 of O
sent346 the O
sent346 distal O
sent346 forearm O
sent347 The O
sent347 mean O
sent347 training O
sent347 time O
sent347 per O
sent347 week O
sent347 was O
sent347 3.2 O
sent347 +/- O
sent347 0.8 O
sent347 h. O
sent347 In O
sent347 the O
sent347 entire O
sent347 group O
sent347 of O
sent347 female O
sent347 dancers O
sent347 , O
sent347 no O
sent347 significant O
sent347 effects O
sent347 of O
sent347 dancing O
sent347 on O
sent347 radial O
sent347 or O
sent347 lumbar O
sent347 bone O
sent347 density O
sent347 could O
sent347 be O
sent347 observed O
sent348 Linear O
sent348 regression O
sent348 analysis O
sent348 showed O
sent348 that O
sent348 the O
sent348 lower O
sent348 the O
sent348 qCT O
sent348 at O
sent348 the O
sent348 beginning O
sent348 of O
sent348 the O
sent348 observation O
sent348 period O
sent348 , O
sent348 the O
sent348 higher O
sent348 was O
sent348 the O
sent348 percentage O
sent348 increase O
sent348 of O
sent348 spinal O
sent348 qCT O
sent348 in O
sent348 the O
sent348 entire O
sent348 group O
sent348 during O
sent348 12 O
sent348 mo O
sent348 of O
sent348 dancing O
sent348 ( O
sent348 r O
sent348 = O
sent348 0.52 O
sent348 , O
sent348 P O
sent348 & O
sent348 # O
sent348 60 O
sent348 ; O
sent348 0.0001 O
sent348 ) O
sent349 For O
sent349 additional O
sent349 evaluation O
sent349 , O
sent349 females O
sent349 were O
sent349 divided O
sent349 into O
sent349 two O
sent349 subgroups O
sent349 , O
sent349 osteoporotic O
sent349 or O
sent349 nonosteoporotic O
sent349 , O
sent349 based O
sent349 on O
sent349 x-rays O
sent349 and O
sent349 lumbar O
sent349 bone O
sent349 mineral O
sent349 density O
sent349 ( O
sent349 BMD O
sent349 ) O
sent349 as O
sent349 measured O
sent349 by O
sent349 qCT O
sent350 The O
sent350 group O
sent350 classified O
sent350 as O
sent350 dancers O
sent350 with O
sent350 osteoporosis O
sent350 ( O
sent350 group O
sent350 I O
sent350 ) O
sent350 showed O
sent350 a O
sent350 significant O
sent350 increase O
sent350 in O
sent350 lumbar O
sent350 bone O
sent350 density O
sent350 , O
sent350 whereas O
sent350 in O
sent350 the O
sent350 group O
sent350 of O
sent350 dancers O
sent350 without O
sent350 signs O
sent350 of O
sent350 osteoporosis D
sent350 ( O
sent350 group O
sent350 II O
sent350 ) O
sent350 , O
sent350 BMD O
sent350 remained O
sent350 unchanged O
sent351 Additionally O
sent351 , O
sent351 radial O
sent351 bone O
sent351 density O
sent351 did O
sent351 not O
sent351 show O
sent351 any O
sent351 changes O
sent351 in O
sent351 either O
sent351 group O
sent352 Group O
sent352 I O
sent352 showed O
sent352 a O
sent352 significant O
sent352 correlation O
sent352 between O
sent352 basal O
sent352 spinal O
sent352 BMD O
sent352 and O
sent352 the O
sent352 percentage O
sent352 change O
sent352 of O
sent352 BMD O
sent352 during O
sent352 the O
sent352 observation O
sent352 period O
sent352 ( O
sent352 r O
sent352 = O
sent352 0.7 O
sent352 , O
sent352 P O
sent352 & O
sent352 # O
sent352 60 O
sent352 ; O
sent352 0.001 O
sent352 ) O
sent353 Changes O
sent353 of O
sent353 the O
sent353 biochemical O
sent353 parameters O
sent353 were O
sent353 observed O
sent353 in O
sent353 the O
sent353 bone-specific O
sent353 isoenzyme O
sent353 of O
sent353 alkaline O
sent353 phosphatase O
sent353 , O
sent353 a O
sent353 marker O
sent353 of O
sent353 osteoblastic O
sent353 activity O
sent353 , O
sent353 in O
sent353 group O
sent353 I O
sent353 giving O
sent353 additional O
sent353 evidence O
sent353 of O
sent353 increased O
sent353 bone O
sent353 formation O
sent354 OBJECTIVES O
sent354 : O
sent354 To O
sent354 estimate O
sent354 the O
sent354 prevalence O
sent354 of O
sent354 Chlamydia D
sent354 trachomatis D
sent354 in O
sent354 asymptomatic O
sent354 women O
sent354 attending O
sent354 general O
sent354 practice O
sent354 : O
sent354 to O
sent354 assess O
sent354 the O
sent354 potential O
sent354 of O
sent354 the O
sent354 ligase O
sent354 chain O
sent354 reaction O
sent354 as O
sent354 a O
sent354 screening O
sent354 tool O
sent354 ; O
sent354 and O
sent354 to O
sent354 evaluate O
sent354 selective O
sent354 screening O
sent354 criteria O
sent355 DESIGN O
sent355 : O
sent355 Cross O
sent355 sectional O
sent355 survey O
sent356 SETTING O
sent356 : O
sent356 Four O
sent356 general O
sent356 practices O
sent356 in O
sent356 northeast O
sent356 London O
sent357 SUBJECTS O
sent357 : O
sent357 890 O
sent357 women O
sent357 aged O
sent357 18-35 O
sent357 years O
sent357 attending O
sent357 general O
sent357 practice O
sent357 for O
sent357 a O
sent357 cervical O
sent357 smear O
sent357 or O
sent357 a O
sent357 `` O
sent357 young O
sent357 well O
sent357 woman O
sent357 '' O
sent357 check O
sent357 between O
sent357 October O
sent357 1994 O
sent357 and O
sent357 January O
sent357 1996 O
sent358 The O
sent358 women O
sent358 were O
sent358 tested O
sent358 for O
sent358 C D
sent358 trachomatis D
sent358 with O
sent358 confirmed O
sent358 enzyme O
sent358 immunoassay O
sent358 ( O
sent358 endocervical O
sent358 specimens O
sent358 ) O
sent358 and O
sent358 ligase O
sent358 chain O
sent358 reaction O
sent358 assay O
sent358 on O
sent358 urine O
sent358 specimens O
sent359 MAIN O
sent359 OUTCOME O
sent359 MEASURES O
sent359 : O
sent359 Prevalence O
sent359 of O
sent359 C D
sent359 trachomatis D
sent359 infection D
sent359 in O
sent359 women O
sent359 aged O
sent359 18-35 O
sent359 on O
sent359 the O
sent359 basis O
sent359 of O
sent359 each O
sent359 test O
sent359 ; O
sent359 sensitivity O
sent359 and O
sent359 specificity O
sent359 of O
sent359 both O
sent359 tests O
sent359 in O
sent359 this O
sent359 population O
sent360 RESULTS O
sent360 : O
sent360 Prevalence O
sent360 of O
sent360 confirmed O
sent360 infection O
sent360 was O
sent360 2.6 O
sent360 % O
sent360 ( O
sent360 95 O
sent360 % O
sent360 confidence O
sent360 interval O
sent360 1.6 O
sent360 % O
sent360 to O
sent360 3.6 O
sent360 % O
sent360 ) O
sent360 in O
sent360 all O
sent360 women O
sent361 Prevalence O
sent361 on O
sent361 the O
sent361 basis O
sent361 of O
sent361 enzyme O
sent361 immunoassay O
sent361 was O
sent361 1.6 O
sent361 % O
sent361 ( O
sent361 0.8 O
sent361 % O
sent361 to O
sent361 2.7 O
sent361 % O
sent361 ) O
sent361 , O
sent361 with O
sent361 a O
sent361 sensitivity O
sent361 of O
sent361 60 O
sent361 % O
sent361 and O
sent361 a O
sent361 specificity O
sent361 of O
sent361 100 O
sent361 % O
sent362 Prevalence O
sent362 on O
sent362 the O
sent362 basis O
sent362 of O
sent362 ligase O
sent362 chain O
sent362 reaction O
sent362 was O
sent362 2.5 O
sent362 % O
sent362 ( O
sent362 1.5 O
sent362 % O
sent362 to O
sent362 3.9 O
sent362 % O
sent362 ) O
sent362 , O
sent362 with O
sent362 90 O
sent362 % O
sent362 sensitivity O
sent362 and O
sent362 99.8 O
sent362 % O
sent362 specificity O
sent363 Screening O
sent363 all O
sent363 women O
sent363 aged O
sent363 & O
sent363 # O
sent363 60 O
sent363 ; O
sent363 or O
sent363 = O
sent363 25 O
sent363 and O
sent363 all O
sent363 women O
sent363 who O
sent363 had O
sent363 had O
sent363 two O
sent363 or O
sent363 more O
sent363 partners O
sent363 in O
sent363 the O
sent363 past O
sent363 year O
sent363 would O
sent363 have O
sent363 detected O
sent363 87 O
sent363 % O
sent363 ( O
sent363 20/23 O
sent363 ) O
sent363 of O
sent363 infections O
sent364 CONCLUSION O
sent364 : O
sent364 Ligase O
sent364 chain O
sent364 reaction O
sent364 on O
sent364 urine O
sent364 samples O
sent364 performs O
sent364 at O
sent364 least O
sent364 as O
sent364 well O
sent364 as O
sent364 enzyme O
sent364 immunoassay O
sent364 on O
sent364 cervical O
sent364 specimens O
sent364 in O
sent364 this O
sent364 low O
sent364 prevalence O
sent364 population O
sent365 It O
sent365 offers O
sent365 potential O
sent365 as O
sent365 a O
sent365 non-invasive O
sent365 screening O
sent365 tool O
sent366 A O
sent366 simple O
sent366 selective O
sent366 screening O
sent366 strategy O
sent366 might O
sent366 be O
sent366 appropriate O
sent366 and O
sent366 would O
sent366 be O
sent366 able O
sent366 to O
sent366 detect O
sent366 most O
sent366 cases O
sent366 of O
sent366 infection D
sent367 However O
sent367 , O
sent367 a O
sent367 rigorous O
sent367 economic O
sent367 evaluation O
sent367 of O
sent367 possible O
sent367 screening O
sent367 strategies O
sent367 is O
sent367 needed O
sent367 first O
sent368 Recently O
sent368 , O
sent368 many O
sent368 advances O
sent368 have O
sent368 been O
sent368 made O
sent368 in O
sent368 the O
sent368 study O
sent368 of O
sent368 sexual O
sent368 differentiation O
sent368 , O
sent368 including O
sent368 the O
sent368 discoveries O
sent368 of O
sent368 the O
sent368 gene O
sent368 for O
sent368 antim1/4llerian O
sent368 hormone O
sent368 as O
sent368 well O
sent368 as O
sent368 the O
sent368 gene O
sent368 for O
sent368 its O
sent368 receptor O
sent369 However O
sent369 , O
sent369 the O
sent369 etiology O
sent369 of O
sent369 the O
sent369 clinical O
sent369 syndrome O
sent369 of O
sent369 m1/4llerian O
sent369 agenesis O
sent369 remains O
sent369 elusive O
sent370 We O
sent370 hypothesize O
sent370 that O
sent370 activating O
sent370 mutations O
sent370 of O
sent370 either O
sent370 the O
sent370 antim1/4llerian O
sent370 hormone O
sent370 gene O
sent370 or O
sent370 its O
sent370 receptor O
sent370 gene O
sent370 may O
sent370 cause O
sent370 m1/4llerian O
sent370 duct O
sent370 regression O
sent370 in O
sent370 a O
sent370 genetic O
sent370 female O
sent370 during O
sent370 embryogenesis O
sent371 This O
sent371 clinical O
sent371 commentary O
sent371 discusses O
sent371 the O
sent371 current O
sent371 management O
sent371 of O
sent371 the O
sent371 syndrome O
sent371 including O
sent371 the O
sent371 Abbe-McIndoe T
sent371 procedure T
sent371 , O
sent371 the O
sent371 most O
sent371 commonly O
sent371 used O
sent371 method O
sent371 of O
sent371 surgical T
sent371 correction T
sent371 , O
sent371 and O
sent371 the O
sent371 Frank T
sent371 vaginal T
sent371 dilation T
sent371 method T
sent371 , O
sent371 the O
sent371 most O
sent371 common O
sent371 nonsurgical O
sent371 method O
sent371 of O
sent371 correction O
sent372 OBJECTIVES O
sent372 : O
sent372 Obesity D
sent372 is O
sent372 an O
sent372 important O
sent372 clinical O
sent372 problem O
sent372 , O
sent372 and O
sent372 the O
sent372 use O
sent372 of O
sent372 dexfenfluramine T
sent372 hydrochloride T
sent372 for O
sent372 weight O
sent372 reduction O
sent372 has O
sent372 been O
sent372 widely O
sent372 publicized O
sent372 since O
sent372 its O
sent372 approval O
sent372 by O
sent372 the O
sent372 Food O
sent372 and O
sent372 Drug O
sent372 Administration O
sent373 However O
sent373 , O
sent373 animal O
sent373 and O
sent373 human O
sent373 studies O
sent373 have O
sent373 demonstrated O
sent373 toxic O
sent373 effects O
sent373 of O
sent373 fenfluramines T
sent373 that O
sent373 clinicians O
sent373 should O
sent373 be O
sent373 aware O
sent373 of O
sent373 when O
sent373 considering O
sent373 prescribing O
sent373 the O
sent373 drugs O
sent374 Our O
sent374 purpose O
sent374 was O
sent374 to O
sent374 systematically O
sent374 review O
sent374 data O
sent374 on O
sent374 brain O
sent374 serotonin O
sent374 neurotoxicity O
sent374 in O
sent374 animals O
sent374 treated O
sent374 with O
sent374 fenfluramines T
sent374 and O
sent374 the O
sent374 evidence O
sent374 linking O
sent374 fenfluramines T
sent374 to O
sent374 primary D
sent374 pulmonary D
sent374 hypertension D
sent374 ( D
sent374 PPH D
sent374 ) D
sent375 DATA O
sent375 SOURCES O
sent375 : O
sent375 Archival O
sent375 articles O
sent375 and O
sent375 reviews O
sent375 identified O
sent375 through O
sent375 a O
sent375 computerized O
sent375 search O
sent375 of O
sent375 MEDLINE O
sent375 from O
sent375 1966 O
sent375 to O
sent375 April O
sent375 1997 O
sent375 using O
sent375 `` O
sent375 fenfluramine O
sent375 ( O
sent375 s O
sent375 ) O
sent375 , O
sent375 '' O
sent375 `` O
sent375 serotonin O
sent375 , O
sent375 '' O
sent375 `` O
sent375 neurotoxicity O
sent375 , O
sent375 '' O
sent375 `` O
sent375 behavior O
sent375 , O
sent375 '' O
sent375 `` O
sent375 anorexigens O
sent375 , O
sent375 '' O
sent375 `` O
sent375 weight O
sent375 loss O
sent375 , O
sent375 '' O
sent375 and O
sent375 `` O
sent375 primary O
sent375 pulmonary O
sent375 hypertension O
sent375 '' O
sent375 as O
sent375 index O
sent375 terms O
sent376 STUDY O
sent376 SELECTION O
sent376 : O
sent376 Reports O
sent376 dealing O
sent376 with O
sent376 long-term O
sent376 effects O
sent376 of O
sent376 fenfluramines T
sent376 on O
sent376 brain O
sent376 serotonin O
sent376 neurons O
sent376 , O
sent376 body O
sent376 weight O
sent376 , O
sent376 and O
sent376 pulmonary O
sent376 function O
sent376 in O
sent376 animals O
sent376 and O
sent376 humans O
sent377 DATA O
sent377 EXTRACTION O
sent377 : O
sent377 Reports O
sent377 were O
sent377 reviewed O
sent377 by O
sent377 individuals O
sent377 with O
sent377 expertise O
sent377 in O
sent377 serotonin O
sent377 neurobiology O
sent377 , O
sent377 neurotoxicity O
sent377 , O
sent377 neuropsychiatry O
sent377 , O
sent377 and O
sent377 pulmonary O
sent377 medicine O
sent377 and O
sent377 evaluated O
sent377 for O
sent377 appropriateness O
sent377 for O
sent377 inclusion O
sent377 in O
sent377 this O
sent377 review O
sent378 DATA O
sent378 SYNTHESIS O
sent378 : O
sent378 Fenfluramines T
sent378 cause O
sent378 dose-related O
sent378 , O
sent378 long-lasting O
sent378 reductions O
sent378 in O
sent378 serotonin O
sent378 axonal O
sent378 markers O
sent378 in O
sent378 all O
sent378 the O
sent378 animal O
sent378 species O
sent378 tested O
sent378 and O
sent378 with O
sent378 all O
sent378 the O
sent378 routes O
sent378 of O
sent378 drug O
sent378 administration O
sent378 used O
sent379 Doses O
sent379 of O
sent379 fenfluramines O
sent379 that O
sent379 produce O
sent379 signs O
sent379 of O
sent379 brain O
sent379 serotonin O
sent379 neurotoxicity O
sent379 in O
sent379 animals O
sent379 are O
sent379 on O
sent379 the O
sent379 same O
sent379 order O
sent379 as O
sent379 those O
sent379 used O
sent379 to O
sent379 treat O
sent379 humans O
sent379 for O
sent379 weight O
sent379 loss O
sent379 when O
sent379 one O
sent379 takes O
sent379 into O
sent379 account O
sent379 known O
sent379 relations O
sent379 between O
sent379 body O
sent379 mass O
sent379 and O
sent379 drug O
sent379 clearance O
sent380 However O
sent380 , O
sent380 no O
sent380 human O
sent380 studies O
sent380 have O
sent380 been O
sent380 conducted O
sent380 , O
sent380 and O
sent380 the O
sent380 pathological O
sent380 and O
sent380 clinical O
sent380 potential O
sent380 for O
sent380 neurotoxicity O
sent380 in O
sent380 humans O
sent380 is O
sent380 unknown O
sent381 Appetite O
sent381 suppressants-most O
sent381 commonly O
sent381 fenfluramines T
sent381 -increase O
sent381 the O
sent381 risk O
sent381 of O
sent381 developing O
sent381 PPH D
sent381 ( O
sent381 odds O
sent381 ratio O
sent381 , O
sent381 6.3 O
sent381 ) O
sent381 , O
sent381 particularly O
sent381 when O
sent381 used O
sent381 for O
sent381 more O
sent381 than O
sent381 3 O
sent381 months O
sent381 ( O
sent381 odds O
sent381 ratio O
sent381 , O
sent381 > O
sent381 20 O
sent381 ) O
sent382 CONCLUSIONS O
sent382 : O
sent382 Fenfluramine T
sent382 and O
sent382 dexfenfluramine T
sent382 have O
sent382 been O
sent382 demonstrated O
sent382 to O
sent382 damage O
sent382 brain O
sent382 serotonin O
sent382 neurons O
sent382 in O
sent382 animal O
sent382 studies O
sent383 It O
sent383 is O
sent383 not O
sent383 known O
sent383 if O
sent383 such O
sent383 damage O
sent383 occurs O
sent383 in O
sent383 humans O
sent383 or O
sent383 if O
sent383 there O
sent383 are O
sent383 clinical O
sent383 consequences O
sent384 Use O
sent384 of O
sent384 fenfluramines T
sent384 is O
sent384 associated O
sent384 with O
sent384 an O
sent384 increased O
sent384 risk O
sent384 of O
sent384 PPH D
sent385 Future O
sent385 studies O
sent385 should O
sent385 address O
sent385 the O
sent385 long-term O
sent385 consequences O
sent385 of O
sent385 prolonged O
sent385 use O
sent385 of O
sent385 fenfluramines T
sent386 Moxonidine T
sent386 ( T
sent386 Physiotens-Solvay T
sent386 ) T
sent386 was O
sent386 introduced O
sent386 last O
sent386 year O
sent386 as O
sent386 the O
sent386 first O
sent386 of O
sent386 a O
sent386 new O
sent386 class O
sent386 of O
sent386 centrally-acting O
sent386 antihypertensive T
sent386 agents T
sent386 , O
sent386 the O
sent386 selective O
sent386 imidazoline O
sent386 receptor O
sent386 agonists O
sent387 The O
sent387 manufacturer O
sent387 claims O
sent387 that O
sent387 moxonidine T
sent387 `` O
sent387 accurately O
sent387 targets O
sent387 imidazoline O
sent387 receptors O
sent387 at O
sent387 the O
sent387 cardiovascular O
sent387 control O
sent387 centre O
sent387 in O
sent387 the O
sent387 brainstem O
sent387 '' O
sent387 and O
sent387 is O
sent387 `` O
sent387 as O
sent387 effective O
sent387 as O
sent387 current O
sent387 first-line O
sent387 therapies O
sent387 for O
sent387 essential D
sent387 hypertension D
sent387 `` O
sent388 Other O
sent388 claims O
sent388 suggest O
sent388 that O
sent388 it O
sent388 causes O
sent388 fewer O
sent388 unwanted O
sent388 effects O
sent388 than O
sent388 older O
sent388 centrally-acting O
sent388 antihypertensive T
sent388 drugs T
sent388 such O
sent388 as O
sent388 clonidine T
sent388 and O
sent388 methyldopa T
sent389 Is O
sent389 moxonidine T
sent389 a O
sent389 useful O
sent389 addition O
sent389 to O
sent389 the O
sent389 growing O
sent389 number O
sent389 of O
sent389 antihypertensives O
sent389 on O
sent389 the O
sent389 market O
sent389 ? O
sent390 This O
sent390 article O
sent390 discusses O
sent390 dental O
sent390 anxiety O
sent390 and O
sent390 phobia O
sent391 The O
sent391 author O
sent391 presents O
sent391 background O
sent391 information O
sent391 , O
sent391 including O
sent391 incidence O
sent391 and O
sent391 etiology O
sent392 A O
sent392 discussion O
sent392 of O
sent392 evaluative O
sent392 techniques O
sent392 for O
sent392 assessing O
sent392 anxiety O
sent392 levels O
sent392 follows O
sent393 Examination O
sent393 and O
sent393 treatment O
sent393 planning O
sent393 are O
sent393 considered O
sent393 in O
sent393 relation O
sent393 to O
sent393 this O
sent393 patient O
sent393 's O
sent393 special O
sent393 needs O
sent394 The O
sent394 article O
sent394 stresses O
sent394 behavioral O
sent394 treatment O
sent394 modalities O
sent394 that O
sent394 eliminate O
sent394 the O
sent394 debilitating O
sent394 phobia O
sent395 In O
sent395 closing O
sent395 , O
sent395 the O
sent395 author O
sent395 presents O
sent395 practical O
sent395 information O
sent395 regarding O
sent395 prevention O
sent395 of O
sent395 dental O
sent395 phobia O
sent395 and O
sent395 the O
sent395 merits O
sent395 of O
sent395 incorporating O
sent395 this O
sent395 type O
sent395 of O
sent395 patient O
sent395 into O
sent395 a O
sent395 dental O
sent395 practice O
sent396 In O
sent396 order O
sent396 to O
sent396 evaluate O
sent396 the O
sent396 applicability O
sent396 of O
sent396 anthelminthic T
sent396 treatment T
sent396 of O
sent396 wild O
sent396 foxes O
sent396 ( O
sent396 Vulpes O
sent396 vulpes O
sent396 ) O
sent396 to O
sent396 limit O
sent396 their O
sent396 infection D
sent396 with D
sent396 Echinococcus D
sent396 multilocularis D
sent396 , O
sent396 bait O
sent396 pellets O
sent396 , O
sent396 each O
sent396 containing O
sent396 50 O
sent396 mg O
sent396 praziquantel T
sent396 , O
sent396 were O
sent396 repeatedly O
sent396 distributed O
sent396 in O
sent396 an O
sent396 area O
sent396 of O
sent396 566 O
sent396 km2 O
sent396 where O
sent396 many O
sent396 foxes O
sent396 are O
sent396 infected O
sent396 , O
sent396 in O
sent396 southern O
sent396 Germany O
sent397 After O
sent397 six O
sent397 baiting O
sent397 campaigns O
sent397 ( O
sent397 15-20 O
sent397 baits/km2 O
sent397 ) O
sent397 over O
sent397 a O
sent397 period O
sent397 of O
sent397 14 O
sent397 months O
sent397 , O
sent397 the O
sent397 prevalence O
sent397 of O
sent397 the O
sent397 cestode O
sent397 in O
sent397 foxes O
sent397 , O
sent397 initially O
sent397 32 O
sent397 % O
sent397 , O
sent397 had O
sent397 fallen O
sent397 to O
sent397 4 O
sent397 % O
sent398 The O
sent398 effect O
sent398 was O
sent398 most O
sent398 pronounced O
sent398 in O
sent398 the O
sent398 central O
sent398 part O
sent398 of O
sent398 the O
sent398 treated O
sent398 area O
sent398 , O
sent398 where O
sent398 no O
sent398 positive O
sent398 fox O
sent398 was O
sent398 found O
sent398 in O
sent398 the O
sent398 2 O
sent398 months O
sent398 before O
sent398 the O
sent398 end O
sent398 of O
sent398 the O
sent398 trial O
sent399 The O
sent399 study O
sent399 was O
sent399 controlled O
sent399 for O
sent399 other O
sent399 factors O
sent399 that O
sent399 could O
sent399 influence O
sent399 the O
sent399 parasite O
sent399 's O
sent399 prevalence O
sent399 , O
sent399 such O
sent399 as O
sent399 the O
sent399 availability O
sent399 of O
sent399 intermediate O
sent399 hosts O
sent400 While O
sent400 the O
sent400 potential O
sent400 of O
sent400 this O
sent400 baiting O
sent400 method O
sent400 to O
sent400 remove O
sent400 E O
sent401 multilocularis O
sent401 from O
sent401 wild O
sent401 hosts O
sent401 has O
sent401 been O
sent401 demonstrated O
sent401 , O
sent401 the O
sent401 question O
sent401 of O
sent401 its O
sent401 long-term O
sent401 efficacy O
sent401 and O
sent401 other O
sent401 unresolved O
sent401 problems O
sent401 have O
sent401 to O
sent401 be O
sent401 addressed O
sent401 by O
sent401 consecutive O
sent401 studies O
sent401 before O
sent401 routine O
sent401 application O
sent401 can O
sent401 be O
sent401 recommended O
sent402 In O
sent402 patients O
sent402 with O
sent402 chronic D
sent402 myeloid D
sent402 leukemia D
sent402 ( D
sent402 CML D
sent402 ) D
sent402 , O
sent402 the O
sent402 neoplastic O
sent402 ( O
sent402 BCR-ABL+ O
sent402 ) O
sent402 progenitor O
sent402 cells O
sent402 are O
sent402 characterized O
sent402 by O
sent402 an O
sent402 increased O
sent402 proliferative O
sent402 activity O
sent403 Whether O
sent403 these O
sent403 cells O
sent403 are O
sent403 also O
sent403 resistant O
sent403 to O
sent403 apoptosis O
sent403 and O
sent403 if O
sent403 so O
sent403 , O
sent403 under O
sent403 what O
sent403 conditions O
sent403 remains O
sent403 controversial O
sent404 We O
sent404 now O
sent404 show O
sent404 that O
sent404 highly O
sent404 purified O
sent404 populations O
sent404 of O
sent404 very O
sent404 primitive O
sent404 neoplastic O
sent404 progenitor O
sent404 cells O
sent404 obtained O
sent404 directly O
sent404 from O
sent404 CML O
sent404 patients O
sent404 survive O
sent404 and O
sent404 proliferate O
sent404 in O
sent404 vitro O
sent404 for O
sent404 several O
sent404 weeks O
sent404 in O
sent404 the O
sent404 absence O
sent404 of O
sent404 any O
sent404 added O
sent404 growth O
sent404 factors O
sent404 ( O
sent404 except O
sent404 insulin O
sent404 ) O
sent405 In O
sent405 contrast O
sent405 , O
sent405 purified O
sent405 primary O
sent405 normal O
sent405 progenitors O
sent405 maintained O
sent405 under O
sent405 the O
sent405 same O
sent405 conditions O
sent405 die O
sent405 rapidly O
sent406 Nevertheless O
sent406 , O
sent406 both O
sent406 primary O
sent406 CML O
sent406 cells O
sent406 and O
sent406 BCR-ABL+ O
sent406 BAF3 O
sent406 cells O
sent406 show O
sent406 the O
sent406 same O
sent406 dose-dependent O
sent406 sensitivity O
sent406 to O
sent406 TNF-alpha O
sent406 or O
sent406 ceramide-induced O
sent406 apoptosis O
sent406 as O
sent406 their O
sent406 respective O
sent406 normal O
sent406 counterparts O
sent407 In O
sent407 fact O
sent407 , O
sent407 time O
sent407 course O
sent407 studies O
sent407 demonstrated O
sent407 an O
sent407 even O
sent407 faster O
sent407 onset O
sent407 of O
sent407 apoptosis O
sent407 in O
sent407 ceramide-treated O
sent407 BCR-ABL+ O
sent407 BAF3 O
sent407 cells O
sent407 as O
sent407 compared O
sent407 to O
sent407 normal O
sent407 controls O
sent408 BCR-ABL+ O
sent408 cells O
sent408 treated O
sent408 with O
sent408 ceramide O
sent408 also O
sent408 showed O
sent408 a O
sent408 rapid O
sent408 and O
sent408 sequential O
sent408 increase O
sent408 in O
sent408 the O
sent408 tyrosine O
sent408 phosphorylation O
sent408 of O
sent408 p210 O
sent408 ( O
sent408 BCR-ABL O
sent408 ) O
sent408 , O
sent408 p46-56SHC O
sent408 and O
sent408 p120Cbl O
sent409 These O
sent409 findings O
sent409 suggest O
sent409 growth O
sent409 factor O
sent409 deprivation O
sent409 and O
sent409 treatment O
sent409 with O
sent409 TNF-alpha O
sent409 or O
sent409 ceramide O
sent409 trigger O
sent409 different O
sent409 initial O
sent409 events O
sent409 both O
sent409 of O
sent409 which O
sent409 can O
sent409 lead O
sent409 to O
sent409 apoptosis O
sent409 in O
sent409 factor-dependent O
sent409 hematopoietic O
sent409 cells O
sent410 However O
sent410 , O
sent410 in O
sent410 the O
sent410 first O
sent410 case O
sent410 , O
sent410 activation O
sent410 of O
sent410 apoptosis O
sent410 is O
sent410 blocked O
sent410 by O
sent410 the O
sent410 basal O
sent410 activity O
sent410 of O
sent410 p210 O
sent410 ( O
sent410 BCR-ABL O
sent410 ) O
sent410 , O
sent410 whereas O
sent410 in O
sent410 the O
sent410 second O
sent410 , O
sent410 the O
sent410 presence O
sent410 of O
sent410 p210 O
sent410 ( O
sent410 BCR-ABL O
sent410 ) O
sent410 appears O
sent410 to O
sent410 accelerate O
sent410 the O
sent410 onset O
sent410 of O
sent410 apoptosis O
sent410 by O
sent410 a O
sent410 mechanism O
sent410 that O
sent410 may O
sent410 involve O
sent410 an O
sent410 activation O
sent410 of O
sent410 its O
sent410 kinase O
sent410 function O
sent411 Clinically O
sent411 , O
sent411 the O
sent411 hallmark O
sent411 of O
sent411 the O
sent411 human D
sent411 amnesic D
sent411 syndrome D
sent411 is O
sent411 an O
sent411 impaired O
sent411 ability O
sent411 to O
sent411 consciously O
sent411 recollect O
sent411 or O
sent411 remember O
sent411 daily O
sent411 events O
sent412 If O
sent412 the O
sent412 medial O
sent412 region O
sent412 of O
sent412 the O
sent412 temporal O
sent412 lobes O
sent412 , O
sent412 including O
sent412 the O
sent412 hippocampus O
sent412 and O
sent412 related O
sent412 structures O
sent412 , O
sent412 is O
sent412 critical O
sent412 for O
sent412 establishing O
sent412 these O
sent412 new O
sent412 memories O
sent412 , O
sent412 then O
sent412 this O
sent412 brain O
sent412 region O
sent412 should O
sent412 be O
sent412 active O
sent412 whenever O
sent412 events O
sent412 are O
sent412 experienced O
sent412 , O
sent412 regardless O
sent412 of O
sent412 whether O
sent412 subjects O
sent412 are O
sent412 asked O
sent412 explicitly O
sent412 to O
sent412 learn O
sent412 and O
sent412 remember O
sent413 Here O
sent413 we O
sent413 show O
sent413 that O
sent413 the O
sent413 medial O
sent413 temporal O
sent413 region O
sent413 is O
sent413 active O
sent413 during O
sent413 encoding O
sent413 and O
sent413 that O
sent413 the O
sent413 hemisphere O
sent413 activated O
sent413 and O
sent413 the O
sent413 amount O
sent413 of O
sent413 activation O
sent413 depend O
sent413 on O
sent413 the O
sent413 type O
sent413 of O
sent413 stimulus O
sent413 presented O
sent413 ( O
sent413 objects O
sent413 or O
sent413 words O
sent413 ) O
sent413 , O
sent413 whether O
sent413 the O
sent413 stimulus O
sent413 can O
sent413 be O
sent413 encoded O
sent413 for O
sent413 meaning O
sent413 ( O
sent413 real O
sent413 objects O
sent413 and O
sent413 words O
sent413 versus O
sent413 nonsense O
sent413 objects O
sent413 and O
sent413 words O
sent413 ) O
sent413 , O
sent413 and O
sent413 task O
sent413 experience O
sent413 ( O
sent413 first O
sent413 versus O
sent413 the O
sent413 second O
sent413 time O
sent413 a O
sent413 task O
sent413 is O
sent413 performed O
sent413 ) O
sent414 These O
sent414 findings O
sent414 demonstrate O
sent414 that O
sent414 the O
sent414 medial O
sent414 temporal O
sent414 lobe O
sent414 memory O
sent414 system O
sent414 is O
sent414 engaged O
sent414 automatically O
sent414 when O
sent414 we O
sent414 attend O
sent414 to O
sent414 a O
sent414 perceptual O
sent414 event O
sent414 and O
sent414 that O
sent414 the O
sent414 location O
sent414 and O
sent414 amount O
sent414 of O
sent414 activation O
sent414 depend O
sent414 on O
sent414 stimulus O
sent414 characteristics O
sent414 ( O
sent414 physical O
sent414 form O
sent414 , O
sent414 meaning O
sent414 ) O
sent414 and O
sent414 experience O
sent415 The O
sent415 involvement O
sent415 of O
sent415 structures O
sent415 in O
sent415 the O
sent415 medial O
sent415 temporal O
sent415 lobe O
sent415 during O
sent415 the O
sent415 encoding O
sent415 of O
sent415 visual O
sent415 associations O
sent415 was O
sent415 studied O
sent415 with O
sent415 functional O
sent415 magnetic O
sent415 resonance O
sent415 imaging O
sent416 In O
sent416 11 O
sent416 out O
sent416 of O
sent416 12 O
sent416 normal O
sent416 healthy O
sent416 volunteers O
sent416 this O
sent416 task O
sent416 resulted O
sent416 in O
sent416 activation O
sent416 in O
sent416 posterior O
sent416 portions O
sent416 of O
sent416 the O
sent416 parahippocampal O
sent416 region O
sent416 , O
sent416 close O
sent416 to O
sent416 the O
sent416 collateral O
sent416 sulcus O
sent417 In O
sent417 seven O
sent417 subjects O
sent417 activation O
sent417 was O
sent417 encountered O
sent417 in O
sent417 the O
sent417 hippocampal O
sent417 formation O
sent418 The O
sent418 visual O
sent418 association O
sent418 task O
sent418 as O
sent418 adapted O
sent418 for O
sent418 this O
sent418 study O
sent418 may O
sent418 provide O
sent418 a O
sent418 sensitive O
sent418 measure O
sent418 to O
sent418 study O
sent418 anterograde O
sent418 amnesia O
sent418 prevalent O
sent418 in O
sent418 Alzheimer O
sent418 's O
sent418 disease O
sent419 Therefore O
sent419 , O
sent419 the O
sent419 present O
sent419 paradigm O
sent419 enables O
sent419 the O
sent419 study O
sent419 of O
sent419 individual O
sent419 changes O
sent419 in O
sent419 learning O
sent419 and O
sent419 memory O
sent419 capacities O
sent419 over O
sent419 time O
sent420 Altered O
sent420 calcium O
sent420 ( O
sent420 Ca2+ O
sent420 ) O
sent420 homeostasis O
sent420 is O
sent420 thought O
sent420 to O
sent420 play O
sent420 a O
sent420 key O
sent420 role O
sent420 in O
sent420 aging O
sent420 and O
sent420 neuropathology O
sent420 resulting O
sent420 in O
sent420 memory O
sent420 deficits O
sent421 Several O
sent421 forms O
sent421 of O
sent421 hippocampal O
sent421 synaptic O
sent421 plasticity O
sent421 are O
sent421 dependent O
sent421 on O
sent421 Ca2+ O
sent421 , O
sent421 providing O
sent421 a O
sent421 potential O
sent421 link O
sent421 between O
sent421 altered O
sent421 Ca2+ O
sent421 homeostasis O
sent421 and O
sent421 memory O
sent421 deficits O
sent421 associated O
sent421 with O
sent421 aging O
sent422 The O
sent422 current O
sent422 study O
sent422 reviews O
sent422 evidence O
sent422 for O
sent422 Ca2+ O
sent422 dysregulation O
sent422 during O
sent422 aging O
sent422 which O
sent422 could O
sent422 interact O
sent422 with O
sent422 Ca O
sent422 ( O
sent422 2+ O
sent422 ) O
sent422 -dependent O
sent422 synaptic O
sent422 plasticity O
sent423 The O
sent423 authors O
sent423 suggest O
sent423 that O
sent423 changes O
sent423 in O
sent423 Ca2+ O
sent423 regulation O
sent423 could O
sent423 adjust O
sent423 the O
sent423 thresholds O
sent423 for O
sent423 synaptic O
sent423 modification O
sent423 , O
sent423 favoring O
sent423 processes O
sent423 for O
sent423 depression O
sent423 of O
sent423 synaptic O
sent423 strength O
sent423 during O
sent423 aging O
sent424 Transiently O
sent424 evolked O
sent424 otoacoustic O
sent424 emissions O
sent424 ( O
sent424 TEOAE O
sent424 ) O
sent424 have O
sent424 been O
sent424 reported O
sent424 in O
sent424 several O
sent424 studies O
sent424 as O
sent424 absent O
sent424 in O
sent424 a O
sent424 small O
sent424 minority O
sent424 of O
sent424 normal O
sent424 ears O
sent425 Other O
sent425 studies O
sent425 have O
sent425 reported O
sent425 TEOAEs O
sent425 in O
sent425 all O
sent425 normal O
sent425 ears O
sent426 Differences O
sent426 between O
sent426 studies O
sent426 may O
sent426 arise O
sent426 directly O
sent426 from O
sent426 criteria O
sent426 for O
sent426 TEOAE O
sent426 identification O
sent426 , O
sent426 criteria O
sent426 for O
sent426 selection O
sent426 of O
sent426 normals O
sent426 , O
sent426 or O
sent426 statistically O
sent426 due O
sent426 to O
sent426 limited O
sent426 sample O
sent426 sizes O
sent427 In O
sent427 order O
sent427 to O
sent427 understand O
sent427 and O
sent427 model O
sent427 cochlear O
sent427 processes O
sent427 involved O
sent427 in O
sent427 TEOAE O
sent427 generation O
sent427 , O
sent427 it O
sent427 needs O
sent427 to O
sent427 be O
sent427 known O
sent427 whether O
sent427 the O
sent427 presence O
sent427 of O
sent427 normal O
sent427 hearing O
sent427 leads O
sent427 automatically O
sent427 to O
sent427 generation O
sent427 of O
sent427 TEOAEs O
sent428 The O
sent428 present O
sent428 study O
sent428 set O
sent428 out O
sent428 to O
sent428 establish O
sent428 in O
sent428 a O
sent428 large O
sent428 sample O
sent428 if O
sent428 any O
sent428 ears O
sent428 could O
sent428 be O
sent428 found O
sent428 that O
sent428 lacked O
sent428 TEOAEs O
sent428 despite O
sent428 normal O
sent428 hearing O
sent428 threshold O
sent428 levels O
sent428 ( O
sent428 HTL O
sent428 ) O
sent429 A O
sent429 total O
sent429 of O
sent429 397 O
sent429 ears O
sent429 from O
sent429 highly O
sent429 cooperative O
sent429 adult O
sent429 subjects O
sent429 were O
sent429 examined O
sent429 under O
sent429 laboratory O
sent429 conditions O
sent430 Using O
sent430 cross O
sent430 correlation O
sent430 between O
sent430 replicate O
sent430 nonlinear O
sent430 waveforms O
sent430 as O
sent430 the O
sent430 criterion O
sent430 , O
sent430 TEOAEs O
sent430 were O
sent430 present O
sent430 in O
sent430 99.2 O
sent430 % O
sent430 of O
sent430 the O
sent430 sample O
sent430 ( O
sent430 lower O
sent430 CI O
sent430 98.1 O
sent430 % O
sent430 ) O
sent431 However O
sent431 , O
sent431 careful O
sent431 visual O
sent431 assessment O
sent431 of O
sent431 the O
sent431 recorded O
sent431 waveforms O
sent431 for O
sent431 the O
sent431 remaining O
sent431 ears O
sent431 did O
sent431 not O
sent431 unequivocally O
sent431 show O
sent431 absence O
sent431 of O
sent431 TEOAE O
sent431 characteristics O
sent431 in O
sent431 any O
sent431 ear O
sent431 with O
sent431 normal O
sent431 HTLs O
sent432 While O
sent432 TEOAE O
sent432 strength O
sent432 varies O
sent432 widely O
sent432 among O
sent432 ears O
sent432 , O
sent432 no O
sent432 clear O
sent432 evidence O
sent432 was O
sent432 found O
sent432 to O
sent432 show O
sent432 that O
sent432 TEOAEs O
sent432 can O
sent432 be O
sent432 absent O
sent432 when O
sent432 HTLs O
sent432 are O
sent432 normal O
sent433 In O
sent433 addition O
sent433 to O
sent433 a O
sent433 long O
sent433 form O
sent433 of O
sent433 591 O
sent433 amino O
sent433 acids O
sent433 ( O
sent433 aa O
sent433 ) O
sent433 , O
sent433 two O
sent433 other O
sent433 forms O
sent433 of O
sent433 PRL O
sent433 receptor O
sent433 ( O
sent433 PRLR O
sent433 ) O
sent433 , O
sent433 differing O
sent433 in O
sent433 the O
sent433 length O
sent433 of O
sent433 their O
sent433 cytoplasmic O
sent433 domains O
sent433 , O
sent433 have O
sent433 been O
sent433 identified O
sent433 in O
sent433 the O
sent433 rat O
sent434 The O
sent434 Nb2 O
sent434 form O
sent434 , O
sent434 lacking O
sent434 198 O
sent434 aa O
sent434 in O
sent434 the O
sent434 cytoplasmic O
sent434 domain O
sent434 , O
sent434 is O
sent434 able O
sent434 to O
sent434 transmit O
sent434 a O
sent434 lactogenic O
sent434 signal O
sent434 similar O
sent434 to O
sent434 the O
sent434 long O
sent434 form O
sent434 , O
sent434 whereas O
sent434 the O
sent434 short O
sent434 form O
sent434 of O
sent434 291 O
sent434 aa O
sent434 is O
sent434 inactive O
sent435 The O
sent435 ability O
sent435 of O
sent435 PRL O
sent435 to O
sent435 activate O
sent435 the O
sent435 promoter O
sent435 of O
sent435 the O
sent435 beta-casein O
sent435 gene O
sent435 or O
sent435 the O
sent435 lactogenic O
sent435 hormone O
sent435 responsive O
sent435 element O
sent435 fused O
sent435 to O
sent435 the O
sent435 luciferase O
sent435 reporter O
sent435 was O
sent435 assessed O
sent435 in O
sent435 Chinese O
sent435 hamster O
sent435 ovary O
sent435 cells O
sent435 or O
sent435 293 O
sent435 fibroblasts O
sent435 transiently O
sent435 transfected O
sent435 with O
sent435 PRLR O
sent435 cDNAs O
sent436 The O
sent436 function O
sent436 of O
sent436 the O
sent436 short O
sent436 form O
sent436 was O
sent436 examined O
sent436 after O
sent436 cotransfection O
sent436 of O
sent436 both O
sent436 the O
sent436 long O
sent436 and O
sent436 short O
sent436 forms O
sent437 These O
sent437 results O
sent437 clearly O
sent437 show O
sent437 that O
sent437 the O
sent437 short O
sent437 form O
sent437 acts O
sent437 as O
sent437 a O
sent437 dominant O
sent437 negative O
sent437 inhibitor O
sent437 through O
sent437 the O
sent437 formation O
sent437 of O
sent437 inactive O
sent437 heterodimers O
sent437 , O
sent437 resulting O
sent437 in O
sent437 an O
sent437 inhibition O
sent437 of O
sent437 Janus O
sent437 kinase O
sent437 2 O
sent437 ( O
sent437 JAK2 O
sent437 ) O
sent437 activation O
sent438 The O
sent438 present O
sent438 study O
sent438 also O
sent438 investigates O
sent438 the O
sent438 possible O
sent438 participation O
sent438 of O
sent438 cytoplasmic O
sent438 receptors O
sent438 in O
sent438 the O
sent438 signal O
sent438 transduction O
sent438 pathway O
sent438 , O
sent438 using O
sent438 cotransfection O
sent438 experiments O
sent438 and O
sent438 a O
sent438 new O
sent438 approach O
sent438 that O
sent438 selectively O
sent438 determines O
sent438 the O
sent438 contribution O
sent438 of O
sent438 cytoplasmic O
sent438 receptors O
sent438 in O
sent438 the O
sent438 process O
sent438 of O
sent438 signal O
sent438 transduction O
sent439 We O
sent439 cotransfected O
sent439 Chinese O
sent439 hamster O
sent439 ovary O
sent439 cells O
sent439 with O
sent439 two O
sent439 cDNA O
sent439 constructs O
sent439 : O
sent439 a O
sent439 cytoplasmic O
sent439 ( O
sent439 soluble O
sent439 ) O
sent439 form O
sent439 of O
sent439 the O
sent439 receptor O
sent439 with O
sent439 a O
sent439 deleted O
sent439 signal O
sent439 peptide O
sent439 ( O
sent439 delta-19 O
sent439 ) O
sent439 , O
sent439 which O
sent439 is O
sent439 unable O
sent439 to O
sent439 bind O
sent439 PRL O
sent439 , O
sent439 and O
sent439 a O
sent439 functionally O
sent439 inactive O
sent439 receptor O
sent439 mutant O
sent439 ( O
sent439 lacking O
sent439 box O
sent439 1 O
sent439 ) O
sent439 , O
sent439 which O
sent439 is O
sent439 anchored O
sent439 in O
sent439 the O
sent439 plasma O
sent439 membrane O
sent439 and O
sent439 able O
sent439 to O
sent439 bind O
sent439 PRL O
sent440 This O
sent440 approach O
sent440 has O
sent440 allowed O
sent440 us O
sent440 to O
sent440 show O
sent440 that O
sent440 delta-19 O
sent440 , O
sent440 lacking O
sent440 expression O
sent440 at O
sent440 the O
sent440 plasma O
sent440 membrane O
sent440 , O
sent440 can O
sent440 transduce O
sent440 the O
sent440 hormonal O
sent440 message O
sent440 , O
sent440 at O
sent440 least O
sent440 to O
sent440 a O
sent440 limited O
sent440 extent O
sent440 ( O
sent440 up O
sent440 to O
sent440 30 O
sent440 % O
sent440 of O
sent440 wild O
sent440 type O
sent440 efficiency O
sent440 ) O
sent440 , O
sent440 providing O
sent440 that O
sent440 association/activation O
sent440 occurs O
sent440 with O
sent440 a O
sent440 PRL-PRLR O
sent440 complex O
sent440 initiated O
sent440 at O
sent440 the O
sent440 cell O
sent440 surface O
sent440 level O
sent440 ; O
sent440 box O
sent440 1 O
sent440 of O
sent440 the O
sent440 cytoplasmic O
sent440 form O
sent440 is O
sent440 necessary O
sent440 to O
sent440 rescue O
sent440 this O
sent440 partial O
sent440 transcriptional O
sent440 activity O
sent440 of O
sent440 the O
sent440 inactive O
sent440 mutant O
sent441 This O
sent441 partial O
sent441 recovery O
sent441 is O
sent441 also O
sent441 parallel O
sent441 to O
sent441 the O
sent441 partial O
sent441 activation O
sent441 of O
sent441 JAK2 O
sent441 , O
sent441 indicating O
sent441 that O
sent441 the O
sent441 signal O
sent441 transduction O
sent441 pathway O
sent441 implicated O
sent441 JAK2 O
sent442 Our O
sent442 results O
sent442 provide O
sent442 evidence O
sent442 that O
sent442 heterodimerization O
sent442 of O
sent442 receptors O
sent442 can O
sent442 be O
sent442 implicated O
sent442 either O
sent442 in O
sent442 the O
sent442 positive O
sent442 or O
sent442 in O
sent442 negative O
sent442 activation O
sent442 of O
sent442 gene O
sent442 transcription O
sent443 BACKGROUND O
sent443 : O
sent443 Inadequate O
sent443 dietary O
sent443 intake O
sent443 of O
sent443 calcium O
sent443 and O
sent443 vitamin O
sent443 D O
sent443 may O
sent443 contribute O
sent443 to O
sent443 the O
sent443 high O
sent443 prevalence O
sent443 of O
sent443 osteoporosis D
sent443 among O
sent443 older O
sent443 persons O
sent444 METHODS O
sent444 : O
sent444 We O
sent444 studied O
sent444 the O
sent444 effects O
sent444 of O
sent444 three O
sent444 years O
sent444 of O
sent444 dietary O
sent444 supplementation O
sent444 with O
sent444 calcium O
sent444 and O
sent444 vitamin O
sent444 D O
sent444 on O
sent444 bone O
sent444 mineral O
sent444 density O
sent444 , O
sent444 biochemical O
sent444 measures O
sent444 of O
sent444 bone O
sent444 metabolism O
sent444 , O
sent444 and O
sent444 the O
sent444 incidence O
sent444 of O
sent444 nonvertebral O
sent444 fractures O
sent444 in O
sent444 176 O
sent444 men O
sent444 and O
sent444 213 O
sent444 women O
sent444 65 O
sent444 years O
sent444 of O
sent444 age O
sent444 or O
sent444 older O
sent444 who O
sent444 were O
sent444 living O
sent444 at O
sent444 home O
sent445 They O
sent445 received O
sent445 either O
sent445 500 O
sent445 mg O
sent445 of O
sent445 calcium O
sent445 plus O
sent445 700 O
sent445 IU O
sent445 of O
sent445 vitamin O
sent445 D3 O
sent445 ( O
sent445 cholecalciferol O
sent445 ) O
sent445 per O
sent445 day O
sent445 or O
sent445 placebo O
sent446 Bone O
sent446 mineral O
sent446 density O
sent446 was O
sent446 measured O
sent446 by O
sent446 dual-energy O
sent446 x-ray O
sent446 absorptiometry O
sent446 , O
sent446 blood O
sent446 and O
sent446 urine O
sent446 were O
sent446 analyzed O
sent446 every O
sent446 six O
sent446 months O
sent446 , O
sent446 and O
sent446 cases O
sent446 of O
sent446 nonvertebral O
sent446 fracture O
sent446 were O
sent446 ascertained O
sent446 by O
sent446 means O
sent446 of O
sent446 interviews O
sent446 and O
sent446 verified O
sent446 with O
sent446 use O
sent446 of O
sent446 hospital O
sent446 records O
sent447 RESULTS O
sent447 : O
sent447 The O
sent447 mean O
sent447 ( O
sent447 +/-SD O
sent447 ) O
sent447 changes O
sent447 in O
sent447 bone O
sent447 mineral O
sent447 density O
sent447 in O
sent447 the O
sent447 calcium-vitamin O
sent447 D O
sent447 and O
sent447 placebo O
sent447 groups O
sent447 were O
sent447 as O
sent447 follows O
sent447 : O
sent447 femoral O
sent447 neck O
sent447 , O
sent447 +0.50+/-4.80 O
sent447 and O
sent447 -0.70+/-5.03 O
sent447 percent O
sent447 , O
sent447 respectively O
sent447 ( O
sent447 P=0.02 O
sent447 ) O
sent447 ; O
sent447 spine O
sent447 , O
sent447 +2.12+/-4.06 O
sent447 and O
sent447 +1.22+/-4.25 O
sent447 percent O
sent447 ( O
sent447 P=0.04 O
sent447 ) O
sent447 ; O
sent447 and O
sent447 total O
sent447 body O
sent447 , O
sent447 +0.06+/-1.83 O
sent447 and O
sent447 -1.09+/-1.71 O
sent447 percent O
sent447 ( O
sent447 P O
sent447 & O
sent447 # O
sent447 60 O
sent447 ; O
sent447 0.001 O
sent447 ) O
sent448 The O
sent448 difference O
sent448 between O
sent448 the O
sent448 calcium-vitamin O
sent448 D O
sent448 and O
sent448 placebo O
sent448 groups O
sent448 was O
sent448 significant O
sent448 at O
sent448 all O
sent448 skeletal O
sent448 sites O
sent448 after O
sent448 one O
sent448 year O
sent448 , O
sent448 but O
sent448 it O
sent448 was O
sent448 significant O
sent448 only O
sent448 for O
sent448 total-body O
sent448 bone O
sent448 mineral O
sent448 density O
sent448 in O
sent448 the O
sent448 second O
sent448 and O
sent448 third O
sent448 years O
sent449 Of O
sent449 37 O
sent449 subjects O
sent449 who O
sent449 had O
sent449 nonvertebral O
sent449 fractures O
sent449 , O
sent449 26 O
sent449 were O
sent449 in O
sent449 the O
sent449 placebo O
sent449 group O
sent449 and O
sent449 11 O
sent449 were O
sent449 in O
sent449 the O
sent449 calcium-vitamin O
sent449 D O
sent449 group O
sent449 ( O
sent449 P=0.02 O
sent449 ) O
sent450 CONCLUSIONS O
sent450 : O
sent450 In O
sent450 men O
sent450 and O
sent450 women O
sent450 65 O
sent450 years O
sent450 of O
sent450 age O
sent450 or O
sent450 older O
sent450 who O
sent450 are O
sent450 living O
sent450 in O
sent450 the O
sent450 community O
sent450 , O
sent450 dietary T
sent450 supplementation T
sent450 with T
sent450 calcium T
sent450 and T
sent450 vitamin T
sent450 D T
sent450 moderately O
sent450 reduced O
sent450 bone D
sent450 loss D
sent450 measured O
sent450 in O
sent450 the O
sent450 femoral O
sent450 neck O
sent450 , O
sent450 spine O
sent450 , O
sent450 and O
sent450 total O
sent450 body O
sent450 over O
sent450 the O
sent450 three-year O
sent450 study O
sent450 period O
sent450 and O
sent450 reduced O
sent450 the O
sent450 incidence O
sent450 of O
sent450 nonvertebral D
sent450 fractures D
sent451 The O
sent451 sterilization O
sent451 and O
sent451 contaminated O
sent451 waste O
sent451 disposal O
sent451 practices O
sent451 in O
sent451 all O
sent451 14 O
sent451 dental O
sent451 clinics O
sent451 operated O
sent451 by O
sent451 the O
sent451 Southern O
sent451 Sydney O
sent451 Area O
sent451 Health O
sent451 Service O
sent451 were O
sent451 surveyed O
sent452 All O
sent452 of O
sent452 the O
sent452 clinics O
sent452 used O
sent452 autoclaves O
sent452 for O
sent452 sterilization O
sent453 All O
sent453 hand O
sent453 instruments O
sent453 , O
sent453 handpieces O
sent453 and O
sent453 triplex O
sent453 syringes O
sent453 were O
sent453 autoclaved O
sent453 between O
sent453 patients O
sent454 Chemical O
sent454 disinfection O
sent454 solutions O
sent454 were O
sent454 used O
sent454 in O
sent454 12 O
sent454 of O
sent454 the O
sent454 14 O
sent454 dental O
sent454 clinics O
sent454 , O
sent454 mainly O
sent454 for O
sent454 surface O
sent454 decontamination O
sent455 Five O
sent455 dental O
sent455 clinics O
sent455 had O
sent455 separate O
sent455 storage O
sent455 areas O
sent455 for O
sent455 contaminated O
sent455 waste O
sent455 which O
sent455 compiled O
sent455 with O
sent455 contaminated O
sent455 waste O
sent455 separation O
sent455 and O
sent455 disposal O
sent455 guidelines O
sent456 The O
sent456 practice O
sent456 of O
sent456 recapping O
sent456 needles O
sent456 with O
sent456 fingers O
sent456 and O
sent456 some O
sent456 inadequate O
sent456 washing O
sent456 facilities O
sent456 are O
sent456 areas O
sent456 that O
sent456 require O
sent456 particular O
sent456 attention O
sent457 Safety O
sent457 and O
sent457 efficacy O
sent457 are O
sent457 crucial O
sent457 but O
sent457 separate O
sent457 issues O
sent457 for O
sent457 vitamin O
sent457 and O
sent457 mineral O
sent457 supplements O
sent458 Misinterpretation O
sent458 of O
sent458 `` O
sent458 safe O
sent458 and O
sent458 adequate O
sent458 '' O
sent458 to O
sent458 mean O
sent458 `` O
sent458 safety O
sent458 limit O
sent458 '' O
sent458 would O
sent458 impose O
sent458 restrictions O
sent458 on O
sent458 vitamin O
sent458 and O
sent458 mineral O
sent458 intakes O
sent458 that O
sent458 are O
sent458 not O
sent458 needed O
sent458 to O
sent458 ensure O
sent458 safety O
sent459 Substantial O
sent459 evidence O
sent459 indicates O
sent459 that O
sent459 intakes O
sent459 greater O
sent459 than O
sent459 the O
sent459 recommended O
sent459 dietary O
sent459 allowances O
sent459 ( O
sent459 RDAs O
sent459 ) O
sent459 of O
sent459 certain O
sent459 vitamins O
sent459 and O
sent459 minerals O
sent459 such O
sent459 as O
sent459 calcium O
sent459 , O
sent459 folic O
sent459 acid O
sent459 , O
sent459 vitamin O
sent459 E O
sent459 , O
sent459 selenium O
sent459 , O
sent459 and O
sent459 chromium O
sent459 reduce O
sent459 the O
sent459 risk O
sent459 of O
sent459 certain O
sent459 diseases O
sent459 for O
sent459 some O
sent459 people O
sent460 Limitation O
sent460 of O
sent460 intakes O
sent460 to O
sent460 the O
sent460 RDAs O
sent460 would O
sent460 preclude O
sent460 reductions O
sent460 in O
sent460 disease O
sent460 risk O
sent460 from O
sent460 these O
sent460 nutrients O
sent461 The O
sent461 margin O
sent461 of O
sent461 safety O
sent461 between O
sent461 the O
sent461 usual O
sent461 dietary O
sent461 intake O
sent461 and O
sent461 the O
sent461 intake O
sent461 that O
sent461 would O
sent461 produce O
sent461 adverse O
sent461 effects O
sent461 varies O
sent461 greatly O
sent461 among O
sent461 the O
sent461 different O
sent461 nutrients O
sent462 Very O
sent462 high O
sent462 intakes O
sent462 of O
sent462 vitamins O
sent462 A O
sent462 and O
sent462 D O
sent462 , O
sent462 niacin O
sent462 , O
sent462 pyridoxine O
sent462 , O
sent462 and O
sent462 selenium O
sent462 have O
sent462 produced O
sent462 adverse O
sent462 effects O
sent463 Many O
sent463 widely O
sent463 discussed O
sent463 putative O
sent463 adverse O
sent463 effects O
sent463 of O
sent463 vitamin O
sent463 C O
sent463 , O
sent463 vitamin O
sent463 E O
sent463 , O
sent463 and O
sent463 trivalent O
sent463 chromium O
sent463 have O
sent463 little O
sent463 factual O
sent463 basis O
sent464 There O
sent464 is O
sent464 no O
sent464 evidence O
sent464 of O
sent464 adverse O
sent464 effects O
sent464 from O
sent464 beta-carotene O
sent464 supplements O
sent464 except O
sent464 in O
sent464 current O
sent464 heavy O
sent464 smokers O
sent465 The O
sent465 mutator O
sent465 hypothesis O
sent465 of O
sent465 tumorigenesis O
sent465 suggests O
sent465 that O
sent465 loss O
sent465 of O
sent465 chromosomal O
sent465 stability O
sent465 or O
sent465 maintenance O
sent465 functions O
sent465 results O
sent465 in O
sent465 elevated O
sent465 mutation O
sent465 rates O
sent465 , O
sent465 leading O
sent465 to O
sent465 the O
sent465 accumulation O
sent465 of O
sent465 the O
sent465 numerous O
sent465 mutations O
sent465 required O
sent465 for O
sent465 multistep O
sent465 carcinogenesis O
sent466 The O
sent466 human O
sent466 DNA O
sent466 mismatch O
sent466 repair O
sent466 ( O
sent466 MMR O
sent466 ) O
sent466 genes O
sent466 are O
sent466 highly O
sent466 conserved O
sent466 homologues O
sent466 of O
sent466 the O
sent466 Escherichia O
sent466 coli O
sent466 MutHLS O
sent466 system O
sent466 , O
sent466 which O
sent466 contribute O
sent466 to O
sent466 genomic O
sent466 stability O
sent466 by O
sent466 surveillance O
sent466 and O
sent466 repair O
sent466 of O
sent466 replication O
sent466 misincorporation O
sent466 errors O
sent466 and O
sent466 exogenous O
sent466 DNA O
sent466 damage O
sent467 Mutations O
sent467 in O
sent467 one O
sent467 of O
sent467 these O
sent467 MMR O
sent467 genes O
sent467 , O
sent467 hMSH2 O
sent467 , O
sent467 account O
sent467 for O
sent467 about O
sent467 half O
sent467 of O
sent467 all O
sent467 cases O
sent467 of O
sent467 genetically O
sent467 linked O
sent467 hereditary O
sent467 non-polyposis O
sent467 colorectal O
sent467 cancer O
sent468 Loss O
sent468 of O
sent468 function O
sent468 of O
sent468 p53 O
sent468 has O
sent468 also O
sent468 been O
sent468 proposed O
sent468 to O
sent468 increase O
sent468 cellular O
sent468 hypermutability O
sent468 , O
sent468 thereby O
sent468 accelerating O
sent468 carcinogenesis O
sent468 , O
sent468 although O
sent468 a O
sent468 clear O
sent468 role O
sent468 for O
sent468 p53 O
sent468 in O
sent468 genomic O
sent468 instability O
sent468 remains O
sent468 controversial O
sent469 p53 O
sent469 is O
sent469 mutated O
sent469 frequently O
sent469 in O
sent469 a O
sent469 wide O
sent469 range O
sent469 of O
sent469 human O
sent469 cancers D
sent469 , O
sent469 including O
sent469 colonic D
sent469 tumours D
sent470 Both O
sent470 Msh2- O
sent470 and O
sent470 p53-targeted O
sent470 knockout O
sent470 mice O
sent470 are O
sent470 viable O
sent470 and O
sent470 susceptible O
sent470 to O
sent470 cancer D
sent471 Here O
sent471 we O
sent471 demonstrate O
sent471 that O
sent471 combined O
sent471 Msh2 O
sent471 and O
sent471 p53 O
sent471 ablation O
sent471 ( O
sent471 Msh2-/-p53-/- O
sent471 ) O
sent471 results O
sent471 in O
sent471 developmental O
sent471 arrest O
sent471 of O
sent471 all O
sent471 female O
sent471 embryos O
sent471 at O
sent471 9.5 O
sent471 days O
sent472 In O
sent472 contrast O
sent472 , O
sent472 male O
sent472 Msh2-/-p53-/- O
sent472 mice O
sent472 are O
sent472 viable O
sent472 , O
sent472 but O
sent472 succumb O
sent472 to O
sent472 tumours D
sent472 significantly O
sent472 earlier O
sent472 ( O
sent472 t1-2 O
sent472 is O
sent472 73 O
sent472 days O
sent472 ) O
sent472 than O
sent472 either O
sent472 Msh2-/- O
sent472 or O
sent472 p53-/- O
sent472 littermates O
sent473 Furthermore O
sent473 , O
sent473 the O
sent473 frequency O
sent473 of O
sent473 microsatellite O
sent473 instability O
sent473 ( O
sent473 MSI O
sent473 ) O
sent473 in O
sent473 tumours O
sent473 from O
sent473 Msh2-/-p53-/- O
sent473 mice O
sent473 is O
sent473 not O
sent473 significantly O
sent473 different O
sent473 than O
sent473 in O
sent473 Msh2-/- O
sent473 mice O
sent474 Synergism O
sent474 in O
sent474 tumorigenesis O
sent474 and O
sent474 independent O
sent474 segregation O
sent474 of O
sent474 the O
sent474 MSI O
sent474 phenotype O
sent474 suggest O
sent474 that O
sent474 Msh2 O
sent474 and O
sent474 p53 O
sent474 are O
sent474 not O
sent474 genetically O
sent474 epistatic O
sent475 Our O
sent475 data O
sent475 ( O
sent475 Reddy O
sent475 et O
sent475 al O
sent475 . O
sent475 , O
sent475 Radiat O
sent476 Res O
sent477 141 O
sent477 , O
sent477 252-258 O
sent477 , O
sent477 1995 O
sent477 ) O
sent477 on O
sent477 the O
sent477 kinetics O
sent477 of O
sent477 the O
sent477 repair O
sent477 of O
sent477 potentially O
sent477 lethal O
sent477 damage O
sent477 in O
sent477 log-phase O
sent477 Chinese O
sent477 hamster O
sent477 V79 O
sent477 cells O
sent477 are O
sent477 used O
sent477 to O
sent477 test O
sent477 some O
sent477 predictions O
sent477 which O
sent477 arise O
sent477 from O
sent477 the O
sent477 different O
sent477 assumptions O
sent477 of O
sent477 the O
sent477 repair-misrepair O
sent477 ( O
sent477 RMR O
sent477 ) O
sent477 ( O
sent477 C O
sent478 A O
sent479 Tobias O
sent479 , O
sent479 Radiat O
sent480 Res O
sent481 104 O
sent481 , O
sent481 S77-S95 O
sent481 , O
sent481 1985 O
sent481 ) O
sent481 , O
sent481 lethal-potentially O
sent481 lethal O
sent481 ( O
sent481 LPL O
sent481 ) O
sent481 ( O
sent481 S. O
sent481 B O
sent482 Curtis O
sent482 , O
sent482 Radiat O
sent483 Res O
sent484 106 O
sent484 , O
sent484 252-270 O
sent484 , O
sent484 1986 O
sent484 ) O
sent484 and O
sent484 double-strand O
sent484 break O
sent484 ( O
sent484 DSB O
sent484 ) O
sent484 ( O
sent484 J O
sent485 Y O
sent486 Ostashevsky O
sent486 , O
sent486 Radiat O
sent487 Res O
sent488 118 O
sent488 , O
sent488 437-466 O
sent488 , O
sent488 1989 O
sent488 ) O
sent488 models O
sent489 The O
sent489 LPL O
sent489 model O
sent489 defines O
sent489 the O
sent489 time O
sent489 available O
sent489 for O
sent489 repair O
sent489 of O
sent489 PLD O
sent489 ( O
sent489 t O
sent489 ( O
sent489 rep O
sent489 ) O
sent489 ) O
sent489 as O
sent489 the O
sent489 time O
sent489 taken O
sent489 to O
sent489 reach O
sent489 maximal O
sent489 survival O
sent489 in O
sent489 a O
sent489 delayed-plating O
sent489 recovery O
sent489 experiment O
sent490 Those O
sent490 data O
sent490 show O
sent490 that O
sent490 after O
sent490 this O
sent490 time O
sent490 has O
sent490 elapsed O
sent490 , O
sent490 contrary O
sent490 to O
sent490 the O
sent490 expectation O
sent490 of O
sent490 the O
sent490 LPL O
sent490 model O
sent490 , O
sent490 survival O
sent490 can O
sent490 be O
sent490 increased O
sent490 by O
sent490 changing O
sent490 the O
sent490 medium O
sent490 used O
sent490 for O
sent490 delayed O
sent490 plating O
sent490 from O
sent490 fresh O
sent490 growth O
sent490 medium O
sent490 to O
sent490 conditioned O
sent490 medium O
sent491 According O
sent491 to O
sent491 the O
sent491 RMR O
sent491 model O
sent491 , O
sent491 all O
sent491 potentially O
sent491 lethal O
sent491 lesions O
sent491 should O
sent491 also O
sent491 be O
sent491 committed O
sent491 by O
sent491 that O
sent491 time O
sent491 and O
sent491 be O
sent491 unavailable O
sent491 for O
sent491 repair O
sent491 in O
sent491 the O
sent491 new O
sent491 medium O
sent492 Only O
sent492 the O
sent492 DSB O
sent492 model O
sent492 correctly O
sent492 predicted O
sent492 that O
sent492 PLD O
sent492 ( O
sent492 = O
sent492 DSBs O
sent492 ) O
sent492 would O
sent492 still O
sent492 be O
sent492 available O
sent492 for O
sent492 repair O
sent492 after O
sent492 that O
sent492 time O
sent493 Second O
sent493 , O
sent493 data O
sent493 for O
sent493 split-dose O
sent493 recovery O
sent493 are O
sent493 used O
sent493 to O
sent493 predict O
sent493 the O
sent493 first-order O
sent493 kinetics O
sent493 time O
sent493 constant O
sent493 for O
sent493 DSB O
sent493 repair O
sent493 ( O
sent493 tau O
sent493 ( O
sent493 DSBR O
sent493 ) O
sent493 ) O
sent493 using O
sent493 the O
sent493 DSB O
sent493 model O
sent493 ( O
sent493 24 O
sent493 +/- O
sent493 1.5 O
sent493 min O
sent493 ) O
sent494 This O
sent494 value O
sent494 is O
sent494 nearly O
sent494 identical O
sent494 to O
sent494 the O
sent494 value O
sent494 of O
sent494 27 O
sent494 +/- O
sent494 1 O
sent494 min O
sent494 determined O
sent494 from O
sent494 the O
sent494 data O
sent494 obtained O
sent494 by O
sent494 Cheong O
sent494 et O
sent494 al O
sent494 . O
sent494 using O
sent494 pulsed-field O
sent494 gel O
sent494 electrophoresis O
sent494 ( O
sent494 PFGE O
sent494 ) O
sent494 ( O
sent494 Mutat O
sent495 Res O
sent496 274 O
sent496 , O
sent496 111-122 O
sent496 , O
sent496 1992 O
sent496 ) O
sent497 The O
sent497 value O
sent497 based O
sent497 on O
sent497 PFGE O
sent497 is O
sent497 used O
sent497 to O
sent497 calculate O
sent497 the O
sent497 value O
sent497 of O
sent497 t O
sent497 ( O
sent497 rep O
sent497 ) O
sent497 predicted O
sent497 by O
sent497 the O
sent497 DSB O
sent497 model O
sent497 ( O
sent497 2.6 O
sent497 +/- O
sent497 0.1 O
sent497 h O
sent497 ) O
sent497 , O
sent497 which O
sent497 agrees O
sent497 with O
sent497 the O
sent497 value O
sent497 determined O
sent497 experimentally O
sent497 as O
sent497 the O
sent497 time O
sent497 when O
sent497 changing O
sent497 the O
sent497 delayed-plating O
sent497 medium O
sent497 from O
sent497 growth O
sent497 medium O
sent497 to O
sent497 conditioned O
sent497 medium O
sent497 no O
sent497 longer O
sent497 gives O
sent497 the O
sent497 full O
sent497 recovery O
sent497 seen O
sent497 with O
sent497 delayed O
sent497 plating O
sent497 in O
sent497 conditioned O
sent497 medium O
sent497 ( O
sent497 2.5 O
sent497 h O
sent497 ) O
sent498 However O
sent498 , O
sent498 some O
sent498 recovery O
sent498 was O
sent498 seen O
sent498 for O
sent498 a O
sent498 change O
sent498 in O
sent498 the O
sent498 medium O
sent498 ( O
sent498 growth O
sent498 medium O
sent498 to O
sent498 conditioned O
sent498 medium O
sent498 ) O
sent498 up O
sent498 to O
sent498 5-6 O
sent498 h O
sent498 postirradiation O
sent499 Reanalysis O
sent499 of O
sent499 the O
sent499 original O
sent499 data O
sent499 on O
sent499 DSB O
sent499 repair O
sent499 shows O
sent499 that O
sent499 they O
sent499 are O
sent499 consistent O
sent499 with O
sent499 two O
sent499 first-order O
sent499 repair O
sent499 rates O
sent499 ( O
sent499 18 O
sent499 +/- O
sent499 7 O
sent499 min O
sent499 and O
sent499 about O
sent499 52 O
sent499 min O
sent499 ) O
sent500 These O
sent500 results O
sent500 are O
sent500 consistent O
sent500 with O
sent500 two O
sent500 pools O
sent500 of O
sent500 DSBs O
sent500 ( O
sent500 or O
sent500 cells O
sent500 ) O
sent500 , O
sent500 each O
sent500 with O
sent500 their O
sent500 own O
sent500 t O
sent500 ( O
sent500 rep O
sent500 ) O
sent501 The O
sent501 early O
sent501 t O
sent501 ( O
sent501 rep O
sent501 ) O
sent501 , O
sent501 associated O
sent501 with O
sent501 tau O
sent501 ( O
sent501 fast O
sent501 ) O
sent501 , O
sent501 is O
sent501 predicted O
sent501 to O
sent501 be O
sent501 1.7 O
sent501 +/- O
sent501 0.7 O
sent501 h O
sent501 , O
sent501 and O
sent501 the O
sent501 late O
sent501 t O
sent501 ( O
sent501 rep O
sent501 ) O
sent501 , O
sent501 associated O
sent501 with O
sent501 tau O
sent501 ( O
sent501 slow O
sent501 ) O
sent501 , O
sent501 is O
sent501 predicted O
sent501 to O
sent501 be O
sent501 about O
sent501 5 O
sent501 h. O
sent501 Both O
sent501 values O
sent501 are O
sent501 in O
sent501 excellent O
sent501 agreement O
sent501 with O
sent501 the O
sent501 times O
sent501 at O
sent501 which O
sent501 changing O
sent501 from O
sent501 growth O
sent501 medium O
sent501 to O
sent501 conditioned O
sent501 medium O
sent501 no O
sent501 longer O
sent501 gives O
sent501 the O
sent501 full O
sent501 recovery O
sent501 seen O
sent501 in O
sent501 conditioned O
sent501 medium O
sent501 only O
sent501 ( O
sent501 the O
sent501 early O
sent501 t O
sent501 ( O
sent501 rep O
sent501 ) O
sent501 ) O
sent501 , O
sent501 and O
sent501 the O
sent501 time O
sent501 when O
sent501 changing O
sent501 from O
sent501 growth O
sent501 medium O
sent501 to O
sent501 conditioned O
sent501 medium O
sent501 produces O
sent501 no O
sent501 further O
sent501 increase O
sent501 in O
sent501 survival O
sent501 ( O
sent501 the O
sent501 late O
sent501 t O
sent501 ( O
sent501 rep O
sent501 ) O
sent501 ) O
sent501 , O
sent501 respectively O
sent502 It O
sent502 is O
sent502 noted O
sent502 that O
sent502 attempts O
sent502 to O
sent502 correlate O
sent502 radiosensitivity O
sent502 with O
sent502 the O
sent502 rates O
sent502 of O
sent502 DSB O
sent502 repair O
sent502 , O
sent502 rather O
sent502 than O
sent502 using O
sent502 an O
sent502 explicit O
sent502 model O
sent502 such O
sent502 as O
sent502 the O
sent502 DSB O
sent502 model O
sent502 , O
sent502 are O
sent502 unlikely O
sent502 to O
sent502 be O
sent502 productive O
sent502 since O
sent502 survival O
sent502 depends O
sent502 on O
sent502 both O
sent502 tau O
sent502 ( O
sent502 DSBR O
sent502 ) O
sent502 and O
sent502 t O
sent502 ( O
sent502 rep O
sent502 ) O
sent502 ( O
sent502 as O
sent502 defined O
sent502 in O
sent502 the O
sent502 DSB O
sent502 model O
sent502 ) O
sent502 and O
sent502 the O
sent502 latter O
sent502 may O
sent502 be O
sent502 the O
sent502 more O
sent502 important O
sent502 determinant O
sent502 of O
sent502 radiosensitivity O
sent502 ( O
sent502 as O
sent502 it O
sent502 appears O
sent502 to O
sent502 be O
sent502 for O
sent502 ataxia O
sent502 telangiectasia O
sent502 cells O
sent502 compared O
sent502 to O
sent502 normal O
sent502 fibroblasts O
sent502 and O
sent502 for O
sent502 irs O
sent502 compared O
sent502 to O
sent502 V79 O
sent502 cells O
sent502 ) O
sent503 CONTEXT O
sent503 : O
sent503 Adolescents O
sent503 ' O
sent503 concerns O
sent503 about O
sent503 privacy O
sent503 in O
sent503 clinical O
sent503 settings O
sent503 decrease O
sent503 their O
sent503 willingness O
sent503 to O
sent503 seek O
sent503 health O
sent503 care O
sent503 for O
sent503 sensitive O
sent503 problems O
sent503 and O
sent503 may O
sent503 inhibit O
sent503 their O
sent503 communication O
sent503 with O
sent503 physicians O
sent504 OBJECTIVE O
sent504 : O
sent504 To O
sent504 investigate O
sent504 the O
sent504 influence O
sent504 of O
sent504 physicians O
sent504 ' O
sent504 assurances O
sent504 of O
sent504 confidentiality O
sent504 on O
sent504 adolescents O
sent504 ' O
sent504 willingness O
sent504 to O
sent504 disclose O
sent504 information O
sent504 and O
sent504 seek O
sent504 future O
sent504 health O
sent504 care O
sent505 DESIGN O
sent505 : O
sent505 Randomized O
sent505 controlled O
sent505 trial O
sent506 SETTING O
sent506 : O
sent506 Three O
sent506 suburban O
sent506 public O
sent506 high O
sent506 schools O
sent506 in O
sent506 California O
sent507 PARTICIPANTS O
sent507 : O
sent507 The O
sent507 562 O
sent507 participating O
sent507 adolescents O
sent507 represented O
sent507 92 O
sent507 % O
sent507 of O
sent507 students O
sent507 in O
sent507 mandatory O
sent507 classes O
sent508 INTERVENTION O
sent508 : O
sent508 After O
sent508 random O
sent508 assignment O
sent508 to O
sent508 1 O
sent508 of O
sent508 3 O
sent508 groups O
sent508 , O
sent508 the O
sent508 adolescents O
sent508 listened O
sent508 to O
sent508 a O
sent508 standardized O
sent508 audiotape O
sent508 depiction O
sent508 of O
sent508 an O
sent508 office O
sent508 visit O
sent508 during O
sent508 which O
sent508 they O
sent508 heard O
sent508 a O
sent508 physician O
sent508 who O
sent508 assured O
sent508 unconditional O
sent508 confidentiality O
sent508 , O
sent508 a O
sent508 physician O
sent508 who O
sent508 assured O
sent508 conditional O
sent508 confidentiality O
sent508 , O
sent508 or O
sent508 a O
sent508 physician O
sent508 who O
sent508 did O
sent508 not O
sent508 mention O
sent508 confidentiality O
sent509 MAIN O
sent509 OUTCOME O
sent509 MEASURES O
sent509 : O
sent509 Adolescents O
sent509 ' O
sent509 willingness O
sent509 to O
sent509 disclose O
sent509 general O
sent509 information O
sent509 , O
sent509 willingness O
sent509 to O
sent509 disclose O
sent509 information O
sent509 about O
sent509 sensitive O
sent509 topics O
sent509 , O
sent509 intended O
sent509 honesty O
sent509 , O
sent509 and O
sent509 likelihood O
sent509 of O
sent509 return O
sent509 visits O
sent509 to O
sent509 the O
sent509 physician O
sent509 depicted O
sent509 in O
sent509 the O
sent509 scenario O
sent509 were O
sent509 assessed O
sent509 by O
sent509 anonymous O
sent509 written O
sent509 questionnaire O
sent510 RESULTS O
sent510 : O
sent510 Assurances O
sent510 of O
sent510 confidentiality O
sent510 increased O
sent510 the O
sent510 number O
sent510 of O
sent510 adolescents O
sent510 willing O
sent510 to O
sent510 disclose O
sent510 sensitive O
sent510 information O
sent510 about O
sent510 sexuality O
sent510 , O
sent510 substance O
sent510 use O
sent510 , O
sent510 and O
sent510 mental O
sent510 health O
sent510 from O
sent510 39 O
sent510 % O
sent510 ( O
sent510 68/175 O
sent510 ) O
sent510 to O
sent510 46.5 O
sent510 % O
sent510 ( O
sent510 178/383 O
sent510 ) O
sent510 ( O
sent510 beta=.10 O
sent510 , O
sent510 P=.02 O
sent510 ) O
sent510 and O
sent510 increased O
sent510 the O
sent510 number O
sent510 willing O
sent510 to O
sent510 seek O
sent510 future O
sent510 health O
sent510 care O
sent510 from O
sent510 53 O
sent510 % O
sent510 ( O
sent510 93/175 O
sent510 ) O
sent510 to O
sent510 67 O
sent510 % O
sent510 ( O
sent510 259/386 O
sent510 ) O
sent510 ( O
sent510 beta=.17 O
sent510 , O
sent510 P O
sent510 & O
sent510 # O
sent510 60 O
sent510 ; O
sent510 .001 O
sent510 ) O
sent511 When O
sent511 comparing O
sent511 the O
sent511 unconditional O
sent511 with O
sent511 the O
sent511 conditional O
sent511 groups O
sent511 , O
sent511 assurances O
sent511 of O
sent511 unconditional O
sent511 confidentiality O
sent511 increased O
sent511 the O
sent511 number O
sent511 of O
sent511 adolescents O
sent511 willing O
sent511 to O
sent511 return O
sent511 for O
sent511 a O
sent511 future O
sent511 visit O
sent511 by O
sent511 10 O
sent511 percentage O
sent511 points O
sent511 , O
sent511 from O
sent511 62 O
sent511 % O
sent511 ( O
sent511 122/196 O
sent511 ) O
sent511 to O
sent511 72 O
sent511 % O
sent511 ( O
sent511 137/190 O
sent511 ) O
sent511 ( O
sent511 beta=.14 O
sent511 , O
sent511 P=.001 O
sent511 ) O
sent512 CONCLUSIONS O
sent512 : O
sent512 Adolescents O
sent512 are O
sent512 more O
sent512 willing O
sent512 to O
sent512 communicate O
sent512 with O
sent512 and O
sent512 seek O
sent512 health O
sent512 care O
sent512 from O
sent512 physicians O
sent512 who O
sent512 assure O
sent512 confidentiality O
sent513 Further O
sent513 investigation O
sent513 is O
sent513 needed O
sent513 to O
sent513 identify O
sent513 a O
sent513 confidentiality O
sent513 assurance O
sent513 statement O
sent513 that O
sent513 explains O
sent513 the O
sent513 legal O
sent513 and O
sent513 ethical O
sent513 limitations O
sent513 of O
sent513 confidentiality O
sent513 without O
sent513 decreasing O
sent513 adolescents O
sent513 ' O
sent513 likelihood O
sent513 of O
sent513 seeking O
sent513 future O
sent513 health O
sent513 care O
sent513 for O
sent513 routine O
sent513 and O
sent513 nonreportable O
sent513 sensitive O
sent513 health O
sent513 concerns O
sent514 BACKGROUND O
sent514 : O
sent514 Diabetic O
sent514 foot D
sent514 infections D
sent514 cause O
sent514 substantial O
sent514 morbidity O
sent514 and O
sent514 mortality O
sent515 Neutrophil O
sent515 superoxide O
sent515 generation O
sent515 , O
sent515 a O
sent515 crucial O
sent515 part O
sent515 of O
sent515 neutrophil O
sent515 bactericidal O
sent515 activity O
sent515 , O
sent515 is O
sent515 impaired O
sent515 in O
sent515 diabetes D
sent516 Granulocyte-colony O
sent516 stimulating O
sent516 factor O
sent516 ( O
sent516 G-CSF O
sent516 ) O
sent516 increases O
sent516 the O
sent516 release O
sent516 of O
sent516 neutrophils O
sent516 from O
sent516 the O
sent516 bone O
sent516 marrow O
sent516 and O
sent516 improves O
sent516 neutrophil O
sent516 function O
sent517 We O
sent517 assessed O
sent517 G-CSF T
sent517 as O
sent517 adjuvant O
sent517 therapy O
sent517 for O
sent517 the O
sent517 treatment O
sent517 of O
sent517 severe D
sent517 foot D
sent517 infections D
sent517 in D
sent517 diabetic D
sent517 patients D
sent518 METHODS O
sent518 : O
sent518 40 O
sent518 diabetic O
sent518 patients O
sent518 with O
sent518 foot D
sent518 infections D
sent518 were O
sent518 enrolled O
sent518 in O
sent518 a O
sent518 double-blind O
sent518 placebo-controlled O
sent518 study O
sent519 On O
sent519 admission O
sent519 , O
sent519 patients O
sent519 were O
sent519 randomly O
sent519 assigned O
sent519 G-CSF T
sent519 ( T
sent519 filgrastim T
sent519 ) T
sent519 therapy T
sent519 ( O
sent519 n O
sent519 = O
sent519 20 O
sent519 ) O
sent519 or O
sent519 placebo O
sent519 ( O
sent519 n O
sent519 = O
sent519 20 O
sent519 ) O
sent519 for O
sent519 7 O
sent519 days O
sent520 Both O
sent520 groups O
sent520 received O
sent520 similar O
sent520 antibiotic T
sent520 and T
sent520 insulin T
sent520 treatment T
sent521 Neutrophils O
sent521 from O
sent521 the O
sent521 peripheral O
sent521 blood O
sent521 of O
sent521 these O
sent521 participants O
sent521 and O
sent521 from O
sent521 healthy O
sent521 controls O
sent521 were O
sent521 stimulated O
sent521 with O
sent521 opsonised O
sent521 zymosan O
sent521 , O
sent521 and O
sent521 superoxide O
sent521 production O
sent521 was O
sent521 measured O
sent521 by O
sent521 a O
sent521 spectrophotometric O
sent521 assay O
sent521 ( O
sent521 reduction O
sent521 of O
sent521 ferricytochrome O
sent521 C O
sent521 ) O
sent522 < O
sent522 TO_SEE O
sent522 > O
sent522 FINDINGS O
sent522 : O
sent522 G-CSF O
sent522 therapy O
sent522 was O
sent522 associated O
sent522 with O
sent522 earlier O
sent522 eradication O
sent522 of O
sent522 pathogens O
sent522 from O
sent522 the O
sent522 infected O
sent522 ulcer O
sent522 ( O
sent522 median O
sent522 4 O
sent522 ( O
sent522 range O
sent522 2-10 O
sent522 ) O
sent522 vs O
sent522 8 O
sent522 ( O
sent522 2-79 O
sent522 ) O
sent522 days O
sent522 in O
sent522 the O
sent522 placebo O
sent522 group O
sent522 ; O
sent522 p O
sent522 = O
sent522 0.02 O
sent522 ) O
sent522 , O
sent522 quicker O
sent522 resolution O
sent522 of O
sent522 cellulitis O
sent522 < O
sent522 ( O
sent522 7 O
sent522 ( O
sent522 5-20 O
sent522 ) O
sent522 vs O
sent522 12 O
sent522 ( O
sent522 5-93 O
sent522 ) O
sent522 days O
sent522 ; O
sent522 p O
sent522 = O
sent522 0.03 O
sent522 ) O
sent522 , O
sent522 shorter O
sent522 hospital O
sent522 stay O
sent522 ( O
sent522 10 O
sent522 ( O
sent522 7-31 O
sent522 ) O
sent522 vs O
sent522 17.5 O
sent522 ( O
sent522 9-100 O
sent522 ) O
sent522 days O
sent522 ; O
sent522 p O
sent522 = O
sent522 0.02 O
sent522 ) O
sent522 , O
sent522 and O
sent522 a O
sent522 shorter O
sent522 duration O
sent522 of O
sent522 intravenous O
sent522 antibiotic O
sent522 treatment O
sent522 ( O
sent522 8.5 O
sent522 ( O
sent522 5-30 O
sent522 ) O
sent522 vs O
sent522 14.5 O
sent522 ( O
sent522 8-63 O
sent522 ) O
sent522 days O
sent522 ; O
sent522 p O
sent522 = O
sent522 0.02 O
sent522 ) O
sent523 No O
sent523 G-CSF-treated O
sent523 patient O
sent523 needed O
sent523 surgery T
sent523 , O
sent523 whereas O
sent523 two O
sent523 placebo O
sent523 recipients O
sent523 underwent O
sent523 to O
sent523 amputation T
sent523 and O
sent523 two O
sent523 had O
sent523 extensive O
sent523 debridement T
sent523 under O
sent523 anaesthesia O
sent524 After O
sent524 7 O
sent524 days O
sent524 ' O
sent524 treatment O
sent524 , O
sent524 neutrophil O
sent524 superoxide O
sent524 production O
sent524 was O
sent524 significantly O
sent524 higher O
sent524 in O
sent524 the O
sent524 G-CSF O
sent524 group O
sent524 than O
sent524 in O
sent524 the O
sent524 placebo O
sent524 group O
sent524 ( O
sent524 16.1 O
sent524 ( O
sent524 4.2-24.2 O
sent524 ) O
sent524 vs O
sent524 7.3 O
sent524 ( O
sent524 2.1-11.5 O
sent524 ) O
sent524 nmol O
sent524 per O
sent524 10 O
sent524 ( O
sent524 6 O
sent524 ) O
sent524 neutrophils O
sent524 in O
sent524 30 O
sent524 min O
sent524 ; O
sent524 p O
sent524 & O
sent524 # O
sent524 60 O
sent524 ; O
sent524 0.0001 O
sent524 ) O
sent525 G-CSF T
sent525 therapy T
sent525 was O
sent525 generally O
sent525 well O
sent525 tolerated O
sent526 INTERPRETATION O
sent526 : O
sent526 G-CSF T
sent526 treatment T
sent526 was O
sent526 associated O
sent526 with O
sent526 improved O
sent526 clinical O
sent526 outcome O
sent526 of O
sent526 foot D
sent526 infection D
sent526 in D
sent526 diabetic D
sent526 patients D
sent527 This O
sent527 improvement O
sent527 may O
sent527 be O
sent527 related O
sent527 to O
sent527 an O
sent527 increase O
sent527 in O
sent527 neutrophil O
sent527 superoxide O
sent527 production O
sent528 BACKGROUND O
sent528 : O
sent528 Accelerated T
sent528 infusion T
sent528 of T
sent528 alteplase T
sent528 ( T
sent528 tissue T
sent528 plasminogen T
sent528 activator T
sent528 ) T
sent528 over O
sent528 a O
sent528 period O
sent528 of O
sent528 90 O
sent528 minutes O
sent528 induces O
sent528 more O
sent528 rapid O
sent528 lysis O
sent528 of O
sent528 coronary-artery D
sent528 thrombi D
sent528 than O
sent528 a O
sent528 3-hour O
sent528 infusion O
sent529 With O
sent529 two O
sent529 bolus O
sent529 doses O
sent529 of O
sent529 alteplase T
sent529 , O
sent529 further O
sent529 shortening O
sent529 the O
sent529 duration O
sent529 of O
sent529 administration O
sent529 , O
sent529 complete O
sent529 reperfusion O
sent529 was O
sent529 achieved O
sent529 in O
sent529 more O
sent529 than O
sent529 85 O
sent529 percent O
sent529 of O
sent529 the O
sent529 patients O
sent529 in O
sent529 initial O
sent529 angiographic O
sent529 studies O
sent530 We O
sent530 tested O
sent530 the O
sent530 hypothesis O
sent530 that O
sent530 double-bolus T
sent530 alteplase T
sent530 is O
sent530 at O
sent530 least O
sent530 as O
sent530 effective O
sent530 as O
sent530 accelerated O
sent530 infusion O
sent531 METHODS O
sent531 : O
sent531 In O
sent531 398 O
sent531 hospitals O
sent531 , O
sent531 7169 O
sent531 patients O
sent531 with O
sent531 acute D
sent531 myocardial D
sent531 infarction D
sent531 were O
sent531 randomly O
sent531 assigned O
sent531 to O
sent531 weight-adjusted O
sent531 , O
sent531 accelerated O
sent531 infusion O
sent531 of O
sent531 100 O
sent531 mg O
sent531 of O
sent531 alteplase T
sent531 or O
sent531 to O
sent531 a O
sent531 bolus O
sent531 of O
sent531 50 O
sent531 mg O
sent531 of O
sent531 alteplase T
sent531 over O
sent531 a O
sent531 period O
sent531 of O
sent531 1 O
sent531 to O
sent531 3 O
sent531 minutes O
sent531 followed O
sent531 30 O
sent531 minutes O
sent531 later O
sent531 by O
sent531 a O
sent531 second O
sent531 bolus O
sent531 of O
sent531 50 O
sent531 mg O
sent531 ( O
sent531 or O
sent531 40 O
sent531 mg O
sent531 for O
sent531 patients O
sent531 who O
sent531 weighed O
sent531 less O
sent531 than O
sent531 60 O
sent531 kg O
sent531 ) O
sent532 The O
sent532 primary O
sent532 end O
sent532 point O
sent532 was O
sent532 death O
sent532 from O
sent532 any O
sent532 cause O
sent532 at O
sent532 30 O
sent532 days O
sent533 The O
sent533 trial O
sent533 was O
sent533 stopped O
sent533 prematurely O
sent533 because O
sent533 of O
sent533 concern O
sent533 about O
sent533 the O
sent533 safety O
sent533 of O
sent533 the O
sent533 double-bolus T
sent533 injection T
sent534 RESULTS O
sent534 : O
sent534 Thirty-day O
sent534 mortality O
sent534 was O
sent534 higher O
sent534 in O
sent534 the O
sent534 double-bolus O
sent534 group O
sent534 than O
sent534 in O
sent534 the O
sent534 accelerated-infusion O
sent534 group O
sent534 : O
sent534 7.98 O
sent534 percent O
sent534 as O
sent534 compared O
sent534 with O
sent534 7.53 O
sent534 percent O
sent535 The O
sent535 absolute O
sent535 difference O
sent535 was O
sent535 0.44 O
sent535 percent O
sent535 , O
sent535 with O
sent535 a O
sent535 one-sided O
sent535 95 O
sent535 percent O
sent535 upper O
sent535 boundary O
sent535 of O
sent535 1.49 O
sent535 percent O
sent535 , O
sent535 which O
sent535 exceeded O
sent535 the O
sent535 prespecified O
sent535 upper O
sent535 limit O
sent535 of O
sent535 0.40 O
sent535 percent O
sent535 to O
sent535 indicate O
sent535 equivalence O
sent535 in O
sent535 30-day O
sent535 mortality O
sent535 between O
sent535 the O
sent535 two O
sent535 regimens O
sent536 The O
sent536 respective O
sent536 rates O
sent536 of O
sent536 any O
sent536 stroke D
sent536 and O
sent536 of O
sent536 hemorrhagic D
sent536 stroke D
sent536 were O
sent536 1.92 O
sent536 and O
sent536 1.12 O
sent536 percent O
sent536 after O
sent536 double-bolus O
sent536 alteplase T
sent536 , O
sent536 as O
sent536 compared O
sent536 with O
sent536 1.53 O
sent536 and O
sent536 0.81 O
sent536 percent O
sent536 after O
sent536 an O
sent536 accelerated O
sent536 infusion O
sent536 of O
sent536 alteplase T
sent536 ( O
sent536 P=0.24 O
sent536 and O
sent536 P=0.23 O
sent536 , O
sent536 respectively O
sent536 ) O
sent537 CONCLUSIONS O
sent537 : O
sent537 Double-bolus O
sent537 alteplase T
sent537 was O
sent537 not O
sent537 shown O
sent537 to O
sent537 be O
sent537 equivalent O
sent537 , O
sent537 according O
sent537 to O
sent537 the O
sent537 prespecified O
sent537 criteria O
sent537 , O
sent537 to O
sent537 accelerated O
sent537 infusion O
sent537 with O
sent537 regard O
sent537 to O
sent537 30-day O
sent537 mortality O
sent538 There O
sent538 was O
sent538 also O
sent538 a O
sent538 slightly O
sent538 higher O
sent538 rate O
sent538 of O
sent538 intracranial D
sent538 hemorrhage D
sent538 with O
sent538 the O
sent538 double-bolus T
sent538 method T
sent539 Therefore O
sent539 , O
sent539 accelerated T
sent539 infusion T
sent539 of T
sent539 alteplase T
sent539 over O
sent539 a O
sent539 period O
sent539 of O
sent539 90 O
sent539 minutes O
sent539 remains O
sent539 the O
sent539 preferred O
sent539 regimen O
sent540 BACKGROUND O
sent540 : O
sent540 Fenfluramine T
sent540 and O
sent540 phentermine T
sent540 have O
sent540 been O
sent540 individually O
sent540 approved O
sent540 as O
sent540 anorectic T
sent540 agents T
sent540 by O
sent540 the O
sent540 Food O
sent540 and O
sent540 Drug O
sent540 Administration O
sent540 ( O
sent540 FDA O
sent540 ) O
sent541 When O
sent541 used O
sent541 in O
sent541 combination O
sent541 the O
sent541 drugs O
sent541 may O
sent541 be O
sent541 just O
sent541 as O
sent541 effective O
sent541 as O
sent541 either O
sent541 drug O
sent541 alone O
sent541 , O
sent541 with O
sent541 the O
sent541 added O
sent541 advantages O
sent541 of O
sent541 the O
sent541 need O
sent541 for O
sent541 lower O
sent541 doses O
sent541 of O
sent541 each O
sent541 agent O
sent541 and O
sent541 perhaps O
sent541 fewer O
sent541 side O
sent541 effects O
sent542 Although O
sent542 the O
sent542 combination O
sent542 has O
sent542 not O
sent542 been O
sent542 approved O
sent542 by O
sent542 the O
sent542 FDA O
sent542 , O
sent542 in O
sent542 1996 O
sent542 the O
sent542 total O
sent542 number O
sent542 of O
sent542 prescriptions O
sent542 in O
sent542 the O
sent542 United O
sent542 States O
sent542 for O
sent542 fenfluramine T
sent542 and O
sent542 phentermine T
sent542 exceeded O
sent542 18 O
sent542 million O
sent543 < O
sent543 TO_SEE O
sent543 > O
sent543 METHODS O
sent543 : O
sent543 We O
sent543 identified O
sent543 valvular O
sent543 heart O
sent543 diseasein O
sent543 24 O
sent543 women O
sent543 treated O
sent543 with O
sent543 fenfluramine-phentermine O
sent543 who O
sent543 had O
sent543 no O
sent543 history O
sent543 of O
sent543 cardiac O
sent543 disease O
sent544 The O
sent544 women O
sent544 presented O
sent544 with O
sent544 cardiovascular D
sent544 symptoms D
sent544 or O
sent544 a O
sent544 heart D
sent544 murmur D
sent545 As O
sent545 increasing O
sent545 numbers O
sent545 of O
sent545 these O
sent545 patients O
sent545 with O
sent545 similar O
sent545 clinical O
sent545 features O
sent545 were O
sent545 identified O
sent545 , O
sent545 there O
sent545 appeared O
sent545 to O
sent545 be O
sent545 an O
sent545 association O
sent545 between O
sent545 these O
sent545 features O
sent545 and O
sent545 fenfluramine-phentermine T
sent545 therapy T
sent546 RESULTS O
sent546 : O
sent546 Twenty-four O
sent546 women O
sent546 ( O
sent546 mean O
sent546 ( O
sent546 +/-SD O
sent546 ) O
sent546 age O
sent546 , O
sent546 44+/-8 O
sent546 years O
sent546 ) O
sent546 were O
sent546 evaluated O
sent546 12.3+/-7.1 O
sent546 months O
sent546 after O
sent546 the O
sent546 initiation O
sent546 of O
sent546 fenfluramine-phentermine T
sent546 therapy T
sent547 Echocardiography O
sent547 demonstrated O
sent547 unusual O
sent547 valvular O
sent547 morphology O
sent547 and O
sent547 regurgitation O
sent547 in O
sent547 all O
sent547 patients O
sent548 Both O
sent548 right-sided O
sent548 and O
sent548 left-sided O
sent548 heart O
sent548 valves O
sent548 were O
sent548 involved O
sent549 Eight O
sent549 women O
sent549 also O
sent549 had O
sent549 newly O
sent549 documented O
sent549 pulmonary D
sent549 hypertension D
sent550 To O
sent550 date O
sent550 , O
sent550 cardiac T
sent550 surgical T
sent550 intervention T
sent550 has O
sent550 been O
sent550 required O
sent550 in O
sent550 five O
sent550 patients O
sent551 The O
sent551 heart O
sent551 valves O
sent551 had O
sent551 a O
sent551 glistening O
sent551 white O
sent551 appearance O
sent552 Histopathological O
sent552 findings O
sent552 included O
sent552 plaque-like O
sent552 encasement O
sent552 of O
sent552 the O
sent552 leaflets O
sent552 and O
sent552 chordal O
sent552 structures O
sent552 with O
sent552 intact O
sent552 valve O
sent552 architecture O
sent553 The O
sent553 histopathological O
sent553 features O
sent553 were O
sent553 identical O
sent553 to O
sent553 those O
sent553 seen O
sent553 in O
sent553 carcinoid O
sent553 or O
sent553 ergotamine-induced O
sent553 valve D
sent553 disease D
sent554 CONCLUSIONS O
sent554 : O
sent554 These O
sent554 cases O
sent554 arouse O
sent554 concern O
sent554 that O
sent554 fenfluramine-phentermine T
sent554 therapy T
sent554 may O
sent554 be O
sent554 associated O
sent554 with O
sent554 valvular D
sent554 heart D
sent554 disease D
sent555 Candidates O
sent555 for O
sent555 fenfluramine-phentermine T
sent555 therapy T
sent555 should O
sent555 be O
sent555 informed O
sent555 about O
sent555 serious O
sent555 potential O
sent555 adverse O
sent555 effects O
sent555 , O
sent555 including O
sent555 pulmonary D
sent555 hypertension D
sent555 and O
sent555 valvular D
sent555 heart D
sent555 disease D
sent556 < O
sent556 TO_SEE O
sent556 > O
sent556 Between O
sent556 1987 O
sent556 and O
sent556 1992 O
sent556 , O
sent556 all O
sent556 patients O
sent556 presenting O
sent556 to O
sent556 the O
sent556 senior O
sent556 author O
sent556 with O
sent556 a O
sent556 symptomatic O
sent556 failed O
sent556 silicone O
sent556 implant O
sent556 arthroplasty O
sent556 refractory O
sent556 to O
sent556 conservative O
sent556 treatment O
sent556 were O
sent556 converted O
sent556 to O
sent556 a O
sent556 metatarsophalangeal O
sent556 joint O
sent556 arthrodesis O
sent557 Internal O
sent557 fixation O
sent557 was O
sent557 achieved O
sent557 with O
sent557 either O
sent557 dual O
sent557 intrameduilary O
sent557 threaded O
sent557 Steinmann O
sent557 pins O
sent557 or O
sent557 an O
sent557 obliquely O
sent557 placed O
sent557 AO O
sent557 compression O
sent557 screw O
sent557 and O
sent557 a O
sent557 three- O
sent557 or O
sent557 four-hole O
sent557 one-third O
sent557 tubular O
sent557 dorsal O
sent557 neutralization O
sent557 plate O
sent558 Bone T
sent558 grafting T
sent558 was O
sent558 used O
sent558 to O
sent558 maintain O
sent558 hallux O
sent558 length O
sent559 Successful O
sent559 arthrodesis T
sent559 was O
sent559 achieved O
sent559 in O
sent559 all O
sent559 five O
sent559 feet O
sent559 in O
sent559 patients O
sent559 with O
sent559 rheumatoid D
sent559 arthritis D
sent560 Subjectively O
sent560 , O
sent560 patients O
sent560 improved O
sent560 from O
sent560 an O
sent560 average O
sent560 of O
sent560 0.69 O
sent560 before O
sent560 arthrodesis T
sent560 to O
sent560 4.89 O
sent560 after O
sent560 arthrodesis T
sent561 The O
sent561 average O
sent561 walking O
sent561 tolerance O
sent561 improved O
sent561 from O
sent561 1.11 O
sent561 to O
sent561 4.80 O
sent561 , O
sent561 and O
sent561 the O
sent561 overall O
sent561 level O
sent561 of O
sent561 satisfaction O
sent561 improved O
sent561 from O
sent561 0.0 O
sent561 to O
sent561 4.79 O
sent562 The O
sent562 patient O
sent562 's O
sent562 ability O
sent562 to O
sent562 wear O
sent562 shoes O
sent562 improved O
sent562 from O
sent562 0.87 O
sent562 to O
sent562 3.1 O
sent563 Successful O
sent563 arthrodesis T
sent563 produces O
sent563 a O
sent563 foot O
sent563 that O
sent563 is O
sent563 more O
sent563 functional O
sent563 and O
sent563 durable O
sent563 than O
sent563 excisional T
sent563 arthroplasty T
sent564 Subjectively O
sent564 , O
sent564 these O
sent564 patients O
sent564 stated O
sent564 that O
sent564 their O
sent564 level O
sent564 of O
sent564 pain O
sent564 , O
sent564 walking O
sent564 tolerance O
sent564 , O
sent564 and O
sent564 overall O
sent564 satisfaction O
sent564 improved O
sent564 significantly O
sent564 after O
sent564 the O
sent564 arthrodesis T
sent565 Clinically O
sent565 , O
sent565 there O
sent565 was O
sent565 no O
sent565 evidence O
sent565 of O
sent565 transfer D
sent565 lesions D
sent565 , O
sent565 tenderness O
sent565 , O
sent565 or O
sent565 hallux D
sent565 subluxation D
sent566 Hallux O
sent566 length O
sent566 was O
sent566 well O
sent566 maintained O
sent566 after O
sent566 surgery T
sent566 with O
sent566 bone T
sent566 grafting T
sent566 , O
sent566 but O
sent566 it O
sent566 was O
sent566 more O
sent566 difficult O
sent566 to O
sent566 obtain O
sent566 the O
sent566 alignment O
sent566 goals O
sent567 The O
sent567 average O
sent567 postoperative O
sent567 metatarsophalangeal O
sent567 dorsiflexion O
sent567 angle O
sent567 was O
sent567 15.6 O
sent567 degrees O
sent567 and O
sent567 the O
sent567 first O
sent567 metatarsophalangeal O
sent567 angle O
sent567 was O
sent567 3.1 O
sent567 degrees O
sent568 Despite O
sent568 this O
sent568 , O
sent568 patient O
sent568 satisfaction O
sent568 was O
sent568 high O
sent569 Arthrodesis T
sent569 of O
sent569 the O
sent569 first O
sent569 metatarsophalangeal O
sent569 joint O
sent569 using O
sent569 a O
sent569 bone T
sent569 graft T
sent569 to O
sent569 salvage O
sent569 failed O
sent569 silicone T
sent569 implant T
sent569 arthroplasty T
sent569 produces O
sent569 acceptable O
sent569 subjective O
sent569 and O
sent569 radiographic O
sent569 results O
sent570 Although O
sent570 technically O
sent570 demanding O
sent570 , O
sent570 it O
sent570 provides O
sent570 long-term O
sent570 stability O
sent570 to O
sent570 the O
sent570 hallux O
sent570 , O
sent570 restores O
sent570 weightbearing O
sent570 , O
sent570 and O
sent570 allows O
sent570 for O
sent570 maintenance O
sent570 of O
sent570 a O
sent570 propulsive O
sent570 gait O
sent571 We O
sent571 recommend O
sent571 this O
sent571 procedure O
sent571 instead O
sent571 of O
sent571 an O
sent571 excisional T
sent571 arthroplasty T
sent571 to O
sent571 maintain O
sent571 high O
sent571 level O
sent571 of O
sent571 function O
sent571 and O
sent571 overall O
sent571 patient O
sent571 satisfaction O
sent572 OBJECTIVE O
sent572 : O
sent572 To O
sent572 estimate O
sent572 the O
sent572 crude O
sent572 incidence O
sent572 rates O
sent572 of O
sent572 cerebrovascular D
sent572 accidents D
sent572 among O
sent572 the O
sent572 black O
sent572 residents O
sent572 of O
sent572 Harare O
sent573 DESIGN O
sent573 : O
sent573 Prospective O
sent573 community-based O
sent573 study O
sent574 SETTING O
sent574 : O
sent574 Black O
sent574 residents O
sent574 of O
sent574 Harare O
sent574 , O
sent574 Zimbabwe O
sent575 PARTICIPANTS O
sent575 : O
sent575 Two O
sent575 hundred O
sent575 and O
sent575 seventy-three O
sent575 'first-ever O
sent575 ' O
sent575 strokes D
sent575 prospectively O
sent575 identified O
sent575 over O
sent575 a O
sent575 12-month O
sent575 period O
sent576 MAIN O
sent576 OUTCOME O
sent576 STUDY O
sent576 FACTORS O
sent576 : O
sent576 Cerebrovascular D
sent576 accident D
sent576 first-week O
sent576 fatality O
sent576 rate O
sent576 ; O
sent576 age- O
sent576 and O
sent576 sex-related O
sent576 incidence O
sent577 RESULTS O
sent577 : O
sent577 The O
sent577 crude O
sent577 incidence O
sent577 rate O
sent577 was O
sent577 estimated O
sent577 to O
sent577 be O
sent577 30.7 O
sent577 per O
sent577 100000 O
sent577 ( O
sent577 95 O
sent577 % O
sent577 confidence O
sent577 interval O
sent577 27.1-34.4 O
sent577 ) O
sent577 and O
sent577 the O
sent577 standardised O
sent577 rate O
sent577 was O
sent577 68 O
sent577 per O
sent577 100000 O
sent578 Fifty-one O
sent578 per O
sent578 cent O
sent578 of O
sent578 stroke D
sent578 victims O
sent578 were O
sent578 below O
sent578 the O
sent578 age O
sent578 of O
sent578 54 O
sent578 years O
sent579 Thirty-five O
sent579 per O
sent579 cent O
sent579 of O
sent579 patients O
sent579 died O
sent579 within O
sent579 1 O
sent579 week O
sent579 of O
sent579 the O
sent579 stroke O
sent580 Overall O
sent580 , O
sent580 the O
sent580 age-specific O
sent580 rates O
sent580 for O
sent580 both O
sent580 sexes O
sent580 rose O
sent580 with O
sent580 age O
sent580 , O
sent580 with O
sent580 the O
sent580 rates O
sent580 for O
sent580 women O
sent580 being O
sent580 higher O
sent580 at O
sent580 all O
sent580 age O
sent580 strata O
sent580 except O
sent580 for O
sent580 the O
sent580 group O
sent580 45-54 O
sent580 years O
sent581 CONCLUSION O
sent581 : O
sent581 With O
sent581 a O
sent581 standardised O
sent581 rate O
sent581 of O
sent581 68 O
sent581 per O
sent581 100000 O
sent581 and O
sent581 a O
sent581 first-week O
sent581 mortality O
sent581 rate O
sent581 of O
sent581 35 O
sent581 % O
sent581 , O
sent581 stroke D
sent581 must O
sent581 now O
sent581 be O
sent581 considered O
sent581 an O
sent581 important O
sent581 cause O
sent581 of O
sent581 morbidity O
sent581 and O
sent581 mortality O
sent581 in O
sent581 the O
sent581 population O
sent582 OBJECTIVE O
sent582 : O
sent582 To O
sent582 explore O
sent582 the O
sent582 long-term O
sent582 effect O
sent582 of O
sent582 calcium T
sent582 supplementation T
sent582 during O
sent582 pregnancy O
sent582 on O
sent582 the O
sent582 offspring O
sent582 's O
sent582 blood O
sent582 pressure O
sent582 during O
sent582 childhood O
sent583 DESIGN O
sent583 : O
sent583 Follow O
sent583 up O
sent583 of O
sent583 a O
sent583 population O
sent583 enrolled O
sent583 in O
sent583 a O
sent583 double O
sent583 blind O
sent583 , O
sent583 randomised O
sent583 , O
sent583 placebo O
sent583 controlled O
sent583 trial O
sent584 SETTING O
sent584 : O
sent584 Perinatal O
sent584 research O
sent584 unit O
sent584 , O
sent584 World O
sent584 Health O
sent584 Organisation O
sent584 's O
sent584 collaborative O
sent584 research O
sent584 centre O
sent585 SUBJECTS O
sent585 : O
sent585 591 O
sent585 children O
sent585 at O
sent585 a O
sent585 mean O
sent585 age O
sent585 of O
sent585 7 O
sent585 years O
sent585 whose O
sent585 mothers O
sent585 were O
sent585 randomly O
sent585 assigned O
sent585 during O
sent585 pregnancy O
sent585 to O
sent585 receive O
sent585 2 O
sent585 g/day O
sent585 of O
sent585 elemental O
sent585 calcium O
sent585 ( O
sent585 n O
sent585 = O
sent585 298 O
sent585 ) O
sent585 or O
sent585 placebo O
sent585 ( O
sent585 n O
sent585 = O
sent585 293 O
sent585 ) O
sent586 MAIN O
sent586 OUTCOME O
sent586 MEASURES O
sent586 : O
sent586 Mean O
sent586 blood O
sent586 pressure O
sent586 and O
sent586 rate O
sent586 of O
sent586 high D
sent586 blood D
sent586 pressure D
sent586 of O
sent586 children O
sent587 RESULTS O
sent587 : O
sent587 Overall O
sent587 , O
sent587 systolic O
sent587 blood O
sent587 pressure O
sent587 was O
sent587 lower O
sent587 in O
sent587 the O
sent587 calcium O
sent587 group O
sent587 ( O
sent587 mean O
sent587 difference O
sent587 -1.4 O
sent587 mm O
sent587 Hg O
sent587 ; O
sent587 95 O
sent587 % O
sent587 confidence O
sent587 interval O
sent587 -3.2 O
sent587 to O
sent587 0.5 O
sent587 ) O
sent587 than O
sent587 in O
sent587 the O
sent587 placebo O
sent587 group O
sent588 The O
sent588 effect O
sent588 was O
sent588 found O
sent588 predominantly O
sent588 among O
sent588 children O
sent588 whose O
sent588 body O
sent588 mass O
sent588 index O
sent588 at O
sent588 assessment O
sent588 was O
sent588 above O
sent588 the O
sent588 median O
sent588 for O
sent588 this O
sent588 population O
sent588 ( O
sent588 mean O
sent588 difference O
sent588 in O
sent588 systolic O
sent588 blood O
sent588 pressure O
sent588 -5.8 O
sent588 mm O
sent588 Hg O
sent588 ( O
sent588 -9.8 O
sent588 mm O
sent588 Hg O
sent588 to O
sent588 -1.7 O
sent588 mm O
sent588 Hg O
sent588 ) O
sent588 for O
sent588 children O
sent588 with O
sent588 an O
sent588 index O
sent588 > O
sent588 17.5 O
sent588 and O
sent588 -3.2 O
sent588 mm O
sent588 Hg O
sent588 ( O
sent588 -6.3 O
sent588 mm O
sent588 Hg O
sent588 to O
sent588 -0.1 O
sent588 mm O
sent588 Hg O
sent588 ) O
sent588 for O
sent588 those O
sent588 with O
sent588 an O
sent588 index O
sent588 of O
sent588 > O
sent588 15.7 O
sent588 to O
sent588 17.5 O
sent588 ) O
sent589 The O
sent589 risk O
sent589 of O
sent589 high O
sent589 systolic O
sent589 blood O
sent589 pressure O
sent589 was O
sent589 also O
sent589 lower O
sent589 in O
sent589 the O
sent589 calcium O
sent589 group O
sent589 than O
sent589 in O
sent589 the O
sent589 placebo O
sent589 group O
sent589 ( O
sent589 relative O
sent589 risk O
sent589 0.59 O
sent589 ; O
sent589 0.39 O
sent589 to O
sent589 0.90 O
sent589 ) O
sent589 and O
sent589 particularly O
sent589 among O
sent589 children O
sent589 in O
sent589 the O
sent589 highest O
sent589 fourth O
sent589 of O
sent589 body O
sent589 mass O
sent589 index O
sent589 ( O
sent589 0.43 O
sent589 ; O
sent589 0.26 O
sent589 to O
sent589 0.71 O
sent589 ) O
sent590 CONCLUSION O
sent590 : O
sent590 Calcium T
sent590 supplementation T
sent590 during O
sent590 pregnancy O
sent590 is O
sent590 associated O
sent590 with O
sent590 lower O
sent590 systolic O
sent590 blood O
sent590 pressure O
sent590 in O
sent590 the O
sent590 offspring O
sent590 , O
sent590 particularly O
sent590 among O
sent590 overweight O
sent590 children O
sent591 The O
sent591 fast O
sent591 reaction O
sent591 of O
sent591 peroxynitrite O
sent591 with O
sent591 CO2 O
sent591 and O
sent591 the O
sent591 high O
sent591 concentration O
sent591 of O
sent591 dissolved O
sent591 CO2 O
sent591 in O
sent591 vivo O
sent591 ( O
sent591 ca O
sent592 1 O
sent592 mM O
sent592 ) O
sent592 suggest O
sent592 that O
sent592 CO2 O
sent592 modulates O
sent592 most O
sent592 of O
sent592 the O
sent592 reactions O
sent592 of O
sent592 peroxynitrite O
sent592 in O
sent592 biological O
sent592 systems O
sent593 The O
sent593 addition O
sent593 of O
sent593 peroxynitrite O
sent593 to O
sent593 CO2 O
sent593 produces O
sent593 of O
sent593 the O
sent593 adduct O
sent593 ONOO-CO2- O
sent593 ( O
sent593 1 O
sent593 ) O
sent594 The O
sent594 production O
sent594 of O
sent594 1 O
sent594 greatly O
sent594 accelerates O
sent594 the O
sent594 decomposition O
sent594 of O
sent594 peroxynitrite O
sent594 to O
sent594 give O
sent594 nitrate O
sent595 We O
sent595 now O
sent595 show O
sent595 that O
sent595 the O
sent595 formation O
sent595 of O
sent595 1 O
sent595 is O
sent595 followed O
sent595 by O
sent595 reformation O
sent595 of O
sent595 CO2 O
sent595 ( O
sent595 rather O
sent595 than O
sent595 another O
sent595 carbonate O
sent595 species O
sent595 such O
sent595 as O
sent595 CO3 O
sent595 = O
sent595 or O
sent595 HCO3- O
sent595 ) O
sent596 To O
sent596 show O
sent596 this O
sent596 , O
sent596 it O
sent596 is O
sent596 necessary O
sent596 to O
sent596 study O
sent596 systems O
sent596 with O
sent596 limiting O
sent596 concentrations O
sent596 of O
sent596 CO2 O
sent597 ( O
sent597 When O
sent597 CO2 O
sent597 is O
sent597 present O
sent597 in O
sent597 excess O
sent597 , O
sent597 its O
sent597 concentration O
sent597 remains O
sent597 nearly O
sent597 constant O
sent597 during O
sent597 the O
sent597 decomposition O
sent597 of O
sent597 peroxynitrite O
sent597 , O
sent597 and O
sent597 the O
sent597 recycling O
sent597 of O
sent597 CO2 O
sent597 , O
sent597 although O
sent597 it O
sent597 occurs O
sent597 , O
sent597 can O
sent597 not O
sent597 be O
sent597 detected O
sent597 kinetically O
sent597 ) O
sent598 We O
sent598 find O
sent598 that O
sent598 CO2 O
sent598 is O
sent598 a O
sent598 true O
sent598 catalyst O
sent598 of O
sent598 the O
sent598 decomposition O
sent598 of O
sent598 peroxynitrite O
sent598 , O
sent598 and O
sent598 this O
sent598 fundamental O
sent598 insight O
sent598 into O
sent598 its O
sent598 action O
sent598 must O
sent598 be O
sent598 rationalized O
sent598 by O
sent598 any O
sent598 in O
sent598 vivo O
sent598 or O
sent598 in O
sent598 vitro O
sent598 reaction O
sent598 mechanism O
sent598 that O
sent598 is O
sent598 proposed O
sent599 When O
sent599 the O
sent599 concentration O
sent599 of O
sent599 CO2 O
sent599 is O
sent599 lower O
sent599 than O
sent599 that O
sent599 of O
sent599 peroxynitrite O
sent599 , O
sent599 the O
sent599 reformation O
sent599 of O
sent599 CO2 O
sent599 amplifies O
sent599 the O
sent599 fraction O
sent599 of O
sent599 peroxynitrite O
sent599 that O
sent599 reacts O
sent599 with O
sent599 CO2 O
sent600 Even O
sent600 low O
sent600 concentrations O
sent600 of O
sent600 CO2 O
sent600 that O
sent600 result O
sent600 from O
sent600 the O
sent600 dissolution O
sent600 of O
sent600 ambient O
sent600 CO2 O
sent600 can O
sent600 have O
sent600 pronounced O
sent600 catalytic O
sent600 effects O
sent601 These O
sent601 effects O
sent601 can O
sent601 cause O
sent601 deviations O
sent601 from O
sent601 predicted O
sent601 kinetic O
sent601 behavior O
sent601 in O
sent601 studies O
sent601 of O
sent601 peroxynitrite O
sent601 in O
sent601 noncarbonate O
sent601 buffers O
sent601 in O
sent601 vitro O
sent601 , O
sent601 and O
sent601 since O
sent601 1 O
sent601 and O
sent601 other O
sent601 intermediates O
sent601 derived O
sent601 from O
sent601 it O
sent601 are O
sent601 oxidants O
sent601 and/or O
sent601 nitrating O
sent601 agents O
sent601 , O
sent601 some O
sent601 of O
sent601 the O
sent601 reactions O
sent601 attributed O
sent601 to O
sent601 peroxynitrite O
sent601 may O
sent601 depend O
sent601 on O
sent601 the O
sent601 availability O
sent601 of O
sent601 CO2 O
sent602 A O
sent602 prospective O
sent602 , O
sent602 randomized O
sent602 , O
sent602 placebo-controlled O
sent602 , O
sent602 double-blind O
sent602 , O
sent602 parallel-group O
sent602 , O
sent602 6-month O
sent602 study O
sent602 assessed O
sent602 the O
sent602 efficacy O
sent602 and O
sent602 safety O
sent602 of O
sent602 ropinirole T
sent602 , T
sent602 a T
sent602 nonergoline T
sent602 D2-dopamine T
sent602 agonist T
sent602 , O
sent602 in O
sent602 patients O
sent602 with O
sent602 early D
sent602 Parkinson D
sent602 's D
sent602 disease D
sent602 ( O
sent602 n O
sent602 = O
sent602 241 O
sent602 ; O
sent602 Hoehn O
sent602 & O
sent602 # O
sent602 38 O
sent602 ; O
sent602 Yahr O
sent602 stages O
sent602 I O
sent602 to O
sent602 III O
sent602 ) O
sent602 with O
sent602 limited O
sent602 or O
sent602 no O
sent602 prior O
sent602 dopaminergic T
sent602 therapy T
sent603 Patients O
sent603 ( O
sent603 mean O
sent603 age O
sent603 , O
sent603 62.8 O
sent603 years O
sent603 ) O
sent603 , O
sent603 stratified O
sent603 by O
sent603 concomitant O
sent603 use O
sent603 of O
sent603 selegiline T
sent603 , O
sent603 were O
sent603 randomized O
sent603 to O
sent603 ropinirole T
sent603 ( O
sent603 n O
sent603 = O
sent603 116 O
sent603 ) O
sent603 or O
sent603 placebo O
sent603 ( O
sent603 n O
sent603 = O
sent603 125 O
sent603 ) O
sent604 The O
sent604 starting O
sent604 dose O
sent604 of O
sent604 ropinirole T
sent604 was O
sent604 0.25 O
sent604 mg O
sent604 tid O
sent604 with O
sent604 titration O
sent604 to O
sent604 at O
sent604 least O
sent604 1.5 O
sent604 mg O
sent604 tid O
sent604 ( O
sent604 maximum O
sent604 dose O
sent604 , O
sent604 8 O
sent604 mg O
sent604 tid O
sent604 ) O
sent605 Primary O
sent605 efficacy O
sent605 endpoint O
sent605 was O
sent605 the O
sent605 percentage O
sent605 improvement O
sent605 in O
sent605 Unified O
sent605 Parkinson D
sent605 's D
sent605 Disease D
sent605 Rating O
sent605 Scale O
sent605 ( O
sent605 UPDRS O
sent605 ) O
sent605 motor O
sent605 score O
sent606 Ropinirole-treated O
sent606 patients O
sent606 had O
sent606 a O
sent606 significantly O
sent606 greater O
sent606 percentage O
sent606 improvement O
sent606 in O
sent606 UPDRS O
sent606 motor O
sent606 score O
sent606 than O
sent606 patients O
sent606 who O
sent606 received O
sent606 placebo O
sent606 ( O
sent606 +24 O
sent606 % O
sent606 vs O
sent606 -3 O
sent606 % O
sent606 ; O
sent606 p O
sent606 & O
sent606 # O
sent606 60 O
sent606 ; O
sent606 0.001 O
sent606 ) O
sent607 Ropinirole T
sent607 was O
sent607 well O
sent607 tolerated O
sent607 and O
sent607 patient O
sent607 withdrawals O
sent607 were O
sent607 infrequent O
sent608 Most O
sent608 adverse O
sent608 experiences O
sent608 were O
sent608 related O
sent608 to O
sent608 peripheral O
sent608 dopaminergic O
sent608 activity O
sent609 Ropinirole T
sent609 monotherapy T
sent609 is O
sent609 an O
sent609 effective O
sent609 and O
sent609 well-tolerated O
sent609 therapeutic O
sent609 option O
sent609 for O
sent609 treatment O
sent609 of O
sent609 early D
sent609 Parkinson D
sent609 's D
sent609 disease D
sent610 Starfish O
sent610 oocytes O
sent610 can O
sent610 be O
sent610 fertilized O
sent610 after O
sent610 germinal O
sent610 vesicle O
sent610 breakdown O
sent610 ( O
sent610 GVBD O
sent610 ) O
sent610 and O
sent610 artificial O
sent610 parthenogenesis O
sent610 can O
sent610 be O
sent610 induced O
sent610 by O
sent610 activating O
sent610 the O
sent610 oocytes O
sent610 after O
sent610 GVBD O
sent610 ( O
sent610 post-GVBD O
sent610 activation O
sent610 ) O
sent611 In O
sent611 the O
sent611 present O
sent611 study O
sent611 , O
sent611 parthenogenotes O
sent611 were O
sent611 obtained O
sent611 by O
sent611 the O
sent611 activation O
sent611 of O
sent611 immature O
sent611 oocytes O
sent611 with O
sent611 caffeine O
sent611 before O
sent611 treatment O
sent611 with O
sent611 1-methyladenine T
sent611 ( T
sent611 1-MeAde T
sent611 ) T
sent611 to O
sent611 induce O
sent611 oocyte O
sent611 maturation O
sent612 Most O
sent612 of O
sent612 the O
sent612 caffeine-treated O
sent612 eggs O
sent612 developed O
sent612 as O
sent612 tetraploids O
sent612 , O
sent612 as O
sent612 parthenogenotes O
sent612 produced O
sent612 by O
sent612 the O
sent612 post-GVBD O
sent612 activation O
sent613 The O
sent613 parthengenotes O
sent613 were O
sent613 derived O
sent613 only O
sent613 from O
sent613 eggs O
sent613 that O
sent613 failed O
sent613 to O
sent613 extrude O
sent613 polar O
sent613 bodies O
sent613 , O
sent613 mostly O
sent613 from O
sent613 eggs O
sent613 failing O
sent613 to O
sent613 extrude O
sent613 a O
sent613 second O
sent613 polar O
sent613 body O
sent614 Eggs O
sent614 derived O
sent614 from O
sent614 immature O
sent614 oocytes O
sent614 activated O
sent614 by O
sent614 A23187 O
sent614 , O
sent614 treated O
sent614 with O
sent614 1-MeAde T
sent614 and O
sent614 post-treated O
sent614 with O
sent614 cytochalasin T
sent614 B T
sent614 failed O
sent614 to O
sent614 extrude O
sent614 polar O
sent614 bodies O
sent614 , O
sent614 and O
sent614 eventually O
sent614 developed O
sent614 into O
sent614 parthenogenetic O
sent614 embryos O
sent615 These O
sent615 results O
sent615 indicate O
sent615 that O
sent615 the O
sent615 present O
sent615 parthenogenesis O
sent615 mechanism O
sent615 shares O
sent615 the O
sent615 same O
sent615 characteristics O
sent615 as O
sent615 that O
sent615 achieved O
sent615 by O
sent615 post-GVBD O
sent615 activation O
sent615 in O
sent615 the O
sent615 suppression O
sent615 of O
sent615 polar O
sent615 body O
sent615 formation O
sent615 as O
sent615 a O
sent615 key O
sent615 means O
sent615 for O
sent615 successful O
sent615 starfish O
sent615 parthenogenesis O
sent616 We O
sent616 hypothesized O
sent616 that O
sent616 fluoride T
sent616 partly O
sent616 acts O
sent616 by O
sent616 changing O
sent616 the O
sent616 levels O
sent616 of O
sent616 circulating O
sent616 calcium-regulating O
sent616 hormones O
sent616 and O
sent616 skeletal O
sent616 growth O
sent616 factors O
sent617 The O
sent617 effects O
sent617 of O
sent617 oral T
sent617 fluoride T
sent617 on O
sent617 24 O
sent617 female O
sent617 , O
sent617 Dutch-Belted O
sent617 , O
sent617 young O
sent617 adult O
sent617 rabbits O
sent617 were O
sent617 studied O
sent618 The O
sent618 rabbits O
sent618 were O
sent618 divided O
sent618 into O
sent618 two O
sent618 study O
sent618 groups O
sent618 , O
sent618 one O
sent618 control O
sent618 and O
sent618 the O
sent618 other O
sent618 receiving O
sent618 about O
sent618 16 O
sent618 mg O
sent618 fluoride/rabbit/day O
sent618 in O
sent618 their O
sent618 drinking O
sent618 water O
sent619 After O
sent619 6 O
sent619 months O
sent619 of O
sent619 fluoride T
sent619 dosing T
sent619 , O
sent619 all O
sent619 rabbits O
sent619 were O
sent619 euthanized O
sent619 and O
sent619 bone O
sent619 and O
sent619 blood O
sent619 samples O
sent619 were O
sent619 taken O
sent619 for O
sent619 analyses O
sent620 Fluoride T
sent620 treatment T
sent620 increased O
sent620 serum O
sent620 and O
sent620 bone O
sent620 fluoride O
sent620 levels O
sent620 by O
sent620 over O
sent620 an O
sent620 order O
sent620 of O
sent620 magnitude O
sent620 ( O
sent620 P O
sent620 & O
sent620 # O
sent620 60 O
sent620 ; O
sent620 0.001 O
sent620 ) O
sent620 , O
sent620 but O
sent620 did O
sent620 not O
sent620 affect O
sent620 body O
sent620 weight O
sent620 or O
sent620 the O
sent620 following O
sent620 serum O
sent620 biochemical O
sent620 variables O
sent620 : O
sent620 urea O
sent620 , O
sent620 creatinine O
sent620 , O
sent620 phosphorus O
sent620 , O
sent620 total O
sent620 protein O
sent620 , O
sent620 albumin O
sent620 , O
sent620 bilirubin O
sent620 , O
sent620 SGOT O
sent620 , O
sent620 or O
sent620 total O
sent620 alkaline O
sent620 phosphatase O
sent621 < O
sent621 TO_SEE O
sent621 > O
sent621 No O
sent621 skeletal D
sent621 fluorosis D
sent621 or O
sent621 osteomalacia D
sent621 was O
sent621 observed O
sent621 histologically O
sent621 , O
sent621 nor O
sent621 did O
sent621 fluoride T
sent621 affect O
sent621 serum O
sent621 PTH O
sent621 or O
sent621 Vitamin O
sent621 D O
sent621 metabolites O
sent621 ( O
sent621 P O
sent621 > O
sent621 0.4 O
sent621 ) O
sent622 BAP O
sent622 was O
sent622 increased O
sent622 37 O
sent622 % O
sent622 ( O
sent622 P O
sent622 & O
sent622 # O
sent622 60 O
sent622 ; O
sent622 0.05 O
sent622 ) O
sent622 by O
sent622 fluoride O
sent622 ; O
sent622 serum O
sent622 TRAP O
sent622 was O
sent622 increased O
sent622 42 O
sent622 % O
sent622 ( O
sent622 P O
sent622 & O
sent622 # O
sent622 60 O
sent622 ; O
sent622 0.05 O
sent622 ) O
sent622 ; O
sent622 serum O
sent622 IGF-1 O
sent622 was O
sent622 increased O
sent622 40 O
sent622 % O
sent622 ( O
sent622 P O
sent622 & O
sent622 # O
sent622 60 O
sent622 ; O
sent622 0.05 O
sent622 ) O
sent623 Fluoride T
sent623 increased O
sent623 the O
sent623 vertebral O
sent623 BV/TV O
sent623 by O
sent623 35 O
sent623 % O
sent623 ( O
sent623 P O
sent623 & O
sent623 # O
sent623 60 O
sent623 ; O
sent623 0.05 O
sent623 ) O
sent623 and O
sent623 tibial O
sent623 ash O
sent623 weight O
sent623 by O
sent623 10 O
sent623 % O
sent623 ( O
sent623 P O
sent623 & O
sent623 # O
sent623 60 O
sent623 ; O
sent623 0.05 O
sent623 ) O
sent624 However O
sent624 , O
sent624 the O
sent624 increases O
sent624 in O
sent624 bone O
sent624 mass O
sent624 and O
sent624 bone O
sent624 formation O
sent624 were O
sent624 not O
sent624 reflected O
sent624 in O
sent624 improved O
sent624 bone O
sent624 strength O
sent625 Fluoride O
sent625 decreased O
sent625 bone O
sent625 strength O
sent625 by O
sent625 about O
sent625 19 O
sent625 % O
sent625 in O
sent625 the O
sent625 L5 O
sent625 vertebra O
sent625 ( O
sent625 P O
sent625 & O
sent625 # O
sent625 60 O
sent625 ; O
sent625 0.01 O
sent625 ) O
sent625 and O
sent625 25 O
sent625 % O
sent625 in O
sent625 the O
sent625 femoral O
sent625 neck O
sent625 ( O
sent625 P O
sent625 & O
sent625 # O
sent625 60 O
sent625 ; O
sent625 0 O
sent626 05 O
sent626 ) O
sent627 X-ray O
sent627 diffraction O
sent627 showed O
sent627 altered O
sent627 mineral O
sent627 crystal O
sent627 thickness O
sent627 in O
sent627 fluoride-treated O
sent627 bones O
sent627 ( O
sent627 P O
sent627 & O
sent627 # O
sent627 60 O
sent627 ; O
sent627 0.001 O
sent627 ) O
sent627 , O
sent627 and O
sent627 there O
sent627 was O
sent627 a O
sent627 negative O
sent627 association O
sent627 between O
sent627 crystal O
sent627 width O
sent627 and O
sent627 fracture O
sent627 stress O
sent627 of O
sent627 the O
sent627 femur O
sent627 ( O
sent627 P O
sent627 & O
sent627 # O
sent627 60 O
sent627 ; O
sent627 0.02 O
sent627 ) O
sent628 In O
sent628 conclusion O
sent628 , O
sent628 fluoride O
sent628 's O
sent628 effects O
sent628 on O
sent628 bone O
sent628 mass O
sent628 and O
sent628 bone O
sent628 turnover O
sent628 were O
sent628 not O
sent628 mediated O
sent628 by O
sent628 PTH O
sent629 IGF-1 O
sent629 was O
sent629 increased O
sent629 by O
sent629 fluoride O
sent629 and O
sent629 was O
sent629 associated O
sent629 with O
sent629 increased O
sent629 bone O
sent629 turnover O
sent629 , O
sent629 but O
sent629 was O
sent629 not O
sent629 correlated O
sent629 with O
sent629 bone O
sent629 formation O
sent629 markers O
sent630 High-dose O
sent630 fluoride T
sent630 treatment T
sent630 did O
sent630 not O
sent630 improve O
sent630 , O
sent630 but O
sent630 decreased O
sent630 , O
sent630 bone O
sent630 strength O
sent630 in O
sent630 rabbits O
sent630 , O
sent630 even O
sent630 in O
sent630 the O
sent630 absence O
sent630 of O
sent630 impaired O
sent630 mineralization O
sent631 PURPOSE O
sent631 : O
sent631 To O
sent631 determine O
sent631 the O
sent631 effect O
sent631 of O
sent631 various O
sent631 methods O
sent631 of O
sent631 managing O
sent631 the O
sent631 posterior O
sent631 capsule O
sent631 and O
sent631 anterior O
sent631 vitreous O
sent631 on O
sent631 the O
sent631 rate O
sent631 of O
sent631 posterior D
sent631 capsule D
sent631 opacification D
sent631 in O
sent631 pediatric O
sent631 eyes O
sent631 implanted O
sent631 with O
sent631 posterior T
sent631 chamber T
sent631 intraocular T
sent631 lenses T
sent631 ( T
sent631 PC T
sent631 IOLs T
sent631 ) T
sent632 SETTING O
sent632 : O
sent632 Cullen O
sent632 Eye O
sent632 Institute O
sent632 , O
sent632 Baylor O
sent632 College O
sent632 of O
sent632 Medicine O
sent632 , O
sent632 Houston O
sent632 , O
sent632 Texas O
sent632 , O
sent632 USA O
sent633 METHODS O
sent633 : O
sent633 We O
sent633 reviewed O
sent633 the O
sent633 charts O
sent633 of O
sent633 20 O
sent633 eyes O
sent633 of O
sent633 15 O
sent633 children O
sent633 ( O
sent633 aged O
sent633 1.5 O
sent633 to O
sent633 2 O
sent633 years O
sent633 ) O
sent633 who O
sent633 had O
sent633 primary O
sent633 cataract D
sent633 surgery T
sent633 with T
sent633 PC T
sent633 IOL T
sent633 implantation T
sent633 during O
sent633 the O
sent633 past O
sent633 5 O
sent633 years O
sent634 The O
sent634 posterior O
sent634 capsule O
sent634 and O
sent634 anterior O
sent634 vitreous O
sent634 were O
sent634 managed O
sent634 in O
sent634 a O
sent634 variety O
sent634 of O
sent634 ways O
sent634 : O
sent634 In O
sent634 5 O
sent634 eyes O
sent634 , O
sent634 the O
sent634 posterior O
sent634 capsule O
sent634 was O
sent634 left O
sent634 intact O
sent634 ; O
sent634 in O
sent634 15 O
sent634 eyes O
sent634 , O
sent634 a O
sent634 posterior T
sent634 continuous T
sent634 curvilinear T
sent634 capsulorhexis T
sent634 ( T
sent634 PCCC T
sent634 ) T
sent634 was O
sent634 performed O
sent634 - O
sent634 6 O
sent634 with O
sent634 and O
sent634 9 O
sent634 without O
sent634 anterior T
sent634 vitrectomy T
sent634 ; O
sent634 in O
sent634 8 O
sent634 eyes O
sent634 , O
sent634 posterior T
sent634 optic T
sent634 capture T
sent634 was O
sent634 performed O
sent634 - O
sent634 3 O
sent634 with O
sent634 and O
sent634 5 O
sent634 without O
sent634 vitrectomy T
sent635 The O
sent635 follow-up O
sent635 ranged O
sent635 from O
sent635 1 O
sent635 to O
sent635 4.5 O
sent635 years O
sent635 ( O
sent635 mean O
sent635 2 O
sent635 years O
sent635 ) O
sent636 RESULTS O
sent636 : O
sent636 Visually O
sent636 significant O
sent636 secondary O
sent636 cataract D
sent636 developed O
sent636 in O
sent636 the O
sent636 five O
sent636 eyes O
sent636 with O
sent636 intact O
sent636 posterior O
sent636 capsules O
sent636 and O
sent636 in O
sent636 the O
sent636 four O
sent636 eyes O
sent636 that O
sent636 had O
sent636 PCCC T
sent636 without O
sent636 vitrectomy T
sent636 and O
sent636 without O
sent636 posterior T
sent636 optic T
sent636 capture T
sent636 ( O
sent636 i.e O
sent636 . O
sent636 , O
sent636 the O
sent636 optic O
sent636 was O
sent636 left O
sent636 in O
sent636 the O
sent636 capsular O
sent636 bag O
sent636 ) O
sent637 The O
sent637 optical O
sent637 axis O
sent637 remained O
sent637 clear O
sent637 in O
sent637 the O
sent637 six O
sent637 eyes O
sent637 that O
sent637 had O
sent637 PC T
sent637 IOL T
sent637 implantation T
sent637 with O
sent637 vitrectomy T
sent637 ( O
sent637 with O
sent637 or O
sent637 without O
sent637 posterior T
sent637 optic T
sent637 capture T
sent637 ) O
sent638 Initially O
sent638 , O
sent638 all O
sent638 eyes O
sent638 that O
sent638 had O
sent638 optic T
sent638 capture T
sent638 without O
sent638 vitrectomy T
sent638 also O
sent638 remained O
sent638 clear O
sent638 , O
sent638 but O
sent638 after O
sent638 6 O
sent638 months O
sent638 , O
sent638 four O
sent638 of O
sent638 five O
sent638 developed O
sent638 opacification D
sent639 CONCLUSION O
sent639 : O
sent639 In O
sent639 this O
sent639 series O
sent639 , O
sent639 PCCC T
sent639 with T
sent639 anterior T
sent639 vitrectomy T
sent639 was O
sent639 the O
sent639 only O
sent639 effective O
sent639 method O
sent639 of O
sent639 preventing O
sent639 or O
sent639 delaying O
sent639 secondary D
sent639 cataract D
sent639 formation D
sent639 in O
sent639 infants O
sent639 and O
sent639 children O
sent640 Evidence O
sent640 for O
sent640 the O
sent640 presence O
sent640 of O
sent640 a O
sent640 serotonin1A O
sent640 ( O
sent640 5-HT1A O
sent640 ) O
sent640 receptor O
sent640 subtype O
sent640 in O
sent640 the O
sent640 salmonid O
sent640 fish O
sent640 brain O
sent640 has O
sent640 recently O
sent640 been O
sent640 presented O
sent641 In O
sent641 the O
sent641 present O
sent641 study O
sent641 the O
sent641 potent O
sent641 5-HT1A O
sent641 receptor O
sent641 agonist O
sent641 , O
sent641 8-hydroxy-2- O
sent641 ( O
sent641 di-n-propylamino O
sent641 ) O
sent641 -tetralin O
sent641 ( O
sent641 8-OH-DPAT O
sent641 ) O
sent641 was O
sent641 tested O
sent641 for O
sent641 its O
sent641 effect O
sent641 on O
sent641 plasma O
sent641 cortisol O
sent641 concentrations O
sent641 in O
sent641 rainbow O
sent641 trout O
sent641 ( O
sent641 Oncorhynchus O
sent641 mykiss O
sent641 ) O
sent642 Blood O
sent642 was O
sent642 sampled O
sent642 and O
sent642 8-OH-DPAT O
sent642 administered O
sent642 through O
sent642 a O
sent642 catheter O
sent642 in O
sent642 the O
sent642 dorsal O
sent642 aorta O
sent643 Thirty O
sent643 minutes O
sent643 after O
sent643 the O
sent643 injection O
sent643 of O
sent643 40 O
sent643 microg O
sent643 of O
sent643 8-OH-DPAT/kg O
sent643 , O
sent643 plasma O
sent643 cortisol O
sent643 levels O
sent643 had O
sent643 increased O
sent643 from O
sent643 12 O
sent643 to O
sent643 149 O
sent643 ng/ml O
sent643 , O
sent643 whereupon O
sent643 they O
sent643 fell O
sent643 , O
sent643 reaching O
sent643 baseline O
sent643 levels O
sent643 after O
sent643 4 O
sent643 h. O
sent643 The O
sent643 effect O
sent643 of O
sent643 1-40 O
sent643 microg O
sent643 8-OH-DPAT/kg O
sent643 on O
sent643 plasma O
sent643 cortisol O
sent643 concentrations O
sent643 was O
sent643 dose-dependent O
sent644 The O
sent644 results O
sent644 lends O
sent644 further O
sent644 support O
sent644 to O
sent644 the O
sent644 hypothesis O
sent644 that O
sent644 the O
sent644 brain O
sent644 serotonergic O
sent644 system O
sent644 plays O
sent644 a O
sent644 key O
sent644 role O
sent644 in O
sent644 integrating O
sent644 autonomic O
sent644 , O
sent644 behavioral O
sent644 and O
sent644 neuroendocrine O
sent644 stress-responses O
sent644 in O
sent644 fish O
sent644 as O
sent644 well O
sent644 as O
sent644 mammals O
sent644 , O
sent644 suggesting O
sent644 that O
sent644 not O
sent644 only O
sent644 the O
sent644 structural O
sent644 and O
sent644 biochemical O
sent644 organization O
sent644 , O
sent644 but O
sent644 also O
sent644 the O
sent644 function O
sent644 of O
sent644 the O
sent644 serotonergic O
sent644 system O
sent644 has O
sent644 been O
sent644 conserved O
sent644 during O
sent644 vertebrate O
sent644 evolution O
sent645 OBJECTIVE O
sent645 : O
sent645 To O
sent645 assess O
sent645 the O
sent645 medicalising O
sent645 effect O
sent645 of O
sent645 prescribing O
sent645 antibiotics T
sent645 for O
sent645 sore D
sent645 throat D
sent646 SETTING O
sent646 : O
sent646 11 O
sent646 general O
sent646 practices O
sent646 in O
sent646 England O
sent647 DESIGN O
sent647 : O
sent647 Randomised O
sent647 trial O
sent647 of O
sent647 three O
sent647 approaches O
sent647 to O
sent647 sore D
sent647 throat D
sent647 : O
sent647 a O
sent647 10 O
sent647 day O
sent647 prescription O
sent647 of O
sent647 antibiotics T
sent647 , O
sent647 no O
sent647 antibiotics O
sent647 , O
sent647 or O
sent647 a O
sent647 delayed O
sent647 prescription O
sent647 if O
sent647 the O
sent647 sore D
sent647 throat D
sent647 had O
sent647 not O
sent647 started O
sent647 to O
sent647 settle O
sent647 after O
sent647 three O
sent647 days O
sent648 PATIENTS O
sent648 : O
sent648 716 O
sent648 patients O
sent648 aged O
sent648 4 O
sent648 and O
sent648 over O
sent648 with O
sent648 sore D
sent648 throat D
sent648 and O
sent648 an O
sent648 abnormal O
sent648 physical O
sent648 sign O
sent648 : O
sent648 84 O
sent648 % O
sent648 had O
sent648 tonsillitis D
sent648 or O
sent648 pharyngitis D
sent649 OUTCOME O
sent649 MEASURES O
sent649 : O
sent649 Number O
sent649 and O
sent649 rate O
sent649 of O
sent649 patients O
sent649 making O
sent649 a O
sent649 first O
sent649 return O
sent649 with O
sent649 sore D
sent649 throat D
sent649 , O
sent649 pharyngitis D
sent649 , O
sent649 or O
sent649 tonsillitis D
sent650 Early O
sent650 returns O
sent650 ( O
sent650 within O
sent650 two O
sent650 weeks O
sent650 ) O
sent650 and O
sent650 complications O
sent650 ( O
sent650 otitis D
sent650 media D
sent650 , O
sent650 sinusitis D
sent650 , O
sent650 quinsy D
sent650 ) O
sent651 Outcomes O
sent651 were O
sent651 documented O
sent651 in O
sent651 675 O
sent651 subjects O
sent651 ( O
sent651 94 O
sent651 % O
sent651 ) O
sent652 RESULTS O
sent652 : O
sent652 Mean O
sent652 follow O
sent652 up O
sent652 time O
sent652 was O
sent652 similar O
sent652 ( O
sent652 antibiotic O
sent652 group O
sent652 1.07 O
sent652 years O
sent652 , O
sent652 other O
sent652 two O
sent652 groups O
sent652 1.03 O
sent652 years O
sent652 ) O
sent653 More O
sent653 of O
sent653 those O
sent653 initially O
sent653 prescribed O
sent653 antibiotics T
sent653 initially O
sent653 returned O
sent653 to O
sent653 the O
sent653 surgery O
sent653 with O
sent653 sore D
sent653 throat D
sent653 ( O
sent653 38 O
sent653 % O
sent653 v O
sent653 27 O
sent653 % O
sent653 , O
sent653 adjusted O
sent653 hazard O
sent653 ratio O
sent653 for O
sent653 return O
sent653 1.39 O
sent653 % O
sent653 , O
sent653 95 O
sent653 % O
sent653 confidence O
sent653 interval O
sent653 1.03 O
sent653 to O
sent653 1.89 O
sent653 ) O
sent654 Antibiotics T
sent654 prescribed O
sent654 for O
sent654 sore D
sent654 throat D
sent654 during O
sent654 the O
sent654 previous O
sent654 year O
sent654 had O
sent654 an O
sent654 additional O
sent654 effect O
sent654 ( O
sent654 hazard O
sent654 ratio O
sent654 1.69 O
sent654 , O
sent654 1.20 O
sent654 to O
sent654 2.37 O
sent654 ) O
sent655 Longer O
sent655 duration O
sent655 of O
sent655 illness O
sent655 ( O
sent655 > O
sent655 5 O
sent655 days O
sent655 ) O
sent655 was O
sent655 associated O
sent655 with O
sent655 increased O
sent655 return O
sent655 within O
sent655 six O
sent655 weeks O
sent655 ( O
sent655 hazard O
sent655 ratio O
sent655 2.90 O
sent655 , O
sent655 1.70 O
sent655 to O
sent655 4.92 O
sent655 ) O
sent656 Prior O
sent656 attendance O
sent656 with O
sent656 upper D
sent656 respiratory D
sent656 conditions D
sent656 was O
sent656 also O
sent656 associated O
sent656 with O
sent656 increased O
sent656 reattendance O
sent657 There O
sent657 was O
sent657 no O
sent657 difference O
sent657 between O
sent657 groups O
sent657 in O
sent657 early O
sent657 return O
sent657 ( O
sent657 13/238 O
sent657 ( O
sent657 5.5 O
sent657 % O
sent657 ) O
sent657 v O
sent657 27/437 O
sent657 ( O
sent657 6 O
sent657 % O
sent657 ) O
sent657 ) O
sent657 , O
sent657 or O
sent657 complications O
sent657 ( O
sent657 2/236 O
sent657 ( O
sent657 0.8 O
sent657 % O
sent657 ) O
sent657 v O
sent657 3/434 O
sent657 ( O
sent657 0.7 O
sent657 % O
sent657 ) O
sent657 ) O
sent658 CONCLUSIONS O
sent658 : O
sent658 Complications O
sent658 and O
sent658 early O
sent658 return O
sent658 resulting O
sent658 from O
sent658 no O
sent658 or O
sent658 delayed O
sent658 prescribing O
sent658 of O
sent658 antibiotics T
sent658 for O
sent658 sore D
sent658 throat D
sent658 are O
sent658 rare O
sent659 Both O
sent659 current O
sent659 and O
sent659 previous O
sent659 prescribing O
sent659 for O
sent659 sore D
sent659 throat D
sent659 increase O
sent659 reattendance O
sent660 To O
sent660 avoid O
sent660 medicalising O
sent660 a O
sent660 self O
sent660 limiting O
sent660 illness O
sent660 doctors O
sent660 should O
sent660 avoid O
sent660 antibiotics T
sent660 or O
sent660 offer O
sent660 a O
sent660 delayed O
sent660 prescription O
sent660 for O
sent660 most O
sent660 patients O
sent660 with O
sent660 sore D
sent660 throat D
sent661 This O
sent661 study O
sent661 was O
sent661 designed O
sent661 to O
sent661 determine O
sent661 and O
sent661 compare O
sent661 the O
sent661 dose-response O
sent661 characteristics O
sent661 , O
sent661 speed O
sent661 of O
sent661 onset O
sent661 , O
sent661 and O
sent661 relative O
sent661 potency O
sent661 of O
sent661 single-dose O
sent661 epidural T
sent661 fentanyl T
sent661 ( T
sent661 F T
sent661 ) T
sent661 and O
sent661 sufentanil T
sent661 ( T
sent661 S T
sent661 ) T
sent661 for O
sent661 postoperative D
sent661 pain D
sent661 relief D
sent662 < O
sent662 TO_SEE O
sent662 > O
sent662 Eighty O
sent662 women O
sent662 undergoing O
sent662 cesarean O
sent662 section O
sent662 ( O
sent662 C/S O
sent662 ) O
sent662 with O
sent662 epidural O
sent662 2 O
sent662 % O
sent662 lidocaine O
sent662 with O
sent662 epinephrine O
sent662 ( O
sent662 1 O
sent662 : O
sent662 200 O
sent662 , O
sent662 000 O
sent662 ) O
sent662 were O
sent662 randomly O
sent662 assigned O
sent662 to O
sent662 receive O
sent662 double-blind O
sent662 epidural O
sent662 administration O
sent662 of O
sent662 F O
sent662 ( O
sent662 25 O
sent662 , O
sent662 50 O
sent662 , O
sent662 100 O
sent662 , O
sent662 or O
sent662 200 O
sent662 microg O
sent662 ) O
sent662 or O
sent662 S O
sent662 ( O
sent662 5 O
sent662 , O
sent662 10 O
sent662 , O
sent662 20 O
sent662 , O
sent662 or O
sent662 30 O
sent662 microg O
sent662 ) O
sent662 ( O
sent662 n O
sent662 = O
sent662 10 O
sent662 per O
sent662 group O
sent662 ) O
sent662 upon O
sent662 complaint O
sent662 of O
sent662 pain O
sent662 postoperatively O
sent663 Visual O
sent663 analog O
sent663 scales O
sent663 ( O
sent663 VAS O
sent663 , O
sent663 0-100 O
sent663 mm O
sent663 ) O
sent663 were O
sent663 used O
sent663 to O
sent663 assess O
sent663 pain O
sent663 and O
sent663 sedation O
sent663 at O
sent663 baseline O
sent663 ; O
sent663 at O
sent663 3 O
sent663 , O
sent663 6 O
sent663 , O
sent663 9 O
sent663 , O
sent663 12 O
sent663 , O
sent663 15 O
sent663 , O
sent663 20 O
sent663 , O
sent663 25 O
sent663 , O
sent663 30 O
sent663 , O
sent663 45 O
sent663 , O
sent663 and O
sent663 60 O
sent663 min O
sent663 ; O
sent663 and O
sent663 every O
sent663 30 O
sent663 min O
sent663 until O
sent663 further O
sent663 analgesia O
sent663 was O
sent663 requested O
sent664 The O
sent664 study O
sent664 was O
sent664 terminated O
sent664 at O
sent664 30 O
sent664 min O
sent664 if O
sent664 satisfactory O
sent664 analgesia O
sent664 was O
sent664 not O
sent664 achieved O
sent665 Side O
sent665 effects O
sent665 were O
sent665 recorded O
sent666 A O
sent666 dose-response O
sent666 was O
sent666 demonstrated O
sent666 for O
sent666 both O
sent666 opioids O
sent667 F O
sent667 25 O
sent667 microg O
sent667 and O
sent667 S O
sent667 5 O
sent667 microg O
sent667 were O
sent667 ineffective O
sent667 , O
sent667 with O
sent667 significantly O
sent667 fewer O
sent667 women O
sent667 achieving O
sent667 VAS O
sent667 scores O
sent667 & O
sent667 # O
sent667 60 O
sent667 ; O
sent667 10 O
sent667 mm O
sent667 ( O
sent667 P O
sent667 & O
sent667 # O
sent667 60 O
sent667 ; O
sent667 0.05 O
sent667 compared O
sent667 with O
sent667 F O
sent667 100 O
sent667 or O
sent667 200 O
sent667 microg O
sent667 and O
sent667 S O
sent667 20 O
sent667 or O
sent667 30 O
sent667 microg O
sent667 ) O
sent668 F O
sent668 100 O
sent668 and O
sent668 200 O
sent668 microg O
sent668 and O
sent668 S O
sent668 20 O
sent668 and O
sent668 30 O
sent668 microg O
sent668 all O
sent668 achieved O
sent668 VAS O
sent668 scores O
sent668 & O
sent668 # O
sent668 60 O
sent668 ; O
sent668 10 O
sent668 mm O
sent668 in O
sent668 all O
sent668 women O
sent668 with O
sent668 no O
sent668 differences O
sent668 in O
sent668 time O
sent668 to O
sent668 50 O
sent668 % O
sent668 reduction O
sent668 in O
sent668 VAS O
sent668 ( O
sent668 mean O
sent668 11-16 O
sent668 min O
sent668 ) O
sent668 and O
sent668 no O
sent668 differences O
sent668 in O
sent668 duration O
sent668 of O
sent668 analgesia O
sent668 ( O
sent668 mean O
sent668 117-138 O
sent668 min O
sent668 ) O
sent669 The O
sent669 50 O
sent669 % O
sent669 and O
sent669 95 O
sent669 % O
sent669 effective O
sent669 dose O
sent669 values O
sent669 for O
sent669 each O
sent669 opioid O
sent669 to O
sent669 achieve O
sent669 a O
sent669 VAS O
sent669 score O
sent669 & O
sent669 # O
sent669 60 O
sent669 ; O
sent669 10 O
sent669 mm O
sent669 were O
sent669 F O
sent669 33 O
sent669 microg O
sent669 and O
sent669 92 O
sent669 microg O
sent669 and O
sent669 S O
sent669 6.7 O
sent669 microg O
sent669 and O
sent669 17.5 O
sent669 microg O
sent670 There O
sent670 were O
sent670 no O
sent670 differences O
sent670 among O
sent670 groups O
sent670 in O
sent670 sedation O
sent670 scores O
sent670 or O
sent670 side O
sent670 effects O
sent671 Our O
sent671 data O
sent671 suggest O
sent671 that O
sent671 the O
sent671 relative O
sent671 analgesic O
sent671 potency O
sent671 of O
sent671 epidural O
sent671 S O
sent671 : O
sent671 F O
sent671 is O
sent671 approximately O
sent671 5 O
sent671 and O
sent671 that O
sent671 there O
sent671 are O
sent671 no O
sent671 differences O
sent671 between O
sent671 the O
sent671 opioids O
sent671 in O
sent671 the O
sent671 onset O
sent671 , O
sent671 duration O
sent671 , O
sent671 and O
sent671 effectiveness O
sent671 of O
sent671 analgesia O
sent671 when O
sent671 equianalgesic O
sent671 doses O
sent671 are O
sent671 administered O
sent671 postoperatively O
sent671 after O
sent671 lidocaine O
sent671 anesthesia O
sent671 for O
sent671 C/S O
sent672 We O
sent672 describe O
sent672 2 O
sent672 cases O
sent672 in O
sent672 which O
sent672 intraoperative O
sent672 transesophageal O
sent672 echocardiography O
sent672 detected O
sent672 complications O
sent672 related O
sent672 to O
sent672 the O
sent672 proximal O
sent672 coronary O
sent672 arteries O
sent672 during O
sent672 homograft T
sent672 aortic T
sent672 valve T
sent672 and T
sent672 root T
sent672 replacement T
sent673 In O
sent673 both O
sent673 cases O
sent673 , O
sent673 cardiopulmonary T
sent673 bypass T
sent673 could O
sent673 not O
sent673 be O
sent673 discontinued O
sent673 despite O
sent673 the O
sent673 use O
sent673 of O
sent673 large O
sent673 doses O
sent673 of O
sent673 inotropic T
sent673 drugs T
sent674 Transesophageal O
sent674 echocardiography O
sent674 demonstrated O
sent674 aliasing O
sent674 on O
sent674 color O
sent674 flow O
sent674 mapping O
sent674 in O
sent674 the O
sent674 left O
sent674 main O
sent674 coronary O
sent674 artery O
sent674 in O
sent674 1 O
sent674 case O
sent674 and O
sent674 proximal O
sent674 right O
sent674 coronary O
sent674 artery O
sent674 in O
sent674 the O
sent674 other O
sent674 , O
sent674 along O
sent674 with O
sent674 severely O
sent674 depressed O
sent674 left O
sent674 ventricular O
sent674 anterior O
sent674 wall O
sent674 and O
sent674 right O
sent674 ventricular O
sent674 function O
sent674 , O
sent674 respectively O
sent675 Coronary T
sent675 artery T
sent675 bypass T
sent675 grafting T
sent675 was O
sent675 performed O
sent675 in O
sent675 both O
sent675 cases O
sent675 , O
sent675 and O
sent675 the O
sent675 outcome O
sent675 was O
sent675 successful O
sent676 < O
sent676 TO_SEE O
sent676 > O
sent676 Granulocyte O
sent676 colony-stimulating O
sent676 factor O
sent676 ( O
sent676 G-CSF O
sent676 ) O
sent676 has O
sent676 been O
sent676 used O
sent676 to O
sent676 improve O
sent676 granulocyte O
sent676 count O
sent676 in O
sent676 chronic O
sent676 neutropenia O
sent676 and O
sent676 myelodysplasia O
sent676 , O
sent676 to O
sent676 minimize O
sent676 the O
sent676 incidence O
sent676 and O
sent676 duration O
sent676 of O
sent676 neutropenia O
sent676 during O
sent676 conventional O
sent676 chemotherapy O
sent676 , O
sent676 and O
sent676 to O
sent676 mobilize O
sent676 peripheral O
sent676 blood O
sent676 stem O
sent676 cells O
sent676 prior O
sent676 to O
sent676 leukapheresis O
sent676 for O
sent676 use O
sent676 in O
sent676 autologous O
sent676 and O
sent676 allogeneic O
sent676 marrow O
sent676 transplantation O
sent677 The O
sent677 most O
sent677 common O
sent677 toxicity O
sent677 is O
sent677 bone D
sent677 pain D
sent677 , O
sent677 and O
sent677 other O
sent677 reactions O
sent677 such O
sent677 as O
sent677 inflammation D
sent677 at O
sent677 the O
sent677 site O
sent677 of O
sent677 injection T
sent677 have O
sent677 also O
sent677 occurred O
sent678 In O
sent678 patients O
sent678 with O
sent678 chronic D
sent678 neutropenia D
sent678 , O
sent678 splenomegaly D
sent678 has O
sent678 been O
sent678 described O
sent678 with O
sent678 long-term O
sent678 use O
sent678 , O
sent678 and O
sent678 extramedullary D
sent678 hematopoiesis D
sent678 has O
sent678 also O
sent678 been O
sent678 reported O
sent679 However O
sent679 , O
sent679 thus O
sent679 far O
sent679 , O
sent679 no O
sent679 life-threatening O
sent679 sequelae O
sent679 of O
sent679 these O
sent679 effects O
sent679 are O
sent679 found O
sent679 in O
sent679 the O
sent679 literature O
sent680 We O
sent680 now O
sent680 describe O
sent680 a O
sent680 case O
sent680 of O
sent680 spontaneous O
sent680 splenic D
sent680 rupture D
sent680 four O
sent680 days O
sent680 following O
sent680 a O
sent680 six-day O
sent680 course O
sent680 of O
sent680 G-CSF T
sent680 therapy T
sent680 in O
sent680 an O
sent680 allogeneic O
sent680 donor O
sent680 of O
sent680 peripheral O
sent680 blood O
sent680 stem O
sent680 cells O
sent681 Evidence-based O
sent681 medicine O
sent681 ( O
sent681 EBM O
sent681 ) O
sent681 aids O
sent681 clinical O
sent681 decision O
sent681 making O
sent681 in O
sent681 all O
sent681 fields O
sent681 of O
sent681 medicine O
sent681 , O
sent681 including O
sent681 primary O
sent681 care O
sent682 General O
sent682 practice O
sent682 is O
sent682 characterized O
sent682 by O
sent682 particular O
sent682 emphasis O
sent682 on O
sent682 the O
sent682 doctor-patient O
sent682 relationship O
sent682 and O
sent682 on O
sent682 biomedical O
sent682 , O
sent682 personal O
sent682 and O
sent682 contextual O
sent682 perspectives O
sent682 in O
sent682 diagnosis O
sent683 Most O
sent683 evidence O
sent683 available O
sent683 to O
sent683 general O
sent683 practitioners O
sent683 ( O
sent683 GPs O
sent683 ) O
sent683 addresses O
sent683 only O
sent683 the O
sent683 bio-medical O
sent683 perspective O
sent683 and O
sent683 is O
sent683 often O
sent683 not O
sent683 directly O
sent683 applicable O
sent683 to O
sent683 primary O
sent683 care O
sent683 , O
sent683 as O
sent683 it O
sent683 derives O
sent683 from O
sent683 secondary O
sent683 or O
sent683 tertiary O
sent683 care O
sent684 Emphasis O
sent684 on O
sent684 the O
sent684 biomedical O
sent684 domain O
sent684 and O
sent684 the O
sent684 randomized O
sent684 controlled O
sent684 trial O
sent684 ( O
sent684 RCT O
sent684 ) O
sent684 alone O
sent684 reflects O
sent684 a O
sent684 reductionist O
sent684 approach O
sent684 that O
sent684 fails O
sent684 to O
sent684 do O
sent684 justice O
sent684 to O
sent684 the O
sent684 philosophy O
sent684 of O
sent684 general O
sent684 practice O
sent685 The O
sent685 art O
sent685 of O
sent685 medicine O
sent685 is O
sent685 founded O
sent685 on O
sent685 context O
sent685 , O
sent685 anecdote O
sent685 , O
sent685 patient O
sent685 stories O
sent685 of O
sent685 illness O
sent685 and O
sent685 personal O
sent685 experience O
sent685 , O
sent685 and O
sent685 we O
sent685 should O
sent685 continue O
sent685 to O
sent685 blend O
sent685 this O
sent685 with O
sent685 good O
sent685 quality O
sent685 and O
sent685 appropriate O
sent685 research O
sent685 findings O
sent685 in O
sent685 patient O
sent685 care O
sent686 Abdominal D
sent686 tuberculosis D
sent686 is O
sent686 not O
sent686 uncommon O
sent686 in O
sent686 the O
sent686 UK O
sent686 , O
sent686 especially O
sent686 in O
sent686 Asian O
sent686 immigrants O
sent687 It O
sent687 resembles O
sent687 Crohn D
sent687 's D
sent687 disease D
sent687 clinically O
sent687 and O
sent687 radiologically O
sent687 , O
sent687 and O
sent687 it O
sent687 may O
sent687 be O
sent687 difficult O
sent687 to O
sent687 differentiate O
sent687 between O
sent687 them O
sent687 , O
sent687 even O
sent687 at O
sent687 laparotomy O
sent687 or O
sent687 histology O
sent688 The O
sent688 distinction O
sent688 is O
sent688 important O
sent688 , O
sent688 however O
sent688 , O
sent688 for O
sent688 proper O
sent688 management O
sent688 of O
sent688 the O
sent688 two O
sent688 conditions O
sent689 < O
sent689 TO_SEE O
sent689 > O
sent689 Every O
sent689 effort O
sent689 must O
sent689 be O
sent689 made O
sent689 to O
sent689 exclude O
sent689 abdominal D
sent689 tuberculosis D
sent689 before O
sent689 the O
sent689 patient O
sent689 is O
sent689 diagnosed O
sent689 as O
sent689 having O
sent689 Crohn D
sent689 's D
sent689 disease D
sent689 and O
sent689 is O
sent689 treated O
sent689 with O
sent689 steroids T
sent690 PURPOSE O
sent690 : O
sent690 The O
sent690 American O
sent690 Urological O
sent690 Association O
sent690 convened O
sent690 the O
sent690 Female D
sent690 Stress D
sent690 Urinary D
sent690 Incontinence D
sent690 Clinical O
sent690 Guidelines O
sent690 Panel O
sent690 to O
sent690 analyze O
sent690 the O
sent690 literature O
sent690 regarding O
sent690 surgical T
sent690 procedures T
sent690 for O
sent690 treating O
sent690 stress D
sent690 urinary D
sent690 incontinence D
sent690 in O
sent690 the O
sent690 otherwise O
sent690 healthy O
sent690 female O
sent690 subject O
sent690 and O
sent690 to O
sent690 make O
sent690 practice O
sent690 recommendations O
sent690 based O
sent690 on O
sent690 the O
sent690 treatment O
sent690 outcomes O
sent690 data O
sent691 MATERIALS O
sent691 AND O
sent691 METHODS O
sent691 : O
sent691 The O
sent691 panel O
sent691 searched O
sent691 the O
sent691 MEDLINE O
sent691 data O
sent691 base O
sent691 for O
sent691 all O
sent691 articles O
sent691 through O
sent691 1993 O
sent691 on O
sent691 surgical T
sent691 treatment T
sent691 of O
sent691 female D
sent691 stress D
sent691 urinary D
sent691 incontinence D
sent692 Outcomes O
sent692 data O
sent692 were O
sent692 extracted O
sent692 from O
sent692 articles O
sent692 accepted O
sent692 after O
sent692 panel O
sent692 review O
sent693 The O
sent693 data O
sent693 were O
sent693 then O
sent693 meta-analyzed O
sent693 to O
sent693 produce O
sent693 outcome O
sent693 estimates O
sent693 for O
sent693 alternative O
sent693 surgical T
sent693 procedures T
sent694 RESULTS O
sent694 : O
sent694 The O
sent694 data O
sent694 indicate O
sent694 that O
sent694 after O
sent694 48 O
sent694 months O
sent694 retropubic T
sent694 suspensions T
sent694 and O
sent694 slings T
sent694 appear O
sent694 to O
sent694 be O
sent694 more O
sent694 efficacious O
sent694 than O
sent694 transvaginal T
sent694 suspensions T
sent694 , O
sent694 and O
sent694 also O
sent694 more O
sent694 efficacious O
sent694 than O
sent694 anterior T
sent694 repairs T
sent695 The O
sent695 literature O
sent695 suggests O
sent695 higher O
sent695 complication O
sent695 rates O
sent695 when O
sent695 synthetic O
sent695 materials O
sent695 are O
sent695 used O
sent695 for O
sent695 slings T
sent696 CONCLUSIONS O
sent696 : O
sent696 The O
sent696 panel O
sent696 found O
sent696 sufficient O
sent696 acceptable O
sent696 long-term O
sent696 outcomes O
sent696 data O
sent696 ( O
sent696 longer O
sent696 than O
sent696 48 O
sent696 months O
sent696 ) O
sent696 to O
sent696 conclude O
sent696 that O
sent696 surgical T
sent696 treatment T
sent696 of O
sent696 female D
sent696 stress D
sent696 urinary D
sent696 incontinence D
sent696 is O
sent696 effective O
sent696 , O
sent696 offering O
sent696 a O
sent696 long-term O
sent696 cure O
sent696 in O
sent696 a O
sent696 significant O
sent696 percentage O
sent696 of O
sent696 women O
sent697 The O
sent697 evidence O
sent697 supports O
sent697 surgery T
sent697 as O
sent697 initial O
sent697 therapy O
sent697 and O
sent697 as O
sent697 a O
sent697 secondary O
sent697 form O
sent697 of O
sent697 therapy O
sent697 after O
sent697 failure O
sent697 of O
sent697 other O
sent697 treatments O
sent697 for O
sent697 stress D
sent697 urinary D
sent697 incontinence D
sent698 Retropubic T
sent698 suspensions T
sent698 and O
sent698 slings T
sent698 are O
sent698 the O
sent698 most O
sent698 efficacious O
sent698 procedures O
sent698 for O
sent698 long-term O
sent698 success O
sent698 ( O
sent698 based O
sent698 on O
sent698 cure/dry O
sent698 rates O
sent698 ) O
sent699 However O
sent699 , O
sent699 in O
sent699 the O
sent699 panel O
sent699 's O
sent699 opinion O
sent699 retropubic T
sent699 suspensions T
sent699 and O
sent699 sling T
sent699 procedures T
sent699 are O
sent699 associated O
sent699 with O
sent699 slightly O
sent699 higher O
sent699 complication O
sent699 rates O
sent699 , O
sent699 including O
sent699 longer O
sent699 convalescence O
sent699 and O
sent699 postoperative D
sent699 voiding D
sent699 dysfunction D
sent700 A O
sent700 55-year-old O
sent700 lady O
sent700 underwent O
sent700 repeat O
sent700 aortic T
sent700 valve T
sent700 replacement T
sent700 using O
sent700 a O
sent700 16-mm O
sent700 Carbomedics O
sent700 prosthesis O
sent701 She O
sent701 made O
sent701 an O
sent701 uneventful O
sent701 postoperative O
sent701 recovery O
sent701 and O
sent701 now O
sent701 leads O
sent701 an O
sent701 unrestricted O
sent701 life O
sent702 Doppler O
sent702 echocardiography O
sent702 reveals O
sent702 a O
sent702 21-mm O
sent702 Hg O
sent702 gradient O
sent702 across O
sent702 the O
sent702 valve O
sent702 at O
sent702 rest O
sent703 This O
sent703 did O
sent703 not O
sent703 increase O
sent703 with O
sent703 an O
sent703 infusion O
sent703 of O
sent703 30 O
sent703 mcg/kg O
sent703 per O
sent703 min O
sent703 of O
sent703 dobutamine O
sent703 , O
sent703 which O
sent703 resulted O
sent703 in O
sent703 an O
sent703 increase O
sent703 in O
sent703 the O
sent703 cardiac O
sent703 output O
sent703 from O
sent703 1.96 O
sent703 to O
sent703 5.46 O
sent703 l/min O
sent704 BACKGROUND O
sent704 : O
sent704 For O
sent704 more O
sent704 than O
sent704 30 O
sent704 years O
sent704 it O
sent704 has O
sent704 been O
sent704 known O
sent704 that O
sent704 gastric O
sent704 acid O
sent704 secretion O
sent704 is O
sent704 inversely O
sent704 related O
sent704 to O
sent704 the O
sent704 extent O
sent704 and O
sent704 severity O
sent704 of O
sent704 corpal D
sent704 gastritis D
sent705 We O
sent705 therefore O
sent705 evaluated O
sent705 the O
sent705 effect O
sent705 of O
sent705 cure O
sent705 of O
sent705 Helicobacter D
sent705 pylori D
sent705 infection D
sent705 on O
sent705 basal O
sent705 and O
sent705 pentagastrin-stimulated O
sent705 acid O
sent705 secretion O
sent706 METHODS O
sent706 : O
sent706 Basal O
sent706 acid O
sent706 output O
sent706 ( O
sent706 BAO O
sent706 ) O
sent706 and O
sent706 maximal O
sent706 acid O
sent706 output O
sent706 ( O
sent706 MAO O
sent706 ) O
sent706 were O
sent706 assessed O
sent706 in O
sent706 11 O
sent706 H. O
sent706 pylori-infected O
sent706 dyspeptic O
sent706 patients O
sent706 ( O
sent706 8 O
sent706 women O
sent706 and O
sent706 3 O
sent706 men O
sent706 ; O
sent706 mean O
sent706 age O
sent706 , O
sent706 28 O
sent706 years O
sent706 ) O
sent706 before O
sent706 and O
sent706 after O
sent706 successful O
sent706 anti-H O
sent707 pylori O
sent707 therapy O
sent708 RESULTS O
sent708 : O
sent708 The O
sent708 gastritis O
sent708 index O
sent708 was O
sent708 significantly O
sent708 lower O
sent708 after O
sent708 therapy O
sent708 and O
sent708 was O
sent708 associated O
sent708 with O
sent708 an O
sent708 increase O
sent708 in O
sent708 both O
sent708 BAO O
sent708 and O
sent708 MAO O
sent708 after O
sent708 cure O
sent708 of O
sent708 the O
sent708 H. D
sent708 pylori D
sent708 infection D
sent708 ( O
sent708 BAO O
sent708 from O
sent708 0.3 O
sent708 mmol/h O
sent708 and O
sent708 MAO O
sent708 from O
sent708 4.8 O
sent708 mmol/h O
sent708 to O
sent708 19 O
sent708 mmol/ O
sent708 h O
sent708 ) O
sent709 Basal O
sent709 and O
sent709 stimulated O
sent709 acid O
sent709 concentrations O
sent709 also O
sent709 increased O
sent709 ( O
sent709 29.1 O
sent709 +/- O
sent709 36.6 O
sent709 to O
sent709 54 O
sent709 +/- O
sent709 31 O
sent709 mmol/l O
sent709 and O
sent709 72.5 O
sent709 +/- O
sent709 46 O
sent709 to O
sent709 120.1 O
sent709 +/- O
sent709 30 O
sent709 mmol/l O
sent709 , O
sent709 respectively O
sent709 , O
sent709 for O
sent709 basal O
sent709 and O
sent709 stimulated O
sent709 acid O
sent709 concentrations O
sent709 ; O
sent709 P O
sent709 & O
sent709 # O
sent709 60 O
sent709 ; O
sent709 0.05 O
sent709 for O
sent709 peak O
sent709 and O
sent709 MAO O
sent709 , O
sent709 P O
sent709 = O
sent709 0.07 O
sent709 for O
sent709 BAO O
sent709 ) O
sent710 CONCLUSION O
sent710 : O
sent710 Gastric O
sent710 acid O
sent710 secretion O
sent710 increased O
sent710 into O
sent710 the O
sent710 normal O
sent710 range O
sent710 after O
sent710 successful O
sent710 treatment O
sent710 of O
sent710 H. D
sent710 pylori D
sent710 infection D
sent710 , O
sent710 suggesting O
sent710 that O
sent710 gastric O
sent710 function O
sent710 can O
sent710 recover O
sent710 to O
sent710 normal O
sent710 or O
sent710 almost O
sent710 normal O
sent710 after O
sent710 cure O
sent710 of O
sent710 H. D
sent710 pylori D
sent710 infection D
sent711 OBJECTIVE O
sent711 : O
sent711 Reports O
sent711 suggest O
sent711 that O
sent711 there O
sent711 is O
sent711 an O
sent711 increased O
sent711 incidence O
sent711 of O
sent711 preeclampsia D
sent711 after O
sent711 a O
sent711 previously O
sent711 normal O
sent711 pregnancy O
sent711 if O
sent711 there O
sent711 is O
sent711 a O
sent711 change O
sent711 in O
sent711 paternity O
sent712 We O
sent712 hypothesize O
sent712 that O
sent712 there O
sent712 is O
sent712 a O
sent712 higher O
sent712 incidence O
sent712 of O
sent712 preeclampsia D
sent712 ( D
sent712 proteinuric D
sent712 hypertension D
sent712 ) D
sent712 in O
sent712 women O
sent712 conceiving O
sent712 by O
sent712 intrauterine O
sent712 insemination O
sent712 with O
sent712 donor O
sent712 sperm O
sent712 versus O
sent712 intrauterine O
sent712 insemination O
sent712 with O
sent712 partner O
sent712 sperm O
sent713 STUDY O
sent713 DESIGN O
sent713 : O
sent713 This O
sent713 was O
sent713 a O
sent713 retrospective O
sent713 cohort O
sent713 study O
sent714 In O
sent714 women O
sent714 with O
sent714 primary O
sent714 infertility D
sent714 all O
sent714 pregnancies O
sent714 achieved O
sent714 by O
sent714 either O
sent714 partner O
sent714 or O
sent714 donor O
sent714 intrauterine T
sent714 insemination T
sent714 carried O
sent714 to O
sent714 birth O
sent714 of O
sent714 a O
sent714 fetus O
sent714 ( O
sent714 > O
sent714 20 O
sent714 weeks O
sent714 ) O
sent714 were O
sent714 identified O
sent715 The O
sent715 medical O
sent715 records O
sent715 were O
sent715 examined O
sent715 for O
sent715 the O
sent715 maternal O
sent715 and O
sent715 pregnancy O
sent715 outcome O
sent715 data O
sent716 The O
sent716 relative O
sent716 risk O
sent716 and O
sent716 95 O
sent716 % O
sent716 confidence O
sent716 interval O
sent716 were O
sent716 calculated O
sent716 for O
sent716 the O
sent716 risk O
sent716 of O
sent716 preeclampsia D
sent717 The O
sent717 baseline O
sent717 data O
sent717 were O
sent717 compared O
sent717 with O
sent717 t O
sent717 tests O
sent717 , O
sent717 chi O
sent717 2 O
sent717 analysis O
sent717 and O
sent717 Fisher O
sent717 's O
sent717 exact O
sent717 test O
sent717 where O
sent717 appropriate O
sent718 RESULTS O
sent718 : O
sent718 Forty-four O
sent718 patients O
sent718 in O
sent718 the O
sent718 partner O
sent718 intrauterine T
sent718 insemination T
sent718 group O
sent718 and O
sent718 37 O
sent718 in O
sent718 the O
sent718 donor T
sent718 insemination T
sent718 group O
sent718 were O
sent718 identified O
sent718 as O
sent718 having O
sent718 primary O
sent718 infertility D
sent719 Three O
sent719 cases O
sent719 of O
sent719 mild O
sent719 preeclampsia D
sent719 were O
sent719 found O
sent719 in O
sent719 the O
sent719 partner T
sent719 insemination T
sent719 program O
sent719 and O
sent719 nine O
sent719 cases O
sent719 of O
sent719 preeclampsia D
sent719 ( O
sent719 five O
sent719 severe O
sent719 , O
sent719 four O
sent719 mild O
sent719 ) O
sent719 in O
sent719 the O
sent719 donor T
sent719 insemination T
sent719 program O
sent719 ( O
sent719 relative O
sent719 risk O
sent719 1.85 O
sent719 , O
sent719 95 O
sent719 % O
sent719 confidence O
sent719 interval O
sent719 1.20 O
sent719 to O
sent719 2.85 O
sent719 ) O
sent719 . O
sent720 CONCLUSIONS O
sent720 : O
sent720 There O
sent720 is O
sent720 a O
sent720 higher O
sent720 incidence O
sent720 of O
sent720 preeclampsia D
sent720 in O
sent720 women O
sent720 conceiving O
sent720 by O
sent720 intrauterine T
sent720 insemination T
sent720 with O
sent720 washed O
sent720 donor O
sent720 sperm O
sent720 compared O
sent720 with O
sent720 intrauterine T
sent720 insemination T
sent720 with O
sent720 washed O
sent720 partner O
sent720 sperm O
sent720 . O
sent721 CONCLUSIONS O
sent721 : O
sent721 There O
sent721 is O
sent721 a O
sent721 higher O
sent721 incidence O
sent721 of O
sent721 preeclampsia D
sent721 in O
sent721 women O
sent721 conceiving O
sent721 by O
sent721 intrauterine T
sent721 insemination T
sent721 with O
sent721 washed O
sent721 donor O
sent721 sperm O
sent721 compared O
sent721 with O
sent721 intrauterine T
sent721 insemination T
sent721 with O
sent721 washed O
sent721 partner O
sent721 sperm O
sent721 . O
sent722 This O
sent722 supports O
sent722 , O
sent722 indirectly O
sent722 , O
sent722 an O
sent722 immunologic O
sent722 basis O
sent722 for O
sent722 preeclampsia D
sent723 The O
sent723 antigenic O
sent723 factor O
sent723 would O
sent723 appear O
sent723 to O
sent723 be O
sent723 located O
sent723 on O
sent723 the O
sent723 sperm O
sent723 as O
sent723 opposed O
sent723 to O
sent723 the O
sent723 seminal O
sent723 fluid O
sent723 itself O
sent724 After O
sent724 a O
sent724 rapid O
sent724 examination O
sent724 of O
sent724 a O
sent724 few O
sent724 basic O
sent724 concepts O
sent724 concerning O
sent724 cellular O
sent724 aging O
sent724 and O
sent724 programmed O
sent724 cell O
sent724 death O
sent724 , O
sent724 the O
sent724 aging O
sent724 of O
sent724 the O
sent724 tissues O
sent724 and O
sent724 organs O
sent724 , O
sent724 the O
sent724 authors O
sent724 discuss O
sent724 the O
sent724 principal O
sent724 theories O
sent724 on O
sent724 senescence O
sent725 They O
sent725 underline O
sent725 that O
sent725 it O
sent725 is O
sent725 necessary O
sent725 to O
sent725 agree O
sent725 in O
sent725 considering O
sent725 the O
sent725 various O
sent725 genetic O
sent725 and O
sent725 epigenetic O
sent725 , O
sent725 endogenous O
sent725 and O
sent725 exogenous O
sent725 mechanisms O
sent725 that O
sent725 lead O
sent725 to O
sent725 the O
sent725 complex O
sent725 aging O
sent725 phenomenon O
sent725 multiple O
sent725 and O
sent725 interrelated O
sent726 In O
sent726 particular O
sent726 they O
sent726 stress O
sent726 the O
sent726 hypothesis O
sent726 that O
sent726 senescence O
sent726 can O
sent726 be O
sent726 due O
sent726 to O
sent726 a O
sent726 sum O
sent726 of O
sent726 molecular O
sent726 damages O
sent726 caused O
sent726 by O
sent726 free O
sent726 radicals O
sent726 , O
sent726 and O
sent726 to O
sent726 the O
sent726 loss O
sent726 of O
sent726 telomeric O
sent726 DNA O
sent727 Radical O
sent727 reactions O
sent727 can O
sent727 cause O
sent727 mutations O
sent727 , O
sent727 inactivation O
sent727 or O
sent727 a O
sent727 decrease O
sent727 in O
sent727 the O
sent727 turnover O
sent727 of O
sent727 mitochondrial O
sent727 DNA O
sent727 which O
sent727 is O
sent727 more O
sent727 vulnerable O
sent727 than O
sent727 the O
sent727 nuclear O
sent727 genoma O
sent727 to O
sent727 the O
sent727 attack O
sent727 of O
sent727 mutagenic O
sent727 agents O
sent727 , O
sent727 acting O
sent727 also O
sent727 as O
sent727 a O
sent727 continuous O
sent727 source O
sent727 of O
sent727 initial O
sent727 and/or O
sent727 promoting O
sent727 factors O
sent727 of O
sent727 the O
sent727 carcinogenetic O
sent727 process O
sent728 The O
sent728 somatic O
sent728 cells O
sent728 become O
sent728 senescent O
sent728 because O
sent728 during O
sent728 cell O
sent728 division O
sent728 , O
sent728 they O
sent728 lose O
sent728 the O
sent728 mechanisms O
sent728 for O
sent728 the O
sent728 lengthening O
sent728 of O
sent728 the O
sent728 telomere O
sent729 The O
sent729 telomerase O
sent729 prevents O
sent729 the O
sent729 shortening O
sent729 of O
sent729 telomeres O
sent729 in O
sent729 neoplastic O
sent729 cells O
sent729 and O
sent729 therefore O
sent729 renders O
sent729 them O
sent729 immortal O
sent730 Paradoxically O
sent730 the O
sent730 protection O
sent730 of O
sent730 the O
sent730 telomere O
sent730 is O
sent730 exactly O
sent730 what O
sent730 must O
sent730 be O
sent730 avoided O
sent730 in O
sent730 the O
sent730 case O
sent730 of O
sent730 tumor O
sent730 cells O
sent731 Recently O
sent731 the O
sent731 demonstration O
sent731 that O
sent731 telomerase O
sent731 is O
sent731 not O
sent731 always O
sent731 involved O
sent731 in O
sent731 the O
sent731 restoration O
sent731 of O
sent731 telomere O
sent731 length O
sent731 shows O
sent731 the O
sent731 complexity O
sent731 of O
sent731 the O
sent731 problems O
sent731 connected O
sent731 to O
sent731 the O
sent731 cause O
sent731 of O
sent731 senescence O
sent732 Chromosomally O
sent732 integrated O
sent732 retroviral O
sent732 switch O
sent732 ( O
sent732 S O
sent732 ) O
sent732 substrates O
sent732 have O
sent732 been O
sent732 developed O
sent732 to O
sent732 reveal O
sent732 switch O
sent732 recombinase-like O
sent732 activities O
sent732 ( O
sent732 SRLA O
sent732 ) O
sent732 in O
sent732 pre-B O
sent732 and O
sent732 mature O
sent732 B O
sent732 cell O
sent732 lines O
sent733 Switch O
sent733 substrate O
sent733 retrovectors O
sent733 ( O
sent733 SSR O
sent733 ) O
sent733 contain O
sent733 a O
sent733 long-terminal O
sent733 repeat-driven O
sent733 neomycin O
sent733 ( O
sent733 Neo O
sent733 ) O
sent733 gene O
sent733 for O
sent733 proviral O
sent733 chromosomal O
sent733 maintenance O
sent733 ( O
sent733 pre- O
sent733 and O
sent733 post-S O
sent733 recombination O
sent733 ) O
sent733 and O
sent733 a O
sent733 CMV O
sent733 promoter-driven O
sent733 , O
sent733 chimeric O
sent733 hygromycin-thymidine O
sent733 kinase O
sent733 ( O
sent733 Hytk O
sent733 ) O
sent733 gene O
sent733 ( O
sent733 flanked O
sent733 by O
sent733 S O
sent733 mu O
sent733 and O
sent733 S O
sent733 gamma O
sent733 2b O
sent733 recombination O
sent733 targets O
sent733 ) O
sent733 to O
sent733 select O
sent733 for O
sent733 ( O
sent733 ganciclovir O
sent733 ) O
sent733 and O
sent733 against O
sent733 ( O
sent733 hygromycin O
sent733 B O
sent733 ) O
sent733 S O
sent733 region O
sent733 recombination O
sent734 The O
sent734 retro-substrates O
sent734 ' O
sent734 strong O
sent734 , O
sent734 constitutive O
sent734 promoters O
sent734 ensure O
sent734 that O
sent734 variations O
sent734 in O
sent734 cellular O
sent734 switch O
sent734 recombinase O
sent734 activities O
sent734 are O
sent734 independent O
sent734 of O
sent734 S O
sent734 region O
sent734 accessibility O
sent734 control O
sent735 By O
sent735 initially O
sent735 selecting O
sent735 for O
sent735 proviral O
sent735 integrants O
sent735 in O
sent735 hygromycin O
sent735 followed O
sent735 by O
sent735 shifting O
sent735 into O
sent735 neomycin O
sent735 + O
sent735 ganciclovir O
sent735 to O
sent735 select O
sent735 for O
sent735 S O
sent735 sequence-mediated O
sent735 deletions O
sent735 , O
sent735 switch O
sent735 recombinations O
sent735 can O
sent735 be O
sent735 specifically O
sent735 forestalled O
sent735 in O
sent735 B O
sent735 cell O
sent735 lines O
sent735 whilst O
sent735 most O
sent735 switch-incompetent O
sent735 cells O
sent735 do O
sent735 not O
sent735 survive O
sent735 secondary O
sent735 selection O
sent736 A O
sent736 qualitative O
sent736 , O
sent736 direct O
sent736 PCR O
sent736 assay O
sent736 reveals O
sent736 that O
sent736 SSR O
sent736 recombinations O
sent736 are O
sent736 stochastic O
sent736 in O
sent736 B O
sent736 cell O
sent736 lines O
sent736 generating O
sent736 a O
sent736 product O
sent736 array O
sent736 akin O
sent736 to O
sent736 natural O
sent736 GH O
sent736 class O
sent736 switching O
sent737 A O
sent737 semi-quantitative O
sent737 DC-PCR O
sent737 assay O
sent737 detects O
sent737 a O
sent737 significant O
sent737 recombinase O
sent737 activity O
sent737 only O
sent737 in O
sent737 a O
sent737 restricted O
sent737 set O
sent737 of O
sent737 late O
sent737 stage O
sent737 pre-B O
sent737 and O
sent737 mature O
sent737 B O
sent737 cell O
sent737 lines O
sent738 BCL1B1 O
sent738 mature O
sent738 B O
sent738 cells O
sent738 have O
sent738 the O
sent738 highest O
sent738 level O
sent738 of O
sent738 recombinase O
sent738 activity O
sent738 with O
sent738 25 O
sent738 % O
sent738 or O
sent738 more O
sent738 of O
sent738 proviral O
sent738 integrants O
sent738 accumulating O
sent738 S O
sent738 mu/S O
sent738 gamma O
sent738 2b O
sent738 substrate O
sent738 recombinations O
sent738 within O
sent738 10-14 O
sent738 cell O
sent738 generations O
sent739 The O
sent739 SSR O
sent739 recombinase O
sent739 assay O
sent739 can O
sent739 be O
sent739 performed O
sent739 in O
sent739 a O
sent739 transient O
sent739 fashion O
sent739 wherein O
sent739 extensive O
sent739 , O
sent739 B O
sent739 cell-specific O
sent739 recombination O
sent739 can O
sent739 be O
sent739 visualized O
sent739 within O
sent739 only O
sent739 a O
sent739 few O
sent739 cell O
sent739 divisions O
sent739 post O
sent739 proviral O
sent739 integration O
sent740 We O
sent740 propose O
sent740 that O
sent740 switch O
sent740 recombinase O
sent740 activity O
sent740 becomes O
sent740 activated O
sent740 during O
sent740 B O
sent740 cell O
sent740 ontogeny O
sent740 independent O
sent740 of O
sent740 or O
sent740 prior O
sent740 to O
sent740 the O
sent740 acquisition O
sent740 of O
sent740 CH O
sent740 locus O
sent740 accessibility O
sent740 and O
sent740 that O
sent740 endogenous O
sent740 S O
sent740 segment O
sent740 targeting O
sent740 to O
sent740 pre-existing O
sent740 recombinase O
sent740 requires O
sent740 a O
sent740 level O
sent740 of O
sent740 accessibility O
sent740 beyond O
sent740 transcriptional O
sent740 activation O
sent741 OBJECTIVE O
sent741 : O
sent741 To O
sent741 determine O
sent741 the O
sent741 prevalence O
sent741 of O
sent741 illicit O
sent741 drug O
sent741 abuse O
sent741 and O
sent741 alcohol O
sent741 use O
sent741 in O
sent741 an O
sent741 obstetric O
sent741 population O
sent741 based O
sent741 in O
sent741 an O
sent741 urban O
sent741 maternity O
sent741 hospital O
sent742 SETTING O
sent742 : O
sent742 A O
sent742 collaborative O
sent742 study O
sent742 between O
sent742 the O
sent742 Rotunda O
sent742 Hospital O
sent742 , O
sent742 Dublin O
sent742 and O
sent742 the O
sent742 Irish O
sent742 National O
sent742 Drug O
sent742 Advisory O
sent742 & O
sent742 # O
sent742 38 O
sent742 ; O
sent742 Treatment O
sent742 Centre O
sent743 DESIGN O
sent743 : O
sent743 A O
sent743 prospective O
sent743 study O
sent743 consisting O
sent743 of O
sent743 anonymous O
sent743 , O
sent743 unlinked O
sent743 urine O
sent743 testing O
sent743 of O
sent743 504 O
sent743 'first O
sent743 visit O
sent743 ' O
sent743 antenatal O
sent743 patients O
sent743 and O
sent743 a O
sent743 separate O
sent743 group O
sent743 of O
sent743 515 O
sent743 patients O
sent743 six O
sent743 weeks O
sent743 after O
sent743 delivery O
sent744 METHODS O
sent744 & O
sent744 # O
sent744 38 O
sent744 ; O
sent744 OUTCOME O
sent744 MEASURES O
sent744 : O
sent744 Toxicological O
sent744 screening O
sent744 using O
sent744 enzyme-linked O
sent744 immunoassay O
sent744 techniques O
sent744 , O
sent744 with O
sent744 all O
sent744 positive O
sent744 samples O
sent744 being O
sent744 reanalysed O
sent745 Drug O
sent745 histories O
sent745 were O
sent745 taken O
sent745 and O
sent745 samples O
sent745 were O
sent745 tested O
sent745 for O
sent745 alcohol O
sent745 and O
sent745 six O
sent745 of O
sent745 the O
sent745 most O
sent745 commonly O
sent745 abused O
sent745 drugs O
sent746 The O
sent746 pre- O
sent746 and O
sent746 postnatal O
sent746 prevalence O
sent746 of O
sent746 abuse O
sent746 was O
sent746 matched O
sent746 with O
sent746 demographic O
sent746 data O
sent747 RESULTS O
sent747 : O
sent747 The O
sent747 prevalence O
sent747 of O
sent747 chemical O
sent747 substance O
sent747 misuse O
sent747 in O
sent747 the O
sent747 antenatal O
sent747 population O
sent747 was O
sent747 2.8 O
sent747 % O
sent747 and O
sent747 5.6 O
sent747 % O
sent747 in O
sent747 the O
sent747 postnatal O
sent747 population O
sent748 Substances O
sent748 identified O
sent748 included O
sent748 benzodiazepines O
sent748 , O
sent748 cannabis O
sent748 , O
sent748 amphetamines O
sent748 , O
sent748 opiates O
sent748 and O
sent748 cocaine O
sent749 Less O
sent749 than O
sent749 2 O
sent749 % O
sent749 of O
sent749 samples O
sent749 tested O
sent749 positive O
sent749 for O
sent749 alcohol O
sent750 None O
sent750 of O
sent750 the O
sent750 women O
sent750 yielding O
sent750 positive O
sent750 samples O
sent750 had O
sent750 been O
sent750 pre-identified O
sent750 on O
sent750 the O
sent750 basis O
sent750 of O
sent750 history O
sent751 A O
sent751 significant O
sent751 proportion O
sent751 of O
sent751 the O
sent751 women O
sent751 were O
sent751 in O
sent751 the O
sent751 high O
sent751 risk O
sent751 categories O
sent751 with O
sent751 regard O
sent751 to O
sent751 age O
sent751 and O
sent751 socio-economic O
sent751 status O
sent752 CONCLUSION O
sent752 : O
sent752 The O
sent752 prevalence O
sent752 of O
sent752 drug O
sent752 misuse O
sent752 antenatally O
sent752 was O
sent752 nearly O
sent752 3 O
sent752 % O
sent752 and O
sent752 postnatally O
sent752 almost O
sent752 6 O
sent752 % O
sent753 Substance O
sent753 abusers O
sent753 in O
sent753 pregnancy O
sent753 are O
sent753 more O
sent753 likely O
sent753 to O
sent753 be O
sent753 single O
sent753 , O
sent753 unemployed O
sent753 , O
sent753 and O
sent753 to O
sent753 have O
sent753 had O
sent753 a O
sent753 previous O
sent753 pregnancy O
sent754 Schizophrenic D
sent754 illnesses D
sent754 occur O
sent754 with O
sent754 approximately O
sent754 the O
sent754 same O
sent754 incidence O
sent754 in O
sent754 all O
sent754 human O
sent754 populations O
sent754 with O
sent754 a O
sent754 characteristic O
sent754 distribution O
sent754 ( O
sent754 slightly O
sent754 earlier O
sent754 in O
sent754 males O
sent754 ) O
sent754 of O
sent754 ages O
sent754 of O
sent754 onset O
sent755 Given O
sent755 that O
sent755 the O
sent755 predisposition O
sent755 ( O
sent755 which O
sent755 presumably O
sent755 is O
sent755 genetic O
sent755 ) O
sent755 is O
sent755 associated O
sent755 with O
sent755 a O
sent755 procreative O
sent755 disadvantage O
sent755 why O
sent755 do O
sent755 such O
sent755 illnesses O
sent755 persist O
sent755 ? O
sent755 Here O
sent755 it O
sent755 is O
sent755 suggested O
sent755 that O
sent755 these O
sent755 conditions O
sent755 are O
sent755 a O
sent755 manifestation O
sent755 of O
sent755 genetic O
sent755 diversity O
sent755 in O
sent755 the O
sent755 evolution O
sent755 of O
sent755 the O
sent755 specifically O
sent755 human O
sent755 characteristic O
sent755 of O
sent755 language O
sent755 , O
sent755 an O
sent755 innovation O
sent755 that O
sent755 has O
sent755 occurred O
sent755 by O
sent755 a O
sent755 process O
sent755 of O
sent755 progressive O
sent755 hemispheric O
sent755 specialization-the O
sent755 establishment O
sent755 of O
sent755 dominance O
sent755 for O
sent755 some O
sent755 critical O
sent755 component O
sent755 of O
sent755 language O
sent755 in O
sent755 one O
sent755 or O
sent755 the O
sent755 other O
sent755 hemisphere O
sent756 Individuals O
sent756 who O
sent756 develop O
sent756 schizophrenic D
sent756 symptoms D
sent756 show O
sent756 lesser O
sent756 anatomical O
sent756 and O
sent756 functional O
sent756 asymmetries O
sent756 than O
sent756 the O
sent756 population O
sent756 as O
sent756 a O
sent756 whole O
sent756 ; O
sent756 such O
sent756 symptoms O
sent756 may O
sent756 reflect O
sent756 'dominance O
sent756 failure O
sent756 ' O
sent756 for O
sent756 language O
sent757 Cloacal D
sent757 anomalies D
sent757 are O
sent757 extremely O
sent757 rare O
sent757 and O
sent757 have O
sent757 variable O
sent757 presentations O
sent758 Prenatal O
sent758 diagnosis O
sent758 can O
sent758 be O
sent758 difficult O
sent758 especially O
sent758 if O
sent758 they O
sent758 present O
sent758 in O
sent758 late O
sent758 gestation O
sent759 Here O
sent759 we O
sent759 present O
sent759 two O
sent759 cases O
sent759 diagnosed O
sent759 in O
sent759 the O
sent759 late O
sent759 third O
sent759 trimester O
sent759 and O
sent759 review O
sent759 the O
sent759 literature O
sent759 regarding O
sent759 prenatal O
sent759 diagnosis O
sent759 of O
sent759 cloacal D
sent759 anomalies D
sent760 OBJECTIVE O
sent760 : O
sent760 To O
sent760 determine O
sent760 whether O
sent760 patients O
sent760 with O
sent760 myocardial D
sent760 amyloidosis D
sent760 due O
sent760 either O
sent760 to O
sent760 AL O
sent760 ( O
sent760 primary O
sent760 ) O
sent760 amyloid O
sent760 or O
sent760 familial O
sent760 amyloid O
sent760 have O
sent760 distinguishing O
sent760 echocardiographic O
sent760 or O
sent760 electrocardiographic O
sent760 features O
sent760 ; O
sent760 and O
sent760 to O
sent760 compare O
sent760 the O
sent760 prevalence O
sent760 of O
sent760 heart D
sent760 failure D
sent760 and O
sent760 survival O
sent760 in O
sent760 the O
sent760 two O
sent760 types O
sent760 of O
sent760 amyloidosis D
sent760 in O
sent760 relation O
sent760 to O
sent760 echocardiographic O
sent760 findings O
sent761 DESIGN O
sent761 : O
sent761 Blinded O
sent761 group O
sent761 comparison O
sent761 of O
sent761 randomly O
sent761 selected O
sent761 cases O
sent761 of O
sent761 cardiac D
sent761 amyloidosis D
sent762 SETTING O
sent762 : O
sent762 International O
sent762 referral O
sent762 centre O
sent762 for O
sent762 amyloid O
sent762 research O
sent762 and O
sent762 treatment O
sent763 PATIENTS O
sent763 : O
sent763 36 O
sent763 patients O
sent763 with O
sent763 cardiac D
sent763 amyloid D
sent763 heart D
sent763 disease D
sent763 , O
sent763 of O
sent763 whom O
sent763 12 O
sent763 had O
sent763 familial O
sent763 and O
sent763 24 O
sent763 had O
sent763 primary O
sent763 AL O
sent763 amyloidosis D
sent764 RESULTS O
sent764 : O
sent764 Familial O
sent764 and O
sent764 AL O
sent764 echocardiograms O
sent764 were O
sent764 morphologically O
sent764 indistinguishable O
sent764 , O
sent764 with O
sent764 similar O
sent764 left O
sent764 ventricular O
sent764 wall O
sent764 thickness O
sent764 , O
sent764 mean O
sent764 ( O
sent764 SD O
sent764 ) O
sent764 15.4 O
sent764 ( O
sent764 2.3 O
sent764 ) O
sent764 nu O
sent764 15.8 O
sent764 ( O
sent764 2.5 O
sent764 ) O
sent764 mm O
sent764 , O
sent764 respectively O
sent764 ; O
sent764 right O
sent764 ventricular O
sent764 wall O
sent764 thickness O
sent764 was O
sent764 also O
sent764 similar O
sent764 between O
sent764 amyloid O
sent764 types O
sent764 : O
sent764 9.6 O
sent764 ( O
sent764 2.8 O
sent764 ) O
sent764 nu O
sent764 9.7 O
sent764 ( O
sent764 6.5 O
sent764 ) O
sent764 mm O
sent764 , O
sent764 respectively O
sent765 Doppler O
sent765 indices O
sent765 of O
sent765 left O
sent765 and O
sent765 right O
sent765 ventricular O
sent765 function O
sent765 , O
sent765 left O
sent765 ventricular O
sent765 volume O
sent765 , O
sent765 and O
sent765 ejection O
sent765 fraction O
sent765 were O
sent765 also O
sent765 similar O
sent766 Low O
sent766 voltage O
sent766 electrocardiograms O
sent766 ( O
sent766 & O
sent766 # O
sent766 60 O
sent766 ; O
sent766 0.5 O
sent766 mV O
sent766 ) O
sent766 were O
sent766 more O
sent766 common O
sent766 in O
sent766 the O
sent766 AL O
sent766 ( O
sent766 16/24 O
sent766 , O
sent766 67 O
sent766 % O
sent766 ) O
sent766 than O
sent766 in O
sent766 the O
sent766 familial O
sent766 group O
sent766 ( O
sent766 4/12 O
sent766 , O
sent766 25 O
sent766 % O
sent766 ) O
sent766 , O
sent766 P O
sent766 & O
sent766 # O
sent766 60 O
sent766 ; O
sent766 0.05 O
sent767 The O
sent767 one O
sent767 year O
sent767 survival O
sent767 for O
sent767 familial O
sent767 and O
sent767 AL O
sent767 forms O
sent767 was O
sent767 92 O
sent767 % O
sent767 ( O
sent767 11/12 O
sent767 ) O
sent767 nu O
sent767 38 O
sent767 % O
sent767 ( O
sent767 6/24 O
sent767 ) O
sent767 , O
sent767 respectively O
sent767 , O
sent767 with O
sent767 virtually O
sent767 all O
sent767 deaths O
sent767 due O
sent767 to O
sent767 cardiac O
sent767 causes O
sent768 CONCLUSIONS O
sent768 : O
sent768 Although O
sent768 cardiac O
sent768 involvement O
sent768 is O
sent768 echocardiographically O
sent768 indistinguishable O
sent768 , O
sent768 cardiac O
sent768 mortality O
sent768 is O
sent768 very O
sent768 different O
sent768 between O
sent768 the O
sent768 two O
sent768 forms O
sent768 of O
sent768 amyloidosis D
sent769 Preservation O
sent769 of O
sent769 electrocardiographic O
sent769 voltage O
sent769 in O
sent769 familial O
sent769 amyloidosis D
sent769 suggests O
sent769 that O
sent769 the O
sent769 particular O
sent769 biochemical O
sent769 characteristics O
sent769 of O
sent769 distinct O
sent769 types O
sent769 of O
sent769 amyloid O
sent769 fibril O
sent769 have O
sent769 different O
sent769 pathological O
sent769 effects O
sent769 on O
sent769 the O
sent769 myocardium O
sent770 This O
sent770 distinction O
sent770 becomes O
sent770 critical O
sent770 in O
sent770 the O
sent770 evaluation O
sent770 , O
sent770 treatment O
sent770 , O
sent770 and O
sent770 management O
sent770 of O
sent770 patients O
sent770 who O
sent770 have O
sent770 a O
sent770 diagnosis O
sent770 within O
sent770 the O
sent770 spectrum O
sent770 of O
sent770 the O
sent770 protein D
sent770 deposition D
sent770 diseases D
sent771 OBJECTIVE O
sent771 : O
sent771 To O
sent771 examine O
sent771 the O
sent771 relationship O
sent771 between O
sent771 plasma O
sent771 plasminogen O
sent771 activator O
sent771 inhibitor O
sent771 1 O
sent771 ( O
sent771 PAI-1 O
sent771 ) O
sent771 activity O
sent771 and O
sent771 PAI-1 O
sent771 gene O
sent771 ( O
sent771 4G/5G O
sent771 ) O
sent771 polymorphism O
sent771 and O
sent771 diabetic D
sent771 retinopathy D
sent771 in O
sent771 Pima O
sent771 Indians O
sent771 with O
sent771 type O
sent771 2 O
sent771 diabetes D
sent772 RESEARCH O
sent772 DESIGN O
sent772 AND O
sent772 METHODS O
sent772 : O
sent772 We O
sent772 studied O
sent772 171 O
sent772 Pima O
sent772 Indians O
sent772 with O
sent772 type O
sent772 2 O
sent772 diabetes D
sent772 between O
sent772 the O
sent772 ages O
sent772 of O
sent772 30-70 O
sent772 years O
sent772 in O
sent772 a O
sent772 population-based O
sent772 epidemiological O
sent772 survey O
sent773 Plasma O
sent773 PAI-1 O
sent773 activity O
sent773 was O
sent773 measured O
sent773 by O
sent773 a O
sent773 spectrophotometric O
sent773 assay O
sent773 and O
sent773 PAI-1 O
sent773 4G/5G O
sent773 promoter O
sent773 genotype O
sent773 by O
sent773 the O
sent773 polymerase O
sent773 chain O
sent773 reaction O
sent773 ( O
sent773 PCR O
sent773 ) O
sent773 using O
sent773 allele-specific O
sent773 primers O
sent774 Retinopathy D
sent774 was O
sent774 assessed O
sent774 by O
sent774 ophthalmoscopy O
sent774 after O
sent774 pupillary O
sent774 dilation O
sent774 and O
sent774 classified O
sent774 as O
sent774 any O
sent774 retinopathy D
sent774 or O
sent774 as O
sent774 nonproliferative O
sent774 and O
sent774 proliferative O
sent775 RESULTS O
sent775 : O
sent775 Retinopathy D
sent775 was O
sent775 present O
sent775 in O
sent775 70 O
sent775 ( O
sent775 41 O
sent775 % O
sent775 ) O
sent775 subjects O
sent775 , O
sent775 and O
sent775 4 O
sent775 ( O
sent775 2.3 O
sent775 % O
sent775 ) O
sent775 subjects O
sent775 had O
sent775 proliferative O
sent775 retinopathy D
sent776 Plasma O
sent776 PAI-1 O
sent776 activity O
sent776 was O
sent776 not O
sent776 significantly O
sent776 different O
sent776 among O
sent776 subjects O
sent776 with O
sent776 and O
sent776 without O
sent776 retinopathy D
sent776 ( O
sent776 17.1 O
sent776 +/- O
sent776 vs. O
sent776 19.7 O
sent776 +/- O
sent776 9.1 O
sent776 arbitrary O
sent776 units O
sent776 ( O
sent776 AU O
sent776 ) O
sent776 /ml O
sent776 , O
sent776 P O
sent776 = O
sent776 0.09 O
sent776 ) O
sent777 PAI-1 O
sent777 activity O
sent777 was O
sent777 negatively O
sent777 correlated O
sent777 with O
sent777 duration O
sent777 of O
sent777 diabetes D
sent777 ( O
sent777 rs O
sent777 = O
sent777 -0.18 O
sent777 , O
sent777 P O
sent777 = O
sent777 0.02 O
sent777 ) O
sent778 In O
sent778 a O
sent778 logistic O
sent778 regression O
sent778 analysis O
sent778 controlled O
sent778 for O
sent778 age O
sent778 , O
sent778 sex O
sent778 , O
sent778 BMI O
sent778 , O
sent778 and O
sent778 duration O
sent778 of O
sent778 diabetes D
sent778 , O
sent778 any O
sent778 retinopathy D
sent778 was O
sent778 significantly O
sent778 associated O
sent778 with O
sent778 fasting O
sent778 plasma O
sent778 glucose O
sent778 concentrations O
sent778 ( O
sent778 P O
sent778 & O
sent778 # O
sent778 60 O
sent778 ; O
sent778 0.05 O
sent778 ) O
sent778 , O
sent778 2-h O
sent778 postload O
sent778 glucose O
sent778 ( O
sent778 P O
sent778 = O
sent778 0.02 O
sent778 ) O
sent778 , O
sent778 and O
sent778 HbA1c O
sent778 ( O
sent778 P O
sent778 = O
sent778 0.008 O
sent778 ) O
sent778 , O
sent778 but O
sent778 not O
sent778 with O
sent778 PAI-1 O
sent778 activity O
sent778 ( O
sent778 P O
sent778 = O
sent778 0.48 O
sent778 ) O
sent779 The O
sent779 prevalence O
sent779 of O
sent779 retinopathy D
sent779 in O
sent779 the O
sent779 three O
sent779 genotype O
sent779 groups O
sent779 differed O
sent779 significantly O
sent779 ( O
sent779 4G/4G O
sent779 , O
sent779 4G/5G O
sent779 , O
sent779 and O
sent779 5G/5G O
sent779 were O
sent779 44 O
sent779 , O
sent779 49 O
sent779 , O
sent779 and O
sent779 24 O
sent779 % O
sent779 , O
sent779 respectively O
sent779 ; O
sent779 chi O
sent779 2 O
sent779 = O
sent779 8.22 O
sent779 , O
sent779 df O
sent779 = O
sent779 2 O
sent779 , O
sent779 P O
sent779 = O
sent779 0.016 O
sent779 ) O
sent779 and O
sent779 remained O
sent779 significant O
sent779 after O
sent779 controlling O
sent779 for O
sent779 age O
sent779 , O
sent779 sex O
sent779 , O
sent779 BMI O
sent779 , O
sent779 duration O
sent779 of O
sent779 diabetes D
sent779 , O
sent779 glycated O
sent779 hemoglobin O
sent779 , O
sent779 and O
sent779 urine O
sent779 albumin-to-creatine O
sent779 ratio O
sent779 in O
sent779 a O
sent779 logistic O
sent779 regression O
sent779 analysis O
sent780 The O
sent780 odds O
sent780 ratios O
sent780 for O
sent780 retinopathy D
sent780 in O
sent780 subjects O
sent780 with O
sent780 4G/4G O
sent780 and O
sent780 4G/5G O
sent780 , O
sent780 compared O
sent780 with O
sent780 the O
sent780 5G/5G O
sent780 genotype O
sent780 , O
sent780 were O
sent780 2.0 O
sent780 and O
sent780 3.1 O
sent780 , O
sent780 respectively O
sent781 CONCLUSIONS O
sent781 : O
sent781 Although O
sent781 diabetic D
sent781 retinopathy D
sent781 in O
sent781 Pima O
sent781 Indians O
sent781 with O
sent781 type O
sent781 2 O
sent781 diabetes D
sent781 is O
sent781 not O
sent781 associated O
sent781 with O
sent781 PAI-1 O
sent781 activity O
sent781 , O
sent781 subjects O
sent781 with O
sent781 the O
sent781 4G/4G O
sent781 and O
sent781 4G/5G O
sent781 genotype O
sent781 had O
sent781 a O
sent781 higher O
sent781 prevalence O
sent781 of O
sent781 retinopathy D
sent781 compared O
sent781 with O
sent781 5G/5G O
sent781 PAI-1genotype O
sent782 These O
sent782 preliminary O
sent782 findings O
sent782 indicate O
sent782 that O
sent782 in O
sent782 Pima O
sent782 Indians O
sent782 with O
sent782 type O
sent782 2 O
sent782 diabetes D
sent782 , O
sent782 presence O
sent782 of O
sent782 the O
sent782 4G O
sent782 allele O
sent782 of O
sent782 the O
sent782 PAI-1 O
sent782 gene O
sent782 was O
sent782 associated O
sent782 with O
sent782 a O
sent782 higher O
sent782 risk O
sent782 of O
sent782 diabetic D
sent782 retinopathy D
sent783 BACKGROUND O
sent783 : O
sent783 Diagnostic O
sent783 peritoneal O
sent783 lavage O
sent783 ( O
sent783 DPL O
sent783 ) O
sent783 is O
sent783 used O
sent783 to O
sent783 diagnose O
sent783 intra-abdominal D
sent783 injury D
sent783 in O
sent783 patients O
sent783 with O
sent783 stab D
sent783 wounds D
sent783 and O
sent783 blunt D
sent783 trauma D
sent784 Because O
sent784 exploratory T
sent784 celiotomy T
sent784 is O
sent784 routinely O
sent784 performed O
sent784 on O
sent784 patients O
sent784 with O
sent784 gunshot D
sent784 wounds D
sent784 to D
sent784 the D
sent784 abdomen D
sent784 , O
sent784 DPL O
sent784 is O
sent784 rarely O
sent784 employed O
sent785 However O
sent785 , O
sent785 several O
sent785 studies O
sent785 have O
sent785 questioned O
sent785 routine O
sent785 exploration O
sent785 and O
sent785 have O
sent785 drawn O
sent785 attention O
sent785 to O
sent785 the O
sent785 associated O
sent785 morbidity O
sent785 of O
sent785 negative O
sent785 celiotomy O
sent786 Diagnostic O
sent786 peritoneal O
sent786 lavage O
sent786 is O
sent786 an O
sent786 easily O
sent786 performed O
sent786 and O
sent786 inexpensive O
sent786 test O
sent786 that O
sent786 may O
sent786 be O
sent786 useful O
sent786 in O
sent786 this O
sent786 situation O
sent787 OBJECTIVE O
sent787 : O
sent787 To O
sent787 evaluate O
sent787 the O
sent787 performance O
sent787 of O
sent787 DPL O
sent787 in O
sent787 the O
sent787 diagnosis O
sent787 of O
sent787 intra-abdominal D
sent787 injury D
sent787 in O
sent787 hemodynamically O
sent787 stable O
sent787 patients O
sent787 with O
sent787 gunshot D
sent787 wounds D
sent787 to O
sent787 the O
sent787 abdomen O
sent788 DESIGN O
sent788 : O
sent788 A O
sent788 prospective O
sent788 clinical O
sent788 trial O
sent789 SETTING O
sent789 : O
sent789 Two O
sent789 urban O
sent789 trauma O
sent789 centers O
sent790 PATIENTS O
sent790 : O
sent790 Patients O
sent790 with O
sent790 gunshot D
sent790 wounds D
sent790 to O
sent790 the O
sent790 abdomen O
sent790 and O
sent790 a O
sent790 systolic O
sent790 blood O
sent790 pressure O
sent790 of O
sent790 at O
sent790 least O
sent790 90 O
sent790 mm O
sent790 Hg O
sent791 INTERVENTIONS O
sent791 : O
sent791 Clinical O
sent791 predication O
sent791 of O
sent791 intra-abdominal D
sent791 injury D
sent791 in O
sent791 the O
sent791 emergency O
sent791 department O
sent791 and O
sent791 DPL O
sent791 performed O
sent791 in O
sent791 the O
sent791 operating O
sent791 room O
sent791 before O
sent791 the O
sent791 initiation O
sent791 of O
sent791 celiotomy O
sent792 Injuries O
sent792 found O
sent792 during O
sent792 the O
sent792 celiotomy O
sent792 were O
sent792 recorded O
sent793 MAIN O
sent793 OUTCOME O
sent793 MEASURES O
sent793 : O
sent793 The O
sent793 results O
sent793 of O
sent793 the O
sent793 clinical O
sent793 evaluation O
sent793 and O
sent793 DPL O
sent793 were O
sent793 compared O
sent793 with O
sent793 the O
sent793 findings O
sent793 of O
sent793 the O
sent793 celiotomy O
sent794 RESULTS O
sent794 : O
sent794 Forty-four O
sent794 patients O
sent794 were O
sent794 enrolled O
sent794 into O
sent794 the O
sent794 study O
sent795 Intra-abdominal D
sent795 injury D
sent795 was O
sent795 present O
sent795 in O
sent795 32 O
sent795 ( O
sent795 73 O
sent795 % O
sent795 ) O
sent795 of O
sent795 these O
sent795 patients O
sent796 The O
sent796 senior O
sent796 surgery O
sent796 resident O
sent796 correctly O
sent796 predicted O
sent796 the O
sent796 presence O
sent796 of O
sent796 intra-abdominal D
sent796 injury D
sent796 in O
sent796 36 O
sent796 ( O
sent796 82 O
sent796 % O
sent796 ) O
sent796 of O
sent796 the O
sent796 patients O
sent796 ( O
sent796 sensitivity O
sent796 = O
sent796 90.0 O
sent796 % O
sent796 , O
sent796 specificity O
sent796 = O
sent796 58.3 O
sent796 % O
sent796 , O
sent796 positive O
sent796 predictive O
sent796 value O
sent796 = O
sent796 85.3 O
sent796 % O
sent796 , O
sent796 negative O
sent796 predictive O
sent796 value O
sent796 = O
sent796 63.6 O
sent796 % O
sent796 , O
sent796 phi O
sent796 = O
sent796 0.52 O
sent796 , O
sent796 P O
sent796 & O
sent796 # O
sent796 60 O
sent796 ; O
sent796 .01 O
sent796 ) O
sent796 in O
sent796 the O
sent796 emergency O
sent796 department O
sent796 before O
sent796 DPL O
sent796 and O
sent796 celiotomy O
sent796 were O
sent796 performed O
sent797 Diagnostic O
sent797 peritoneal O
sent797 lavage O
sent797 correctly O
sent797 identified O
sent797 the O
sent797 presence O
sent797 or O
sent797 absence O
sent797 of O
sent797 intra-abdominal D
sent797 injury D
sent797 in O
sent797 40 O
sent797 ( O
sent797 91 O
sent797 % O
sent797 ) O
sent797 of O
sent797 the O
sent797 patients O
sent797 ( O
sent797 positive O
sent797 predictive O
sent797 value O
sent797 = O
sent797 96.7 O
sent797 % O
sent797 , O
sent797 negative O
sent797 predictive O
sent797 value O
sent797 = O
sent797 78.6 O
sent797 % O
sent797 , O
sent797 phi O
sent797 = O
sent797 0.79 O
sent797 , O
sent797 P O
sent797 & O
sent797 # O
sent797 60 O
sent797 ; O
sent797 .01 O
sent797 ) O
sent798 CONCLUSIONS O
sent798 : O
sent798 Clinical O
sent798 judgment O
sent798 is O
sent798 highly O
sent798 accurate O
sent798 in O
sent798 separating O
sent798 patients O
sent798 with O
sent798 tangential O
sent798 gunshot D
sent798 wounds D
sent798 to O
sent798 the O
sent798 abdomen O
sent798 from O
sent798 those O
sent798 with O
sent798 intra-abdominal D
sent798 injury D
sent798 but O
sent798 may O
sent798 miss O
sent798 patients O
sent798 with O
sent798 intra-abdominal D
sent798 hemorrhage D
sent799 Diagnostic O
sent799 peritoneal O
sent799 lavage O
sent799 is O
sent799 highly O
sent799 predictive O
sent799 of O
sent799 the O
sent799 presence O
sent799 of O
sent799 intra-abdominal D
sent799 injury D
sent800 The O
sent800 return O
sent800 of O
sent800 gross O
sent800 blood O
sent800 on O
sent800 aspiration O
sent800 or O
sent800 a O
sent800 lavage O
sent800 red O
sent800 blood O
sent800 cell O
sent800 count O
sent800 greater O
sent800 than O
sent800 10 O
sent800 x O
sent800 10 O
sent800 ( O
sent800 9 O
sent800 ) O
sent800 /L O
sent800 should O
sent800 prompt O
sent800 an O
sent800 urgent O
sent800 celiotomy O
sent801 Missed O
sent801 injuries O
sent801 are O
sent801 rare O
sent801 and O
sent801 most O
sent801 likely O
sent801 to O
sent801 be O
sent801 bowel D
sent801 perforations D
sent802 Diagnostic O
sent802 peritoneal O
sent802 lavage O
sent802 is O
sent802 an O
sent802 objective O
sent802 test O
sent802 that O
sent802 may O
sent802 augment O
sent802 clinical O
sent802 judgment O
sent802 in O
sent802 selecting O
sent802 hemodynamically O
sent802 stable O
sent802 patients O
sent802 with O
sent802 potential O
sent802 tangential O
sent802 gunshot D
sent802 wounds D
sent802 for O
sent802 observation O
sent802 and O
sent802 is O
sent802 especially O
sent802 useful O
sent802 in O
sent802 identifying O
sent802 intra-abdominal D
sent802 hemorrhage D
sent803 BACKGROUND O
sent803 : O
sent803 To O
sent803 evaluate O
sent803 the O
sent803 frequency O
sent803 of O
sent803 Blastocystis D
sent803 hominis D
sent803 parasitation D
sent803 and O
sent803 to O
sent803 ascertain O
sent803 its O
sent803 role O
sent803 as O
sent803 an O
sent803 intestinal O
sent803 a O
sent803 prospective O
sent803 study O
sent803 during O
sent803 18 O
sent803 months O
sent803 pathogen O
sent803 has O
sent803 been O
sent803 carried O
sent803 out O
sent804 SUBJECTS O
sent804 AND O
sent804 METHODS O
sent804 : O
sent804 The O
sent804 study O
sent804 included O
sent804 2 O
sent804 , O
sent804 039 O
sent804 patients O
sent804 , O
sent804 which O
sent804 were O
sent804 classified O
sent804 in O
sent804 three O
sent804 groups O
sent804 ( O
sent804 asymptomatic O
sent804 ( O
sent804 group O
sent804 A O
sent804 ) O
sent804 , O
sent804 with O
sent804 suspicion O
sent804 of O
sent804 parasitosis D
sent804 ( O
sent804 group O
sent804 B O
sent804 ) O
sent804 , O
sent804 with O
sent804 diarrhoea D
sent804 ( O
sent804 group O
sent804 C O
sent804 ) O
sent804 ) O
sent805 In O
sent805 all O
sent805 cases O
sent805 a O
sent805 coproparasitological O
sent805 study O
sent805 was O
sent805 performed O
sent806 In O
sent806 the O
sent806 group O
sent806 C O
sent806 the O
sent806 presence O
sent806 of O
sent806 non-parasitic O
sent806 enteropathogens O
sent806 was O
sent806 also O
sent806 investigated O
sent807 In O
sent807 patients O
sent807 with O
sent807 B O
sent808 hominis O
sent808 in O
sent808 the O
sent808 absence O
sent808 of O
sent808 other O
sent808 pathogens O
sent808 clinical O
sent808 and O
sent808 epidemiological O
sent808 characteristics O
sent808 were O
sent808 evaluated O
sent809 Also O
sent809 , O
sent809 its O
sent809 was O
sent809 determined O
sent809 the O
sent809 morphology O
sent809 and O
sent809 quantification O
sent809 of O
sent809 parasites O
sent810 RESULTS O
sent810 : O
sent810 Parasites O
sent810 were O
sent810 identified O
sent810 in O
sent810 26.2 O
sent810 % O
sent810 of O
sent810 population O
sent811 B O
sent812 hominis O
sent812 was O
sent812 identified O
sent812 in O
sent812 336 O
sent812 patients O
sent812 ( O
sent812 16.5 O
sent812 % O
sent812 ) O
sent813 The O
sent813 frequency O
sent813 of O
sent813 parasitation D
sent813 was O
sent813 superior O
sent813 in O
sent813 adults O
sent813 ( O
sent813 p O
sent813 & O
sent813 # O
sent813 60 O
sent813 ; O
sent813 0.0001 O
sent813 ) O
sent813 , O
sent813 with O
sent813 a O
sent813 slight O
sent813 predominance O
sent813 in O
sent813 the O
sent813 female O
sent813 sex O
sent814 The O
sent814 rate O
sent814 of O
sent814 asymptomatic O
sent814 carriers O
sent814 was O
sent814 3.3 O
sent814 % O
sent815 In O
sent815 21 O
sent815 patients O
sent815 B O
sent816 hominis O
sent816 ( O
sent816 group O
sent816 C O
sent816 ) O
sent816 was O
sent816 observed O
sent816 in O
sent816 absence O
sent816 of O
sent816 other O
sent816 enteropathogens O
sent817 Statistical O
sent817 significant O
sent817 association O
sent817 was O
sent817 found O
sent817 between O
sent817 B O
sent818 hominis O
sent818 , O
sent818 in O
sent818 absence O
sent818 of O
sent818 other O
sent818 pathogens O
sent818 and O
sent818 the O
sent818 presence O
sent818 of O
sent818 clinical O
sent818 manifestations O
sent818 ( O
sent818 p O
sent818 & O
sent818 # O
sent818 60 O
sent818 ; O
sent818 0.0001 O
sent818 ) O
sent818 , O
sent818 the O
sent818 most O
sent818 common O
sent818 of O
sent818 which O
sent818 were O
sent818 diarrhoea D
sent818 and O
sent818 abdominal D
sent818 pain D
sent819 We O
sent819 did O
sent819 not O
sent819 find O
sent819 a O
sent819 statistically O
sent819 significant O
sent819 association O
sent819 between O
sent819 the O
sent819 number O
sent819 of O
sent819 B O
sent820 hominis O
sent820 present O
sent820 and O
sent820 stool O
sent820 characteristics O
sent821 The O
sent821 vacuolar O
sent821 form O
sent821 was O
sent821 the O
sent821 predominant O
sent821 morphological O
sent821 type O
sent822 The O
sent822 ameboid O
sent822 form O
sent822 was O
sent822 observed O
sent822 only O
sent822 in O
sent822 diarrhoeal O
sent822 stools O
sent823 CONCLUSIONS O
sent823 : O
sent823 B O
sent824 hominis O
sent824 is O
sent824 the O
sent824 most O
sent824 frequent O
sent824 parasite O
sent824 found O
sent824 in O
sent824 faecal O
sent824 parasitological O
sent824 investigation O
sent825 In O
sent825 absence O
sent825 of O
sent825 other O
sent825 causes O
sent825 , O
sent825 B O
sent826 hominis O
sent826 must O
sent826 be O
sent826 considered O
sent826 as O
sent826 a O
sent826 pathogen O
sent827 < O
sent827 TO_SEE O
sent827 > O
sent827 BACKGROUND O
sent827 : O
sent827 The O
sent827 cause O
sent827 of O
sent827 severe O
sent827 acquired O
sent827 hyperammonemia O
sent827 , O
sent827 an O
sent827 uncommon O
sent827 but O
sent827 often O
sent827 fatal O
sent827 complication O
sent827 of O
sent827 organ O
sent827 transplantation O
sent827 and O
sent827 chemotherapy O
sent827 for O
sent827 cancer O
sent827 , O
sent827 is O
sent827 obscure O
sent828 < O
sent828 /TO_SEES O
sent828 > O
sent828 OBJECTIVE O
sent828 : O
sent828 To O
sent828 test O
sent828 the O
sent828 hypothesis O
sent828 that O
sent828 liver O
sent828 glutamine O
sent828 synthetase O
sent828 deficiency O
sent828 may O
sent828 explain O
sent828 hyperammonemia D
sent828 in O
sent828 patients O
sent828 who O
sent828 have O
sent828 had O
sent828 organ T
sent828 transplantation T
sent828 or O
sent828 are O
sent828 receiving O
sent828 chemotherapy T
sent829 DESIGN O
sent829 : O
sent829 Case O
sent829 report O
sent830 PATIENTS O
sent830 : O
sent830 Two O
sent830 patients O
sent830 who O
sent830 had O
sent830 fatal O
sent830 hyperammonemia D
sent830 after O
sent830 orthotopic O
sent830 lung T
sent830 transplantation T
sent830 . O
sent831 MEASUREMENTS O
sent831 : O
sent831 Liver O
sent831 tissue O
sent831 was O
sent831 analyzed O
sent831 to O
sent831 determine O
sent831 the O
sent831 activities O
sent831 of O
sent831 two O
sent831 urea O
sent831 cycle O
sent831 enzymes O
sent831 and O
sent831 glutamine O
sent831 synthetase O
sent832 Western O
sent832 blot O
sent832 assays O
sent832 for O
sent832 hepatic O
sent832 glutamine O
sent832 synthetase O
sent832 were O
sent832 performed O
sent832 to O
sent832 determine O
sent832 whether O
sent832 glutamine O
sent832 synthetase O
sent832 deficiency O
sent832 resulted O
sent832 from O
sent832 reduced O
sent832 enzyme O
sent832 levels O
sent833 RESULTS O
sent833 : O
sent833 Activities O
sent833 of O
sent833 carbamoyl O
sent833 phosphate O
sent833 synthetase O
sent833 I O
sent833 and O
sent833 ornithine O
sent833 carbamoyltransferase O
sent833 in O
sent833 the O
sent833 liver O
sent833 were O
sent833 normal O
sent834 The O
sent834 activity O
sent834 of O
sent834 hepatic O
sent834 glutamine O
sent834 synthetase O
sent834 was O
sent834 markedly O
sent834 reduced O
sent834 ( O
sent834 in O
sent834 patient O
sent834 1 O
sent834 , O
sent834 12 O
sent834 % O
sent834 of O
sent834 the O
sent834 mean O
sent834 value O
sent834 in O
sent834 controls O
sent834 ; O
sent834 in O
sent834 patient O
sent834 2 O
sent834 , O
sent834 28 O
sent834 % O
sent834 of O
sent834 the O
sent834 mean O
sent834 value O
sent834 in O
sent834 controls O
sent834 ) O
sent834 , O
sent834 and O
sent834 a O
sent834 concomitant O
sent834 reduction O
sent834 in O
sent834 the O
sent834 amount O
sent834 of O
sent834 glutamine O
sent834 synthetase O
sent834 protein O
sent834 was O
sent834 observed O
sent835 < O
sent835 TO_SEE O
sent835 > O
sent835 CONCLUSION O
sent835 : O
sent835 Hyperammonemia O
sent835 after O
sent835 transplantation O
sent835 was O
sent835 associated O
sent835 with O
sent835 hepatic O
sent835 glutamine O
sent835 synthetase O
sent835 deficiency O
sent835 in O
sent835 two O
sent835 patients O
sent835 , O
sent835 but O
sent835 the O
sent835 causal O
sent835 relation O
sent835 between O
sent835 these O
sent835 two O
sent835 conditions O
sent835 must O
sent835 be O
sent835 further O
sent835 studied O
sent836 Postnatal O
sent836 growth O
sent836 was O
sent836 prospectively O
sent836 measured O
sent836 from O
sent836 birth O
sent836 to O
sent836 1 O
sent836 y O
sent836 in O
sent836 54 O
sent836 term O
sent836 infants O
sent836 born O
sent836 small O
sent836 for O
sent836 gestational O
sent836 age O
sent836 ( O
sent836 SGA O
sent836 ) O
sent836 , O
sent836 fed O
sent836 either O
sent836 breast O
sent836 milk O
sent836 or O
sent836 a O
sent836 standard O
sent836 term O
sent836 infant O
sent836 formula O
sent837 Breastfeeding O
sent837 was O
sent837 associated O
sent837 with O
sent837 a O
sent837 0.36 O
sent837 and O
sent837 0.64 O
sent837 standard O
sent837 deviation O
sent837 ( O
sent837 SD O
sent837 ) O
sent837 increase O
sent837 in O
sent837 weight O
sent837 at O
sent837 2 O
sent837 weeks O
sent837 and O
sent837 3 O
sent837 months O
sent837 of O
sent837 age O
sent837 , O
sent837 respectively O
sent837 , O
sent837 which O
sent837 persisted O
sent837 beyond O
sent837 the O
sent837 breastfeeding O
sent837 period O
sent837 ( O
sent837 0.64 O
sent837 SD O
sent837 at O
sent837 1 O
sent837 y O
sent837 ) O
sent838 Breastfed O
sent838 infants O
sent838 also O
sent838 showed O
sent838 greater O
sent838 catch-up O
sent838 growth O
sent838 in O
sent838 head O
sent838 circumference O
sent838 ( O
sent838 SD O
sent838 score O
sent838 ( O
sent838 SDS O
sent838 ) O
sent838 0.53 O
sent838 higher O
sent838 at O
sent838 3 O
sent838 months O
sent838 ) O
sent838 , O
sent838 and O
sent838 greater O
sent838 body O
sent838 length O
sent838 gain O
sent838 ( O
sent838 SDS O
sent838 0.68 O
sent838 higher O
sent838 at O
sent838 6 O
sent838 months O
sent838 ) O
sent839 This O
sent839 increased O
sent839 growth O
sent839 was O
sent839 independent O
sent839 of O
sent839 potentially O
sent839 confounding O
sent839 obstetric O
sent839 , O
sent839 social O
sent839 and O
sent839 demographic O
sent839 factors O
sent840 Our O
sent840 findings O
sent840 suggest O
sent840 that O
sent840 breastfeeding O
sent840 may O
sent840 promote O
sent840 faster O
sent840 growth O
sent840 in O
sent840 infants O
sent840 compromised O
sent840 by O
sent840 poor O
sent840 growth O
sent840 in O
sent840 utero O
sent841 SGA O
sent841 infants O
sent841 may O
sent841 be O
sent841 programmed O
sent841 for O
sent841 a O
sent841 number O
sent841 of O
sent841 adverse O
sent841 outcomes O
sent841 ; O
sent841 the O
sent841 possibility O
sent841 that O
sent841 such O
sent841 events O
sent841 are O
sent841 altered O
sent841 by O
sent841 choice O
sent841 of O
sent841 postnatal O
sent841 diet O
sent841 is O
sent841 a O
sent841 key O
sent841 issue O
sent841 for O
sent841 future O
sent841 research O
sent842 BACKGROUND O
sent842 : O
sent842 Few O
sent842 studies O
sent842 have O
sent842 explored O
sent842 the O
sent842 health O
sent842 practices O
sent842 of O
sent842 critical O
sent842 care O
sent842 nurses O
sent843 Critical O
sent843 care O
sent843 nurses O
sent843 routinely O
sent843 teach O
sent843 patients O
sent843 about O
sent843 using O
sent843 healthy O
sent843 practices O
sent843 such O
sent843 as O
sent843 low-fat O
sent843 diets O
sent843 , O
sent843 exercise O
sent843 , O
sent843 and O
sent843 routine O
sent843 screening O
sent843 examinations O
sent844 However O
sent844 , O
sent844 it O
sent844 may O
sent844 be O
sent844 even O
sent844 more O
sent844 important O
sent844 that O
sent844 the O
sent844 nurses O
sent844 themselves O
sent844 have O
sent844 a O
sent844 healthy O
sent844 lifestyle O
sent844 , O
sent844 thus O
sent844 serving O
sent844 as O
sent844 role O
sent844 models O
sent844 for O
sent844 patients O
sent845 Nurses O
sent845 are O
sent845 selling O
sent845 a O
sent845 product O
sent845 , O
sent845 and O
sent845 that O
sent845 product O
sent845 is O
sent845 health O
sent846 The O
sent846 best O
sent846 salespersons O
sent846 are O
sent846 those O
sent846 who O
sent846 are O
sent846 genuinely O
sent846 committed O
sent846 to O
sent846 their O
sent846 product O
sent846 and O
sent846 model O
sent846 its O
sent846 benefits O
sent847 Therefore O
sent847 , O
sent847 critical O
sent847 care O
sent847 nurses O
sent847 ' O
sent847 healthful O
sent847 practices O
sent847 can O
sent847 have O
sent847 a O
sent847 profound O
sent847 effect O
sent847 on O
sent847 their O
sent847 patients O
sent848 OBJECTIVES O
sent848 : O
sent848 The O
sent848 purpose O
sent848 of O
sent848 this O
sent848 descriptive O
sent848 exploratory O
sent848 study O
sent848 was O
sent848 to O
sent848 examine O
sent848 critical O
sent848 care O
sent848 nurses O
sent848 ' O
sent848 responses O
sent848 to O
sent848 three O
sent848 questions O
sent848 about O
sent848 health O
sent848 practices O
sent848 in O
sent848 their O
sent848 daily O
sent848 lives O
sent848 : O
sent848 ( O
sent848 1 O
sent848 ) O
sent848 What O
sent848 are O
sent848 critical O
sent848 care O
sent848 nurses O
sent848 doing O
sent848 currently O
sent848 to O
sent848 stay O
sent848 healthy O
sent848 ? O
sent848 ( O
sent848 2 O
sent848 ) O
sent848 Do O
sent848 they O
sent848 anticipate O
sent848 making O
sent848 any O
sent848 changes O
sent848 in O
sent848 their O
sent848 lifestyle O
sent848 in O
sent848 the O
sent848 future O
sent848 ? O
sent848 ( O
sent848 3 O
sent848 ) O
sent848 Would O
sent848 they O
sent848 recommend O
sent848 their O
sent848 lifestyle O
sent848 to O
sent848 their O
sent848 patients O
sent848 ? O
sent848 METHODS O
sent848 : O
sent848 One O
sent848 hundred O
sent848 twenty-seven O
sent848 critical O
sent848 care O
sent848 nurses O
sent848 attending O
sent848 a O
sent848 midwestern O
sent848 critical O
sent848 care O
sent848 conference O
sent848 completed O
sent848 a O
sent848 two-part O
sent848 questionnaire O
sent848 designed O
sent848 to O
sent848 produce O
sent848 a O
sent848 health O
sent848 profile O
sent849 In O
sent849 a O
sent849 man-on-the-street O
sent849 approach O
sent849 , O
sent849 23 O
sent849 nurses O
sent849 participated O
sent849 in O
sent849 an O
sent849 interview O
sent849 via O
sent849 video O
sent849 camera O
sent850 Descriptive O
sent850 statistics O
sent850 were O
sent850 used O
sent850 to O
sent850 analyze O
sent850 the O
sent850 data O
sent850 retrieved O
sent850 from O
sent850 the O
sent850 questionnaires O
sent851 Interviews O
sent851 were O
sent851 transcribed O
sent851 verbatim O
sent851 and O
sent851 analyzed O
sent851 for O
sent851 themes O
sent851 with O
sent851 a O
sent851 constant O
sent851 comparative O
sent851 method O
sent852 RESULTS O
sent852 : O
sent852 More O
sent852 than O
sent852 70 O
sent852 % O
sent852 of O
sent852 the O
sent852 critical O
sent852 care O
sent852 nurses O
sent852 who O
sent852 responded O
sent852 engage O
sent852 in O
sent852 exercise O
sent852 and O
sent852 follow O
sent852 a O
sent852 healthy O
sent852 , O
sent852 low-fat O
sent852 diet O
sent853 Seventy-one O
sent853 percent O
sent853 said O
sent853 that O
sent853 they O
sent853 anticipate O
sent853 making O
sent853 a O
sent853 change O
sent853 in O
sent853 their O
sent853 lifestyle O
sent853 in O
sent853 the O
sent853 future O
sent853 , O
sent853 and O
sent853 70 O
sent853 % O
sent853 said O
sent853 that O
sent853 they O
sent853 would O
sent853 recommend O
sent853 their O
sent853 lifestyle O
sent853 to O
sent853 their O
sent853 patients O
sent854 Five O
sent854 themes O
sent854 emerged O
sent854 from O
sent854 the O
sent854 videotaped O
sent854 interviews O
sent854 : O
sent854 ( O
sent854 1 O
sent854 ) O
sent854 Heart-healthy O
sent854 practices O
sent854 predominated O
sent854 the O
sent854 responses O
sent855 ( O
sent855 2 O
sent855 ) O
sent855 Incorporating O
sent855 a O
sent855 healthy O
sent855 lifestyle O
sent855 was O
sent855 easy O
sent855 for O
sent855 some O
sent855 and O
sent855 a O
sent855 struggle O
sent855 for O
sent855 others O
sent856 ( O
sent856 3 O
sent856 ) O
sent856 Critical O
sent856 care O
sent856 nurses O
sent856 readily O
sent856 listed O
sent856 barriers O
sent856 to O
sent856 healthy O
sent856 living O
sent857 ( O
sent857 4 O
sent857 ) O
sent857 The O
sent857 nurses O
sent857 had O
sent857 a O
sent857 positive O
sent857 attitude O
sent857 about O
sent857 their O
sent857 healthy O
sent857 lifestyles O
sent857 and O
sent857 felt O
sent857 optimistic O
sent857 about O
sent857 being O
sent857 role O
sent857 models O
sent857 for O
sent857 their O
sent857 patients O
sent858 ( O
sent858 5 O
sent858 ) O
sent858 Future O
sent858 plans O
sent858 were O
sent858 either O
sent858 singular O
sent858 in O
sent858 focus O
sent858 or O
sent858 limited O
sent858 to O
sent858 maintenance O
sent858 of O
sent858 current O
sent858 health O
sent858 habits O
sent859 CONCLUSIONS O
sent859 : O
sent859 The O
sent859 majority O
sent859 of O
sent859 the O
sent859 nurses O
sent859 reported O
sent859 practicing O
sent859 a O
sent859 healthy O
sent859 lifestyle O
sent859 and O
sent859 thought O
sent859 that O
sent859 they O
sent859 were O
sent859 good O
sent859 role O
sent859 models O
sent859 for O
sent859 patients O
sent860 Cytochrome O
sent860 P450 O
sent860 1A1 O
sent860 ( O
sent860 CYP1A1 O
sent860 ) O
sent860 and O
sent860 glutathione O
sent860 S-transferase O
sent860 M1 O
sent860 ( O
sent860 GSTM1 O
sent860 ) O
sent860 genetic O
sent860 polymorphisms O
sent860 are O
sent860 involved O
sent860 in O
sent860 the O
sent860 activation O
sent860 and O
sent860 detoxification O
sent860 of O
sent860 chemical O
sent860 carcinogens O
sent860 found O
sent860 in O
sent860 tobacco O
sent860 smoke O
sent860 ; O
sent860 thus O
sent860 they O
sent860 may O
sent860 influence O
sent860 host O
sent860 susceptibility O
sent860 to O
sent860 lung D
sent860 cancer D
sent861 In O
sent861 this O
sent861 study O
sent861 at O
sent861 Massachusetts O
sent861 General O
sent861 Hospital O
sent861 ( O
sent861 Boston O
sent861 , O
sent861 MA O
sent861 , O
sent861 USA O
sent861 ) O
sent861 of O
sent861 416 O
sent861 cases O
sent861 and O
sent861 446 O
sent861 controls O
sent861 ( O
sent861 mostly O
sent861 White O
sent861 ) O
sent861 we O
sent861 evaluated O
sent861 the O
sent861 association O
sent861 between O
sent861 the O
sent861 CYP1A1 O
sent861 MspI O
sent861 and O
sent861 GSTM1 O
sent861 polymorphisms O
sent861 and O
sent861 lung D
sent861 cancer D
sent861 risk O
sent861 , O
sent861 and O
sent861 their O
sent861 interaction O
sent861 with O
sent861 cigarette O
sent861 smoke O
sent862 The O
sent862 CYP1A1 O
sent862 MspI O
sent862 heterozygous O
sent862 genotype O
sent862 was O
sent862 present O
sent862 in O
sent862 18 O
sent862 percent O
sent862 of O
sent862 cases O
sent862 and O
sent862 16 O
sent862 percent O
sent862 of O
sent862 controls O
sent862 , O
sent862 and O
sent862 one O
sent862 percent O
sent862 of O
sent862 cases O
sent862 and O
sent862 controls O
sent862 were O
sent862 CYP1A1 O
sent862 MspI O
sent862 homozygous O
sent862 variant O
sent863 The O
sent863 GSTM1 O
sent863 null O
sent863 genotype O
sent863 was O
sent863 detected O
sent863 in O
sent863 54 O
sent863 percent O
sent863 of O
sent863 cases O
sent863 and O
sent863 52 O
sent863 percent O
sent863 of O
sent863 controls O
sent864 After O
sent864 adjusting O
sent864 for O
sent864 age O
sent864 , O
sent864 gender O
sent864 , O
sent864 pack-years O
sent864 of O
sent864 smoking O
sent864 , O
sent864 and O
sent864 years O
sent864 since O
sent864 quitting O
sent864 smoking O
sent864 , O
sent864 while O
sent864 neither O
sent864 the O
sent864 CYP1A1 O
sent864 MspI O
sent864 heterozygous O
sent864 genotype O
sent864 alone O
sent864 nor O
sent864 the O
sent864 GSTM1 O
sent864 null O
sent864 genotype O
sent864 alone O
sent864 were O
sent864 associated O
sent864 with O
sent864 a O
sent864 significant O
sent864 increase O
sent864 in O
sent864 lung D
sent864 cancer D
sent864 risk O
sent864 , O
sent864 having O
sent864 both O
sent864 genetic O
sent864 traits O
sent864 was O
sent864 associated O
sent864 with O
sent864 a O
sent864 twofold O
sent864 increase O
sent864 in O
sent864 risk O
sent864 ( O
sent864 95 O
sent864 percent O
sent864 confidence O
sent864 interval O
sent864 ( O
sent864 CI O
sent864 ) O
sent864 = O
sent864 1.0-3.4 O
sent864 ) O
sent865 Our O
sent865 data O
sent865 did O
sent865 not O
sent865 provide O
sent865 enough O
sent865 evidence O
sent865 for O
sent865 a O
sent865 substantial O
sent865 modification O
sent865 of O
sent865 the O
sent865 effect O
sent865 of O
sent865 pack-years O
sent865 on O
sent865 lung D
sent865 cancer D
sent865 risk O
sent865 by O
sent865 the O
sent865 CYP1A1 O
sent865 MspI O
sent865 and O
sent865 GSTM1 O
sent865 genotypes O
sent866 However O
sent866 , O
sent866 limitations O
sent866 of O
sent866 our O
sent866 study O
sent866 preclude O
sent866 a O
sent866 conclusion O
sent866 about O
sent866 this O
sent866 potential O
sent866 interaction O
sent867 BACKGROUND O
sent867 : O
sent867 Thrombolytic T
sent867 treatment T
sent867 has O
sent867 been O
sent867 shown O
sent867 to O
sent867 accelerate O
sent867 resolution O
sent867 of O
sent867 major D
sent867 pulmonary D
sent867 embolism D
sent867 and O
sent867 lead O
sent867 to O
sent867 a O
sent867 rapid O
sent867 improvement O
sent867 of O
sent867 right-side O
sent867 hemodynamics O
sent868 However O
sent868 , O
sent868 the O
sent868 association O
sent868 between O
sent868 these O
sent868 favorable O
sent868 effects O
sent868 and O
sent868 the O
sent868 clinical O
sent868 outcome O
sent868 of O
sent868 patients O
sent868 who O
sent868 have O
sent868 no O
sent868 severe O
sent868 hemodynamic D
sent868 compromise D
sent868 at O
sent868 presentation O
sent868 remains O
sent868 unknown O
sent869 METHODS O
sent869 AND O
sent869 RESULTS O
sent869 : O
sent869 The O
sent869 present O
sent869 multicenter O
sent869 registry O
sent869 included O
sent869 719 O
sent869 consecutive O
sent869 patients O
sent869 with O
sent869 major D
sent869 pulmonary D
sent869 embolism D
sent869 according O
sent869 to O
sent869 clinical O
sent869 , O
sent869 echocardiographic O
sent869 , O
sent869 scintigraphic O
sent869 , O
sent869 and O
sent869 cardiac O
sent869 catheterization O
sent869 criteria O
sent870 Symptom O
sent870 onset O
sent870 was O
sent870 acute O
sent870 ( O
sent870 & O
sent870 # O
sent870 60 O
sent870 ; O
sent870 48 O
sent870 hours O
sent870 ) O
sent870 in O
sent870 63 O
sent870 % O
sent870 of O
sent870 patients O
sent871 All O
sent871 patients O
sent871 were O
sent871 hemodynamically O
sent871 stable O
sent871 ( O
sent871 ie O
sent871 , O
sent871 without O
sent871 evidence O
sent871 of O
sent871 cardiogenic D
sent871 shock D
sent871 ) O
sent871 at O
sent871 presentation O
sent872 treatment T
sent872 ( O
sent872 within O
sent872 24 O
sent872 hours O
sent872 of O
sent872 diagnosis O
sent872 ) O
sent872 was O
sent872 given O
sent872 to O
sent872 169 O
sent872 patients O
sent872 ( O
sent872 23.5 O
sent872 % O
sent872 ) O
sent872 , O
sent872 whereas O
sent872 the O
sent872 remaining O
sent872 550 O
sent872 patients O
sent872 were O
sent872 initially O
sent872 treated O
sent872 with O
sent872 heparin T
sent872 alone O
sent873 Overall O
sent873 30-day O
sent873 mortality O
sent873 was O
sent873 significantly O
sent873 lower O
sent873 in O
sent873 the O
sent873 patients O
sent873 who O
sent873 received O
sent873 thrombolytic T
sent873 agents T
sent873 ( O
sent873 4.7 O
sent873 versus O
sent873 11.1 O
sent873 % O
sent873 , O
sent873 P=.016 O
sent873 ) O
sent874 Clinical O
sent874 factors O
sent874 associated O
sent874 with O
sent874 a O
sent874 higher O
sent874 death O
sent874 rate O
sent874 were O
sent874 syncope D
sent874 ( O
sent874 P=.012 O
sent874 ) O
sent874 , O
sent874 arterial D
sent874 hypotension D
sent874 ( O
sent874 P=.021 O
sent874 ) O
sent874 , O
sent874 history O
sent874 of O
sent874 congestive D
sent874 heart D
sent874 failure D
sent874 ( O
sent874 P=.013 O
sent874 ) O
sent874 , O
sent874 and O
sent874 chronic D
sent874 pulmonary D
sent874 disease D
sent874 ( O
sent874 P=.032 O
sent874 ) O
sent875 However O
sent875 , O
sent875 only O
sent875 primary D
sent875 thrombolysis D
sent875 was O
sent875 found O
sent875 by O
sent875 multivariate O
sent875 analysis O
sent875 to O
sent875 be O
sent875 an O
sent875 independent O
sent875 predictor O
sent875 of O
sent875 survival O
sent875 ( O
sent875 odds O
sent875 ratio O
sent875 for O
sent875 in-hospital O
sent875 death O
sent875 , O
sent875 0.46 O
sent875 ; O
sent875 95 O
sent875 % O
sent875 confidence O
sent875 interval O
sent875 , O
sent875 0.21 O
sent875 to O
sent875 1.00 O
sent875 ) O
sent876 < O
sent876 TO_SEE O
sent876 > O
sent876 Patients O
sent876 who O
sent876 underwent O
sent876 early O
sent876 thrombolytic O
sent876 treatment O
sent876 had O
sent876 a O
sent876 reduced O
sent876 rate O
sent876 of O
sent876 recurrent O
sent876 pulmonary O
sent876 embolism O
sent876 ( O
sent876 7.7 O
sent876 versus O
sent876 18.7 O
sent876 % O
sent876 , O
sent876 P O
sent876 & O
sent876 # O
sent876 60 O
sent876 ; O
sent876 .001 O
sent876 ) O
sent876 but O
sent876 also O
sent876 a O
sent876 higher O
sent876 frequency O
sent876 of O
sent876 major O
sent876 bleeding O
sent876 episodes O
sent876 ( O
sent876 21.9 O
sent876 % O
sent876 versus O
sent876 7.8 O
sent876 % O
sent876 , O
sent876 P O
sent876 & O
sent876 # O
sent876 60 O
sent876 ; O
sent876 .001 O
sent876 ) O
sent877 Cerebral D
sent877 bleeding D
sent877 occurred O
sent877 in O
sent877 2 O
sent877 patients O
sent877 in O
sent877 each O
sent877 treatment O
sent877 group O
sent877 , O
sent877 and O
sent877 1 O
sent877 patient O
sent877 in O
sent877 each O
sent877 group O
sent877 died O
sent877 of O
sent877 a O
sent877 bleeding D
sent877 complication O
sent878 CONCLUSIONS O
sent878 : O
sent878 The O
sent878 results O
sent878 of O
sent878 our O
sent878 study O
sent878 suggest O
sent878 that O
sent878 thrombolysis T
sent878 may O
sent878 favorably O
sent878 affect O
sent878 the O
sent878 clinical O
sent878 outcome O
sent878 of O
sent878 hemodynamically O
sent878 stable O
sent878 patients O
sent878 with O
sent878 major D
sent878 pulmonary D
sent878 embolism D
sent879 A O
sent879 66-year-old O
sent879 male O
sent879 engineer O
sent879 diagnosed O
sent879 with O
sent879 malignant D
sent879 pleural D
sent879 mesothelioma D
sent879 4 O
sent879 years O
sent879 previously O
sent879 had O
sent879 thoracotomy T
sent879 , T
sent879 radiotherapy T
sent879 , T
sent879 and T
sent879 chemotherapy T
sent880 He O
sent880 was O
sent880 followed O
sent880 regularly O
sent880 with O
sent880 chest O
sent880 computed O
sent880 tomography O
sent880 ( O
sent880 CT O
sent880 ) O
sent880 scan O
sent880 and O
sent880 had O
sent880 been O
sent880 asymptomatic O
sent881 During O
sent881 one O
sent881 of O
sent881 his O
sent881 physical O
sent881 examinations O
sent881 , O
sent881 routine O
sent881 sigmoidoscopy O
sent881 showed O
sent881 incidental O
sent881 colonic D
sent881 polyps D
sent881 which O
sent881 were O
sent881 biopsied O
sent882 Subsequently O
sent882 , O
sent882 recurrence O
sent882 of O
sent882 pleural D
sent882 mesothelioma D
sent882 and O
sent882 peritoneal O
sent882 involvement O
sent882 by O
sent882 mesothelioma D
sent882 was O
sent882 documented O
sent883 Two O
sent883 of O
sent883 the O
sent883 polyps O
sent883 showed O
sent883 metastatic D
sent883 malignant D
sent883 mesothelioma D
sent883 in O
sent883 the O
sent883 lamina O
sent883 propia O
sent883 which O
sent883 strongly O
sent883 resembled O
sent883 adenocarcinoma D
sent883 histologically O
sent883 causing O
sent883 difficulty O
sent883 in O
sent883 making O
sent883 definitive O
sent883 diagnosis O
sent884 Review O
sent884 of O
sent884 the O
sent884 literature O
sent884 disclosed O
sent884 no O
sent884 previously O
sent884 documented O
sent884 similar O
sent884 occurrence O
sent885 This O
sent885 case O
sent885 shows O
sent885 the O
sent885 importance O
sent885 of O
sent885 clinical O
sent885 history O
sent885 and O
sent885 ancillary O
sent885 laboratory O
sent885 procedures O
sent885 such O
sent885 as O
sent885 immunohistochemistry O
sent885 and O
sent885 electron O
sent885 microscopy O
sent885 to O
sent885 avoid O
sent885 diagnostic O
sent885 pitfalls O
sent886 The O
sent886 authors O
sent886 report O
sent886 the O
sent886 postoperative O
sent886 magnetic O
sent886 resonance O
sent886 ( O
sent886 MR O
sent886 ) O
sent886 imaging O
sent886 findings O
sent886 in O
sent886 36 O
sent886 patients O
sent886 with O
sent886 advanced D
sent886 Parkinson D
sent886 's D
sent886 disease D
sent886 who O
sent886 underwent O
sent886 unilateral T
sent886 microelectrode-guided T
sent886 posteroventral T
sent886 pallidotomy T
sent887 The O
sent887 lesions O
sent887 were O
sent887 placed O
sent887 within O
sent887 1 O
sent887 mm O
sent887 of O
sent887 the O
sent887 ventral O
sent887 border O
sent887 of O
sent887 the O
sent887 globus O
sent887 pallidus O
sent887 internus O
sent887 ( O
sent887 GPi O
sent887 ) O
sent887 to O
sent887 include O
sent887 pallidothalamic O
sent887 outflow O
sent887 pathways O
sent888 Sequential O
sent888 MR O
sent888 studies O
sent888 were O
sent888 obtained O
sent888 within O
sent888 1 O
sent888 to O
sent888 3 O
sent888 days O
sent888 postoperatively O
sent888 and O
sent888 at O
sent888 6-month O
sent888 follow-up O
sent888 examination O
sent889 Thirty-four O
sent889 ( O
sent889 94 O
sent889 % O
sent889 ) O
sent889 of O
sent889 the O
sent889 36 O
sent889 patients O
sent889 enjoyed O
sent889 sustained O
sent889 moderate O
sent889 or O
sent889 marked O
sent889 improvement O
sent889 of O
sent889 their O
sent889 parkinsonian D
sent889 symptoms D
sent889 6 O
sent889 months O
sent889 postoperatively O
sent890 Transient O
sent890 side O
sent890 effects O
sent890 occurred O
sent890 in O
sent890 five O
sent890 patients O
sent890 ( O
sent890 14 O
sent890 % O
sent890 ) O
sent890 , O
sent890 but O
sent890 there O
sent890 were O
sent890 no O
sent890 persistent O
sent890 complications O
sent891 The O
sent891 pallidal O
sent891 radiofrequency O
sent891 lesions O
sent891 were O
sent891 prolate O
sent891 spheroid O
sent891 shaped O
sent891 and O
sent891 were O
sent891 composed O
sent891 of O
sent891 three O
sent891 concentric O
sent891 zones O
sent891 in O
sent891 the O
sent891 early O
sent891 postoperative O
sent891 studies O
sent892 The O
sent892 mean O
sent892 volume O
sent892 of O
sent892 the O
sent892 middle O
sent892 zone O
sent892 , O
sent892 corresponding O
sent892 to O
sent892 the O
sent892 area O
sent892 of O
sent892 hemorrhagic D
sent892 coagulation D
sent892 necrosis D
sent892 , O
sent892 was O
sent892 44.4 O
sent892 +/- O
sent892 17.6 O
sent892 mm3 O
sent892 ; O
sent892 the O
sent892 mean O
sent892 lesion O
sent892 volume O
sent892 as O
sent892 defined O
sent892 by O
sent892 the O
sent892 outer O
sent892 zone O
sent892 , O
sent892 corresponding O
sent892 to O
sent892 perilesional D
sent892 edema D
sent892 , O
sent892 was O
sent892 262.2 O
sent892 +/- O
sent892 111.6 O
sent892 mm3 O
sent893 Additional O
sent893 edema D
sent893 spreading O
sent893 to O
sent893 the O
sent893 internal O
sent893 capsule O
sent893 was O
sent893 noted O
sent893 in O
sent893 32 O
sent893 of O
sent893 34 O
sent893 cases O
sent893 and O
sent893 to O
sent893 the O
sent893 optic O
sent893 tract O
sent893 in O
sent893 11 O
sent893 of O
sent893 34 O
sent893 cases O
sent894 In O
sent894 two O
sent894 patients O
sent894 small O
sent894 ischemic D
sent894 infarctions D
sent894 involving O
sent894 the O
sent894 corona O
sent894 radiata O
sent894 were O
sent894 found O
sent894 , O
sent894 and O
sent894 in O
sent894 one O
sent894 a O
sent894 venous D
sent894 infarction D
sent894 was O
sent894 detected O
sent895 Ischemic D
sent895 infarction D
sent895 resulted O
sent895 in O
sent895 mild O
sent895 transient O
sent895 Broca D
sent895 's D
sent895 aphasia D
sent895 in O
sent895 one O
sent895 patient O
sent895 , O
sent895 but O
sent895 there O
sent895 was O
sent895 no O
sent895 detectable O
sent895 neurological O
sent895 deficit O
sent895 in O
sent895 the O
sent895 other O
sent895 two O
sent896 The O
sent896 mean O
sent896 volume O
sent896 of O
sent896 late-phase O
sent896 ( O
sent896 6 O
sent896 months O
sent896 ) O
sent896 lesions O
sent896 was O
sent896 22 O
sent896 +/- O
sent896 28.8 O
sent896 mm3 O
sent897 In O
sent897 three O
sent897 patients O
sent897 no O
sent897 lesion O
sent897 was O
sent897 identified O
sent897 despite O
sent897 sustained O
sent897 clinical O
sent897 improvement O
sent898 The O
sent898 lesion O
sent898 was O
sent898 located O
sent898 in O
sent898 the O
sent898 posteroventral O
sent898 GPi O
sent898 in O
sent898 all O
sent898 cases O
sent898 except O
sent898 in O
sent898 one O
sent898 patient O
sent898 in O
sent898 whom O
sent898 it O
sent898 was O
sent898 confined O
sent898 to O
sent898 the O
sent898 GP O
sent898 externus O
sent898 ( O
sent898 GPe O
sent898 ) O
sent899 This O
sent899 49-year-old O
sent899 woman O
sent899 did O
sent899 not O
sent899 experience O
sent899 sustained O
sent899 benefit O
sent900 The O
sent900 authors O
sent900 found O
sent900 no O
sent900 consistent O
sent900 correlations O
sent900 between O
sent900 lesion O
sent900 size O
sent900 and O
sent900 location O
sent900 and O
sent900 clinical O
sent900 outcome O
sent900 as O
sent900 measured O
sent900 by O
sent900 a O
sent900 global O
sent900 outcome O
sent900 score O
sent900 , O
sent900 the O
sent900 Unified O
sent900 Parkinson O
sent900 's O
sent900 Disease O
sent900 Rating O
sent900 Scale O
sent900 motor O
sent900 , O
sent900 activities O
sent900 of O
sent900 daily O
sent900 living O
sent900 , O
sent900 and O
sent900 bradykinesia O
sent900 `` O
sent900 off O
sent900 '' O
sent900 scores O
sent900 or O
sent900 rating O
sent900 of O
sent900 dyskinesias O
sent901 Lesioning O
sent901 of O
sent901 pallidal O
sent901 and O
sent901 subpallidal O
sent901 pathways O
sent901 may O
sent901 contribute O
sent901 to O
sent901 the O
sent901 sustained O
sent901 clinical O
sent901 benefit O
sent901 in O
sent901 this O
sent901 series O
sent902 Magnetic O
sent902 resonance O
sent902 imaging O
sent902 analysis O
sent902 showed O
sent902 that O
sent902 intraoperative O
sent902 microelectrode O
sent902 recording O
sent902 facilitated O
sent902 accurate O
sent902 placement O
sent902 of O
sent902 the O
sent902 lesion O
sent902 in O
sent902 this O
sent902 critical O
sent902 area O
sent903 A O
sent903 commercially O
sent903 available O
sent903 health O
sent903 food O
sent903 product O
sent903 of O
sent903 cold-pressed O
sent903 hemp O
sent903 seed O
sent903 oil O
sent903 ingested O
sent903 by O
sent903 one O
sent903 volunteer O
sent903 twice O
sent903 a O
sent903 day O
sent903 for O
sent903 4 O
sent903 1/2 O
sent903 days O
sent903 ( O
sent903 135 O
sent903 mL O
sent903 total O
sent903 ) O
sent904 Urine O
sent904 specimens O
sent904 collected O
sent904 from O
sent904 the O
sent904 volunteer O
sent904 were O
sent904 subjected O
sent904 to O
sent904 standard O
sent904 workplace O
sent904 urine O
sent904 drug O
sent904 testing O
sent904 procedures O
sent904 , O
sent904 and O
sent904 the O
sent904 following O
sent904 concentrations O
sent904 of O
sent904 11-nor-delta9- O
sent904 tetrahydrocannabinol O
sent904 carboxylic O
sent904 acid O
sent904 ( O
sent904 9-THCA O
sent904 ) O
sent904 were O
sent904 detected O
sent904 : O
sent904 41 O
sent904 ng/mL O
sent904 9-THCA O
sent904 at O
sent904 45 O
sent904 h O
sent904 , O
sent904 49 O
sent904 ng/mL O
sent904 at O
sent904 69 O
sent904 h O
sent904 , O
sent904 and O
sent904 55 O
sent904 ng/mL O
sent904 at O
sent904 93 O
sent904 h. O
sent904 Ingestion O
sent904 was O
sent904 discontinued O
sent904 after O
sent904 93 O
sent904 h O
sent904 , O
sent904 and O
sent904 the O
sent904 following O
sent904 concentrations O
sent904 were O
sent904 detected O
sent904 : O
sent904 68 O
sent904 ng/mL O
sent904 at O
sent904 108 O
sent904 h O
sent904 , O
sent904 57 O
sent904 ng/mL O
sent904 at O
sent904 117 O
sent904 h O
sent904 , O
sent904 31 O
sent904 ng/mL O
sent904 at O
sent904 126 O
sent904 h O
sent904 , O
sent904 and O
sent904 20 O
sent904 ng/mL O
sent904 at O
sent904 142 O
sent904 h. O
sent904 The O
sent904 first O
sent904 specimen O
sent904 that O
sent904 tested O
sent904 negative O
sent904 ( O
sent904 50 O
sent904 ng/mL O
sent904 initial O
sent904 immunoassay O
sent904 test O
sent904 , O
sent904 15 O
sent904 ng/mL O
sent904 confirmatory O
sent904 gas O
sent904 chromatographic-mass O
sent904 spectrometric O
sent904 test O
sent904 ) O
sent904 was O
sent904 at O
sent904 146 O
sent904 h O
sent904 , O
sent904 which O
sent904 was O
sent904 53 O
sent904 h O
sent904 after O
sent904 the O
sent904 last O
sent904 hemp O
sent904 seed O
sent904 oil O
sent904 ingestion O
sent905 Four O
sent905 subsequent O
sent905 specimens O
sent905 taken O
sent905 to O
sent905 177 O
sent905 h O
sent905 were O
sent905 also O
sent905 negative O
sent906 This O
sent906 study O
sent906 indicates O
sent906 that O
sent906 a O
sent906 workplace O
sent906 urine O
sent906 drug O
sent906 test O
sent906 positive O
sent906 for O
sent906 cannabinoids O
sent906 may O
sent906 arise O
sent906 from O
sent906 the O
sent906 consumption O
sent906 of O
sent906 commercially O
sent906 available O
sent906 cold-pressed O
sent906 hemp O
sent906 seed O
sent906 oil O
sent907 OBJECTIVE O
sent907 : O
sent907 We O
sent907 determined O
sent907 the O
sent907 sensitivity O
sent907 and O
sent907 specificity O
sent907 of O
sent907 neonatal O
sent907 brain-stem O
sent907 auditory O
sent907 evoked O
sent907 potentials O
sent907 ( O
sent907 BAEP O
sent907 ) O
sent907 as O
sent907 markers O
sent907 for O
sent907 subsequent O
sent907 hearing D
sent907 impairment D
sent907 and O
sent907 for O
sent907 developmental D
sent907 problems D
sent907 found O
sent907 later O
sent907 in O
sent907 infancy O
sent907 and O
sent907 childhood O
sent908 METHODS O
sent908 : O
sent908 BAEP O
sent908 studies O
sent908 were O
sent908 performed O
sent908 before O
sent908 discharge O
sent908 in O
sent908 infants O
sent908 treated O
sent908 with O
sent908 extracorporeal T
sent908 membrane T
sent908 oxygenation T
sent908 ( T
sent908 ECMO T
sent908 ) T
sent908 , O
sent908 and O
sent908 two O
sent908 specific O
sent908 abnormalities O
sent908 were O
sent908 analyzed O
sent908 : O
sent908 elevated O
sent908 threshold O
sent908 and O
sent908 delayed O
sent908 central O
sent908 auditory O
sent908 conduction O
sent909 Behavioral O
sent909 audiometry O
sent909 was O
sent909 repeated O
sent909 during O
sent909 periodic O
sent909 follow-up O
sent909 until O
sent909 reliable O
sent909 responses O
sent909 were O
sent909 obtained O
sent909 for O
sent909 all O
sent909 frequencies O
sent909 , O
sent909 and O
sent909 standardized O
sent909 developmental O
sent909 testing O
sent909 was O
sent909 also O
sent909 conducted O
sent910 The O
sent910 sensitivity O
sent910 and O
sent910 specificity O
sent910 of O
sent910 an O
sent910 elevated O
sent910 threshold O
sent910 on O
sent910 the O
sent910 neonatal O
sent910 BAEP O
sent910 for O
sent910 detecting O
sent910 subsequent O
sent910 hearing O
sent910 loss O
sent910 , O
sent910 and O
sent910 the O
sent910 relationship O
sent910 of O
sent910 any O
sent910 neonatal O
sent910 BAEP O
sent910 abnormality O
sent910 to O
sent910 language O
sent910 or O
sent910 developmental O
sent910 disorders O
sent910 in O
sent910 infancy O
sent910 , O
sent910 were O
sent910 calculated O
sent911 RESULTS O
sent911 : O
sent911 Test O
sent911 results O
sent911 for O
sent911 46 O
sent911 ECMO-treated O
sent911 infants O
sent911 ( O
sent911 57.5 O
sent911 % O
sent911 ) O
sent911 were O
sent911 normal O
sent911 , O
sent911 and O
sent911 those O
sent911 for O
sent911 34 O
sent911 infants O
sent911 ( O
sent911 42.5 O
sent911 % O
sent911 ) O
sent911 were O
sent911 abnormal O
sent911 , O
sent911 with O
sent911 either O
sent911 elevated O
sent911 wave O
sent911 V O
sent911 threshold O
sent911 , O
sent911 prolonged O
sent911 wave O
sent911 I-V O
sent911 interval O
sent911 , O
sent911 or O
sent911 both O
sent911 on O
sent911 neonatal O
sent911 BAEP O
sent911 recordings O
sent912 Most O
sent912 significantly O
sent912 , O
sent912 7 O
sent912 ( O
sent912 58 O
sent912 % O
sent912 ) O
sent912 of O
sent912 the O
sent912 12 O
sent912 children O
sent912 with O
sent912 subsequent O
sent912 sensorineural D
sent912 hearing D
sent912 loss D
sent912 had O
sent912 left O
sent912 the O
sent912 hospital O
sent912 after O
sent912 showing O
sent912 normal O
sent912 results O
sent912 on O
sent912 threshold O
sent912 tests O
sent913 There O
sent913 was O
sent913 no O
sent913 significant O
sent913 difference O
sent913 in O
sent913 the O
sent913 frequency O
sent913 of O
sent913 hearing D
sent913 loss D
sent913 between O
sent913 subjects O
sent913 with O
sent913 abnormal O
sent913 ( O
sent913 5/21 O
sent913 , O
sent913 or O
sent913 24 O
sent913 % O
sent913 ) O
sent913 and O
sent913 those O
sent913 with O
sent913 normal O
sent913 BAEP O
sent913 thresholds O
sent913 ( O
sent913 7/59 O
sent913 , O
sent913 or O
sent913 12 O
sent913 % O
sent913 ; O
sent913 Fisher O
sent913 Exact O
sent913 Test O
sent913 , O
sent913 p O
sent913 = O
sent913 0.28 O
sent913 ) O
sent914 Therefore O
sent914 the O
sent914 sensitivity O
sent914 of O
sent914 neonatal O
sent914 BAEP O
sent914 testing O
sent914 for O
sent914 predicting O
sent914 subsequent O
sent914 hearing D
sent914 loss D
sent914 was O
sent914 only O
sent914 42 O
sent914 % O
sent915 Neonatal O
sent915 BAEP O
sent915 specificity O
sent915 for O
sent915 excluding O
sent915 subsequent O
sent915 hearing D
sent915 loss D
sent915 was O
sent915 76 O
sent915 % O
sent916 In O
sent916 contrast O
sent916 , O
sent916 on O
sent916 language O
sent916 development O
sent916 testing O
sent916 , O
sent916 19 O
sent916 children O
sent916 demonstrated O
sent916 receptive O
sent916 language O
sent916 delay O
sent917 Of O
sent917 these O
sent917 children O
sent917 , O
sent917 12 O
sent917 ( O
sent917 63 O
sent917 % O
sent917 ) O
sent917 had O
sent917 abnormal O
sent917 neonatal O
sent917 BAEP O
sent917 recordings O
sent917 and O
sent917 7 O
sent917 ( O
sent917 37 O
sent917 % O
sent917 ) O
sent917 had O
sent917 a O
sent917 normal O
sent917 BAEP O
sent917 threshold O
sent917 , O
sent917 normal O
sent917 central O
sent917 auditory O
sent917 conduction O
sent917 test O
sent917 results O
sent917 , O
sent917 or O
sent917 both O
sent917 ( O
sent917 p O
sent917 = O
sent917 0.04 O
sent917 ) O
sent918 CONCLUSIONS O
sent918 : O
sent918 Neonatal O
sent918 BAEP O
sent918 threshold O
sent918 recordings O
sent918 were O
sent918 of O
sent918 limited O
sent918 value O
sent918 for O
sent918 predicting O
sent918 subsequent O
sent918 hearing D
sent918 loss D
sent918 common O
sent918 in O
sent918 ECMO T
sent918 -treated O
sent918 survivors O
sent919 However O
sent919 , O
sent919 an O
sent919 abnormal O
sent919 neonatal O
sent919 BAEP O
sent919 significantly O
sent919 increased O
sent919 the O
sent919 probability O
sent919 of O
sent919 finding O
sent919 a O
sent919 receptive O
sent919 language O
sent919 delay O
sent919 during O
sent919 early O
sent919 childhood O
sent919 , O
sent919 even O
sent919 in O
sent919 those O
sent919 with O
sent919 subsequently O
sent919 normal O
sent919 audiometry O
sent919 findings O
sent920 Because O
sent920 neonatal O
sent920 ECMO T
sent920 is O
sent920 associated O
sent920 with O
sent920 a O
sent920 high O
sent920 risk O
sent920 of O
sent920 hearing D
sent920 and D
sent920 receptive D
sent920 language D
sent920 disorders D
sent920 , O
sent920 parents O
sent920 should O
sent920 be O
sent920 counseled O
sent920 that O
sent920 audiologic O
sent920 and O
sent920 developmental O
sent920 follow-up O
sent920 evaluations O
sent920 in O
sent920 surviving O
sent920 children O
sent920 are O
sent920 essential O
sent920 regardless O
sent920 of O
sent920 the O
sent920 results O
sent920 of O
sent920 neonatal O
sent920 BAEP O
sent920 testing O
sent921 The O
sent921 Federated O
sent921 Council O
sent921 of O
sent921 Internal O
sent921 Medicine O
sent921 has O
sent921 developed O
sent921 a O
sent921 resource O
sent921 guide O
sent921 to O
sent921 help O
sent921 internal O
sent921 medicine O
sent921 residency O
sent921 programs O
sent921 produce O
sent921 internists O
sent921 who O
sent921 are O
sent921 prepared O
sent921 for O
sent921 today O
sent921 's O
sent921 practice O
sent921 of O
sent921 internal O
sent921 medicine O
sent921 and O
sent921 the O
sent921 challenges O
sent921 of O
sent921 practice O
sent921 in O
sent921 the O
sent921 future O
sent922 The O
sent922 guide O
sent922 situates O
sent922 general O
sent922 internal O
sent922 medicine O
sent922 as O
sent922 the O
sent922 primary O
sent922 care O
sent922 profession O
sent922 that O
sent922 focuses O
sent922 on O
sent922 preventive O
sent922 , O
sent922 short-term O
sent922 , O
sent922 and O
sent922 long-term O
sent922 care O
sent922 of O
sent922 adult O
sent922 patients O
sent923 It O
sent923 assumes O
sent923 that O
sent923 a O
sent923 single O
sent923 pathway O
sent923 is O
sent923 sufficient O
sent923 for O
sent923 educating O
sent923 general O
sent923 internists O
sent923 and O
sent923 subspecialty-bound O
sent923 trainees O
sent924 It O
sent924 identifies O
sent924 the O
sent924 learning O
sent924 experiences O
sent924 that O
sent924 should O
sent924 be O
sent924 part O
sent924 of O
sent924 general O
sent924 internal O
sent924 medicine O
sent924 residency O
sent924 training O
sent924 , O
sent924 lists O
sent924 the O
sent924 clinical O
sent924 competencies O
sent924 that O
sent924 are O
sent924 important O
sent924 for O
sent924 primary O
sent924 care O
sent924 practice O
sent924 , O
sent924 and O
sent924 describes O
sent924 the O
sent924 role O
sent924 of O
sent924 the O
sent924 integrative O
sent924 disciplines O
sent924 that O
sent924 should O
sent924 inform O
sent924 the O
sent924 care O
sent924 of O
sent924 every O
sent924 patient O
sent925 It O
sent925 also O
sent925 describes O
sent925 a O
sent925 process O
sent925 that O
sent925 program O
sent925 directors O
sent925 and O
sent925 local O
sent925 program O
sent925 committees O
sent925 can O
sent925 use O
sent925 to O
sent925 develop O
sent925 competency-based O
sent925 curricula O
sent926 BACKGROUND O
sent926 : O
sent926 Darier D
sent926 disease D
sent926 is O
sent926 an O
sent926 uncommon O
sent926 genodermatosis D
sent926 characterized O
sent926 by O
sent926 the O
sent926 symmetrical O
sent926 eruption O
sent926 of O
sent926 keratotic O
sent926 reddish-brown O
sent926 papules O
sent926 occurring O
sent926 in O
sent926 the O
sent926 seborrheic O
sent926 areas O
sent926 of O
sent926 the O
sent926 body O
sent927 A O
sent927 unilateral O
sent927 , O
sent927 or O
sent927 localized O
sent927 , O
sent927 variant O
sent927 has O
sent927 been O
sent927 identified O
sent928 We O
sent928 report O
sent928 4 O
sent928 new O
sent928 cases O
sent928 of O
sent928 localized O
sent928 Darier D
sent928 disease D
sent928 and O
sent928 review O
sent928 the O
sent928 English-language O
sent928 literature O
sent929 The O
sent929 implications O
sent929 of O
sent929 these O
sent929 cases O
sent929 on O
sent929 future O
sent929 genetic O
sent929 studies O
sent929 are O
sent929 also O
sent929 discussed O
sent930 OBSERVATIONS O
sent930 : O
sent930 Localized O
sent930 Darier D
sent930 disease D
sent930 occurred O
sent930 with O
sent930 equal O
sent930 frequency O
sent930 in O
sent930 males O
sent930 and O
sent930 females O
sent931 The O
sent931 average O
sent931 age O
sent931 at O
sent931 onset O
sent931 was O
sent931 27 O
sent931 years O
sent932 The O
sent932 most O
sent932 frequent O
sent932 site O
sent932 of O
sent932 involvement O
sent932 was O
sent932 the O
sent932 trunk O
sent932 ( O
sent932 40 O
sent932 % O
sent932 ( O
sent932 16/40 O
sent932 ) O
sent932 ) O
sent933 This O
sent933 condition O
sent933 was O
sent933 aggravated O
sent933 by O
sent933 sunlight O
sent933 , O
sent933 heat O
sent933 , O
sent933 or O
sent933 sweating O
sent933 in O
sent933 42 O
sent933 % O
sent933 ( O
sent933 19/40 O
sent933 ) O
sent933 of O
sent933 reported O
sent933 cases O
sent933 , O
sent933 and O
sent933 38 O
sent933 % O
sent933 ( O
sent933 15/40 O
sent933 ) O
sent933 of O
sent933 the O
sent933 patients O
sent933 responded O
sent933 to O
sent933 treatment O
sent933 with O
sent933 topical O
sent933 tretinoin T
sent934 CONCLUSIONS O
sent934 : O
sent934 Many O
sent934 of O
sent934 the O
sent934 clinical O
sent934 features O
sent934 of O
sent934 localized O
sent934 Darier D
sent934 disease D
sent934 suggest O
sent934 that O
sent934 it O
sent934 is O
sent934 a O
sent934 genetic O
sent934 mosaic O
sent934 of O
sent934 generalized O
sent934 Darier D
sent934 disease D
sent935 Further O
sent935 studies O
sent935 of O
sent935 localized O
sent935 Darier D
sent935 disease D
sent935 may O
sent935 therefore O
sent935 prove O
sent935 to O
sent935 be O
sent935 instrumental O
sent935 in O
sent935 the O
sent935 search O
sent935 for O
sent935 the O
sent935 Darier D
sent935 disease D
sent935 gene O
sent936 UV O
sent936 radiation O
sent936 induces O
sent936 two O
sent936 major O
sent936 DNA O
sent936 damage O
sent936 products O
sent936 , O
sent936 the O
sent936 cyclobutane O
sent936 pyrimidine O
sent936 dimer O
sent936 ( O
sent936 CPD O
sent936 ) O
sent936 and O
sent936 , O
sent936 at O
sent936 a O
sent936 lower O
sent936 frequency O
sent936 , O
sent936 the O
sent936 pyrimidine O
sent936 ( O
sent936 6-4 O
sent936 ) O
sent936 pyrimidinone O
sent936 dimer O
sent936 ( O
sent936 6-4 O
sent936 product O
sent936 ) O
sent937 Although O
sent937 Escherichia O
sent937 coli O
sent937 and O
sent937 Saccharomyes O
sent937 cerevisiae O
sent937 produce O
sent937 a O
sent937 CPD-specific O
sent937 photolyase O
sent937 that O
sent937 eliminates O
sent937 only O
sent937 this O
sent937 class O
sent937 of O
sent937 dimer O
sent937 , O
sent937 Arabidopsis O
sent937 thaliana O
sent937 , O
sent937 Drosphila O
sent937 melanogaster O
sent937 , O
sent937 Crotalus O
sent937 atrox O
sent937 , O
sent937 and O
sent937 Xenopus O
sent937 laevis O
sent937 have O
sent937 recently O
sent937 been O
sent937 shown O
sent937 to O
sent937 photoreactivate O
sent937 both O
sent937 CPDs O
sent937 and O
sent937 6-4 O
sent937 products O
sent938 We O
sent938 describe O
sent938 the O
sent938 isolation O
sent938 and O
sent938 characterization O
sent938 of O
sent938 two O
sent938 new O
sent938 classes O
sent938 of O
sent938 mutants O
sent938 of O
sent938 Arabidopsis O
sent938 , O
sent938 termed O
sent938 uvr2 O
sent938 and O
sent938 uvr3 O
sent938 , O
sent938 that O
sent938 are O
sent938 defective O
sent938 in O
sent938 the O
sent938 photoreactivation O
sent938 of O
sent938 CPDs O
sent938 and O
sent938 6-4 O
sent938 products O
sent938 , O
sent938 respectively O
sent939 We O
sent939 demonstrate O
sent939 that O
sent939 the O
sent939 CPD O
sent939 photolyase O
sent939 mutation O
sent939 is O
sent939 genetically O
sent939 linked O
sent939 to O
sent939 a O
sent939 DNA O
sent939 sequence O
sent939 encoding O
sent939 a O
sent939 type O
sent939 II O
sent939 ( O
sent939 metazoan O
sent939 ) O
sent939 CPD O
sent939 photolyase O
sent940 In O
sent940 addition O
sent940 , O
sent940 we O
sent940 are O
sent940 able O
sent940 to O
sent940 generate O
sent940 plants O
sent940 in O
sent940 which O
sent940 only O
sent940 CPDs O
sent940 or O
sent940 6-4 O
sent940 products O
sent940 are O
sent940 photoreactivated O
sent940 in O
sent940 the O
sent940 nuclear O
sent940 genome O
sent940 by O
sent940 exposing O
sent940 these O
sent940 mutants O
sent940 to O
sent940 UV O
sent940 light O
sent940 and O
sent940 then O
sent940 allowing O
sent940 them O
sent940 to O
sent940 repair O
sent940 one O
sent940 or O
sent940 the O
sent940 other O
sent940 class O
sent940 of O
sent940 dimers O
sent941 This O
sent941 provides O
sent941 us O
sent941 with O
sent941 a O
sent941 unique O
sent941 opportunity O
sent941 to O
sent941 study O
sent941 the O
sent941 biological O
sent941 consequences O
sent941 of O
sent941 each O
sent941 of O
sent941 these O
sent941 two O
sent941 major O
sent941 UV-induced O
sent941 photoproducts O
sent941 in O
sent941 an O
sent941 intact O
sent941 living O
sent941 system O
sent942 A O
sent942 diffuse O
sent942 macular D
sent942 erythroderma D
sent942 and O
sent942 subsequent O
sent942 desquamation D
sent942 after O
sent942 1 O
sent942 to O
sent942 2 O
sent942 weeks O
sent942 are O
sent942 two O
sent942 of O
sent942 the O
sent942 five O
sent942 major O
sent942 diagnostic O
sent942 criteria O
sent942 of O
sent942 toxic D
sent942 shock D
sent942 syndrome D
sent942 ( D
sent942 TSS D
sent942 ) D
sent943 We O
sent943 present O
sent943 the O
sent943 case O
sent943 of O
sent943 a O
sent943 15-month-old O
sent943 girl O
sent943 with O
sent943 TSS D
sent943 , O
sent943 but O
sent943 without O
sent943 erythroderma D
sent943 or O
sent943 desquamation D
sent944 She O
sent944 was O
sent944 admitted O
sent944 with O
sent944 high D
sent944 fever D
sent944 , O
sent944 shock D
sent944 , O
sent944 and O
sent944 multiorgan O
sent944 involvement O
sent945 Minimal O
sent945 or O
sent945 no O
sent945 cutaneous O
sent945 signs O
sent945 were O
sent945 present O
sent946 Initially O
sent946 the O
sent946 diagnosis O
sent946 of O
sent946 the O
sent946 syndrome O
sent946 of O
sent946 hemorrhagic D
sent946 shock D
sent946 and O
sent946 encephalopathy D
sent946 was O
sent946 made O
sent947 After O
sent947 7 O
sent947 days O
sent947 , O
sent947 a O
sent947 TSS D
sent947 toxin O
sent947 1-producing O
sent947 strain O
sent947 of O
sent947 Staphylococcus O
sent947 aureus O
sent947 was O
sent947 cultured O
sent947 from O
sent947 an O
sent947 inguinal O
sent947 lymph O
sent947 node O
sent947 , O
sent947 where O
sent947 inflammation D
sent947 had O
sent947 already O
sent947 been O
sent947 noticed O
sent947 on O
sent947 admission O
sent948 Moreover O
sent948 , O
sent948 the O
sent948 girl O
sent948 had O
sent948 no O
sent948 antibodies O
sent948 against O
sent948 this O
sent948 toxin O
sent949 The O
sent949 serum O
sent949 cytokine O
sent949 profile O
sent949 during O
sent949 the O
sent949 acute O
sent949 phase O
sent949 of O
sent949 her O
sent949 illness O
sent949 showed O
sent949 high O
sent949 levels O
sent949 of O
sent949 tumor O
sent949 necrosis O
sent949 factor-alpha O
sent949 , O
sent949 interleukin-6 O
sent949 and O
sent949 interferon-gamma O
sent949 , O
sent949 as O
sent949 is O
sent949 seen O
sent949 during O
sent949 activation O
sent949 of O
sent949 the O
sent949 immune O
sent949 system O
sent949 by O
sent949 TSS D
sent949 toxin O
sent949 1 O
sent950 Other O
sent950 possible O
sent950 causes O
sent950 for O
sent950 the O
sent950 patient O
sent950 's O
sent950 illness O
sent950 were O
sent950 excluded O
sent951 We O
sent951 conclude O
sent951 that O
sent951 the O
sent951 patient O
sent951 had O
sent951 TSS D
sent951 without O
sent951 rash D
sent952 Without O
sent952 the O
sent952 evidence O
sent952 implicating O
sent952 a O
sent952 TSS D
sent952 toxin O
sent952 1-producing O
sent952 strain O
sent952 of O
sent952 S. O
sent952 aureus O
sent952 as O
sent952 the O
sent952 cause O
sent952 of O
sent952 her O
sent952 disease O
sent952 , O
sent952 a O
sent952 diagnosis O
sent952 of O
sent952 syndrome O
sent952 of O
sent952 hemorrhagic D
sent952 shock D
sent952 and O
sent952 encephalopathy D
sent952 would O
sent952 have O
sent952 been O
sent952 made O
sent953 It O
sent953 is O
sent953 possible O
sent953 that O
sent953 some O
sent953 cases O
sent953 of O
sent953 syndrome O
sent953 of O
sent953 hemorrhagic D
sent953 shock D
sent953 and O
sent953 encephalopathy D
sent953 represent O
sent953 a O
sent953 variant O
sent953 of O
sent953 TSS D
sent953 in O
sent953 small O
sent953 children O
sent954 < O
sent954 TO_SEE O
sent954 > O
sent954 BACKGROUND O
sent954 : O
sent954 The O
sent954 growing O
sent954 teratoma O
sent954 syndrome O
sent954 refers O
sent954 to O
sent954 the O
sent954 phenomenon O
sent954 whereby O
sent954 germ O
sent954 cell O
sent954 tumors O
sent954 enlarge O
sent954 after O
sent954 chemotherapy O
sent954 despite O
sent954 complete O
sent954 eradication O
sent954 of O
sent954 malignant O
sent954 cells O
sent954 and O
sent954 normalization O
sent954 of O
sent954 serum O
sent954 tumor O
sent954 markers O
sent955 This O
sent955 clinical O
sent955 scenario O
sent955 must O
sent955 be O
sent955 differentiated O
sent955 from O
sent955 that O
sent955 in O
sent955 which O
sent955 germ D
sent955 cell D
sent955 tumors D
sent955 maintain O
sent955 their O
sent955 malignant O
sent955 characteristics O
sent955 with O
sent955 elevated O
sent955 levels O
sent955 of O
sent955 serum O
sent955 tumor O
sent955 markers O
sent956 METHODS O
sent956 : O
sent956 Hospital O
sent956 record O
sent956 review O
sent956 was O
sent956 conducted O
sent956 of O
sent956 2 O
sent956 cases O
sent957 RESULTS O
sent957 : O
sent957 Two O
sent957 male O
sent957 patients O
sent957 are O
sent957 presented O
sent957 , O
sent957 1 O
sent957 with O
sent957 a O
sent957 metastatic D
sent957 germ D
sent957 cell D
sent957 tumor D
sent957 of O
sent957 both O
sent957 the O
sent957 retroperitoneum O
sent957 and O
sent957 mediastinum O
sent957 ( O
sent957 with O
sent957 elevated O
sent957 alpha-fetoprotein O
sent957 level O
sent957 ) O
sent957 and O
sent957 1 O
sent957 with O
sent957 a O
sent957 primary D
sent957 germ D
sent957 cell D
sent957 tumor D
sent957 of O
sent957 the O
sent957 mediastinum O
sent957 ( O
sent957 with O
sent957 elevated O
sent957 alpha-fetoprotein O
sent957 and O
sent957 beta-human O
sent957 chorionic O
sent957 gonadotropin O
sent957 levels O
sent957 ) O
sent958 After O
sent958 completion O
sent958 of O
sent958 chemotherapy T
sent958 and O
sent958 normalization O
sent958 of O
sent958 tumor O
sent958 markers O
sent958 , O
sent958 both O
sent958 patients O
sent958 presented O
sent958 with O
sent958 pulmonary D
sent958 symptoms D
sent958 attributable O
sent958 to O
sent958 their O
sent958 massively O
sent958 enlarging O
sent958 mediastinal D
sent958 teratomas D
sent958 . O
sent959 The O
sent959 clinical O
sent959 and O
sent959 roentgenographic O
sent959 features O
sent959 of O
sent959 patients O
sent959 with O
sent959 thoracic O
sent959 manifestations O
sent959 of O
sent959 the O
sent959 growing O
sent959 teratoma D
sent959 syndrome D
sent959 , O
sent959 as O
sent959 well O
sent959 as O
sent959 its O
sent959 management O
sent959 , O
sent959 are O
sent959 reviewed O
sent960 < O
sent960 TO_SEE O
sent960 > O
sent960 CONCLUSIONS O
sent960 : O
sent960 After O
sent960 chemotherapy T
sent960 in O
sent960 patients O
sent960 with O
sent960 primary D
sent960 or D
sent960 metastatic D
sent960 mediastinal D
sent960 germ D
sent960 cell D
sent960 tumors D
sent960 whose O
sent960 tumor O
sent960 markers O
sent960 normalize O
sent960 , O
sent960 a O
sent960 growing O
sent960 mass O
sent960 in O
sent960 the O
sent960 mediastinum O
sent960 may O
sent960 represent O
sent960 the O
sent960 growing O
sent960 teratoma D
sent960 syndrome D
sent961 The O
sent961 chicken O
sent961 calmodulin O
sent961 I O
sent961 ( O
sent961 CaMI O
sent961 ) O
sent961 gene O
sent961 has O
sent961 been O
sent961 isolated O
sent961 and O
sent961 characterized O
sent961 on O
sent961 the O
sent961 level O
sent961 of O
sent961 cDNA O
sent961 and O
sent961 genomic O
sent961 DNA O
sent962 The O
sent962 deduced O
sent962 amino O
sent962 acid O
sent962 ( O
sent962 aa O
sent962 ) O
sent962 sequence O
sent962 is O
sent962 identical O
sent962 to O
sent962 the O
sent962 one O
sent962 of O
sent962 chicken O
sent962 CaMII O
sent962 which O
sent962 consists O
sent962 of O
sent962 148 O
sent962 aa O
sent963 The O
sent963 CaMI O
sent963 gene O
sent963 contains O
sent963 six O
sent963 exons O
sent964 Its O
sent964 intron/exon O
sent964 organization O
sent964 is O
sent964 identical O
sent964 to O
sent964 that O
sent964 of O
sent964 the O
sent964 chicken O
sent964 CaMII O
sent964 and O
sent964 the O
sent964 CaMI O
sent964 and O
sent964 CaMIII O
sent964 genes O
sent964 of O
sent964 rat O
sent964 and O
sent964 human O
sent965 Expression O
sent965 of O
sent965 the O
sent965 CaMI O
sent965 gene O
sent965 was O
sent965 detected O
sent965 in O
sent965 all O
sent965 chicken O
sent965 tissues O
sent965 examined O
sent965 , O
sent965 although O
sent965 at O
sent965 varying O
sent965 levels O
sent966 The O
sent966 gene O
sent966 is O
sent966 transcribed O
sent966 into O
sent966 four O
sent966 mRNAs O
sent966 of O
sent966 0.8 O
sent966 , O
sent966 1.4 O
sent966 , O
sent966 1.7 O
sent966 and O
sent966 4.4 O
sent966 kb O
sent966 as O
sent966 determined O
sent966 by O
sent966 Northern O
sent966 blot O
sent966 analysis O
sent967 Our O
sent967 results O
sent967 demonstrate O
sent967 that O
sent967 the O
sent967 `` O
sent967 multigene-one-protein O
sent967 '' O
sent967 principle O
sent967 of O
sent967 CaM O
sent967 synthesis O
sent967 is O
sent967 not O
sent967 only O
sent967 applicable O
sent967 to O
sent967 mammals O
sent967 whose O
sent967 CaM O
sent967 is O
sent967 encoded O
sent967 by O
sent967 three O
sent967 different O
sent967 genes O
sent967 , O
sent967 but O
sent967 also O
sent967 to O
sent967 chickens O
sent968 BACKGROUND O
sent968 : O
sent968 We O
sent968 assessed O
sent968 the O
sent968 accuracy O
sent968 of O
sent968 two O
sent968 electron O
sent968 beam O
sent968 computed O
sent968 tomography O
sent968 ( O
sent968 EBCT O
sent968 ) O
sent968 protocols O
sent968 for O
sent968 predicting O
sent968 coronary D
sent968 events D
sent969 METHODS O
sent969 AND O
sent969 RESULTS O
sent969 : O
sent969 In O
sent969 1994 O
sent969 , O
sent969 24 O
sent969 months O
sent969 after O
sent969 enrollment O
sent969 in O
sent969 a O
sent969 longitudinal O
sent969 study O
sent969 , O
sent969 326 O
sent969 high-risk O
sent969 adults O
sent969 underwent O
sent969 both O
sent969 3- O
sent969 and O
sent969 6-mm O
sent969 image-slice O
sent969 thickness O
sent969 EBCT O
sent969 scanning O
sent969 and O
sent969 were O
sent969 followed O
sent969 up O
sent969 for O
sent969 32.0+/-4.0 O
sent969 additional O
sent969 months O
sent970 Events O
sent970 were O
sent970 defined O
sent970 as O
sent970 either O
sent970 coronary O
sent970 death O
sent970 , O
sent970 myocardial D
sent970 infarction D
sent970 , O
sent970 or O
sent970 revascularization D
sent971 We O
sent971 monitored O
sent971 these O
sent971 subjects O
sent971 for O
sent971 the O
sent971 32-month O
sent971 postscanning O
sent971 period O
sent971 with O
sent971 yearly O
sent971 phone O
sent971 calls O
sent971 and O
sent971 acquisition O
sent971 of O
sent971 records O
sent971 for O
sent971 all O
sent971 hospital O
sent971 admissions O
sent972 At O
sent972 the O
sent972 time O
sent972 of O
sent972 scanning O
sent972 , O
sent972 11 O
sent972 subjects O
sent972 ( O
sent972 3 O
sent972 % O
sent972 ) O
sent972 had O
sent972 already O
sent972 suffered O
sent972 12 O
sent972 events O
sent972 ( O
sent972 5 O
sent972 infarctions D
sent972 and O
sent972 7 O
sent972 revascularizations D
sent972 ) O
sent972 during O
sent972 the O
sent972 24-month O
sent972 prescanning O
sent972 period O
sent973 During O
sent973 the O
sent973 postscanning O
sent973 period O
sent973 , O
sent973 18 O
sent973 subjects O
sent973 ( O
sent973 6 O
sent973 % O
sent973 ) O
sent973 suffered O
sent973 23 O
sent973 events O
sent973 ( O
sent973 5 O
sent973 coronary O
sent973 deaths O
sent973 , O
sent973 6 O
sent973 infarctions D
sent973 , O
sent973 and O
sent973 12 O
sent973 revascularizations D
sent973 ) O
sent974 Thus O
sent974 , O
sent974 28 O
sent974 subjects O
sent974 ( O
sent974 9 O
sent974 % O
sent974 ) O
sent974 suffered O
sent974 35 O
sent974 events O
sent975 Calcium O
sent975 quantities O
sent975 calculated O
sent975 for O
sent975 both O
sent975 protocols O
sent975 , O
sent975 performed O
sent975 on O
sent975 the O
sent975 same O
sent975 subjects O
sent975 , O
sent975 were O
sent975 sorted O
sent975 in O
sent975 ascending O
sent975 order O
sent975 and O
sent975 divided O
sent975 into O
sent975 equal O
sent975 quartiles O
sent976 When O
sent976 revascularizations D
sent976 were O
sent976 included O
sent976 , O
sent976 there O
sent976 was O
sent976 a O
sent976 significant O
sent976 trend O
sent976 toward O
sent976 higher O
sent976 frequencies O
sent976 of O
sent976 events O
sent976 with O
sent976 increasing O
sent976 calcium O
sent976 quantity O
sent976 ( O
sent976 P O
sent976 & O
sent976 # O
sent976 60 O
sent976 ; O
sent976 .01 O
sent976 ) O
sent977 However O
sent977 , O
sent977 coronary O
sent977 death O
sent977 and O
sent977 infarction D
sent977 were O
sent977 not O
sent977 significantly O
sent977 more O
sent977 frequent O
sent977 in O
sent977 higher O
sent977 quartiles O
sent978 These O
sent978 relationships O
sent978 were O
sent978 preserved O
sent978 in O
sent978 the O
sent978 subjects O
sent978 without O
sent978 prior O
sent978 events O
sent978 at O
sent978 the O
sent978 time O
sent978 of O
sent978 scanning O
sent979 CONCLUSIONS O
sent979 : O
sent979 Calcium O
sent979 quantities O
sent979 from O
sent979 the O
sent979 3-mm O
sent979 and O
sent979 the O
sent979 more O
sent979 reproducible O
sent979 6-mm O
sent979 scanning O
sent979 are O
sent979 equally O
sent979 accurate O
sent979 for O
sent979 predicting O
sent979 events O
sent980 Coronary O
sent980 calcium O
sent980 amount O
sent980 appears O
sent980 to O
sent980 be O
sent980 a O
sent980 weak O
sent980 predictor O
sent980 of O
sent980 coronary O
sent980 death O
sent980 and O
sent980 infarction D
sent981 Its O
sent981 predictive O
sent981 accuracy O
sent981 is O
sent981 superior O
sent981 for O
sent981 predicting O
sent981 revascularization D
sent982 Research O
sent982 into O
sent982 the O
sent982 genetic O
sent982 component O
sent982 of O
sent982 some O
sent982 complex O
sent982 behaviors O
sent982 often O
sent982 causes O
sent982 controversy O
sent982 , O
sent982 depending O
sent982 on O
sent982 the O
sent982 social O
sent982 meaning O
sent982 and O
sent982 significance O
sent982 of O
sent982 the O
sent982 behavior O
sent982 under O
sent982 study O
sent983 Research O
sent983 into O
sent983 sexual O
sent983 orientation-simplistically O
sent983 referred O
sent983 to O
sent983 as O
sent983 `` O
sent983 gay O
sent983 gene O
sent983 '' O
sent983 research-is O
sent983 an O
sent983 example O
sent983 of O
sent983 research O
sent983 that O
sent983 provokes O
sent983 intense O
sent983 controversy O
sent984 This O
sent984 research O
sent984 is O
sent984 worrisome O
sent984 for O
sent984 many O
sent984 reasons O
sent984 , O
sent984 including O
sent984 the O
sent984 fact O
sent984 that O
sent984 it O
sent984 has O
sent984 been O
sent984 used O
sent984 to O
sent984 harm O
sent984 lesbians O
sent984 and O
sent984 gay O
sent984 men O
sent985 Many O
sent985 homosexual O
sent985 people O
sent985 have O
sent985 been O
sent985 forced O
sent985 to O
sent985 undergo O
sent985 `` O
sent985 treatments O
sent985 '' O
sent985 to O
sent985 change O
sent985 their O
sent985 sexual O
sent985 orientation O
sent986 Other O
sent986 chose O
sent986 to O
sent986 undergo O
sent986 them O
sent986 to O
sent986 escape O
sent986 discrimination O
sent986 and O
sent986 social O
sent986 disapprobation O
sent987 But O
sent987 there O
sent987 are O
sent987 other O
sent987 reasons O
sent987 to O
sent987 worry O
sent987 about O
sent987 such O
sent987 research O
sent988 The O
sent988 very O
sent988 motivation O
sent988 for O
sent988 seeking O
sent988 an O
sent988 `` O
sent988 origin O
sent988 '' O
sent988 of O
sent988 homosexuality O
sent988 reveals O
sent988 homophobia O
sent989 Moreover O
sent989 , O
sent989 such O
sent989 research O
sent989 may O
sent989 lead O
sent989 to O
sent989 prenatal O
sent989 tests O
sent989 that O
sent989 claim O
sent989 to O
sent989 predict O
sent989 for O
sent989 homosexuality O
sent990 For O
sent990 homosexual O
sent990 people O
sent990 who O
sent990 live O
sent990 in O
sent990 countries O
sent990 with O
sent990 no O
sent990 legal O
sent990 protections O
sent990 these O
sent990 dangers O
sent990 are O
sent990 particularly O
sent990 serious O
sent991 The O
sent991 efficiency O
sent991 of O
sent991 testicular T
sent991 sperm T
sent991 retrieval T
sent991 by T
sent991 testicular T
sent991 fine T
sent991 needle T
sent991 aspiration T
sent991 ( T
sent991 TEFNA T
sent991 ) T
sent991 was O
sent991 compared O
sent991 with O
sent991 open T
sent991 biopsy T
sent991 and T
sent991 testicular T
sent991 sperm T
sent991 extraction T
sent991 ( T
sent991 TESE T
sent991 ) T
sent991 , O
sent991 in O
sent991 37 O
sent991 rigorously O
sent991 selected O
sent991 patients O
sent991 with O
sent991 non-obstructive D
sent991 azoospermia D
sent992 All O
sent992 patients O
sent992 underwent O
sent992 TEFNA T
sent992 and O
sent992 TESE T
sent992 consecutively O
sent993 Thus O
sent993 , O
sent993 each O
sent993 patient O
sent993 served O
sent993 as O
sent993 his O
sent993 own O
sent993 control O
sent994 The O
sent994 case O
sent994 was O
sent994 regarded O
sent994 as O
sent994 successful O
sent994 if O
sent994 at O
sent994 least O
sent994 one O
sent994 testicular O
sent994 spermatozoon O
sent994 was O
sent994 found O
sent994 allowing O
sent994 intracytoplasmic O
sent994 sperm O
sent994 injection O
sent994 ( O
sent994 ICSI O
sent994 ) O
sent994 of O
sent994 at O
sent994 least O
sent994 one O
sent994 oocyte O
sent995 The O
sent995 mean O
sent995 age O
sent995 of O
sent995 the O
sent995 male O
sent995 patients O
sent995 was O
sent995 32.7 O
sent995 years O
sent995 ( O
sent995 range O
sent995 24-47 O
sent995 ) O
sent996 Whereas O
sent996 by O
sent996 TEFNA T
sent996 spermatozoa O
sent996 enabling O
sent996 performance O
sent996 of O
sent996 ICSI O
sent996 were O
sent996 found O
sent996 in O
sent996 only O
sent996 four O
sent996 patients O
sent996 out O
sent996 of O
sent996 37 O
sent996 ( O
sent996 11 O
sent996 % O
sent996 ) O
sent996 , O
sent996 open T
sent996 biopsy T
sent996 and T
sent996 TESE T
sent996 yielded O
sent996 spermatozoa O
sent996 in O
sent996 16 O
sent996 cases O
sent996 ( O
sent996 43 O
sent996 % O
sent996 ) O
sent997 The O
sent997 negative O
sent997 predictive O
sent997 value O
sent997 of O
sent997 high O
sent997 serum O
sent997 follicle O
sent997 stimulating O
sent997 hormone O
sent997 ( O
sent997 FSH O
sent997 ) O
sent997 concentrations O
sent997 ( O
sent997 > O
sent997 or O
sent997 =10 O
sent997 IU/l O
sent997 ) O
sent997 ( O
sent997 predicting O
sent997 failure O
sent997 to O
sent997 find O
sent997 spermatozoa O
sent997 for O
sent997 ICSI O
sent997 ) O
sent997 was O
sent997 low O
sent997 ( O
sent997 38.4 O
sent997 % O
sent997 ) O
sent998 The O
sent998 positive O
sent998 predictive O
sent998 value O
sent998 ( O
sent998 predicting O
sent998 the O
sent998 chance O
sent998 to O
sent998 find O
sent998 spermatozoa O
sent998 for O
sent998 ICSI O
sent998 ) O
sent998 of O
sent998 normal-sized O
sent998 testicle O
sent998 was O
sent998 not O
sent998 different O
sent998 from O
sent998 that O
sent998 of O
sent998 small-sized O
sent998 ( O
sent998 & O
sent998 # O
sent998 60 O
sent998 ; O
sent998 15 O
sent998 ml O
sent998 ) O
sent998 testicle O
sent998 ( O
sent998 50 O
sent998 % O
sent998 ) O
sent999 Complications O
sent999 included O
sent999 one O
sent999 case O
sent999 of O
sent999 testicular D
sent999 bleeding D
sent999 following O
sent999 fine T
sent999 needle T
sent999 aspiration T
sent999 , O
sent999 treated O
sent999 locally O
sent999 , O
sent999 and O
sent999 two O
sent999 cases O
sent999 of O
sent999 extratunical D
sent999 haematomata D
sent999 following O
sent999 TESE O
sent999 requiring O
sent999 no O
sent999 intervention O
sent1000 < O
sent1000 TO_SEE O
sent1000 > O
sent1000 In O
sent1000 patients O
sent1000 with O
sent1000 non-obstructive O
sent1000 azoospermia O
sent1000 , O
sent1000 TEFNA O
sent1000 has O
sent1000 a O
sent1000 significantly O
sent1000 lower O
sent1000 yield O
sent1000 compared O
sent1000 to O
sent1000 TESE O
sent1001 Performance O
sent1001 of O
sent1001 ICSI O
sent1001 with O
sent1001 testicular O
sent1001 sperm O
sent1001 in O
sent1001 these O
sent1001 cases O
sent1001 resulted O
sent1001 in O
sent1001 satisfactory O
sent1001 fertilization O
sent1001 and O
sent1001 high O
sent1001 embryo O
sent1001 transfer O
sent1001 rates O
sent1002 The O
sent1002 implantation O
sent1002 and O
sent1002 pregnancy O
sent1002 rates O
sent1002 per O
sent1002 embryo O
sent1002 transfer O
sent1002 were O
sent1002 13 O
sent1002 and O
sent1002 29 O
sent1002 % O
sent1002 respectively O
sent1003 Neither O
sent1003 serum O
sent1003 FSH O
sent1003 values O
sent1003 nor O
sent1003 testicular O
sent1003 size O
sent1003 were O
sent1003 predictive O
sent1003 of O
sent1003 the O
sent1003 chances O
sent1003 to O
sent1003 find O
sent1003 spermatozoa O
sent1003 for O
sent1003 ICSI O
sent1004 Some O
sent1004 complications O
sent1004 may O
sent1004 occur O
sent1004 even O
sent1004 following O
sent1004 TEFNA T
sent1005 Cyclin O
sent1005 D1 O
sent1005 , O
sent1005 the O
sent1005 regulatory O
sent1005 subunit O
sent1005 of O
sent1005 certain O
sent1005 protein O
sent1005 kinases O
sent1005 thought O
sent1005 to O
sent1005 advance O
sent1005 the O
sent1005 G1 O
sent1005 phase O
sent1005 of O
sent1005 the O
sent1005 cell O
sent1005 cycle O
sent1005 , O
sent1005 is O
sent1005 now O
sent1005 established O
sent1005 as O
sent1005 a O
sent1005 proto-oncogene O
sent1005 , O
sent1005 with O
sent1005 evidence O
sent1005 indicating O
sent1005 that O
sent1005 its O
sent1005 derangement O
sent1005 may O
sent1005 contribute O
sent1005 to O
sent1005 the O
sent1005 uncontrolled O
sent1005 cell O
sent1005 growth O
sent1005 characteristic O
sent1005 of O
sent1005 tumors D
sent1006 The O
sent1006 chromosomal O
sent1006 translocation O
sent1006 t O
sent1006 ( O
sent1006 11 O
sent1006 ; O
sent1006 14 O
sent1006 ) O
sent1006 ( O
sent1006 q13 O
sent1006 : O
sent1006 q32 O
sent1006 ) O
sent1006 , O
sent1006 involving O
sent1006 rearrangement O
sent1006 of O
sent1006 the O
sent1006 BCL-1 O
sent1006 locus O
sent1006 , O
sent1006 is O
sent1006 closely O
sent1006 associated O
sent1006 with O
sent1006 human D
sent1006 lymphoid D
sent1006 neoplasia D
sent1006 affecting O
sent1006 mantle D
sent1006 cell D
sent1006 lymphomas D
sent1006 ( D
sent1006 MCL D
sent1006 ) D
sent1007 Recently O
sent1007 , O
sent1007 the O
sent1007 putative O
sent1007 BCL-1 O
sent1007 proto-oncogene O
sent1007 turned O
sent1007 out O
sent1007 to O
sent1007 be O
sent1007 none O
sent1007 other O
sent1007 than O
sent1007 the O
sent1007 cyclin O
sent1007 D1 O
sent1007 gene O
sent1008 Although O
sent1008 the O
sent1008 observed O
sent1008 break O
sent1008 points O
sent1008 in O
sent1008 the O
sent1008 BCL-1 O
sent1008 locus O
sent1008 are O
sent1008 not O
sent1008 tightly O
sent1008 clustered O
sent1008 , O
sent1008 its O
sent1008 rearrangement O
sent1008 has O
sent1008 been O
sent1008 documented O
sent1008 in O
sent1008 40-70 O
sent1008 % O
sent1008 of O
sent1008 cases O
sent1008 of O
sent1008 mantle D
sent1008 cell D
sent1008 lymphoma D
sent1008 , O
sent1008 whereas O
sent1008 it O
sent1008 only O
sent1008 rarely O
sent1008 occurs O
sent1008 in O
sent1008 other O
sent1008 B D
sent1008 cell D
sent1008 lymphomas D
sent1009 Of O
sent1009 note O
sent1009 , O
sent1009 all O
sent1009 of O
sent1009 the O
sent1009 known O
sent1009 break O
sent1009 points O
sent1009 leave O
sent1009 the O
sent1009 cyclin O
sent1009 D1 O
sent1009 coding O
sent1009 region O
sent1009 structurally O
sent1009 intact O
sent1009 and O
sent1009 result O
sent1009 in O
sent1009 increased O
sent1009 protein O
sent1009 expression O
sent1009 , O
sent1009 implying O
sent1009 that O
sent1009 this O
sent1009 may O
sent1009 provide O
sent1009 a O
sent1009 highly O
sent1009 sensitive O
sent1009 and O
sent1009 specific O
sent1009 marker O
sent1009 for O
sent1009 MCL D
sent1010 Recent O
sent1010 studies O
sent1010 demonstrated O
sent1010 that O
sent1010 immunohistochemical O
sent1010 detection O
sent1010 in O
sent1010 paraffin-embedded O
sent1010 material O
sent1010 , O
sent1010 using O
sent1010 a O
sent1010 monoclonal O
sent1010 antibody O
sent1010 , O
sent1010 is O
sent1010 very O
sent1010 useful O
sent1010 for O
sent1010 routine O
sent1010 diagnosis O
sent1011 Current O
sent1011 knowledge O
sent1011 of O
sent1011 cyclin O
sent1011 D1 O
sent1011 overexpression O
sent1011 in O
sent1011 malignant D
sent1011 lymphomas D
sent1011 , O
sent1011 with O
sent1011 emphasis O
sent1011 on O
sent1011 its O
sent1011 clinicopathologic O
sent1011 significance O
sent1011 , O
sent1011 is O
sent1011 reviewed O
sent1012 In O
sent1012 the O
sent1012 mammalian O
sent1012 central O
sent1012 nervous O
sent1012 system O
sent1012 , O
sent1012 a O
sent1012 diverse O
sent1012 group O
sent1012 of O
sent1012 basic O
sent1012 helix-loop-helix O
sent1012 ( O
sent1012 bHLH O
sent1012 ) O
sent1012 proteins O
sent1012 is O
sent1012 involved O
sent1012 in O
sent1012 the O
sent1012 determination O
sent1012 of O
sent1012 progenitor O
sent1012 cells O
sent1012 and O
sent1012 , O
sent1012 subsequently O
sent1012 , O
sent1012 in O
sent1012 regulating O
sent1012 neuronal O
sent1012 differentiation O
sent1013 Here O
sent1013 we O
sent1013 report O
sent1013 the O
sent1013 identification O
sent1013 of O
sent1013 a O
sent1013 novel O
sent1013 subfamily O
sent1013 of O
sent1013 bHLH O
sent1013 proteins O
sent1013 , O
sent1013 defined O
sent1013 by O
sent1013 two O
sent1013 mammalian O
sent1013 enhancer-of-split- O
sent1013 and O
sent1013 hairy-related O
sent1013 proteins O
sent1013 , O
sent1013 termed O
sent1013 SHARP-1 O
sent1013 and O
sent1013 SHARP-2 O
sent1014 In O
sent1014 contrast O
sent1014 to O
sent1014 known O
sent1014 bHLH O
sent1014 genes O
sent1014 , O
sent1014 detectable O
sent1014 transcription O
sent1014 of O
sent1014 SHARP O
sent1014 genes O
sent1014 begins O
sent1014 at O
sent1014 the O
sent1014 end O
sent1014 of O
sent1014 embryonic O
sent1014 development O
sent1014 marking O
sent1014 differentiated O
sent1014 neurons O
sent1014 that O
sent1014 have O
sent1014 reached O
sent1014 a O
sent1014 final O
sent1014 position O
sent1014 , O
sent1014 and O
sent1014 increases O
sent1014 as O
sent1014 postnatal O
sent1014 development O
sent1014 proceeds O
sent1015 In O
sent1015 the O
sent1015 adult O
sent1015 , O
sent1015 SHARP O
sent1015 genes O
sent1015 are O
sent1015 expressed O
sent1015 in O
sent1015 subregions O
sent1015 of O
sent1015 the O
sent1015 CNS O
sent1015 that O
sent1015 have O
sent1015 been O
sent1015 associated O
sent1015 with O
sent1015 adult O
sent1015 plasticity O
sent1016 In O
sent1016 PC12 O
sent1016 cells O
sent1016 , O
sent1016 a O
sent1016 model O
sent1016 system O
sent1016 to O
sent1016 study O
sent1016 neurite O
sent1016 outgrowth O
sent1016 , O
sent1016 SHARP O
sent1016 genes O
sent1016 can O
sent1016 be O
sent1016 induced O
sent1016 by O
sent1016 NGF O
sent1016 with O
sent1016 the O
sent1016 kinetics O
sent1016 of O
sent1016 an O
sent1016 immediate-early O
sent1016 gene O
sent1017 Similarly O
sent1017 , O
sent1017 within O
sent1017 1 O
sent1017 h O
sent1017 after O
sent1017 the O
sent1017 administration O
sent1017 of O
sent1017 kainic O
sent1017 acid O
sent1017 in O
sent1017 vivo O
sent1017 , O
sent1017 SHARP-2 O
sent1017 is O
sent1017 induced O
sent1017 in O
sent1017 neurons O
sent1017 throughout O
sent1017 the O
sent1017 rat O
sent1017 cerebral O
sent1017 cortex O
sent1018 This O
sent1018 suggests O
sent1018 that O
sent1018 neuronal O
sent1018 bHLH O
sent1018 proteins O
sent1018 are O
sent1018 also O
sent1018 involved O
sent1018 in O
sent1018 the O
sent1018 `` O
sent1018 adaptive O
sent1018 '' O
sent1018 changes O
sent1018 of O
sent1018 mature O
sent1018 CNS O
sent1018 neurons O
sent1018 which O
sent1018 are O
sent1018 coupled O
sent1018 to O
sent1018 glutamatergic O
sent1018 stimulation O
sent1019 The O
sent1019 embryonic O
sent1019 development O
sent1019 of O
sent1019 the O
sent1019 face O
sent1019 has O
sent1019 been O
sent1019 studied O
sent1019 in O
sent1019 many O
sent1019 reviews O
sent1019 , O
sent1019 this O
sent1019 work O
sent1019 purposes O
sent1019 only O
sent1019 to O
sent1019 clear O
sent1019 up O
sent1019 some O
sent1019 points O
sent1019 which O
sent1019 remain O
sent1019 obscure O
sent1019 concerning O
sent1019 cervico-facial O
sent1019 morphogenesis O
sent1020 In O
sent1020 the O
sent1020 first O
sent1020 part O
sent1020 of O
sent1020 this O
sent1020 study O
sent1020 only O
sent1020 the O
sent1020 facial O
sent1020 development O
sent1020 , O
sent1020 properly O
sent1020 speaking O
sent1020 , O
sent1020 is O
sent1020 considered O
sent1020 , O
sent1020 although O
sent1020 it O
sent1020 can O
sent1020 not O
sent1020 be O
sent1020 separate O
sent1020 of O
sent1020 cervical O
sent1020 development O
sent1020 to O
sent1020 which O
sent1020 a O
sent1020 second O
sent1020 study O
sent1020 will O
sent1020 be O
sent1020 reserved O
sent1021 In O
sent1021 the O
sent1021 present O
sent1021 study O
sent1021 we O
sent1021 recall O
sent1021 the O
sent1021 particular O
sent1021 aspects O
sent1021 of O
sent1021 the O
sent1021 neurulation O
sent1021 in O
sent1021 the O
sent1021 cephalic O
sent1021 area O
sent1021 , O
sent1021 then O
sent1021 the O
sent1021 establishment O
sent1021 of O
sent1021 the O
sent1021 facial O
sent1021 processes O
sent1022 Then O
sent1022 we O
sent1022 approach O
sent1022 among O
sent1022 other O
sent1022 things O
sent1022 the O
sent1022 way O
sent1022 to O
sent1022 consider O
sent1022 the O
sent1022 maxillary O
sent1022 process O
sent1022 with O
sent1022 regard O
sent1022 to O
sent1022 the O
sent1022 other O
sent1022 facial O
sent1022 processes O
sent1023 After O
sent1023 is O
sent1023 considered O
sent1023 constitution O
sent1023 and O
sent1023 natured O
sent1023 of O
sent1023 the O
sent1023 prechordal O
sent1023 plate O
sent1023 which O
sent1023 has O
sent1023 been O
sent1023 diversely O
sent1023 explained O
sent1024 Finally O
sent1024 , O
sent1024 the O
sent1024 modelling O
sent1024 of O
sent1024 the O
sent1024 face O
sent1024 is O
sent1024 evocated O
sent1024 , O
sent1024 in O
sent1024 which O
sent1024 the O
sent1024 dissociation O
sent1024 between O
sent1024 the O
sent1024 olfactive O
sent1024 and O
sent1024 buccal O
sent1024 spheres O
sent1024 is O
sent1024 pointed O
sent1024 out O
sent1024 , O
sent1024 with O
sent1024 the O
sent1024 disparition O
sent1024 of O
sent1024 the O
sent1024 muzzle O
sent1024 , O
sent1024 as O
sent1024 it O
sent1024 is O
sent1024 established O
sent1024 in O
sent1024 the O
sent1024 haplorhinae O
sent1024 , O
sent1024 a O
sent1024 class O
sent1024 of O
sent1024 primates O
sent1024 in O
sent1024 which O
sent1024 the O
sent1024 human O
sent1024 being O
sent1024 is O
sent1024 involved O
sent1025 This O
sent1025 phenomenon O
sent1025 raises O
sent1025 different O
sent1025 questions O
sent1025 , O
sent1025 in O
sent1025 particular O
sent1025 about O
sent1025 the O
sent1025 relation O
sent1025 of O
sent1025 this O
sent1025 disposition O
sent1025 with O
sent1025 the O
sent1025 nasoseptal O
sent1025 center O
sent1025 , O
sent1025 the O
sent1025 medial O
sent1025 part O
sent1025 of O
sent1025 the O
sent1025 nasodorsal O
sent1025 center O
sent1026 A O
sent1026 case-control O
sent1026 study O
sent1026 was O
sent1026 performed O
sent1026 in O
sent1026 eight O
sent1026 pairs O
sent1026 of O
sent1026 women O
sent1026 to O
sent1026 determine O
sent1026 whether O
sent1026 preeclamptic O
sent1026 women O
sent1026 developed O
sent1026 abnormalities O
sent1026 in O
sent1026 minor O
sent1026 hemoglobins O
sent1026 , O
sent1026 glycolytic O
sent1026 enzymes O
sent1026 , O
sent1026 or O
sent1026 other O
sent1026 blood O
sent1026 components O
sent1026 that O
sent1026 might O
sent1026 provide O
sent1026 insight O
sent1026 into O
sent1026 the O
sent1026 pathophysiology O
sent1026 of O
sent1026 preeclampsia D
sent1026 , O
sent1026 or O
sent1026 that O
sent1026 in O
sent1026 combination O
sent1026 might O
sent1026 be O
sent1026 used O
sent1026 as O
sent1026 a O
sent1026 marker O
sent1026 for O
sent1026 the O
sent1026 condition O
sent1027 These O
sent1027 variables O
sent1027 and O
sent1027 standard O
sent1027 clinical O
sent1027 tests O
sent1027 were O
sent1027 analyzed O
sent1027 as O
sent1027 discriminators O
sent1027 between O
sent1027 preeclamptic O
sent1027 and O
sent1027 control O
sent1027 women O
sent1028 The O
sent1028 subjects O
sent1028 were O
sent1028 matched O
sent1028 for O
sent1028 age O
sent1028 , O
sent1028 ethnicity O
sent1028 , O
sent1028 parity O
sent1028 , O
sent1028 and O
sent1028 gestational O
sent1028 age O
sent1029 Blood O
sent1029 samples O
sent1029 were O
sent1029 taken O
sent1029 at O
sent1029 the O
sent1029 time O
sent1029 of O
sent1029 diagnosis O
sent1029 of O
sent1029 preeclampsia D
sent1029 and O
sent1029 at O
sent1029 comparable O
sent1029 gestational O
sent1029 ages O
sent1029 for O
sent1029 matched O
sent1029 normal O
sent1029 controls O
sent1030 Variables O
sent1030 differing O
sent1030 significantly O
sent1030 between O
sent1030 groups O
sent1030 included O
sent1030 increases O
sent1030 in O
sent1030 uric O
sent1030 acid O
sent1030 ( O
sent1030 UA O
sent1030 ) O
sent1030 , O
sent1030 low-density O
sent1030 lipoproteins O
sent1030 ( O
sent1030 LDL O
sent1030 ) O
sent1030 , O
sent1030 phosphoglycerate O
sent1030 kinase O
sent1030 ( O
sent1030 PGK O
sent1030 ) O
sent1030 , O
sent1030 and O
sent1030 mean O
sent1030 platelet O
sent1030 volume O
sent1030 ( O
sent1030 MPV O
sent1030 ) O
sent1030 , O
sent1030 and O
sent1030 decreases O
sent1030 in O
sent1030 glyceraldehyde O
sent1030 phosphate O
sent1030 dehydrogenase O
sent1030 ( O
sent1030 G3PD O
sent1030 ) O
sent1030 in O
sent1030 preeclamptic O
sent1030 women O
sent1030 compared O
sent1030 to O
sent1030 normal O
sent1030 controls O
sent1031 Discriminant O
sent1031 analysis O
sent1031 revealed O
sent1031 the O
sent1031 following O
sent1031 function O
sent1031 to O
sent1031 separate O
sent1031 the O
sent1031 groups O
sent1031 : O
sent1031 0.7764 O
sent1031 ( O
sent1031 UA O
sent1031 ) O
sent1031 + O
sent1031 0.8086 O
sent1031 ( O
sent1031 PGK O
sent1031 ) O
sent1031 -0.7032 O
sent1031 ( O
sent1031 G3PD O
sent1031 ) O
sent1031 + O
sent1031 0.1399 O
sent1031 ( O
sent1031 LDL O
sent1031 ) O
sent1031 -0.2386 O
sent1031 ( O
sent1031 MPV O
sent1031 ) O
sent1032 A O
sent1032 discriminant O
sent1032 score O
sent1032 of O
sent1032 > O
sent1032 or O
sent1032 = O
sent1032 275 O
sent1032 indicated O
sent1032 a O
sent1032 > O
sent1032 or O
sent1032 = O
sent1032 90 O
sent1032 % O
sent1032 probability O
sent1032 of O
sent1032 preeclampsia D
sent1033 The O
sent1033 results O
sent1033 are O
sent1033 consistent O
sent1033 with O
sent1033 perturbations O
sent1033 in O
sent1033 red O
sent1033 cell O
sent1033 glycolysis O
sent1033 in O
sent1033 preeclampsia D
sent1034 Further O
sent1034 prospective O
sent1034 studies O
sent1034 are O
sent1034 warranted O
sent1034 to O
sent1034 test O
sent1034 the O
sent1034 efficacy O
sent1034 of O
sent1034 this O
sent1034 discriminant O
sent1034 function O
sent1034 in O
sent1034 predicting O
sent1034 preeclampsia D
sent1035 A O
sent1035 novel O
sent1035 technique O
sent1035 for O
sent1035 patterning O
sent1035 immobilized O
sent1035 antibody O
sent1035 layers O
sent1035 based O
sent1035 upon O
sent1035 photolithography O
sent1035 and O
sent1035 oxygen O
sent1035 plasma O
sent1035 exposure O
sent1035 has O
sent1035 been O
sent1035 developed O
sent1036 Mouse O
sent1036 monoclonal O
sent1036 antibodies O
sent1036 specific O
sent1036 for O
sent1036 thiabendazole T
sent1036 ( O
sent1036 a O
sent1036 post-harvest O
sent1036 fungicide O
sent1036 and O
sent1036 veterinary O
sent1036 anthelmintic O
sent1036 ) O
sent1036 were O
sent1036 covalently O
sent1036 linked O
sent1036 through O
sent1036 free O
sent1036 amine O
sent1036 groups O
sent1036 to O
sent1036 aminosilanized O
sent1036 silicon O
sent1036 dioxide O
sent1036 films O
sent1036 using O
sent1036 glutaraldehyde O
sent1037 Immobilized O
sent1037 antibody O
sent1037 layers O
sent1037 were O
sent1037 stabilized O
sent1037 with O
sent1037 sucrose O
sent1037 , O
sent1037 dehydrated O
sent1037 , O
sent1037 and O
sent1037 stored O
sent1037 refrigerated O
sent1037 with O
sent1037 desiccant O
sent1038 Photolithographic O
sent1038 patterning O
sent1038 was O
sent1038 performed O
sent1038 with O
sent1038 a O
sent1038 positive O
sent1038 photoresist O
sent1038 with O
sent1038 modified O
sent1038 bake O
sent1038 temperatures O
sent1038 and O
sent1038 times O
sent1038 , O
sent1038 selective O
sent1038 UV O
sent1038 exposure O
sent1038 with O
sent1038 a O
sent1038 contact O
sent1038 mask O
sent1038 , O
sent1038 and O
sent1038 aqueous O
sent1038 alkaline O
sent1038 solubilization O
sent1038 of O
sent1038 exposed O
sent1038 resist O
sent1039 Exposed O
sent1039 regions O
sent1039 of O
sent1039 immobilized O
sent1039 antibody O
sent1039 were O
sent1039 then O
sent1039 removed O
sent1039 by O
sent1039 exposure O
sent1039 to O
sent1039 a O
sent1039 low O
sent1039 power O
sent1039 , O
sent1039 radio O
sent1039 frequency O
sent1039 oxygen O
sent1039 discharge O
sent1040 Residual O
sent1040 resist O
sent1040 was O
sent1040 stripped O
sent1040 with O
sent1040 acetone O
sent1041 Successful O
sent1041 patterning O
sent1041 was O
sent1041 demonstrated O
sent1041 by O
sent1041 challenging O
sent1041 surfaces O
sent1041 with O
sent1041 goat O
sent1041 anti-mouse O
sent1041 antibody O
sent1041 conjugated O
sent1041 to O
sent1041 tetramethylrhodamine O
sent1041 isothiocyanate O
sent1042 Sucrose O
sent1042 stabilization O
sent1042 was O
sent1042 necessary O
sent1042 for O
sent1042 antibody O
sent1042 to O
sent1042 undergo O
sent1042 photoresist O
sent1042 processing O
sent1042 without O
sent1042 loss O
sent1042 of O
sent1042 binding O
sent1042 activity O
sent1043 Challenge O
sent1043 with O
sent1043 enzyme O
sent1043 linked O
sent1043 antigen O
sent1043 of O
sent1043 oxygen O
sent1043 plasma O
sent1043 exposed O
sent1043 antibody O
sent1043 layers O
sent1043 demonstrated O
sent1043 that O
sent1043 plasma O
sent1043 treatment O
sent1043 completely O
sent1043 neutralized O
sent1043 antibody O
sent1043 capture O
sent1043 ability O
sent1044 Ellipsometry O
sent1044 measurements O
sent1044 of O
sent1044 oxygen O
sent1044 plasma O
sent1044 exposed O
sent1044 antibody O
sent1044 layers O
sent1044 indicated O
sent1044 complete O
sent1044 removal O
sent1044 of O
sent1044 immobilized O
sent1044 antibodies O
sent1045 Fluorescent O
sent1045 imaging O
sent1045 demonstrated O
sent1045 smallest O
sent1045 line O
sent1045 widths O
sent1045 of O
sent1045 2-3 O
sent1045 microns O
sent1046 Immune O
sent1046 cells O
sent1046 in O
sent1046 vivo O
sent1046 routinely O
sent1046 perform O
sent1046 highly O
sent1046 selective O
sent1046 immunosensing O
sent1046 in O
sent1046 blood O
sent1046 and O
sent1046 tissues O
sent1046 as O
sent1046 part O
sent1046 of O
sent1046 their O
sent1046 normal O
sent1046 immune O
sent1046 surveillance O
sent1046 functions O
sent1047 We O
sent1047 have O
sent1047 been O
sent1047 investigating O
sent1047 the O
sent1047 potential O
sent1047 of O
sent1047 exploiting O
sent1047 the O
sent1047 immunosensing O
sent1047 detection O
sent1047 abilities O
sent1047 of O
sent1047 excitable O
sent1047 immune O
sent1047 cells O
sent1047 ( O
sent1047 i.e O
sent1047 . O
sent1047 the O
sent1047 mast O
sent1047 cell O
sent1047 ) O
sent1047 for O
sent1047 the O
sent1047 development O
sent1047 of O
sent1047 whole O
sent1047 cell O
sent1047 immunobiosensors O
sent1048 A O
sent1048 key O
sent1048 feature O
sent1048 is O
sent1048 that O
sent1048 these O
sent1048 immune O
sent1048 cells O
sent1048 can O
sent1048 be O
sent1048 selectively O
sent1048 engineered O
sent1048 to O
sent1048 recognize O
sent1048 specific O
sent1048 antigens O
sent1048 in O
sent1048 vitro O
sent1049 In O
sent1049 the O
sent1049 presence O
sent1049 of O
sent1049 antigen O
sent1049 , O
sent1049 these O
sent1049 cells O
sent1049 undergo O
sent1049 excitable O
sent1049 activation O
sent1049 responses O
sent1049 which O
sent1049 result O
sent1049 in O
sent1049 increased O
sent1049 metabolism O
sent1049 and O
sent1049 the O
sent1049 exocytosis O
sent1049 of O
sent1049 stored O
sent1049 intracellular O
sent1049 mediators O
sent1050 We O
sent1050 have O
sent1050 previously O
sent1050 determined O
sent1050 that O
sent1050 mast O
sent1050 cell O
sent1050 metabolic O
sent1050 responses O
sent1050 can O
sent1050 be O
sent1050 thermally O
sent1050 transduced O
sent1050 in O
sent1050 real O
sent1050 time O
sent1050 , O
sent1050 thus O
sent1050 indicating O
sent1050 the O
sent1050 possibility O
sent1050 of O
sent1050 whole O
sent1050 cell O
sent1050 thermoelectric O
sent1050 immunobiosensing O
sent1051 In O
sent1051 this O
sent1051 work O
sent1051 we O
sent1051 investigated O
sent1051 the O
sent1051 use O
sent1051 of O
sent1051 enzyme O
sent1051 amplification O
sent1051 systems O
sent1051 to O
sent1051 enhance O
sent1051 the O
sent1051 direct O
sent1051 transduction O
sent1051 of O
sent1051 immune O
sent1051 cell O
sent1051 responses O
sent1051 to O
sent1051 analyte O
sent1052 It O
sent1052 was O
sent1052 found O
sent1052 that O
sent1052 with O
sent1052 appropriate O
sent1052 enzymes O
sent1052 , O
sent1052 peak O
sent1052 outputs O
sent1052 occurred O
sent1052 within O
sent1052 approximately O
sent1052 5 O
sent1052 min O
sent1052 ( O
sent1052 4-20 O
sent1052 times O
sent1052 faster O
sent1052 than O
sent1052 without O
sent1052 enzymes O
sent1052 ) O
sent1052 and O
sent1052 peak O
sent1052 response O
sent1052 magnitudes O
sent1052 were O
sent1052 up O
sent1052 to O
sent1052 nine-fold O
sent1052 greater O
sent1052 than O
sent1052 without O
sent1052 enzymes O
sent1053 An O
sent1053 easy-to-use O
sent1053 technique O
sent1053 for O
sent1053 detection O
sent1053 of O
sent1053 antibodies O
sent1053 specific O
sent1053 for O
sent1053 the O
sent1053 parasite O
sent1053 L. O
sent1053 donovani O
sent1053 in O
sent1053 human O
sent1053 serum O
sent1053 sample O
sent1053 has O
sent1053 been O
sent1053 developed O
sent1054 The O
sent1054 method O
sent1054 is O
sent1054 based O
sent1054 on O
sent1054 an O
sent1054 evanescent O
sent1054 wave O
sent1054 generated O
sent1054 from O
sent1054 a O
sent1054 tapered O
sent1054 configuration O
sent1054 of O
sent1054 decladded O
sent1054 optical O
sent1054 fibre O
sent1054 and O
sent1054 does O
sent1054 not O
sent1054 require O
sent1054 any O
sent1054 volumetric O
sent1054 measurement O
sent1055 Tapered O
sent1055 fibres O
sent1055 are O
sent1055 immobilized O
sent1055 with O
sent1055 the O
sent1055 purified O
sent1055 cell O
sent1055 surface O
sent1055 protein O
sent1055 of O
sent1055 L. O
sent1055 donovani O
sent1055 by O
sent1055 covalent O
sent1055 bonding O
sent1056 Treated O
sent1056 fibres O
sent1056 are O
sent1056 incubated O
sent1056 with O
sent1056 the O
sent1056 patient O
sent1056 serum O
sent1056 for O
sent1056 10 O
sent1056 min O
sent1056 followed O
sent1056 by O
sent1056 incubation O
sent1056 with O
sent1056 goat O
sent1056 anti O
sent1056 human O
sent1056 IgG O
sent1056 tagged O
sent1056 FITC O
sent1057 Fluorescent O
sent1057 intensity O
sent1057 from O
sent1057 the O
sent1057 fibre O
sent1057 has O
sent1057 been O
sent1057 shown O
sent1057 to O
sent1057 be O
sent1057 proportional O
sent1057 to O
sent1057 L. O
sent1057 donovani O
sent1057 specific O
sent1057 antibodies O
sent1057 present O
sent1057 in O
sent1057 the O
sent1057 test O
sent1057 sera O
sent1058 Direct O
sent1058 readings O
sent1058 can O
sent1058 be O
sent1058 obtained O
sent1058 after O
sent1058 signal O
sent1058 enhancement O
sent1058 through O
sent1058 a O
sent1058 photomultiplier O
sent1058 tube O
sent1058 within O
sent1058 5 O
sent1058 min O
sent1059 The O
sent1059 system O
sent1059 , O
sent1059 when O
sent1059 tested O
sent1059 on O
sent1059 12 O
sent1059 positive O
sent1059 sera O
sent1059 , O
sent1059 did O
sent1059 not O
sent1059 show O
sent1059 any O
sent1059 false O
sent1059 negative O
sent1059 result O
sent1060 Also O
sent1060 , O
sent1060 no O
sent1060 false O
sent1060 positive O
sent1060 result O
sent1060 was O
sent1060 obtained O
sent1060 with O
sent1060 serum O
sent1060 samples O
sent1060 of O
sent1060 patients O
sent1060 infected O
sent1060 with O
sent1060 leprosy D
sent1060 , O
sent1060 tuberculosis D
sent1060 , O
sent1060 typhoid D
sent1060 and O
sent1060 malaria D
sent1060 , O
sent1060 showing O
sent1060 the O
sent1060 specificity O
sent1060 of O
sent1060 the O
sent1060 sensor O
sent1060 and O
sent1060 efficacy O
sent1060 of O
sent1060 the O
sent1060 technique O
sent1061 We O
sent1061 present O
sent1061 an O
sent1061 optical O
sent1061 biosensor O
sent1061 design O
sent1061 that O
sent1061 expands O
sent1061 the O
sent1061 utility O
sent1061 of O
sent1061 enzyme O
sent1061 biosensors O
sent1062 These O
sent1062 biosensors O
sent1062 are O
sent1062 fabricated O
sent1062 by O
sent1062 site-selective O
sent1062 photodeposition O
sent1062 of O
sent1062 analyte-sensitive O
sent1062 polymer O
sent1062 matrices O
sent1062 on O
sent1062 optical O
sent1062 imaging O
sent1062 fibres O
sent1063 These O
sent1063 dual-analyte O
sent1063 arrays O
sent1063 allow O
sent1063 for O
sent1063 the O
sent1063 simultaneous O
sent1063 , O
sent1063 independent O
sent1063 measurement O
sent1063 of O
sent1063 the O
sent1063 analyte O
sent1063 of O
sent1063 interest O
sent1063 and O
sent1063 the O
sent1063 transducing O
sent1063 analyte O
sent1064 The O
sent1064 first O
sent1064 integrated O
sent1064 optical-biosensors O
sent1064 using O
sent1064 this O
sent1064 design O
sent1064 have O
sent1064 been O
sent1064 prepared O
sent1064 that O
sent1064 allow O
sent1064 both O
sent1064 the O
sent1064 dependent O
sent1064 and O
sent1064 independent O
sent1064 analytes O
sent1064 to O
sent1064 be O
sent1064 measured O
sent1064 simultaneously O
sent1064 , O
sent1064 for O
sent1064 example O
sent1064 penicillin O
sent1064 and O
sent1064 pH O
sent1064 ( O
sent1064 Healey O
sent1064 & O
sent1064 # O
sent1064 38 O
sent1064 ; O
sent1064 Walt O
sent1064 , O
sent1064 1995 O
sent1064 ) O
sent1064 or O
sent1064 glucose O
sent1064 and O
sent1064 O2 O
sent1064 ( O
sent1064 Li O
sent1064 & O
sent1064 # O
sent1064 38 O
sent1064 ; O
sent1064 Walt O
sent1064 , O
sent1064 1995 O
sent1064 ) O
sent1065 Independent O
sent1065 measurement O
sent1065 of O
sent1065 the O
sent1065 transducing O
sent1065 analyte O
sent1065 allows O
sent1065 penicillin T
sent1065 or O
sent1065 glucose O
sent1065 to O
sent1065 be O
sent1065 quantitated O
sent1065 in O
sent1065 the O
sent1065 presence O
sent1065 of O
sent1065 a O
sent1065 concurrent O
sent1065 pH O
sent1065 or O
sent1065 O2 O
sent1065 change O
sent1065 , O
sent1065 respectively O
sent1066 Penicillin T
sent1066 can O
sent1066 be O
sent1066 measured O
sent1066 in O
sent1066 the O
sent1066 range O
sent1066 0.25-10.0 O
sent1066 mM O
sent1066 in O
sent1066 the O
sent1066 pH O
sent1066 range O
sent1066 6.2-7.5 O
sent1067 Glucose O
sent1067 can O
sent1067 be O
sent1067 measured O
sent1067 in O
sent1067 the O
sent1067 range O
sent1067 0.6-20.0 O
sent1067 mM O
sent1067 in O
sent1067 the O
sent1067 O2 O
sent1067 range O
sent1067 20-100 O
sent1067 % O
sent1068 The O
sent1068 utility O
sent1068 of O
sent1068 the O
sent1068 sensor O
sent1068 design O
sent1068 was O
sent1068 demonstrated O
sent1068 by O
sent1068 using O
sent1068 the O
sent1068 penicillin-dual-analyte O
sent1068 biosensor O
sent1068 to O
sent1068 quantitate O
sent1068 penicillin T
sent1068 produced O
sent1068 during O
sent1068 a O
sent1068 Penicillium O
sent1068 chrysogenum O
sent1068 fermentation O
sent1069 The O
sent1069 characterization O
sent1069 of O
sent1069 low O
sent1069 molecular O
sent1069 weight O
sent1069 ligand O
sent1069 interaction O
sent1069 with O
sent1069 receptor O
sent1069 molecules O
sent1069 is O
sent1069 of O
sent1069 importance O
sent1069 for O
sent1069 the O
sent1069 investigation O
sent1069 of O
sent1069 biological O
sent1069 processes O
sent1069 and O
sent1069 for O
sent1069 drug O
sent1069 research O
sent1070 We O
sent1070 report O
sent1070 on O
sent1070 the O
sent1070 investigation O
sent1070 of O
sent1070 the O
sent1070 binding O
sent1070 of O
sent1070 low O
sent1070 molecular O
sent1070 weight O
sent1070 ligands O
sent1070 to O
sent1070 immobilized O
sent1070 receptors O
sent1070 by O
sent1070 label-free O
sent1070 detection O
sent1071 Reflectometric O
sent1071 interference O
sent1071 spectroscopy O
sent1071 , O
sent1071 an O
sent1071 optical O
sent1071 transducer O
sent1071 which O
sent1071 allows O
sent1071 the O
sent1071 monitoring O
sent1071 of O
sent1071 a O
sent1071 few O
sent1071 picograms O
sent1071 per O
sent1071 square O
sent1071 millimetre O
sent1071 changes O
sent1071 in O
sent1071 surface O
sent1071 coverage O
sent1071 , O
sent1071 was O
sent1071 used O
sent1071 to O
sent1071 study O
sent1071 two O
sent1071 model O
sent1071 systems O
sent1072 In O
sent1072 both O
sent1072 cases O
sent1072 detection O
sent1072 of O
sent1072 the O
sent1072 binding O
sent1072 event O
sent1072 was O
sent1072 successful O
sent1073 High O
sent1073 affinity O
sent1073 binding O
sent1073 of O
sent1073 biotin O
sent1073 to O
sent1073 immobilized O
sent1073 streptavidin O
sent1073 was O
sent1073 clearly O
sent1073 detectable O
sent1073 at O
sent1073 receptor O
sent1073 surface O
sent1073 concentrations O
sent1073 as O
sent1073 low O
sent1073 as O
sent1073 1-2 O
sent1073 x O
sent1073 10 O
sent1073 ( O
sent1073 10 O
sent1073 ) O
sent1073 binding O
sent1073 sites/mm2 O
sent1074 Linear O
sent1074 correlation O
sent1074 between O
sent1074 the O
sent1074 receptor O
sent1074 surface O
sent1074 concentration O
sent1074 and O
sent1074 the O
sent1074 response O
sent1074 to O
sent1074 biotin O
sent1074 binding O
sent1074 was O
sent1074 observed O
sent1075 Using O
sent1075 immobilized O
sent1075 DNA O
sent1075 , O
sent1075 we O
sent1075 investigated O
sent1075 the O
sent1075 binding O
sent1075 of O
sent1075 common O
sent1075 intercalators O
sent1075 with O
sent1075 respect O
sent1075 to O
sent1075 kinetics O
sent1075 and O
sent1075 thermodynamics O
sent1075 by O
sent1075 evaluation O
sent1075 of O
sent1075 the O
sent1075 association O
sent1075 and O
sent1075 the O
sent1075 dissociation O
sent1075 part O
sent1075 of O
sent1075 the O
sent1075 binding O
sent1075 curve O
sent1076 Bi-exponential O
sent1076 increase O
sent1076 and O
sent1076 decrease O
sent1076 of O
sent1076 intercalator O
sent1076 loading O
sent1076 was O
sent1076 observed O
sent1076 , O
sent1076 indicating O
sent1076 complex O
sent1076 interaction O
sent1076 kinetics O
sent1077 The O
sent1077 four O
sent1077 structurally O
sent1077 different O
sent1077 intercalators O
sent1077 showed O
sent1077 significant O
sent1077 distinction O
sent1077 in O
sent1077 binding O
sent1077 kinetics O
sent1077 and O
sent1077 equilibrium O
sent1077 signals O
sent1078 Improvement O
sent1078 of O
sent1078 experimental O
sent1078 parameters O
sent1078 is O
sent1078 required O
sent1078 to O
sent1078 obtain O
sent1078 more O
sent1078 reliable O
sent1078 kinetic O
sent1078 data O
sent1079 An O
sent1079 amperometric O
sent1079 lactate O
sent1079 oxidase O
sent1079 catheter O
sent1079 has O
sent1079 been O
sent1079 developed O
sent1079 for O
sent1079 in O
sent1079 vivo O
sent1079 application O
sent1079 to O
sent1079 real-time O
sent1079 lactate O
sent1079 monitoring O
sent1080 The O
sent1080 electrochemical O
sent1080 behaviour O
sent1080 of O
sent1080 the O
sent1080 1 O
sent1080 x O
sent1080 3 O
sent1080 mm O
sent1080 Pt-Ag/AgCl O
sent1080 thin O
sent1080 film O
sent1080 electrode O
sent1080 is O
sent1080 not O
sent1080 significantly O
sent1080 influenced O
sent1080 by O
sent1080 lactate O
sent1080 oxidase-polyurethane O
sent1080 covering O
sent1081 Gamma-irradiation O
sent1081 ( O
sent1081 25 O
sent1081 kGy O
sent1081 ) O
sent1081 is O
sent1081 suitable O
sent1081 for O
sent1081 the O
sent1081 sterilization O
sent1081 procedure O
sent1082 The O
sent1082 final O
sent1082 lactate O
sent1082 catheter O
sent1082 is O
sent1082 characterized O
sent1082 by O
sent1082 a O
sent1082 linear O
sent1082 concentration O
sent1082 range O
sent1082 between O
sent1082 0.5 O
sent1082 and O
sent1082 20 O
sent1082 mmol/l O
sent1082 lactate O
sent1082 with O
sent1082 a O
sent1082 sensitivity O
sent1082 around O
sent1082 2 O
sent1082 nA O
sent1082 mmol-1 O
sent1082 l-1 O
sent1082 lactate O
sent1083 The O
sent1083 accuracy O
sent1083 is O
sent1083 demonstrated O
sent1083 by O
sent1083 the O
sent1083 measurement O
sent1083 of O
sent1083 control O
sent1083 sera O
sent1084 Both O
sent1084 physiological O
sent1084 and O
sent1084 pathological O
sent1084 materials O
sent1084 correlate O
sent1084 well O
sent1084 with O
sent1084 the O
sent1084 declared O
sent1084 values O
sent1085 The O
sent1085 dry O
sent1085 stored O
sent1085 lactate O
sent1085 catheter O
sent1085 needs O
sent1085 about O
sent1085 10 O
sent1085 min O
sent1085 for O
sent1085 hydration O
sent1085 and O
sent1085 is O
sent1085 characterized O
sent1085 by O
sent1085 response O
sent1085 times O
sent1085 t98 O
sent1085 % O
sent1085 of O
sent1085 less O
sent1085 than O
sent1085 2 O
sent1085 min O
sent1086 Ex O
sent1086 vivo O
sent1086 whole O
sent1086 blood O
sent1086 measurements O
sent1086 using O
sent1086 the O
sent1086 lactate O
sent1086 catheter O
sent1086 ( O
sent1086 y O
sent1086 ) O
sent1086 give O
sent1086 a O
sent1086 correlation O
sent1086 with O
sent1086 the O
sent1086 BIOSEN O
sent1086 Med O
sent1086 L O
sent1086 ( O
sent1086 x O
sent1086 ) O
sent1086 of O
sent1086 y O
sent1086 = O
sent1086 ( O
sent1086 1.010x O
sent1086 + O
sent1086 0.513 O
sent1086 ) O
sent1086 mmol/l O
sent1086 ( O
sent1086 r O
sent1086 = O
sent1086 0.9748 O
sent1086 ) O
sent1087 Lactate O
sent1087 values O
sent1087 obtained O
sent1087 by O
sent1087 continuous O
sent1087 catheter O
sent1087 operation O
sent1087 ex O
sent1087 vivo O
sent1087 correlate O
sent1087 well O
sent1087 with O
sent1087 those O
sent1087 obtained O
sent1087 by O
sent1087 BIOSEN O
sent1087 Med O
sent1087 L. O
sent1087 First O
sent1087 subcutaneous O
sent1087 implantation O
sent1087 ( O
sent1087 dog O
sent1087 ) O
sent1087 underlines O
sent1087 the O
sent1087 characteristics O
sent1087 obtained O
sent1087 ex O
sent1087 vivo O
sent1087 : O
sent1087 after O
sent1087 30 O
sent1087 min O
sent1087 hydration O
sent1087 the O
sent1087 lactate O
sent1087 catheter O
sent1087 follows O
sent1087 the O
sent1087 lactate O
sent1087 concentration O
sent1087 measured O
sent1087 ex O
sent1087 vivo O
sent1087 with O
sent1087 samples O
sent1087 from O
sent1087 the O
sent1087 leg O
sent1087 vein O
sent1087 by O
sent1087 BIOSEN O
sent1087 Med O
sent1087 L. O
sent1088 The O
sent1088 diffusion-limited O
sent1088 binding O
sent1088 kinetics O
sent1088 of O
sent1088 antigen O
sent1088 ( O
sent1088 or O
sent1088 antibody O
sent1088 ) O
sent1088 in O
sent1088 solution O
sent1088 to O
sent1088 antibody O
sent1088 ( O
sent1088 or O
sent1088 antigen O
sent1088 ) O
sent1088 immobilized O
sent1088 on O
sent1088 a O
sent1088 biosensor O
sent1088 and O
sent1088 other O
sent1088 surfaces O
sent1088 is O
sent1088 analyzed O
sent1088 within O
sent1088 a O
sent1088 fractal O
sent1088 framework O
sent1089 Often O
sent1089 , O
sent1089 the O
sent1089 binding O
sent1089 kinetics O
sent1089 may O
sent1089 be O
sent1089 described O
sent1089 by O
sent1089 a O
sent1089 single-fractal O
sent1089 analysis O
sent1090 In O
sent1090 some O
sent1090 cases O
sent1090 , O
sent1090 the O
sent1090 binding O
sent1090 curve O
sent1090 exhibits O
sent1090 complexities O
sent1091 Then O
sent1091 , O
sent1091 for O
sent1091 these O
sent1091 cases O
sent1091 , O
sent1091 the O
sent1091 dual-fractal O
sent1091 analysis O
sent1091 provides O
sent1091 an O
sent1091 improved O
sent1091 fit O
sent1091 when O
sent1091 compared O
sent1091 with O
sent1091 a O
sent1091 single-fractal O
sent1091 analysis O
sent1092 This O
sent1092 indicates O
sent1092 a O
sent1092 change O
sent1092 in O
sent1092 the O
sent1092 reaction O
sent1092 mechanism O
sent1092 on O
sent1092 the O
sent1092 surface O
sent1093 It O
sent1093 is O
sent1093 of O
sent1093 interest O
sent1093 to O
sent1093 note O
sent1093 that O
sent1093 the O
sent1093 state O
sent1093 of O
sent1093 disorder O
sent1093 ( O
sent1093 or O
sent1093 the O
sent1093 fractal O
sent1093 dimension O
sent1093 ) O
sent1093 and O
sent1093 the O
sent1093 binding O
sent1093 rate O
sent1093 coefficient O
sent1093 both O
sent1093 increase O
sent1093 as O
sent1093 the O
sent1093 reaction O
sent1093 progresses O
sent1093 on O
sent1093 the O
sent1093 biosensor O
sent1093 surface O
sent1094 For O
sent1094 example O
sent1094 , O
sent1094 for O
sent1094 the O
sent1094 binding O
sent1094 of O
sent1094 10 O
sent1094 nM O
sent1094 insulin O
sent1094 growth O
sent1094 factor-1 O
sent1094 in O
sent1094 solution O
sent1094 to O
sent1094 insulin O
sent1094 growth O
sent1094 factor O
sent1094 binding O
sent1094 protein-1 O
sent1094 immobilized O
sent1094 on O
sent1094 a O
sent1094 biosensor O
sent1094 surface O
sent1094 , O
sent1094 a O
sent1094 64 O
sent1094 % O
sent1094 increase O
sent1094 in O
sent1094 the O
sent1094 fractal O
sent1094 dimension O
sent1094 from O
sent1094 1.73 O
sent1094 ( O
sent1094 Df1 O
sent1094 ) O
sent1094 to O
sent1094 2.85 O
sent1094 ( O
sent1094 Df2 O
sent1094 ) O
sent1094 leads O
sent1094 to O
sent1094 an O
sent1094 increase O
sent1094 in O
sent1094 the O
sent1094 binding O
sent1094 rate O
sent1094 coefficient O
sent1094 by O
sent1094 a O
sent1094 factor O
sent1094 of O
sent1094 31.8 O
sent1094 from O
sent1094 3.92 O
sent1094 ( O
sent1094 k1 O
sent1094 ) O
sent1094 to O
sent1094 125 O
sent1094 ( O
sent1094 k2 O
sent1094 ) O
sent1095 Furthermore O
sent1095 , O
sent1095 as O
sent1095 the O
sent1095 IGF-1 O
sent1095 concentration O
sent1095 in O
sent1095 solution O
sent1095 increases O
sent1095 from O
sent1095 10 O
sent1095 to O
sent1095 80 O
sent1095 nM O
sent1095 in O
sent1095 solution O
sent1095 , O
sent1095 k2 O
sent1095 and O
sent1095 Df2 O
sent1095 exhibit O
sent1095 a O
sent1095 linear O
sent1095 increase O
sent1096 k1 O
sent1096 and O
sent1096 Df1 O
sent1096 exhibit O
sent1096 a O
sent1096 linear O
sent1096 increase O
sent1096 with O
sent1096 the O
sent1096 reciprocal O
sent1096 of O
sent1096 the O
sent1096 IGF-1 O
sent1096 concentration O
sent1096 in O
sent1096 solution O
sent1097 The O
sent1097 different O
sent1097 examples O
sent1097 analyzed O
sent1097 and O
sent1097 presented O
sent1097 together O
sent1097 provide O
sent1097 a O
sent1097 means O
sent1097 by O
sent1097 which O
sent1097 the O
sent1097 antigen-antibody O
sent1097 reactions O
sent1097 may O
sent1097 be O
sent1097 better O
sent1097 controlled O
sent1097 by O
sent1097 noting O
sent1097 the O
sent1097 magnitude O
sent1097 of O
sent1097 the O
sent1097 changes O
sent1097 in O
sent1097 the O
sent1097 fractal O
sent1097 dimension O
sent1097 and O
sent1097 in O
sent1097 the O
sent1097 binding O
sent1097 rate O
sent1097 coefficient O
sent1097 as O
sent1097 the O
sent1097 reaction O
sent1097 progresses O
sent1097 on O
sent1097 the O
sent1097 biosensor O
sent1097 surface O
sent1098 Also O
sent1098 , O
sent1098 the O
sent1098 magnitude O
sent1098 of O
sent1098 the O
sent1098 changes O
sent1098 in O
sent1098 the O
sent1098 binding O
sent1098 rate O
sent1098 coefficients O
sent1098 ( O
sent1098 k1 O
sent1098 and O
sent1098 k2 O
sent1098 ) O
sent1098 and O
sent1098 in O
sent1098 the O
sent1098 fractal O
sent1098 dimensions O
sent1098 ( O
sent1098 Df1 O
sent1098 and O
sent1098 Df2 O
sent1098 ) O
sent1098 as O
sent1098 different O
sent1098 parameters O
sent1098 are O
sent1098 changed O
sent1098 for O
sent1098 the O
sent1098 different O
sent1098 biosensor O
sent1098 applications O
sent1098 are O
sent1098 of O
sent1098 particular O
sent1098 value O
sent1098 , O
sent1098 since O
sent1098 they O
sent1098 provide O
sent1098 us O
sent1098 with O
sent1098 a O
sent1098 measure O
sent1098 or O
sent1098 extent O
sent1098 of O
sent1098 changes O
sent1098 in O
sent1098 the O
sent1098 binding O
sent1098 rate O
sent1098 coefficient O
sent1098 on O
sent1098 changing O
sent1098 different O
sent1098 experimental O
sent1098 parameter O
sent1098 values O
sent1099 It O
sent1099 is O
sent1099 of O
sent1099 interest O
sent1099 to O
sent1099 note O
sent1099 the O
sent1099 effect O
sent1099 of O
sent1099 different O
sent1099 parameters O
sent1099 on O
sent1099 the O
sent1099 extent O
sent1099 or O
sent1099 heterogeneity O
sent1099 that O
sent1099 exists O
sent1099 on O
sent1099 the O
sent1099 surface O
sent1099 and O
sent1099 how O
sent1099 this O
sent1099 influences O
sent1099 the O
sent1099 binding O
sent1099 rate O
sent1099 coefficients O
sent1100 This O
sent1100 may O
sent1100 be O
sent1100 one O
sent1100 method O
sent1100 to O
sent1100 help O
sent1100 manipulate O
sent1100 or O
sent1100 control O
sent1100 the O
sent1100 binding O
sent1100 rate O
sent1100 coefficients O
sent1100 on O
sent1100 the O
sent1100 reaction O
sent1100 surface O
sent1101 To O
sent1101 determine O
sent1101 if O
sent1101 microscopic O
sent1101 urinalysis O
sent1101 is O
sent1101 needed O
sent1101 in O
sent1101 all O
sent1101 pediatric O
sent1101 emergency O
sent1101 room O
sent1101 patients O
sent1101 screened O
sent1101 for O
sent1101 urinary D
sent1101 tract D
sent1101 infections D
sent1101 ( D
sent1101 UTI D
sent1101 ) D
sent1101 , O
sent1101 we O
sent1101 compared O
sent1101 the O
sent1101 dipstick O
sent1101 urinalysis O
sent1101 and O
sent1101 complete O
sent1101 urinalysis O
sent1101 ( O
sent1101 dipstick O
sent1101 and O
sent1101 microscopy O
sent1101 ) O
sent1101 with O
sent1101 urine O
sent1101 cultures O
sent1101 in O
sent1101 236 O
sent1101 children O
sent1101 , O
sent1101 aged O
sent1101 3 O
sent1101 weeks O
sent1101 to O
sent1101 21 O
sent1101 years O
sent1102 The O
sent1102 ability O
sent1102 to O
sent1102 detect O
sent1102 UTI D
sent1102 by O
sent1102 dipstick O
sent1102 only O
sent1102 and O
sent1102 by O
sent1102 complete O
sent1102 urinalysis O
sent1102 was O
sent1102 the O
sent1102 same O
sent1102 , O
sent1102 however O
sent1102 microscopic O
sent1102 evaluation O
sent1102 added O
sent1102 many O
sent1102 false-positive O
sent1102 results O
sent1102 without O
sent1102 detecting O
sent1102 additional O
sent1102 UTIs D
sent1103 Because O
sent1103 the O
sent1103 ability O
sent1103 to O
sent1103 detect O
sent1103 UTI D
sent1103 ( O
sent1103 sensitivity O
sent1103 ) O
sent1103 is O
sent1103 maintained O
sent1103 , O
sent1103 we O
sent1103 now O
sent1103 offer O
sent1103 a O
sent1103 dipstick O
sent1103 only O
sent1103 urinalysis O
sent1103 to O
sent1103 our O
sent1103 emergency O
sent1103 room O
sent1103 for O
sent1103 children O
sent1103 2 O
sent1103 years O
sent1103 of O
sent1103 age O
sent1103 or O
sent1103 older O
sent1103 , O
sent1103 with O
sent1103 a O
sent1103 microscopic O
sent1103 analysis O
sent1103 performed O
sent1103 automatically O
sent1103 if O
sent1103 dipstick O
sent1103 results O
sent1103 are O
sent1103 positive O
sent1104 If O
sent1104 no O
sent1104 microscopic O
sent1104 urinalysis O
sent1104 is O
sent1104 required O
sent1104 , O
sent1104 testing O
sent1104 turn-around O
sent1104 time O
sent1104 is O
sent1104 reduced O
sent1104 by O
sent1104 12.3 O
sent1104 min/test O
sent1104 and O
sent1104 the O
sent1104 hospital O
sent1104 charge O
sent1104 is O
sent1104 reduced O
sent1104 from O
sent1104 U.S O
sent1105 $ O
sent1105 32 O
sent1105 to O
sent1105 U.S O
sent1106 $ O
sent1106 12 O
sent1107 Using O
sent1107 video-intensified O
sent1107 fluorescence O
sent1107 microscopy O
sent1107 and O
sent1107 a O
sent1107 pseudocolor O
sent1107 display O
sent1107 of O
sent1107 fluorescence O
sent1107 intensity O
sent1107 , O
sent1107 we O
sent1107 analyzed O
sent1107 the O
sent1107 distribution O
sent1107 of O
sent1107 microinjected O
sent1107 molecules O
sent1107 within O
sent1107 the O
sent1107 nurse-cell/oocyte O
sent1107 syncytium O
sent1107 of O
sent1107 Drosophila O
sent1107 ovarian O
sent1107 follicles O
sent1108 We O
sent1108 varied O
sent1108 the O
sent1108 composition O
sent1108 and O
sent1108 the O
sent1108 osmolarity O
sent1108 of O
sent1108 the O
sent1108 culture O
sent1108 solution O
sent1108 as O
sent1108 well O
sent1108 as O
sent1108 the O
sent1108 electrical O
sent1108 charge O
sent1108 and O
sent1108 the O
sent1108 molecular O
sent1108 mass O
sent1108 of O
sent1108 the O
sent1108 microinjected O
sent1108 fluorescent O
sent1108 probe O
sent1109 As O
sent1109 culture O
sent1109 solutions O
sent1109 , O
sent1109 we O
sent1109 used O
sent1109 four O
sent1109 simple O
sent1109 salines O
sent1109 ( O
sent1109 IMADS O
sent1109 ) O
sent1109 and O
sent1109 a O
sent1109 complex O
sent1109 tissue-culture O
sent1109 medium O
sent1109 ( O
sent1109 R-14 O
sent1109 ) O
sent1109 that O
sent1109 matched O
sent1109 the O
sent1109 osmolarity O
sent1109 of O
sent1109 adult O
sent1109 hemolymph O
sent1110 Small O
sent1110 amounts O
sent1110 of O
sent1110 two O
sent1110 anionic O
sent1110 dyes O
sent1110 ( O
sent1110 Lucifer O
sent1110 Yellow O
sent1110 CH O
sent1110 and O
sent1110 Lucifer O
sent1110 Yellow O
sent1110 dextran O
sent1110 ) O
sent1110 as O
sent1110 well O
sent1110 as O
sent1110 of O
sent1110 two O
sent1110 cationic O
sent1110 dyes O
sent1110 ( O
sent1110 rhodamine O
sent1110 6G O
sent1110 and O
sent1110 tetramethylrhodamine O
sent1110 dextran-lysine O
sent1110 ) O
sent1110 were O
sent1110 iontophoretically O
sent1110 microinjected O
sent1110 either O
sent1110 into O
sent1110 a O
sent1110 nurse O
sent1110 cell O
sent1110 or O
sent1110 into O
sent1110 the O
sent1110 oocyte O
sent1110 of O
sent1110 stage-10 O
sent1110 follicles O
sent1111 In O
sent1111 the O
sent1111 tissue-culture O
sent1111 medium O
sent1111 , O
sent1111 within O
sent1111 a O
sent1111 few O
sent1111 seconds O
sent1111 following O
sent1111 microinjection O
sent1111 , O
sent1111 all O
sent1111 tested O
sent1111 dyes O
sent1111 passed O
sent1111 through O
sent1111 the O
sent1111 intercellular O
sent1111 bridges O
sent1111 in O
sent1111 both O
sent1111 the O
sent1111 anterior O
sent1111 direction O
sent1111 ( O
sent1111 to O
sent1111 the O
sent1111 nurse O
sent1111 cells O
sent1111 ) O
sent1111 and O
sent1111 the O
sent1111 posterior O
sent1111 direction O
sent1111 ( O
sent1111 to O
sent1111 the O
sent1111 oocyte O
sent1111 ) O
sent1111 , O
sent1111 independent O
sent1111 of O
sent1111 their O
sent1111 electrical O
sent1111 charge O
sent1111 or O
sent1111 molecular O
sent1111 mass O
sent1112 In O
sent1112 all O
sent1112 simple O
sent1112 salines O
sent1112 , O
sent1112 irrespective O
sent1112 of O
sent1112 their O
sent1112 osmolarity O
sent1112 , O
sent1112 Lucifer O
sent1112 Yellow O
sent1112 CH O
sent1112 was O
sent1112 found O
sent1112 to O
sent1112 preferentially O
sent1112 migrate O
sent1112 in O
sent1112 the O
sent1112 posterior O
sent1112 direction O
sent1112 and O
sent1112 to O
sent1112 accumulate O
sent1112 in O
sent1112 the O
sent1112 oocyte O
sent1112 due O
sent1112 to O
sent1112 progressive O
sent1112 binding O
sent1112 to O
sent1112 yolk O
sent1112 spheres O
sent1113 Thus O
sent1113 , O
sent1113 with O
sent1113 this O
sent1113 sensitive O
sent1113 method O
sent1113 , O
sent1113 no O
sent1113 correlation O
sent1113 was O
sent1113 detectable O
sent1113 between O
sent1113 the O
sent1113 external O
sent1113 osmolarity O
sent1113 , O
sent1113 the O
sent1113 electrical O
sent1113 charge O
sent1113 and O
sent1113 the O
sent1113 preferential O
sent1113 direction O
sent1113 of O
sent1113 migration O
sent1113 of O
sent1113 a O
sent1113 microinjected O
sent1113 probe O
sent1114 Our O
sent1114 results O
sent1114 indicate O
sent1114 that O
sent1114 the O
sent1114 electrical O
sent1114 gradient O
sent1114 described O
sent1114 by O
sent1114 other O
sent1114 authors O
sent1114 does O
sent1114 not O
sent1114 exert O
sent1114 significant O
sent1114 influence O
sent1114 on O
sent1114 the O
sent1114 migration O
sent1114 of O
sent1114 charged O
sent1114 molecules O
sent1114 through O
sent1114 intercellular O
sent1114 bridges O
sent1114 in O
sent1114 situ O
sent1115 The O
sent1115 AF-4 O
sent1115 gene O
sent1115 on O
sent1115 human O
sent1115 chromosome O
sent1115 4q21 O
sent1115 is O
sent1115 involved O
sent1115 in O
sent1115 reciprocal O
sent1115 translocations O
sent1115 to O
sent1115 the O
sent1115 ALL-1 O
sent1115 gene O
sent1115 on O
sent1115 chromosome O
sent1115 11q23 O
sent1115 , O
sent1115 which O
sent1115 are O
sent1115 associated O
sent1115 with O
sent1115 acute D
sent1115 lymphoblastic D
sent1115 leukaemias D
sent1116 A O
sent1116 set O
sent1116 of O
sent1116 recombinant O
sent1116 phage O
sent1116 carrying O
sent1116 genomic O
sent1116 fragments O
sent1116 for O
sent1116 the O
sent1116 coding O
sent1116 region O
sent1116 and O
sent1116 flanking O
sent1116 sequences O
sent1116 of O
sent1116 the O
sent1116 AF-4 O
sent1116 gene O
sent1116 were O
sent1116 isolated O
sent1117 Phage O
sent1117 inserts O
sent1117 were O
sent1117 assembled O
sent1117 into O
sent1117 four O
sent1117 contigs O
sent1117 with O
sent1117 21 O
sent1117 exons O
sent1117 , O
sent1117 and O
sent1117 an O
sent1117 intron O
sent1117 phase O
sent1117 map O
sent1117 was O
sent1117 produced O
sent1117 enabling O
sent1117 the O
sent1117 interpretation O
sent1117 of O
sent1117 translocation-generated O
sent1117 fusion O
sent1117 proteins O
sent1118 The O
sent1118 gene O
sent1118 contains O
sent1118 two O
sent1118 alternative O
sent1118 first O
sent1118 exons O
sent1118 , O
sent1118 1a O
sent1118 and O
sent1118 1b O
sent1118 , O
sent1118 both O
sent1118 including O
sent1118 a O
sent1118 translation O
sent1118 initiation O
sent1118 codon O
sent1119 The O
sent1119 translocation O
sent1119 breakpoint O
sent1119 cluster O
sent1119 region O
sent1119 is O
sent1119 flanked O
sent1119 by O
sent1119 exons O
sent1119 3 O
sent1119 and O
sent1119 6 O
sent1119 and O
sent1119 two O
sent1119 different O
sent1119 polyadenylation O
sent1119 signals O
sent1119 were O
sent1119 identified O
sent1120 Polyclonal O
sent1120 antisera O
sent1120 directed O
sent1120 against O
sent1120 three O
sent1120 different O
sent1120 portions O
sent1120 of O
sent1120 the O
sent1120 AF-4 O
sent1120 protein O
sent1120 were O
sent1120 produced O
sent1120 and O
sent1120 used O
sent1120 to O
sent1120 detect O
sent1120 a O
sent1120 116 O
sent1120 kD O
sent1120 protein O
sent1120 in O
sent1120 cellular O
sent1120 extracts O
sent1120 of O
sent1120 human O
sent1120 B-lymphoblastoid O
sent1120 and O
sent1120 proB O
sent1120 cell O
sent1120 lines O
sent1121 In O
sent1121 mitogen-stimulated O
sent1121 human O
sent1121 peripheral O
sent1121 blood O
sent1121 mononuclear O
sent1121 cells O
sent1121 the O
sent1121 AF-4 O
sent1121 antigen O
sent1121 was O
sent1121 predominantly O
sent1121 located O
sent1121 in O
sent1121 the O
sent1121 nucleus O
sent1122 The O
sent1122 AF-4 O
sent1122 gene O
sent1122 is O
sent1122 a O
sent1122 member O
sent1122 of O
sent1122 the O
sent1122 AF-4 O
sent1122 , O
sent1122 LAF-4 O
sent1122 and O
sent1122 FMR-2 O
sent1122 gene O
sent1122 family O
sent1123 The O
sent1123 members O
sent1123 of O
sent1123 this O
sent1123 family O
sent1123 encode O
sent1123 serine-proline-rich O
sent1123 proteins O
sent1123 with O
sent1123 properties O
sent1123 of O
sent1123 nuclear O
sent1123 transcription O
sent1123 factors O
sent1124 Comparison O
sent1124 of O
sent1124 AF-4 O
sent1124 protein O
sent1124 coding O
sent1124 sequences O
sent1124 with O
sent1124 the O
sent1124 LAF-4 O
sent1124 and O
sent1124 FMR-2 O
sent1124 sequences O
sent1124 revealed O
sent1124 five O
sent1124 highly O
sent1124 conserved O
sent1124 domains O
sent1124 of O
sent1124 potential O
sent1124 functional O
sent1124 relevance O
sent1125 Immunoglobulin O
sent1125 superfamily O
sent1125 molecules O
sent1125 in O
sent1125 the O
sent1125 brain O
sent1125 are O
sent1125 involved O
sent1125 in O
sent1125 distinct O
sent1125 aspects O
sent1125 of O
sent1125 nervous O
sent1125 system O
sent1125 histogenesis O
sent1125 , O
sent1125 for O
sent1125 example O
sent1125 neuronal O
sent1125 migration O
sent1125 and O
sent1125 axonal O
sent1125 growth O
sent1126 To O
sent1126 identify O
sent1126 novel O
sent1126 members O
sent1126 of O
sent1126 this O
sent1126 superfamily O
sent1126 in O
sent1126 the O
sent1126 chick O
sent1126 nervous O
sent1126 system O
sent1126 , O
sent1126 we O
sent1126 developed O
sent1126 a O
sent1126 polymerase O
sent1126 chain O
sent1126 reaction-based O
sent1126 approach O
sent1126 making O
sent1126 use O
sent1126 of O
sent1126 sequence O
sent1126 motifs O
sent1126 of O
sent1126 immunoglobulin-like O
sent1126 domains O
sent1127 In O
sent1127 the O
sent1127 present O
sent1127 study O
sent1127 , O
sent1127 we O
sent1127 report O
sent1127 the O
sent1127 molecular O
sent1127 cloning O
sent1127 of O
sent1127 three O
sent1127 isoforms O
sent1127 , O
sent1127 the O
sent1127 biochemical O
sent1127 analysis O
sent1127 and O
sent1127 the O
sent1127 immunohistochemical O
sent1127 characterization O
sent1127 of O
sent1127 one O
sent1127 of O
sent1127 the O
sent1127 proteins O
sent1127 identified O
sent1127 in O
sent1127 this O
sent1127 screen O
sent1128 This O
sent1128 molecule O
sent1128 has O
sent1128 91 O
sent1128 % O
sent1128 sequence O
sent1128 identity O
sent1128 with O
sent1128 the O
sent1128 limbic O
sent1128 system-associated O
sent1128 membrane O
sent1128 protein O
sent1128 ( O
sent1128 LAMP O
sent1128 ) O
sent1128 characterized O
sent1128 in O
sent1128 the O
sent1128 rat O
sent1128 and O
sent1128 is O
sent1128 therefore O
sent1128 referred O
sent1128 to O
sent1128 as O
sent1128 the O
sent1128 chicken O
sent1128 homologue O
sent1128 of O
sent1128 the O
sent1128 latter O
sent1128 ( O
sent1128 chLAMP O
sent1128 ) O
sent1129 The O
sent1129 molecule O
sent1129 is O
sent1129 a O
sent1129 glycosylphosphatidyl-inositol-anchored O
sent1129 60 O
sent1129 kDa O
sent1129 protein O
sent1129 with O
sent1129 three O
sent1129 immunoglobulin-like O
sent1129 domains O
sent1129 and O
sent1129 contains O
sent1129 40 O
sent1129 % O
sent1129 N-linked O
sent1129 carbohydrate O
sent1130 We O
sent1130 identify O
sent1130 three O
sent1130 different O
sent1130 mRNA O
sent1130 forms O
sent1130 of O
sent1130 chLAMP O
sent1130 and O
sent1130 show O
sent1130 that O
sent1130 two O
sent1130 forms O
sent1130 with O
sent1130 distinct O
sent1130 5'-termini O
sent1130 are O
sent1130 differentially O
sent1130 transcribed O
sent1130 in O
sent1130 neural O
sent1130 development O
sent1131 In O
sent1131 addition O
sent1131 , O
sent1131 we O
sent1131 demonstrate O
sent1131 using O
sent1131 a O
sent1131 fusion O
sent1131 protein O
sent1131 expressed O
sent1131 in O
sent1131 eukaryotic O
sent1131 cells O
sent1131 that O
sent1131 chLAMP O
sent1131 has O
sent1131 homophilic O
sent1131 binding O
sent1131 activity O
sent1132 The O
sent1132 protein O
sent1132 was O
sent1132 found O
sent1132 on O
sent1132 a O
sent1132 subset O
sent1132 of O
sent1132 axons O
sent1132 in O
sent1132 the O
sent1132 central O
sent1132 and O
sent1132 peripheral O
sent1132 nervous O
sent1132 system O
sent1132 and O
sent1132 is O
sent1132 likely O
sent1132 to O
sent1132 be O
sent1132 involved O
sent1132 in O
sent1132 specific O
sent1132 cell-cell O
sent1132 interactions O
sent1132 in O
sent1132 neurohistogenesis O
sent1133 Two O
sent1133 novel O
sent1133 cDNAs O
sent1133 , O
sent1133 DNAS1L2 O
sent1133 and O
sent1133 DNAS1L3 O
sent1133 , O
sent1133 are O
sent1133 predicted O
sent1133 to O
sent1133 encode O
sent1133 proteins O
sent1133 of O
sent1133 299 O
sent1133 and O
sent1133 305 O
sent1133 amino O
sent1133 acids O
sent1133 with O
sent1133 56 O
sent1133 and O
sent1133 46 O
sent1133 % O
sent1133 residue O
sent1133 identity O
sent1133 ( O
sent1133 71 O
sent1133 and O
sent1133 63 O
sent1133 % O
sent1133 similarity O
sent1133 ) O
sent1133 , O
sent1133 respectively O
sent1133 , O
sent1133 to O
sent1133 deoxyribonuclease O
sent1133 I O
sent1133 ( O
sent1133 DNase O
sent1133 I O
sent1133 ) O
sent1134 DNAS1L2 O
sent1134 is O
sent1134 located O
sent1134 on O
sent1134 a O
sent1134 16p13.3 O
sent1134 cosmid O
sent1134 , O
sent1134 while O
sent1134 DNAS1L3 O
sent1134 maps O
sent1134 to O
sent1134 3p14.3-p21.1 O
sent1134 by O
sent1134 fluorescence O
sent1134 in O
sent1134 situ O
sent1134 hybridization O
sent1134 and O
sent1134 by O
sent1134 PCR O
sent1134 analysis O
sent1134 of O
sent1134 a O
sent1134 radiation O
sent1134 hybrid O
sent1134 panel O
sent1135 Northern O
sent1135 analysis O
sent1135 revealed O
sent1135 DNAS1L3 O
sent1135 expression O
sent1135 nearly O
sent1135 exclusively O
sent1135 in O
sent1135 liver O
sent1135 , O
sent1135 while O
sent1135 DNAS1L2 O
sent1135 expression O
sent1135 was O
sent1135 detected O
sent1135 in O
sent1135 brain O
sent1135 by O
sent1135 RT-PCR O
sent1136 The O
sent1136 previously O
sent1136 defined O
sent1136 DNL1L O
sent1136 or O
sent1136 DNAS1L1 O
sent1136 is O
sent1136 expressed O
sent1136 highest O
sent1136 in O
sent1136 heart O
sent1136 and O
sent1136 skeletal O
sent1136 muscle O
sent1136 , O
sent1136 while O
sent1136 DNase O
sent1136 I O
sent1136 is O
sent1136 expressed O
sent1136 in O
sent1136 the O
sent1136 pancreas O
sent1136 , O
sent1136 parotid O
sent1136 gland O
sent1136 , O
sent1136 and O
sent1136 kidney O
sent1137 Thus O
sent1137 , O
sent1137 to O
sent1137 date O
sent1137 , O
sent1137 four O
sent1137 DNase O
sent1137 I-like O
sent1137 genes O
sent1137 that O
sent1137 show O
sent1137 different O
sent1137 tissue O
sent1137 expression O
sent1137 patterns O
sent1137 are O
sent1137 known O
sent1138 A O
sent1138 comparison O
sent1138 of O
sent1138 DNAS1L1 O
sent1138 , O
sent1138 DNAS1L2 O
sent1138 , O
sent1138 and O
sent1138 DNAS1L3 O
sent1138 with O
sent1138 the O
sent1138 well-characterized O
sent1138 DNase O
sent1138 I O
sent1138 suggests O
sent1138 that O
sent1138 the O
sent1138 DNAS1L O
sent1138 proteins O
sent1138 are O
sent1138 unlikely O
sent1138 to O
sent1138 be O
sent1138 glycosylated O
sent1138 or O
sent1138 bind O
sent1138 actin O
sent1138 ; O
sent1138 however O
sent1138 , O
sent1138 catalytic O
sent1138 and O
sent1138 calcium- O
sent1138 and O
sent1138 DNA-binding O
sent1138 residues O
sent1138 are O
sent1138 conserved O
sent1138 , O
sent1138 and O
sent1138 potentially O
sent1138 cleavable O
sent1138 signal O
sent1138 peptides O
sent1138 are O
sent1138 present O
sent1138 among O
sent1138 all O
sent1138 these O
sent1138 proteins O
sent1139 This O
sent1139 analysis O
sent1139 also O
sent1139 identifies O
sent1139 regions O
sent1139 of O
sent1139 high O
sent1139 conservation O
sent1139 among O
sent1139 these O
sent1139 proteins O
sent1139 with O
sent1139 no O
sent1139 currently O
sent1139 assigned O
sent1139 function O
sent1140 Two O
sent1140 different O
sent1140 responses O
sent1140 to O
sent1140 the O
sent1140 therapy O
sent1140 were O
sent1140 observed O
sent1140 in O
sent1140 a O
sent1140 group O
sent1140 of O
sent1140 patients O
sent1140 receiving O
sent1140 the O
sent1140 protease T
sent1140 inhibitor T
sent1140 indinavir T
sent1141 In O
sent1141 one O
sent1141 , O
sent1141 suppression O
sent1141 of O
sent1141 virus O
sent1141 replication O
sent1141 occurred O
sent1141 and O
sent1141 has O
sent1141 persisted O
sent1141 for O
sent1141 90 O
sent1141 weeks O
sent1141 ( O
sent1141 bDNA O
sent1141 , O
sent1141 & O
sent1141 # O
sent1141 60 O
sent1141 ; O
sent1141 500 O
sent1141 human O
sent1141 immunodeficiency O
sent1141 virus O
sent1141 type O
sent1141 1 O
sent1141 ( O
sent1141 HIV-1 O
sent1141 ) O
sent1141 RNA O
sent1141 copies/ml O
sent1141 ) O
sent1142 In O
sent1142 the O
sent1142 second O
sent1142 group O
sent1142 , O
sent1142 a O
sent1142 rebound O
sent1142 in O
sent1142 virus O
sent1142 levels O
sent1142 in O
sent1142 plasma O
sent1142 followed O
sent1142 the O
sent1142 initial O
sent1142 sharp O
sent1142 decline O
sent1142 observed O
sent1142 at O
sent1142 the O
sent1142 start O
sent1142 of O
sent1142 therapy O
sent1143 This O
sent1143 was O
sent1143 associated O
sent1143 with O
sent1143 the O
sent1143 emergence O
sent1143 of O
sent1143 drug-resistant O
sent1143 variants O
sent1144 Sequence O
sent1144 analysis O
sent1144 of O
sent1144 the O
sent1144 protease O
sent1144 gene O
sent1144 during O
sent1144 the O
sent1144 course O
sent1144 of O
sent1144 therapy O
sent1144 revealed O
sent1144 that O
sent1144 in O
sent1144 this O
sent1144 second O
sent1144 group O
sent1144 there O
sent1144 was O
sent1144 a O
sent1144 sequential O
sent1144 acquisition O
sent1144 of O
sent1144 protease O
sent1144 mutations O
sent1144 at O
sent1144 amino O
sent1144 acids O
sent1144 46 O
sent1144 , O
sent1144 82 O
sent1144 , O
sent1144 54 O
sent1144 , O
sent1144 71 O
sent1144 , O
sent1144 89 O
sent1144 , O
sent1144 and O
sent1144 90 O
sent1145 In O
sent1145 the O
sent1145 six O
sent1145 patients O
sent1145 in O
sent1145 this O
sent1145 group O
sent1145 , O
sent1145 there O
sent1145 was O
sent1145 also O
sent1145 an O
sent1145 identical O
sent1145 mutation O
sent1145 in O
sent1145 the O
sent1145 gag O
sent1145 p7/p1 O
sent1145 gag O
sent1145 protease O
sent1145 cleavage O
sent1145 site O
sent1146 In O
sent1146 three O
sent1146 of O
sent1146 the O
sent1146 patients O
sent1146 , O
sent1146 this O
sent1146 change O
sent1146 was O
sent1146 seen O
sent1146 as O
sent1146 early O
sent1146 as O
sent1146 6 O
sent1146 to O
sent1146 10 O
sent1146 weeks O
sent1146 after O
sent1146 the O
sent1146 start O
sent1146 of O
sent1146 therapy O
sent1147 In O
sent1147 one O
sent1147 patient O
sent1147 , O
sent1147 a O
sent1147 second O
sent1147 mutation O
sent1147 occurred O
sent1147 at O
sent1147 the O
sent1147 gag O
sent1147 p1/p6 O
sent1147 cleavage O
sent1147 site O
sent1147 , O
sent1147 but O
sent1147 it O
sent1147 appeared O
sent1147 18 O
sent1147 weeks O
sent1147 after O
sent1147 the O
sent1147 time O
sent1147 of O
sent1147 appearance O
sent1147 of O
sent1147 the O
sent1147 p7/p1 O
sent1147 mutation O
sent1148 Recombinant O
sent1148 HIV-1 O
sent1148 variants O
sent1148 containing O
sent1148 two O
sent1148 or O
sent1148 three O
sent1148 mutations O
sent1148 in O
sent1148 the O
sent1148 protease O
sent1148 gene O
sent1148 were O
sent1148 constructed O
sent1148 either O
sent1148 with O
sent1148 mutations O
sent1148 at O
sent1148 the O
sent1148 p7/p1 O
sent1148 cleavage O
sent1148 site O
sent1148 or O
sent1148 with O
sent1148 wild-type O
sent1148 ( O
sent1148 WT O
sent1148 ) O
sent1148 gag O
sent1148 sequences O
sent1149 When O
sent1149 recombinant O
sent1149 HIV-1-containing O
sent1149 protease O
sent1149 mutations O
sent1149 at O
sent1149 46 O
sent1149 and O
sent1149 82 O
sent1149 was O
sent1149 grown O
sent1149 in O
sent1149 MT2 O
sent1149 cells O
sent1149 , O
sent1149 there O
sent1149 was O
sent1149 a O
sent1149 68 O
sent1149 % O
sent1149 reduction O
sent1149 in O
sent1149 its O
sent1149 rate O
sent1149 of O
sent1149 replication O
sent1149 compared O
sent1149 to O
sent1149 the O
sent1149 WT O
sent1149 virus O
sent1150 Introduction O
sent1150 of O
sent1150 an O
sent1150 additional O
sent1150 mutation O
sent1150 at O
sent1150 the O
sent1150 gag O
sent1150 p7/p1 O
sent1150 protease O
sent1150 cleavage O
sent1150 site O
sent1150 compensated O
sent1150 for O
sent1150 the O
sent1150 partially O
sent1150 defective O
sent1150 protease O
sent1150 gene O
sent1151 Similarly O
sent1151 , O
sent1151 rates O
sent1151 of O
sent1151 replication O
sent1151 of O
sent1151 viruses O
sent1151 with O
sent1151 mutations O
sent1151 M46L/I O
sent1151 , O
sent1151 I54V O
sent1151 , O
sent1151 and O
sent1151 V82A O
sent1151 in O
sent1151 protease O
sent1151 were O
sent1151 enhanced O
sent1151 both O
sent1151 in O
sent1151 the O
sent1151 presence O
sent1151 and O
sent1151 in O
sent1151 the O
sent1151 absence O
sent1151 of O
sent1151 Indinavir O
sent1151 when O
sent1151 combined O
sent1151 with O
sent1151 mutations O
sent1151 in O
sent1151 the O
sent1151 gag O
sent1151 p7/p1 O
sent1151 and O
sent1151 the O
sent1151 gag O
sent1151 p1/p6 O
sent1151 cleavage O
sent1151 sites O
sent1152 Optimal O
sent1152 rates O
sent1152 of O
sent1152 virus O
sent1152 replication O
sent1152 require O
sent1152 protease O
sent1152 cleavage O
sent1152 of O
sent1152 precursor O
sent1152 polyproteins O
sent1153 A O
sent1153 mutation O
sent1153 in O
sent1153 the O
sent1153 cleavage O
sent1153 site O
sent1153 that O
sent1153 enhanced O
sent1153 the O
sent1153 availability O
sent1153 of O
sent1153 a O
sent1153 protein O
sent1153 that O
sent1153 was O
sent1153 rate O
sent1153 limiting O
sent1153 for O
sent1153 virus O
sent1153 maturation O
sent1153 would O
sent1153 confer O
sent1153 on O
sent1153 that O
sent1153 virus O
sent1153 a O
sent1153 significant O
sent1153 growth O
sent1153 advantage O
sent1153 and O
sent1153 may O
sent1153 explain O
sent1153 the O
sent1153 uniform O
sent1153 emergence O
sent1153 of O
sent1153 viruses O
sent1153 with O
sent1153 alterations O
sent1153 at O
sent1153 the O
sent1153 p7/p1 O
sent1153 cleavage O
sent1153 site O
sent1154 This O
sent1154 is O
sent1154 the O
sent1154 first O
sent1154 report O
sent1154 of O
sent1154 the O
sent1154 emergence O
sent1154 of O
sent1154 mutations O
sent1154 in O
sent1154 the O
sent1154 gag O
sent1154 p7/p1 O
sent1154 protease O
sent1154 cleavage O
sent1154 sites O
sent1154 in O
sent1154 patients O
sent1154 receiving O
sent1154 protease T
sent1154 therapy T
sent1154 and O
sent1154 identifies O
sent1154 this O
sent1154 change O
sent1154 as O
sent1154 an O
sent1154 important O
sent1154 determinant O
sent1154 of O
sent1154 HIV-1 O
sent1154 resistance O
sent1154 to O
sent1154 protease O
sent1154 inhibitors O
sent1154 in O
sent1154 patient O
sent1154 populations O
sent1155 A O
sent1155 novel O
sent1155 intracellular O
sent1155 calcium-binding O
sent1155 protein O
sent1155 from O
sent1155 Echinococcus O
sent1155 granulosus O
sent1155 is O
sent1155 described O
sent1155 in O
sent1155 this O
sent1155 work O
sent1156 A O
sent1156 cDNA O
sent1156 was O
sent1156 isolated O
sent1156 from O
sent1156 a O
sent1156 lambdagt11 O
sent1156 protoscolex O
sent1156 expression O
sent1156 library O
sent1156 and O
sent1156 the O
sent1156 deduced O
sent1156 amino O
sent1156 acid O
sent1156 sequence O
sent1156 has O
sent1156 at O
sent1156 least O
sent1156 fifteen O
sent1156 sequentially O
sent1156 repeated O
sent1156 twelve-residue O
sent1156 repeats O
sent1156 that O
sent1156 resemble O
sent1156 the O
sent1156 calcium-binding O
sent1156 loop O
sent1156 of O
sent1156 EF-hands O
sent1156 ; O
sent1156 however O
sent1156 , O
sent1156 the O
sent1156 dodecamer O
sent1156 motif O
sent1156 has O
sent1156 no O
sent1156 flanking O
sent1156 helices O
sent1157 The O
sent1157 cDNA O
sent1157 was O
sent1157 expressed O
sent1157 in O
sent1157 Escherichia O
sent1157 coli O
sent1157 using O
sent1157 the O
sent1157 pGEX O
sent1157 vector O
sent1157 , O
sent1157 and O
sent1157 a O
sent1157 recombinant O
sent1157 fusion O
sent1157 protein O
sent1157 ( O
sent1157 EgCaBP1-GST O
sent1157 ) O
sent1157 was O
sent1157 obtained O
sent1158 The O
sent1158 recombinant O
sent1158 fusion O
sent1158 protein O
sent1158 binds O
sent1158 calcium O
sent1158 when O
sent1158 assayed O
sent1158 with O
sent1158 45Ca O
sent1159 It O
sent1159 is O
sent1159 possible O
sent1159 that O
sent1159 the O
sent1159 calcium-binding O
sent1159 motifs O
sent1159 present O
sent1159 a O
sent1159 secondary O
sent1159 structure O
sent1159 similar O
sent1159 to O
sent1159 the O
sent1159 parallel O
sent1159 beta O
sent1159 roll O
sent1159 structure O
sent1159 described O
sent1159 for O
sent1159 an O
sent1159 alkaline O
sent1159 protease O
sent1159 from O
sent1159 Pseudomonas O
sent1159 aeruginosa O
sent1160 A O
sent1160 native O
sent1160 protein O
sent1160 of O
sent1160 more O
sent1160 than O
sent1160 300 O
sent1160 kDa O
sent1160 was O
sent1160 recognized O
sent1160 by O
sent1160 an O
sent1160 anti-EgCaBP1 O
sent1160 monoclonal O
sent1160 antibody O
sent1160 by O
sent1160 Western-blot O
sent1160 analysis O
sent1161 Immunohistochemistry O
sent1161 using O
sent1161 a O
sent1161 pool O
sent1161 of O
sent1161 anti-EgCaBP1-GST O
sent1161 mouse O
sent1161 sera O
sent1161 demonstrated O
sent1161 a O
sent1161 strong O
sent1161 association O
sent1161 of O
sent1161 the O
sent1161 protein O
sent1161 with O
sent1161 calcareous O
sent1161 corpuscles O
sent1162 The O
sent1162 possible O
sent1162 role O
sent1162 of O
sent1162 this O
sent1162 protein O
sent1162 and O
sent1162 that O
sent1162 of O
sent1162 the O
sent1162 calcareous O
sent1162 corpuscles O
sent1162 in O
sent1162 the O
sent1162 protoscolex O
sent1162 are O
sent1162 discussed O
sent1163 The O
sent1163 enzyme O
sent1163 activity O
sent1163 of O
sent1163 mitogen-activated O
sent1163 protein O
sent1163 kinase O
sent1163 ( O
sent1163 MAP O
sent1163 kinase O
sent1163 ) O
sent1163 increases O
sent1163 in O
sent1163 response O
sent1163 to O
sent1163 agents O
sent1163 acting O
sent1163 on O
sent1163 a O
sent1163 variety O
sent1163 of O
sent1163 cell O
sent1163 surface O
sent1163 receptors O
sent1163 , O
sent1163 including O
sent1163 receptors O
sent1163 linked O
sent1163 to O
sent1163 heterotrimeric O
sent1163 G O
sent1163 proteins O
sent1164 In O
sent1164 this O
sent1164 report O
sent1164 , O
sent1164 we O
sent1164 demonstrated O
sent1164 that O
sent1164 Raf-1 O
sent1164 protein O
sent1164 kinase O
sent1164 activity O
sent1164 in O
sent1164 the O
sent1164 mouse O
sent1164 parotid O
sent1164 glands O
sent1164 was O
sent1164 induced O
sent1164 by O
sent1164 chronic O
sent1164 isoproterenol O
sent1164 administration O
sent1164 in O
sent1164 whole O
sent1164 animals O
sent1165 To O
sent1165 investigate O
sent1165 the O
sent1165 molecular O
sent1165 nature O
sent1165 underlying O
sent1165 cellular O
sent1165 responses O
sent1165 to O
sent1165 Raf-1 O
sent1165 activation O
sent1165 , O
sent1165 we O
sent1165 have O
sent1165 stably O
sent1165 transfected O
sent1165 rat O
sent1165 salivary O
sent1165 epithelial O
sent1165 Pa-4 O
sent1165 cells O
sent1165 with O
sent1165 human O
sent1165 Raf-1-estrogen O
sent1165 receptor O
sent1165 fusion O
sent1165 gene O
sent1165 ( O
sent1165 DeltaRaf-1 O
sent1165 : O
sent1165 ER O
sent1165 ) O
sent1165 and O
sent1165 used O
sent1165 mRNA O
sent1165 differential O
sent1165 display O
sent1165 in O
sent1165 search O
sent1165 of O
sent1165 messages O
sent1165 induced O
sent1165 by O
sent1165 DeltaRaf-1 O
sent1165 : O
sent1165 ER O
sent1165 activation O
sent1166 Through O
sent1166 this O
sent1166 approach O
sent1166 , O
sent1166 the O
sent1166 gene O
sent1166 encoding O
sent1166 non-histone O
sent1166 chromosomal O
sent1166 protein O
sent1166 HMGI-C O
sent1166 was O
sent1166 identified O
sent1166 as O
sent1166 one O
sent1166 of O
sent1166 the O
sent1166 target O
sent1166 genes O
sent1166 activated O
sent1166 by O
sent1166 oncogenic O
sent1166 Raf-1 O
sent1166 kinase O
sent1167 Activation O
sent1167 of O
sent1167 Raf-1 O
sent1167 kinase O
sent1167 resulted O
sent1167 in O
sent1167 a O
sent1167 delayed O
sent1167 and O
sent1167 sustained O
sent1167 increase O
sent1167 of O
sent1167 HMGI-C O
sent1167 expression O
sent1167 in O
sent1167 the O
sent1167 Pa-4 O
sent1167 cells O
sent1168 The O
sent1168 induction O
sent1168 of O
sent1168 HMGI-C O
sent1168 mRNA O
sent1168 level O
sent1168 is O
sent1168 sensitive O
sent1168 to O
sent1168 both O
sent1168 the O
sent1168 protein O
sent1168 synthesis O
sent1168 inhibitor O
sent1168 cycloheximide O
sent1168 and O
sent1168 transcription O
sent1168 inhibitor O
sent1168 actinomycin O
sent1168 D O
sent1169 The O
sent1169 role O
sent1169 of O
sent1169 the O
sent1169 extracellular O
sent1169 signal-related O
sent1169 kinase O
sent1169 ( O
sent1169 ERK O
sent1169 ) O
sent1169 signaling O
sent1169 pathway O
sent1169 in O
sent1169 the O
sent1169 HMGI-C O
sent1169 induction O
sent1169 was O
sent1169 highlighted O
sent1169 by O
sent1169 the O
sent1169 result O
sent1169 that O
sent1169 the O
sent1169 MAP O
sent1169 kinase O
sent1169 kinase O
sent1169 ( O
sent1169 MEK O
sent1169 ) O
sent1169 inhibitor O
sent1169 , O
sent1169 PD O
sent1169 98059 O
sent1169 , O
sent1169 blocked O
sent1169 DeltaRaf-1 O
sent1169 : O
sent1169 ER- O
sent1169 and O
sent1169 12-O-tetradecanoylphorbol-13-acetate-stimulated O
sent1169 HMGI-C O
sent1169 induction O
sent1170 Altogether O
sent1170 , O
sent1170 these O
sent1170 findings O
sent1170 support O
sent1170 the O
sent1170 notion O
sent1170 that O
sent1170 the O
sent1170 Raf/MEK/ERK O
sent1170 signaling O
sent1170 module O
sent1170 , O
sent1170 at O
sent1170 least O
sent1170 in O
sent1170 part O
sent1170 , O
sent1170 regulates O
sent1170 transcriptional O
sent1170 activation O
sent1170 of O
sent1170 the O
sent1170 chromosomal O
sent1170 architectural O
sent1170 protein O
sent1170 HMGI-C O
sent1171 Pendred D
sent1171 syndrome D
sent1171 is O
sent1171 a O
sent1171 recessively O
sent1171 inherited O
sent1171 disorder O
sent1171 with O
sent1171 the O
sent1171 hallmark O
sent1171 features O
sent1171 of O
sent1171 congenital D
sent1171 deafness D
sent1171 and O
sent1171 thyroid D
sent1171 goitre D
sent1172 By O
sent1172 some O
sent1172 estimates O
sent1172 , O
sent1172 the O
sent1172 disorder O
sent1172 may O
sent1172 account O
sent1172 for O
sent1172 upwards O
sent1172 of O
sent1172 10 O
sent1172 % O
sent1172 of O
sent1172 hereditary D
sent1172 deafness D
sent1173 Previous O
sent1173 genetic O
sent1173 linkage O
sent1173 studies O
sent1173 localized O
sent1173 the O
sent1173 gene O
sent1173 to O
sent1173 a O
sent1173 broad O
sent1173 interval O
sent1173 on O
sent1173 human O
sent1173 chromosome O
sent1173 7q22-31.1 O
sent1174 Using O
sent1174 a O
sent1174 positional O
sent1174 cloning O
sent1174 strategy O
sent1174 , O
sent1174 we O
sent1174 have O
sent1174 identified O
sent1174 the O
sent1174 gene O
sent1174 ( O
sent1174 PDS O
sent1174 ) O
sent1174 mutated O
sent1174 in O
sent1174 Pendred D
sent1174 syndrome D
sent1174 and O
sent1174 found O
sent1174 three O
sent1174 apparently O
sent1174 deleterious O
sent1174 mutations O
sent1174 , O
sent1174 each O
sent1174 segregating O
sent1174 with O
sent1174 the O
sent1174 disease O
sent1174 in O
sent1174 the O
sent1174 respective O
sent1174 families O
sent1174 in O
sent1174 which O
sent1174 they O
sent1174 occur O
sent1175 PDS O
sent1175 produces O
sent1175 a O
sent1175 transcript O
sent1175 of O
sent1175 approximately O
sent1175 5 O
sent1175 kb O
sent1175 that O
sent1175 was O
sent1175 found O
sent1175 to O
sent1175 be O
sent1175 expressed O
sent1175 at O
sent1175 significant O
sent1175 levels O
sent1175 only O
sent1175 in O
sent1175 the O
sent1175 thyroid O
sent1176 The O
sent1176 predicted O
sent1176 protein O
sent1176 , O
sent1176 pendrin O
sent1176 , O
sent1176 is O
sent1176 closely O
sent1176 related O
sent1176 to O
sent1176 a O
sent1176 number O
sent1176 of O
sent1176 known O
sent1176 sulphate O
sent1176 transporters O
sent1177 These O
sent1177 studies O
sent1177 provide O
sent1177 compelling O
sent1177 evidence O
sent1177 that O
sent1177 defects O
sent1177 in O
sent1177 pendrin O
sent1177 cause O
sent1177 Pendred D
sent1177 syndrome D
sent1177 thereby O
sent1177 launching O
sent1177 a O
sent1177 new O
sent1177 area O
sent1177 of O
sent1177 investigation O
sent1177 into O
sent1177 thyroid O
sent1177 physiology O
sent1177 , O
sent1177 the O
sent1177 pathogenesis O
sent1177 of O
sent1177 congenital D
sent1177 deafness D
sent1177 and O
sent1177 the O
sent1177 role O
sent1177 of O
sent1177 altered O
sent1177 sulphate O
sent1177 transport O
sent1177 in O
sent1177 human O
sent1177 disease O
sent1178 We O
sent1178 report O
sent1178 the O
sent1178 cDNA O
sent1178 cloning O
sent1178 , O
sent1178 partial O
sent1178 genomic O
sent1178 organization O
sent1178 , O
sent1178 and O
sent1178 expression O
sent1178 pattern O
sent1178 of O
sent1178 Stra10 O
sent1178 , O
sent1178 a O
sent1178 novel O
sent1178 retinoic O
sent1178 acid-inducible O
sent1178 gene O
sent1178 in O
sent1178 P19 O
sent1178 embryonal D
sent1178 carcinoma D
sent1178 cells O
sent1179 Four O
sent1179 murine O
sent1179 cDNA O
sent1179 isoforms O
sent1179 have O
sent1179 been O
sent1179 isolated O
sent1179 , O
sent1179 which O
sent1179 are O
sent1179 likely O
sent1179 to O
sent1179 result O
sent1179 from O
sent1179 alternative O
sent1179 splicing O
sent1180 The O
sent1180 predicted O
sent1180 protein O
sent1180 sequences O
sent1180 exhibit O
sent1180 approximately O
sent1180 85 O
sent1180 % O
sent1180 identity O
sent1180 with O
sent1180 the O
sent1180 Pbx-related O
sent1180 Meis1 O
sent1180 homeobox O
sent1180 gene O
sent1180 products O
sent1180 , O
sent1180 which O
sent1180 are O
sent1180 involved O
sent1180 in O
sent1180 myeloid D
sent1180 leukemia D
sent1180 in O
sent1180 BXH-2 O
sent1180 mice O
sent1180 , O
sent1180 and O
sent1180 one O
sent1180 of O
sent1180 the O
sent1180 Stra10 O
sent1180 isoforms O
sent1180 corresponds O
sent1180 to O
sent1180 the O
sent1180 recently O
sent1180 published O
sent1180 Meis2 O
sent1180 sequence O
sent1180 ( O
sent1180 Nakamura O
sent1180 et O
sent1180 al O
sent1180 . O
sent1180 ( O
sent1180 1996 O
sent1180 ) O
sent1180 Oncogene O
sent1180 13 O
sent1180 : O
sent1180 2235-2242 O
sent1180 ) O
sent1181 The O
sent1181 Meis2 O
sent1181 homeodomain O
sent1181 is O
sent1181 identical O
sent1181 to O
sent1181 that O
sent1181 of O
sent1181 Meis1 O
sent1181 , O
sent1181 and O
sent1181 is O
sent1181 most O
sent1181 closely O
sent1181 related O
sent1181 to O
sent1181 those O
sent1181 of O
sent1181 the O
sent1181 Pbx/TGIF O
sent1181 homeobox O
sent1181 gene O
sent1181 products O
sent1182 By O
sent1182 in O
sent1182 situ O
sent1182 hybridization O
sent1182 analysis O
sent1182 , O
sent1182 we O
sent1182 show O
sent1182 that O
sent1182 the O
sent1182 Meis2 O
sent1182 gene O
sent1182 displays O
sent1182 spatially O
sent1182 restricted O
sent1182 expression O
sent1182 patterns O
sent1182 in O
sent1182 the O
sent1182 developing O
sent1182 nervous O
sent1182 system O
sent1182 , O
sent1182 limbs O
sent1182 , O
sent1182 face O
sent1182 , O
sent1182 and O
sent1182 in O
sent1182 various O
sent1182 viscera O
sent1183 In O
sent1183 adult O
sent1183 mice O
sent1183 , O
sent1183 Meis2 O
sent1183 is O
sent1183 mainly O
sent1183 expressed O
sent1183 in O
sent1183 the O
sent1183 brain O
sent1183 and O
sent1183 female O
sent1183 genital O
sent1183 tract O
sent1183 , O
sent1183 with O
sent1183 a O
sent1183 different O
sent1183 distribution O
sent1183 of O
sent1183 the O
sent1183 alternative O
sent1183 splice O
sent1183 forms O
sent1183 in O
sent1183 these O
sent1183 organs O
sent1184 A O
sent1184 methodical O
sent1184 strategy O
sent1184 for O
sent1184 the O
sent1184 isolation O
sent1184 of O
sent1184 microsatellite O
sent1184 markers O
sent1184 specific O
sent1184 for O
sent1184 targeted O
sent1184 regions O
sent1184 of O
sent1184 bovine O
sent1184 chromosomes O
sent1184 is O
sent1184 presented O
sent1185 The O
sent1185 procedure O
sent1185 involves O
sent1185 directed O
sent1185 microdissection O
sent1185 of O
sent1185 one O
sent1185 defined O
sent1185 subchromosomal O
sent1185 area O
sent1185 , O
sent1185 its O
sent1185 DOP-PCR-amplification O
sent1185 and O
sent1185 cloning O
sent1186 With O
sent1186 this O
sent1186 approach O
sent1186 , O
sent1186 a O
sent1186 library O
sent1186 specific O
sent1186 to O
sent1186 the O
sent1186 BTA O
sent1186 6q21-31 O
sent1186 chromosomal O
sent1186 region O
sent1186 was O
sent1186 constructed O
sent1187 Eleven O
sent1187 unique O
sent1187 microsatellite-containing O
sent1187 sequences O
sent1187 were O
sent1187 isolated O
sent1187 , O
sent1187 converted O
sent1187 into O
sent1187 sequence-tagged O
sent1187 microsatellite O
sent1187 sites O
sent1187 , O
sent1187 and O
sent1187 characterized O
sent1187 concerning O
sent1187 their O
sent1187 species-specific O
sent1187 origin O
sent1188 Seven O
sent1188 primer O
sent1188 pairs O
sent1188 generated O
sent1188 bovine-specific O
sent1188 PCR O
sent1188 products O
sent1188 and O
sent1188 provided O
sent1188 a O
sent1188 set O
sent1188 of O
sent1188 microsatellite O
sent1188 markers O
sent1188 that O
sent1188 generally O
sent1188 revealed O
sent1188 high O
sent1188 informativity O
sent1188 in O
sent1188 the O
sent1188 HF O
sent1188 breed O
sent1189 Linkage O
sent1189 analysis O
sent1189 assigned O
sent1189 six O
sent1189 of O
sent1189 them O
sent1189 to O
sent1189 their O
sent1189 predefined O
sent1189 subchromosomal O
sent1189 origin O
sent1189 on O
sent1189 BTA O
sent1189 6 O
sent1189 corresponding O
sent1189 to O
sent1189 the O
sent1189 specific O
sent1189 rehybridization O
sent1189 signal O
sent1189 of O
sent1189 the O
sent1189 DOP-PCR O
sent1189 product O
sent1189 generated O
sent1189 from O
sent1189 the O
sent1189 microdissected O
sent1189 chromosome O
sent1189 area O
sent1189 6q21-31 O
sent1190 The O
sent1190 results O
sent1190 underline O
sent1190 the O
sent1190 usefulness O
sent1190 of O
sent1190 the O
sent1190 BTA O
sent1190 6q21-31 O
sent1190 library O
sent1190 for O
sent1190 targeted O
sent1190 isolation O
sent1190 of O
sent1190 unique O
sent1190 sequences O
sent1190 that O
sent1190 are O
sent1190 specific O
sent1190 for O
sent1190 the O
sent1190 dissected O
sent1190 chromosomal O
sent1190 region O
sent1190 as O
sent1190 demonstrated O
sent1190 here O
sent1190 by O
sent1190 the O
sent1190 isolation O
sent1190 of O
sent1190 microsatellite O
sent1190 markers O
sent1191 Phylogeographic O
sent1191 structure O
sent1191 was O
sent1191 determined O
sent1191 for O
sent1191 the O
sent1191 yellow O
sent1191 mongoose O
sent1191 , O
sent1191 Cynictis O
sent1191 penicillata O
sent1191 , O
sent1191 using O
sent1191 mtDNA O
sent1191 RFLPs O
sent1191 and O
sent1191 control O
sent1191 region O
sent1191 sequences O
sent1192 The O
sent1192 RFLP O
sent1192 analysis O
sent1192 revealed O
sent1192 13 O
sent1192 haplotypes O
sent1192 which O
sent1192 showed O
sent1192 weak O
sent1192 geographical O
sent1192 patterning O
sent1192 consistent O
sent1192 with O
sent1192 a O
sent1192 recent O
sent1192 range O
sent1192 expansion O
sent1192 from O
sent1192 a O
sent1192 refugial O
sent1192 population O
sent1192 ( O
sent1192 s O
sent1192 ) O
sent1193 An O
sent1193 analysis O
sent1193 of O
sent1193 molecular O
sent1193 variance O
sent1193 ( O
sent1193 AMOVA O
sent1193 ) O
sent1193 revealed O
sent1193 no O
sent1193 correspondence O
sent1193 between O
sent1193 mtDNA O
sent1193 phylogeography O
sent1193 and O
sent1193 subspecies O
sent1193 delimitation O
sent1193 , O
sent1193 nor O
sent1193 between O
sent1193 matrilines O
sent1193 and O
sent1193 areas O
sent1193 characterized O
sent1193 by O
sent1193 a O
sent1193 high O
sent1193 incidence O
sent1193 of O
sent1193 the O
sent1193 viverrid-type D
sent1193 rabies D
sent1193 , O
sent1193 of O
sent1193 which O
sent1193 the O
sent1193 yellow O
sent1193 mongoose O
sent1193 is O
sent1193 the O
sent1193 principal O
sent1193 vector O
sent1194 The O
sent1194 lack O
sent1194 of O
sent1194 structure O
sent1194 was O
sent1194 also O
sent1194 shown O
sent1194 by O
sent1194 control O
sent1194 region O
sent1194 sequences O
sent1194 although O
sent1194 four O
sent1194 of O
sent1194 the O
sent1194 maternal O
sent1194 lineages O
sent1194 shared O
sent1194 a O
sent1194 near-perfect O
sent1194 81 O
sent1194 bp O
sent1194 repeat O
sent1195 We O
sent1195 speculate O
sent1195 that O
sent1195 regional O
sent1195 hot O
sent1195 spots O
sent1195 of O
sent1195 the O
sent1195 viverrid D
sent1195 rabies D
sent1195 biotype O
sent1195 reflect O
sent1195 population O
sent1195 density O
sent1195 differences O
sent1195 in O
sent1195 the O
sent1195 yellow O
sent1195 mongoose O
sent1195 that O
sent1195 are O
sent1195 not O
sent1195 underscored O
sent1195 by O
sent1195 genetic O
sent1195 partitioning O
sent1195 , O
sent1195 at O
sent1195 least O
sent1195 at O
sent1195 the O
sent1195 level O
sent1195 of O
sent1195 resolution O
sent1195 provided O
sent1195 by O
sent1195 our O
sent1195 analyses O
sent1196 The O
sent1196 indoor O
sent1196 pollution O
sent1196 , O
sent1196 where O
sent1196 the O
sent1196 patients O
sent1196 pass O
sent1196 in O
sent1196 general O
sent1196 close O
sent1196 to O
sent1196 90 O
sent1196 % O
sent1196 of O
sent1196 their O
sent1196 time O
sent1196 , O
sent1196 is O
sent1196 an O
sent1196 important O
sent1196 factor O
sent1196 to O
sent1196 take O
sent1196 in O
sent1196 consideration O
sent1196 if O
sent1196 one O
sent1196 wants O
sent1196 to O
sent1196 evaluate O
sent1196 suitably O
sent1196 the O
sent1196 effects O
sent1196 of O
sent1196 the O
sent1196 air O
sent1196 pollution O
sent1196 on O
sent1196 the O
sent1196 health O
sent1197 Causes O
sent1197 of O
sent1197 this O
sent1197 kind O
sent1197 of O
sent1197 pollution O
sent1197 are O
sent1197 partially O
sent1197 linked O
sent1197 to O
sent1197 the O
sent1197 external O
sent1197 pollution O
sent1197 and O
sent1197 the O
sent1197 outdoor O
sent1197 environment O
sent1197 and O
sent1197 also O
sent1197 are O
sent1197 function O
sent1197 of O
sent1197 human O
sent1197 activities O
sent1197 and O
sent1197 introduced O
sent1197 products O
sent1197 in O
sent1197 the O
sent1197 habitat O
sent1197 ( O
sent1197 heating O
sent1197 , O
sent1197 tabagisme O
sent1197 , O
sent1197 handywork O
sent1197 , O
sent1197 products O
sent1197 of O
sent1197 maintenance O
sent1197 , O
sent1197 coatings O
sent1197 , O
sent1197 materials O
sent1197 of O
sent1197 construction O
sent1197 , O
sent1197 etc O
sent1198 ) O
sent1199 The O
sent1199 effects O
sent1199 on O
sent1199 health O
sent1199 are O
sent1199 as O
sent1199 various O
sent1199 as O
sent1199 the O
sent1199 pollutants O
sent1199 , O
sent1199 going O
sent1199 from O
sent1199 sharp O
sent1199 intoxication O
sent1199 to O
sent1199 irritations O
sent1199 or O
sent1199 simply O
sent1199 desagreements O
sent1200 In O
sent1200 this O
sent1200 problem O
sent1200 of O
sent1200 public O
sent1200 health O
sent1200 we O
sent1200 may O
sent1200 not O
sent1200 underestimated O
sent1200 sensitive O
sent1200 persons O
sent1200 and O
sent1200 risky O
sent1200 group O
sent1200 as O
sent1200 well O
sent1200 as O
sent1200 long O
sent1200 terme O
sent1200 effects O
sent1200 , O
sent1200 and O
sent1200 chronic O
sent1200 exposition O
sent1200 effects O
sent1201 The O
sent1201 search O
sent1201 of O
sent1201 solutions O
sent1201 needs O
sent1201 multiple O
sent1201 competences O
sent1201 from O
sent1201 the O
sent1201 physician O
sent1201 , O
sent1201 who O
sent1201 has O
sent1201 to O
sent1201 play O
sent1201 an O
sent1201 essential O
sent1201 role O
sent1202 Dioxins O
sent1202 are O
sent1202 a O
sent1202 family O
sent1202 of O
sent1202 chlorinated O
sent1202 aromatic O
sent1202 hydrocarbons O
sent1202 that O
sent1202 are O
sent1202 produced O
sent1202 during O
sent1202 combustion O
sent1202 processes O
sent1202 in O
sent1202 the O
sent1202 presence O
sent1202 of O
sent1202 a O
sent1202 chlorine O
sent1202 donor O
sent1202 and O
sent1202 as O
sent1202 by-products O
sent1202 of O
sent1202 the O
sent1202 chlorine-processing O
sent1202 chemical O
sent1202 industries O
sent1203 Several O
sent1203 dioxins O
sent1203 are O
sent1203 extremely O
sent1203 stable O
sent1203 compounds O
sent1203 and O
sent1203 persist O
sent1203 for O
sent1203 years O
sent1203 in O
sent1203 the O
sent1203 environment O
sent1204 Exposure O
sent1204 to O
sent1204 dioxins O
sent1204 occurs O
sent1204 mainly O
sent1204 via O
sent1204 the O
sent1204 ingestion O
sent1204 of O
sent1204 contaminated O
sent1204 food O
sent1205 The O
sent1205 lipophilic O
sent1205 character O
sent1205 of O
sent1205 dioxins O
sent1205 prevents O
sent1205 their O
sent1205 excretion O
sent1205 in O
sent1205 the O
sent1205 urine O
sent1205 and O
sent1205 causes O
sent1205 their O
sent1205 accumulation O
sent1205 in O
sent1205 body O
sent1205 fat O
sent1206 The O
sent1206 mechanisms O
sent1206 of O
sent1206 dioxin O
sent1206 action O
sent1206 are O
sent1206 similar O
sent1206 to O
sent1206 those O
sent1206 of O
sent1206 a O
sent1206 hormone O
sent1207 Dioxins O
sent1207 bind O
sent1207 to O
sent1207 a O
sent1207 specific O
sent1207 intracellular O
sent1207 receptor O
sent1207 and O
sent1207 the O
sent1207 complex O
sent1207 acts O
sent1207 as O
sent1207 a O
sent1207 transcription O
sent1207 factor O
sent1207 that O
sent1207 induces O
sent1207 the O
sent1207 production O
sent1207 of O
sent1207 a O
sent1207 great O
sent1207 number O
sent1207 of O
sent1207 proteins O
sent1208 Certain O
sent1208 dioxins O
sent1208 , O
sent1208 particularly O
sent1208 2 O
sent1208 , O
sent1208 3 O
sent1208 , O
sent1208 7 O
sent1208 , O
sent1208 8-tetrachlorodibenzo-p-dioxin O
sent1208 , O
sent1208 are O
sent1208 very O
sent1208 toxic O
sent1208 and O
sent1208 able O
sent1208 to O
sent1208 induce O
sent1208 numerous O
sent1208 clinical O
sent1208 conditions O
sent1209 The O
sent1209 carcinogenicity O
sent1209 of O
sent1209 dioxins O
sent1209 is O
sent1209 well O
sent1209 documented O
sent1209 in O
sent1209 animal O
sent1209 models O
sent1209 and O
sent1209 has O
sent1209 been O
sent1209 described O
sent1209 in O
sent1209 humans O
sent1209 after O
sent1209 professional O
sent1209 and O
sent1209 accidental O
sent1209 exposures O
sent1210 Recent O
sent1210 experimental O
sent1210 data O
sent1210 also O
sent1210 indicate O
sent1210 that O
sent1210 dioxins O
sent1210 can O
sent1210 cause O
sent1210 dysfunction D
sent1210 of D
sent1210 the D
sent1210 sexual D
sent1210 and D
sent1210 thyroid D
sent1210 hormone D
sent1210 systems D
sent1210 and O
sent1210 that O
sent1210 the O
sent1210 administration O
sent1210 of O
sent1210 dioxins O
sent1210 induces O
sent1210 several O
sent1210 conditions O
sent1210 related O
sent1210 to O
sent1210 hormonal D
sent1210 dysfunction D
sent1211 Chronic O
sent1211 exposure O
sent1211 of O
sent1211 female O
sent1211 Rhesus O
sent1211 monkeys O
sent1211 increases O
sent1211 the O
sent1211 incidence O
sent1211 and O
sent1211 severity O
sent1211 of O
sent1211 endometriosis D
sent1212 The O
sent1212 administration O
sent1212 of O
sent1212 dioxins O
sent1212 during O
sent1212 pregnancy O
sent1212 and O
sent1212 nursing O
sent1212 causes O
sent1212 altered O
sent1212 development O
sent1212 of O
sent1212 the O
sent1212 reproductive O
sent1212 system O
sent1212 , O
sent1212 decreased O
sent1212 spermatogenesis O
sent1212 , O
sent1212 hypothyroidism D
sent1212 and O
sent1212 disturbed O
sent1212 psychomotor O
sent1212 development O
sent1212 in O
sent1212 the O
sent1212 offspring O
sent1213 The O
sent1213 particular O
sent1213 sensibility O
sent1213 of O
sent1213 the O
sent1213 fetus O
sent1213 and O
sent1213 newborn O
sent1213 is O
sent1213 of O
sent1213 concern O
sent1213 because O
sent1213 the O
sent1213 exposition O
sent1213 to O
sent1213 dioxins O
sent1213 is O
sent1213 particularly O
sent1213 important O
sent1213 during O
sent1213 those O
sent1213 periods O
sent1213 of O
sent1213 life O
sent1214 In O
sent1214 humans O
sent1214 a O
sent1214 series O
sent1214 of O
sent1214 conditions O
sent1214 related O
sent1214 to O
sent1214 hormonal D
sent1214 dysfunction D
sent1214 as O
sent1214 undescended O
sent1214 testis O
sent1214 , O
sent1214 decreased O
sent1214 spermatogenesis O
sent1214 , O
sent1214 testicular D
sent1214 cancer D
sent1214 and O
sent1214 endometriosis D
sent1214 have O
sent1214 increased O
sent1214 in O
sent1214 incidence O
sent1214 during O
sent1214 the O
sent1214 last O
sent1214 decades O
sent1215 The O
sent1215 chronological O
sent1215 parallelism O
sent1215 with O
sent1215 the O
sent1215 appearance O
sent1215 of O
sent1215 dioxins O
sent1215 in O
sent1215 the O
sent1215 environment O
sent1215 suggests O
sent1215 that O
sent1215 these O
sent1215 might O
sent1215 exert O
sent1215 biological O
sent1215 effects O
sent1215 at O
sent1215 the O
sent1215 prevailing O
sent1215 level O
sent1215 of O
sent1215 exposure O
sent1216 Nevertheless O
sent1216 this O
sent1216 hypothesis O
sent1216 is O
sent1216 currently O
sent1216 unconfirmed O
sent1216 by O
sent1216 epidemiological O
sent1216 studies O
sent1217 The O
sent1217 implications O
sent1217 of O
sent1217 this O
sent1217 scientific O
sent1217 incertitude O
sent1217 for O
sent1217 the O
sent1217 implementation O
sent1217 of O
sent1217 preventive O
sent1217 measures O
sent1217 are O
sent1217 briefly O
sent1217 discussed O
sent1218 This O
sent1218 presentation O
sent1218 summarizes O
sent1218 the O
sent1218 debate O
sent1218 on O
sent1218 the O
sent1218 suggested O
sent1218 progressive O
sent1218 impairment O
sent1218 of O
sent1218 semen O
sent1218 quality O
sent1218 ( O
sent1218 the O
sent1218 `` O
sent1218 sperm O
sent1218 fall O
sent1218 '' O
sent1218 ) O
sent1218 in O
sent1218 the O
sent1218 last O
sent1218 forty O
sent1218 years O
sent1218 in O
sent1218 the O
sent1218 developed O
sent1218 countries O
sent1219 The O
sent1219 various O
sent1219 available O
sent1219 data O
sent1219 strongly O
sent1219 suggesting O
sent1219 an O
sent1219 environmental O
sent1219 toxic O
sent1219 origin O
sent1219 for O
sent1219 the O
sent1219 `` O
sent1219 sperm O
sent1219 fall O
sent1219 '' O
sent1219 will O
sent1219 be O
sent1219 presented O
sent1219 as O
sent1219 well O
sent1219 as O
sent1219 the O
sent1219 most O
sent1219 frequently O
sent1219 suspected O
sent1219 class O
sent1219 of O
sent1219 substances O
sent1219 , O
sent1219 the O
sent1219 xenoestrogens O
sent1220 Diabetes D
sent1220 mellitus D
sent1220 is O
sent1220 a O
sent1220 still O
sent1220 growing O
sent1220 disease O
sent1221 New O
sent1221 diagnostic O
sent1221 criteria O
sent1221 lowered O
sent1221 the O
sent1221 cut O
sent1221 off O
sent1221 value O
sent1221 to O
sent1221 126 O
sent1221 mg/dl O
sent1221 , O
sent1221 in O
sent1221 order O
sent1221 to O
sent1221 detect O
sent1221 more O
sent1221 rapidly O
sent1221 diabetes D
sent1221 and O
sent1221 its O
sent1221 complications O
sent1222 The O
sent1222 treatment O
sent1222 of O
sent1222 diabetes D
sent1222 2 D
sent1222 by O
sent1222 the O
sent1222 classic T
sent1222 oral T
sent1222 antidiabetic T
sent1222 drugs T
sent1222 ( T
sent1222 sulfamides T
sent1222 and T
sent1222 biguanides T
sent1222 ) T
sent1222 is O
sent1222 completed O
sent1222 by O
sent1222 intestinal T
sent1222 glycosidases T
sent1222 inhibitors T
sent1222 and O
sent1222 thiazolidendiones T
sent1223 These O
sent1223 last O
sent1223 drugs O
sent1223 seem O
sent1223 very O
sent1223 attractive O
sent1223 because O
sent1223 they O
sent1223 decrease O
sent1223 insulin O
sent1223 resistance O
sent1223 in O
sent1223 obese O
sent1223 , O
sent1223 diabetics O
sent1224 Their O
sent1224 hepatic O
sent1224 side O
sent1224 effects O
sent1224 must O
sent1224 be O
sent1224 however O
sent1224 under O
sent1224 control O
sent1225 Better O
sent1225 knowledge O
sent1225 of O
sent1225 non O
sent1225 lipidic O
sent1225 effects O
sent1225 of O
sent1225 statins O
sent1225 on O
sent1225 the O
sent1225 arterial O
sent1225 wall O
sent1225 and O
sent1225 the O
sent1225 discovery O
sent1225 of O
sent1225 the O
sent1225 action O
sent1225 of O
sent1225 fibrates O
sent1225 on O
sent1225 PPAR O
sent1225 ( O
sent1225 Peroxisome O
sent1225 Proliferator O
sent1225 Activated O
sent1225 Receptors O
sent1225 ) O
sent1225 improved O
sent1225 strongly O
sent1225 the O
sent1225 therapeutic O
sent1225 management O
sent1225 of O
sent1225 hyperlipidemias D
sent1226 Recent O
sent1226 intervention O
sent1226 studies O
sent1226 have O
sent1226 demonstrated O
sent1226 the O
sent1226 necessity O
sent1226 to O
sent1226 treat O
sent1226 vigorously O
sent1226 dysipidemias D
sent1227 < O
sent1227 TO_SEE O
sent1227 > O
sent1227 Despite O
sent1227 Beta-blockade T
sent1227 therapy T
sent1227 has O
sent1227 been O
sent1227 considered O
sent1227 as O
sent1227 an O
sent1227 absolute O
sent1227 contraindication O
sent1227 in O
sent1227 the O
sent1227 treatment O
sent1227 of O
sent1227 heart D
sent1227 failure D
sent1227 , O
sent1227 it O
sent1227 has O
sent1227 been O
sent1227 shown O
sent1227 that O
sent1227 they O
sent1227 could O
sent1227 have O
sent1227 a O
sent1227 beneficial O
sent1227 effect O
sent1227 , O
sent1227 provided O
sent1227 that O
sent1227 they O
sent1227 were O
sent1227 introduced O
sent1227 at O
sent1227 very O
sent1227 low O
sent1227 dose O
sent1227 , O
sent1227 and O
sent1227 very O
sent1227 progressively O
sent1227 in O
sent1227 addition O
sent1227 of O
sent1227 the O
sent1227 traditional O
sent1227 treatment O
sent1228 The O
sent1228 advances O
sent1228 in O
sent1228 the O
sent1228 understanding O
sent1228 of O
sent1228 the O
sent1228 neuro-hormonal O
sent1228 mechanisms O
sent1228 of O
sent1228 heart O
sent1228 failure O
sent1228 have O
sent1228 modified O
sent1228 the O
sent1228 therapeutic O
sent1228 strategy O
sent1228 : O
sent1228 the O
sent1228 deleterious O
sent1228 effect O
sent1228 of O
sent1228 the O
sent1228 activation O
sent1228 of O
sent1228 the O
sent1228 sympathetic O
sent1228 nervous O
sent1228 system O
sent1228 on O
sent1228 the O
sent1228 myocardium O
sent1228 has O
sent1228 served O
sent1228 as O
sent1228 the O
sent1228 rationale O
sent1228 for O
sent1228 randomized O
sent1228 clinical O
sent1228 trials O
sent1228 comparing O
sent1228 beta-blockade O
sent1228 to O
sent1228 placebo O
sent1228 : O
sent1228 the O
sent1228 current O
sent1228 data O
sent1228 are O
sent1228 promising O
sent1228 , O
sent1228 suggesting O
sent1228 a O
sent1228 beneficial O
sent1228 effect O
sent1228 on O
sent1228 survival O
sent1228 as O
sent1228 well O
sent1228 as O
sent1228 on O
sent1228 quality O
sent1228 of O
sent1228 life O
sent1229 However O
sent1229 , O
sent1229 these O
sent1229 results O
sent1229 have O
sent1229 to O
sent1229 be O
sent1229 confirmed O
sent1229 by O
sent1229 larger O
sent1229 trials O
sent1229 , O
sent1229 currently O
sent1229 underway O
sent1229 , O
sent1229 before O
sent1229 to O
sent1229 consider O
sent1229 that O
sent1229 beta-blockade O
sent1229 should O
sent1229 definitely O
sent1229 be O
sent1229 incorporated O
sent1229 in O
sent1229 the O
sent1229 treatment O
sent1229 of O
sent1229 heart O
sent1229 failure O
sent1230 Calcium T
sent1230 antagonists T
sent1230 have O
sent1230 been O
sent1230 used O
sent1230 for O
sent1230 treatment O
sent1230 of O
sent1230 cardiovascular D
sent1230 diseases D
sent1230 for O
sent1230 more O
sent1230 than O
sent1230 25 O
sent1230 years O
sent1231 Several O
sent1231 recent O
sent1231 retrospective O
sent1231 studies O
sent1231 have O
sent1231 suggested O
sent1231 that O
sent1231 chronic O
sent1231 treatment O
sent1231 with O
sent1231 short-acting T
sent1231 dihydropyridines T
sent1231 increased O
sent1231 the O
sent1231 incidence O
sent1231 of O
sent1231 cardiac D
sent1231 events D
sent1231 , O
sent1231 cancer D
sent1231 and O
sent1231 gastrointestinal D
sent1231 bleedings D
sent1232 Randomized O
sent1232 prospective O
sent1232 studies O
sent1232 have O
sent1232 , O
sent1232 however O
sent1232 , O
sent1232 never O
sent1232 been O
sent1232 able O
sent1232 to O
sent1232 confirm O
sent1232 these O
sent1232 observations O
sent1233 In O
sent1233 addition O
sent1233 , O
sent1233 well-conducted O
sent1233 studies O
sent1233 using O
sent1233 verapamil T
sent1233 and O
sent1233 diltiazem T
sent1233 have O
sent1233 suggested O
sent1233 that O
sent1233 these O
sent1233 calcium T
sent1233 antagonists T
sent1233 may O
sent1233 even O
sent1233 improve O
sent1233 cardiovascular D
sent1233 mortality D
sent1233 and D
sent1233 morbidity D
sent1233 of O
sent1233 the O
sent1233 hypertensive O
sent1233 patient O
sent1234 < O
sent1234 TO_SEE O
sent1234 > O
sent1234 There O
sent1234 is O
sent1234 therefore O
sent1234 no O
sent1234 reason O
sent1234 to O
sent1234 believe O
sent1234 that O
sent1234 the O
sent1234 questionable O
sent1234 results O
sent1234 derived O
sent1234 from O
sent1234 retrospective O
sent1234 studies O
sent1234 of O
sent1234 the O
sent1234 effects O
sent1234 of O
sent1234 short-acting O
sent1234 calcium O
sent1234 antagonists O
sent1234 on O
sent1234 cardiac O
sent1234 and O
sent1234 noncardiac O
sent1234 events O
sent1234 may O
sent1234 apply O
sent1234 to O
sent1234 the O
sent1234 newer O
sent1234 generation O
sent1234 of O
sent1234 long-acting O
sent1234 calcium O
sent1234 antagonists O
sent1235 Sumatriptan T
sent1235 and O
sent1235 other O
sent1235 selective O
sent1235 serotonin T
sent1235 agonists T
sent1235 represent O
sent1235 a O
sent1235 major O
sent1235 breakthrough O
sent1235 in O
sent1235 acute D
sent1235 migraine D
sent1235 treatment O
sent1236 These O
sent1236 drugs O
sent1236 are O
sent1236 very O
sent1236 efficacious O
sent1236 and O
sent1236 generally O
sent1236 devoided O
sent1236 of O
sent1236 important O
sent1236 side O
sent1236 effects O
sent1236 , O
sent1236 but O
sent1236 they O
sent1236 are O
sent1236 expensive O
sent1236 and O
sent1236 therefore O
sent1236 have O
sent1236 to O
sent1236 be O
sent1236 compared O
sent1236 with O
sent1236 other O
sent1236 , O
sent1236 more O
sent1236 conventional O
sent1236 drugs O
sent1236 with O
sent1236 established O
sent1236 or O
sent1236 assumed O
sent1236 efficacy O
sent1237 We O
sent1237 summarize O
sent1237 the O
sent1237 pharmacologic O
sent1237 characteristics O
sent1237 of O
sent1237 Sumatriptan T
sent1237 and O
sent1237 give O
sent1237 recommendations O
sent1237 about O
sent1237 its O
sent1237 use O
sent1237 in O
sent1237 clinical O
sent1237 practice O
sent1238 Fiercer O
sent1238 competition O
sent1238 between O
sent1238 athletes O
sent1238 and O
sent1238 a O
sent1238 wider O
sent1238 knowledge O
sent1238 of O
sent1238 optimal O
sent1238 training O
sent1238 regimens O
sent1238 dramatically O
sent1238 influence O
sent1238 current O
sent1238 training O
sent1238 methods O
sent1239 A O
sent1239 single O
sent1239 training O
sent1239 bout O
sent1239 per O
sent1239 day O
sent1239 was O
sent1239 previously O
sent1239 considered O
sent1239 sufficient O
sent1239 , O
sent1239 whereas O
sent1239 today O
sent1239 athletes O
sent1239 regularly O
sent1239 train O
sent1239 twice O
sent1239 a O
sent1239 day O
sent1239 or O
sent1239 more O
sent1240 Consequently O
sent1240 , O
sent1240 the O
sent1240 number O
sent1240 of O
sent1240 athletes O
sent1240 who O
sent1240 are O
sent1240 overtraining O
sent1240 and O
sent1240 have O
sent1240 insufficient O
sent1240 rest O
sent1240 is O
sent1240 increasing O
sent1241 Positive O
sent1241 overtraining O
sent1241 can O
sent1241 be O
sent1241 regarded O
sent1241 as O
sent1241 a O
sent1241 natural O
sent1241 process O
sent1241 when O
sent1241 the O
sent1241 end O
sent1241 result O
sent1241 is O
sent1241 adaptation O
sent1241 and O
sent1241 improved O
sent1241 performance O
sent1241 : O
sent1241 the O
sent1241 supercompensation O
sent1241 principle O
sent1241 -- O
sent1241 which O
sent1241 includes O
sent1241 the O
sent1241 breakdown O
sent1241 process O
sent1241 ( O
sent1241 training O
sent1241 ) O
sent1241 followed O
sent1241 by O
sent1241 the O
sent1241 recovery O
sent1241 process O
sent1241 ( O
sent1241 rest O
sent1241 ) O
sent1241 -- O
sent1241 is O
sent1241 well O
sent1241 known O
sent1241 in O
sent1241 sports O
sent1242 However O
sent1242 , O
sent1242 negative O
sent1242 overtraining O
sent1242 , O
sent1242 causing O
sent1242 maladaptation O
sent1242 and O
sent1242 other O
sent1242 negative O
sent1242 consequences O
sent1242 such O
sent1242 as O
sent1242 staleness O
sent1242 , O
sent1242 can O
sent1242 occur O
sent1243 Physiological O
sent1243 , O
sent1243 psychological O
sent1243 , O
sent1243 biochemical O
sent1243 and O
sent1243 immunological O
sent1243 symptoms O
sent1243 must O
sent1243 be O
sent1243 considered O
sent1243 , O
sent1243 both O
sent1243 independently O
sent1243 and O
sent1243 together O
sent1243 , O
sent1243 to O
sent1243 fully O
sent1243 understand O
sent1243 the O
sent1243 'staleness O
sent1243 ' O
sent1243 syndrome O
sent1244 However O
sent1244 , O
sent1244 psychological O
sent1244 testing O
sent1244 may O
sent1244 reveal O
sent1244 early-warning O
sent1244 signs O
sent1244 more O
sent1244 readily O
sent1244 than O
sent1244 the O
sent1244 various O
sent1244 physiological O
sent1244 or O
sent1244 immunological O
sent1244 markers O
sent1245 The O
sent1245 time O
sent1245 frame O
sent1245 of O
sent1245 training O
sent1245 and O
sent1245 recovery O
sent1245 is O
sent1245 also O
sent1245 important O
sent1245 since O
sent1245 the O
sent1245 consequences O
sent1245 of O
sent1245 negative O
sent1245 overtraining O
sent1245 comprise O
sent1245 an O
sent1245 overtraining-response O
sent1245 continuum O
sent1245 from O
sent1245 short O
sent1245 to O
sent1245 long O
sent1245 term O
sent1245 effects O
sent1246 An O
sent1246 athlete O
sent1246 failing O
sent1246 to O
sent1246 recover O
sent1246 within O
sent1246 72 O
sent1246 hours O
sent1246 has O
sent1246 presumably O
sent1246 negatively O
sent1246 overtrained O
sent1246 and O
sent1246 is O
sent1246 in O
sent1246 an O
sent1246 overreached O
sent1246 state O
sent1247 For O
sent1247 an O
sent1247 elite O
sent1247 athlete O
sent1247 to O
sent1247 refrain O
sent1247 from O
sent1247 training O
sent1247 for O
sent1247 > O
sent1247 72 O
sent1247 hours O
sent1247 is O
sent1247 extremely O
sent1247 undesirable O
sent1247 , O
sent1247 highlighting O
sent1247 the O
sent1247 importance O
sent1247 of O
sent1247 a O
sent1247 carefully O
sent1247 monitored O
sent1247 recovery O
sent1247 process O
sent1248 There O
sent1248 are O
sent1248 many O
sent1248 methods O
sent1248 used O
sent1248 to O
sent1248 measure O
sent1248 the O
sent1248 training O
sent1248 process O
sent1248 but O
sent1248 few O
sent1248 with O
sent1248 which O
sent1248 to O
sent1248 match O
sent1248 the O
sent1248 recovery O
sent1248 process O
sent1248 against O
sent1248 it O
sent1249 One O
sent1249 such O
sent1249 framework O
sent1249 for O
sent1249 this O
sent1249 is O
sent1249 referred O
sent1249 to O
sent1249 as O
sent1249 the O
sent1249 total O
sent1249 quality O
sent1249 recovery O
sent1249 ( O
sent1249 TQR O
sent1249 ) O
sent1249 process O
sent1250 By O
sent1250 using O
sent1250 a O
sent1250 TQR O
sent1250 scale O
sent1250 , O
sent1250 structured O
sent1250 around O
sent1250 the O
sent1250 scale O
sent1250 developed O
sent1250 for O
sent1250 ratings O
sent1250 of O
sent1250 perceived O
sent1250 exertion O
sent1250 ( O
sent1250 RPE O
sent1250 ) O
sent1250 , O
sent1250 the O
sent1250 recovery O
sent1250 process O
sent1250 can O
sent1250 be O
sent1250 monitored O
sent1250 and O
sent1250 matched O
sent1250 against O
sent1250 the O
sent1250 breakdown O
sent1250 ( O
sent1250 training O
sent1250 ) O
sent1250 process O
sent1250 ( O
sent1250 TQR O
sent1250 versus O
sent1250 RPE O
sent1250 ) O
sent1251 The O
sent1251 TQR O
sent1251 scale O
sent1251 emphasises O
sent1251 both O
sent1251 the O
sent1251 athlete O
sent1251 's O
sent1251 perception O
sent1251 of O
sent1251 recovery O
sent1251 and O
sent1251 the O
sent1251 importance O
sent1251 of O
sent1251 active O
sent1251 measures O
sent1251 to O
sent1251 improve O
sent1251 the O
sent1251 recovery O
sent1251 process O
sent1252 Furthermore O
sent1252 , O
sent1252 directing O
sent1252 attention O
sent1252 to O
sent1252 psychophysiological O
sent1252 cues O
sent1252 serves O
sent1252 the O
sent1252 same O
sent1252 purpose O
sent1252 as O
sent1252 in O
sent1252 RPE O
sent1252 , O
sent1252 i.e O
sent1252 . O
sent1252 increasing O
sent1252 self-awareness O
sent1253 This O
sent1253 article O
sent1253 reviews O
sent1253 and O
sent1253 conceptualises O
sent1253 the O
sent1253 whole O
sent1253 overtraining O
sent1253 process O
sent1254 In O
sent1254 doing O
sent1254 so O
sent1254 , O
sent1254 it O
sent1254 ( O
sent1254 i O
sent1254 ) O
sent1254 aims O
sent1254 to O
sent1254 differentiate O
sent1254 between O
sent1254 the O
sent1254 types O
sent1254 of O
sent1254 stress O
sent1254 affecting O
sent1254 an O
sent1254 athlete O
sent1254 's O
sent1254 performance O
sent1254 : O
sent1254 ( O
sent1254 ii O
sent1254 ) O
sent1254 identifies O
sent1254 factors O
sent1254 influencing O
sent1254 an O
sent1254 athlete O
sent1254 's O
sent1254 ability O
sent1254 to O
sent1254 adapt O
sent1254 to O
sent1254 physical O
sent1254 training O
sent1254 : O
sent1254 ( O
sent1254 iii O
sent1254 ) O
sent1254 structures O
sent1254 the O
sent1254 recovery O
sent1254 process O
sent1255 The O
sent1255 TQR O
sent1255 method O
sent1255 to O
sent1255 facilitate O
sent1255 monitoring O
sent1255 of O
sent1255 the O
sent1255 recovery O
sent1255 process O
sent1255 is O
sent1255 then O
sent1255 suggested O
sent1255 and O
sent1255 a O
sent1255 conceptual O
sent1255 model O
sent1255 that O
sent1255 incorporates O
sent1255 all O
sent1255 of O
sent1255 the O
sent1255 important O
sent1255 parameters O
sent1255 for O
sent1255 performance O
sent1255 gain O
sent1255 ( O
sent1255 adaptation O
sent1255 ) O
sent1255 and O
sent1255 loss O
sent1255 ( O
sent1255 maladaptation O
sent1255 ) O
sent1256 Little O
sent1256 attention O
sent1256 has O
sent1256 been O
sent1256 directed O
sent1256 toward O
sent1256 identifying O
sent1256 the O
sent1256 changes O
sent1256 which O
sent1256 occur O
sent1256 in O
sent1256 salivary O
sent1256 composition O
sent1256 in O
sent1256 response O
sent1256 to O
sent1256 exercise O
sent1257 To O
sent1257 address O
sent1257 this O
sent1257 , O
sent1257 our O
sent1257 article O
sent1257 first O
sent1257 refers O
sent1257 to O
sent1257 the O
sent1257 main O
sent1257 aspects O
sent1257 of O
sent1257 salivary O
sent1257 gland O
sent1257 physiology O
sent1258 A O
sent1258 knowledge O
sent1258 of O
sent1258 the O
sent1258 neural O
sent1258 control O
sent1258 of O
sent1258 salivary O
sent1258 secretion O
sent1258 is O
sent1258 especially O
sent1258 important O
sent1258 for O
sent1258 the O
sent1258 understanding O
sent1258 of O
sent1258 the O
sent1258 effects O
sent1258 of O
sent1258 exertion O
sent1258 on O
sent1258 salivary O
sent1258 secretion O
sent1259 Both O
sent1259 salivary O
sent1259 output O
sent1259 and O
sent1259 composition O
sent1259 depend O
sent1259 on O
sent1259 the O
sent1259 activity O
sent1259 of O
sent1259 the O
sent1259 autonomic O
sent1259 nervous O
sent1259 system O
sent1259 and O
sent1259 any O
sent1259 modification O
sent1259 of O
sent1259 this O
sent1259 activity O
sent1259 can O
sent1259 be O
sent1259 observed O
sent1259 indirectly O
sent1259 by O
sent1259 alternations O
sent1259 in O
sent1259 the O
sent1259 salivary O
sent1259 excretion O
sent1260 The O
sent1260 effects O
sent1260 of O
sent1260 physical O
sent1260 activity O
sent1260 ( O
sent1260 with O
sent1260 reference O
sent1260 to O
sent1260 factors O
sent1260 such O
sent1260 as O
sent1260 exercise O
sent1260 intensity O
sent1260 and O
sent1260 duration O
sent1260 , O
sent1260 or O
sent1260 type O
sent1260 of O
sent1260 exercise O
sent1260 protocol O
sent1260 ) O
sent1260 on O
sent1260 salivary O
sent1260 composition O
sent1260 are O
sent1260 then O
sent1260 considered O
sent1261 Exercise O
sent1261 might O
sent1261 indeed O
sent1261 induce O
sent1261 changes O
sent1261 in O
sent1261 several O
sent1261 salivary O
sent1261 components O
sent1261 such O
sent1261 as O
sent1261 immunoglobulins O
sent1261 , O
sent1261 hormones O
sent1261 , O
sent1261 lactate O
sent1261 , O
sent1261 proteins O
sent1261 and O
sent1261 electrolytes O
sent1262 Saliva O
sent1262 composition O
sent1262 might O
sent1262 therefore O
sent1262 be O
sent1262 used O
sent1262 as O
sent1262 an O
sent1262 alternative O
sent1262 noninvasive O
sent1262 indicator O
sent1262 of O
sent1262 the O
sent1262 response O
sent1262 of O
sent1262 the O
sent1262 different O
sent1262 body O
sent1262 tissues O
sent1262 and O
sent1262 systems O
sent1262 to O
sent1262 physical O
sent1262 exertion O
sent1263 In O
sent1263 this O
sent1263 respect O
sent1263 , O
sent1263 the O
sent1263 response O
sent1263 of O
sent1263 salivary O
sent1263 amylase O
sent1263 and O
sent1263 salivary O
sent1263 electrolytes O
sent1263 to O
sent1263 incremental O
sent1263 levels O
sent1263 of O
sent1263 exercise O
sent1263 is O
sent1263 of O
sent1263 particular O
sent1263 interest O
sent1264 Beyond O
sent1264 a O
sent1264 certain O
sent1264 intensity O
sent1264 of O
sent1264 exercise O
sent1264 , O
sent1264 and O
sent1264 coinciding O
sent1264 with O
sent1264 the O
sent1264 accumulation O
sent1264 of O
sent1264 blood O
sent1264 lactate O
sent1264 ( O
sent1264 anaerobic O
sent1264 threshold O
sent1264 or O
sent1264 AT O
sent1264 ) O
sent1264 , O
sent1264 a O
sent1264 'saliva O
sent1264 threshold O
sent1264 ' O
sent1264 ( O
sent1264 Tsa O
sent1264 ) O
sent1264 does O
sent1264 indeed O
sent1264 exist O
sent1265 Tsa O
sent1265 is O
sent1265 the O
sent1265 point O
sent1265 during O
sent1265 exercise O
sent1265 at O
sent1265 which O
sent1265 the O
sent1265 levels O
sent1265 of O
sent1265 salivary O
sent1265 alpha-amylase O
sent1265 and O
sent1265 electrolytes O
sent1265 ( O
sent1265 especially O
sent1265 Na+ O
sent1265 ) O
sent1265 also O
sent1265 begin O
sent1265 to O
sent1265 rise O
sent1265 above O
sent1265 baseline O
sent1265 levels O
sent1266 The O
sent1266 occurrence O
sent1266 of O
sent1266 the O
sent1266 2 O
sent1266 thresholds O
sent1266 ( O
sent1266 AT O
sent1266 and O
sent1266 Tsa O
sent1266 ) O
sent1266 might O
sent1266 , O
sent1266 in O
sent1266 turn O
sent1266 , O
sent1266 be O
sent1266 attributable O
sent1266 to O
sent1266 the O
sent1266 same O
sent1266 underlying O
sent1266 mechanism O
sent1266 , O
sent1266 that O
sent1266 of O
sent1266 increased O
sent1266 adrenal O
sent1266 sympathetic O
sent1266 activity O
sent1266 at O
sent1266 high O
sent1266 exercise O
sent1266 intensities O
sent1267 Fat O
sent1267 is O
sent1267 an O
sent1267 extremely O
sent1267 important O
sent1267 substrate O
sent1267 for O
sent1267 muscle O
sent1267 contraction O
sent1267 , O
sent1267 both O
sent1267 at O
sent1267 rest O
sent1267 and O
sent1267 during O
sent1267 exercise O
sent1268 Triglycerides O
sent1268 ( O
sent1268 TGs O
sent1268 ) O
sent1268 , O
sent1268 stored O
sent1268 in O
sent1268 adipose O
sent1268 tissue O
sent1268 and O
sent1268 within O
sent1268 muscle O
sent1268 fibres O
sent1268 , O
sent1268 are O
sent1268 considered O
sent1268 to O
sent1268 be O
sent1268 the O
sent1268 main O
sent1268 source O
sent1268 of O
sent1268 the O
sent1268 free O
sent1268 fatty O
sent1268 acids O
sent1268 ( O
sent1268 FFAs O
sent1268 ) O
sent1268 oxidised O
sent1268 during O
sent1268 exercise O
sent1269 It O
sent1269 is O
sent1269 still O
sent1269 unclear O
sent1269 , O
sent1269 however O
sent1269 , O
sent1269 how O
sent1269 the O
sent1269 use O
sent1269 of O
sent1269 these O
sent1269 substrates O
sent1269 is O
sent1269 regulated O
sent1269 during O
sent1269 exercise O
sent1270 The O
sent1270 regulation O
sent1270 seems O
sent1270 to O
sent1270 be O
sent1270 multifactorial O
sent1270 and O
sent1270 includes O
sent1270 : O
sent1270 ( O
sent1270 i O
sent1270 ) O
sent1270 dietary O
sent1270 and O
sent1270 nutritional O
sent1270 status O
sent1270 ; O
sent1270 ( O
sent1270 ii O
sent1270 ) O
sent1270 hormonal O
sent1270 milieu O
sent1270 ; O
sent1270 ( O
sent1270 iii O
sent1270 ) O
sent1270 exercise O
sent1270 mode O
sent1270 , O
sent1270 intensity O
sent1270 and O
sent1270 duration O
sent1270 ; O
sent1270 and O
sent1270 ( O
sent1270 iv O
sent1270 ) O
sent1270 training O
sent1270 status O
sent1271 On O
sent1271 the O
sent1271 other O
sent1271 hand O
sent1271 , O
sent1271 the O
sent1271 mechanism O
sent1271 for O
sent1271 FFA O
sent1271 transport O
sent1271 from O
sent1271 its O
sent1271 storage O
sent1271 as O
sent1271 triglycerides O
sent1271 in O
sent1271 adipose O
sent1271 tissue O
sent1271 and O
sent1271 muscle O
sent1271 to O
sent1271 its O
sent1271 place O
sent1271 of O
sent1271 utilisation O
sent1271 in O
sent1271 heart O
sent1271 , O
sent1271 skeletal O
sent1271 muscle O
sent1271 , O
sent1271 kidney O
sent1271 and O
sent1271 liver O
sent1271 is O
sent1271 more O
sent1271 clearly O
sent1271 understood O
sent1272 It O
sent1272 has O
sent1272 been O
sent1272 determined O
sent1272 that O
sent1272 the O
sent1272 plasma O
sent1272 FFA O
sent1272 turnover O
sent1272 rate O
sent1272 is O
sent1272 sufficiently O
sent1272 rapid O
sent1272 to O
sent1272 account O
sent1272 for O
sent1272 most O
sent1272 of O
sent1272 the O
sent1272 fat O
sent1272 metabolised O
sent1272 during O
sent1272 low O
sent1272 intensity O
sent1272 exercise O
sent1272 ( O
sent1272 25 O
sent1272 to O
sent1272 40 O
sent1272 % O
sent1272 VO2max O
sent1272 ) O
sent1273 However O
sent1273 , O
sent1273 an O
sent1273 exercise O
sent1273 intensity O
sent1273 of O
sent1273 65 O
sent1273 % O
sent1273 VO2max O
sent1273 results O
sent1273 in O
sent1273 a O
sent1273 slight O
sent1273 decrease O
sent1273 in O
sent1273 the O
sent1273 amount O
sent1273 of O
sent1273 plasma O
sent1273 FFA O
sent1273 uptake O
sent1273 by O
sent1273 muscle O
sent1273 tissue O
sent1274 Other O
sent1274 studies O
sent1274 have O
sent1274 found O
sent1274 that O
sent1274 during O
sent1274 prolonged O
sent1274 exercise O
sent1274 , O
sent1274 muscle O
sent1274 TGs O
sent1274 become O
sent1274 the O
sent1274 predominant O
sent1274 source O
sent1274 of O
sent1274 energy O
sent1274 obtained O
sent1274 from O
sent1274 fat O
sent1275 Furthermore O
sent1275 , O
sent1275 it O
sent1275 is O
sent1275 widely O
sent1275 documented O
sent1275 that O
sent1275 endurance O
sent1275 activities O
sent1275 increase O
sent1275 the O
sent1275 energy O
sent1275 utilisation O
sent1275 from O
sent1275 fat O
sent1275 while O
sent1275 sparing O
sent1275 carbohydrate O
sent1275 sources O
sent1276 For O
sent1276 example O
sent1276 , O
sent1276 during O
sent1276 exercise O
sent1276 on O
sent1276 a O
sent1276 cycle O
sent1276 ergometer O
sent1276 , O
sent1276 nonplasma O
sent1276 FFAs O
sent1276 and O
sent1276 plasma O
sent1276 FFAs O
sent1276 contribute O
sent1276 40 O
sent1276 % O
sent1276 , O
sent1276 and O
sent1276 carbohydrates O
sent1276 60 O
sent1276 % O
sent1276 , O
sent1276 of O
sent1276 the O
sent1276 total O
sent1276 calculated O
sent1276 amount O
sent1276 of O
sent1276 energy O
sent1276 expenditure O
sent1276 before O
sent1276 exercise O
sent1276 and O
sent1276 vice O
sent1276 versa O
sent1276 after O
sent1276 exercise O
sent1276 ( O
sent1276 60 O
sent1276 % O
sent1276 nonplasma O
sent1276 and O
sent1276 plasma O
sent1276 FFAs O
sent1276 and O
sent1276 40 O
sent1276 % O
sent1276 carbohydrates O
sent1276 ) O
sent1277 Although O
sent1277 it O
sent1277 was O
sent1277 many O
sent1277 years O
sent1277 before O
sent1277 it O
sent1277 was O
sent1277 fully O
sent1277 demonstrated O
sent1277 , O
sent1277 fat O
sent1277 is O
sent1277 now O
sent1277 known O
sent1277 to O
sent1277 be O
sent1277 transported O
sent1277 in O
sent1277 the O
sent1277 blood O
sent1277 as O
sent1277 FFA O
sent1277 bound O
sent1277 to O
sent1277 the O
sent1277 protein O
sent1277 carrier O
sent1277 albumin O
sent1278 The O
sent1278 mobilisation O
sent1278 of O
sent1278 FFA O
sent1278 is O
sent1278 primarily O
sent1278 a O
sent1278 function O
sent1278 of O
sent1278 sympathetic O
sent1278 nervous O
sent1278 activity O
sent1278 directed O
sent1278 towards O
sent1278 the O
sent1278 adipocytes O
sent1278 , O
sent1278 or O
sent1278 the O
sent1278 'fat O
sent1278 pad O
sent1278 ' O
sent1278 . O
sent1278 This O
sent1278 nervous O
sent1278 activity O
sent1278 can O
sent1278 be O
sent1278 direct O
sent1278 or O
sent1278 may O
sent1278 be O
sent1278 an O
sent1278 effect O
sent1278 of O
sent1278 circulating O
sent1278 catecholamines O
sent1278 such O
sent1278 as O
sent1278 adrenaline O
sent1278 ( O
sent1278 epinephrine O
sent1278 ) O
sent1279 This O
sent1279 article O
sent1279 summarises O
sent1279 the O
sent1279 role O
sent1279 of O
sent1279 fat O
sent1279 metabolism O
sent1279 during O
sent1279 exercise O
sent1280 As O
sent1280 the O
sent1280 clinical O
sent1280 availability O
sent1280 of O
sent1280 glycohaemoglobin/GHb O
sent1280 measurement O
sent1280 increases O
sent1280 , O
sent1280 so O
sent1280 does O
sent1280 the O
sent1280 need O
sent1280 for O
sent1280 comparable O
sent1280 and O
sent1280 accurate O
sent1280 values O
sent1280 among O
sent1280 different O
sent1280 laboratories O
sent1280 and O
sent1280 different O
sent1280 methods O
sent1281 At O
sent1281 least O
sent1281 there O
sent1281 should O
sent1281 be O
sent1281 comparability O
sent1281 , O
sent1281 i.e O
sent1281 . O
sent1281 , O
sent1281 commutability O
sent1281 or O
sent1281 feasibility O
sent1281 of O
sent1281 providing O
sent1281 comparable O
sent1281 results O
sent1281 from O
sent1281 different O
sent1281 assays O
sent1281 in O
sent1281 different O
sent1281 laboratories O
sent1282 A O
sent1282 clinical O
sent1282 joint O
sent1282 study O
sent1282 on O
sent1282 insulin T
sent1282 therapy T
sent1282 , O
sent1282 a O
sent1282 survey O
sent1282 of O
sent1282 the O
sent1282 actual O
sent1282 inter-laboratory O
sent1282 differences O
sent1282 in O
sent1282 GHb O
sent1282 measurement O
sent1282 among O
sent1282 41 O
sent1282 institutions O
sent1282 and O
sent1282 an O
sent1282 assessment O
sent1282 of O
sent1282 11 O
sent1282 assay O
sent1282 methods O
sent1282 for O
sent1282 the O
sent1282 determination O
sent1282 of O
sent1282 GHb O
sent1282 were O
sent1282 performed O
sent1282 using O
sent1282 commercial O
sent1282 calibrators O
sent1282 and O
sent1282 fresh O
sent1282 blood O
sent1282 samples O
sent1283 Data O
sent1283 on O
sent1283 the O
sent1283 actual O
sent1283 state O
sent1283 of O
sent1283 inter-laboratory O
sent1283 and O
sent1283 inter-assay O
sent1283 differences O
sent1283 of O
sent1283 observed O
sent1283 values O
sent1283 were O
sent1283 useful O
sent1283 for O
sent1283 comparing O
sent1283 results O
sent1283 among O
sent1283 facilities O
sent1284 The O
sent1284 recommendation O
sent1284 of O
sent1284 the O
sent1284 Japan O
sent1284 Diabetes O
sent1284 Society O
sent1284 to O
sent1284 measure O
sent1284 only O
sent1284 the O
sent1284 stable O
sent1284 GHb O
sent1284 component O
sent1284 and O
sent1284 to O
sent1284 correct O
sent1284 the O
sent1284 GHb O
sent1284 percentage O
sent1284 by O
sent1284 two-point O
sent1284 calibration O
sent1284 with O
sent1284 assigned O
sent1284 values O
sent1284 , O
sent1284 was O
sent1284 effective O
sent1284 but O
sent1284 not O
sent1284 sufficient O
sent1285 Even O
sent1285 after O
sent1285 correction O
sent1285 , O
sent1285 8 O
sent1285 out O
sent1285 of O
sent1285 11 O
sent1285 methods O
sent1285 still O
sent1285 remained O
sent1285 of O
sent1285 little O
sent1285 practical O
sent1285 use O
sent1285 because O
sent1285 of O
sent1285 their O
sent1285 large O
sent1285 relative O
sent1285 errors O
sent1286 Inter-method O
sent1286 differences O
sent1286 among O
sent1286 11 O
sent1286 available O
sent1286 assay O
sent1286 methods O
sent1286 were O
sent1286 great O
sent1286 even O
sent1286 after O
sent1286 correction O
sent1286 and O
sent1286 depended O
sent1286 on O
sent1286 not O
sent1286 only O
sent1286 the O
sent1286 methods O
sent1286 but O
sent1286 the O
sent1286 samples O
sent1286 used O
sent1286 for O
sent1286 the O
sent1286 determination O
sent1287 The O
sent1287 performance O
sent1287 of O
sent1287 some O
sent1287 methods O
sent1287 or O
sent1287 instruments O
sent1287 used O
sent1287 are O
sent1287 only O
sent1287 poor O
sent1287 at O
sent1287 distinguishing O
sent1287 the O
sent1287 stable O
sent1287 glycated O
sent1287 haemoglobin O
sent1287 itself O
sent1288 Some O
sent1288 alternative O
sent1288 measurement O
sent1288 system O
sent1288 with O
sent1288 comparability O
sent1288 , O
sent1288 commutability O
sent1288 and O
sent1288 precision O
sent1288 should O
sent1288 be O
sent1288 established O
sent1289 An O
sent1289 urgent O
sent1289 and O
sent1289 worldwide O
sent1289 problem O
sent1289 to O
sent1289 remove O
sent1289 inter-laboratory O
sent1289 differences O
sent1289 in O
sent1289 the O
sent1289 measurement O
sent1289 of O
sent1289 GHb O
sent1289 needs O
sent1289 to O
sent1289 be O
sent1289 solved O
sent1290 Users O
sent1290 in O
sent1290 clinical O
sent1290 practice O
sent1290 must O
sent1290 recognize O
sent1290 these O
sent1290 problems O
sent1290 , O
sent1290 and O
sent1290 , O
sent1290 before O
sent1290 supply O
sent1290 , O
sent1290 the O
sent1290 providers O
sent1290 should O
sent1290 check O
sent1290 their O
sent1290 method O
sent1290 and O
sent1290 keep O
sent1290 records O
sent1290 that O
sent1290 are O
sent1290 readily O
sent1290 traceable O
sent1291 A O
sent1291 postal O
sent1291 survey O
sent1291 was O
sent1291 performed O
sent1291 to O
sent1291 determine O
sent1291 the O
sent1291 current O
sent1291 practices O
sent1291 and O
sent1291 attitudes O
sent1291 of O
sent1291 radiologists O
sent1291 towards O
sent1291 the O
sent1291 imaging O
sent1291 of O
sent1291 suspected O
sent1291 lower O
sent1291 limb O
sent1291 deep D
sent1291 vein D
sent1291 thrombosis D
sent1291 ( D
sent1291 DVT D
sent1291 ) D
sent1292 One O
sent1292 hundred O
sent1292 and O
sent1292 twenty-seven O
sent1292 departments O
sent1292 responded O
sent1292 to O
sent1292 a O
sent1292 questionnaire O
sent1292 sent O
sent1292 in O
sent1292 March O
sent1292 1996 O
sent1293 The O
sent1293 results O
sent1293 show O
sent1293 that O
sent1293 87 O
sent1293 % O
sent1293 of O
sent1293 hospitals O
sent1293 possess O
sent1293 colour O
sent1293 Doppler O
sent1293 ultrasound O
sent1293 ( O
sent1293 CDUS O
sent1293 ) O
sent1293 machines O
sent1293 and O
sent1293 that O
sent1293 46 O
sent1293 % O
sent1293 of O
sent1293 departments O
sent1293 perform O
sent1293 ultrasound O
sent1293 as O
sent1293 the O
sent1293 first O
sent1293 line O
sent1293 investigation O
sent1293 in O
sent1293 over O
sent1293 90 O
sent1293 % O
sent1293 of O
sent1293 cases O
sent1294 Thirty O
sent1294 per O
sent1294 cent O
sent1294 of O
sent1294 departments O
sent1294 considered O
sent1294 calf O
sent1294 vein O
sent1294 visualization O
sent1294 to O
sent1294 be O
sent1294 generally O
sent1294 adequate O
sent1294 and O
sent1294 34 O
sent1294 % O
sent1294 thought O
sent1294 that O
sent1294 clinicians O
sent1294 in O
sent1294 their O
sent1294 hospitals O
sent1294 invariably O
sent1294 anticoagulated O
sent1294 patients O
sent1294 with O
sent1294 isolated T
sent1294 calf T
sent1294 thrombus T
sent1295 In O
sent1295 hospitals O
sent1295 where O
sent1295 venography O
sent1295 was O
sent1295 routinely O
sent1295 used O
sent1295 as O
sent1295 the O
sent1295 first O
sent1295 line O
sent1295 investigation O
sent1295 , O
sent1295 the O
sent1295 most O
sent1295 common O
sent1295 reasons O
sent1295 were O
sent1295 : O
sent1295 the O
sent1295 perceived O
sent1295 inferiority O
sent1295 of O
sent1295 ultrasound O
sent1295 ( O
sent1295 US O
sent1295 ) O
sent1295 in O
sent1295 demonstrating O
sent1295 below-knee O
sent1295 clot D
sent1295 , O
sent1295 its O
sent1295 time-consuming O
sent1295 nature O
sent1295 and O
sent1295 the O
sent1295 limited O
sent1295 access O
sent1295 to O
sent1295 suitable O
sent1295 ultrasound O
sent1295 machines O
sent1296 The O
sent1296 widespread O
sent1296 use O
sent1296 of O
sent1296 ultrasound O
sent1296 is O
sent1296 encouraging O
sent1296 , O
sent1296 however O
sent1296 , O
sent1296 there O
sent1296 are O
sent1296 clearly O
sent1296 diverse O
sent1296 views O
sent1297 A O
sent1297 significant O
sent1297 minority O
sent1297 of O
sent1297 departments O
sent1297 depend O
sent1297 principally O
sent1297 upon O
sent1297 venography O
sent1297 in O
sent1297 the O
sent1297 diagnosis O
sent1297 of O
sent1297 DVT D
sent1298 Existential O
sent1298 phenomenology O
sent1298 and O
sent1298 the O
sent1298 sociological O
sent1298 tradition O
sent1299 Dual O
sent1299 leadership O
sent1299 in O
sent1299 complex O
sent1299 organizations O
sent1300 Scientists O
sent1300 at O
sent1300 major O
sent1300 and O
sent1300 minor O
sent1300 universities O
sent1300 : O
sent1300 a O
sent1300 study O
sent1300 of O
sent1300 productivity O
sent1300 and O
sent1300 recognition O
sent1301 Demotion O
sent1301 in O
sent1301 industrial O
sent1301 management O
sent1302 Career O
sent1302 anchorage O
sent1302 : O
sent1302 managerial O
sent1302 mobility O
sent1302 motivations O
sent1303 Social O
sent1303 class O
sent1303 and O
sent1303 premarital O
sent1303 sexual O
sent1303 permissiveness O
sent1303 : O
sent1303 a O
sent1303 re-examination O
sent1304 A O
sent1304 comment O
sent1304 on O
sent1304 `` O
sent1304 anomy O
sent1304 '' O
sent1305 A O
sent1305 factor O
sent1305 analytic O
sent1305 exploration O
sent1305 of O
sent1305 the O
sent1305 alienation O
sent1305 , O
sent1305 anomia O
sent1305 and O
sent1305 authoritarianism O
sent1305 domain O
sent1306 Technical O
sent1306 note O
sent1306 on O
sent1306 two O
sent1306 rates O
sent1306 of O
sent1306 mixed O
sent1306 marriage O
sent1307 Some O
sent1307 comments O
sent1307 on O
sent1307 awareness O
sent1308 On O
sent1308 experimental O
sent1308 design O
sent1309 Observations O
sent1309 on O
sent1309 the O
sent1309 incidence O
sent1309 of O
sent1309 following O
sent1309 of O
sent1309 visual O
sent1309 and O
sent1309 auditory O
sent1309 stimuli O
sent1309 in O
sent1309 naive O
sent1309 mallard O
sent1309 ducklings O
sent1309 ( O
sent1309 Anas O
sent1309 platyrhynchos O
sent1309 ) O
sent1310 The O
sent1310 comfort O
sent1310 movements O
sent1310 of O
sent1310 Anatidae O
sent1311 Potential O
sent1311 ethological O
sent1311 isolating O
sent1311 mechanisms O
sent1311 and O
sent1311 assortative O
sent1311 mating O
sent1311 in O
sent1311 the O
sent1311 domestic O
sent1311 fowl O
sent1312 An O
sent1312 experimental O
sent1312 study O
sent1312 of O
sent1312 conflict O
sent1312 and O
sent1312 fear O
sent1312 : O
sent1312 an O
sent1312 analysis O
sent1312 of O
sent1312 behavior O
sent1312 of O
sent1312 young O
sent1312 chicks O
sent1312 toward O
sent1312 a O
sent1312 mealworm O
sent1313 I O
sent1313 . O
sent1313 The O
sent1313 behavior O
sent1313 of O
sent1313 chicks O
sent1313 which O
sent1313 do O
sent1313 not O
sent1313 eat O
sent1313 the O
sent1313 mealworm O
sent1314 The O
sent1314 measuring O
sent1314 function O
sent1314 of O
sent1314 the O
sent1314 first O
sent1314 legs O
sent1314 of O
sent1314 Araneus O
sent1314 diadematus O
sent1314 Cl O
sent1315 The O
sent1315 transport O
sent1315 of O
sent1315 prey O
sent1315 by O
sent1315 ants O
sent1316 Courtship O
sent1316 behaviour O
sent1316 in O
sent1316 the O
sent1316 Drosophila O
sent1316 obscura O
sent1316 group O
sent1317 II O
sent1318 Comparative O
sent1318 studies O
sent1319 Vision O
sent1319 versus O
sent1319 touch O
sent1319 in O
sent1319 form O
sent1319 discrimination O
sent1320 Short-term O
sent1320 retention O
sent1320 as O
sent1320 a O
sent1320 function O
sent1320 of O
sent1320 method O
sent1320 of O
sent1320 measurement O
sent1320 , O
sent1320 recording O
sent1320 time O
sent1320 , O
sent1320 and O
sent1320 meaningfulness O
sent1320 of O
sent1320 the O
sent1320 material O
sent1321 The O
sent1321 conservation O
sent1321 of O
sent1321 a O
sent1321 shape O
sent1321 property O
sent1321 and O
sent1321 a O
sent1321 proposal O
sent1321 about O
sent1321 the O
sent1321 origin O
sent1321 of O
sent1321 the O
sent1321 conservations O
sent1322 Persisting O
sent1322 odours O
sent1322 as O
sent1322 a O
sent1322 biasing O
sent1322 factor O
sent1322 in O
sent1322 open-field O
sent1322 research O
sent1322 with O
sent1322 mice O
sent1323 The O
sent1323 display O
sent1323 of O
sent1323 information O
sent1323 and O
sent1323 the O
sent1323 judgment O
sent1323 of O
sent1323 contingency O
sent1324 Vividness O
sent1324 of O
sent1324 words O
sent1324 and O
sent1324 learning O
sent1324 to O
sent1324 learn O
sent1324 in O
sent1324 free-recall O
sent1324 learning O
sent1325 Genetic O
sent1325 study O
sent1325 of O
sent1325 the O
sent1325 memorization O
sent1325 of O
sent1325 words O
sent1325 and O
sent1325 pictures O
sent1326 Amylase O
sent1326 production O
sent1326 by O
sent1326 Streptomyces O
sent1326 species O
sent1327 Physico-chemical O
sent1327 studies O
sent1327 on O
sent1327 the O
sent1327 stability O
sent1327 of O
sent1327 penicillin T
sent1327 salts T
sent1328 IV O
sent1329 A O
sent1329 statistical O
sent1329 evaluation O
sent1330 Studies O
sent1330 on O
sent1330 nitrogen O
sent1330 metabolism O
sent1330 of O
sent1330 Penicillium O
sent1330 chrysogenum O
sent1330 Thom O
sent1330 . O
sent1330 I O
sent1330 . O
sent1330 Effects O
sent1330 of O
sent1330 lactose O
sent1330 and O
sent1330 sucrose O
sent1330 additions O
sent1330 on O
sent1330 nitrogen O
sent1330 metabolism O
sent1331 Studies O
sent1331 on O
sent1331 nitrogen O
sent1331 metabolism O
sent1331 of O
sent1331 Penicillium O
sent1331 chrysogenum O
sent1331 Thom O
sent1331 . O
sent1331 II O
sent1332 Amino O
sent1332 acid O
sent1332 metabolism O
sent1332 and O
sent1332 its O
sent1332 relation O
sent1332 to O
sent1332 the O
sent1332 biosynthesis O
sent1332 of O
sent1332 penicillin T
sent1333 The O
sent1333 contribution O
sent1333 of O
sent1333 thoracic T
sent1333 surgery T
sent1333 to O
sent1333 our O
sent1333 discipline O
sent1334 Research O
sent1334 past O
sent1334 and O
sent1334 present O
sent1334 , O
sent1334 with O
sent1334 particular O
sent1334 reference O
sent1334 to O
sent1334 the O
sent1334 application O
sent1334 of O
sent1334 the O
sent1334 techniques O
sent1334 of O
sent1334 basic O
sent1334 science O
sent1334 to O
sent1334 the O
sent1334 problems O
sent1334 of O
sent1334 adrenal O
sent1334 pathology O
sent1335 Some O
sent1335 inflammatory D
sent1335 disorders D
sent1335 of O
sent1335 the O
sent1335 large O
sent1335 intestine O
sent1336 Coexistence O
sent1336 of O
sent1336 subdural O
sent1336 and O
sent1336 archnoidal O
sent1336 collections O
sent1336 of O
sent1336 fluid O
sent1336 : O
sent1336 an O
sent1336 unusual O
sent1336 case O
sent1337 The O
sent1337 scope O
sent1337 of O
sent1337 sphincterotomy T
sent1337 in O
sent1337 biliary T
sent1337 and T
sent1337 pancreatic T
sent1337 surgery T
sent1338 Sarcoidosis T
sent1338 involving O
sent1338 the O
sent1338 veriform O
sent1338 appendix O
sent1339 `` O
sent1339 Chronic D
sent1339 pancreatitis D
sent1339 `` O
sent1339 and O
sent1339 carcinoma D
sent1339 of D
sent1339 the D
sent1339 pancreas D
sent1340 A O
sent1340 method O
sent1340 to O
sent1340 aid O
sent1340 correct O
sent1340 diagnosis O
sent1341 Control O
sent1341 of O
sent1341 post-haemorrhoidectomy D
sent1341 bleeding D
sent1341 with O
sent1341 a T
sent1341 Foley T
sent1341 catheter T
sent1341 and T
sent1341 a T
sent1341 pack T
sent1342 Diagnosis O
sent1342 and O
sent1342 therapy O
sent1342 of O
sent1342 chronic D
sent1342 aspecific D
sent1342 pancreatitis D
sent1343 Behavior O
sent1343 of O
sent1343 the O
sent1343 tetanus D
sent1343 patient O
sent1343 subjected O
sent1343 to O
sent1343 resuscitation T
sent1343 treatment T
sent1344 Further O
sent1344 data O
sent1344 on O
sent1344 mediastinal D
sent1344 and D
sent1344 pulmonary D
sent1344 tumors D
sent1344 of O
sent1344 the O
sent1344 child O
sent1345 Review O
sent1345 and O
sent1345 personal O
sent1345 cases O
sent1346 Dextran O
sent1346 of O
sent1346 low O
sent1346 molecular O
sent1346 weight O
sent1346 in O
sent1346 peripheral D
sent1346 arterial D
sent1346 insufficiency D
sent1347 Clinico-statistical O
sent1347 considerations O
sent1347 on O
sent1347 vescicular D
sent1347 mole D
sent1348 On O
sent1348 the O
sent1348 significance O
sent1348 of O
sent1348 histologic O
sent1348 findings O
sent1348 in O
sent1348 neoplasms D
sent1348 of O
sent1348 the O
sent1348 trophoblast O
sent1348 ( O
sent1348 case O
sent1348 contributions O
sent1348 ) O
sent1349 Diagnostic O
sent1349 evaluation O
sent1349 of O
sent1349 the O
sent1349 patient O
sent1349 with O
sent1349 high D
sent1349 blood D
sent1349 pressure D
sent1350 Epidemiology O
sent1350 of O
sent1350 hypertension D
sent1351 Renal D
sent1351 vascular D
sent1351 hypertension D
sent1351 ; O
sent1351 diagnosis O
sent1351 and O
sent1351 treatment O
sent1352 The O
sent1352 use O
sent1352 of O
sent1352 radioactive O
sent1352 isotopes O
sent1352 in O
sent1352 the O
sent1352 diagnosis O
sent1352 of O
sent1352 hypertension D
sent1353 The O
sent1353 angiogram O
sent1353 in O
sent1353 the O
sent1353 study O
sent1353 of O
sent1353 hypertension D
sent1354 Guanethidine O
sent1355 Hepatocerebral D
sent1355 degeneration D
sent1355 ( D
sent1355 portal D
sent1355 systemic D
sent1355 encephalopathy D
sent1355 ) D
sent1356 The O
sent1356 relationship O
sent1356 to O
sent1356 fatty O
sent1356 acids O
sent1357 Oviposition O
sent1357 and O
sent1357 its O
sent1357 regulation O
sent1357 in O
sent1357 the O
sent1357 polygynous O
sent1357 society O
sent1357 of O
sent1357 Polistes O
sent1357 gallicus O
sent1357 L. O
sent1358 Interaction O
sent1358 of O
sent1358 aggressive O
sent1358 and O
sent1358 sexual O
sent1358 behavior O
sent1358 in O
sent1358 male O
sent1358 mice O
sent1359 Conflict O
sent1359 and O
sent1359 conditioned O
sent1359 aversive O
sent1359 stimuli O
sent1359 in O
sent1359 the O
sent1359 development O
sent1359 of O
sent1359 experimental O
sent1359 neuroses O
sent1360 Study O
sent1360 of O
sent1360 the O
sent1360 effect O
sent1360 of O
sent1360 newer O
sent1360 analeptic O
sent1360 ( O
sent1360 Micoren O
sent1360 ) O
sent1360 in O
sent1360 hypoventilation O
sent1360 syndrome O
sent1361 Treatment O
sent1361 of O
sent1361 a D
sent1361 disorder D
sent1361 of D
sent1361 perception D
sent1361 and D
sent1361 concept D
sent1361 formation D
sent1361 in O
sent1361 a O
sent1361 case O
sent1361 of O
sent1361 school O
sent1361 failure O
sent1362 Rorschach O
sent1362 correlates O
sent1362 of O
sent1362 time O
sent1362 estimation O
sent1363 Use O
sent1363 of O
sent1363 food O
sent1363 in O
sent1363 child T
sent1363 psychotherapy T
sent1364 About O
sent1364 genital O
sent1364 discharge O
sent1364 with O
sent1364 special O
sent1364 consideration O
sent1364 of O
sent1364 its O
sent1364 cervical O
sent1364 manifestation O
sent1365 Auto-uro T
sent1365 therapy T
sent1365 : O
sent1365 status O
sent1365 and O
sent1365 future O
sent1365 prospects O
sent1366 Clinical O
sent1366 experience O
sent1366 with O
sent1366 the O
sent1366 surface T
sent1366 anesthetic T
sent1366 xylocaine T
sent1366 in O
sent1366 obstetrics O
sent1367 The O
sent1367 problem O
sent1367 of O
sent1367 medicinal O
sent1367 management O
sent1367 of O
sent1367 labor O
sent1368 Conglutination O
sent1368 of O
sent1368 the O
sent1368 labia O
sent1368 minora O
sent1369 The O
sent1369 fight O
sent1369 against O
sent1369 hemolytic D
sent1369 disease D
sent1369 of O
sent1369 the O
sent1369 newborn O
sent1369 in O
sent1369 general O
sent1369 practice O
sent1370 Long O
sent1370 term O
sent1370 results O
sent1370 in O
sent1370 the O
sent1370 300 O
sent1370 most O
sent1370 grave O
sent1370 cases O
sent1370 out O
sent1370 of O
sent1370 4000 O
sent1370 hyperthyroid D
sent1370 patients D
sent1370 treated O
sent1370 with O
sent1370 iodine T
sent1370 I-131 T
sent1370 at O
sent1370 the O
sent1370 center O
sent1370 of O
sent1370 Ancona O
sent1371 On O
sent1371 socalled O
sent1371 nervous O
sent1371 exhaustion O
sent1372 Examination O
sent1372 of O
sent1372 neonatal O
sent1372 archaic O
sent1372 ( O
sent1372 primitive O
sent1372 ) O
sent1372 reflexes O
sent1372 in O
sent1372 icterus D
sent1372 gravis D
sent1373 Urologic O
sent1373 complications O
sent1373 in O
sent1373 non-recurrent D
sent1373 cancer D
sent1373 of O
sent1373 the O
sent1373 cervix O
sent1374 Prolonged T
sent1374 cortisone T
sent1374 therapy T
sent1374 in O
sent1374 treatment O
sent1374 of O
sent1374 allergic D
sent1374 diseases D
sent1375 The O
sent1375 complexing O
sent1375 of O
sent1375 calcium O
sent1375 by O
sent1375 citrate O
sent1375 , O
sent1375 ortho- O
sent1375 and O
sent1375 polyphosphates O
sent1376 A O
sent1376 method O
sent1376 of O
sent1376 determining O
sent1376 the O
sent1376 patency O
sent1376 of O
sent1376 the O
sent1376 nasolacrimal O
sent1376 apparatus O
sent1377 Intra-arterial O
sent1377 infusion O
sent1377 of O
sent1377 the O
sent1377 head O
sent1377 and O
sent1377 neck O
sent1378 Anatomic O
sent1378 and O
sent1378 distributional O
sent1378 problems O
sent1379 Lymphatics O
sent1379 of O
sent1379 the O
sent1379 mouth O
sent1379 and O
sent1379 neck O
sent1380 Effect O
sent1380 of O
sent1380 sodium O
sent1380 ions O
sent1380 on O
sent1380 the O
sent1380 behavior O
sent1380 of O
sent1380 rest O
sent1380 and O
sent1380 action O
sent1380 potentials O
sent1380 of O
sent1380 the O
sent1380 cell O
sent1380 membrane O
sent1380 of O
sent1380 the O
sent1380 rat O
sent1380 myometrium O
sent1381 Studies O
sent1381 on O
sent1381 contractile O
sent1381 properties O
sent1381 of O
sent1381 the O
sent1381 blood O
sent1381 serum O
sent1382 Twin O
sent1382 pregnancy O
sent1382 and O
sent1382 fetal O
sent1382 and O
sent1382 infantile O
sent1382 perinatal D
sent1382 mortality D
sent1383 Fate O
sent1383 of O
sent1383 the O
sent1383 2d O
sent1383 twin O
sent1384 Differential O
sent1384 diagnosis O
sent1384 of O
sent1384 infectious D
sent1384 hepatitis D
sent1384 in O
sent1384 pregnancy O
sent1385 Epithelial O
sent1385 metaplasia D
sent1385 of O
sent1385 the O
sent1385 endometrium O
sent1386 Leukoplakia D
sent1386 of O
sent1386 the O
sent1386 vaginal O
sent1386 portion O
sent1386 of O
sent1386 the O
sent1386 uterus O
sent1386 and O
sent1386 its O
sent1386 clinical O
sent1386 evaluation O
sent1387 Blood O
sent1387 loss O
sent1387 in O
sent1387 artificial O
sent1387 interruption O
sent1387 of O
sent1387 pregnancy O
sent1388 Modified T
sent1388 bra T
sent1388 in O
sent1388 the O
sent1388 prevention O
sent1388 of O
sent1388 mastitis D
sent1388 in O
sent1388 nursing O
sent1388 mothers O
sent1389 Hormonal O
sent1389 phenomenon O
sent1389 after O
sent1389 the O
sent1389 excision O
sent1389 of O
sent1389 hydatiform O
sent1389 mole O
sent1390 Fetal O
sent1390 chondrodystrophy O
sent1391 Malignant D
sent1391 mesodermal D
sent1391 mixed D
sent1391 tumor D
sent1391 of O
sent1391 the O
sent1391 uterus O
sent1391 following O
sent1391 irradiation T
sent1392 Supportive O
sent1392 role O
sent1392 of O
sent1392 nurse O
sent1392 in O
sent1392 first O
sent1392 stage O
sent1392 of O
sent1392 labor O
sent1392 `` O
sent1392 can O
sent1392 not O
sent1392 be O
sent1392 emphasized O
sent1392 enough O
sent1392 '' O
sent1392 , O
sent1392 according O
sent1392 to O
sent1392 patient O
sent1393 Toxemia D
sent1393 of O
sent1393 pregnancy O
sent1394 Outpatient O
sent1394 care O
sent1394 -- O
sent1394 the O
sent1394 role O
sent1394 of O
sent1394 the O
sent1394 nurse O
sent1395 Abandonment O
sent1395 : O
sent1395 deepest O
sent1395 fear O
sent1395 of O
sent1395 hospitalized O
sent1395 children O
sent1396 Support O
sent1396 in O
sent1396 first O
sent1396 stage O
sent1396 of O
sent1396 labor O
sent1397 The O
sent1397 family O
sent1397 physician O
sent1397 and O
sent1397 cervical D
sent1397 carcinoma D
sent1397 -- O
sent1397 challenge O
sent1397 and O
sent1397 opportunity O
sent1398 Purposeful O
sent1398 `` O
sent1398 heroic O
sent1398 '' O
sent1398 heart O
sent1398 treatment O
sent1399 Skilled O
sent1399 workers O
sent1399 are O
sent1399 vital O
sent1399 to O
sent1399 maintenance O
sent1399 cost O
sent1399 cuts O
sent1400 Karen O
sent1400 : O
sent1400 the O
sent1400 other O
sent1400 side O
sent1400 of O
sent1400 the O
sent1400 picture O
sent1401 Rhesus D
sent1401 haemolytic D
sent1401 disease D
sent1401 ; O
sent1401 an O
sent1401 approach O
sent1401 to O
sent1401 prevention O
sent1402 Tumours D
sent1402 of O
sent1402 the O
sent1402 uterus O
sent1403 2 O
sent1404 Malignancy O
sent1405 Cancer D
sent1405 of O
sent1405 the O
sent1405 vulva O
sent1406 Effects O
sent1406 of O
sent1406 smoking O
sent1406 on O
sent1406 selected O
sent1406 clinical O
sent1406 obstetric O
sent1406 factors O
sent1407 Amniotic D
sent1407 fluid D
sent1407 embolism D
sent1408 A O
sent1408 review O
sent1408 of O
sent1408 the O
sent1408 syndrome O
sent1408 with O
sent1408 a O
sent1408 report O
sent1408 of O
sent1408 4 O
sent1408 cases O
sent1409 Chronic D
sent1409 histiocytosis D
sent1409 X D
sent1409 associated O
sent1409 with O
sent1409 pregnancy O
sent1410 Disseminated D
sent1410 lupus D
sent1410 erythematosus D
sent1410 in O
sent1410 pregnancy O
sent1411 Intralesional T
sent1411 therapy T
sent1411 with T
sent1411 betamethasone T
sent1412 Strucutre O
sent1412 of O
sent1412 the O
sent1412 influenza D
sent1412 virus D
sent1413 2 O
sent1413 students O
sent1413 at O
sent1413 Quo O
sent1413 Vadis O
sent1414 Double O
sent1414 aortic O
sent1414 arch O
sent1414 associated O
sent1414 with O
sent1414 tetralogy O
sent1414 of O
sent1414 Fallot O
sent1414 in O
sent1414 infants O
sent1414 ; O
sent1414 report O
sent1414 of O
sent1414 two O
sent1414 cases O
sent1415 Tested O
sent1415 questionnaires O
sent1415 help O
sent1415 administration O
sent1415 learn O
sent1415 if O
sent1415 programs O
sent1415 are O
sent1415 a O
sent1415 success O
sent1415 , O
sent1415 and O
sent1415 why O
sent1416 Dumping D
sent1416 syndrome D
sent1416 following O
sent1416 pyloroplasty T
sent1416 . O
sent1417 Measured O
sent1417 subtotal O
sent1417 gastrectomy O
sent1417 for O
sent1417 duodenal O
sent1417 ulcer O
sent1418 The O
sent1418 lesions O
sent1418 in O
sent1418 bovine O
sent1418 udders O
sent1418 shedding O
sent1418 nonhemolytic O
sent1418 coagulase-negative O
sent1418 staphylococci O
sent1419 Repository O
sent1419 vitamin O
sent1419 B O
sent1419 12 O
sent1419 preparations O
sent1420 Mass O
sent1420 spectrometry O
sent1420 in O
sent1420 structural O
sent1420 and O
sent1420 stereochemical O
sent1420 problems O
sent1421 93 O
sent1422 Further O
sent1422 observations O
sent1422 on O
sent1422 the O
sent1422 importance O
sent1422 of O
sent1422 interatomic O
sent1422 distance O
sent1422 in O
sent1422 the O
sent1422 McLafferty O
sent1422 rearrangement O
sent1423 Synthesis O
sent1423 and O
sent1423 fragmentation O
sent1423 behavior O
sent1423 of O
sent1423 deuterium-labeled O
sent1423 12-keto O
sent1423 steroids O
sent1424 Treatment O
sent1424 of O
sent1424 childhood D
sent1424 schizophrenia D
sent1425 A O
sent1425 three-year O
sent1425 comparison O
sent1425 of O
sent1425 day O
sent1425 and O
sent1425 residental O
sent1425 treatment O
sent1426 Polycystic O
sent1426 ovaries O
sent1426 associated O
sent1426 with O
sent1426 congenital D
sent1426 adrenal D
sent1426 hyperplasia D
sent1427 Beta-propiolactone T
sent1427 as O
sent1427 used O
sent1427 in O
sent1427 sterilization O
sent1427 of O
sent1427 homografts O
sent1427 not O
sent1427 carcinogenic O
sent1427 for O
sent1427 mice O
sent1428 New O
sent1428 operations O
sent1428 in O
sent1428 children O
sent1428 's O
sent1428 cardiac O
sent1428 disease O
sent1429 Effect O
sent1429 of O
sent1429 diabetes D
sent1429 and O
sent1429 starvation O
sent1429 on O
sent1429 myocardial O
sent1429 triglyceride O
sent1429 and O
sent1429 free O
sent1429 fatty O
sent1429 acid O
sent1429 utilization O
sent1430 Effect O
sent1430 of O
sent1430 epinephrine O
sent1430 on O
sent1430 myocardial O
sent1430 triglyceride O
sent1430 and O
sent1430 free O
sent1430 fatty O
sent1430 acid O
sent1430 utilization O
sent1431 Diurnal O
sent1431 periodicity O
sent1431 in O
sent1431 the O
sent1431 metabolic O
sent1431 activity O
sent1431 of O
sent1431 bone O
sent1431 tissue O
sent1432 Fine O
sent1432 structure O
sent1432 of O
sent1432 desmosomes O
sent1433 , O
sent1433 hemidesmosomes O
sent1433 , O
sent1433 and O
sent1433 an O
sent1433 adepidermal O
sent1433 globular O
sent1433 layer O
sent1433 in O
sent1433 developing O
sent1433 newt O
sent1433 epidermis O
sent1434 Redundant O
sent1434 myelin O
sent1434 sheaths O
sent1434 and O
sent1434 other O
sent1434 ultrastructural O
sent1434 features O
sent1434 of O
sent1434 the O
sent1434 toad O
sent1434 cerebellum O
sent1435 A O
sent1435 radioautographic O
sent1435 study O
sent1435 with O
sent1435 H3-thymidine O
sent1435 on O
sent1435 adrenal O
sent1435 medulla O
sent1435 nuclei O
sent1435 of O
sent1435 rats O
sent1435 intermittently O
sent1435 exposed O
sent1435 to O
sent1435 cold O
sent1436 A O
sent1436 fine O
sent1436 structural O
sent1436 analysis O
sent1436 of O
sent1436 the O
sent1436 epidermis O
sent1436 of O
sent1436 the O
sent1436 earthworm O
sent1436 , O
sent1436 Lumbricus O
sent1436 terrestris O
sent1436 L. O
sent1437 Effect O
sent1437 of O
sent1437 thoracic O
sent1437 cava O
sent1437 obstruction O
sent1437 on O
sent1437 response O
sent1437 of O
sent1437 proximal O
sent1437 tubule O
sent1437 sodium O
sent1437 reabsorption O
sent1437 to O
sent1437 saline O
sent1437 infusion O
sent1438 The O
sent1438 metabolism O
sent1438 of O
sent1438 intravenously O
sent1438 injected O
sent1438 isotopic O
sent1438 cholic O
sent1438 acid O
sent1438 in O
sent1438 Laennec D
sent1438 's D
sent1438 cirrhosis D
sent1439 The O
sent1439 origin O
sent1439 and O
sent1439 glyceride O
sent1439 distribution O
sent1439 of O
sent1439 fatty O
sent1439 acids O
sent1439 in O
sent1439 rat O
sent1439 adipose O
sent1439 tissue O
sent1440 Absorption O
sent1440 of O
sent1440 medium O
sent1440 and O
sent1440 long O
sent1440 chain O
sent1440 triglycerides O
sent1440 : O
sent1440 factors O
sent1440 influencing O
sent1440 their O
sent1440 hydrolysis O
sent1440 and O
sent1440 transport O
sent1441 The O
sent1441 effect O
sent1441 of O
sent1441 epinephrine O
sent1441 on O
sent1441 immunoreactive O
sent1441 insulin O
sent1441 levels O
sent1441 in O
sent1441 man O
sent1442 The O
sent1442 role O
sent1442 of O
sent1442 the O
sent1442 liver O
sent1442 in O
sent1442 serum-induced O
sent1442 hypercoagulability D
sent1443 Comparative O
sent1443 fates O
sent1443 of O
sent1443 intravenously O
sent1443 and O
sent1443 orally O
sent1443 administered O
sent1443 aldosterone O
sent1443 : O
sent1443 evidence O
sent1443 for O
sent1443 extrahepatic O
sent1443 formation O
sent1443 of O
sent1443 acid-hydrolyzable O
sent1443 conjugate O
sent1443 in O
sent1443 man O
sent1444 Binding O
sent1444 of O
sent1444 sulfobromophthalein O
sent1444 ( O
sent1444 BSP O
sent1444 ) O
sent1444 sodium O
sent1444 by O
sent1444 plasma O
sent1444 albumin O
sent1445 Its O
sent1445 role O
sent1445 in O
sent1445 hepatic O
sent1445 BSP O
sent1445 extraction O
sent1446 The O
sent1446 rationale O
sent1446 of O
sent1446 extended T
sent1446 resection T
sent1446 for O
sent1446 complicated D
sent1446 cancer D
sent1446 of D
sent1446 the D
sent1446 large D
sent1446 bowel D
sent1447 Etiology O
sent1447 and O
sent1447 incidence O
sent1447 of O
sent1447 renal D
sent1447 stones D
sent1448 Diagnosis O
sent1448 of O
sent1448 stone D
sent1448 disease D
sent1449 Medical T
sent1449 treatment T
sent1449 of O
sent1449 stone D
sent1449 disease D
sent1450 Surgical T
sent1450 treatment T
sent1450 of O
sent1450 urinary D
sent1450 stones D
sent1451 Prevention O
sent1451 of O
sent1451 stone D
sent1451 formation D
sent1452 Urinary O
sent1452 calculi O
sent1453 Is O
sent1453 the O
sent1453 task O
sent1453 hopeless O
sent1453 ? O
sent1454 The O
sent1454 family O
sent1454 medicine O
sent1454 program O
sent1454 of O
sent1454 the O
sent1454 University O
sent1454 of O
sent1454 Miami O
sent1455 Electron O
sent1455 microscopic O
sent1455 studies O
sent1455 of O
sent1455 Mycoplasma O
sent1455 ( O
sent1455 PPLO O
sent1455 strain O
sent1455 880 O
sent1455 ) O
sent1455 in O
sent1455 artificial O
sent1455 medium O
sent1455 and O
sent1455 in O
sent1455 tissue O
sent1455 culture O
sent1456 Chemotherapeutic O
sent1456 effects O
sent1456 on O
sent1456 mammalian D
sent1456 tumor D
sent1456 cells D
sent1457 3 O
sent1458 Modification O
sent1458 of O
sent1458 leukemia O
sent1458 L1210 O
sent1458 growth O
sent1458 kinetics O
sent1458 with O
sent1458 an O
sent1458 antimetabolite O
sent1459 Comparison O
sent1459 of O
sent1459 the O
sent1459 sensitivity O
sent1459 of O
sent1459 normal O
sent1459 hematopoietic O
sent1459 and O
sent1459 transplanted O
sent1459 lymphoma O
sent1459 colony-forming O
sent1459 cells O
sent1459 of O
sent1459 mice O
sent1459 to O
sent1459 vinblastine O
sent1459 administered O
sent1459 in O
sent1459 vivo O
sent1460 Evidence O
sent1460 for O
sent1460 an O
sent1460 immunological O
sent1460 reaction O
sent1460 of O
sent1460 the O
sent1460 host O
sent1460 directed O
sent1460 against O
sent1460 its O
sent1460 own O
sent1460 actively O
sent1460 growing O
sent1460 primary D
sent1460 tumor D
sent1461 Hyperbaric T
sent1461 oxygen T
sent1461 , T
sent1461 whole-body T
sent1461 X T
sent1461 irradiation T
sent1461 , T
sent1461 and T
sent1461 cyclophosphamide T
sent1461 combination T
sent1461 therapy T
sent1461 in O
sent1461 mouse D
sent1461 leukemia D
sent1461 L1210 D
sent1462 Clinical O
sent1462 staging O
sent1462 in O
sent1462 cancer D
sent1462 of D
sent1462 the D
sent1462 larynx D
sent1462 : O
sent1462 a O
sent1462 report O
sent1462 on O
sent1462 788 O
sent1462 cases O
sent1462 using O
sent1462 the O
sent1462 American O
sent1462 Joint O
sent1462 Committee O
sent1462 's O
sent1462 method O
sent1462 of O
sent1462 stage O
sent1462 classification O
sent1463 Comparison O
sent1463 of O
sent1463 the O
sent1463 international O
sent1463 and O
sent1463 American O
sent1463 systems O
sent1463 for O
sent1463 the O
sent1463 staging O
sent1463 of O
sent1463 breast D
sent1463 cancer D
sent1464 Effects O
sent1464 of O
sent1464 tryptophan O
sent1464 mustard O
sent1464 on O
sent1464 incorporation O
sent1464 of O
sent1464 amino O
sent1464 acids O
sent1464 into O
sent1464 proteins O
sent1464 in O
sent1464 tumor-bearing O
sent1464 rats O
sent1465 An O
sent1465 electron O
sent1465 microscope O
sent1465 study O
sent1465 of O
sent1465 plant D
sent1465 neoplasia D
sent1465 induced O
sent1465 by O
sent1465 wound D
sent1465 tumor D
sent1465 virus D
sent1466 Possibilities O
sent1466 of O
sent1466 surgical T
sent1466 correction T
sent1466 of O
sent1466 malformations D
sent1466 of D
sent1466 the D
sent1466 bones D
sent1466 of D
sent1466 the D
sent1466 foot D
sent1467 The O
sent1467 postprandial O
sent1467 period O
sent1467 of O
sent1467 the O
sent1467 gastrectomized O
sent1467 patient O
sent1468 Radiocinematographic O
sent1468 and O
sent1468 clinical O
sent1468 correlation O
sent1469 Muscle O
sent1469 pathology O
sent1469 ; O
sent1469 contribution O
sent1469 of O
sent1469 experimentation O
sent1470 Origin O
sent1470 of O
sent1470 milk O
sent1470 cholesterol O
sent1470 in O
sent1470 the O
sent1470 rat O
sent1470 : O
sent1470 dietary O
sent1470 versus O
sent1470 endogenous O
sent1470 sources O
sent1471 Comparative O
sent1471 effects O
sent1471 of O
sent1471 two O
sent1471 benzodiazepine O
sent1471 compounds O
sent1471 on O
sent1471 isolated O
sent1471 human O
sent1471 myometrium O
sent1472 Histochemistry O
sent1472 of O
sent1472 hydrolytic O
sent1472 and O
sent1472 oxidative O
sent1472 enzymes O
sent1472 in O
sent1472 the O
sent1472 human O
sent1472 and O
sent1472 experimentally O
sent1472 induced O
sent1472 adenocarcinoma D
sent1472 of O
sent1472 the O
sent1472 endometrium O
sent1473 Cardiac O
sent1473 monitors O
sent1473 work O
sent1473 -- O
sent1473 but O
sent1473 they O
sent1473 should O
sent1473 report O
sent1473 more O
sent1473 than O
sent1473 they O
sent1473 do O
sent1474 Delivery O
sent1474 room O
sent1474 pediatrics O
sent1475 The O
sent1475 responsibilities O
sent1475 of O
sent1475 the O
sent1475 obstetrician O
sent1476 A O
sent1476 pediatrician O
sent1476 's O
sent1476 checklist O
sent1476 for O
sent1476 adolescents O
sent1477 Community O
sent1477 clinic O
sent1477 treatment O
sent1477 for O
sent1477 back-ward O
sent1477 patients O
sent1478 Studies O
sent1478 in O
sent1478 infantile D
sent1478 malnutrition D
sent1479 V O
sent1480 The O
sent1480 effect O
sent1480 of O
sent1480 dietary O
sent1480 protein O
sent1480 source O
sent1480 on O
sent1480 serum O
sent1480 proteins O
sent1481 Fish T
sent1481 protein T
sent1481 concentrates T
sent1481 in O
sent1481 the O
sent1481 treatment O
sent1481 of O
sent1481 kwashiorkor D
sent1482 athyrism D
sent1482 in O
sent1482 the O
sent1482 fetal O
sent1482 rat O
sent1483 Evidence O
sent1483 for O
sent1483 impairment O
sent1483 of O
sent1483 elastin O
sent1483 formation O
sent1484 Familial D
sent1484 vitamin D
sent1484 D D
sent1484 resistant D
sent1484 rickets D
sent1484 in O
sent1484 untreated O
sent1484 adult O
sent1485 Bony O
sent1485 proliferation O
sent1485 of O
sent1485 neural O
sent1485 arches O
sent1485 with O
sent1485 cord O
sent1485 compression O
sent1486 Amyloidosis D
sent1486 of O
sent1486 the O
sent1486 cornea O
sent1487 Report O
sent1487 of O
sent1487 a O
sent1487 case O
sent1487 without O
sent1487 conjunctival O
sent1487 involvement O
sent1488 Effect O
sent1488 of O
sent1488 tranquilizing T
sent1488 drugs T
sent1488 on O
sent1488 postnatal O
sent1488 behavior O
sent1489 Fathers O
sent1489 in O
sent1489 the O
sent1489 delivery O
sent1489 room O
sent1489 -- O
sent1489 an O
sent1489 opposition O
sent1489 standpoint O
sent1490 Fathers O
sent1490 in O
sent1490 the O
sent1490 delivery O
sent1490 -- O
sent1490 '' O
sent1490 helpful O
sent1490 and O
sent1490 supportive O
sent1490 '' O
sent1491 `` O
sent1491 Return O
sent1491 the O
sent1491 joy O
sent1491 of O
sent1491 home O
sent1491 delivery O
sent1491 '' O
sent1491 with O
sent1491 fathers O
sent1491 in O
sent1491 the O
sent1491 delivery O
sent1491 room O
sent1492 Fathers O
sent1492 in O
sent1492 the O
sent1492 delivery O
sent1492 room O
sent1492 -- O
sent1492 long O
sent1492 experience O
sent1492 molds O
sent1492 one O
sent1492 viewpoint O
sent1493 Doctors O
sent1493 -- O
sent1493 we O
sent1493 need O
sent1493 you O
sent1494 Pharmacological O
sent1494 blockade O
sent1494 of O
sent1494 ovulation O
sent1494 in O
sent1494 the O
sent1494 ewe O
sent1495 Some O
sent1495 factors O
sent1495 affecting O
sent1495 the O
sent1495 response O
sent1495 of O
sent1495 the O
sent1495 immature O
sent1495 mouse O
sent1495 to O
sent1495 pregnant O
sent1495 mare O
sent1495 serum O
sent1495 gonadotrophin O
sent1495 and O
sent1495 human O
sent1495 chorionic O
sent1495 gonadotrophin O
sent1496 The O
sent1496 metabolism O
sent1496 of O
sent1496 cortisol O
sent1496 by O
sent1496 human O
sent1496 extra-hepatic O
sent1496 tissues O
sent1497 Aromatization O
sent1497 of O
sent1497 7-alpha-hydroxydehydroepiandrosterone O
sent1497 and O
sent1497 of O
sent1497 its O
sent1497 3-sulphate O
sent1497 by O
sent1497 ovarian O
sent1497 and O
sent1497 placental O
sent1497 tissue O
sent1497 cultures O
sent1498 Metabolic O
sent1498 and O
sent1498 endocrine O
sent1498 effects O
sent1498 of O
sent1498 lysergic O
sent1498 acid O
sent1498 diethylamide O
sent1498 ( O
sent1498 LSD-25 O
sent1498 ) O
sent1498 on O
sent1498 male O
sent1498 rats O
sent1499 Mutation O
sent1499 frequencies O
sent1499 detected O
sent1499 following O
sent1499 irradiation T
sent1499 of O
sent1499 virgin O
sent1499 and O
sent1499 inseminated O
sent1499 Drosophila O
sent1499 melanogaster O
sent1499 females O
sent1500 Relationship O
sent1500 of O
sent1500 fractons O
sent1500 of O
sent1500 soybeans O
sent1500 and O
sent1500 a O
sent1500 crystalline O
sent1500 soybean O
sent1500 trypsin O
sent1500 inhibitor O
sent1500 to O
sent1500 the O
sent1500 effects O
sent1500 of O
sent1500 feeding O
sent1500 unheated O
sent1500 soybean O
sent1500 meal O
sent1500 to O
sent1500 chicks O
sent1501 Metabolism O
sent1501 of O
sent1501 polyunsaturated O
sent1501 fatty O
sent1501 acids O
sent1501 and O
sent1501 serum O
sent1501 cholesterol O
sent1501 levels O
sent1501 in O
sent1501 the O
sent1501 rat O
sent1502 Comparison O
sent1502 of O
sent1502 neutral O
sent1502 fat O
sent1502 and O
sent1502 free O
sent1502 fatty O
sent1502 acids O
sent1502 in O
sent1502 high O
sent1502 lipid-low O
sent1502 carbohydrate O
sent1502 diets O
sent1502 for O
sent1502 the O
sent1502 growing O
sent1502 chicken O
sent1503 An O
sent1503 approach O
sent1503 to O
sent1503 quantitative O
sent1503 analysis O
sent1503 of O
sent1503 intrauterine O
sent1503 pressure O
sent1503 data O
sent1504 Intracranial D
sent1504 teratomas D
sent1504 in O
sent1504 fetal O
sent1504 life O
sent1504 and O
sent1504 infancy O
sent1505 Twinning O
sent1505 in O
sent1505 relation O
sent1505 to O
sent1505 birth O
sent1505 weight O
sent1505 , O
sent1505 mortality O
sent1505 , O
sent1505 and O
sent1505 congenital D
sent1505 anomalies D
sent1506 Breast O
sent1506 engorgement O
sent1506 and O
sent1506 postpartum D
sent1506 fever D
sent1507 Evolution O
sent1507 of O
sent1507 a O
sent1507 placenta O
sent1507 circumvallata O
sent1508 Sequential O
sent1508 estrogen-progestogen T
sent1508 therapy T
sent1508 in O
sent1508 gynecology O
sent1509 Ovarian D
sent1509 carcinoma D
sent1510 The O
sent1510 problems O
sent1510 of O
sent1510 staging O
sent1510 and O
sent1510 grading O
sent1511 Oxytocin O
sent1511 induction O
sent1511 in O
sent1511 pregnant O
sent1511 rabbits O
sent1511 , O
sent1511 with O
sent1511 special O
sent1511 reference O
sent1511 to O
sent1511 the O
sent1511 stillbirth O
sent1511 rate O
sent1512 Significance O
sent1512 of O
sent1512 a O
sent1512 single O
sent1512 umbilical O
sent1512 artery O
sent1513 Report O
sent1513 from O
sent1513 the O
sent1513 collaborative O
sent1513 study O
sent1513 of O
sent1513 cerebral O
sent1513 palsy O
sent1514 Perforated D
sent1514 peptic D
sent1514 ulcer D
sent1514 in O
sent1514 pregnancy O
sent1515 Poverty O
sent1515 as O
sent1515 an O
sent1515 isolated O
sent1515 factor O
sent1515 in O
sent1515 relation O
sent1515 to O
sent1515 perinatal D
sent1515 asphyxia D
sent1516 Perforation D
sent1516 of D
sent1516 the D
sent1516 postpartum D
sent1516 uterus D
sent1516 with O
sent1516 an O
sent1516 intrauterine O
sent1516 contraceptive O
sent1516 device O
sent1517 Congenital D
sent1517 heart D
sent1517 disease D
sent1517 , O
sent1517 deaf-mutism D
sent1517 and O
sent1517 associated D
sent1517 somatic D
sent1517 malformations D
sent1517 occurring O
sent1517 in O
sent1517 several O
sent1517 members O
sent1517 of O
sent1517 one O
sent1517 family O
sent1518 Toward O
sent1518 a O
sent1518 community O
sent1518 alcoholism O
sent1518 program O
sent1519 Cases O
sent1519 8 O
sent1519 and O
sent1519 9 O
sent1520 Anesthesia T
sent1520 accidents O
sent1521 Gynaecological O
sent1521 pain O
sent1522 Profileplasty T
sent1523 Hypertrophic O
sent1523 obstructive O
sent1523 cardiomyopathy D
sent1524 Oral T
sent1524 contraceptives T
sent1524 , O
sent1524 thrombosis D
sent1524 , O
sent1524 and O
sent1524 cyclical O
sent1524 factors O
sent1524 affecting O
sent1524 veins O
sent1524 . O
sent1525 On O
sent1525 the O
sent1525 influence O
sent1525 of O
sent1525 cytostatic O
sent1525 agents O
sent1525 and O
sent1525 immune O
sent1525 bodies O
sent1525 on O
sent1525 choriocarcinoma O
sent1525 cells O
sent1525 in O
sent1525 tissue O
sent1525 culture O
sent1526 Fat O
sent1526 absorption O
sent1526 : O
sent1526 a O
sent1526 transport O
sent1526 problem O
sent1527 Corpora D
sent1527 lutea D
sent1527 in O
sent1527 proven O
sent1527 mules O
sent1528 Reconstructive O
sent1528 tubal T
sent1528 surgery T
sent1529 Studies O
sent1529 on O
sent1529 the O
sent1529 natural O
sent1529 posterior O
sent1529 pituitary O
sent1529 hormones O
sent1530 II O
sent1531 On O
sent1531 the O
sent1531 official O
sent1531 inspection O
sent1531 of O
sent1531 coal-tar O
sent1531 dyes O
sent1531 in O
sent1531 1969 O
sent1532 3 O
sent1533 Analysis O
sent1533 of O
sent1533 Cr O
sent1533 , O
sent1533 Zn O
sent1533 , O
sent1533 Fe O
sent1533 and O
sent1533 Pb O
sent1533 contaminants O
sent1533 in O
sent1533 food O
sent1533 coal-tar O
sent1533 dyes O
sent1533 and O
sent1533 their O
sent1533 aluminium O
sent1533 lakes O
sent1533 by O
sent1533 atomic O
sent1533 absorption O
sent1533 spectrophotometry O
sent1534 Radiosterilization O
sent1534 of O
sent1534 medical O
sent1534 products O
sent1535 I O
sent1535 . O
sent1535 Effects O
sent1535 of O
sent1535 radiation O
sent1535 on O
sent1535 physical O
sent1535 and O
sent1535 chemical O
sent1535 properties O
sent1535 of O
sent1535 injection O
sent1535 needles O
sent1536 Screening O
sent1536 tests O
sent1536 of O
sent1536 microorganisms O
sent1536 for O
sent1536 the O
sent1536 microbial O
sent1536 transformation O
sent1536 of O
sent1536 griseophenone O
sent1536 A O
sent1536 , O
sent1536 N-methylcoclaurine O
sent1536 and O
sent1536 sparteine O
sent1537 Gas O
sent1537 chromatographic O
sent1537 studies O
sent1537 on O
sent1537 organic O
sent1537 mercurials O
sent1538 Application O
sent1538 of O
sent1538 infra-red O
sent1538 absorption O
sent1538 spectroscopy O
sent1538 to O
sent1538 examination O
sent1538 of O
sent1538 drugs O
sent1538 and O
sent1538 their O
sent1538 preparation O
sent1539 XIX O
sent1540 Determination O
sent1540 of O
sent1540 silicone O
sent1540 oil O
sent1540 in O
sent1540 disposable O
sent1540 plastic O
sent1540 syringes O
sent1541 Observation O
sent1541 of O
sent1541 air O
sent1541 pollution O
sent1541 with O
sent1541 the O
sent1541 aid O
sent1541 of O
sent1541 continuous O
sent1541 analysers O
sent1542 3 O
sent1543 Correlation O
sent1543 between O
sent1543 the O
sent1543 concentration O
sent1543 of O
sent1543 various O
sent1543 kinds O
sent1543 of O
sent1543 pollutants O
sent1543 in O
sent1543 atmosphere O
sent1543 and O
sent1543 wind O
sent1543 direction O
sent1543 and O
sent1543 velocity O
sent1543 at O
sent1543 Kasumigaseki O
sent1543 , O
sent1543 central O
sent1543 district O
sent1543 of O
sent1543 Tokyo O
sent1544 Ultramicro-analysis O
sent1544 of O
sent1544 cyclohexylamine O
sent1544 and O
sent1544 low O
sent1544 fatty O
sent1544 amines O
sent1544 by O
sent1544 gas O
sent1544 chromatography O
sent1545 Some O
sent1545 knowledges O
sent1545 on O
sent1545 the O
sent1545 potency O
sent1545 of O
sent1545 heparin O
sent1545 fractions O
sent1545 obtained O
sent1545 by O
sent1545 gel O
sent1545 filtration O
sent1546 On O
sent1546 the O
sent1546 peripheral O
sent1546 effects O
sent1546 of O
sent1546 endotoxin O
sent1546 and O
sent1546 leucocyte O
sent1546 pyrogen O
sent1546 in O
sent1546 rabbit O
sent1547 A O
sent1547 tentative O
sent1547 draft O
sent1547 of O
sent1547 qualitative O
sent1547 test O
sent1547 of O
sent1547 fluoride O
sent1547 for O
sent1547 adoption O
sent1547 to O
sent1547 the O
sent1547 general O
sent1547 tests O
sent1547 of O
sent1547 eighth O
sent1547 revised O
sent1547 edition O
sent1547 of O
sent1547 the O
sent1547 Pharmacopoeia O
sent1547 of O
sent1547 Japan O
sent1548 Identification O
sent1548 of O
sent1548 tranquillizers T
sent1548 by O
sent1548 thin-layer O
sent1548 chromatography O
sent1549 Analysis O
sent1549 of O
sent1549 steroids O
sent1550 II O
sent1551 A O
sent1551 note O
sent1551 on O
sent1551 the O
sent1551 assay O
sent1551 of O
sent1551 corticoid O
sent1551 preparations O
sent1551 by O
sent1551 tetrazolium O
sent1551 salt O
sent1552 Analysis O
sent1552 of O
sent1552 steroids O
sent1553 3 O
sent1554 Colorimetric O
sent1554 assay O
sent1554 of O
sent1554 thiomesterone O
sent1555 Studies O
sent1555 on O
sent1555 the O
sent1555 radioimmunoassay O
sent1555 of O
sent1555 insulin T
sent1556 I O
sent1556 . O
sent1556 The O
sent1556 production O
sent1556 and O
sent1556 detection O
sent1556 of O
sent1556 anti-insulin O
sent1556 serum O
sent1556 and O
sent1556 anti-guinea-pig O
sent1556 globulin O
sent1556 rabbit O
sent1556 serum O
sent1557 Synthesis O
sent1557 of O
sent1557 lysergic O
sent1557 acid O
sent1557 diethylamide O
sent1557 ( O
sent1557 LSD O
sent1557 ) O
sent1558 Studies O
sent1558 on O
sent1558 the O
sent1558 anti-microbial O
sent1558 activity O
sent1558 of O
sent1558 nonionic O
sent1558 and O
sent1558 anionic O
sent1558 surfactants O
sent1559 On O
sent1559 the O
sent1559 National O
sent1559 Institute O
sent1559 of O
sent1559 Hygienic O
sent1559 Sciences O
sent1559 Standard O
sent1559 `` O
sent1559 lysozyme O
sent1559 standard O
sent1559 '' O
sent1560 On O
sent1560 the O
sent1560 examination O
sent1560 of O
sent1560 ginseng O
sent1560 and O
sent1560 powdered O
sent1560 ginseng O
sent1560 in O
sent1560 1969 O
sent1561 On O
sent1561 the O
sent1561 standardization O
sent1561 of O
sent1561 plastic T
sent1561 suture T
sent1562 Undergraduate O
sent1562 research O
sent1562 assistants O
sent1562 in O
sent1562 the O
sent1562 Faculty O
sent1562 of O
sent1562 Medicine O
sent1563 University O
sent1563 College O
sent1563 of O
sent1563 Rhodesia O
sent1564 Congenital D
sent1564 aortic D
sent1564 stenosis D
sent1565 Sodium O
sent1565 in O
sent1565 heart D
sent1565 failure D
sent1566 Potassium O
sent1566 in O
sent1566 heart D
sent1566 failure D
sent1567 Hydrogen O
sent1567 ion O
sent1567 equilibrium O
sent1567 in O
sent1567 heart D
sent1567 failure D
sent1568 Various O
sent1568 aspects O
sent1568 of O
sent1568 water-salt O
sent1568 metabolism O
sent1568 in O
sent1568 heart D
sent1568 congestive D
sent1568 failure D
sent1569 Clinical O
sent1569 physiopathology O
sent1569 of O
sent1569 the O
sent1569 patency O
sent1569 of O
sent1569 the O
sent1569 interatrial O
sent1569 septum O
sent1570 Various O
sent1570 aspects O
sent1570 of O
sent1570 diuresis D
sent1570 in O
sent1570 heart D
sent1570 congestive D
sent1570 failure D
sent1571 Changes O
sent1571 in O
sent1571 the O
sent1571 mechanism O
sent1571 of O
sent1571 renal O
sent1571 acidification O
sent1571 in O
sent1571 congestive D
sent1571 heart D
sent1571 failure D
sent1571 : O
sent1571 effects O
sent1571 of O
sent1571 diuretic T
sent1571 treatment T
sent1571 on O
sent1571 the O
sent1571 acid-base O
sent1571 equilibrium O
sent1572 Defects O
sent1572 of O
sent1572 the O
sent1572 interventricular O
sent1572 septum O
sent1572 not O
sent1572 associated O
sent1572 with O
sent1572 other O
sent1572 malformations O
sent1573 Clinical O
sent1573 physiopathology O
sent1573 of O
sent1573 the O
sent1573 patency O
sent1573 of O
sent1573 Botallo D
sent1573 's D
sent1573 ductus D
sent1573 arteriosus D
sent1574 Clinical O
sent1574 physiopathology O
sent1574 of O
sent1574 congenital D
sent1574 cyanogenic D
sent1574 cardiopathies D
sent1575 Electronic O
sent1575 computers O
sent1575 in O
sent1575 medical O
sent1575 education O
sent1575 of O
sent1575 the O
sent1575 future O
sent1576 Anesthesiology O
sent1576 and O
sent1576 computers O
sent1577 Immediate O
sent1577 outcome O
sent1577 and O
sent1577 long-term O
sent1577 results O
sent1577 of O
sent1577 108 O
sent1577 sphincterotomies O
sent1577 of O
sent1577 Oddi O
sent1577 's O
sent1577 sphincter O
sent1577 of O
sent1577 biliary O
sent1577 indication O
sent1578 Neuraminic O
sent1578 acid-containing O
sent1578 oligosaccharides O
sent1578 of O
sent1578 human O
sent1578 urine O
sent1578 : O
sent1578 isolation O
sent1578 and O
sent1578 identification O
sent1578 of O
sent1578 di-N-acetylneuraminyl-3-galactosyl-N-acetylgalactosamine O
sent1578 , O
sent1578 6-2-Nacetylneuraminyl-lactose O
sent1578 , O
sent1578 6-2-N-acetylneuraminyl-N-acetyllactosamine O
sent1578 and O
sent1578 3-2-N-acetylneuraminyl-lactose O
sent1579 Determination O
sent1579 of O
sent1579 serum O
sent1579 oxytocinase O
sent1579 ( O
sent1579 1-cystine-aminopeptidase O
sent1579 ) O
sent1579 activity O
sent1580 Intolerance O
sent1580 to O
sent1580 milk O
sent1580 in O
sent1580 ulcerative D
sent1580 colitis D
sent1581 A O
sent1581 preliminary O
sent1581 report O
sent1582 Rhinitis D
sent1582 in O
sent1582 herds O
sent1582 with O
sent1582 piglet D
sent1582 influenza D
sent1583 Research O
sent1583 on O
sent1583 breeding O
sent1583 hygiene O
sent1583 in O
sent1583 pigs O
sent1583 and O
sent1583 piglets O
sent1583 free O
sent1583 from O
sent1583 epidemic D
sent1583 diseases D
sent1584 The O
sent1584 stimulatory O
sent1584 effect O
sent1584 of O
sent1584 luteinizing O
sent1584 hormone O
sent1584 on O
sent1584 adenosine O
sent1584 3 O
sent1584 ' O
sent1584 , O
sent1584 5'-monophosphate O
sent1584 accumulation O
sent1584 in O
sent1584 corpus O
sent1584 luteum O
sent1584 slices O
sent1585 Electrolyte O
sent1585 and O
sent1585 acid-base O
sent1585 balance O
sent1585 in O
sent1585 fetal O
sent1585 and O
sent1585 maternal O
sent1585 blood O
sent1586 An O
sent1586 experimental O
sent1586 and O
sent1586 a O
sent1586 clinical O
sent1586 study O
sent1587 Q D
sent1587 fever D
sent1587 at O
sent1587 a O
sent1587 combined O
sent1587 meat O
sent1587 and O
sent1587 poultry O
sent1587 abattoir O
sent1588 Some O
sent1588 functional O
sent1588 and O
sent1588 morphological O
sent1588 alterations O
sent1588 occurring O
sent1588 during O
sent1588 and O
sent1588 after O
sent1588 the O
sent1588 adaptation O
sent1588 of O
sent1588 BHK O
sent1588 21 O
sent1588 clone O
sent1588 13 O
sent1588 cells O
sent1588 to O
sent1588 suspension O
sent1588 culture O
sent1589 Asbestos O
sent1589 as O
sent1589 an O
sent1589 urban O
sent1589 air O
sent1589 contaminant O
sent1590 Gas O
sent1590 permeability O
sent1590 of O
sent1590 plastic O
sent1590 membranes O
sent1590 for O
sent1590 artificial T
sent1590 lungs T
sent1591 Technoogy O
sent1591 , O
sent1591 automation O
sent1591 and O
sent1591 human O
sent1591 welfare O
sent1592 A O
sent1592 radium O
sent1592 accident O
sent1592 in O
sent1592 a O
sent1592 hospital O
sent1593 High O
sent1593 energy O
sent1593 roentgen O
sent1593 ray O
sent1593 contamination O
sent1593 of O
sent1593 the O
sent1593 electron O
sent1593 beam O
sent1593 from O
sent1593 a O
sent1593 medical O
sent1593 betatron O
sent1594 The O
sent1594 genetically O
sent1594 significant O
sent1594 dose O
sent1594 from O
sent1594 roentgen O
sent1594 examinations O
sent1594 in O
sent1594 Finland O
sent1594 in O
sent1594 1963 O
sent1595 Differential O
sent1595 expression O
sent1595 of O
sent1595 fibroblast O
sent1595 growth O
sent1595 factor-2 O
sent1595 and O
sent1595 receptor O
sent1595 by O
sent1595 glial O
sent1595 cells O
sent1595 in O
sent1595 experimental O
sent1595 autoimmune D
sent1595 encephalomelitis D
sent1595 ( D
sent1595 EAE D
sent1595 ) D
sent1596 Cesarean O
sent1596 deliveries O
sent1596 at O
sent1596 a O
sent1596 university O
sent1596 hospital O
sent1596 : O
sent1596 analysis O
sent1596 of O
sent1596 rates O
sent1596 and O
sent1596 indications O
sent1597 Increase O
sent1597 in O
sent1597 ambient O
sent1597 temperature O
sent1597 may O
sent1597 explain O
sent1597 decrease O
sent1597 in O
sent1597 amniotic O
sent1597 fluid O
sent1597 index O
sent1598 Early O
sent1598 treatment O
sent1598 of O
sent1598 gestational D
sent1598 diabetes D
sent1598 reduces O
sent1598 the O
sent1598 rate O
sent1598 of O
sent1598 fetal D
sent1598 macrosomia D
sent1599 Antenatally O
sent1599 detectable O
sent1599 markers O
sent1599 for O
sent1599 the O
sent1599 diagnosis O
sent1599 of O
sent1599 autosomally D
sent1599 trisomic D
sent1599 fetuses D
sent1599 in O
sent1599 at-risk O
sent1599 pregnancies O
sent1600 The O
sent1600 rate O
sent1600 of O
sent1600 severe O
sent1600 preeclampsia D
sent1600 is O
sent1600 increased O
sent1600 in O
sent1600 triplet O
sent1600 as O
sent1600 compared O
sent1600 to O
sent1600 twin O
sent1600 gestations O
sent1601 Thermal O
sent1601 equipment O
sent1601 usage O
sent1601 patterns O
sent1601 in O
sent1601 neonatal O
sent1601 intensive O
sent1601 care O
sent1601 units O
sent1601 : O
sent1601 interunit O
sent1601 variability O
sent1601 and O
sent1601 intraunit O
sent1601 consistency O
sent1602 Massive O
sent1602 fetomaternal D
sent1602 hemorrhage D
sent1603 Perinatal O
sent1603 features O
sent1603 of O
sent1603 omphalocele-exstrophy-imperforate D
sent1603 anus-spinal D
sent1603 defects D
sent1603 ( D
sent1603 OEIS D
sent1603 complex D
sent1603 ) D
sent1603 associated O
sent1603 with O
sent1603 large O
sent1603 meningomyeloceles D
sent1603 and O
sent1603 severe D
sent1603 limb D
sent1603 defects D
sent1604 Subchorial D
sent1604 hematoma D
sent1604 : O
sent1604 a O
sent1604 probable O
sent1604 cause O
sent1604 of O
sent1604 reversible O
sent1604 nonimmune O
sent1604 hydrops O
sent1604 fetalis D
sent1605 Pregnancy O
sent1605 in O
sent1605 chronic O
sent1605 progressive O
sent1605 external O
sent1605 ophthalmoplegia D
sent1605 : O
sent1605 a O
sent1605 case O
sent1605 report O
sent1606 Effect O
sent1606 of O
sent1606 magnesium O
sent1606 sulfate O
sent1606 on O
sent1606 the O
sent1606 development O
sent1606 of O
sent1606 cystic O
sent1606 periventricular O
sent1606 leukomalacia D
sent1606 in O
sent1606 preterm O
sent1606 infants O
sent1607 < O
sent1607 TO_SEE O
sent1607 > O
sent1607 Repeated O
sent1607 courses O
sent1607 of O
sent1607 steroids O
sent1607 in O
sent1607 preterm O
sent1607 membrane O
sent1607 rupture O
sent1607 do O
sent1607 not O
sent1607 increase O
sent1607 the O
sent1607 risk O
sent1607 of O
sent1607 histologic O
sent1607 chorioamnionitis O
sent1608 Intrapartum O
sent1608 sonography O
sent1608 of O
sent1608 the O
sent1608 lower O
sent1608 uterine O
sent1608 segment O
sent1608 in O
sent1608 patients O
sent1608 with O
sent1608 breech-presenting O
sent1608 fetuses O
sent1609 Isolated O
sent1609 persistent O
sent1609 fetal O
sent1609 bradycardia O
sent1609 in O
sent1609 complete O
sent1609 A-V O
sent1609 block O
sent1609 : O
sent1609 a O
sent1609 conservative O
sent1609 approach O
sent1609 is O
sent1609 appropriate O
sent1610 A O
sent1610 case O
sent1610 report O
sent1610 and O
sent1610 a O
sent1610 review O
sent1610 of O
sent1610 the O
sent1610 literature O
sent1611 Spontaneous O
sent1611 rectus D
sent1611 sheath D
sent1611 hematoma D
sent1611 during O
sent1611 pregnancy O
sent1611 mimicking O
sent1611 abruptio D
sent1611 placenta D
sent1612 Amnioinfusion T
sent1612 for O
sent1612 prevention O
sent1612 of O
sent1612 pulmonary D
sent1612 hypoplasia D
sent1612 in O
sent1612 second-trimester O
sent1612 rupture O
sent1612 of O
sent1612 membranes O
sent1613 Trauma O
sent1613 and O
sent1613 pregnancy O
sent1614 Fetal O
sent1614 breathing O
sent1614 movements O
sent1614 within O
sent1614 24 O
sent1614 hours O
sent1614 of O
sent1614 delivery O
sent1614 in O
sent1614 prematurity O
sent1614 are O
sent1614 related O
sent1614 to O
sent1614 histologic O
sent1614 and O
sent1614 clinical O
sent1614 evidence O
sent1614 of O
sent1614 amnionitis D
sent1615 Laerdal O
sent1615 infant O
sent1615 resuscitators O
sent1615 are O
sent1615 unreliable O
sent1615 as O
sent1615 free-flow O
sent1615 oxygen O
sent1615 delivery O
sent1615 devices O
sent1616 Laryngeal D
sent1616 obstruction D
sent1616 caused O
sent1616 by O
sent1616 lingual D
sent1616 thyroglossal D
sent1616 duct D
sent1616 cyst D
sent1616 presenting O
sent1616 at O
sent1616 birth O
sent1617 Oligohydramnios O
sent1617 and O
sent1617 the O
sent1617 appropriately O
sent1617 grown O
sent1617 fetus O
sent1618 Ultrastructure O
sent1618 of O
sent1618 human O
sent1618 colostral O
sent1618 cells O
sent1619 Dubowitz O
sent1619 assessment O
sent1619 of O
sent1619 gestational O
sent1619 age O
sent1619 and O
sent1619 agreement O
sent1619 with O
sent1619 prenatal O
sent1619 methods O
sent1620 Low O
sent1620 prenatal O
sent1620 weight O
sent1620 gain O
sent1620 among O
sent1620 low-income O
sent1620 women O
sent1620 : O
sent1620 what O
sent1620 are O
sent1620 the O
sent1620 risk O
sent1620 factors O
sent1620 ? O
sent1621 Depression D
sent1621 after O
sent1621 childbirth O
sent1621 : O
sent1621 the O
sent1621 views O
sent1621 of O
sent1621 medical O
sent1621 students O
sent1621 and O
sent1621 women O
sent1621 compared O
sent1622 Breastfeeding O
sent1622 and O
sent1622 the O
sent1622 use O
sent1622 of O
sent1622 pacifiers O
sent1623 Care O
sent1623 in O
sent1623 normal O
sent1623 birth O
sent1623 : O
sent1623 a O
sent1623 practical O
sent1623 guide O
sent1624 Technical O
sent1624 Working O
sent1624 Group O
sent1624 , O
sent1624 World O
sent1624 Health O
sent1624 Organization O
sent1625 Cesarean O
sent1625 sections O
sent1625 : O
sent1625 women O
sent1625 's O
sent1625 choice O
sent1625 for O
sent1625 giving O
sent1625 birth O
sent1625 ? O
sent1626 Epidurals T
sent1626 and O
sent1626 breastfeeding O
sent1627 Lamaze O
sent1627 and O
sent1627 Bradley O
sent1627 childbirth O
sent1627 classes O
sent1628 Concerns O
sent1628 about O
sent1628 the O
sent1628 institutionalization O
sent1628 of O
sent1628 childbirth O
sent1628 education O
sent1629 Index O
sent1629 to O
sent1629 current O
sent1629 literature O
sent1630 A O
sent1630 randomized O
sent1630 trial O
sent1630 of O
sent1630 one-to-one O
sent1630 nurse O
sent1630 support O
sent1630 of O
sent1630 women O
sent1630 in O
sent1630 labor O
sent1631 Commentary O
sent1631 : O
sent1631 are O
sent1631 nurses O
sent1631 effective O
sent1631 providers O
sent1631 of O
sent1631 labor O
sent1631 support O
sent1631 ? O
sent1631 Should O
sent1631 they O
sent1631 be O
sent1631 ? O
sent1631 Can O
sent1631 they O
sent1631 be O
sent1631 ? O
sent1632 Women O
sent1632 's O
sent1632 views O
sent1632 of O
sent1632 different O
sent1632 models O
sent1632 of O
sent1632 antenatal O
sent1632 care O
sent1632 in O
sent1632 Victoria O
sent1632 , O
sent1632 Australia O
sent1633 The O
sent1633 effect O
sent1633 of O
sent1633 discharge O
sent1633 pack O
sent1633 formula O
sent1633 and O
sent1633 breast O
sent1633 pumps O
sent1633 on O
sent1633 breastfeeding O
sent1633 duration O
sent1633 and O
sent1633 choice O
sent1633 of O
sent1633 infant O
sent1633 feeding O
sent1633 method O
sent1634 Commentary O
sent1634 : O
sent1634 discharge O
sent1634 packs O
sent1634 : O
sent1634 how O
sent1634 much O
sent1634 do O
sent1634 they O
sent1634 matter O
sent1634 ? O
sent1635 Quality O
sent1635 framework O
sent1635 for O
sent1635 force O
sent1635 plate O
sent1635 testing O
sent1636 Bone O
sent1636 registration O
sent1636 method O
sent1636 for O
sent1636 robot T
sent1636 assisted T
sent1636 surgery T
sent1636 : O
sent1636 pedicle O
sent1636 screw O
sent1636 insertion O
sent1637 Parameter O
sent1637 sensitivity O
sent1637 of O
sent1637 a O
sent1637 mathematical O
sent1637 model O
sent1637 of O
sent1637 the O
sent1637 anterior O
sent1637 cruciate O
sent1637 ligament O
sent1638 Simultaneous O
sent1638 measurement O
sent1638 of O
sent1638 stiffness O
sent1638 and O
sent1638 energy O
sent1638 absorptive O
sent1638 properties O
sent1638 of O
sent1638 articular O
sent1638 cartilage O
sent1638 and O
sent1638 subchondral O
sent1638 trabecular O
sent1638 bone O
sent1639 Estimation O
sent1639 of O
sent1639 loads O
sent1639 and O
sent1639 stresses O
sent1639 in O
sent1639 abdominal O
sent1639 muscles O
sent1639 during O
sent1639 slow O
sent1639 lifts O
sent1640 Contralateral O
sent1640 modification O
sent1640 of O
sent1640 transitory O
sent1640 evoked O
sent1640 otoacoustic O
sent1640 emissions O
sent1641 Treatment O
sent1641 of O
sent1641 cavernous D
sent1641 hemangiomas D
sent1641 with O
sent1641 the O
sent1641 neodymium T
sent1641 : T
sent1641 YAG T
sent1641 laser T
sent1642 Mucous D
sent1642 membrane D
sent1642 melanomas D
sent1642 of O
sent1642 the O
sent1642 upper O
sent1642 aerodigestive O
sent1642 tract O
sent1643 An O
sent1643 analysis O
sent1643 of O
sent1643 34 O
sent1643 cases O
sent1644 Are O
sent1644 the O
sent1644 products O
sent1644 of O
sent1644 CD44 O
sent1644 exons O
sent1644 v5 O
sent1644 and O
sent1644 v6 O
sent1644 markers O
sent1644 for O
sent1644 metastasis O
sent1644 of O
sent1644 laryngeal D
sent1644 carcinomas D
sent1644 ? O
sent1645 Detection O
sent1645 of O
sent1645 differentially O
sent1645 expressed O
sent1645 genes O
sent1645 in O
sent1645 head-neck D
sent1645 carcinomas D
sent1646 Tuberculosis D
sent1646 of O
sent1646 the O
sent1646 parotid O
sent1646 gland O
sent1646 : O
sent1646 a O
sent1646 rare O
sent1646 differential O
sent1646 diagnosis O
sent1646 of O
sent1646 parotid D
sent1646 tumor D
sent1647 A O
sent1647 case O
sent1647 of O
sent1647 sarcoidosis D
sent1647 of O
sent1647 the O
sent1647 mastoid O
sent1648 Genomic O
sent1648 medicine O
sent1649 Internet O
sent1649 resources O
sent1649 for O
sent1649 medical O
sent1649 genetics O
sent1650 Genetics O
sent1651 A O
sent1651 piece O
sent1651 of O
sent1651 my O
sent1651 mind O
sent1652 A O
sent1652 'normal O
sent1652 ' O
sent1652 practice O
sent1653 Predisposition O
sent1653 genetic O
sent1653 testing O
sent1653 for O
sent1653 late-onset D
sent1653 disorders D
sent1653 in O
sent1653 adults O
sent1654 A O
sent1654 position O
sent1654 paper O
sent1654 of O
sent1654 the O
sent1654 National O
sent1654 Society O
sent1654 of O
sent1654 Genetic O
sent1654 Counselors O
sent1655 Scientists O
sent1655 revel O
sent1655 in O
sent1655 new O
sent1655 research O
sent1655 tool O
sent1655 : O
sent1655 an O
sent1655 online O
sent1655 index O
sent1655 of O
sent1655 cancer O
sent1655 genes O
sent1656 Center O
sent1656 for O
sent1656 genetic O
sent1656 research O
sent1656 on O
sent1656 scleroderma D
sent1657 As O
sent1657 discoveries O
sent1657 unfold O
sent1657 , O
sent1657 a O
sent1657 new O
sent1657 urgency O
sent1657 to O
sent1657 bring O
sent1657 genetic O
sent1657 literacy O
sent1657 to O
sent1657 physicians O
sent1658 > O
sent1658 From O
sent1658 the O
sent1658 Centers O
sent1658 for O
sent1658 Disease O
sent1658 Control O
sent1658 and O
sent1658 Prevention O
sent1659 Gonorrhea D
sent1659 among O
sent1659 men O
sent1659 who O
sent1659 have O
sent1659 sex O
sent1659 with O
sent1659 men O
sent1659 -- O
sent1659 selected O
sent1659 sexually O
sent1659 transmitted O
sent1659 diseases O
sent1659 clinics O
sent1659 , O
sent1659 1993-1996 O
sent1660 > O
sent1660 From O
sent1660 the O
sent1660 Centers O
sent1660 for O
sent1660 Disease O
sent1660 Control O
sent1660 and O
sent1660 Prevention O
sent1661 Chlamydia D
sent1661 screening O
sent1661 practices O
sent1661 of O
sent1661 primary-care O
sent1661 providers O
sent1661 -- O
sent1661 Wake O
sent1661 County O
sent1661 , O
sent1661 North O
sent1661 Carolina O
sent1661 , O
sent1661 1996 O
sent1662 Social O
sent1662 ties O
sent1662 and O
sent1662 susceptibility O
sent1662 to O
sent1662 the O
sent1662 common D
sent1662 cold D
sent1663 Prevention O
sent1663 of O
sent1663 bacterial D
sent1663 endocarditis D
sent1663 : O
sent1663 American O
sent1663 Heart O
sent1663 Association O
sent1663 recommendations O
sent1664 Issues O
sent1664 regarding O
sent1664 antiretroviral T
sent1664 treatment T
sent1664 for O
sent1664 patients O
sent1664 with O
sent1664 HIV-1 D
sent1664 infection D
sent1665 Prescribing O
sent1665 protease T
sent1665 inhibitors T
sent1665 for O
sent1665 the O
sent1665 homeless O
sent1666 Treatment O
sent1666 of O
sent1666 verruca D
sent1666 vulgaris D
sent1666 with O
sent1666 topical T
sent1666 cidofovir T
sent1667 Complete O
sent1667 genomic O
sent1667 screen O
sent1667 in O
sent1667 late-onset O
sent1667 familial O
sent1667 Alzheimer D
sent1667 disease D
sent1668 Evidence O
sent1668 for O
sent1668 a O
sent1668 new O
sent1668 locus O
sent1668 on O
sent1668 chromosome O
sent1668 12 O
sent1669 BRCA1 O
sent1669 sequence O
sent1669 analysis O
sent1669 in O
sent1669 women O
sent1669 at O
sent1669 high O
sent1669 risk O
sent1669 for O
sent1669 susceptibility O
sent1669 mutations O
sent1670 Risk O
sent1670 factor O
sent1670 analysis O
sent1670 and O
sent1670 implications O
sent1670 for O
sent1670 genetic O
sent1670 testing O
sent1671 Characteristics O
sent1671 of O
sent1671 prostate D
sent1671 cancer D
sent1671 in O
sent1671 families O
sent1671 potentially O
sent1671 linked O
sent1671 to O
sent1671 the O
sent1671 hereditary O
sent1671 prostate O
sent1671 cancer O
sent1671 1 O
sent1671 ( O
sent1671 HPC1 O
sent1671 ) O
sent1671 locus O
sent1672 Chromosome O
sent1672 19 O
sent1672 single-locus O
sent1672 and O
sent1672 multilocus O
sent1672 haplotype O
sent1672 associations O
sent1672 with O
sent1672 multiple D
sent1672 sclerosis D
sent1673 Evidence O
sent1673 of O
sent1673 a O
sent1673 new O
sent1673 susceptibility O
sent1673 locus O
sent1673 in O
sent1673 Caucasian O
sent1673 and O
sent1673 Chinese O
sent1673 patients O
sent1674 Cancer D
sent1674 incidence O
sent1674 after O
sent1674 retinoblastoma D
sent1675 Radiation O
sent1675 dose O
sent1675 and O
sent1675 sarcoma O
sent1675 risk O
sent1676 Genetic O
sent1676 testing O
sent1676 in O
sent1676 hereditary O
sent1676 colorectal D
sent1676 cancer D
sent1677 Molecular O
sent1677 neurogenetics O
sent1677 : O
sent1677 the O
sent1677 genome O
sent1677 is O
sent1677 settling O
sent1677 the O
sent1677 issue O
sent1678 Family O
sent1678 history O
sent1678 and O
sent1678 genetic O
sent1678 risk O
sent1678 factors O
sent1678 : O
sent1678 forward O
sent1678 to O
sent1678 the O
sent1678 future O
sent1679 Preparing O
sent1679 health O
sent1679 professionals O
sent1679 for O
sent1679 the O
sent1679 genetic O
sent1679 revolution O
sent1680 Preterm O
sent1680 premature O
sent1680 rupture D
sent1680 of D
sent1680 the D
sent1680 membranes D
sent1680 associated O
sent1680 with O
sent1680 recent O
sent1680 cocaine O
sent1680 use O
sent1681 Attitudes O
sent1681 toward O
sent1681 health-care O
sent1681 , O
sent1681 HIV D
sent1681 infection D
sent1681 , O
sent1681 and O
sent1681 perinatal O
sent1681 transmission O
sent1681 interventions O
sent1681 in O
sent1681 a O
sent1681 cohort O
sent1681 of O
sent1681 inner-city O
sent1681 , O
sent1681 pregnant O
sent1681 women O
sent1682 Association O
sent1682 of O
sent1682 parvovirus D
sent1682 infection D
sent1682 with O
sent1682 isolated O
sent1682 fetal O
sent1682 effusions O
sent1683 Early O
sent1683 and O
sent1683 long-term O
sent1683 results O
sent1683 of O
sent1683 rehabilitation O
sent1683 of O
sent1683 cochlear T
sent1683 implant T
sent1683 patients O
sent1683 ) O
sent1684 Principles O
sent1684 of O
sent1684 signal O
sent1684 detection O
sent1684 in O
sent1684 pharmacovigilance O
sent1685 Homology O
sent1685 modeling O
sent1685 of O
sent1685 adenylosuccinate O
sent1685 synthetase O
sent1685 from O
sent1685 Saccharomyces O
sent1685 cerevisiae O
sent1685 reveals O
sent1685 a O
sent1685 possible O
sent1685 binding O
sent1685 region O
sent1685 for O
sent1685 single-stranded O
sent1685 ARS O
sent1685 sequences O
sent1686 Deletion O
sent1686 analysis O
sent1686 of O
sent1686 the O
sent1686 p16/CDKN2 O
sent1686 gene O
sent1686 in O
sent1686 head O
sent1686 and O
sent1686 neck O
sent1686 squamous O
sent1686 cell O
sent1686 carcinoma D
sent1686 using O
sent1686 quantitative O
sent1686 polymerase O
sent1686 chain O
sent1686 reaction O
sent1686 method O
sent1687 Ribosomal O
sent1687 S6 O
sent1687 kinase O
sent1687 p90rsk O
sent1687 and O
sent1687 mRNA O
sent1687 cap-binding O
sent1687 protein O
sent1687 eIF4E O
sent1687 phosphorylations O
sent1687 correlate O
sent1687 with O
sent1687 MAP O
sent1687 kinase O
sent1687 activation O
sent1687 during O
sent1687 meiotic O
sent1687 reinitiation O
sent1687 of O
sent1687 mouse O
sent1687 oocytes O
sent1688 Hyaluronidase O
sent1688 activity O
sent1688 of O
sent1688 macaque O
sent1688 sperm O
sent1688 assessed O
sent1688 by O
sent1688 an O
sent1688 in O
sent1688 vitro O
sent1688 cumulus O
sent1688 penetration O
sent1688 assay O
sent1689 The O
sent1689 comparison O
sent1689 of O
sent1689 the O
sent1689 responsiveness O
sent1689 of O
sent1689 human O
sent1689 isolated O
sent1689 internal O
sent1689 mammary O
sent1689 and O
sent1689 gastroepiploic O
sent1689 arteries O
sent1689 to O
sent1689 levcromakalim O
sent1689 : O
sent1689 an O
sent1689 alternative O
sent1689 approach O
sent1689 to O
sent1689 the O
sent1689 management O
sent1689 of O
sent1689 graft O
sent1689 spasm O
sent1690 Single-dose O
sent1690 pharmacokinetics O
sent1690 of O
sent1690 felbamate O
sent1690 in O
sent1690 patients O
sent1690 with O
sent1690 renal O
sent1690 dysfunction O
sent1691 Reporting O
sent1691 of O
sent1691 adverse O
sent1691 drug O
sent1691 reactions O
sent1691 by O
sent1691 hospital O
sent1691 doctors O
sent1691 and O
sent1691 the O
sent1691 response O
sent1691 to O
sent1691 intervention O
sent1692 Glutamate O
sent1692 receptors O
sent1692 and O
sent1692 gene O
sent1692 induction O
sent1692 : O
sent1692 signalling O
sent1692 from O
sent1692 receptor O
sent1692 to O
sent1692 nucleus O
sent1693 Role O
sent1693 of O
sent1693 phosphatidylinositol O
sent1693 3-kinase O
sent1693 in O
sent1693 degranulation O
sent1693 induced O
sent1693 by O
sent1693 IgE-dependent O
sent1693 and O
sent1693 -independent O
sent1693 mechanisms O
sent1693 in O
sent1693 rat O
sent1693 basophilic O
sent1693 RBL-2H3 O
sent1693 ( O
sent1693 ml O
sent1693 ) O
sent1693 cells O
sent1694 Platelet-derived O
sent1694 growth O
sent1694 factor O
sent1694 activates O
sent1694 a O
sent1694 mammalian O
sent1694 Ste20 O
sent1694 coupled O
sent1694 mitogen-activated O
sent1694 protein O
sent1694 kinase O
sent1694 in O
sent1694 airway O
sent1694 smooth O
sent1694 muscle O
sent1695 Cyclic O
sent1695 AMP O
sent1695 inhibitors O
sent1695 inhibits O
sent1695 PDGF-stimulated O
sent1695 mitogen-activated O
sent1695 protein O
sent1695 kinase O
sent1695 activity O
sent1695 in O
sent1695 rat O
sent1695 aortic O
sent1695 smooth O
sent1695 muscle O
sent1695 cells O
sent1695 via O
sent1695 inactivation O
sent1695 of O
sent1695 c-Raf-1 O
sent1695 kinase O
sent1695 and O
sent1695 induction O
sent1695 of O
sent1695 MAP O
sent1695 kinase O
sent1695 phosphatase-1 O
sent1696 Mitochondrial O
sent1696 cytopathies O
sent1696 and O
sent1696 renal D
sent1696 tubular D
sent1696 acidosis D
sent1697 Elective T
sent1697 surgery T
sent1697 for O
sent1697 colorectal D
sent1697 cancer D
sent1697 in O
sent1697 the O
sent1697 aged O
sent1697 : O
sent1697 a O
sent1697 clinical-economical O
sent1697 evaluation O
sent1698 Leukaemia D
sent1698 and O
sent1698 non-Hodgkin D
sent1698 's D
sent1698 lymphoma D
sent1698 in O
sent1698 children O
sent1698 and O
sent1698 young O
sent1698 adults O
sent1698 : O
sent1698 are O
sent1698 prenatal O
sent1698 and O
sent1698 neonatal O
sent1698 factors O
sent1698 important O
sent1698 determinants O
sent1698 of O
sent1698 disease O
sent1698 ? O
sent1699 Inverse O
sent1699 correlation O
sent1699 between O
sent1699 loss O
sent1699 of O
sent1699 heterozygosity O
sent1699 of O
sent1699 the O
sent1699 short O
sent1699 arm O
sent1699 of O
sent1699 chromosome O
sent1699 12 O
sent1699 and O
sent1699 p15ink4B/p16ink4 O
sent1699 gene O
sent1699 inactivation O
sent1699 in O
sent1699 childhood D
sent1699 acute D
sent1699 lymphoblastic D
sent1699 leukaemia D
sent1700 Drug O
sent1700 resistance O
sent1700 markers O
sent1700 : O
sent1700 are O
sent1700 they O
sent1700 bad O
sent1700 or O
sent1700 good O
sent1700 ? O
sent1701 Elective T
sent1701 surgery T
sent1701 for O
sent1701 gastrointestinal D
sent1701 tumours D
sent1701 in O
sent1701 the O
sent1701 elderly O
sent1702 Folate T
sent1702 and O
sent1702 heart D
sent1702 disease D
sent1702 : O
sent1702 theoretical O
sent1702 link O
sent1702 needs O
sent1702 study O
sent1702 . O
sent1703 A O
sent1703 call O
sent1703 for O
sent1703 stepped-up O
sent1703 melanoma D
sent1703 screening O
sent1704 New O
sent1704 approaches O
sent1704 to O
sent1704 stroke D
sent1704 require O
sent1704 immediate O
sent1704 action O
sent1705 The O
sent1705 focus O
sent1705 is O
sent1705 now O
sent1705 on O
sent1705 standards O
sent1705 and O
sent1705 privacy O
sent1705 in O
sent1705 electronic O
sent1705 patient O
sent1705 records O
sent1706 Osteopathic O
sent1706 manifesto O
sent1707 I O
sent1707 . O
sent1707 Introduction O
sent1708 II O
sent1709 The O
sent1709 roots O
sent1710 1981 O
sent1711 Treatment O
sent1711 uncertainties O
sent1711 surround O
sent1711 early O
sent1711 diagnosis O
sent1711 of O
sent1711 breast D
sent1711 cancer D
sent1712 Depression D
sent1712 in O
sent1712 the O
sent1712 chronically O
sent1712 ill O
sent1712 needs O
sent1712 separate O
sent1712 treatment O
sent1713 Medical O
sent1713 centers O
sent1713 tackle O
sent1713 delays O
sent1713 , O
sent1713 reduce O
sent1713 wait O
sent1713 times O
sent1714 Epilepsy O
sent1714 and O
sent1714 attention O
sent1714 deficit O
sent1714 hyperactivity O
sent1714 disorder O
sent1714 : O
sent1714 is O
sent1714 methylphenidate O
sent1714 safe O
sent1714 and O
sent1714 effective O
sent1714 ? O
sent1715 Applying O
sent1715 the O
sent1715 AIDS D
sent1715 paradigm O
sent1715 to O
sent1715 hepatitis D
sent1716 New O
sent1716 asthma D
sent1716 guidelines O
sent1716 emphasize O
sent1716 better O
sent1716 diagnosis O
sent1716 , O
sent1716 stricter O
sent1716 control O
sent1717 Osteopathic O
sent1717 manifesto O
sent1718 IV O
sent1719 The O
sent1719 search O
sent1720 1981 O
sent1721 Researchers O
sent1721 puzzle O
sent1721 over O
sent1721 origin O
sent1721 of O
sent1721 type O
sent1721 2 O
sent1721 diabetes D
sent1722 Ovarian D
sent1722 cancer D
sent1722 : O
sent1722 diagnostic O
sent1722 limitations O
sent1722 , O
sent1722 treatment O
sent1722 obstacles O
sent1723 Osteopathic O
sent1723 manifesto O
sent1724 V O
sent1725 Legislative O
sent1725 and O
sent1725 legal O
sent1725 vigilance O
sent1726 1981 O
sent1727 Osteopathic O
sent1727 manifesto O
sent1728 VI O
sent1729 The O
sent1729 light O
sent1729 of O
sent1729 the O
sent1729 profession O
sent1730 1981 O
sent1731 Electrophysiological O
sent1731 evidence O
sent1731 on O
sent1731 the O
sent1731 time O
sent1731 course O
sent1731 of O
sent1731 semantic O
sent1731 and O
sent1731 phonological O
sent1731 processes O
sent1731 in O
sent1731 speech O
sent1731 production O
sent1732 Effects O
sent1732 of O
sent1732 alanine O
sent1732 and O
sent1732 glycine O
sent1732 substitution O
sent1732 for O
sent1732 tryptophan O
sent1732 on O
sent1732 the O
sent1732 heterogeneity O
sent1732 of O
sent1732 gramicidin O
sent1732 A O
sent1732 analogs O
sent1732 in O
sent1732 micelles O
sent1733 Torsion-angle O
sent1733 molecular O
sent1733 dynamics O
sent1733 as O
sent1733 a O
sent1733 new O
sent1733 efficient O
sent1733 tool O
sent1733 for O
sent1733 NMR O
sent1733 structure O
sent1733 calculation O
sent1734 Time-domain O
sent1734 quanification O
sent1734 of O
sent1734 amplitude O
sent1734 , O
sent1734 chemical O
sent1734 shift O
sent1734 , O
sent1734 apparent O
sent1734 relaxation O
sent1734 time O
sent1734 T2 O
sent1734 , O
sent1734 and O
sent1734 phase O
sent1734 by O
sent1734 wavelet-transform O
sent1734 analysis O
sent1735 Application O
sent1735 to O
sent1735 biomedical O
sent1735 magnetic O
sent1735 resonance O
sent1735 spectroscopy O
sent1736 Investigation O
sent1736 of O
sent1736 uncertainties O
sent1736 in O
sent1736 relaxation O
sent1736 analysis O
sent1736 of O
sent1736 2D O
sent1736 NOE O
sent1736 which O
sent1736 arise O
sent1736 from O
sent1736 spectral O
sent1736 noise O
sent1737 An O
sent1737 efficient O
sent1737 HN O
sent1737 ( O
sent1737 CA O
sent1737 ) O
sent1737 NH O
sent1737 pluse O
sent1737 scheme O
sent1737 for O
sent1737 triple-resonance O
sent1737 4D O
sent1737 correlation O
sent1737 of O
sent1737 sequential O
sent1737 amide O
sent1737 protons O
sent1737 and O
sent1737 nitrogens-15 O
sent1737 in O
sent1737 deuterated O
sent1737 proteins O
sent1738 Optimal O
sent1738 detection O
sent1738 of O
sent1738 weak O
sent1738 nJ O
sent1738 ( O
sent1738 1H- O
sent1738 119Sn O
sent1738 ) O
sent1738 couplings O
sent1738 by O
sent1738 gradient-enhanced O
sent1738 1D O
sent1738 and O
sent1738 2D O
sent1738 heteronuclear O
sent1738 multiple-quantum O
sent1738 correlation O
sent1738 spectroscopy O
sent1739 Application O
sent1739 to O
sent1739 a O
sent1739 novel O
sent1739 tin O
sent1739 derivative O
sent1739 of O
sent1739 erythromycin O
sent1739 A O
sent1740 Thermoelectric O
sent1740 cooling O
sent1740 for O
sent1740 NMR O
sent1740 sample O
sent1740 temperature O
sent1740 control O
sent1741 H2NCO-E.COSY O
sent1741 , O
sent1741 a O
sent1741 simple O
sent1741 method O
sent1741 for O
sent1741 the O
sent1741 sterospecific O
sent1741 assignment O
sent1741 of O
sent1741 side-chain O
sent1741 amide O
sent1741 protons O
sent1741 in O
sent1741 proteins O
sent1742 Applying O
sent1742 excitation O
sent1742 sculpting O
sent1742 to O
sent1742 construct O
sent1742 singly O
sent1742 and O
sent1742 doubly O
sent1742 selective O
sent1742 1D O
sent1742 NMR O
sent1742 experiments O
sent1743 Radiation O
sent1743 dosimetry O
sent1743 by O
sent1743 localized O
sent1743 magnetic O
sent1743 resonance O
sent1743 spectroscopy O
sent1744 The O
sent1744 2D O
sent1744 NMR O
sent1744 experiments O
sent1744 H O
sent1744 ( O
sent1744 C O
sent1744 ) O
sent1744 CO2 O
sent1744 and O
sent1744 HCCO2 O
sent1744 for O
sent1744 assignment O
sent1744 and O
sent1744 pH O
sent1744 titration O
sent1744 of O
sent1744 carboxylate O
sent1744 groups O
sent1744 in O
sent1744 uniformly O
sent1744 15N/13C-labeled O
sent1744 proteins O
sent1745 Post-acquisition O
sent1745 solvent O
sent1745 suppression O
sent1745 by O
sent1745 singular-value O
sent1745 decomposition O
sent1746 Osteopathic O
sent1746 manifesto O
sent1747 IX O
sent1748 What O
sent1748 about O
sent1748 our O
sent1748 distinctiveness O
sent1748 ? O
sent1748 1981 O
sent1749 Preparing O
sent1749 for O
sent1749 thalidomide T
sent1749 's T
sent1749 comeback O
sent1750 Heart D
sent1750 disease D
sent1750 : O
sent1750 women O
sent1750 's O
sent1750 unique O
sent1750 risks O
sent1750 demand O
sent1750 attention O
sent1751 Resolution O
sent1751 due O
sent1751 in O
sent1751 medical O
sent1751 software O
sent1751 regulation O
sent1752 Osteopathic O
sent1752 manifesto O
sent1753 VII O
sent1754 Shadows O
sent1754 and O
sent1754 images O
sent1755 1981 O
sent1756 The O
sent1756 practical O
sent1756 use O
sent1756 of O
sent1756 PCR O
sent1756 for O
sent1756 rapid O
sent1756 detection O
sent1756 of O
sent1756 methicillin T
sent1756 resistance O
sent1756 among O
sent1756 staphylococcal O
sent1756 clinical O
sent1756 isolates O
sent1756 from O
sent1756 Turkish O
sent1756 hospitals O
sent1757 Randomised O
sent1757 double-blind O
sent1757 trial O
sent1757 of O
sent1757 fixed O
sent1757 low-dose O
sent1757 warfarin T
sent1757 with T
sent1757 aspirin T
sent1757 after O
sent1757 myocardial D
sent1757 infarction D
sent1758 Coumadin O
sent1758 Aspirin O
sent1758 Reinfarction O
sent1758 Study O
sent1758 ( O
sent1758 CARS O
sent1758 ) O
sent1758 Investigators O
sent1759 Randomised O
sent1759 trial O
sent1759 of O
sent1759 roxithromycin T
sent1759 in O
sent1759 non-Q-wave D
sent1759 coronary D
sent1759 syndromes D
sent1759 : O
sent1759 ROXIS O
sent1759 Pilot O
sent1759 Study O
sent1760 ROXIS O
sent1760 Study O
sent1760 Group O
sent1761 Association O
sent1761 between O
sent1761 5-HT2A O
sent1761 gene O
sent1761 promoter O
sent1761 polymorphism O
sent1761 and O
sent1761 anorexia D
sent1761 nervosa D
sent1762 Randomised O
sent1762 study O
sent1762 of O
sent1762 radical T
sent1762 surgery T
sent1762 versus T
sent1762 radiotherapy T
sent1762 for O
sent1762 stage D
sent1762 Ib-IIa D
sent1762 cervical D
sent1762 cancer D
sent1763 State O
sent1763 regulation O
sent1763 in O
sent1763 a O
sent1763 world O
sent1763 of O
sent1763 `` O
sent1763 boundary-less O
sent1763 '' O
sent1763 technology O
sent1764 Screening O
sent1764 for O
sent1764 Chlamydia D
sent1764 trachomatis D
sent1764 ? O
sent1765 Physician-assisted O
sent1765 suicide O
sent1765 in O
sent1765 Oregon O
sent1766 Common O
sent1766 nutritional O
sent1766 issues O
sent1766 in O
sent1766 pediatric O
sent1766 and O
sent1766 adult O
sent1766 critical O
sent1766 care O
sent1766 medicine O
sent1767 A O
sent1767 multifactorial O
sent1767 analysis O
sent1767 of O
sent1767 facial O
sent1767 nerve O
sent1767 results O
sent1767 in O
sent1767 surgery O
sent1767 for O
sent1767 cerebellopontine O
sent1767 angle O
sent1767 tumors O
sent1768 Osteopathic O
sent1768 manifesto O
sent1769 VIII O
sent1770 Our O
sent1770 distinct O
sent1770 image O
sent1771 1981 O
sent1772 Quality O
sent1772 in O
sent1772 general O
sent1772 practice O
sent1773 Winning O
sent1773 the O
sent1773 war O
sent1773 on O
sent1773 cancer D
sent1774 Clinical O
sent1774 problem-solving O
sent1774 -- O
sent1774 where O
sent1774 did O
sent1774 good O
sent1774 old O
sent1774 clinical O
sent1774 diagnosis O
sent1774 go O
sent1774 ? O
sent1775 The O
sent1775 named O
sent1775 nurse O
sent1775 : O
sent1775 patient O
sent1775 and O
sent1775 nurse O
sent1775 expectations O
sent1776 Genetic O
sent1776 testing O
sent1776 opens O
sent1776 brave O
sent1776 new O
sent1776 world O
sent1777 Heterologous O
sent1777 vaccines T
sent1777 : O
sent1777 proponent O
sent1777 sparks O
sent1777 some O
sent1777 interest O
sent1778 Steps O
sent1778 still O
sent1778 being O
sent1778 taken O
sent1778 to O
sent1778 undo O
sent1778 damage O
sent1778 of O
sent1778 `` O
sent1778 America O
sent1778 's O
sent1778 Nuremberg O
sent1778 '' O
sent1779 Patient-centered O
sent1779 ethics O
sent1779 reclaiming O
sent1779 center O
sent1779 stage O
sent1780 Social O
sent1780 ties O
sent1780 and O
sent1780 susceptibility O
sent1780 to O
sent1780 the O
sent1780 common D
sent1780 cold D
sent1781 Connecting O
sent1781 peptide O
sent1781 , O
sent1781 correcting O
sent1781 peptide O
sent1781 ? O
sent1782 Winning O
sent1782 health O
sent1782 victories O
sent1782 with O
sent1782 community O
sent1782 commitment O
sent1783 Telemedicine O
sent1783 gets O
sent1783 a O
sent1783 chance O
sent1783 to O
sent1783 prove O
sent1783 itself O
sent1784 Additional O
sent1784 opinions O
sent1784 on O
sent1784 the O
sent1784 mortality O
sent1784 of O
sent1784 animal O
sent1784 research O
sent1785 Recurrent D
sent1785 strokes D
sent1785 in O
sent1785 a O
sent1785 34-year-old O
sent1785 man O
sent1786 A O
sent1786 plan O
sent1786 for O
sent1786 improving O
sent1786 outcomes O
sent1786 for O
sent1786 patients O
sent1786 with O
sent1786 chronic D
sent1786 renal D
sent1786 failure D
sent1787 Scientific O
sent1787 evidence O
sent1787 in O
sent1787 family O
sent1787 and O
sent1787 community O
sent1787 medicine O
sent1788 Evidence O
sent1788 that O
sent1788 the O
sent1788 expression O
sent1788 of O
sent1788 progesterone-induced O
sent1788 blocking O
sent1788 factor O
sent1788 by O
sent1788 maternal O
sent1788 T-lymphocytes O
sent1788 is O
sent1788 positively O
sent1788 correlated O
sent1788 with O
sent1788 conception O
sent1789 Another O
sent1789 use O
sent1789 of O
sent1789 androgens T
sent1789 : O
sent1789 treatment O
sent1789 of O
sent1789 anemia D
sent1789 of D
sent1789 end-stage D
sent1789 renal D
sent1789 disease D
sent1790 Isotopic O
sent1790 evidence O
sent1790 for O
sent1790 extraterrestrial O
sent1790 non-racemic O
sent1790 amino O
sent1790 acids O
sent1790 in O
sent1790 the O
sent1790 Murchison O
sent1790 meteorite O
sent1791 The O
sent1791 American O
sent1791 Medical O
sent1791 Association O
sent1791 Guidelines O
sent1791 for O
sent1791 Adolescent O
sent1791 Preventive O
sent1791 Services O
sent1792 Classification O
sent1792 of O
sent1792 malignant D
sent1792 lymphomas D
sent1792 : O
sent1792 the O
sent1792 updated O
sent1792 Kiel O
sent1792 classification O
sent1793 Rethink O
sent1793 on O
sent1793 screening O
sent1793 for O
sent1793 breast D
sent1793 cancer D
sent1794 Sports-related O
sent1794 ocular D
sent1794 injuries D
sent1795 Fruit O
sent1795 juice O
sent1795 consumption O
sent1796 The O
sent1796 case O
sent1796 of O
sent1796 the O
sent1796 missing O
sent1796 methylphenidate T
sent1797 < O
sent1797 TO_SEE O
sent1797 > O
sent1797 Intensive T
sent1797 insulin T
sent1797 treatment T
sent1797 after O
sent1797 acute D
sent1797 myocardial D
sent1797 infarction D
sent1797 in O
sent1797 diabetes D
sent1797 mellitus D
sent1798 Intensive O
sent1798 insulin O
sent1798 regimens O
sent1798 in O
sent1798 primary O
sent1798 prevention O
sent1798 should O
sent1798 be O
sent1798 assessed O
sent1799 GPs O
sent1799 ' O
sent1799 perceptions O
sent1799 of O
sent1799 tolerability O
sent1799 of O
sent1799 selective O
sent1799 serotonin O
sent1799 reuptake O
sent1799 inhibitors O
sent1799 and O
sent1799 tricyclic O
sent1799 antidepressants T
sent1800 Research O
sent1800 into O
sent1800 long O
sent1800 term O
sent1800 use O
sent1800 is O
sent1800 needed O
sent1801 Diagnosing O
sent1801 and O
sent1801 managing O
sent1801 polymyalgia D
sent1801 rheumatica D
sent1801 and O
sent1801 temporal D
sent1801 arteritis D
sent1802 Sensitivity O
sent1802 of O
sent1802 temporal O
sent1802 artery O
sent1802 biopsy O
sent1802 varies O
sent1802 with O
sent1802 biopsy O
sent1802 length O
sent1802 and O
sent1802 sectioning O
sent1802 strategy O
sent1803 Obstructive O
sent1803 sleep D
sent1803 apnoea D
sent1804 Authors O
sent1804 ' O
sent1804 reply O
sent1805 Impact O
sent1805 of O
sent1805 postmenopausal O
sent1805 hormone T
sent1805 therapy T
sent1805 on O
sent1805 cardiovascular O
sent1805 events O
sent1805 and O
sent1805 cancer D
sent1805 . O
sent1806 Search O
sent1806 for O
sent1806 studies O
sent1806 was O
sent1806 limited O
sent1807 Treating O
sent1807 shoulder O
sent1807 complaints O
sent1807 in O
sent1807 general O
sent1807 practice O
sent1808 Diagnostic O
sent1808 criteria O
sent1808 must O
sent1808 be O
sent1808 used O
sent1808 and O
sent1808 therapeutic O
sent1808 regimens O
sent1808 standardised O
sent1809 Authorship O
sent1810 System O
sent1810 acknowledging O
sent1810 roles O
sent1810 of O
sent1810 contributors O
sent1810 is O
sent1810 best O
sent1811 Authorship O
sent1812 New O
sent1812 authorship O
sent1812 practices O
sent1812 are O
sent1812 needed O
sent1812 in O
sent1812 developing O
sent1812 countries O
sent1813 Authorship O
sent1814 Researchers O
sent1814 ' O
sent1814 objective O
sent1814 is O
sent1814 to O
sent1814 get O
sent1814 the O
sent1814 job O
sent1814 done O
sent1815 Quality O
sent1815 and O
sent1815 clinical O
sent1815 audit O
sent1816 Transurethral T
sent1816 microwave T
sent1816 thermotherapy T
sent1817 Management O
sent1817 of O
sent1817 ileosigmoid D
sent1817 knotting D
sent1818 Epitome O
sent1818 of O
sent1818 myocarditis D
sent1819 Producing O
sent1819 consistent O
sent1819 estimates O
sent1819 of O
sent1819 the O
sent1819 power O
sent1819 spectral O
sent1819 density O
sent1819 of O
sent1819 NN O
sent1819 sequences O
sent1820 Environmental O
sent1820 tobacco O
sent1820 smoke O
sent1820 and O
sent1820 coronary D
sent1820 heart D
sent1820 disease D
sent1821 Long-term O
sent1821 benefit O
sent1821 of O
sent1821 one O
sent1821 thrombolytic T
sent1821 over O
sent1821 another O
sent1822 Coupling O
sent1822 of O
sent1822 hemodynamic O
sent1822 measurements O
sent1822 with O
sent1822 oxygen O
sent1822 during O
sent1822 exercise O
sent1822 does O
sent1822 not O
sent1822 improve O
sent1822 risk O
sent1822 stratification O
sent1822 in O
sent1822 patients O
sent1822 with O
sent1822 heart D
sent1822 failure D
sent1823 Smoking O
sent1823 -- O
sent1823 good O
sent1823 or O
sent1823 bad O
sent1823 for O
sent1823 semen O
sent1823 ? O
sent1824 The O
sent1824 pruning O
sent1824 of O
sent1824 Doctor O
sent1824 McDonough O
sent1824 and O
sent1824 the O
sent1824 `` O
sent1824 humanizing O
sent1824 '' O
sent1824 of O
sent1824 statistics O
sent1825 Violence O
sent1826 Prevention O
sent1826 in O
sent1826 the O
sent1826 home O
sent1826 health O
sent1826 setting O
sent1827 Contempo O
sent1827 1997 O
sent1827 : O
sent1827 obstetrics O
sent1827 and O
sent1827 gynecology O
sent1828 Mortality O
sent1828 and O
sent1828 refusal O
sent1828 of O
sent1828 ICU O
sent1828 admission O
sent1829 Extracorporeal O
sent1829 photopheresis O
sent1829 in O
sent1829 S O
sent1829 ( O
sent1829 c O
sent1829 ) O
sent1829 zary O
sent1829 syndrome O
sent1830 Attacks O
sent1830 on O
sent1830 tobacco O
sent1830 industry O
sent1831 Does O
sent1831 blinding O
sent1831 of O
sent1831 readers O
sent1831 affect O
sent1831 results O
sent1831 of O
sent1831 meta-analyses O
sent1831 ? O
sent1832 Consumption O
sent1832 of O
sent1832 alcohol O
sent1832 and O
sent1832 mortality O
sent1832 in O
sent1832 Russia O
sent1833 Presenilin O
sent1833 polymorphisms O
sent1833 in O
sent1833 Alzheimer D
sent1833 's D
sent1833 disease D
sent1834 Autoimmune D
sent1834 enteropathy D
sent1834 in O
sent1834 adults O
sent1835 Cyclosporiasis D
sent1835 and O
sent1835 raspberries O
sent1836 Protean O
sent1836 agonists O
sent1837 Keys O
sent1837 to O
sent1837 receptor O
sent1837 active O
sent1837 states O
sent1837 ? O
sent1838 Kinetic O
sent1838 models O
sent1838 of O
sent1838 ion O
sent1838 channels O
sent1839 Agonist O
sent1839 efficacy O
sent1839 and O
sent1839 allosteric O
sent1839 models O
sent1839 of O
sent1839 receptor O
sent1839 action O
sent1840 Receptor O
sent1840 Classification O
sent1840 : O
sent1840 The O
sent1840 Integration O
sent1840 of O
sent1840 Operational O
sent1840 , O
sent1840 Structural O
sent1840 , O
sent1840 and O
sent1840 Transductional O
sent1840 Information O
sent1841 Conference O
sent1841 proceedings O
sent1842 Verona O
sent1842 , O
sent1842 Italy O
sent1842 , O
sent1842 September O
sent1842 21-22 O
sent1842 , O
sent1842 1995 O
sent1843 Policies O
sent1843 for O
sent1843 posting O
sent1843 biomedical O
sent1843 journal O
sent1843 information O
sent1843 on O
sent1843 the O
sent1843 Internet O
sent1844 International O
sent1844 Committee O
sent1844 of O
sent1844 Medical O
sent1844 Journal O
sent1844 Editors O
sent1845 Who O
sent1845 understands O
sent1845 the O
sent1845 menopause O
sent1845 ? O
sent1846 Comparison O
sent1846 of O
sent1846 two O
sent1846 methods O
sent1846 of O
sent1846 screening O
sent1846 for O
sent1846 genital O
sent1846 chlamydial D
sent1846 infection D
sent1846 in O
sent1846 women O
sent1846 attending O
sent1846 in O
sent1846 general O
sent1846 practice O
sent1846 : O
sent1846 cross O
sent1846 sectional O
sent1846 survey O
sent1847 Antimicrobial T
sent1847 therapy T
sent1847 in O
sent1847 neutropenia D
sent1848 M1/4llerian O
sent1848 agenesis O
sent1848 : O
sent1848 an O
sent1848 update O
sent1849 The O
sent1849 US O
sent1849 attack O
sent1849 on O
sent1849 Cuba O
sent1849 's O
sent1849 health O
sent1850 Patient O
sent1850 consent O
sent1850 for O
sent1850 publication O
sent1850 and O
sent1850 the O
sent1850 health O
sent1850 of O
sent1850 the O
sent1850 public O
sent1851 Brain D
sent1851 serotonin D
sent1851 neurotoxicity D
sent1851 and O
sent1851 primary D
sent1851 pulmonary D
sent1851 hypertension D
sent1851 from O
sent1851 fenfluramine T
sent1851 and O
sent1851 dexfenfluramine T
sent1852 Battling O
sent1852 HI D
sent1852 on O
sent1852 many O
sent1852 fronts O
sent1853 Medical O
sent1853 Injury O
sent1853 Compensation O
sent1853 Reform O
sent1853 Act O
sent1853 : O
sent1853 good O
sent1853 or O
sent1853 bad O
sent1853 ? O
sent1854 Fever O
sent1854 of O
sent1854 unknown O
sent1854 origin O
sent1855 Moxonidine T
sent1855 for O
sent1855 hypertension D
sent1856 Researchers O
sent1856 make O
sent1856 slow O
sent1856 headway O
sent1856 in O
sent1856 managing O
sent1856 dry D
sent1856 mouth D
sent1857 A O
sent1857 kinder O
sent1857 , O
sent1857 gentler O
sent1857 approach O
sent1858 Putting O
sent1858 patients O
sent1858 first O
sent1858 ? O
sent1859 Managing O
sent1859 the O
sent1859 anxious O
sent1859 and O
sent1859 phobic O
sent1859 dental O
sent1859 patient O
sent1860 Do O
sent1860 it O
sent1860 or O
sent1860 lose O
sent1860 it O
sent1861 Assessment O
sent1861 of O
sent1861 fetal O
sent1861 nuchal O
sent1861 translucency O
sent1861 test O
sent1861 for O
sent1861 Down D
sent1861 's D
sent1861 syndrome D
sent1862 Amiodarone T
sent1862 and O
sent1862 thyroid O
sent1862 function O
sent1863 Chemotherapy T
sent1863 with T
sent1863 praziquantel T
sent1863 has O
sent1863 the O
sent1863 potential O
sent1863 to O
sent1863 reduce O
sent1863 the O
sent1863 prevalence O
sent1863 of O
sent1863 Echinococcus D
sent1863 multilocularis D
sent1863 in O
sent1863 wild O
sent1863 foxes O
sent1863 ( O
sent1863 Vulpes O
sent1863 vulpes O
sent1863 ) O
sent1864 Death O
sent1864 rates O
sent1864 from O
sent1864 childhood D
sent1864 leukaemia D
sent1864 near O
sent1864 nuclear O
sent1864 sites O
sent1865 Other O
sent1865 studies O
sent1865 showed O
sent1865 that O
sent1865 radiation O
sent1865 levels O
sent1865 in O
sent1865 Newbury O
sent1865 area O
sent1865 were O
sent1865 low O
sent1866 Haemoptysis D
sent1866 : O
sent1866 a O
sent1866 rare O
sent1866 cause O
sent1867 Human D
sent1867 papillomavirus D
sent1867 types O
sent1867 52 O
sent1867 and O
sent1867 58 O
sent1867 are O
sent1867 prevalent O
sent1867 in O
sent1867 cervical D
sent1867 cancer D
sent1867 from O
sent1867 Chinese O
sent1867 women O
sent1868 Breastfeeding O
sent1868 after O
sent1868 early O
sent1868 discharge O
sent1869 Malnutrition D
sent1869 and O
sent1869 microcephaly D
sent1869 in O
sent1869 Australian O
sent1869 aboriginal O
sent1869 children O
sent1870 < O
sent1870 TO_SEE O
sent1870 > O
sent1870 Probucol T
sent1870 and T
sent1870 multivitamins T
sent1870 in O
sent1870 the O
sent1870 prevention O
sent1870 of O
sent1870 restenosis D
sent1870 after O
sent1870 coronary O
sent1870 angioplasty O
sent1871 Generalised O
sent1871 caseous D
sent1871 lymphadenitis D
sent1872 Public O
sent1872 health O
sent1872 approach O
sent1872 to O
sent1872 activated O
sent1872 protein O
sent1872 C O
sent1872 resistance O
sent1872 assay O
sent1873 Hormone T
sent1873 replacement T
sent1873 therapy T
sent1874 Dose-volume O
sent1874 histograms O
sent1874 can O
sent1874 be O
sent1874 interpreted O
sent1874 in O
sent1874 different O
sent1874 ways O
sent1875 Addressing O
sent1875 needle-stick O
sent1875 concerns O
sent1876 Cervical D
sent1876 cancer D
sent1876 screening O
sent1877 CyberCHEST O
sent1878 An O
sent1878 open O
sent1878 future O
sent1879 Keeping O
sent1879 us O
sent1879 on O
sent1879 our O
sent1879 toes O
sent1879 ! O
sent1880 Thalidomide O
sent1880 in O
sent1880 oral O
sent1880 Crohn O
sent1880 's O
sent1880 disease O
sent1880 refractory O
sent1880 to O
sent1880 conventional O
sent1880 medical O
sent1880 treatment O
sent1881 Mortality O
sent1881 and O
sent1881 length O
sent1881 of O
sent1881 stay O
sent1881 in O
sent1881 teaching O
sent1881 vs O
sent1881 nonteaching O
sent1881 hospitals O
sent1882 Early O
sent1882 discharge O
sent1882 of O
sent1882 newborns O
sent1883 Patient O
sent1883 consent O
sent1883 for O
sent1883 publication O
sent1884 Flucticasone T
sent1884 propionate T
sent1884 is O
sent1884 safe O
sent1884 in O
sent1884 recommended O
sent1884 doses O
sent1885 Fetal O
sent1885 nuchal O
sent1885 translucency O
sent1885 test O
sent1885 for O
sent1885 Down D
sent1885 's D
sent1885 syndrome D
sent1886 Treatment O
sent1886 of O
sent1886 hypertension D
sent1886 in O
sent1886 elderly O
sent1886 patients O
sent1887 Meta-analyses O
sent1887 and O
sent1887 large O
sent1887 randomized O
sent1887 , O
sent1887 controlled O
sent1887 trials O
sent1888 Low-fat O
sent1888 diets O
sent1889 Ultrasonographic O
sent1889 evaluation O
sent1889 of O
sent1889 parathyroid D
sent1889 hyperplasia D
sent1890 Misconceptions O
sent1890 about O
sent1890 mosaicism D
sent1891 Are O
sent1891 normal O
sent1891 hearing O
sent1891 thresholds O
sent1891 a O
sent1891 sufficient O
sent1891 condition O
sent1891 for O
sent1891 click-evoked O
sent1891 otoacoustic O
sent1891 emissions O
sent1891 ? O
sent1892 Structure O
sent1892 and O
sent1892 in O
sent1892 vitro O
sent1892 substrate O
sent1892 specificity O
sent1892 of O
sent1892 the O
sent1892 murine O
sent1892 multidrug O
sent1892 resistance-associated O
sent1892 protein O
sent1893 ATP-dependent O
sent1893 transport O
sent1893 of O
sent1893 lipophilic O
sent1893 cytotoxic O
sent1893 drugs O
sent1893 by O
sent1893 membrane O
sent1893 vesicles O
sent1893 prepared O
sent1893 from O
sent1893 MRP-overexpressing O
sent1893 HL60/ADR O
sent1893 cells O
sent1894 Cellular O
sent1894 and O
sent1894 in O
sent1894 vitro O
sent1894 transport O
sent1894 of O
sent1894 glutathione O
sent1894 conjugates O
sent1894 by O
sent1894 MRP O
sent1895 Dominant O
sent1895 negative O
sent1895 and O
sent1895 cooperative O
sent1895 effects O
sent1895 of O
sent1895 mutant O
sent1895 forms O
sent1895 of O
sent1895 prolactin O
sent1895 receptor O
sent1896 Effect O
sent1896 of O
sent1896 calcium O
sent1896 and O
sent1896 vitamin O
sent1896 D O
sent1896 supplementation O
sent1896 on O
sent1896 bone O
sent1896 density O
sent1896 in O
sent1896 men O
sent1896 and O
sent1896 women O
sent1896 65 O
sent1896 years O
sent1896 of O
sent1896 age O
sent1896 or O
sent1896 older O
sent1897 Infection O
sent1897 control O
sent1897 and O
sent1897 contaminated O
sent1897 waste O
sent1897 disposal O
sent1897 practices O
sent1897 in O
sent1897 Southern O
sent1897 Sydney O
sent1897 Area O
sent1897 Health O
sent1897 Service O
sent1897 Dental O
sent1897 Clinics O
sent1898 Vitamins O
sent1898 and O
sent1898 minerals O
sent1898 : O
sent1898 efficacy O
sent1898 and O
sent1898 safety O
sent1899 Joint O
sent1899 Commission O
sent1899 on O
sent1899 Accreditation O
sent1899 of O
sent1899 Healthcare O
sent1899 Organizations O
sent1899 ' O
sent1899 infection O
sent1899 control O
sent1899 requirements O
sent1899 : O
sent1899 fact O
sent1899 or O
sent1899 fiction O
sent1899 ? O
sent1900 Poppy O
sent1900 tea O
sent1900 and O
sent1900 the O
sent1900 baker O
sent1900 's O
sent1900 first O
sent1900 seizure D
sent1901 ABC O
sent1901 of O
sent1901 mental O
sent1901 health O
sent1902 Mental O
sent1902 health O
sent1902 and O
sent1902 the O
sent1902 law O
sent1903 Female O
sent1903 embryonic O
sent1903 lethality O
sent1903 in O
sent1903 mice O
sent1903 nullizygous O
sent1903 for O
sent1903 both O
sent1903 Msh2 O
sent1903 and O
sent1903 p53 O
sent1904 Tests O
sent1904 of O
sent1904 the O
sent1904 double-strand O
sent1904 break O
sent1904 , O
sent1904 lethal-potentially O
sent1904 lethal O
sent1904 and O
sent1904 repair-misrepair O
sent1904 models O
sent1904 for O
sent1904 mammalian O
sent1904 cell O
sent1904 survival O
sent1904 using O
sent1904 data O
sent1904 for O
sent1904 survival O
sent1904 as O
sent1904 a O
sent1904 function O
sent1904 of O
sent1904 delayed-plating O
sent1904 interval O
sent1904 for O
sent1904 log-phase O
sent1904 Chinese O
sent1904 hamster O
sent1904 V79 O
sent1904 cells O
sent1905 Influence O
sent1905 of O
sent1905 physician O
sent1905 confidentiality O
sent1905 assurances O
sent1905 on O
sent1905 adolescents O
sent1905 ' O
sent1905 willingness O
sent1905 to O
sent1905 disclose O
sent1905 information O
sent1905 and O
sent1905 seek O
sent1905 future O
sent1905 health O
sent1905 care O
sent1906 A O
sent1906 randomized O
sent1906 controlled O
sent1906 trial O
sent1907 Fever D
sent1907 in O
sent1907 Africa O
sent1907 : O
sent1907 do O
sent1907 patients O
sent1907 know O
sent1907 when O
sent1907 they O
sent1907 are O
sent1907 hot O
sent1907 ? O
sent1908 Randomised O
sent1908 placebo-controlled O
sent1908 trial O
sent1908 of O
sent1908 granulocyte-colony T
sent1908 stimulating T
sent1908 factor T
sent1908 in O
sent1908 diabetic D
sent1908 foot D
sent1908 infection D
sent1909 Systemic O
sent1909 absorption O
sent1909 of O
sent1909 sunscreen O
sent1909 after O
sent1909 topical O
sent1909 application O
sent1910 A O
sent1910 comparison O
sent1910 of O
sent1910 continuous T
sent1910 infusion T
sent1910 of T
sent1910 alteplase T
sent1910 with T
sent1910 double-bolus T
sent1910 administration T
sent1910 for O
sent1910 acute D
sent1910 myocardial D
sent1910 infarction D
sent1911 The O
sent1911 Continuous O
sent1911 Infusion O
sent1911 versus O
sent1911 Double-Bolus O
sent1911 Administration O
sent1911 of O
sent1911 Alteplase O
sent1911 ( O
sent1911 COBALT O
sent1911 ) O
sent1911 Investigators O
sent1912 Evaluation O
sent1912 and O
sent1912 management O
sent1912 of O
sent1912 traumatic D
sent1912 lacerations D
sent1913 Atrial D
sent1913 fibrillation D
sent1913 begets O
sent1913 trouble O
sent1914 Ethics O
sent1914 of O
sent1914 HIV O
sent1914 trials O
sent1915 The O
sent1915 ethics O
sent1915 industry O
sent1916 Fever D
sent1916 in O
sent1916 Africa O
sent1916 and O
sent1916 WHO O
sent1916 recommendation O
sent1917 `` D
sent1917 Whiplash D
sent1917 '' D
sent1917 injury D
sent1917 of O
sent1917 the O
sent1917 cervical O
sent1917 spine O
sent1917 : O
sent1917 value O
sent1917 of O
sent1917 modern O
sent1917 diagnostic O
sent1917 imaging O
sent1918 Guidelines O
sent1918 and O
sent1918 cardiac O
sent1918 anaesthetists O
sent1919 Antibiotic T
sent1919 management T
sent1919 of O
sent1919 sore D
sent1919 throat D
sent1920 Lansoprazole T
sent1920 , O
sent1920 H. O
sent1920 pylori O
sent1920 , O
sent1920 and O
sent1920 atrophic D
sent1920 gastritis D
sent1920 . O
sent1921 Help O
sent1921 wanted O
sent1921 : O
sent1921 ultrasonographers O
sent1922 `` O
sent1922 Children O
sent1922 are O
sent1922 not O
sent1922 supposed O
sent1922 to O
sent1922 die O
sent1923 '' O
sent1923 Combined O
sent1923 pediatric O
sent1923 and O
sent1923 radiation O
sent1923 oncology O
sent1923 grand O
sent1923 rounds O
sent1923 addresses O
sent1923 severe O
sent1923 illness O
sent1923 and O
sent1923 death O
sent1924 Structure-activity O
sent1924 and O
sent1924 mechanism O
sent1924 studies O
sent1924 on O
sent1924 silicon O
sent1924 phthalocyanines O
sent1924 with O
sent1924 Plasmodium O
sent1924 falciparum O
sent1924 in O
sent1924 the O
sent1924 dark O
sent1924 and O
sent1924 under O
sent1924 red O
sent1924 light O
sent1925 The O
sent1925 importance O
sent1925 of O
sent1925 being O
sent1925 where O
sent1925 ? O
sent1925 Balancing O
sent1925 the O
sent1925 perspective O
sent1925 on O
sent1925 practice O
sent1925 coverage O
sent1926 Effects O
sent1926 of O
sent1926 dobutamine T
sent1926 at O
sent1926 maximally O
sent1926 tolerated O
sent1926 dose O
sent1926 on O
sent1926 myocardial O
sent1926 blood O
sent1926 flow O
sent1926 in O
sent1926 humans O
sent1926 with O
sent1926 ischemic D
sent1926 heart D
sent1926 disease D
sent1926 . O
sent1927 Cholesterol-lowering T
sent1927 therapy T
sent1928 Ion O
sent1928 composition O
sent1928 of O
sent1928 airway O
sent1928 surface O
sent1928 liquid O
sent1928 of O
sent1928 patients O
sent1928 with O
sent1928 cystic D
sent1928 fibrosis D
sent1928 as O
sent1928 compared O
sent1928 with O
sent1928 normal O
sent1928 and O
sent1928 disease-control O
sent1928 subjects O
sent1929 Research O
sent1929 in O
sent1929 Copenhagen O
sent1929 hospitals O
sent1929 -- O
sent1929 a O
sent1929 bibliometric O
sent1929 evaluation O
sent1930 More O
sent1930 on O
sent1930 infertility D
sent1931 Dermatobia O
sent1931 -- O
sent1931 tropical D
sent1931 myiasis D
sent1932 Progressive O
sent1932 sensorineural O
sent1932 hearing D
sent1932 loss D
sent1932 , O
sent1932 subjective O
sent1932 tinnitus D
sent1932 and O
sent1932 vertigo D
sent1932 caused O
sent1932 by O
sent1932 elevated O
sent1932 blood O
sent1932 lipids O
sent1933 Chronic O
sent1933 telogen D
sent1933 effluvium D
sent1933 : O
sent1933 potential O
sent1933 complication O
sent1933 for O
sent1933 clinical O
sent1933 trials O
sent1933 in O
sent1933 female O
sent1933 androgenetic D
sent1933 alopecia D
sent1933 ? O
sent1934 < O
sent1934 TO_SEE O
sent1934 > O
sent1934 Measles D
sent1934 vaccination T
sent1934 and O
sent1934 inflammatory O
sent1934 bowel O
sent1934 disease O
sent1935 Treatment O
sent1935 of O
sent1935 suicidal O
sent1935 patients O
sent1936 The O
sent1936 systemic O
sent1936 amyloidoses T
sent1937 Cancer D
sent1937 therapy T
sent1937 and O
sent1937 tumor O
sent1937 physiology O
sent1938 Mutual O
sent1938 relationships O
sent1938 based O
sent1938 on O
sent1938 equality O
sent1939 Specialists O
sent1939 and O
sent1939 nurses O
sent1939 : O
sent1939 the O
sent1939 pillars O
sent1939 of O
sent1939 hospital O
sent1939 care O
sent1940 Disability O
sent1940 models O
sent1940 in O
sent1940 geriatrics O
sent1940 : O
sent1940 comprehensive O
sent1940 rather O
sent1940 than O
sent1940 competing O
sent1940 models O
sent1940 should O
sent1940 be O
sent1940 promoted O
sent1941 Ethical O
sent1941 issues O
sent1941 in O
sent1941 interventional T
sent1941 radiology T
sent1942 Taking O
sent1942 issue O
sent1942 with O
sent1942 UK O
sent1942 funding O
sent1942 priorities O
sent1943 Phototherapeutic T
sent1943 keratectomy T
sent1943 in O
sent1943 recurrent D
sent1943 corneal D
sent1943 erosions D
sent1943 refractory O
sent1943 to O
sent1943 other O
sent1943 forms O
sent1943 of O
sent1943 treatment O
sent1944 Wegener D
sent1944 's D
sent1944 granulomatosis D
sent1944 from O
sent1944 infancy O
sent1944 to O
sent1944 adolescence O
sent1945 Hormonal O
sent1945 responses O
sent1945 to O
sent1945 restraint O
sent1945 in O
sent1945 rhesus O
sent1945 monkeys O
sent1946 Planned O
sent1946 parenthood O
sent1946 and O
sent1946 artifical O
sent1946 selection O
sent1947 Valvular D
sent1947 heart D
sent1947 disease D
sent1947 associated O
sent1947 with O
sent1947 fenfluramine-phentermine T
sent1948 The O
sent1948 role O
sent1948 of O
sent1948 procedures O
sent1948 in O
sent1948 family O
sent1948 practice O
sent1948 : O
sent1948 is O
sent1948 there O
sent1948 a O
sent1948 right O
sent1948 answer O
sent1948 ? O
sent1949 Arthrodesis T
sent1949 of T
sent1949 the T
sent1949 first T
sent1949 metatarsophalangeal T
sent1949 joint T
sent1949 to O
sent1949 salvage O
sent1949 failed D
sent1949 silicone D
sent1949 implant D
sent1949 arthroplasty D
sent1950 Methadone T
sent1950 maintenance T
sent1950 treatment T
sent1950 : O
sent1950 a O
sent1950 Canadian O
sent1950 perspective O
sent1951 Survey O
sent1951 on O
sent1951 rotavirus D
sent1951 infections D
sent1951 in O
sent1951 a O
sent1951 German O
sent1951 pediatric O
sent1951 hospital O
sent1952 Stroke D
sent1952 incidence O
sent1952 rates O
sent1952 among O
sent1952 black O
sent1952 residents O
sent1952 of O
sent1952 Harare O
sent1952 -- O
sent1952 a O
sent1952 prospective O
sent1952 community-based O
sent1952 study O
sent1953 Long-term O
sent1953 effect O
sent1953 of O
sent1953 calcium O
sent1953 supplementation O
sent1953 during O
sent1953 pregnancy O
sent1953 on O
sent1953 the O
sent1953 blood O
sent1953 pressure O
sent1953 of O
sent1953 offspring O
sent1953 : O
sent1953 follow O
sent1953 up O
sent1953 of O
sent1953 a O
sent1953 randomised O
sent1953 controlled O
sent1953 trial O
sent1954 The O
sent1954 catalytic O
sent1954 role O
sent1954 of O
sent1954 carbon O
sent1954 dioxide O
sent1954 in O
sent1954 the O
sent1954 decomposition O
sent1954 of O
sent1954 peroxynitrite O
sent1955 Unethical O
sent1955 trials O
sent1955 of O
sent1955 interventions O
sent1955 to O
sent1955 reduce O
sent1955 perinatal O
sent1955 transmission O
sent1955 of O
sent1955 the O
sent1955 human O
sent1955 immunodeficiency O
sent1955 virus O
sent1955 in O
sent1955 developing O
sent1955 countries O
sent1956 Ropinirole T
sent1956 for O
sent1956 the O
sent1956 treatment O
sent1956 of O
sent1956 early D
sent1956 Parkinson D
sent1956 's D
sent1956 disease D
sent1957 The O
sent1957 Ropinirole O
sent1957 Study O
sent1957 Group O
sent1958 DOTS O
sent1958 -- O
sent1958 are O
sent1958 we O
sent1958 over-optimistic O
sent1958 ? O
sent1959 Activation O
sent1959 at O
sent1959 the O
sent1959 germinal O
sent1959 vesicle O
sent1959 stage O
sent1959 of O
sent1959 starfish O
sent1959 oocytes O
sent1959 produces O
sent1959 parthenogenetic O
sent1959 development O
sent1959 through O
sent1959 the O
sent1959 failure O
sent1959 of O
sent1959 polar O
sent1959 body O
sent1959 extrusion O
sent1960 Female O
sent1960 genital O
sent1960 mutilation O
sent1960 : O
sent1960 a O
sent1960 contemporary O
sent1960 issue O
sent1960 , O
sent1960 and O
sent1960 a O
sent1960 Victorian O
sent1960 obsession O
sent1961 Early O
sent1961 death O
sent1961 amongst O
sent1961 anaesthetists O
sent1962 Fluoride T
sent1962 treatment T
sent1962 increased O
sent1962 serum O
sent1962 IGF-1 O
sent1962 , O
sent1962 bone O
sent1962 turnover O
sent1962 , O
sent1962 and O
sent1962 bone O
sent1962 mass O
sent1962 , O
sent1962 but O
sent1962 not O
sent1962 bone O
sent1962 strength O
sent1962 , O
sent1962 in O
sent1962 rabbits O
sent1963 Retrospective O
sent1963 comparison O
sent1963 of O
sent1963 techniques O
sent1963 to O
sent1963 prevent O
sent1963 secondary D
sent1963 cataract D
sent1963 formation D
sent1963 after O
sent1963 posterior O
sent1963 chamber O
sent1963 intraocular O
sent1963 lens T
sent1963 implantation T
sent1963 in O
sent1963 infants O
sent1963 and O
sent1963 children O
sent1964 Serotonin O
sent1964 as O
sent1964 a O
sent1964 regulator O
sent1964 of O
sent1964 hypothalamic-pituitary-interrenal O
sent1964 activity O
sent1964 in O
sent1964 teleost O
sent1964 fish O
sent1965 Predicting O
sent1965 functional O
sent1965 appliance O
sent1965 treatment O
sent1965 outcome O
sent1965 in O
sent1965 Class O
sent1965 II O
sent1965 malocclusions D
sent1965 -- O
sent1965 a O
sent1965 review O
sent1966 Effect O
sent1966 of O
sent1966 cereal O
sent1966 fibre O
sent1966 source O
sent1966 and O
sent1966 processing O
sent1966 on O
sent1966 rectal O
sent1966 epithelial O
sent1966 cell O
sent1966 proliferation O
sent1967 Update O
sent1967 : O
sent1967 influenza D
sent1967 activity O
sent1967 -- O
sent1967 worldwide O
sent1967 , O
sent1967 March-August O
sent1967 1997 O
sent1968 A O
sent1968 drop O
sent1968 in O
sent1968 pediatric O
sent1968 subject O
sent1968 examination O
sent1968 scores O
sent1968 after O
sent1968 curriculum O
sent1968 changes O
sent1968 that O
sent1968 emphasize O
sent1968 general O
sent1968 pediatric O
sent1968 topics O
sent1969 Paradigms O
sent1969 and O
sent1969 the O
sent1969 rise O
sent1969 ( O
sent1969 or O
sent1969 fall O
sent1969 ? O
sent1969 ) O
sent1969 of O
sent1969 molecular O
sent1969 biology O
sent1970 Water O
sent1970 fluoridation O
sent1970 , O
sent1970 tooth D
sent1970 decay D
sent1970 in O
sent1970 5 O
sent1970 year O
sent1970 olds O
sent1970 , O
sent1970 and O
sent1970 social O
sent1970 deprivation O
sent1970 measured O
sent1970 by O
sent1970 the O
sent1970 Jarman O
sent1970 score O
sent1970 : O
sent1970 analysis O
sent1970 of O
sent1970 data O
sent1970 from O
sent1970 British O
sent1970 dental O
sent1970 surveys O
sent1971 The O
sent1971 diabetes D
sent1971 audit O
sent1971 and O
sent1971 research O
sent1971 in O
sent1971 Tayside O
sent1971 Scotland O
sent1971 ( O
sent1971 DARTS O
sent1971 ) O
sent1971 study O
sent1971 : O
sent1971 electronic O
sent1971 record O
sent1971 linkage O
sent1971 to O
sent1971 create O
sent1971 a O
sent1971 diabetes O
sent1971 register O
sent1972 DARTS/MEMO O
sent1972 Collaboration O
sent1973 Pharmaceutical O
sent1973 industry O
sent1973 is O
sent1973 invited O
sent1973 to O
sent1973 respond O
sent1973 to O
sent1973 amnesty O
sent1973 for O
sent1973 unreported O
sent1973 trials O
sent1974 Should O
sent1974 we O
sent1974 screen O
sent1974 for O
sent1974 gestational D
sent1974 diabetes D
sent1974 ? O
sent1975 Vesico-uterine D
sent1975 fistula D
sent1975 -- O
sent1975 a O
sent1975 rare O
sent1975 complication O
sent1975 of O
sent1975 vacuum T
sent1975 extraction T
sent1975 in O
sent1975 a O
sent1975 patient O
sent1975 with O
sent1975 previous O
sent1975 caesarean T
sent1975 section T
sent1976 Managing O
sent1976 endophthalmitis D
sent1977 The O
sent1977 plug O
sent1977 and O
sent1977 patch O
sent1977 repair O
sent1977 for O
sent1977 managing O
sent1977 the O
sent1977 inguinal O
sent1977 hernia O
sent1977 of O
sent1977 the O
sent1977 adult O
sent1978 Human O
sent1978 herpesvirus O
sent1978 8 O
sent1978 variants O
sent1978 in O
sent1978 sarcoid O
sent1978 tissues O
sent1979 Practice O
sent1979 parameters O
sent1979 for O
sent1979 the O
sent1979 assessment O
sent1979 and O
sent1979 treatment O
sent1979 of O
sent1979 children O
sent1979 and O
sent1979 adolescents O
sent1979 with O
sent1979 schizophrenia D
sent1980 American O
sent1980 Academy O
sent1980 of O
sent1980 Child O
sent1980 and O
sent1980 Adolescent O
sent1980 Psychiatry O
sent1981 Practice O
sent1981 parameters O
sent1981 for O
sent1981 the O
sent1981 psychiatric O
sent1981 assessment O
sent1981 of O
sent1981 infants O
sent1981 and O
sent1981 toddlers O
sent1981 ( O
sent1981 0-36 O
sent1981 months O
sent1981 ) O
sent1982 American O
sent1982 Academy O
sent1982 of O
sent1982 Child O
sent1982 and O
sent1982 Adolescent O
sent1982 Psychiatry O
sent1983 Practice O
sent1983 parameters O
sent1983 for O
sent1983 the O
sent1983 forensic O
sent1983 evaluation O
sent1983 of O
sent1983 children O
sent1983 and O
sent1983 adolescents O
sent1983 who O
sent1983 may O
sent1983 have O
sent1983 been O
sent1983 physically O
sent1983 or O
sent1983 sexually O
sent1983 abused O
sent1984 American O
sent1984 Academy O
sent1984 of O
sent1984 Child O
sent1984 and O
sent1984 Adolescent O
sent1984 Psychiatry O
sent1985 Practice O
sent1985 parameters O
sent1985 for O
sent1985 the O
sent1985 psychiatric O
sent1985 assessment O
sent1985 of O
sent1985 children O
sent1985 and O
sent1985 adolescents O
sent1986 American O
sent1986 Academy O
sent1986 of O
sent1986 Child O
sent1986 and O
sent1986 Adolescent O
sent1986 Psychiatry O
sent1987 Alternative O
sent1987 medicine O
sent1988 Leprosy D
sent1988 beyond O
sent1988 the O
sent1988 year O
sent1988 2000 O
sent1989 Effect O
sent1989 of O
sent1989 danaparoid T
sent1989 sodium T
sent1989 on O
sent1989 hard O
sent1989 exudates O
sent1989 in O
sent1989 diabetic D
sent1989 retinopathy D
sent1989 . O
sent1990 Lead O
sent1990 based O
sent1990 paint O
sent1990 hazards O
sent1990 in O
sent1990 early O
sent1990 childhood O
sent1990 centres O
sent1990 in O
sent1990 the O
sent1990 Wellington O
sent1990 region O
sent1991 Gene O
sent1991 technology O
sent1991 and O
sent1991 democracy O
sent1992 Use O
sent1992 of O
sent1992 statins T
sent1993 Adequacy O
sent1993 of O
sent1993 SMAC O
sent1993 's O
sent1993 statement O
sent1993 should O
sent1993 be O
sent1993 judged O
sent1993 by O
sent1993 clinicians O
sent1993 , O
sent1993 not O
sent1993 health O
sent1993 economists O
sent1994 Glasgow O
sent1994 has O
sent1994 already O
sent1994 produced O
sent1994 strategy O
sent1994 for O
sent1994 treatment O
sent1995 Evidence O
sent1995 on O
sent1995 effectiveness O
sent1995 is O
sent1995 stronger O
sent1995 for O
sent1995 statins T
sent1995 than O
sent1995 for O
sent1995 other O
sent1995 treatments O
sent1996 Evidence O
sent1996 based O
sent1996 advertising O
sent1996 ? O
sent1996 Half O
sent1996 of O
sent1996 drug O
sent1996 advertisements O
sent1996 in O
sent1996 BMJ O
sent1996 over O
sent1996 six O
sent1996 months O
sent1996 cited O
sent1996 no O
sent1996 supporting O
sent1996 evidence O
sent1997 Non-steroidal T
sent1997 anti-inflammatory T
sent1997 therapy T
sent1997 for O
sent1997 bronchial D
sent1997 asthma D
sent1998 Drugs O
sent1998 for O
sent1998 the O
sent1998 Third O
sent1998 World O
sent1999 Getting O
sent1999 a O
sent1999 handle O
sent1999 on O
sent1999 the O
sent1999 molecules O
sent1999 that O
sent1999 guide O
sent1999 axons O
sent2000 The O
sent2000 functional O
sent2000 neuroanatomy O
sent2000 of O
sent2000 episodic O
sent2000 memory O
sent2000 retrieval O
sent2001 Re O
sent2001 : O
sent2001 `` O
sent2001 Biologic O
sent2001 synergism O
sent2001 and O
sent2001 parallelism O
sent2001 '' O
sent2002 Shifting O
sent2002 medical O
sent2002 education O
sent2002 from O
sent2002 the O
sent2002 icebox O
sent2002 to O
sent2002 the O
sent2002 refrigerator O
sent2003 Reattendance O
sent2003 and O
sent2003 complications O
sent2003 in O
sent2003 a O
sent2003 randomised O
sent2003 trial O
sent2003 of O
sent2003 prescribing O
sent2003 strategies O
sent2003 for O
sent2003 sore O
sent2003 throat O
sent2003 : O
sent2003 the O
sent2003 medicalising O
sent2003 effect O
sent2003 of O
sent2003 prescribing O
sent2003 antibiotics O
sent2004 Pure D
sent2004 alexia D
sent2004 could O
sent2004 not O
sent2004 be O
sent2004 a O
sent2004 disconnection O
sent2004 syndrome O
sent2005 A O
sent2005 randomized O
sent2005 , O
sent2005 double-blind O
sent2005 , O
sent2005 dose-response O
sent2005 comparison O
sent2005 of O
sent2005 epidural T
sent2005 fentanyl T
sent2005 versus O
sent2005 sufentanil T
sent2005 analgesia T
sent2005 after O
sent2005 cesarean T
sent2005 section T
sent2006 < O
sent2006 TO_SEE O
sent2006 > O
sent2006 Coronary O
sent2006 artery O
sent2006 problems O
sent2006 during O
sent2006 homograft O
sent2006 aortic O
sent2006 valve O
sent2006 replacement O
sent2006 : O
sent2006 role O
sent2006 of O
sent2006 transesophageal O
sent2006 echocardiography O
sent2007 Spontaneous O
sent2007 splenic D
sent2007 rupture D
sent2007 following O
sent2007 administration O
sent2007 of O
sent2007 granulocyte T
sent2007 colony-stimulating T
sent2007 factor T
sent2007 ( T
sent2007 G-CSF T
sent2007 ) T
sent2007 : O
sent2007 occurrence O
sent2007 in O
sent2007 an O
sent2007 allogeneic O
sent2007 donor O
sent2007 of O
sent2007 peripheral O
sent2007 blood O
sent2007 stem O
sent2007 cells O
sent2008 Evidence-based O
sent2008 medicine O
sent2008 and O
sent2008 general O
sent2008 practice O
sent2009 Koch O
sent2009 's O
sent2009 or O
sent2009 Crohn O
sent2009 's O
sent2009 ? O
sent2010 Female O
sent2010 Stress O
sent2010 Urinary O
sent2010 Incontinence O
sent2010 Clinical O
sent2010 Guidelines O
sent2010 Panel O
sent2010 summary O
sent2010 report O
sent2010 on O
sent2010 surgical T
sent2010 management T
sent2010 of O
sent2010 female D
sent2010 stress D
sent2010 urinary D
sent2010 incontinence D
sent2011 The O
sent2011 American O
sent2011 Urological O
sent2011 Association O
sent2012 Haemodynamic O
sent2012 performance O
sent2012 of O
sent2012 a O
sent2012 16-mm O
sent2012 Carbomedics O
sent2012 aortic O
sent2012 prosthesis O
sent2013 Case O
sent2013 records O
sent2013 of O
sent2013 the O
sent2013 Massachusetts O
sent2013 General O
sent2013 Hospital O
sent2014 Weekly O
sent2014 clinicopathological O
sent2014 exercises O
sent2015 Case O
sent2015 30-1997 O
sent2016 A O
sent2016 preterm O
sent2016 newborn O
sent2016 female O
sent2016 triplet O
sent2016 with O
sent2016 diffuse O
sent2016 cystic O
sent2016 changes O
sent2016 in O
sent2016 the O
sent2016 left O
sent2016 lung O
sent2017 Cure O
sent2017 of O
sent2017 Helicobacter D
sent2017 pylori D
sent2017 infection D
sent2017 improves O
sent2017 gastric O
sent2017 acid O
sent2017 secretion O
sent2017 in O
sent2017 patients O
sent2017 with O
sent2017 corpus D
sent2017 gastritis D
sent2018 < O
sent2018 TO_SEE O
sent2018 > O
sent2018 Increased O
sent2018 incidence O
sent2018 of O
sent2018 preeclampsia D
sent2018 in O
sent2018 women O
sent2018 conceiving O
sent2018 by O
sent2018 intrauterine T
sent2018 insemination T
sent2018 with T
sent2018 donor T
sent2018 versus T
sent2018 partner T
sent2018 sperm T
sent2018 for O
sent2018 treatment O
sent2018 of O
sent2018 primary D
sent2018 infertility D
sent2019 Pediatric D
sent2019 cervical D
sent2019 spine D
sent2019 injury D
sent2019 sustained O
sent2019 in O
sent2019 falls O
sent2019 from O
sent2019 low O
sent2019 heights O
sent2020 Prophylaxis O
sent2020 after O
sent2020 occupational O
sent2020 exposure O
sent2020 to O
sent2020 HIV O
sent2021 How O
sent2021 critical O
sent2021 are O
sent2021 critical O
sent2021 values O
sent2021 ? O
sent2022 Back O
sent2022 from O
sent2022 the O
sent2022 dead O
sent2022 : O
sent2022 extracorporeal T
sent2022 rewarming T
sent2022 of O
sent2022 severe D
sent2022 accidental D
sent2022 hypothermia D
sent2022 victims O
sent2022 in O
sent2022 accident O
sent2022 and O
sent2022 emergency O
sent2023 A O
sent2023 classification O
sent2023 of O
sent2023 nucleotide-diphospho-sugar O
sent2023 glycosyltransferases O
sent2023 based O
sent2023 on O
sent2023 amino O
sent2023 acid O
sent2023 sequence O
sent2023 similarities O
sent2024 EU O
sent2024 directive O
sent2024 on O
sent2024 bovine D
sent2024 spongiform D
sent2024 encephalopathy D
sent2024 will O
sent2024 not O
sent2024 affect O
sent2024 drugs O
sent2025 Management O
sent2025 of O
sent2025 patients O
sent2025 with O
sent2025 HIV/AIDS D
sent2026 Who O
sent2026 should O
sent2026 care O
sent2026 ? O
sent2027 Anesthesiology O
sent2028 Second O
sent2028 of O
sent2028 two O
sent2028 parts O
sent2029 Overdrugging O
sent2029 and O
sent2029 undertreatment O
sent2029 in O
sent2029 primary O
sent2029 health O
sent2029 care O
sent2030 Transesophageal O
sent2030 echocardiography O
sent2030 probe O
sent2030 holder O
sent2031 Pregnancy O
sent2031 outcomes O
sent2031 in O
sent2031 women O
sent2031 with O
sent2031 gestational D
sent2031 diabetes D
sent2031 compared O
sent2031 with O
sent2031 the O
sent2031 general O
sent2031 obstetric O
sent2031 population O
sent2032 Confidentiality O
sent2032 as O
sent2032 a O
sent2032 barrier O
sent2032 to O
sent2032 treatment O
sent2033 Recombinant O
sent2033 human O
sent2033 DNase O
sent2033 ( O
sent2033 rhDNase O
sent2033 ) O
sent2033 influences O
sent2033 phospholipid O
sent2033 composition O
sent2033 , O
sent2033 surface O
sent2033 activity O
sent2033 , O
sent2033 rheology O
sent2033 and O
sent2033 consecutively O
sent2033 clearance O
sent2033 indices O
sent2033 of O
sent2033 cystic D
sent2033 fibrosis D
sent2033 sputum O
sent2034 Palliative O
sent2034 options O
sent2034 of O
sent2034 last O
sent2034 resort O
sent2034 : O
sent2034 a O
sent2034 comparison O
sent2034 of O
sent2034 voluntarily O
sent2034 stopping O
sent2034 eating O
sent2034 and O
sent2034 drinking O
sent2034 , O
sent2034 terminal O
sent2034 sedation O
sent2034 , O
sent2034 physician-assisted O
sent2034 suicide O
sent2034 , O
sent2034 and O
sent2034 voluntary O
sent2034 active O
sent2034 euthanasia O
sent2035 Automation O
sent2035 in O
sent2035 cervical O
sent2035 cytology O
sent2035 : O
sent2035 whose O
sent2035 cost O
sent2035 and O
sent2035 whose O
sent2035 benefit O
sent2035 ? O
sent2036 Losing O
sent2036 weight O
sent2036 -- O
sent2036 an O
sent2036 ill-fated O
sent2036 New O
sent2036 Year O
sent2036 's O
sent2036 resolution O
sent2037 Lumbar D
sent2037 puncture D
sent2037 need O
sent2037 n't O
sent2037 be O
sent2037 a O
sent2037 headache O
sent2038 Profiting O
sent2038 from O
sent2038 closure O
sent2038 : O
sent2038 the O
sent2038 private O
sent2038 finance O
sent2038 initiative O
sent2038 and O
sent2038 the O
sent2038 NHS O
sent2039 Incidence O
sent2039 of O
sent2039 dog D
sent2039 bite D
sent2039 injuries D
sent2039 treated O
sent2039 in O
sent2039 emergency O
sent2039 departments O
sent2040 Use O
sent2040 of O
sent2040 rotational O
sent2040 movements O
sent2040 to O
sent2040 remove O
sent2040 mandibular O
sent2040 molars O
sent2041 Comparison O
sent2041 of O
sent2041 three O
sent2041 methods O
sent2041 used O
sent2041 for O
sent2041 assessment O
sent2041 of O
sent2041 pain D
sent2041 in O
sent2041 dogs O
sent2042 Randomised O
sent2042 controlled O
sent2042 trial O
sent2042 of O
sent2042 magnetic-resonance T
sent2042 pelvimetry T
sent2042 in O
sent2042 breech D
sent2042 presentation D
sent2042 at D
sent2042 term D
sent2043 Single-breath O
sent2043 diffusing O
sent2043 capacities O
sent2043 for O
sent2043 NO O
sent2043 , O
sent2043 CO O
sent2043 and O
sent2043 C18O2 O
sent2043 in O
sent2043 rabbits O
sent2044 Improved O
sent2044 control O
sent2044 will O
sent2044 provide O
sent2044 better O
sent2044 quality O
sent2045 Interview O
sent2045 by O
sent2045 Tom O
sent2045 Heinemann O
sent2046 Case O
sent2046 of O
sent2046 the O
sent2046 month O
sent2047 Autopsy O
sent2047 Committee O
sent2047 of O
sent2047 the O
sent2047 College O
sent2047 of O
sent2047 American O
sent2047 Pathologists O
sent2048 Cor O
sent2048 pulmonale O
sent2049 Human O
sent2049 papillomavirus O
sent2049 in O
sent2049 the O
sent2049 woman O
sent2049 with O
sent2049 HIV O
sent2050 Reducing O
sent2050 risk O
sent2050 is O
sent2050 best O
sent2050 strategy O
sent2051 The O
sent2051 realpolitik O
sent2051 of O
sent2051 a O
sent2051 new O
sent2051 National O
sent2051 Health O
sent2051 Service O
sent2051 for O
sent2051 the O
sent2051 UK O
sent2052 What O
sent2052 is O
sent2052 your O
sent2052 diagnosis O
sent2052 ? O
sent2052 Foreign O
sent2052 body O
sent2052 in O
sent2052 the O
sent2052 abdomen O
sent2053 Septic D
sent2053 arthritis D
sent2054 Brain D
sent2054 tumours D
sent2054 and O
sent2054 mobile O
sent2054 phones O
sent2054 ? O
sent2055 Lung D
sent2055 cancer D
sent2055 , O
sent2055 tobacco O
sent2055 smoking O
sent2055 and O
sent2055 environmental O
sent2055 factors O
sent2055 in O
sent2055 Denmark O
sent2056 Emergency O
sent2056 department O
sent2056 use O
sent2056 as O
sent2056 a O
sent2056 component O
sent2056 of O
sent2056 total O
sent2056 ambulatory O
sent2056 care O
sent2056 : O
sent2056 a O
sent2056 population O
sent2056 perspective O
sent2057 Occupational T
sent2057 therapy T
sent2057 and O
sent2057 outcomes O
sent2057 for O
sent2057 older O
sent2057 adults O
sent2058 Anesthesiology O
sent2059 Low-molecular-weight O
sent2059 heparins O
sent2060 Case O
sent2060 30-1997 O
sent2060 : O
sent2060 pulmonary D
sent2060 interstitial D
sent2060 emphysema D
sent2060 in O
sent2060 infancy O
sent2061 The O
sent2061 tobacco O
sent2061 settlement O
sent2062 Two O
sent2062 actions O
sent2062 are O
sent2062 possible O
sent2062 for O
sent2062 doctors O
sent2062 wanting O
sent2062 to O
sent2062 promote O
sent2062 human O
sent2062 welfare O
sent2062 in O
sent2062 Africa O
sent2063 Carcinogenesis O
sent2063 in O
sent2063 transgenic O
sent2063 mouse O
sent2063 models O
sent2064 Trouble O
sent2064 in O
sent2064 paradise O
sent2065 Atomic O
sent2065 legacy O
sent2065 in O
sent2065 the O
sent2065 Marshall O
sent2065 Islands O
sent2066 The O
sent2066 road O
sent2066 to O
sent2066 justice O
sent2067 Solvent O
sent2067 solution O
sent2068 Role O
sent2068 of O
sent2068 free O
sent2068 radicals O
sent2068 , O
sent2068 telomeres O
sent2068 , O
sent2068 and O
sent2068 telomerases O
sent2068 in O
sent2068 aging O
sent2068 and O
sent2068 cancerogenesis O
sent2069 The O
sent2069 effect O
sent2069 of O
sent2069 ephedrine O
sent2069 on O
sent2069 the O
sent2069 onset O
sent2069 time O
sent2069 of O
sent2069 rocuronium O
sent2070 Antibody O
sent2070 class O
sent2070 switch O
sent2070 recombinase O
sent2070 activity O
sent2070 is O
sent2070 B O
sent2070 cell O
sent2070 stage O
sent2070 specific O
sent2070 and O
sent2070 functions O
sent2070 stochastically O
sent2070 in O
sent2070 the O
sent2070 absence O
sent2070 of O
sent2070 'targeted O
sent2070 accessibility O
sent2070 ' O
sent2070 control O
sent2071 Systematic O
sent2071 review O
sent2071 of O
sent2071 prophylactic O
sent2071 vs O
sent2071 rescue O
sent2071 surfactant O
sent2072 The O
sent2072 safety-net O
sent2072 role O
sent2072 of O
sent2072 international O
sent2072 medical O
sent2072 graduates O
sent2073 The O
sent2073 prevalence O
sent2073 of O
sent2073 chemical O
sent2073 substance O
sent2073 and O
sent2073 alcohol O
sent2073 abuse O
sent2073 in O
sent2073 an O
sent2073 obstetric O
sent2073 population O
sent2073 in O
sent2073 Dublin O
sent2074 schizophrenia D
sent2074 as O
sent2074 failure O
sent2074 of O
sent2074 hemispheric O
sent2074 dominance O
sent2074 for O
sent2074 language O
sent2075 Late O
sent2075 prenatal O
sent2075 ultrasound O
sent2075 features O
sent2075 of O
sent2075 hydrometrocolpos O
sent2075 secondary O
sent2075 to O
sent2075 cloacal D
sent2075 anomaly D
sent2075 : O
sent2075 case O
sent2075 reports O
sent2075 and O
sent2075 review O
sent2075 of O
sent2075 the O
sent2075 literature O
sent2076 Familial O
sent2076 and O
sent2076 primary O
sent2076 ( O
sent2076 AL O
sent2076 ) O
sent2076 cardiac D
sent2076 amyloidosis D
sent2076 : O
sent2076 echocardiographically O
sent2076 similar O
sent2076 diseases O
sent2076 with O
sent2076 distinctly O
sent2076 different O
sent2076 clinical O
sent2076 outcomes O
sent2077 Diabetic O
sent2077 retinopathy O
sent2077 , O
sent2077 promoter O
sent2077 ( O
sent2077 4G/5G O
sent2077 ) O
sent2077 polymorphism O
sent2077 of O
sent2077 PAI-1 O
sent2077 gene O
sent2077 , O
sent2077 and O
sent2077 PAI-1 O
sent2077 activity O
sent2077 in O
sent2077 Pima O
sent2077 Indians O
sent2077 with O
sent2077 type O
sent2077 2 O
sent2077 diabetes D
sent2078 Evaluation O
sent2078 of O
sent2078 diagnostic O
sent2078 peritoneal O
sent2078 lavage O
sent2078 in O
sent2078 stable O
sent2078 patients O
sent2078 with O
sent2078 gunshot D
sent2078 wounds D
sent2078 to O
sent2078 the O
sent2078 abdomen O
sent2079 Cerebral D
sent2079 abscesses D
sent2079 in O
sent2079 a O
sent2079 patient O
sent2079 with O
sent2079 AIDS D
sent2079 caused O
sent2079 by O
sent2079 methicillin-resistant O
sent2079 Staphylococcus O
sent2079 aureus O
sent2079 ( O
sent2079 MRSA O
sent2079 ) O
sent2080 A O
sent2080 randomised O
sent2080 comparison O
sent2080 of O
sent2080 the O
sent2080 EuroQol O
sent2080 and O
sent2080 Short O
sent2080 Form-36 O
sent2080 after O
sent2080 stroke D
sent2081 United O
sent2081 Kingdom O
sent2081 collaborators O
sent2081 in O
sent2081 the O
sent2081 International O
sent2081 Stroke O
sent2081 Trial O
sent2082 Clinical O
sent2082 significance O
sent2082 of O
sent2082 Blastocystis D
sent2082 hominis D
sent2082 infection D
sent2082 : O
sent2082 epidemiologic O
sent2082 study O
sent2083 Karolinska O
sent2083 Institute O
sent2083 rocked O
sent2083 by O
sent2083 research O
sent2083 misconduct O
sent2084 < O
sent2084 TO_SEE O
sent2084 > O
sent2084 Hepatic O
sent2084 glutamine O
sent2084 synthetase O
sent2084 deficiency O
sent2084 in O
sent2084 fatal O
sent2084 hyperammonemia O
sent2084 after O
sent2084 lung O
sent2084 transplantation O
sent2085 Where O
sent2085 next O
sent2085 in O
sent2085 the O
sent2085 treatment O
sent2085 of O
sent2085 rectal D
sent2085 cancer D
sent2085 ? O
sent2086 GAPS O
sent2086 ( O
sent2086 AMA O
sent2086 Guidelines O
sent2086 for O
sent2086 Adolescent O
sent2086 Preventive O
sent2086 Services O
sent2086 ) O
sent2087 Protocols O
sent2087 for O
sent2087 wound O
sent2087 management O
sent2088 Chronic O
sent2088 leg D
sent2088 ulcers D
sent2088 : O
sent2088 beware O
sent2088 the O
sent2088 'wolf O
sent2088 in O
sent2088 sheep O
sent2088 's O
sent2088 clothing O
sent2088 ! O
sent2088 ' O
sent2088 . O
sent2089 Role O
sent2089 of O
sent2089 fine T
sent2089 needle T
sent2089 aspiration T
sent2089 cytology T
sent2089 in O
sent2089 the O
sent2089 management O
sent2089 of O
sent2089 the O
sent2089 discrete D
sent2089 parotid D
sent2089 lump D
sent2090 More O
sent2090 than O
sent2090 20 O
sent2090 years O
sent2090 second-look O
sent2090 surgery T
sent2090 in O
sent2090 advanced D
sent2090 epithelial D
sent2090 ovarian D
sent2090 cancer D
sent2090 : O
sent2090 what O
sent2090 did O
sent2090 we O
sent2090 learn O
sent2090 ? O
sent2091 Evaluating O
sent2091 prostate T
sent2091 needle T
sent2091 biopsy T
sent2091 : O
sent2091 therapeutic O
sent2091 and O
sent2091 prognostic O
sent2091 importance O
sent2092 Sudden O
sent2092 cryptococcal D
sent2092 deafness D
sent2093 Methicillin-resistant O
sent2093 Staphylococcus O
sent2093 aureus O
sent2093 clinical O
sent2093 strain O
sent2093 with O
sent2093 reduced O
sent2093 vancomycin T
sent2093 susceptibility O
sent2094 HIV O
sent2094 and O
sent2094 AIDS D
sent2094 awareness O
sent2094 : O
sent2094 an O
sent2094 evaluation O
sent2094 of O
sent2094 a O
sent2094 short O
sent2094 training O
sent2094 programme O
sent2094 for O
sent2094 midwives O
sent2095 What O
sent2095 investigations O
sent2095 and O
sent2095 procedures O
sent2095 do O
sent2095 patients O
sent2095 in O
sent2095 hospices O
sent2095 want O
sent2095 ? O
sent2095 Interview O
sent2095 based O
sent2095 survey O
sent2095 of O
sent2095 patients O
sent2095 and O
sent2095 their O
sent2095 nurses O
sent2096 Occupational O
sent2096 asthma D
sent2096 due O
sent2096 to O
sent2096 porcine O
sent2096 pancreatic O
sent2096 amylase O
sent2097 Double-blind O
sent2097 study O
sent2097 of O
sent2097 pulsing T
sent2097 magnetic T
sent2097 field T
sent2097 effects O
sent2097 on O
sent2097 multiple D
sent2097 sclerosis D
sent2097 . O
sent2098 CDA O
sent2098 opposes O
sent2098 proposed O
sent2098 HBV O
sent2098 recommendations O
sent2099 The O
sent2099 influence O
sent2099 of O
sent2099 allergy D
sent2099 and O
sent2099 smoking O
sent2099 on O
sent2099 the O
sent2099 sulphation O
sent2099 of O
sent2099 nasal O
sent2099 mucins O
sent2100 Clinical O
sent2100 problem-solving O
sent2101 A O
sent2101 hidden O
sent2101 agenda O
sent2102 A O
sent2102 comparison O
sent2102 of O
sent2102 the O
sent2102 early O
sent2102 outcome O
sent2102 of O
sent2102 acute O
sent2102 myocardial D
sent2102 infarction D
sent2102 in O
sent2102 women O
sent2102 and O
sent2102 men O
sent2103 The O
sent2103 Third O
sent2103 International O
sent2103 Study O
sent2103 of O
sent2103 Infarct O
sent2103 Survival O
sent2103 Collaborative O
sent2103 Group O
sent2104 Management O
sent2104 of O
sent2104 life-threatening O
sent2104 acid-base D
sent2104 disorders D
sent2105 Second O
sent2105 of O
sent2105 two O
sent2105 parts O
sent2106 < O
sent2106 TO_SEE O
sent2106 > O
sent2106 Freeze-dried O
sent2106 cortical O
sent2106 allograft O
sent2106 in O
sent2106 posterior O
sent2106 spinal O
sent2106 arthrodesis O
sent2106 : O
sent2106 use O
sent2106 with O
sent2106 segmental O
sent2106 instrumentation O
sent2106 for O
sent2106 idiopathic O
sent2106 adolescent O
sent2106 scoliosis O
sent2107 Removal O
sent2107 of O
sent2107 a O
sent2107 broken O
sent2107 solid-core O
sent2107 intramedullary O
sent2107 femoral O
sent2107 nail O
sent2107 using O
sent2107 both O
sent2107 antegrade O
sent2107 and O
sent2107 retrograde O
sent2107 starting O
sent2107 points O
sent2108 Do O
sent2108 no O
sent2108 harm O
sent2109 Thalidomide T
sent2109 , O
sent2109 laser O
sent2109 cavity O
sent2109 preparation O
sent2109 and O
sent2109 oral O
sent2109 hydrogen O
sent2109 peroxide O
sent2110 Emergency O
sent2110 ! O
sent2110 Meningococcal D
sent2110 disease D
sent2111 First O
sent2111 the O
sent2111 bad O
sent2111 news O
sent2111 ... O
sent2112 Does O
sent2112 hyperglycemia D
sent2112 really O
sent2112 cause O
sent2112 coronary D
sent2112 heart D
sent2112 disease D
sent2112 ? O
sent2113 Diagnosis O
sent2113 and O
sent2113 therapy O
sent2113 of O
sent2113 primary O
sent2113 stomach D
sent2113 lymphoma D
sent2114 Consensus O
sent2114 of O
sent2114 the O
sent2114 Surgical O
sent2114 Working O
sent2114 Group O
sent2114 for O
sent2114 Oncology O
sent2114 , O
sent2114 the O
sent2114 Working O
sent2114 Group O
sent2114 for O
sent2114 Medical O
sent2114 Oncology O
sent2114 and O
sent2114 the O
sent2114 Working O
sent2114 Group O
sent2114 for O
sent2114 Radiologic O
sent2114 Oncology O
sent2115 Rate O
sent2115 of O
sent2115 RhD O
sent2115 sensitisation O
sent2115 before O
sent2115 and O
sent2115 after O
sent2115 implementation O
sent2115 of O
sent2115 a O
sent2115 community O
sent2115 based O
sent2115 antenatal O
sent2115 prophylaxis O
sent2115 programme O
sent2116 Ovine D
sent2116 Johne D
sent2116 's D
sent2116 disease D
sent2117 Effect O
sent2117 of O
sent2117 HAART O
sent2117 on O
sent2117 natural O
sent2117 history O
sent2117 of O
sent2117 AIDS-related D
sent2117 opportunistic D
sent2117 disorders D
sent2118 Psoas D
sent2118 abscess D
sent2119 Diagnosed O
sent2119 if O
sent2119 suspected O
sent2120 Breastfeeding O
sent2120 and O
sent2120 catch-up O
sent2120 growth O
sent2120 in O
sent2120 infants O
sent2120 born O
sent2120 small O
sent2120 for O
sent2120 gestational O
sent2120 age O
sent2121 Health O
sent2121 practices O
sent2121 of O
sent2121 critical O
sent2121 care O
sent2121 nurses O
sent2121 : O
sent2121 are O
sent2121 these O
sent2121 nurses O
sent2121 good O
sent2121 role O
sent2121 models O
sent2121 for O
sent2121 patients O
sent2121 ? O
sent2122 Testing O
sent2122 for O
sent2122 Helicobacter D
sent2122 pylori D
sent2122 infection D
sent2122 after O
sent2122 antibiotic T
sent2122 treatment T
sent2122 . O
sent2123 Bullous O
sent2123 eruption O
sent2123 in O
sent2123 a O
sent2123 patient O
sent2123 with O
sent2123 systemic D
sent2123 lupus D
sent2123 erythematosus D
sent2123 : O
sent2123 mite D
sent2123 dermatitis D
sent2123 caused O
sent2123 by O
sent2123 Cheyletiella O
sent2123 blakei O
sent2124 A O
sent2124 case-control O
sent2124 study O
sent2124 of O
sent2124 cytochrome O
sent2124 P450 O
sent2124 1A1 O
sent2124 , O
sent2124 glutathione O
sent2124 S-transferase O
sent2124 M1 O
sent2124 , O
sent2124 cigarette O
sent2124 smoking O
sent2124 and O
sent2124 lung O
sent2124 cancer O
sent2124 susceptibility O
sent2124 ( O
sent2124 Massachusetts O
sent2124 , O
sent2124 United O
sent2124 States O
sent2124 ) O
sent2125 Association O
sent2125 between O
sent2125 thrombolytic T
sent2125 treatment T
sent2125 and O
sent2125 the O
sent2125 prognosis O
sent2125 of O
sent2125 hemodynamically O
sent2125 stable O
sent2125 patients O
sent2125 with O
sent2125 major D
sent2125 pulmonary D
sent2125 embolism D
sent2125 : O
sent2125 results O
sent2125 of O
sent2125 a O
sent2125 multicenter O
sent2125 registry O
sent2125 . O
sent2126 Metastatic D
sent2126 malignant D
sent2126 mesothelioma D
sent2126 presenting O
sent2126 as O
sent2126 colonic O
sent2126 polyps O
sent2127 Microelectrode-guided T
sent2127 posteroventral T
sent2127 pallidotomy T
sent2127 for O
sent2127 treatment O
sent2127 of O
sent2127 Parkinson D
sent2127 's D
sent2127 disease D
sent2127 : O
sent2127 postoperative O
sent2127 magnetic O
sent2127 resonance O
sent2127 imaging O
sent2127 analysis O
sent2128 A O
sent2128 positive O
sent2128 cannabinoids O
sent2128 workplace O
sent2128 drug O
sent2128 test O
sent2128 following O
sent2128 the O
sent2128 ingestion O
sent2128 of O
sent2128 commercially O
sent2128 available O
sent2128 hemp O
sent2128 seed O
sent2128 oil O
sent2129 Congenital D
sent2129 diaphragmatic D
sent2129 hernia D
sent2129 : O
sent2129 what O
sent2129 happens O
sent2129 after O
sent2129 discharge O
sent2129 ? O
sent2130 Goldilocks O
sent2130 and O
sent2130 Mrs O
sent2131 Ilych O
sent2131 : O
sent2131 a O
sent2131 critical O
sent2131 look O
sent2131 at O
sent2131 the O
sent2131 `` O
sent2131 philosophy O
sent2131 of O
sent2131 hospice O
sent2131 '' O
sent2132 Sensitivity O
sent2132 and O
sent2132 specificity O
sent2132 of O
sent2132 the O
sent2132 neonatal O
sent2132 brain-stem O
sent2132 auditory O
sent2132 evoked O
sent2132 potential O
sent2132 for O
sent2132 hearing O
sent2132 and O
sent2132 language O
sent2132 deficits O
sent2132 in O
sent2132 survivors O
sent2132 of O
sent2132 extracorporeal O
sent2132 membrane O
sent2132 oxygenation O
sent2133 The O
sent2133 Federated O
sent2133 Council O
sent2133 of O
sent2133 Internal O
sent2133 Medicine O
sent2133 's O
sent2133 resource O
sent2133 guide O
sent2133 for O
sent2133 residency O
sent2133 education O
sent2133 : O
sent2133 an O
sent2133 instrument O
sent2133 for O
sent2133 curricular O
sent2133 change O
sent2134 A O
sent2134 reluctant O
sent2134 doctor O
sent2134 shopper O
sent2135 Frequent O
sent2135 users O
sent2135 of O
sent2135 emergency O
sent2135 services O
sent2136 Localized O
sent2136 Darier D
sent2136 disease D
sent2137 Implications O
sent2137 for O
sent2137 genetic O
sent2137 studies O
sent2138 Follow O
sent2138 up O
sent2138 after O
sent2138 potential O
sent2138 curative O
sent2138 surgery T
sent2138 of O
sent2138 colorectal D
sent2138 cancer D
sent2139 Guidelines O
sent2139 from O
sent2139 the O
sent2139 Norwegian O
sent2139 Gastrointestinal O
sent2139 Cancer O
sent2139 Group O
sent2140 The O
sent2140 prison O
sent2140 patient O
sent2141 Fulminant O
sent2141 hepatic D
sent2141 failure D
sent2141 in O
sent2141 murine D
sent2141 hepatitis D
sent2141 virus D
sent2141 strain D
sent2141 3 D
sent2141 infection D
sent2141 : O
sent2141 tissue-specific O
sent2141 expression O
sent2141 of O
sent2141 a O
sent2141 novel O
sent2141 fgl2 O
sent2141 prothrombinase O
sent2142 Lung T
sent2142 volume T
sent2142 reduction T
sent2142 surgery T
sent2142 for O
sent2142 emphysema D
sent2143 The O
sent2143 use O
sent2143 and O
sent2143 effects O
sent2143 of O
sent2143 postcoital O
sent2143 contraception O
sent2144 Vancomycin-resistant O
sent2144 Staphylococcus O
sent2144 aureus O
sent2144 : O
sent2144 apocalypse O
sent2144 now O
sent2144 ? O
sent2145 Reflex D
sent2145 sympathetic D
sent2145 dystrophy D
sent2145 : O
sent2145 fact O
sent2145 and O
sent2145 fiction O
sent2146 Acute D
sent2146 hydrocephalus D
sent2146 and O
sent2146 brain D
sent2146 abscess D
sent2146 in O
sent2146 Listeria D
sent2146 monocytogenes D
sent2146 meningitis D
sent2147 Antisense O
sent2147 suppression O
sent2147 of O
sent2147 4-coumarate O
sent2147 : O
sent2147 coenzyme O
sent2147 A O
sent2147 ligase O
sent2147 activity O
sent2147 in O
sent2147 Arabidopsis O
sent2147 leads O
sent2147 to O
sent2147 altered O
sent2147 lignin O
sent2147 subunit O
sent2147 composition O
sent2148 < O
sent2148 TO_SEE O
sent2148 > O
sent2148 Alopecia O
sent2148 as O
sent2148 a O
sent2148 consequence O
sent2148 of O
sent2148 tacrolimus O
sent2148 therapy O
sent2148 in O
sent2148 renal O
sent2148 transplantation O
sent2148 ? O
sent2149 Implementation O
sent2149 of O
sent2149 pharmaceutical O
sent2149 practice O
sent2149 guidelines O
sent2150 In O
sent2150 vitro O
sent2150 interactions O
sent2150 of O
sent2150 oxidatively O
sent2150 modified O
sent2150 LDL O
sent2150 with O
sent2150 type O
sent2150 I O
sent2150 , O
sent2150 II O
sent2150 , O
sent2150 III O
sent2150 , O
sent2150 IV O
sent2150 , O
sent2150 and O
sent2150 V O
sent2150 collagen O
sent2150 , O
sent2150 laminin O
sent2150 , O
sent2150 fibronectin O
sent2150 , O
sent2150 and O
sent2150 poly-D-lysine O
sent2151 Factors O
sent2151 influencing O
sent2151 blood O
sent2151 flow O
sent2151 in O
sent2151 the O
sent2151 optic O
sent2151 nerve O
sent2151 head O
sent2152 Mutations O
sent2152 of O
sent2152 the O
sent2152 Drosophila O
sent2152 dDP O
sent2152 , O
sent2152 dE2F O
sent2152 , O
sent2152 and O
sent2152 cyclin O
sent2152 E O
sent2152 genes O
sent2152 reveal O
sent2152 distinct O
sent2152 roles O
sent2152 for O
sent2152 the O
sent2152 E2F-DP O
sent2152 transcription O
sent2152 factor O
sent2152 and O
sent2152 cyclin O
sent2152 E O
sent2152 during O
sent2152 the O
sent2152 G1-S O
sent2152 transition O
sent2153 SYT-SSX O
sent2153 gene O
sent2153 fusion O
sent2153 as O
sent2153 a O
sent2153 determinant O
sent2153 of O
sent2153 morphology O
sent2153 and O
sent2153 prognosis O
sent2153 in O
sent2153 synovial O
sent2153 sarcoma O
sent2154 A O
sent2154 rapid O
sent2154 molecular O
sent2154 method O
sent2154 ( O
sent2154 polymerase O
sent2154 chain O
sent2154 reaction O
sent2154 with O
sent2154 sequence-specific O
sent2154 primers O
sent2154 ) O
sent2154 to O
sent2154 genotype O
sent2154 for O
sent2154 ABO O
sent2154 blood O
sent2154 group O
sent2154 and O
sent2154 secretor O
sent2154 status O
sent2154 and O
sent2154 its O
sent2154 potential O
sent2154 for O
sent2154 organ T
sent2154 transplants T
sent2155 A O
sent2155 population-based O
sent2155 registry O
sent2155 on O
sent2155 paraproteinaemia D
sent2155 in O
sent2155 The O
sent2155 Netherlands O
sent2156 Comprehensive O
sent2156 Cancer O
sent2156 Centre O
sent2156 West O
sent2156 , O
sent2156 Leiden O
sent2156 , O
sent2156 The O
sent2156 Netherlands O
sent2157 Intra- O
sent2157 and O
sent2157 inter-individual O
sent2157 biological O
sent2157 variability O
sent2157 data O
sent2157 bank O
sent2158 Genetic O
sent2158 testing O
sent2158 for O
sent2158 cancer D
sent2158 risk O
sent2158 : O
sent2158 how O
sent2158 to O
sent2158 reconcile O
sent2158 the O
sent2158 conflicts O
sent2159 Run-in O
sent2159 periods O
sent2159 in O
sent2159 randomized O
sent2159 trials O
sent2159 : O
sent2159 implications O
sent2159 for O
sent2159 the O
sent2159 application O
sent2159 of O
sent2159 results O
sent2159 in O
sent2159 clinical O
sent2159 practice O
sent2160 Rapid O
sent2160 and O
sent2160 ultrarapid O
sent2160 opioid T
sent2160 detoxification T
sent2160 techniques O
sent2161 Fulminant O
sent2161 hepatitis T
sent2161 associated O
sent2161 with O
sent2161 hepatitis T
sent2161 A T
sent2161 virus T
sent2161 superinfection T
sent2161 in O
sent2161 patients O
sent2161 with O
sent2161 chronic O
sent2161 hepatitis T
sent2161 C T
sent2162 The O
sent2162 Overactive T
sent2162 Bladder T
sent2162 : O
sent2162 From O
sent2162 Basic O
sent2162 Science O
sent2162 to O
sent2162 Clinical O
sent2162 Management O
sent2162 Consensus O
sent2162 Conference O
sent2163 Proceedings O
sent2164 London O
sent2164 , O
sent2164 England O
sent2164 , O
sent2164 June O
sent2164 29 O
sent2164 , O
sent2164 1997 O
sent2165 Techniques O
sent2165 for O
sent2165 erbium T
sent2165 : T
sent2165 YAG T
sent2165 laser T
sent2165 skin T
sent2165 resurfacing T
sent2165 : O
sent2165 initial O
sent2165 pearls O
sent2165 from O
sent2165 the O
sent2165 first O
sent2165 100 O
sent2165 patients O
sent2166 Predicting O
sent2166 changes O
sent2166 in O
sent2166 the O
sent2166 distribution O
sent2166 of O
sent2166 sweating D
sent2166 following O
sent2166 thoracoscopic T
sent2166 sympathectomy T
sent2166 . O
sent2167 The O
sent2167 AACC O
sent2167 Lectureship O
sent2167 Award O
sent2167 Address O
sent2168 The O
sent2168 market O
sent2168 for O
sent2168 health O
sent2168 care O
sent2168 : O
sent2168 where O
sent2168 is O
sent2168 the O
sent2168 patient O
sent2168 ? O
sent2169 Human O
sent2169 fetal O
sent2169 pituitary O
sent2169 expresses O
sent2169 functional O
sent2169 growth O
sent2169 hormone-releasing O
sent2169 peptide O
sent2169 receptors O
sent2170 The O
sent2170 Bizarro O
sent2170 world O
sent2170 of O
sent2170 osteodistraction T
sent2171 A O
sent2171 piece O
sent2171 of O
sent2171 my O
sent2171 mind O
sent2172 Leaders O
sent2172 or O
sent2172 lemmings O
sent2172 ? O
sent2173 Sales O
sent2173 of O
sent2173 food O
sent2173 aid O
sent2173 as O
sent2173 sign O
sent2173 of O
sent2173 distress O
sent2173 , O
sent2173 not O
sent2173 excess O
sent2174 Gastrointestinal O
sent2174 absorption O
sent2174 of O
sent2174 metals O
sent2175 Embryonic O
sent2175 stem O
sent2175 cells O
sent2175 and O
sent2175 hematopoietic O
sent2175 stem O
sent2175 cell O
sent2175 biology O
sent2176 Shark T
sent2176 cartilage T
sent2176 for O
sent2176 cancer D
sent2176 ? O
sent2177 The O
sent2177 role O
sent2177 of O
sent2177 the O
sent2177 school O
sent2177 in O
sent2177 the O
sent2177 management O
sent2177 of O
sent2177 attention D
sent2177 deficit D
sent2177 hyperactivity D
sent2177 disorder D
sent2178 Photorepair O
sent2178 mutants O
sent2178 of O
sent2178 Arabidopsis O
sent2179 Toxic D
sent2179 shock D
sent2179 syndrome D
sent2179 without O
sent2179 rash D
sent2179 in O
sent2179 a O
sent2179 young O
sent2179 child O
sent2179 : O
sent2179 link O
sent2179 with O
sent2179 syndrome O
sent2179 of O
sent2179 hemorrhagic D
sent2179 shock D
sent2179 and O
sent2179 encephalopathy D
sent2179 ? O
sent2180 Mediastinal O
sent2180 growing O
sent2180 teratoma D
sent2180 syndrome D
sent2181 Structure O
sent2181 and O
sent2181 expression O
sent2181 of O
sent2181 the O
sent2181 chicken O
sent2181 calmodulin O
sent2181 I O
sent2181 gene O
sent2182 Fibromyalgia D
sent2182 -- O
sent2182 out O
sent2182 of O
sent2182 control O
sent2182 ? O
sent2183 Fibromyalgia D
sent2183 : O
sent2183 La O
sent2183 Maladie O
sent2183 est O
sent2183 Morte O
sent2184 Vive O
sent2184 le O
sent2184 Malade O
sent2184 ! O
sent2185 Electron O
sent2185 beam O
sent2185 computed O
sent2185 tomographic O
sent2185 coronary O
sent2185 calcium O
sent2185 as O
sent2185 a O
sent2185 predictor O
sent2185 of O
sent2185 coronary O
sent2185 events O
sent2185 : O
sent2185 comparison O
sent2185 of O
sent2185 two O
sent2185 protocols O
sent2186 The O
sent2186 ethics O
sent2186 of O
sent2186 genetic O
sent2186 research O
sent2186 on O
sent2186 sexual O
sent2186 orientation O
sent2187 Testicular T
sent2187 sperm T
sent2187 retrieval T
sent2187 by T
sent2187 percutaneous T
sent2187 fine T
sent2187 needle T
sent2187 sperm T
sent2187 aspiration T
sent2187 compared O
sent2187 with O
sent2187 testicular T
sent2187 sperm T
sent2187 extraction T
sent2187 by T
sent2187 open T
sent2187 biopsy T
sent2187 in O
sent2187 men O
sent2187 with O
sent2187 non-obstructive D
sent2187 azoospermia D
sent2188 Cyclin O
sent2188 D1 O
sent2188 overexpression O
sent2188 in O
sent2188 malignant D
sent2188 lymphomas D
sent2189 Patient O
sent2189 safety O
sent2189 and O
sent2189 scented O
sent2189 pediatric O
sent2189 anesthesia O
sent2189 facemasks O
sent2190 Ion O
sent2190 channels O
sent2191 SHARPs O
sent2191 : O
sent2191 mammalian O
sent2191 enhancer-of-split- O
sent2191 and O
sent2191 hairy-related O
sent2191 proteins O
sent2191 coupled O
sent2191 to O
sent2191 neuronal O
sent2191 stimulation O
sent2192 Complementary O
sent2192 and O
sent2192 alternative O
sent2192 medicine O
sent2192 : O
sent2192 friend O
sent2192 , O
sent2192 foe O
sent2192 , O
sent2192 or O
sent2192 OWA O
sent2192 ? O
sent2193 Ondansetron T
sent2193 is O
sent2193 not O
sent2193 a O
sent2193 panacea O
sent2194 Masking O
sent2194 , O
sent2194 blinding O
sent2194 , O
sent2194 and O
sent2194 peer O
sent2194 review O
sent2194 : O
sent2194 the O
sent2194 blind O
sent2194 leading O
sent2194 the O
sent2194 blinded O
sent2195 Human O
sent2195 cervico-facial O
sent2195 morphogenesis O
sent2196 Evaluation O
sent2196 of O
sent2196 acquired O
sent2196 data O
sent2196 and O
sent2196 current O
sent2196 outlook O
sent2197 ( O
sent2197 Part O
sent2197 1 O
sent2197 : O
sent2197 facial O
sent2197 morphogenesis O
sent2197 ) O
sent2198 The O
sent2198 effect O
sent2198 of O
sent2198 TRK-530 T
sent2198 on O
sent2198 experimental O
sent2198 arthritis D
sent2198 in O
sent2198 mice O
sent2199 Spontaneous O
sent2199 exfoliation O
sent2199 of O
sent2199 teeth O
sent2199 following O
sent2199 severe O
sent2199 elemental O
sent2199 mercury D
sent2199 poisoning D
sent2199 : O
sent2199 case O
sent2199 report O
sent2199 and O
sent2199 histological O
sent2199 investigation O
sent2199 for O
sent2199 mechanism O
sent2200 Small D
sent2200 cell D
sent2200 lung D
sent2200 cancer D
sent2200 can O
sent2200 express O
sent2200 CD34 O
sent2200 antigen O
sent2201 X O
sent2201 inactivation O
sent2201 in O
sent2201 females O
sent2201 with O
sent2201 X-linked D
sent2201 disease D
sent2202 Report O
sent2202 of O
sent2202 spores O
sent2202 of O
sent2202 Henneguya O
sent2202 salminicola O
sent2202 ( O
sent2202 Myxozoa O
sent2202 ) O
sent2202 in O
sent2202 human O
sent2202 stool O
sent2202 specimens O
sent2202 : O
sent2202 possible O
sent2202 source O
sent2202 of O
sent2202 confusion O
sent2202 with O
sent2202 human O
sent2202 spermatozoa O
sent2203 Evaluation O
sent2203 of O
sent2203 a O
sent2203 ventilation T
sent2203 strategy T
sent2203 to O
sent2203 prevent O
sent2203 barotrauma D
sent2203 in O
sent2203 patients O
sent2203 at O
sent2203 high O
sent2203 risk O
sent2203 for O
sent2203 acute D
sent2203 respiratory D
sent2203 distress D
sent2203 syndrome D
sent2204 Pressure- O
sent2204 and O
sent2204 Volume-Limited O
sent2204 Ventilation O
sent2204 Strategy O
sent2204 Group O
sent2205 Audit O
sent2205 commission O
sent2205 tackles O
sent2205 anaesthetic O
sent2205 services O
sent2206 Abdominal D
sent2206 tuberculosis D
sent2206 involving O
sent2206 hepatic O
sent2206 hilar O
sent2206 lymph O
sent2206 nodes O
sent2207 A O
sent2207 cause O
sent2207 of O
sent2207 portal D
sent2207 vein D
sent2207 thrombosis D
sent2207 and O
sent2207 portal D
sent2207 hypertension D
sent2208 Treatment O
sent2208 of O
sent2208 men O
sent2208 with O
sent2208 paraphilia D
sent2208 with O
sent2208 a O
sent2208 long-acting O
sent2208 analogue T
sent2208 of T
sent2208 gonadotropin-releasing T
sent2208 hormone T
sent2209 Analgesic D
sent2209 nephropathy D
sent2210 Translocations O
sent2210 of O
sent2210 11q13 O
sent2210 in O
sent2210 mantle D
sent2210 cell D
sent2210 lymphoma D
sent2210 fail O
sent2210 to O
sent2210 disrupt O
sent2210 the O
sent2210 S O
sent2210 mu O
sent2210 bp-2 O
sent2210 gene O
sent2211 Variation O
sent2211 in O
sent2211 proficiency O
sent2211 testing O
sent2211 performance O
sent2211 by O
sent2211 testing O
sent2211 site O
sent2212 The T
sent2212 `` T
sent2212 H T
sent2212 '' T
sent2212 graft T
sent2212 : O
sent2212 an O
sent2212 alternative O
sent2212 approach O
sent2212 for O
sent2212 performing O
sent2212 minimally O
sent2212 invasive O
sent2212 direct T
sent2212 coronary T
sent2212 artery T
sent2212 bypass T
sent2213 Effect O
sent2213 of O
sent2213 interferon T
sent2213 on O
sent2213 hepatitis D
sent2213 B D
sent2213 . O
sent2214 Health O
sent2214 insurance O
sent2214 for O
sent2214 children O
sent2214 -- O
sent2214 a O
sent2214 model O
sent2214 for O
sent2214 incremental O
sent2214 health O
sent2214 reform O
sent2214 ? O
sent2215 Distinction O
sent2215 awards O
sent2215 and O
sent2215 racial O
sent2215 discrimination O
sent2216 Potential O
sent2216 biases O
sent2216 were O
sent2216 not O
sent2216 taken O
sent2216 into O
sent2216 account O
sent2216 in O
sent2216 study O
sent2216 of O
sent2216 waiting O
sent2216 times O
sent2217 Factors O
sent2217 affecting O
sent2217 uptake O
sent2217 of O
sent2217 antenatal O
sent2217 HIV O
sent2217 testing O
sent2217 in O
sent2217 London O
sent2217 : O
sent2217 results O
sent2217 of O
sent2217 a O
sent2217 multicentre O
sent2217 study O
sent2218 Coronary O
sent2218 arterioluminal O
sent2218 communications O
sent2218 in O
sent2218 routine O
sent2218 angiography O
sent2219 Peptide O
sent2219 nucleic O
sent2219 acid O
sent2219 ( O
sent2219 PNA O
sent2219 ) O
sent2219 from O
sent2219 DNA O
sent2219 recognition O
sent2219 to O
sent2219 antisense O
sent2219 and O
sent2219 DNA O
sent2219 structure O
sent2220 Homeopathy T
sent2220 for O
sent2220 postoperative D
sent2220 ileus D
sent2220 ? O
sent2220 A O
sent2220 meta-analysis O
sent2221 Treatment O
sent2221 of O
sent2221 postmenopausal D
sent2221 osteoporosis D
sent2222 Fascioloidiasis D
sent2222 in O
sent2222 game-ranched O
sent2222 elk O
sent2222 from O
sent2222 Montana O
sent2223 Connexin-26 O
sent2223 mutations O
sent2223 in O
sent2223 sporadic O
sent2223 non-syndromal D
sent2223 sensorineural D
sent2223 deafness D
sent2224 Lyme D
sent2224 disease D
sent2224 presenting O
sent2224 as O
sent2224 Tourette D
sent2224 's D
sent2224 syndrome D
sent2225 The O
sent2225 screening O
sent2225 muddle O
sent2226 Treatment O
sent2226 of O
sent2226 hypertensive O
sent2226 patients O
sent2226 with O
sent2226 diabetes D
sent2227 China O
sent2227 's O
sent2227 human-organ O
sent2227 trade O
sent2227 highlighted O
sent2227 by O
sent2227 US O
sent2227 arrest O
sent2227 of O
sent2227 `` O
sent2227 salesman O
sent2227 '' O
sent2228 Dimension O
sent2228 in O
sent2228 defining O
sent2228 tumor D
sent2228 response O
sent2229 Administration O
sent2229 of O
sent2229 dexamethasone T
sent2229 induces O
sent2229 proteinuria D
sent2229 of O
sent2229 glomerular O
sent2229 origin O
sent2229 in O
sent2229 mice O
sent2230 Preoperative O
sent2230 thromboxane O
sent2230 A2/prostaglandin O
sent2230 H2 O
sent2230 receptor O
sent2230 activity O
sent2230 predicts O
sent2230 early O
sent2230 graft D
sent2230 thrombosis D
sent2231 Hypertension D
sent2231 treatment O
sent2231 and O
sent2231 control O
sent2231 in O
sent2231 sub-Saharan O
sent2231 Africa O
sent2231 : O
sent2231 the O
sent2231 epidemiological O
sent2231 basis O
sent2231 for O
sent2231 policy O
sent2232 Needle-exchange O
sent2232 programmes O
sent2232 in O
sent2232 the O
sent2232 USA O
sent2233 A O
sent2233 discriminant O
sent2233 function O
sent2233 for O
sent2233 preeclampsia D
sent2233 : O
sent2233 case-control O
sent2233 study O
sent2233 of O
sent2233 minor O
sent2233 hemoglobins O
sent2233 , O
sent2233 red O
sent2233 cell O
sent2233 enzymes O
sent2233 , O
sent2233 and O
sent2233 clinical O
sent2233 laboratory O
sent2233 values O
sent2234 Patterning O
sent2234 of O
sent2234 immobilized O
sent2234 antibody O
sent2234 layers O
sent2234 via O
sent2234 photolithography O
sent2234 and O
sent2234 oxygen O
sent2234 plasma O
sent2234 exposure O
sent2235 A O
sent2235 cell-based O
sent2235 immunobiosensor O
sent2235 with O
sent2235 engineered O
sent2235 molecular O
sent2235 recognition O
sent2235 -- O
sent2235 Part O
sent2235 II O
sent2235 : O
sent2235 Enzyme O
sent2235 amplification O
sent2235 systems O
sent2236 Evanescent O
sent2236 wave O
sent2236 fibre O
sent2236 optic O
sent2236 sensor O
sent2236 for O
sent2236 detection O
sent2236 of O
sent2236 L. O
sent2236 donovani O
sent2236 specific O
sent2236 antibodies O
sent2236 in O
sent2236 sera O
sent2236 of O
sent2236 kala O
sent2236 azar O
sent2236 patients O
sent2237 Multianalyte O
sent2237 biosensors O
sent2237 on O
sent2237 optical O
sent2237 imaging O
sent2237 bundles O
sent2238 Specific O
sent2238 binding O
sent2238 of O
sent2238 low O
sent2238 molecular O
sent2238 weight O
sent2238 ligands O
sent2238 with O
sent2238 direct O
sent2238 optical O
sent2238 detection O
sent2239 Amperometric O
sent2239 lactate O
sent2239 oxidase O
sent2239 catheter O
sent2239 for O
sent2239 real-time O
sent2239 lactate O
sent2239 monitoring O
sent2239 based O
sent2239 on O
sent2239 thin O
sent2239 film O
sent2239 technology O
sent2240 Dual-fractal O
sent2240 analysis O
sent2240 for O
sent2240 antigen O
sent2240 -- O
sent2240 antibody O
sent2240 binding O
sent2240 kinetics O
sent2240 for O
sent2240 biosensor O
sent2240 applications O
sent2241 Dipstick O
sent2241 only O
sent2241 urinalysis O
sent2241 screen O
sent2241 for O
sent2241 the O
sent2241 pediatric O
sent2241 emergency O
sent2241 room O
sent2242 Cytoplasmic O
sent2242 transport O
sent2242 in O
sent2242 Drosophila O
sent2242 ovarian O
sent2242 follicles O
sent2242 : O
sent2242 the O
sent2242 migration O
sent2242 of O
sent2242 microinjected O
sent2242 fluorescent O
sent2242 probes O
sent2242 through O
sent2242 intercellular O
sent2242 bridges O
sent2242 depends O
sent2242 neither O
sent2242 on O
sent2242 electrical O
sent2242 charge O
sent2242 nor O
sent2242 on O
sent2242 external O
sent2242 osmolarity O
sent2243 Further O
sent2243 evidence O
sent2243 for O
sent2243 the O
sent2243 importance O
sent2243 of O
sent2243 an O
sent2243 androgen O
sent2243 response O
sent2243 element O
sent2243 in O
sent2243 the O
sent2243 factor O
sent2243 IX O
sent2243 promoter O
sent2244 The O
sent2244 obstetric O
sent2244 experience O
sent2244 of O
sent2244 carriers O
sent2244 of O
sent2244 haemophilia D
sent2245 Acquired O
sent2245 haemophilia D
sent2245 , O
sent2245 an O
sent2245 unusual O
sent2245 cause O
sent2245 of O
sent2245 severe O
sent2245 postpartum D
sent2245 haemorrhage D
sent2246 Zoonotic O
sent2246 and O
sent2246 viral D
sent2246 infection D
sent2246 in O
sent2246 fetal O
sent2246 loss O
sent2246 after O
sent2246 12 O
sent2246 weeks O
sent2247 High-affinity O
sent2247 binding O
sent2247 of O
sent2247 the O
sent2247 neonatal O
sent2247 Fc O
sent2247 receptor O
sent2247 to O
sent2247 its O
sent2247 IgG O
sent2247 ligand O
sent2247 requires O
sent2247 receptor O
sent2247 immobilization O
sent2248 Molecular O
sent2248 distances O
sent2248 from O
sent2248 dipolar O
sent2248 coupled O
sent2248 spin-labels O
sent2248 : O
sent2248 the O
sent2248 global O
sent2248 analysis O
sent2248 of O
sent2248 multifrequency O
sent2248 continuous O
sent2248 wave O
sent2248 electron O
sent2248 paramagnetic O
sent2248 resonance O
sent2248 data O
sent2249 Computer O
sent2249 science O
sent2249 and O
sent2249 biology O
sent2249 -- O
sent2249 the O
sent2249 German O
sent2249 Conference O
sent2249 on O
sent2249 Bioinformatics O
sent2249 ( O
sent2249 GCB'96 O
sent2249 ) O
sent2250 Surface O
sent2250 plasmon O
sent2250 resonance O
sent2250 analysis O
sent2250 of O
sent2250 topoisomerase O
sent2250 I-DNA O
sent2250 binding O
sent2250 : O
sent2250 effect O
sent2250 of O
sent2250 Mg2+ O
sent2250 and O
sent2250 DNA O
sent2250 sequence O
sent2251 The O
sent2251 1996 O
sent2251 list O
sent2252 Proposed O
sent2252 new O
sent2252 bacterial O
sent2252 taxa O
sent2252 and O
sent2252 proposed O
sent2252 changes O
sent2252 of O
sent2252 bacterial O
sent2252 names O
sent2252 published O
sent2252 during O
sent2252 1996 O
sent2252 and O
sent2252 considered O
sent2252 to O
sent2252 be O
sent2252 of O
sent2252 interest O
sent2252 to O
sent2252 medical O
sent2252 or O
sent2252 veterinary O
sent2252 bacteriology O
sent2253 An O
sent2253 informational O
sent2253 note O
sent2254 The O
sent2254 1995 O
sent2254 list O
sent2255 Proposed O
sent2255 new O
sent2255 bacterial O
sent2255 taxa O
sent2255 and O
sent2255 proposed O
sent2255 changes O
sent2255 of O
sent2255 bacterial O
sent2255 names O
sent2255 published O
sent2255 during O
sent2255 1995 O
sent2255 and O
sent2255 considered O
sent2255 to O
sent2255 be O
sent2255 of O
sent2255 interest O
sent2255 to O
sent2255 medical O
sent2255 or O
sent2255 veterinary O
sent2255 bacteriology O
sent2256 An O
sent2256 informational O
sent2256 note O
sent2257 Biobehavioral O
sent2257 pain D
sent2257 research O
sent2257 : O
sent2257 a O
sent2257 multi-institute O
sent2257 assessment O
sent2257 of O
sent2257 cross-cutting O
sent2257 issues O
sent2257 and O
sent2257 research O
sent2257 needs O
sent2258 Use O
sent2258 of O
sent2258 surface O
sent2258 plasmon O
sent2258 resonance O
sent2258 to O
sent2258 probe O
sent2258 the O
sent2258 equilibrium O
sent2258 and O
sent2258 dynamic O
sent2258 aspects O
sent2258 of O
sent2258 interactions O
sent2258 between O
sent2258 biological O
sent2258 macromolecules O
sent2259 ABC O
sent2259 of O
sent2259 mental O
sent2259 health O
sent2260 Psychosexual D
sent2260 problems D
sent2261 Hazards O
sent2261 of O
sent2261 running O
sent2261 a O
sent2261 marathon O
sent2262 Troponin-T O
sent2262 concentrations O
sent2262 should O
sent2262 be O
sent2262 measured O
sent2263 Second O
sent2263 Strang O
sent2263 International O
sent2263 Cancer O
sent2263 Conference O
sent2263 : O
sent2263 genetics O
sent2263 and O
sent2263 the O
sent2263 environment O
sent2263 New O
sent2263 York O
sent2263 , O
sent2263 USA O
sent2263 , O
sent2263 15-16 O
sent2263 November O
sent2263 1996 O
sent2264 Use O
sent2264 of O
sent2264 a O
sent2264 modified O
sent2264 version O
sent2264 of O
sent2264 the O
sent2264 Overt O
sent2264 Aggression O
sent2264 Scale O
sent2264 in O
sent2264 the O
sent2264 measurement O
sent2264 and O
sent2264 assessment O
sent2264 of O
sent2264 aggressive O
sent2264 behaviours O
sent2264 following O
sent2264 brain D
sent2264 injury D
sent2265 Ectopic D
sent2265 pregnancy D
sent2265 recurrence O
sent2265 : O
sent2265 role O
sent2265 of O
sent2265 gynecologic O
sent2265 , O
sent2265 obstetric O
sent2265 , O
sent2265 contraceptive O
sent2265 and O
sent2265 smoking O
sent2265 history O
sent2266 AIDS O
sent2266 : O
sent2266 a O
sent2266 world O
sent2266 , O
sent2266 a O
sent2266 desire O
sent2267 Urogynaecology O
sent2267 proceedings O
sent2267 of O
sent2267 the O
sent2267 joint O
sent2267 RCOG/BAUS O
sent2267 urogynaecology O
sent2267 meeting O
sent2268 19 O
sent2268 September O
sent2268 1996 O
sent2269 The O
sent2269 naming O
sent2269 of O
sent2269 a O
sent2269 syndrome O
sent2270 The O
sent2270 use O
sent2270 of O
sent2270 implantable O
sent2270 venous O
sent2270 access O
sent2270 devices O
sent2270 ( O
sent2270 IVADs O
sent2270 ) O
sent2270 in O
sent2270 children O
sent2270 with O
sent2270 hemophilia D
sent2271 Nephrotic D
sent2271 syndrome D
sent2271 associated O
sent2271 with O
sent2271 hypocomplementemia D
sent2271 in O
sent2271 a O
sent2271 4-year-old O
sent2271 boy O
sent2271 with O
sent2271 hemophilia D
sent2271 B D
sent2272 Growth O
sent2272 hormone O
sent2272 secretion O
sent2272 in O
sent2272 HIV-positive O
sent2272 versus O
sent2272 HIV-negative O
sent2272 hemophilic O
sent2272 males O
sent2272 with O
sent2272 abnormal O
sent2272 growth O
sent2272 and O
sent2272 pubertal O
sent2272 development O
sent2273 The O
sent2273 Hemophilia O
sent2273 Growth O
sent2273 and O
sent2273 Development O
sent2273 Study O
sent2274 Trends O
sent2274 in O
sent2274 HIV O
sent2274 counseling O
sent2274 and O
sent2274 testing O
sent2274 of O
sent2274 clients O
sent2274 attending O
sent2274 a O
sent2274 public O
sent2274 sexually O
sent2274 transmitted O
sent2274 disease O
sent2274 clinic O
sent2274 in O
sent2274 Portland O
sent2274 , O
sent2274 Oregon O
sent2274 , O
sent2274 1989-1995 O
sent2275 Risk O
sent2275 factors O
sent2275 for O
sent2275 HIV-1 D
sent2275 infection D
sent2275 among O
sent2275 pregnant O
sent2275 women O
sent2275 in O
sent2275 French O
sent2275 Guiana O
sent2276 Angiogenesis O
sent2276 in O
sent2276 inflammatory D
sent2276 disease D
sent2277 Epidemiology O
sent2277 and O
sent2277 association O
sent2277 with O
sent2277 extra-gastrointestinal D
sent2277 diseases D
sent2278 Extra-gastrointestinal D
sent2278 diseases D
sent2278 and O
sent2278 Helicobacter O
sent2278 pylori O
sent2279 Update O
sent2279 on O
sent2279 Helicobacter O
sent2279 pylori O
sent2279 research O
sent2280 Diagnosis O
sent2281 Uptake O
sent2281 on O
sent2281 Helicobacter O
sent2281 pylori O
sent2281 research O
sent2282 Pathogenesis O
sent2282 and O
sent2282 host O
sent2282 response O
sent2283 Update O
sent2283 on O
sent2283 Helicobacter O
sent2283 pylori O
sent2283 research O
sent2284 Malignancies O
sent2285 Update O
sent2285 on O
sent2285 Helicobacter O
sent2285 pylori O
sent2285 research O
sent2286 Dyspepsia D
sent2287 Update O
sent2287 on O
sent2287 Helicobacter O
sent2287 pylori O
sent2287 research O
sent2288 Eradication O
sent2289 Sequence O
sent2289 analysis O
sent2289 of O
sent2289 the O
sent2289 36-kb O
sent2289 region O
sent2289 between O
sent2289 gntZ O
sent2289 and O
sent2289 trnY O
sent2289 genes O
sent2289 of O
sent2289 Bacillus O
sent2289 subtilis O
sent2289 genome O
sent2290 A O
sent2290 review O
sent2290 of O
sent2290 interferon O
sent2290 immunogenicity O
sent2291 Based O
sent2291 on O
sent2291 a O
sent2291 roundtable O
sent2291 workshop O
sent2291 held O
sent2291 in O
sent2291 London O
sent2291 , O
sent2291 United O
sent2291 Kingdom O
sent2291 , O
sent2291 9 O
sent2291 February O
sent2291 1996 O
sent2292 Histologic O
sent2292 diagnosis O
sent2292 of O
sent2292 chronic D
sent2292 hepatitis D
sent2292 , O
sent2292 grading O
sent2292 and O
sent2292 staging O
sent2293 Inositol T
sent2293 treatment O
sent2293 of O
sent2293 autism D
sent2294 Current O
sent2294 progress O
sent2294 in O
sent2294 early O
sent2294 pregnancy O
sent2294 investigation O
sent2295 Truncated-gene O
sent2295 reporter O
sent2295 system O
sent2295 for O
sent2295 studying O
sent2295 the O
sent2295 regulation O
sent2295 of O
sent2295 manganese O
sent2295 peroxidase O
sent2295 expression O
sent2296 Disparate O
sent2296 sequence O
sent2296 characteristics O
sent2296 of O
sent2296 the O
sent2296 Erysiphe O
sent2296 graminis O
sent2296 f.sp O
sent2297 hordei O
sent2297 glyceraldehyde-3-phosphate O
sent2297 dehydrogenase O
sent2297 gene O
sent2298 The O
sent2298 Integrative O
sent2298 Neurobiology O
sent2298 of O
sent2298 Affiliation O
sent2299 Proceedings O
sent2299 of O
sent2299 a O
sent2299 conference O
sent2300 Washington O
sent2300 , O
sent2300 DC O
sent2300 , O
sent2300 USA O
sent2301 March O
sent2301 14-17 O
sent2301 , O
sent2301 1996 O
sent2302 Proceedings O
sent2302 of O
sent2302 the O
sent2302 10th O
sent2302 International O
sent2302 Symposium O
sent2302 on O
sent2302 the O
sent2302 Pharmacology O
sent2302 of O
sent2302 Thermoregulation O
sent2303 Memphis O
sent2303 , O
sent2303 Tennessee O
sent2303 , O
sent2303 USA O
sent2304 August O
sent2304 17-22 O
sent2304 , O
sent2304 1996 O
sent2305 Neuropeptides O
sent2305 in O
sent2305 Development O
sent2305 and O
sent2305 Aging O
sent2306 Proceedings O
sent2306 of O
sent2306 a O
sent2306 conference O
sent2307 Breckenridge O
sent2307 , O
sent2307 Colorado O
sent2307 , O
sent2307 USA O
sent2308 February O
sent2308 3-6 O
sent2308 , O
sent2308 1996 O
sent2309 Receptor O
sent2309 Classification O
sent2309 : O
sent2309 The O
sent2309 Integration O
sent2309 of O
sent2309 Operational O
sent2309 , O
sent2309 Structural O
sent2309 , O
sent2309 and O
sent2309 Transductional O
sent2309 Information O
sent2310 Proceedings O
sent2310 of O
sent2310 a O
sent2310 conference O
sent2311 Verona O
sent2311 , O
sent2311 Italy O
sent2311 , O
sent2311 September O
sent2311 21-22 O
sent2311 , O
sent2311 1995 O
sent2312 Psychobiology O
sent2312 of O
sent2312 Postraumatic D
sent2312 Stress D
sent2312 Disorder D
sent2313 Proceedings O
sent2313 of O
sent2313 a O
sent2313 conference O
sent2314 New O
sent2314 York O
sent2314 , O
sent2314 New O
sent2314 York O
sent2314 , O
sent2314 USA O
sent2315 September O
sent2315 7-10 O
sent2315 , O
sent2315 1996 O
sent2316 Adolescent O
sent2316 Gynecology O
sent2316 and O
sent2316 Endocrinology O
sent2316 : O
sent2316 Basic O
sent2316 and O
sent2316 Clinical O
sent2316 Aspects O
sent2317 Proceedings O
sent2317 of O
sent2317 the O
sent2317 3rd O
sent2317 International O
sent2317 Congress O
sent2318 Athens O
sent2318 , O
sent2318 Greece O
sent2318 , O
sent2318 December O
sent2318 6-9 O
sent2318 , O
sent2318 1995 O
sent2319 Proceedings O
sent2319 of O
sent2319 the O
sent2319 3rd O
sent2319 International O
sent2319 Conference O
sent2319 on O
sent2319 Neuroprotective O
sent2319 Agents O
sent2319 : O
sent2319 Clinical O
sent2319 and O
sent2319 Experimental O
sent2319 Aspects O
sent2320 Lake O
sent2320 Como O
sent2320 , O
sent2320 Italy O
sent2320 , O
sent2320 September O
sent2320 9-12 O
sent2320 , O
sent2320 1996 O
sent2321 Exon/intron O
sent2321 structure O
sent2321 of O
sent2321 the O
sent2321 human O
sent2321 AF-4 O
sent2321 gene O
sent2321 , O
sent2321 a O
sent2321 member O
sent2321 of O
sent2321 the O
sent2321 AF-4/LAF-4/FMR-2 O
sent2321 gene O
sent2321 family O
sent2321 coding O
sent2321 for O
sent2321 a O
sent2321 nuclear O
sent2321 protein O
sent2321 with O
sent2321 structural O
sent2321 alterations O
sent2321 in O
sent2321 acute O
sent2321 leukaemia D
sent2322 Cloning O
sent2322 and O
sent2322 characterization O
sent2322 of O
sent2322 a O
sent2322 neural O
sent2322 cell O
sent2322 recognition O
sent2322 molecule O
sent2322 on O
sent2322 axons O
sent2322 of O
sent2322 the O
sent2322 retinotectal O
sent2322 system O
sent2322 and O
sent2322 spinal O
sent2322 cord O
sent2323 Identification O
sent2323 , O
sent2323 localization O
sent2323 , O
sent2323 and O
sent2323 expression O
sent2323 of O
sent2323 two O
sent2323 novel O
sent2323 human O
sent2323 genes O
sent2323 similar O
sent2323 to O
sent2323 deoxyribonuclease O
sent2323 I O
sent2323 . O
sent2324 Drug O
sent2324 resistance O
sent2324 during O
sent2324 indinavir T
sent2324 therapy T
sent2324 is O
sent2324 caused O
sent2324 by O
sent2324 mutations O
sent2324 in O
sent2324 the O
sent2324 protease O
sent2324 gene O
sent2324 and O
sent2324 in O
sent2324 its O
sent2324 Gag O
sent2324 substrate O
sent2324 cleavage O
sent2324 sites O
sent2325 A O
sent2325 protein O
sent2325 with O
sent2325 a O
sent2325 novel O
sent2325 calcium-binding O
sent2325 domain O
sent2325 associated O
sent2325 with O
sent2325 calcareous O
sent2325 corpuscles O
sent2325 in O
sent2325 Echinococcus D
sent2325 granulosus D
sent2326 Oncogenic O
sent2326 raf-1 O
sent2326 induces O
sent2326 the O
sent2326 expression O
sent2326 of O
sent2326 non-histone O
sent2326 chromosomal O
sent2326 architectural O
sent2326 protein O
sent2326 HMGI-C O
sent2326 via O
sent2326 a O
sent2326 p44/p42 O
sent2326 mitogen-activated O
sent2326 protein O
sent2326 kinase-dependent O
sent2326 pathway O
sent2326 in O
sent2326 salivary O
sent2326 epithelial O
sent2326 cells O
sent2327 Pendred D
sent2327 syndrome D
sent2327 is O
sent2327 caused O
sent2327 by O
sent2327 mutations O
sent2327 in O
sent2327 a O
sent2327 putative O
sent2327 sulphate O
sent2327 transporter O
sent2327 gene O
sent2327 ( O
sent2327 PDS O
sent2327 ) O
sent2328 Meis2 O
sent2328 , O
sent2328 a O
sent2328 novel O
sent2328 mouse O
sent2328 Pbx-related O
sent2328 homeobox O
sent2328 gene O
sent2328 induced O
sent2328 by O
sent2328 retinoic O
sent2328 acid O
sent2328 during O
sent2328 differentiation O
sent2328 of O
sent2328 P19 O
sent2328 embryonal O
sent2328 carcinoma O
sent2328 cells O
sent2329 Proceedings O
sent2329 of O
sent2329 the O
sent2329 VIIIth O
sent2329 International O
sent2329 Conference O
sent2329 on O
sent2329 the O
sent2329 Na/K-ATPase O
sent2329 and O
sent2329 Related O
sent2329 Transport O
sent2329 ATPases O
sent2330 Mar O
sent2330 del O
sent2330 Plata O
sent2330 , O
sent2330 Argentina O
sent2330 , O
sent2330 August O
sent2330 26-30 O
sent2330 , O
sent2330 1996 O
sent2331 Targeted O
sent2331 development O
sent2331 of O
sent2331 microsatellite O
sent2331 markers O
sent2331 from O
sent2331 the O
sent2331 defined O
sent2331 region O
sent2331 of O
sent2331 bovine O
sent2331 chromosome O
sent2331 6q21-31 O
sent2332 Genetic O
sent2332 population O
sent2332 structure O
sent2332 in O
sent2332 the O
sent2332 yellow O
sent2332 mongoose O
sent2332 , O
sent2332 Cynictis O
sent2332 penicillata O
sent2333 ETTIN O
sent2333 patterns O
sent2333 the O
sent2333 Arabidopsis O
sent2333 floral O
sent2333 meristem O
sent2333 and O
sent2333 reproductive O
sent2333 organs O
sent2334 Ancient O
sent2334 DNA O
sent2334 from O
sent2334 amber O
sent2334 fossil O
sent2334 bees O
sent2334 ? O
sent2335 The O
sent2335 histone O
sent2335 H1 O
sent2335 genes O
sent2335 of O
sent2335 the O
sent2335 dipteran O
sent2335 insect O
sent2335 , O
sent2335 Chironomus O
sent2335 thummi O
sent2335 , O
sent2335 fall O
sent2335 under O
sent2335 two O
sent2335 divergent O
sent2335 classes O
sent2335 and O
sent2335 encode O
sent2335 proteins O
sent2335 with O
sent2335 distinct O
sent2335 intranuclear O
sent2335 distribution O
sent2335 and O
sent2335 potentially O
sent2335 different O
sent2335 functions O
sent2336 Characterization O
sent2336 of O
sent2336 the O
sent2336 orf31-petG O
sent2336 gene O
sent2336 cluster O
sent2336 from O
sent2336 the O
sent2336 plastid O
sent2336 genome O
sent2336 of O
sent2336 Populus O
sent2336 deltoides O
sent2337 Xenopus O
sent2337 Pax-2 O
sent2337 displays O
sent2337 multiple O
sent2337 splice O
sent2337 forms O
sent2337 during O
sent2337 embryogenesis O
sent2337 and O
sent2337 pronephric O
sent2337 kidney O
sent2337 development O
sent2338 International O
sent2338 Workshop O
sent2338 on O
sent2338 Bone O
sent2338 Research O
sent2338 in O
sent2338 Space O
sent2339 Tokyo O
sent2339 , O
sent2339 Japan O
sent2339 , O
sent2339 November O
sent2339 11-13 O
sent2339 , O
sent2339 1996 O
sent2340 Proceedings O
sent2341 Joint O
sent2341 meeting O
sent2341 of O
sent2341 the O
sent2341 Benelux O
sent2341 Society O
sent2341 for O
sent2341 Microcirculation O
sent2341 and O
sent2341 the O
sent2341 Gesellschaft O
sent2341 f1/4r O
sent2341 Mikrozirkulation O
sent2341 e.V O
sent2342 Mainz O
sent2342 , O
sent2342 Germany O
sent2342 , O
sent2342 October O
sent2342 23-25 O
sent2342 , O
sent2342 1997 O
sent2343 Abstracts O
sent2344 3rd O
sent2344 Congress O
sent2344 of O
sent2344 the O
sent2344 French O
sent2344 Society O
sent2344 of O
sent2344 Blood T
sent2344 Transfusion T
sent2345 Marseille O
sent2345 , O
sent2345 France O
sent2345 , O
sent2345 28-30 O
sent2345 April O
sent2345 1998 O
sent2346 Central O
sent2346 and O
sent2346 East O
sent2346 European O
sent2346 Regional O
sent2346 INTERASMA O
sent2346 Conference O
sent2347 Budapest O
sent2347 , O
sent2347 Hungary O
sent2347 , O
sent2347 August O
sent2347 24-27 O
sent2347 , O
sent2347 1997 O
sent2348 Summary O
sent2348 of O
sent2348 symposium O
sent2348 , O
sent2348 antisense O
sent2348 oligonucleotides O
sent2348 : O
sent2348 strategies O
sent2348 and O
sent2348 successes O
sent2349 Sarasota O
sent2349 , O
sent2349 Florida O
sent2349 , O
sent2349 USA O
sent2350 April O
sent2350 21 O
sent2350 , O
sent2350 1995 O
sent2351 International O
sent2351 forensic O
sent2351 science O
sent2351 and O
sent2351 justice O
sent2352 Proceedings O
sent2352 of O
sent2352 the O
sent2352 6th O
sent2352 Congress O
sent2352 of O
sent2352 the O
sent2352 Soci O
sent2352 ( O
sent2352 c O
sent2352 ) O
sent2352 t O
sent2352 ( O
sent2352 c O
sent2352 ) O
sent2352 de O
sent2352 Pharmaco-Toxicologie O
sent2352 Cellulaire O
sent2352 and O
sent2352 the O
sent2352 Soci O
sent2352 ( O
sent2352 c O
sent2352 ) O
sent2352 t O
sent2352 ( O
sent2352 c O
sent2352 ) O
sent2352 Française O
sent2352 de O
sent2352 Toxicologie O
sent2352 G O
sent2352 ( O
sent2352 c O
sent2352 ) O
sent2352 n O
sent2352 ( O
sent2352 c O
sent2352 ) O
sent2352 tique O
sent2353 Paris O
sent2353 , O
sent2353 France O
sent2353 , O
sent2353 March O
sent2353 6-7 O
sent2353 , O
sent2353 1997 O
sent2354 The O
sent2354 Italian O
sent2354 Association O
sent2354 for O
sent2354 the O
sent2354 Study O
sent2354 of O
sent2354 Glaucoma D
sent2355 Proceedings O
sent2355 of O
sent2355 the O
sent2355 12th O
sent2355 annual O
sent2355 general O
sent2355 meeting O
sent2356 Rapallo O
sent2356 , O
sent2356 Italy O
sent2356 , O
sent2356 14-15 O
sent2356 March O
sent2356 1997 O
sent2357 Report O
sent2357 of O
sent2357 the O
sent2357 61st O
sent2357 National O
sent2357 Scientific O
sent2357 Meeting O
sent2357 of O
sent2357 the O
sent2357 American O
sent2357 College O
sent2357 of O
sent2357 Rheumatology O
sent2357 , O
sent2357 Washington O
sent2357 DC O
sent2357 , O
sent2357 8-12 O
sent2357 November O
sent2357 1997 O
sent2358 Topical O
sent2358 dictionary O
sent2359 USAN O
sent2359 Council O
sent2360 List O
sent2360 No O
sent2361 404 O
sent2362 New O
sent2362 names O
sent2363 Nagrestipen O
sent2364 Proposed O
sent2364 genetic O
sent2364 nomenclature O
sent2364 rules O
sent2364 for O
sent2364 Tetrahymena O
sent2364 thermophila O
sent2364 , O
sent2364 Paramecium O
sent2364 primaurelia O
sent2364 and O
sent2364 Paramecium O
sent2364 tetraurelia O
sent2365 The O
sent2365 Seventh O
sent2365 International O
sent2365 Meeting O
sent2365 on O
sent2365 Ciliate O
sent2365 Molecular O
sent2365 Biology O
sent2365 Genetics O
sent2365 Nomenclature O
sent2366 Joint O
sent2366 annual O
sent2366 session O
sent2366 of O
sent2366 the O
sent2366 North O
sent2366 German O
sent2366 Society O
sent2366 of O
sent2366 Radiology O
sent2366 and O
sent2366 the O
sent2366 Radiology O
sent2366 Society O
sent2366 of O
sent2366 Lower O
sent2366 Saxony O
sent2366 and O
sent2366 Sachsen O
sent2366 Anhalt O
sent2367 Kiel O
sent2367 , O
sent2367 20-21 O
sent2367 February O
sent2367 1998 O
sent2368 Abstracts O
sent2369 Neurone O
sent2369 development O
sent2369 and O
sent2369 death O
sent2369 , O
sent2369 from O
sent2369 a O
sent2369 cell O
sent2369 biologist O
sent2369 's O
sent2369 perspective O
sent2370 3rd O
sent2370 Neurotrauma/Polytrauma O
sent2370 Symposium O
sent2371 Cologne O
sent2371 , O
sent2371 Germany O
sent2371 , O
sent2371 March O
sent2371 14-15 O
sent2371 , O
sent2371 1998 O
sent2372 Abstracts O
sent2373 Neuroimmunomodulation O
sent2373 : O
sent2373 Molecular O
sent2373 Aspects O
sent2373 , O
sent2373 Integrative O
sent2373 Systems O
sent2373 , O
sent2373 and O
sent2373 Clinical O
sent2373 Advances O
sent2374 Proceedings O
sent2374 of O
sent2374 the O
sent2374 3rd O
sent2374 Congress O
sent2374 of O
sent2374 the O
sent2374 International O
sent2374 Society O
sent2374 of O
sent2374 NeuroImmunoModulation O
sent2374 ( O
sent2374 ISNIM O
sent2374 ) O
sent2375 Bethesda O
sent2375 , O
sent2375 Maryland O
sent2375 , O
sent2375 USA O
sent2376 November O
sent2376 13-15 O
sent2376 , O
sent2376 1996 O
sent2377 8th O
sent2377 European O
sent2377 Meeting O
sent2377 on O
sent2377 Dysmorphology O
sent2378 Strasbourg O
sent2378 , O
sent2378 France O
sent2378 , O
sent2378 3-6 O
sent2378 September O
sent2378 1997 O
sent2379 Abstracts O
sent2380 EU O
sent2380 Working O
sent2380 Group O
sent2380 on O
sent2380 Tobacco O
sent2380 and O
sent2380 Oral O
sent2380 Health O
sent2380 Consensus O
sent2380 Meeting O
sent2381 Copenhagen O
sent2381 , O
sent2381 23-26 O
sent2381 October O
sent2381 1997 O
sent2382 Abstracts O
sent2383 Presentations O
sent2383 from O
sent2383 the O
sent2383 2nd O
sent2383 NIH O
sent2383 Symposium O
sent2383 on O
sent2383 Therapeutic O
sent2383 Oligonucleotides O
sent2383 : O
sent2383 Targeting O
sent2383 Transcription O
sent2383 Factors O
sent2383 and O
sent2383 Signaling O
sent2383 Pathways O
sent2384 Bethesda O
sent2384 , O
sent2384 Maryland O
sent2384 , O
sent2384 USA O
sent2385 December O
sent2385 5 O
sent2385 , O
sent2385 1997 O
sent2386 Infectious D
sent2386 diseases D
sent2386 : O
sent2386 their O
sent2386 impact O
sent2386 on O
sent2386 dentistry O
sent2387 What O
sent2387 's O
sent2387 new O
sent2387 in O
sent2387 protein O
sent2387 folding O
sent2387 ? O
sent2387 EMBO O
sent2387 workshop O
sent2387 : O
sent2387 protein O
sent2387 folding O
sent2387 and O
sent2387 misfolding O
sent2387 inside O
sent2387 and O
sent2387 outside O
sent2387 the O
sent2387 cell O
sent2388 Meeting O
sent2388 of O
sent2388 the O
sent2388 European O
sent2388 forum O
sent2388 of O
sent2388 nurses O
sent2389 17th O
sent2389 European O
sent2389 Workshop O
sent2389 on O
sent2389 the O
sent2389 Cell O
sent2389 Biology O
sent2389 of O
sent2389 Phagocytes O
sent2390 Catania O
sent2390 , O
sent2390 Italy O
sent2390 , O
sent2390 May O
sent2390 27-31 O
sent2390 , O
sent2390 1998 O
sent2391 Abstracts O
sent2392 Onset O
sent2392 of O
sent2392 the O
sent2392 preovulatory O
sent2392 luteinizing O
sent2392 hormone O
sent2392 surge O
sent2392 : O
sent2392 diurnal O
sent2392 timing O
sent2392 and O
sent2392 critical O
sent2392 follicular O
sent2392 prerequisites O
sent2393 Municipal O
sent2393 animal O
sent2393 control O
sent2393 ordinances O
sent2393 -- O
sent2393 some O
sent2393 legal O
sent2393 issues O
sent2394 Psychosexual O
sent2394 care O
sent2394 in O
sent2394 a O
sent2394 multi-ethnic O
sent2394 society O
sent2395 Serologic O
sent2395 evidence O
sent2395 for O
sent2395 mother-to-child O
sent2395 transmission O
sent2395 of O
sent2395 Kaposi D
sent2395 sarcoma-associated D
sent2395 herpesvirus D
sent2395 infection D
sent2396 Brandon/Hill O
sent2396 selected O
sent2396 list O
sent2396 of O
sent2396 nursing O
sent2396 books O
sent2396 and O
sent2396 journals O
sent2397 Retraction O
sent2398 The O
sent2398 TSG101 O
sent2398 tumor O
sent2398 susceptibility O
sent2398 gene O
sent2398 is O
sent2398 located O
sent2398 in O
sent2398 chromosome O
sent2398 11 O
sent2398 band O
sent2398 p15 O
sent2398 and O
sent2398 is O
sent2398 mutated O
sent2398 in O
sent2398 human O
sent2398 breast D
sent2398 cancer D
sent2399 An O
sent2399 omission O
sent2400 Indoor O
sent2400 pollution O
sent2400 and O
sent2400 health O
sent2401 Dioxins O
sent2401 : O
sent2401 current O
sent2401 knowledge O
sent2401 about O
sent2401 health O
sent2401 effects O
sent2402 Influence O
sent2402 of O
sent2402 environmental O
sent2402 factors O
sent2402 on O
sent2402 fertility O
sent2402 : O
sent2402 example O
sent2402 of O
sent2402 the O
sent2402 diminution O
sent2402 of O
sent2402 sperm O
sent2402 quality O
sent2403 New O
sent2403 developments O
sent2403 in O
sent2403 the O
sent2403 treatment O
sent2403 of O
sent2403 diabetes D
sent2403 and O
sent2403 hyperlipidemias D
sent2404 Role O
sent2404 of O
sent2404 beta-blockers T
sent2404 in O
sent2404 the O
sent2404 treatment O
sent2404 of O
sent2404 cardiac D
sent2404 insufficiency D
sent2405 Which O
sent2405 calcium T
sent2405 antagonists T
sent2405 for O
sent2405 hypertension D
sent2405 ? O
sent2406 Correct O
sent2406 use O
sent2406 of O
sent2406 serotonin T
sent2406 agonists T
sent2406 in O
sent2406 migraine D
sent2406 : O
sent2406 oral O
sent2406 or O
sent2406 injectable O
sent2406 form O
sent2406 ? O
sent2407 Overtraining O
sent2407 and O
sent2407 recovery O
sent2408 A O
sent2408 conceptual O
sent2408 model O
sent2409 Saliva O
sent2409 composition O
sent2409 and O
sent2409 exercise O
sent2410 Lipid O
sent2410 metabolism O
sent2410 during O
sent2410 exercise O
sent2411 Golf D
sent2411 injuries D
sent2412 An O
sent2412 overview O
sent2413 Prevention O
sent2413 of O
sent2413 ankle D
sent2413 injuries D
sent2414 Academic O
sent2414 medicine O
sent2414 -- O
sent2414 alternative O
sent2414 medicine O
sent2414 from O
sent2414 the O
sent2414 viewpoint O
sent2414 of O
sent2414 public O
sent2414 health O
sent2414 public O
sent2414 health O
sent2414 directors O
sent2415 Academic O
sent2415 medicine O
sent2415 and O
sent2415 complementary O
sent2415 medicine O
sent2415 -- O
sent2415 campaign O
sent2415 for O
sent2415 the O
sent2415 truth O
sent2415 in O
sent2415 medical O
sent2415 theories O
sent2416 The O
sent2416 academic O
sent2416 medicine O
sent2416 -- O
sent2416 alternative O
sent2416 medicine O
sent2416 tension O
sent2416 field O
sent2417 Are O
sent2417 academic O
sent2417 medicine-alternative O
sent2417 medicine O
sent2417 incompatible O
sent2417 , O
sent2417 compatible O
sent2417 , O
sent2417 complementary O
sent2417 ? O
sent2418 Research O
sent2418 in O
sent2418 complementary O
sent2418 medicine O
sent2418 : O
sent2418 results O
sent2418 and O
sent2418 problems O
sent2419 Subcutaneous D
sent2419 hematomas D
sent2419 , O
sent2419 reduced O
sent2419 Quick O
sent2419 value O
sent2420 Factor D
sent2420 VII D
sent2420 deficiency D
sent2421 Mononucleosis D
sent2421 infectiosa D
sent2421 ( O
sent2421 Epstein-Barr D
sent2421 virus D
sent2421 infection D
sent2422 Morphology O
sent2422 and O
sent2422 molecular O
sent2422 biology O
sent2422 of O
sent2422 malignant O
sent2422 soft D
sent2422 tissue D
sent2422 sarcomas D
sent2423 Surgical O
sent2423 aspects O
sent2423 in O
sent2423 the O
sent2423 multidisciplinary O
sent2423 treatment O
sent2423 of O
sent2423 soft D
sent2423 tissue D
sent2423 sarcomas D
sent2424 Surgical T
sent2424 management T
sent2424 of O
sent2424 soft D
sent2424 tissue D
sent2424 sarcomas D
sent2424 : O
sent2424 principles O
sent2424 of O
sent2424 resection T
sent2424 and O
sent2424 reconstructive O
sent2424 plastic O
sent2424 procedures O
sent2425 Adjuvant T
sent2425 chemotherapy T
sent2425 in O
sent2425 early O
sent2425 soft D
sent2425 tissue D
sent2425 sarcoma D
sent2425 and O
sent2425 palliative T
sent2425 chemotherapy T
sent2425 in O
sent2425 advanced O
sent2425 soft D
sent2425 tissue D
sent2425 sarcoma D
sent2425 in O
sent2425 adults O
sent2426 Radiotherapy T
sent2426 of O
sent2426 soft D
sent2426 tissue D
sent2426 sarcomas D
sent2427 Spinal D
sent2427 muscular D
sent2427 atrophy D
sent2427 : O
sent2427 where O
sent2427 are O
sent2427 we O
sent2427 in O
sent2427 1998 O
sent2427 ? O
sent2428 Diseases O
sent2428 transmitted O
sent2428 by O
sent2428 non-conventional O
sent2428 agents O
sent2428 ( O
sent2428 `` O
sent2428 prions O
sent2428 '' O
sent2428 ) O
sent2428 : O
sent2428 nosology O
sent2428 and O
sent2428 diagnosis O
sent2429 A O
sent2429 note O
sent2429 on O
sent2429 the O
sent2429 epidemiology O
sent2429 of O
sent2429 Creutzfeldt-Jakob D
sent2429 syndrome D
sent2430 Biology O
sent2430 of O
sent2430 non-conventional O
sent2430 transmissible O
sent2430 agents O
sent2430 or O
sent2430 prions O
sent2431 Cerebral D
sent2431 hemosiderosis D
sent2431 related O
sent2431 to O
sent2431 hereditary O
sent2431 ceruloplasmin D
sent2431 deficiency D
sent2432 Clinical O
sent2432 familial O
sent2432 case O
sent2432 study O
sent2433 Intramedullary O
sent2433 metastases O
sent2433 of O
sent2433 bronchogenic D
sent2433 carcinoma D
sent2434 Two O
sent2434 cases O
sent2435 Nervous D
sent2435 system D
sent2435 borreliosis D
sent2435 with O
sent2435 pseudo-lymphoma O
sent2435 cells O
sent2435 in O
sent2435 cerebrospinal O
sent2435 fluid O
sent2436 Epidural O
sent2436 and O
sent2436 intramedullary O
sent2436 abscess O
sent2436 of O
sent2436 acute O
sent2436 onset O
sent2437 Cranial D
sent2437 nerve D
sent2437 injuries D
sent2437 during O
sent2437 multifocal O
sent2437 neuropathies O
sent2437 with O
sent2437 persistent O
sent2437 conduction O
sent2437 blocks O
sent2438 Cytokines O
sent2438 and O
sent2438 peripheral O
sent2438 neuropathies O
sent2439 Clinical O
sent2439 diagnosis O
sent2439 of O
sent2439 frontotemporal D
sent2439 dementia D
sent2440 Study O
sent2440 of O
sent2440 cortical D
sent2440 atrophy D
sent2440 with O
sent2440 magnetic O
sent2440 resonance O
sent2440 imaging O
sent2440 in O
sent2440 corticobasal D
sent2440 degeneration D
sent2441 Autosomal O
sent2441 dominant O
sent2441 nocturnal O
sent2441 frontal O
sent2441 lobe O
sent2441 epilepsy D
sent2442 Eosinophilic D
sent2442 meningitis D
sent2442 due O
sent2442 to O
sent2442 Angiostrongylus O
sent2442 cantonensis O
sent2443 Case O
sent2443 of O
sent2443 superficial D
sent2443 hemosiderosis D
sent2443 of D
sent2443 the D
sent2443 central D
sent2443 nervous D
sent2443 system D
sent2443 treated O
sent2443 with O
sent2443 trientine T
sent2444 Germinal D
sent2444 tumor D
sent2444 metastases D
sent2445 Case O
sent2445 report O
sent2446 Bradycardia D
sent2446 : O
sent2446 an O
sent2446 unrecognized O
sent2446 complication O
sent2446 of O
sent2446 some O
sent2446 epileptic O
sent2446 crises O
sent2447 Facial D
sent2447 palsy O
sent2447 relevant O
sent2447 to O
sent2447 HIV O
sent2447 seropositivity O
sent2448 Pneumosinus O
sent2448 dilatans O
sent2448 : O
sent2448 a O
sent2448 little-known O
sent2448 diagnostic O
sent2448 tool O
sent2449 Current O
sent2449 status O
sent2449 of O
sent2449 mitochondrial D
sent2449 diseases D
sent2450 Vascular D
sent2450 Parkinson D
sent2450 syndromes D
sent2450 : O
sent2450 a O
sent2450 controversial O
sent2450 concept O
sent2451 Epilepsy D
sent2451 and O
sent2451 psychiatric D
sent2451 disorders D
sent2451 : O
sent2451 epidemiological O
sent2451 data O
sent2452 Auditory D
sent2452 perception D
sent2452 disorders D
sent2452 due O
sent2452 to O
sent2452 bilateral D
sent2452 cortical D
sent2452 lesions D
sent2453 An O
sent2453 electrophysiology O
sent2453 study O
sent2454 Zinc T
sent2454 gluconate T
sent2454 lozenges T
sent2454 for O
sent2454 treating O
sent2454 the O
sent2454 common D
sent2454 cold D
sent2455 Body O
sent2455 weight O
sent2455 and O
sent2455 mortality O
sent2455 among O
sent2455 women O
sent2456 Survey O
sent2456 and O
sent2456 assessment O
sent2456 of O
sent2456 the O
sent2456 actual O
sent2456 state O
sent2456 of O
sent2456 routine O
sent2456 measurement O
sent2456 of O
sent2456 glycohaemoglobin/GHb O
sent2456 by O
sent2456 commercial O
sent2456 methods O
sent2456 : O
sent2456 warning O
sent2456 to O
sent2456 the O
sent2456 users O
sent2456 and O
sent2456 the O
sent2456 providers O
sent2457 The O
sent2457 radiological O
sent2457 investigation O
sent2457 of O
sent2457 suspected O
sent2457 lower O
sent2457 limb O
sent2457 deep D
sent2457 vein D
sent2457 thrombosis D
sent2458 p53 O
sent2458 mutations O
sent2458 in O
sent2458 BRCA1-associated O
sent2458 familial O
sent2458 breast D
sent2458 cancer D
sent2459 Metronidazole T
sent2459 ( O
sent2459 Flagyl O
sent2459 ) O
sent2460 The O
sent2460 Preterm O
sent2460 Prediction O
sent2460 Study O
sent2460 : O
sent2460 association O
sent2460 of O
sent2460 cesarean T
sent2460 delivery T
sent2460 with O
sent2460 increases O
sent2460 in O
sent2460 maternal O
sent2460 weight O
sent2460 and O
sent2460 body O
sent2460 mass O
sent2460 index O
sent2461 Controversies O
sent2461 in O
sent2461 hydrating O
sent2461 the O
sent2461 terminally O
sent2461 ill O
sent2461 patient O
sent2462 Frequency O
sent2462 and O
sent2462 significance O
sent2462 of O
sent2462 antinuclear O
sent2462 antibodies O
sent2462 in O
sent2462 multiple D
sent2462 sclerosis D
sent2463 Magnetic O
sent2463 resonance O
sent2463 imaging O
sent2463 of O
sent2463 the O
sent2463 bone O
sent2463 marrow O
sent2463 in O
sent2463 hematologic D
sent2463 malignancies D
sent2464 Generation O
sent2464 of O
sent2464 diversity O
sent2464 in O
sent2464 mammalian O
sent2464 gut-associated O
sent2464 lymphoid O
sent2464 tissues O
sent2464 : O
sent2464 restricted O
sent2464 V O
sent2464 gene O
sent2464 usage O
sent2464 does O
sent2464 not O
sent2464 preclude O
sent2464 complex O
sent2464 V O
sent2464 gene O
sent2464 organization O
sent2465 A O
sent2465 major O
sent2465 non-LTR O
sent2465 retrotransposon O
sent2465 of O
sent2465 Bombyx O
sent2465 mori O
sent2465 , O
sent2465 L1Bm O
sent2466 Algae O
sent2466 or O
sent2466 protozoa O
sent2466 : O
sent2466 phylogenetic O
sent2466 position O
sent2466 of O
sent2466 euglenophytes O
sent2466 and O
sent2466 dinoflagellates O
sent2466 as O
sent2466 inferred O
sent2466 from O
sent2466 mitochondrial O
sent2466 sequences O
sent2467 Structure O
sent2467 and O
sent2467 function O
sent2467 of O
sent2467 the O
sent2467 long O
sent2467 terminal O
sent2467 repeats O
sent2467 of O
sent2467 feline O
sent2467 leukemia O
sent2467 viruses O
sent2467 derived O
sent2467 from O
sent2467 naturally O
sent2467 occurring O
sent2467 acute D
sent2467 myeloid D
sent2467 leukemias D
sent2467 in O
sent2467 cats O
sent2468 Use O
sent2468 of O
sent2468 protein-C T
sent2468 concentrate T
sent2468 , T
sent2468 heparin T
sent2468 , T
sent2468 and T
sent2468 haemodiafiltration T
sent2468 in O
sent2468 meningococcus-induced D
sent2468 purpura D
sent2468 fulminans D
sent2469 Satellite O
sent2469 DNA O
sent2469 repeat O
sent2469 sequence O
sent2469 variation O
sent2469 is O
sent2469 low O
sent2469 in O
sent2469 three O
sent2469 species O
sent2469 of O
sent2469 burying O
sent2469 beetles O
sent2469 in O
sent2469 the O
sent2469 genus O
sent2469 Nicrophorus O
sent2469 ( O
sent2469 Coleoptera O
sent2469 : O
sent2469 Silphidae O
sent2469 ) O
sent2470 The O
sent2470 importance O
sent2470 of O
sent2470 patient O
sent2470 registration O
sent2470 and O
sent2470 processing O
sent2471 Dose-dependent O
sent2471 effects O
sent2471 of O
sent2471 recombinant O
sent2471 human O
sent2471 interleukin-6 O
sent2471 on O
sent2471 glucose O
sent2471 regulation O
sent2472 Genomic O
sent2472 sequence O
sent2472 of O
sent2472 a O
sent2472 Lyme D
sent2472 disease D
sent2472 spirochaete O
sent2472 , O
sent2472 Borrelia O
sent2472 burgdorferi O
sent2473 Interaction O
sent2473 between O
sent2473 electronic O
sent2473 article O
sent2473 surveillance O
sent2473 systems O
sent2473 and O
sent2473 implantable O
sent2473 defibrillators O
sent2473 : O
sent2473 insights O
sent2473 from O
sent2473 a O
sent2473 fourth O
sent2473 generation O
sent2473 ICD O
sent2474 Human O
sent2474 bodily O
sent2474 health O
sent2474 and O
sent2474 the O
sent2474 common O
sent2474 good O
sent2475 Proposals O
sent2475 for O
sent2475 action O
sent2475 by O
sent2475 individuals O
sent2475 and O
sent2475 the O
sent2475 Catholic O
sent2475 Church O
sent2476 Invited O
sent2476 commentary O
sent2476 : O
sent2476 le O
sent2476 mystère O
sent2476 de O
sent2476 Montr O
sent2476 ( O
sent2476 c O
sent2476 ) O
sent2476 al O
sent2476 . O
sent2477 Why O
sent2477 Oedipus O
sent2477 and O
sent2477 not O
sent2477 Christ O
sent2477 ? O
sent2477 : O
sent2477 a O
sent2477 psychoanalytic O
sent2477 inquiry O
sent2477 into O
sent2477 innocence O
sent2477 , O
sent2477 human O
sent2477 sacrifice O
sent2477 , O
sent2477 and O
sent2477 the O
sent2477 sacred O
sent2477 -- O
sent2477 Part O
sent2477 I O
sent2477 : O
sent2477 Innocence O
sent2477 , O
sent2477 spirituality O
sent2477 , O
sent2477 and O
sent2477 human O
sent2477 sacrifice O
sent2478 Equine O
sent2478 dinucleotide O
sent2478 repeat O
sent2478 loci O
sent2478 LEX049-LEX063 O
sent2479 Molecular O
sent2479 systematics O
sent2479 of O
sent2479 tanagers O
sent2479 ( O
sent2479 Thraupinae O
sent2479 ) O
sent2479 : O
sent2479 evolution O
sent2479 and O
sent2479 biogeography O
sent2479 of O
sent2479 a O
sent2479 diverse O
sent2479 radiation O
sent2479 of O
sent2479 neotropical O
sent2479 birds O
sent2480 Expression O
sent2480 of O
sent2480 cytokeratin O
sent2480 20 O
sent2480 in O
sent2480 urinary O
sent2480 cytology O
sent2480 of O
sent2480 patients O
sent2480 with O
sent2480 bladder D
sent2480 carcinoma D
sent2481 A O
sent2481 family O
sent2481 of O
sent2481 highly O
sent2481 repetitive O
sent2481 DNAs O
sent2481 from O
sent2481 `` O
sent2481 ginbuna O
sent2481 '' O
sent2481 ( O
sent2481 Carassius O
sent2481 auratus O
sent2481 langsdorfi O
sent2481 ) O
sent2481 genome O
sent2481 common O
sent2481 to O
sent2481 Carassius O
sent2481 auratus O
sent2481 populations O
sent2482 Characterization O
sent2482 of O
sent2482 cDNA O
sent2482 clones O
sent2482 in O
sent2482 size-fractionated O
sent2482 cDNA O
sent2482 libraries O
sent2482 from O
sent2482 human O
sent2482 brain O
sent2483 < O
sent2483 TO_SEE O
sent2483 > O
sent2483 Respiratory O
sent2483 arrest O
sent2483 following O
sent2483 peribulbar O
sent2483 anesthesia O
sent2483 for O
sent2483 cataract O
sent2483 surgery O
sent2483 : O
sent2483 case O
sent2483 report O
sent2483 and O
sent2483 review O
sent2483 of O
sent2483 the O
sent2483 literature O
sent2484 Mouse O
sent2484 LIM-kinase O
sent2484 2 O
sent2484 gene O
sent2484 : O
sent2484 cDNA O
sent2484 cloning O
sent2484 , O
sent2484 genomic O
sent2484 organization O
sent2484 , O
sent2484 and O
sent2484 tissue-specific O
sent2484 expression O
sent2484 of O
sent2484 two O
sent2484 alternatively O
sent2484 initiated O
sent2484 transcripts O
sent2485 A O
sent2485 gross O
sent2485 and O
sent2485 microscopic O
sent2485 study O
sent2485 of O
sent2485 cerebral D
sent2485 injuries D
sent2485 accompanying O
sent2485 maxillofacial O
sent2485 high-velocity O
sent2485 projectile D
sent2485 wounding D
sent2485 in O
sent2485 dogs O
sent2486 Does O
sent2486 this O
sent2486 patient O
sent2486 have O
sent2486 a O
sent2486 mole O
sent2486 or O
sent2486 a O
sent2486 melanoma D
sent2486 ? O
sent2487 Methotrexate T
sent2487 and O
sent2487 trimethoprim T
sent2487 : O
sent2487 a O
sent2487 fatal O
sent2487 interaction O
sent2488 Pellagra D
sent2488 and O
sent2488 the O
sent2488 origin O
sent2488 of O
sent2488 a O
sent2488 myth O
sent2488 : O
sent2488 evidence O
sent2488 from O
sent2488 European O
sent2488 literature O
sent2488 and O
sent2488 folklore O
sent2489 Absorbable T
sent2489 suture T
sent2489 technique T
sent2489 : O
sent2489 solution O
sent2489 to O
sent2489 the O
sent2489 growth O
sent2489 problem O
sent2489 in O
sent2489 pediatric O
sent2489 pacing O
sent2489 with O
sent2489 endocardial O
sent2489 leads O
sent2490 Undergraduate O
sent2490 orthodontic O
sent2490 education O
sent2490 : O
sent2490 what O
sent2490 should O
sent2490 we O
sent2490 teach O
sent2490 rather O
sent2490 than O
sent2490 what O
sent2490 can O
sent2490 we O
sent2490 teach O
sent2490 ? O
sent2491 Genetic O
sent2491 variation O
sent2491 in O
sent2491 the O
sent2491 dimorphic O
sent2491 regions O
sent2491 of O
sent2491 RAP-1 O
sent2491 genes O
sent2491 and O
sent2491 rap-1 O
sent2491 loci O
sent2491 of O
sent2491 Babesia D
sent2491 bigemina D
sent2492 History O
sent2492 -- O
sent2492 a O
sent2492 living O
sent2492 museum O
sent2493 Interview O
sent2493 by O
sent2493 Grethe O
sent2493 Kjaergaard O
sent2494 Gastric O
sent2494 site O
sent2494 of O
sent2494 epidermoid D
sent2494 carcinoma D
sent2495 Hypodermic O
sent2495 needles O
sent2495 in O
sent2495 the O
sent2495 neuropathic O
sent2495 foot O
sent2495 of O
sent2495 a O
sent2495 patient O
sent2495 with O
sent2495 diabetes D
sent2496 Helicobacter O
sent2496 pylori O
sent2496 -- O
sent2496 more O
sent2496 light O
sent2496 , O
sent2496 less O
sent2496 heat O
sent2497 A O
sent2497 national O
sent2497 survey O
sent2497 of O
sent2497 physician-assisted O
sent2497 suicide O
sent2497 and O
sent2497 euthanasia O
sent2497 in O
sent2497 the O
sent2497 United O
sent2497 States O
sent2498 Death O
sent2498 is O
sent2498 a O
sent2498 journey O
sent2498 to O
sent2498 be O
sent2498 undertaken O
sent2499 Replicated O
sent2499 declines O
sent2499 in O
sent2499 assault O
sent2499 rates O
sent2499 after O
sent2499 implementation O
sent2499 of O
sent2499 the O
sent2499 Assaulted O
sent2499 Staff O
sent2499 Action O
sent2499 Program O
sent2500 Positive O
sent2500 patch O
sent2500 test O
sent2500 to O
sent2500 cocamidopropyl O
sent2500 betaine O
sent2500 in O
sent2500 a O
sent2500 hairdresser O
sent2501 Management O
sent2501 of O
sent2501 dyslipidemia D
sent2501 in O
sent2501 adults O
sent2501 with O
sent2501 diabetes D
sent2502 American O
sent2502 Diabetes O
sent2502 Association O
sent2503 Acute D
sent2503 diverticulitis D
sent2504 Investigation O
sent2504 of O
sent2504 the O
sent2504 yeast O
sent2504 mitochondrial O
sent2504 unselective O
sent2504 channel O
sent2504 in O
sent2504 intact O
sent2504 and O
sent2504 permeabilized O
sent2504 spheroplasts O
sent2505 Acute D
sent2505 sciatica D
sent2505 with O
sent2505 an O
sent2505 infective O
sent2505 cause O
sent2506 An O
sent2506 ecologic O
sent2506 analysis O
sent2506 of O
sent2506 psychosocial D
sent2506 stress D
sent2506 and O
sent2506 heart D
sent2506 disease D
sent2506 in O
sent2506 British O
sent2506 Columbia O
sent2507 Human O
sent2507 leukocyte O
sent2507 antigen O
sent2507 frequencies O
sent2507 in O
sent2507 a O
sent2507 selected O
sent2507 group O
sent2507 of O
sent2507 Lebanese O
sent2507 Greek O
sent2507 Orthodox O
sent2508 Alcohol O
sent2508 and O
sent2508 the O
sent2508 heart O
sent2509 Spontaneous D
sent2509 ovarian D
sent2509 hyperstimulation D
sent2509 syndrome D
sent2509 with O
sent2509 pregnancy O
sent2510 Will O
sent2510 the O
sent2510 real O
sent2510 plastic O
sent2510 surgeon O
sent2510 please O
sent2510 stand O
sent2510 up O
sent2510 ? O
sent2511 Modulation O
sent2511 of O
sent2511 ultraviolet O
sent2511 light-induced O
sent2511 epidermal D
sent2511 damage D
sent2511 : O
sent2511 beneficial O
sent2511 effects O
sent2511 of O
sent2511 tocopherol T
sent2512 A O
sent2512 survey O
sent2512 of O
sent2512 the O
sent2512 attitudes O
sent2512 of O
sent2512 chronic O
sent2512 psychiatric O
sent2512 patients O
sent2512 living O
sent2512 in O
sent2512 the O
sent2512 community O
sent2512 toward O
sent2512 their O
sent2512 medication O
sent2513 Alterations O
sent2513 in O
sent2513 the O
sent2513 developing O
sent2513 immune O
sent2513 system O
sent2513 of O
sent2513 the O
sent2513 F344 O
sent2513 rat O
sent2513 after O
sent2513 perinatal O
sent2513 exposure O
sent2513 to O
sent2513 2 O
sent2513 , O
sent2513 3 O
sent2513 , O
sent2513 7 O
sent2513 , O
sent2513 8-tetrachlorodibenzo-p-dioxin O
sent2513 : O
sent2513 II O
sent2514 Effects O
sent2514 on O
sent2514 the O
sent2514 pup O
sent2514 and O
sent2514 the O
sent2514 adult O
sent2515 Renal O
sent2515 ultrasonography O
sent2515 : O
sent2515 a O
sent2515 procedure O
sent2515 for O
sent2515 nephrologists O
sent2516 Use O
sent2516 of O
sent2516 cisapride T
sent2516 in O
sent2516 treatment O
sent2516 of O
sent2516 constipation D
sent2516 in O
sent2516 children O
sent2517 Bilateral O
sent2517 sampling O
sent2517 of O
sent2517 the O
sent2517 internal O
sent2517 jugular O
sent2517 vein O
sent2517 to O
sent2517 distinguish O
sent2517 between O
sent2517 mechanisms O
sent2517 of O
sent2517 adrenocorticotropic O
sent2517 hormone-dependent O
sent2517 Cushing D
sent2517 syndrome D
sent2518 The O
sent2518 influence O
sent2518 of O
sent2518 patients O
sent2518 ' O
sent2518 hopes O
sent2518 of O
sent2518 receiving O
sent2518 a O
sent2518 prescription O
sent2518 on O
sent2518 doctors O
sent2518 ' O
sent2518 perceptions O
sent2518 and O
sent2518 the O
sent2518 decision O
sent2518 to O
sent2518 prescribe O
sent2518 : O
sent2518 a O
sent2518 questionnaire O
sent2518 survey O
sent2519 Coronary D
sent2519 endothelial D
sent2519 dysfunction D
sent2519 in O
sent2519 humans O
sent2519 is O
sent2519 associated O
sent2519 with O
sent2519 myocardial D
sent2519 perfusion D
sent2519 defects D
sent2520 Medical O
sent2520 devices O
sent2520 and O
sent2520 the O
sent2520 year O
sent2520 2000 O
sent2520 problem O
sent2521 Internists O
sent2521 ' O
sent2521 and O
sent2521 surgeons O
sent2521 ' O
sent2521 attitudes O
sent2521 toward O
sent2521 guns O
sent2521 and O
sent2521 firearm O
sent2521 injury O
sent2521 prevention O
sent2522 Firearm O
sent2522 injury O
sent2522 prevention O
sent2523 American O
sent2523 College O
sent2523 of O
sent2523 Physicians O
sent2524 Management O
sent2524 of O
sent2524 vaginal D
sent2524 vault D
sent2524 prolapse D
sent2525 Death O
sent2525 rates O
sent2525 of O
sent2525 characters O
sent2525 in O
sent2525 soap O
sent2525 operas O
sent2525 on O
sent2525 British O
sent2525 television O
sent2525 : O
sent2525 is O
sent2525 a O
sent2525 government O
sent2525 health O
sent2525 warning O
sent2525 required O
sent2525 ? O
sent2526 Child O
sent2526 sexual O
sent2526 abuse O
sent2526 : O
sent2526 when O
sent2526 a O
sent2526 doctor O
sent2526 's O
sent2526 duty O
sent2526 to O
sent2526 report O
sent2526 abuse O
sent2526 conflicts O
sent2526 with O
sent2526 a O
sent2526 duty O
sent2526 of O
sent2526 confidentiality O
sent2526 to O
sent2526 the O
sent2526 victim O
sent2527 Tissue O
sent2527 adhesives O
sent2527 -- O
sent2527 revisited O
sent2528 Racial O
sent2528 discrimination O
sent2528 in O
sent2528 the O
sent2528 allocation O
sent2528 of O
sent2528 distinction O
sent2528 awards O
sent2528 ? O
sent2528 Analysis O
sent2528 of O
sent2528 list O
sent2528 of O
sent2528 award O
sent2528 holders O
sent2528 by O
sent2528 type O
sent2528 of O
sent2528 award O
sent2528 , O
sent2528 specialty O
sent2528 and O
sent2528 region O
sent2529 Multicenter O
sent2529 study O
sent2529 of O
sent2529 surfactant T
sent2529 ( T
sent2529 beractant T
sent2529 ) T
sent2529 use O
sent2529 in O
sent2529 the O
sent2529 treatment O
sent2529 of O
sent2529 term O
sent2529 infants O
sent2529 with O
sent2529 severe D
sent2529 respiratory D
sent2529 failure D
sent2530 Survanta O
sent2530 in O
sent2530 Term O
sent2530 Infants O
sent2530 Study O
sent2530 Group O
sent2531 Consultation O
sent2531 section O
sent2532 Cataract D
sent2532 surgical O
sent2532 problem O
sent2533 Changing O
sent2533 the O
sent2533 law O
sent2533 on O
sent2533 decision O
sent2533 making O
sent2533 for O
sent2533 mentally O
sent2533 incapacitated O
sent2533 adults O
sent2534 The O
sent2534 coding O
sent2534 audit O
sent2535 Providing O
sent2535 primary O
sent2535 care O
sent2535 in O
sent2535 the O
sent2535 accident O
sent2535 and O
sent2535 emergency O
sent2535 department O
sent2536 Challenges O
sent2536 to O
sent2536 Native O
sent2536 American O
sent2536 health O
sent2536 care O
sent2537 Federal O
sent2537 programs O
sent2537 and O
sent2537 Indian O
sent2537 country O
sent2537 : O
sent2537 a O
sent2537 time O
sent2537 for O
sent2537 reinvention O
sent2538 Chicago O
sent2538 report O
sent2538 profiles O
sent2539 Big O
sent2539 city O
sent2539 health O
sent2540 College-age O
sent2540 drinking O
sent2540 problems O
sent2541 Using O
sent2541 YPLL O
sent2541 in O
sent2541 health O
sent2541 planning O
sent2542 WHO O
sent2542 decides O
sent2542 : O
sent2542 food O
sent2542 irradiation O
sent2542 safe O
sent2542 at O
sent2542 any O
sent2542 level O
sent2543 Genetic O
sent2543 sampling O
sent2543 : O
sent2543 big O
sent2543 brother O
sent2543 or O
sent2543 big O
sent2543 science O
sent2543 ? O
sent2544 Physician O
sent2544 assistants O
sent2544 and O
sent2544 nurse O
sent2544 practitioners O
sent2544 in O
sent2544 hospital O
sent2544 outpatient O
sent2544 departments O
sent2544 , O
sent2544 1993-1994 O
sent2545 Laying O
sent2545 the O
sent2545 foundation O
sent2545 for O
sent2545 Healthy O
sent2545 People O
sent2545 2010 O
sent2546 The O
sent2546 first O
sent2546 year O
sent2546 of O
sent2546 consultation O
sent2547 The O
sent2547 veracious O
sent2547 etiology O
sent2547 of O
sent2547 ectopic D
sent2547 pregnancy D
sent2548 Is O
sent2548 dietary O
sent2548 fat O
sent2548 a O
sent2548 major O
sent2548 determinant O
sent2548 of O
sent2548 body O
sent2548 fat O
sent2548 ? O
sent2549 Factors O
sent2549 involved O
sent2549 in O
sent2549 the O
sent2549 rate O
sent2549 of O
sent2549 fall O
sent2549 of O
sent2549 thyroid O
sent2549 stimulating O
sent2549 hormone O
sent2549 in O
sent2549 treated O
sent2549 hypothyroidism D
sent2550 Case O
sent2550 complexity O
sent2551 Imaging O
sent2551 pulmonary D
sent2551 embolism D
sent2552 Early O
sent2552 inpatient O
sent2552 rehabilitation O
sent2552 after O
sent2552 elective O
sent2552 hip O
sent2552 and O
sent2552 knee O
sent2552 arthroplasty T
sent2553 Inpatient O
sent2553 rehabilitation O
sent2553 after O
sent2553 total O
sent2553 joint T
sent2553 replacement T
sent2554 Delayed O
sent2554 healing O
sent2554 of O
sent2554 rhytidectomy T
sent2554 flap O
sent2554 resurfaced O
sent2554 with O
sent2554 CO2 O
sent2554 laser O
sent2555 The O
sent2555 SAPHO D
sent2555 syndrome D
sent2555 : O
sent2555 an O
sent2555 evolving O
sent2555 concept O
sent2555 for O
sent2555 unifying O
sent2555 several O
sent2555 idiopathic O
sent2555 disorders O
sent2555 of O
sent2555 bone O
sent2555 and O
sent2555 skin O
sent2556 Beverage O
sent2556 use O
sent2556 and O
sent2556 risk O
sent2556 for O
sent2556 kidney D
sent2556 stones D
sent2556 in O
sent2556 women O
sent2557 Use O
sent2557 of O
sent2557 a O
sent2557 Foley O
sent2557 catheter O
sent2557 in O
sent2557 the O
sent2557 removal O
sent2557 of O
sent2557 a O
sent2557 substernal D
sent2557 goiter D
sent2558 Early O
sent2558 identification O
sent2558 of O
sent2558 variant O
sent2558 Creutzfeldt-Jakob D
sent2558 disease D
sent2559 Slater O
sent2559 revisited O
sent2559 : O
sent2559 6 O
sent2559 year O
sent2559 follow O
sent2559 up O
sent2559 study O
sent2559 of O
sent2559 patients O
sent2559 with O
sent2559 medically O
sent2559 unexplained O
sent2559 motor D
sent2559 symptoms D
sent2560 Re O
sent2560 : O
sent2560 Intermediate O
sent2560 term O
sent2560 assessment O
sent2560 of O
sent2560 the O
sent2560 reliability O
sent2560 , O
sent2560 function O
sent2560 and O
sent2560 patient O
sent2560 satisfaction O
sent2560 with O
sent2560 the O
sent2560 AMS700 O
sent2560 ultrex O
sent2560 penile O
sent2560 prosthesis O
sent2561 Reduced O
sent2561 ratio O
sent2561 of O
sent2561 male O
sent2561 to O
sent2561 female O
sent2561 births O
sent2561 in O
sent2561 several O
sent2561 industrial O
sent2561 countries O
sent2561 : O
sent2561 a O
sent2561 sentinel O
sent2561 health O
sent2561 indicator O
sent2561 ? O
sent2562 Should O
sent2562 we O
sent2562 accept O
sent2562 mediocrity O
sent2562 ? O
sent2563 Resolution O
sent2563 of O
sent2563 recalcitrant D
sent2563 molluscum D
sent2563 contagiosum D
sent2563 virus D
sent2563 lesions D
sent2563 in O
sent2563 human O
sent2563 immunodeficiency O
sent2563 virus-infected O
sent2563 patients O
sent2563 treated O
sent2563 with O
sent2563 cidofovir T
sent2564 Colonoscopic O
sent2564 removal O
sent2564 of O
sent2564 chicken O
sent2564 bones O
sent2564 impacted O
sent2564 in O
sent2564 the O
sent2564 sigmoid O
sent2564 in O
sent2564 two O
sent2564 patients O
sent2565 `` O
sent2565 Pull O
sent2565 '' O
sent2565 or O
sent2565 `` O
sent2565 push O
sent2565 '' O
sent2565 PEG O
sent2565 : O
sent2565 the O
sent2565 reinsertion O
sent2565 of O
sent2565 the O
sent2565 gastroscope O
sent2565 is O
sent2565 often O
sent2565 unnecessary O
sent2566 Clear D
sent2566 cell D
sent2566 papulosis D
sent2566 : O
sent2566 case O
sent2566 report O
sent2566 and O
sent2566 literature O
sent2566 review O
sent2567 Malignant D
sent2567 melanoma D
sent2567 in O
sent2567 situ O
sent2567 : O
sent2567 an O
sent2567 oxymoron O
sent2567 whose O
sent2567 time O
sent2567 has O
sent2567 come O
sent2568 External T
sent2568 beam T
sent2568 radiation T
sent2568 therapy T
sent2568 for O
sent2568 choroidal D
sent2568 neovascularization D
sent2569 Somatic O
sent2569 mesoderm O
sent2569 differentiation O
sent2569 and O
sent2569 the O
sent2569 development O
sent2569 of O
sent2569 a O
sent2569 subset O
sent2569 of O
sent2569 pericardial O
sent2569 cells O
sent2569 depend O
sent2569 on O
sent2569 the O
sent2569 not O
sent2569 enough O
sent2569 muscles O
sent2569 ( O
sent2569 nem O
sent2569 ) O
sent2569 locus O
sent2569 , O
sent2569 which O
sent2569 contains O
sent2569 the O
sent2569 inscuteable O
sent2569 gene O
sent2569 and O
sent2569 the O
sent2569 intron O
sent2569 located O
sent2569 gene O
sent2569 , O
sent2569 skittles O
sent2570 Hemodynamic O
sent2570 effects O
sent2570 of O
sent2570 acute O
sent2570 tetrandrine O
sent2570 and O
sent2570 terlipressin O
sent2570 administration O
sent2570 on O
sent2570 portal O
sent2570 hypertensive O
sent2570 rats O
sent2571 Nonneoplastic D
sent2571 disorders D
sent2571 of D
sent2571 the D
sent2571 eccrine D
sent2571 glands D
sent2572 Cerebrospinal O
sent2572 fluid O
sent2572 and O
sent2572 plasma O
sent2572 insulin O
sent2572 levels O
sent2572 in O
sent2572 Alzheimer D
sent2572 's D
sent2572 disease D
sent2572 : O
sent2572 relationship O
sent2572 to O
sent2572 severity O
sent2572 of O
sent2572 dementia D
sent2572 and O
sent2572 apolipoprotein O
sent2572 E O
sent2572 genotype O
sent2573 Isolated O
sent2573 internal D
sent2573 ophthalmoplegia D
sent2573 associated O
sent2573 with O
sent2573 IgG O
sent2573 anti-GQ1b O
sent2573 antibody O
sent2574 Bolus T
sent2574 thrombolytic T
sent2574 infusions T
sent2574 during O
sent2574 CPR O
sent2574 for O
sent2574 patients O
sent2574 with O
sent2574 refractory D
sent2574 arrest D
sent2574 rhythms D
sent2574 : O
sent2574 outcome O
sent2574 of O
sent2574 a O
sent2574 case O
sent2574 series O
sent2575 Enthesopathy D
sent2575 in O
sent2575 a O
sent2575 case O
sent2575 of O
sent2575 primary D
sent2575 biliary D
sent2575 cirrhosis D
sent2575 with O
sent2575 positive O
sent2575 HLA-B27 O
sent2576 Remifentanil T
sent2576 in O
sent2576 the O
sent2576 critically O
sent2576 ill O
sent2577 Hyponatremia D
sent2577 with O
sent2577 venlafaxine T
sent2577 . O
sent2578 Use O
sent2578 of O
sent2578 a O
sent2578 nerve T
sent2578 stimulator T
sent2578 for O
sent2578 phrenic D
sent2578 nerve D
sent2578 block D
sent2578 in O
sent2578 treatment O
sent2578 of O
sent2578 hiccups D
sent2579 Anaesthesia O
sent2579 for O
sent2579 laparoscopic T
sent2579 cholecystectomy T
sent2579 in O
sent2579 a O
sent2579 patient O
sent2579 with O
sent2579 Eisenmenger D
sent2579 's D
sent2579 syndrome D
sent2580 Micronutrients T
sent2580 and O
sent2580 human O
sent2580 cancer D
sent2580 risks D
sent2580 -- O
sent2580 prospects O
sent2580 for O
sent2580 prevention O
sent2581 Joint O
sent2581 International O
sent2581 Symposium O
sent2581 of O
sent2581 the O
sent2581 Danish O
sent2581 Cancer O
sent2581 Society O
sent2581 , O
sent2581 European O
sent2581 Cancer O
sent2581 Prevention O
sent2581 Organization O
sent2581 and O
sent2581 National O
sent2581 Food O
sent2581 Agency O
sent2581 of O
sent2581 Denmark O
sent2582 Aarhus O
sent2582 , O
sent2582 Denmark O
sent2582 , O
sent2582 21-24 O
sent2582 May O
sent2582 1997 O
sent2583 Abstracts O
sent2584 Vitamin O
sent2584 K2 O
sent2584 and O
sent2584 serum O
sent2584 cholesterol O
sent2584 in O
sent2584 patients O
sent2584 on O
sent2584 continuous O
sent2584 ambulatory O
sent2584 peritoneal T
sent2584 dialysis T
sent2585 Income O
sent2585 inequality O
sent2585 and O
sent2585 population O
sent2585 health O
sent2586 Naloxone T
sent2586 -precipitated O
sent2586 acute D
sent2586 opioid D
sent2586 withdrawal D
sent2586 syndrome D
sent2586 after O
sent2586 epidural T
sent2586 morphine T
sent2587 Idiopathic D
sent2587 atrial D
sent2587 flutter D
sent2588 Munchausen D
sent2588 's D
sent2588 syndrome D
sent2589 Clinical O
sent2589 evaluation O
sent2589 of O
sent2589 adjuvant T
sent2589 chemoradiotherapy T
sent2589 with T
sent2589 CDDP T
sent2589 , T
sent2589 5-FU T
sent2589 , T
sent2589 and T
sent2589 VP-16 T
sent2589 for O
sent2589 advanced D
sent2589 esophageal D
sent2589 cancer D
sent2590 New T
sent2590 drug T
sent2590 treatment T
sent2590 for O
sent2590 Alzheimer D
sent2590 's D
sent2590 disease D
sent2590 : O
sent2590 lessons O
sent2590 for O
sent2590 healthcare O
sent2590 policy O
sent2591 Development O
sent2591 of O
sent2591 neurosurgery T
sent2591 in O
sent2591 Greece O
sent2591 : O
sent2591 past O
sent2591 , O
sent2591 present O
sent2591 , O
sent2591 and O
sent2591 future O
sent2592 Intravascular-catheter-related D
sent2592 infections D
sent2593 The O
sent2593 effect O
sent2593 of O
sent2593 a O
sent2593 social O
sent2593 support O
sent2593 boosting O
sent2593 intervention O
sent2593 on O
sent2593 stress O
sent2593 , O
sent2593 coping O
sent2593 , O
sent2593 and O
sent2593 social O
sent2593 support O
sent2593 in O
sent2593 caregivers O
sent2593 of O
sent2593 children O
sent2593 with O
sent2593 HIV/AIDS D
sent2594 Point-counterpoint O
sent2595 Mass O
sent2595 population O
sent2595 skin D
sent2595 cancer D
sent2595 screening O
sent2595 is O
sent2595 not O
sent2595 worthwhile O
sent2596 Persons O
sent2596 successful O
sent2596 at O
sent2596 long-term O
sent2596 weight O
sent2596 loss O
sent2596 and O
sent2596 maintenance O
sent2596 continue O
sent2596 to O
sent2596 consume O
sent2596 a O
sent2596 low-energy O
sent2596 , O
sent2596 low-fat O
sent2596 diet O
sent2597 Ultrasound O
sent2597 measurements O
sent2597 of O
sent2597 the O
sent2597 newborn O
sent2597 hip O
sent2598 Comparison O
sent2598 of O
sent2598 two O
sent2598 methods O
sent2598 in O
sent2598 657 O
sent2598 newborns O
sent2599 Inferences O
sent2599 from O
sent2599 symphysiotomy T
sent2599 experience O
sent2600 1995 O
sent2600 coronary T
sent2600 artery T
sent2600 bypass T
sent2600 risk O
sent2600 model O
sent2600 : O
sent2600 The O
sent2600 Society O
sent2600 of O
sent2600 Thoracic O
sent2600 Surgeons O
sent2600 Adult O
sent2600 Cardiac O
sent2600 National O
sent2600 Database O
sent2601 Informed O
sent2601 consent O
sent2601 : O
sent2601 edging O
sent2601 forwards O
sent2601 ( O
sent2601 and O
sent2601 backwards O
sent2601 ) O
sent2602 Online O
sent2602 medical O
sent2602 surveys O
sent2602 : O
sent2602 using O
sent2602 the O
sent2602 Internet O
sent2602 as O
sent2602 a O
sent2602 research O
sent2602 tool O
sent2603 US-guided O
sent2603 puncture O
sent2603 of O
sent2603 the O
sent2603 internal O
sent2603 jugular O
sent2603 vein O
sent2603 : O
sent2603 complications O
sent2603 and O
sent2603 anatomic O
sent2603 considerations O
sent2604 Mouth O
sent2604 care O
sent2604 and O
sent2604 skin O
sent2604 care O
sent2604 in O
sent2604 palliative O
sent2604 medicine O
sent2605 Simple O
sent2605 antiseptic T
sent2605 mouthwashes T
sent2605 are O
sent2605 best O
sent2605 for O
sent2605 infection D
sent2606 The O
sent2606 effect O
sent2606 of O
sent2606 melatonin O
sent2606 administration O
sent2606 on O
sent2606 ethanol-induced O
sent2606 lipid O
sent2606 peroxidation O
sent2606 in O
sent2606 rats O
sent2607 A O
sent2607 comparison O
sent2607 of O
sent2607 aspirin T
sent2607 plus T
sent2607 tirofiban T
sent2607 with O
sent2607 aspirin T
sent2607 plus T
sent2607 heparin T
sent2607 for O
sent2607 unstable D
sent2607 angina D
sent2608 Platelet O
sent2608 Receptor O
sent2608 Inhibition O
sent2608 in O
sent2608 Ischemic O
sent2608 Syndrome O
sent2608 Management O
sent2608 ( O
sent2608 PRISM O
sent2608 ) O
sent2608 Study O
sent2608 Investigators O
sent2609 Mike O
sent2609 Grace O
sent2609 talks O
sent2609 to O
sent2609 Mike O
sent2609 Joy O
sent2610 Interview O
sent2610 by O
sent2610 Mike O
sent2610 Grace O
sent2611 Multivalent O
sent2611 cations O
sent2611 depress O
sent2611 ligand O
sent2611 affinity O
sent2611 of O
sent2611 insulin-like O
sent2611 growth O
sent2611 factor-binding O
sent2611 proteins-3 O
sent2611 and O
sent2611 -5 O
sent2611 on O
sent2611 human O
sent2611 GM-10 O
sent2611 fibroblast O
sent2611 cell O
sent2611 surfaces O
sent2612 Effect O
sent2612 of O
sent2612 continuous O
sent2612 spinal O
sent2612 remifentanil O
sent2612 infusion O
sent2612 on O
sent2612 behaviour O
sent2612 and O
sent2612 spinal O
sent2612 glutamate O
sent2612 release O
sent2612 evoked O
sent2612 by O
sent2612 subcutaneous O
sent2612 formalin O
sent2612 in O
sent2612 the O
sent2612 rat O
sent2613 How O
sent2613 long O
sent2613 should O
sent2613 suction O
sent2613 drains O
sent2613 stay O
sent2613 in O
sent2613 after O
sent2613 breast T
sent2613 surgery T
sent2613 with O
sent2613 axillary T
sent2613 dissection T
sent2613 ? O
sent2614 Physicians O
sent2614 disciplined O
sent2614 for O
sent2614 sex-related O
sent2614 offenses O
sent2615 Something O
sent2615 from O
sent2615 nothing O
sent2615 : O
sent2615 the O
sent2615 evolution O
sent2615 and O
sent2615 utility O
sent2615 of O
sent2615 satellite O
sent2615 repeats O
sent2616 Sudden O
sent2616 death O
sent2616 in O
sent2616 young O
sent2616 athletes O
sent2616 : O
sent2616 screening O
sent2616 for O
sent2616 the O
sent2616 needle O
sent2616 in O
sent2616 a O
sent2616 haystack O
sent2617 Chemotherapy T
sent2617 alone T
sent2617 compared O
sent2617 with O
sent2617 chemotherapy T
sent2617 plus T
sent2617 radiotherapy T
sent2617 for O
sent2617 localized O
sent2617 intermediate- O
sent2617 and O
sent2617 high-grade O
sent2617 non-Hodgkin D
sent2617 's D
sent2617 lymphoma D
sent2618 < O
sent2618 TO_SEE O
sent2618 > O
sent2618 Prevention O
sent2618 of O
sent2618 a O
sent2618 first O
sent2618 stroke D
sent2618 by O
sent2618 transfusions T
sent2618 in O
sent2618 children O
sent2618 with O
sent2618 sickle O
sent2618 cell O
sent2618 anemia O
sent2618 and O
sent2618 abnormal O
sent2618 results O
sent2618 on O
sent2618 transcranial O
sent2618 Doppler O
sent2618 ultrasonography O
sent2619 HIV T
sent2619 vaccines T
sent2619 : O
sent2619 prospects O
sent2619 and O
sent2619 challenges O
sent2620 Occupation O
sent2620 : O
sent2620 the O
sent2620 keystone O
sent2620 of O
sent2620 a O
sent2620 curriculum O
sent2620 for O
sent2620 a O
sent2620 self-defined O
sent2620 profession O
sent2621 Touch O
sent2621 sensibility O
sent2621 in O
sent2621 the O
sent2621 breast O
sent2621 after O
sent2621 subcutaneous T
sent2621 mastectomy T
sent2621 and O
sent2621 immediate O
sent2621 reconstruction O
sent2621 with O
sent2621 a O
sent2621 prosthesis O
sent2622 Iatrogenic T
sent2622 ruptures T
sent2622 of O
sent2622 the O
sent2622 tracheobronchial O
sent2622 tree O
sent2623 Endoscopic T
sent2623 hemostasis T
sent2623 of O
sent2623 bleeding D
sent2623 duodenal D
sent2623 ulcer D
sent2623 in O
sent2623 a O
sent2623 child O
sent2623 with O
sent2623 Henoch-Schönlein D
sent2623 purpura D
sent2624 Classification O
sent2624 of O
sent2624 primary O
sent2624 gastric D
sent2624 lymphomas D
sent2624 according O
sent2624 to O
sent2624 histologic O
sent2624 features O
sent2625 SCIM O
sent2625 -- O
sent2625 spinal O
sent2625 cord O
sent2625 independence O
sent2625 measure O
sent2625 : O
sent2625 a O
sent2625 new O
sent2625 disability O
sent2625 scale O
sent2625 for O
sent2625 patients O
sent2625 with O
sent2625 spinal D
sent2625 cord D
sent2625 lesions D
sent2626 Molecular O
sent2626 analysis O
sent2626 of O
sent2626 cellulose O
sent2626 biosynthesis O
sent2626 in O
sent2626 Arabidopsis O
sent2627 Users O
sent2627 ' O
sent2627 guides O
sent2627 to O
sent2627 the O
sent2627 medical O
sent2627 literature O
sent2627 : O
sent2627 XIV O
sent2628 How O
sent2628 to O
sent2628 decide O
sent2628 on O
sent2628 the O
sent2628 applicability O
sent2628 of O
sent2628 clinical O
sent2628 trial O
sent2628 results O
sent2628 to O
sent2628 your O
sent2628 patient O
sent2629 Evidence-Based O
sent2629 Medicine O
sent2629 Working O
sent2629 Group O
sent2630 Hemispheric O
sent2630 difference O
sent2630 in O
sent2630 human O
sent2630 skin O
sent2630 color O
sent2631 Limitations O
sent2631 of O
sent2631 diagnostic O
sent2631 criteria O
sent2631 and O
sent2631 assessment O
sent2631 instruments O
sent2631 for O
sent2631 mental D
sent2631 disorders D
sent2632 Implications O
sent2632 for O
sent2632 research O
sent2632 and O
sent2632 policy O
sent2633 Causing O
sent2633 death O
sent2633 or O
sent2633 allowing O
sent2633 to O
sent2633 die O
sent2633 ? O
sent2633 Developments O
sent2633 in O
sent2633 the O
sent2633 law O
sent2634 Albumin O
sent2634 synthesis O
sent2634 rates O
sent2634 are O
sent2634 not O
sent2634 decreased O
sent2634 in O
sent2634 hypoalbuminemic D
sent2634 cachectic D
sent2634 cancer D
sent2634 patients O
sent2634 with O
sent2634 an O
sent2634 ongoing O
sent2634 acute-phase O
sent2634 protein O
sent2634 response O
sent2635 Brain-gut O
sent2635 axis O
sent2635 in O
sent2635 health O
sent2635 and O
sent2635 disease O
sent2636 Pins O
sent2636 and O
sent2636 Rubbers O
sent2636 Traction O
sent2636 System O
sent2637 A O
sent2637 specialist O
sent2637 nurse O
sent2637 can O
sent2637 replace O
sent2637 pre-registration O
sent2637 house O
sent2637 officers O
sent2637 in O
sent2637 the O
sent2637 surgical O
sent2637 pre-admission O
sent2637 clinic O
sent2638 Voluntary O
sent2638 death O
sent2638 : O
sent2638 a O
sent2638 comparison O
sent2638 of O
sent2638 terminal O
sent2638 dehydration D
sent2638 and O
sent2638 physician-assisted O
sent2638 suicide O
sent2639 Ionized O
sent2639 magnesium O
sent2639 in O
sent2639 serum O
sent2639 and O
sent2639 ultrafiltrate O
sent2639 : O
sent2639 pH O
sent2639 and O
sent2639 bicarbonate O
sent2639 effect O
sent2639 on O
sent2639 measurements O
sent2639 with O
sent2639 the O
sent2639 AVL O
sent2639 988-4 O
sent2639 electrolyte O
sent2639 analyzer O
sent2640 Anterior D
sent2640 glenohumeral D
sent2640 dislocations D
sent2640 : O
sent2640 what O
sent2640 to O
sent2640 do O
sent2640 and O
sent2640 how O
sent2640 to O
sent2640 do O
sent2640 it O
sent2641 Relationship O
sent2641 between O
sent2641 topotecan T
sent2641 systemic O
sent2641 exposure O
sent2641 and O
sent2641 tumor O
sent2641 response O
sent2641 in O
sent2641 human O
sent2641 neuroblastoma D
sent2641 xenografts D
sent2642 Cerebral D
sent2642 infarct D
sent2642 following O
sent2642 central T
sent2642 venous T
sent2642 cannulation T
sent2643 The O
sent2643 Gram O
sent2643 stain O
sent2644 Heavy O
sent2644 caffeine O
sent2644 intake O
sent2644 in O
sent2644 pregnancy O
sent2644 and O
sent2644 sudden D
sent2644 infant D
sent2644 death D
sent2644 syndrome D
sent2645 New O
sent2645 Zealand O
sent2645 Cot O
sent2645 Death O
sent2645 Study O
sent2645 Group O
sent2646 When O
sent2646 can O
sent2646 odds O
sent2646 ratios O
sent2646 mislead O
sent2646 ? O
sent2647 Treatment O
sent2647 of O
sent2647 renal D
sent2647 failure D
sent2647 in O
sent2647 idiopathic D
sent2647 membranous D
sent2647 nephropathy D
sent2647 with O
sent2647 azathioprine T
sent2647 and T
sent2647 prednisolone T
sent2648 Enzyme O
sent2648 structure O
sent2648 with O
sent2648 two O
sent2648 catalytic O
sent2648 sites O
sent2648 for O
sent2648 double-sieve O
sent2648 selection O
sent2648 of O
sent2648 substrate O
sent2649 Role O
sent2649 of O
sent2649 the O
sent2649 ketogenic T
sent2649 diet T
sent2649 in O
sent2649 children O
sent2649 with O
sent2649 intractable D
sent2649 seizures D
sent2649 . O
sent2650 Building-associated O
sent2650 pulmonary D
sent2650 disease D
sent2650 from O
sent2650 exposure O
sent2650 to O
sent2650 Stachybotrys O
sent2650 chartarum O
sent2650 and O
sent2650 Aspergillus O
sent2650 versicolor O
sent2651 Interleukin-8 O
sent2651 participates O
sent2651 in O
sent2651 angiogenesis O
sent2651 in O
sent2651 non-small O
sent2651 cell O
sent2651 , O
sent2651 but O
sent2651 not O
sent2651 small O
sent2651 cell O
sent2651 carcinoma D
sent2651 of O
sent2651 the O
sent2651 lung O
sent2652 Antenatal T
sent2652 indomethacin T
sent2652 -- O
sent2652 adverse O
sent2652 fetal O
sent2652 effects O
sent2652 confirmed O
sent2653 Evaluation O
sent2653 of O
sent2653 the O
sent2653 microparticle O
sent2653 enzyme O
sent2653 immunoassay O
sent2653 Abbott O
sent2653 IMx O
sent2653 Select O
sent2653 Chlamydia O
sent2653 and O
sent2653 the O
sent2653 importance O
sent2653 of O
sent2653 urethral O
sent2653 site O
sent2653 sampling O
sent2653 to O
sent2653 detect O
sent2653 Chlamydia D
sent2653 trachomatis D
sent2653 in O
sent2653 women O
sent2654 The O
sent2654 persistent O
sent2654 vegetative O
sent2654 state O
sent2654 after O
sent2654 closed D
sent2654 head D
sent2654 injury D
sent2654 : O
sent2654 clinical O
sent2654 and O
sent2654 magnetic O
sent2654 resonance O
sent2654 imaging O
sent2654 findings O
sent2654 in O
sent2654 42 O
sent2654 patients O
sent2655 Wegener D
sent2655 's D
sent2655 granulomatosis D
sent2655 of O
sent2655 the O
sent2655 head O
sent2655 and O
sent2655 neck O
sent2656 Chromosomal O
sent2656 abnormalities O
sent2656 of O
sent2656 a O
sent2656 new O
sent2656 nasopharyngeal D
sent2656 carcinoma D
sent2656 cell O
sent2656 line O
sent2656 ( O
sent2656 NPC-BM1 O
sent2656 ) O
sent2656 derived O
sent2656 from O
sent2656 a O
sent2656 bone D
sent2656 marrow D
sent2656 metastatic D
sent2656 lesion D
sent2657 Relation O
sent2657 between O
sent2657 intellectual D
sent2657 dysfunctioning D
sent2657 and O
sent2657 mortality O
sent2657 in O
sent2657 community-residing O
sent2657 older O
sent2657 people O
sent2658 Anxiety O
sent2658 and O
sent2658 autonomic O
sent2658 flexibility O
sent2658 : O
sent2658 a O
sent2658 cardiovascular O
sent2658 approach O
sent2659 Cross-reactivity O
sent2659 of O
sent2659 specific O
sent2659 antibodies O
sent2659 directed O
sent2659 to O
sent2659 heat O
sent2659 shock O
sent2659 proteins O
sent2659 from O
sent2659 periodontopathogenic O
sent2659 bacteria O
sent2659 and O
sent2659 of O
sent2659 human O
sent2659 origin O
sent2659 ( O
sent2659 corrected O
sent2659 ) O
sent2660 Immunogenicity O
sent2660 of O
sent2660 hepatitis D
sent2660 B D
sent2660 vaccine T
sent2660 in O
sent2660 term O
sent2660 and O
sent2660 preterm O
sent2660 infants O
sent2661 Secondary O
sent2661 prevention O
sent2661 for O
sent2661 stroke D
sent2661 after O
sent2661 CAPRIE T
sent2661 and T
sent2661 ESPS-2 T
sent2662 < O
sent2662 TO_SEE O
sent2662 > O
sent2662 New-onset O
sent2662 angina O
sent2662 preceding O
sent2662 acute O
sent2662 myocardial O
sent2662 infarction O
sent2662 is O
sent2662 associated O
sent2662 with O
sent2662 improved O
sent2662 contractile O
sent2662 recovery O
sent2662 after O
sent2662 thrombolysis O
sent2663 Magnetic O
sent2663 resonance O
sent2663 imaging O
sent2663 in O
sent2663 focal D
sent2663 myositis D
sent2664 Concomitant D
sent2664 alveolitis D
sent2664 and O
sent2664 asthma D
sent2664 following O
sent2664 exposure O
sent2664 to O
sent2664 triphenylmethane O
sent2664 triisocyanate O
sent2665 Gorlin D
sent2665 syndrome D
sent2665 : O
sent2665 identification O
sent2665 of O
sent2665 4 O
sent2665 novel O
sent2665 germ-line O
sent2665 mutations O
sent2665 of O
sent2665 the O
sent2665 human O
sent2665 patched O
sent2665 ( O
sent2665 PTCH O
sent2665 ) O
sent2665 gene O
sent2666 Mutations O
sent2666 in O
sent2666 brief O
sent2666 no O
sent2667 137 O
sent2668 Online O
sent2669 Genetic O
sent2669 findings O
sent2669 in O
sent2669 congenital D
sent2669 bilateral D
sent2669 aplasia D
sent2669 of O
sent2669 vas O
sent2669 deferens O
sent2669 patients O
sent2669 and O
sent2669 identification O
sent2669 of O
sent2669 six O
sent2669 novel O
sent2669 mutatations O
sent2670 Mutations O
sent2670 in O
sent2670 brief O
sent2670 no O
sent2671 138 O
sent2672 Online O
sent2673 A O
sent2673 novel O
sent2673 point O
sent2673 mutation O
sent2673 in O
sent2673 a O
sent2673 splice O
sent2673 acceptor O
sent2673 site O
sent2673 of O
sent2673 intron O
sent2673 1 O
sent2673 of O
sent2673 the O
sent2673 human O
sent2673 low O
sent2673 density O
sent2673 lipoprotein O
sent2673 receptor O
sent2673 gene O
sent2673 which O
sent2673 causes O
sent2673 severe O
sent2673 hypercholesterolemia D
sent2673 : O
sent2673 an O
sent2673 unexpected O
sent2673 absence O
sent2673 of O
sent2673 exon O
sent2673 skipping O
sent2674 Mutations O
sent2674 in O
sent2674 brief O
sent2674 no O
sent2675 139 O
sent2676 Online O
sent2677 A O
sent2677 de O
sent2677 novo O
sent2677 missense O
sent2677 mutation O
sent2677 ( O
sent2677 R1623Q O
sent2677 ) O
sent2677 of O
sent2677 the O
sent2677 SCN5A O
sent2677 gene O
sent2677 in O
sent2677 a O
sent2677 Japanese O
sent2677 girl O
sent2677 with O
sent2677 sporadic D
sent2677 long D
sent2677 QT D
sent2677 sydrome D
sent2678 Mutations O
sent2678 in O
sent2678 brief O
sent2678 no O
sent2679 140 O
sent2680 Online O
sent2681 Missense O
sent2681 mutation O
sent2681 in O
sent2681 exon O
sent2681 11 O
sent2681 ( O
sent2681 Codon O
sent2681 378 O
sent2681 ) O
sent2681 of O
sent2681 the O
sent2681 presenilin-1 O
sent2681 gene O
sent2681 in O
sent2681 a O
sent2681 French O
sent2681 family O
sent2681 with O
sent2681 early-onset O
sent2681 Alzheimer D
sent2681 's D
sent2681 disease D
sent2681 and O
sent2681 transmission O
sent2681 study O
sent2681 by O
sent2681 mismatch O
sent2681 enhanced O
sent2681 allele O
sent2681 specific O
sent2681 amplification O
sent2682 Mutations O
sent2682 in O
sent2682 brief O
sent2682 no O
sent2683 141 O
sent2684 Online O
sent2685 besancon O
sent2685 @ O
sent2685 rockefeller1.univ.lyon1.fr O
sent2686 Mutation O
sent2686 sharing O
sent2686 , O
sent2686 predominant O
sent2686 involvement O
sent2686 of O
sent2686 the O
sent2686 MLH1 O
sent2686 gene O
sent2686 and O
sent2686 description O
sent2686 of O
sent2686 four O
sent2686 novel O
sent2686 mutations O
sent2686 in O
sent2686 hereditary D
sent2686 nonpolyposis D
sent2686 colorectal D
sent2686 cancer D
sent2687 Mutations O
sent2687 in O
sent2687 brief O
sent2687 no O
sent2688 144 O
sent2689 Online O
sent2690 A O
sent2690 new O
sent2690 informative O
sent2690 Alw O
sent2690 26 O
sent2690 I O
sent2690 polymorphism O
sent2690 in O
sent2690 exon O
sent2690 10 O
sent2690 of O
sent2690 the O
sent2690 human O
sent2690 low O
sent2690 density O
sent2690 lipoprotein O
sent2690 receptor O
sent2690 gene O
sent2691 Application O
sent2691 to O
sent2691 prenatal O
sent2691 diagnosis O
sent2692 Mutations O
sent2692 in O
sent2692 brief O
sent2692 no O
sent2693 145 O
sent2694 Online O
sent2695 Novel O
sent2695 acceptor O
sent2695 splice O
sent2695 site O
sent2695 mutation O
sent2695 in O
sent2695 the O
sent2695 invariant O
sent2695 AG O
sent2695 of O
sent2695 intron O
sent2695 6 O
sent2695 of O
sent2695 alpha-galactosidase O
sent2695 A O
sent2695 gene O
sent2695 , O
sent2695 causing O
sent2695 Fabry D
sent2695 disease D
sent2696 Mutations O
sent2696 in O
sent2696 brief O
sent2696 no O
sent2697 146 O
sent2698 Online O
sent2699 Meta-analysis O
sent2699 of O
sent2699 trials O
sent2699 comparing O
sent2699 antidepressants T
sent2699 with O
sent2699 active O
sent2699 placebos O
sent2700 Evidence-based O
sent2700 guidelines O
sent2700 for O
sent2700 universal O
sent2700 counselling O
sent2700 and O
sent2700 offering O
sent2700 of O
sent2700 HIV O
sent2700 testing O
sent2700 in O
sent2700 pregnancy O
sent2700 in O
sent2700 Canada O
sent2701 Chelation T
sent2701 therapy T
sent2701 for O
sent2701 peripheral D
sent2701 arterial D
sent2701 occlusive D
sent2701 disease D
sent2701 : O
sent2701 a O
sent2701 systematic O
sent2701 review O
sent2702 < O
sent2702 TO_SEE O
sent2702 > O
sent2702 Sodium T
sent2702 channel T
sent2702 block T
sent2702 with T
sent2702 mexiletine T
sent2702 is O
sent2702 effective O
sent2702 in O
sent2702 reducing O
sent2702 dispersion O
sent2702 of O
sent2702 repolarization O
sent2702 and O
sent2702 preventing O
sent2702 torsade D
sent2702 des D
sent2702 pointes D
sent2702 in O
sent2702 LQT2 O
sent2702 and O
sent2702 LQT3 O
sent2702 models O
sent2702 of O
sent2702 the O
sent2702 long-QT O
sent2702 syndrome O
sent2703 Simultaneous O
sent2703 microsurgical T
sent2703 vasal T
sent2703 reconstruction T
sent2703 and O
sent2703 varicocele T
sent2703 ligation T
sent2703 : O
sent2703 safety O
sent2703 profile O
sent2703 and O
sent2703 outcomes O
sent2704 A O
sent2704 predetermined O
sent2704 design O
sent2704 for O
sent2704 easier O
sent2704 aesthetic T
sent2704 abdominoplasty T
sent2705 Significance O
sent2705 of O
sent2705 revision O
sent2705 of O
sent2705 the O
sent2705 occupational O
sent2705 illness O
sent2705 legislation O
sent2705 for O
sent2705 evaluating O
sent2705 intervertebral D
sent2705 disk D
sent2705 damage D
sent2706 Serum O
sent2706 urate O
sent2706 during O
sent2706 bouts O
sent2706 of O
sent2706 acute D
sent2706 gouty D
sent2706 arthritis D
sent2707 Isolated O
sent2707 axial O
sent2707 lateral O
sent2707 pulse O
sent2707 as O
sent2707 a O
sent2707 sign O
sent2707 of O
sent2707 latero-bulbar D
sent2707 ischemia D
sent2707 : O
sent2707 clinical O
sent2707 topographic O
sent2707 correlation O
sent2708 Microalbuminuria D
sent2708 is O
sent2708 positively O
sent2708 associated O
sent2708 with O
sent2708 usual O
sent2708 dietary O
sent2708 saturated O
sent2708 fat O
sent2708 intake O
sent2708 and O
sent2708 negatively O
sent2708 associated O
sent2708 with O
sent2708 usual O
sent2708 dietary O
sent2708 protein O
sent2708 intake O
sent2708 in O
sent2708 people O
sent2708 with O
sent2708 insulin-dependent D
sent2708 diabetes D
sent2708 mellitus D
sent2709 Endoscopic T
sent2709 ultrasound T
sent2709 miniprobe-guided T
sent2709 steroid T
sent2709 injection T
sent2709 for O
sent2709 treatment O
sent2709 of O
sent2709 refractory D
sent2709 esophageal D
sent2709 strictures D
sent2710 Purification O
sent2710 and O
sent2710 characterization O
sent2710 of O
sent2710 an O
sent2710 acetyl O
sent2710 xylan O
sent2710 esterase O
sent2710 from O
sent2710 Bacillus O
sent2710 pumilus O
sent2711 The O
sent2711 Stresst'er O
sent2711 ergometer O
sent2711 as O
sent2711 an O
sent2711 alternative O
sent2711 to O
sent2711 treadmill O
sent2711 testing O
sent2711 in O
sent2711 patients O
sent2711 with O
sent2711 claudication D
sent2712 Renal D
sent2712 trauma D
sent2712 and O
sent2712 the O
sent2712 risk O
sent2712 of O
sent2712 long-term O
sent2712 complications O
sent2712 in O
sent2712 shock T
sent2712 wave T
sent2712 lithotripsy T
sent2713 Current O
sent2713 management O
sent2713 of O
sent2713 corneal D
sent2713 abrasions D
sent2713 : O
sent2713 evidence O
sent2713 based O
sent2713 practice O
sent2713 ? O
sent2714 Placebo O
sent2714 in O
sent2714 drug O
sent2714 clinical O
sent2714 trials O
sent2715 Chromosome O
sent2715 22qII O
sent2715 deletions O
sent2716 An O
sent2716 under-recognised O
sent2716 cause O
sent2716 of O
sent2716 idiopathic D
sent2716 learning D
sent2716 disability D
sent2717 Serial O
sent2717 magnetic O
sent2717 resonance O
sent2717 imaging O
sent2717 findings O
sent2717 for O
sent2717 a O
sent2717 spontaneously O
sent2717 resolving O
sent2717 spinal D
sent2717 subdural D
sent2717 hematoma D
sent2717 : O
sent2717 case O
sent2717 report O
sent2718 A O
sent2718 simple O
sent2718 technique O
sent2718 for O
sent2718 correction O
sent2718 of O
sent2718 mucosal D
sent2718 irregularities D
sent2718 of D
sent2718 the D
sent2718 lip D
sent2719 Cancer D
sent2719 risk O
sent2719 in O
sent2719 the O
sent2719 rubber O
sent2719 industry O
sent2719 : O
sent2719 a O
sent2719 review O
sent2719 of O
sent2719 the O
sent2719 recent O
sent2719 epidemiological O
sent2719 evidence O
sent2720 HIV O
sent2720 treatment O
sent2720 strategies O
sent2720 : O
sent2720 planning O
sent2720 for O
sent2720 the O
sent2720 long O
sent2720 term O
sent2721 The O
sent2721 project O
sent2721 of O
sent2721 a O
sent2721 national O
sent2721 control O
sent2721 program O
sent2721 for O
sent2721 tuberculosis D
sent2721 in O
sent2721 Spain O
sent2722 Decrease O
sent2722 in O
sent2722 antibiotic O
sent2722 susceptibility O
sent2722 or O
sent2722 increase O
sent2722 in O
sent2722 resistance O
sent2722 ? O
sent2723 Helicobacter O
sent2723 pylori O
sent2723 and O
sent2723 abdominal O
sent2723 symptoms O
sent2723 : O
sent2723 a O
sent2723 population-based O
sent2723 study O
sent2723 among O
sent2723 preschool O
sent2723 children O
sent2723 in O
sent2723 southern O
sent2723 Germany O
sent2724 Have O
sent2724 we O
sent2724 treated O
sent2724 AIDS D
sent2724 too O
sent2724 well O
sent2724 ? O
sent2724 Rationing O
sent2724 and O
sent2724 the O
sent2724 future O
sent2724 of O
sent2724 AIDS O
sent2724 exceptionalism O
sent2725 Recommendations O
sent2725 on O
sent2725 antiretroviral T
sent2725 treatment T
sent2726 The O
sent2726 AIDS O
sent2726 Study O
sent2726 Group O
sent2726 of O
sent2726 the O
sent2726 Spanish O
sent2726 Society O
sent2726 of O
sent2726 Infectious O
sent2726 Diseases O
sent2726 and O
sent2726 Clinical O
sent2726 Microbiology O
sent2727 Requirements O
sent2727 for O
sent2727 training O
sent2727 to O
sent2727 ensure O
sent2727 competence O
sent2727 of O
sent2727 endoscopists O
sent2727 performing O
sent2727 invasive O
sent2727 procedures O
sent2727 in O
sent2727 children O
sent2728 Safe O
sent2728 motherhood O
sent2728 : O
sent2728 can O
sent2728 we O
sent2728 make O
sent2728 a O
sent2728 difference O
sent2728 ? O
sent2729 Lumbar D
sent2729 spine D
sent2729 stenosis D
sent2729 : O
sent2729 a O
sent2729 common O
sent2729 cause O
sent2729 of O
sent2729 back O
sent2729 and O
sent2729 leg O
sent2729 pain D
sent2730 Myoepithelial D
sent2730 carcinoma D
sent2730 with O
sent2730 predominance O
sent2730 of O
sent2730 plasmacytoid O
sent2730 cells O
sent2730 arising O
sent2730 in O
sent2730 a O
sent2730 pleomorphic D
sent2730 adenoma D
sent2730 of O
sent2730 the O
sent2730 parotid O
sent2730 gland O
sent2731 Lonomia O
sent2731 obliqua O
sent2731 caterpillar O
sent2731 spicules O
sent2731 trigger O
sent2731 human O
sent2731 blood O
sent2731 coagulation O
sent2731 via O
sent2731 activation O
sent2731 of O
sent2731 factor O
sent2731 X O
sent2731 and O
sent2731 prothrombin O
sent2732 Doing O
sent2732 everything O
sent2733 Successful O
sent2733 replantation O
sent2733 of O
sent2733 an O
sent2733 amputated O
sent2733 tongue O
sent2734 Morbidity O
sent2734 and O
sent2734 healthcare O
sent2734 utilisation O
sent2734 of O
sent2734 children O
sent2734 in O
sent2734 households O
sent2734 with O
sent2734 one O
sent2734 adult O
sent2734 : O
sent2734 comparative O
sent2734 observational O
sent2734 study O
sent2735 A O
sent2735 novel O
sent2735 frameshift O
sent2735 mutation O
sent2735 840delA O
sent2735 and O
sent2735 a O
sent2735 novel O
sent2735 polymorphism O
sent2735 D203A O
sent2735 in O
sent2735 the O
sent2735 steroidogenic O
sent2735 acute O
sent2735 regulatory O
sent2735 protein O
sent2735 gene O
sent2735 in O
sent2735 a O
sent2735 Japanese O
sent2735 patient O
sent2735 with O
sent2735 congenital D
sent2735 lipoid D
sent2735 adrenal D
sent2735 hyperplasia D
sent2736 Mutations O
sent2736 in O
sent2736 brief O
sent2736 no O
sent2737 117 O
sent2738 Online O
sent2739 Identification O
sent2739 of O
sent2739 five O
sent2739 new O
sent2739 mutations O
sent2739 and O
sent2739 three O
sent2739 novel O
sent2739 polymorphisms O
sent2739 in O
sent2739 the O
sent2739 muscle O
sent2739 chloride O
sent2739 channel O
sent2739 gene O
sent2739 ( O
sent2739 CLCN1 O
sent2739 ) O
sent2739 in O
sent2739 20 O
sent2739 Italian O
sent2739 patients O
sent2739 with O
sent2739 dominant O
sent2739 and O
sent2739 recessive O
sent2739 myotonia D
sent2739 congenita D
sent2740 Mutations O
sent2740 in O
sent2740 brief O
sent2740 no O
sent2741 118 O
sent2742 Online O
sent2743 Identification O
sent2743 of O
sent2743 a O
sent2743 large O
sent2743 insertion O
sent2743 and O
sent2743 two O
sent2743 novel O
sent2743 point O
sent2743 mutations O
sent2743 ( O
sent2743 3671del8 O
sent2743 and O
sent2743 S1221X O
sent2743 ) O
sent2743 in O
sent2743 tuberous D
sent2743 sclerosis D
sent2743 complex D
sent2743 ( D
sent2743 TSC D
sent2743 ) D
sent2743 patients O
sent2744 Mutations O
sent2744 in O
sent2744 brief O
sent2744 no O
sent2745 119 O
sent2746 Online O
sent2747 Mutational O
sent2747 analysis O
sent2747 of O
sent2747 the O
sent2747 cystathionine O
sent2747 beta-synthase O
sent2747 gene O
sent2747 : O
sent2747 a O
sent2747 splicing O
sent2747 mutation O
sent2747 , O
sent2747 two O
sent2747 missense O
sent2747 mutations O
sent2747 and O
sent2747 an O
sent2747 insertion O
sent2747 in O
sent2747 patients O
sent2747 with O
sent2747 homocystinuria D
sent2748 Mutations O
sent2748 in O
sent2748 brief O
sent2748 no O
sent2749 120 O
sent2750 Online O
sent2751 Analysis O
sent2751 of O
sent2751 five O
sent2751 mutations O
sent2751 in O
sent2751 20 O
sent2751 mucopolysaccharidois D
sent2751 type O
sent2751 1 O
sent2751 patients O
sent2751 : O
sent2751 high O
sent2751 prevalence O
sent2751 of O
sent2751 the O
sent2751 W402X O
sent2751 mutation O
sent2752 Mutations O
sent2752 in O
sent2752 brief O
sent2752 no O
sent2753 121 O
sent2754 Online O
sent2755 A O
sent2755 novel O
sent2755 missense O
sent2755 mutation O
sent2755 Ile538Val O
sent2755 in O
sent2755 the O
sent2755 fibroblast O
sent2755 growth O
sent2755 factor O
sent2755 receptor O
sent2755 3 O
sent2755 in O
sent2755 hypochondroplasia D
sent2756 Mutations O
sent2756 in O
sent2756 brief O
sent2756 no O
sent2757 122 O
sent2758 Online O
sent2759 Detection O
sent2759 of O
sent2759 four O
sent2759 novel O
sent2759 mutations O
sent2759 in O
sent2759 the O
sent2759 iduronate-2-sulfatase O
sent2759 gene O
sent2760 Mutations O
sent2760 in O
sent2760 brief O
sent2760 no O
sent2761 123 O
sent2762 Online O
sent2763 Polymorphisms O
sent2763 in O
sent2763 the O
sent2763 coding O
sent2763 exons O
sent2763 of O
sent2763 the O
sent2763 human O
sent2763 luteinizing O
sent2763 hormone O
sent2763 receptor O
sent2763 gene O
sent2764 Mutations O
sent2764 in O
sent2764 brief O
sent2764 no O
sent2765 124 O
sent2766 Online O
sent2767 Independent O
sent2767 occurrence O
sent2767 of O
sent2767 the O
sent2767 novel O
sent2767 Arg2163 O
sent2767 to O
sent2767 His O
sent2767 mutation O
sent2767 in O
sent2767 the O
sent2767 factor O
sent2767 VIII O
sent2767 gene O
sent2767 in O
sent2767 three O
sent2767 unrelated O
sent2767 families O
sent2767 with O
sent2767 haemophila D
sent2767 A D
sent2767 with O
sent2767 different O
sent2767 phenotypes O
sent2768 Mutations O
sent2768 in O
sent2768 brief O
sent2768 no O
sent2769 126 O
sent2770 Online O
sent2771 Are O
sent2771 Japanese O
sent2771 researchers O
sent2771 exploiting O
sent2771 Thai O
sent2771 HIV O
sent2771 patients O
sent2771 ? O
sent2772 Underutilization O
sent2772 of O
sent2772 aspirin T
sent2772 in O
sent2772 older O
sent2772 patients O
sent2772 with O
sent2772 prior D
sent2772 myocardial D
sent2772 infarction D
sent2772 at O
sent2772 the O
sent2772 time O
sent2772 of O
sent2772 admission O
sent2772 to O
sent2772 a O
sent2772 nursing O
sent2772 home O
sent2772 . O
sent2773 Distinguishing O
sent2773 silent D
sent2773 lacunar D
sent2773 infarction D
sent2773 from O
sent2773 enlarged D
sent2773 Virchow-Robin D
sent2773 spaces D
sent2773 : O
sent2773 a O
sent2773 magnetic O
sent2773 resonance O
sent2773 imaging O
sent2773 and O
sent2773 pathological O
sent2773 study O
sent2774 Correlation O
sent2774 is O
sent2774 not O
sent2774 causation O
sent2775 Inhalation O
sent2775 of O
sent2775 ammonium O
sent2775 nitrate O
sent2775 fuel O
sent2775 oil O
sent2775 explosive O
sent2775 ( O
sent2775 ANFO O
sent2775 ) O
sent2776 Management O
sent2776 of O
sent2776 polycythaemia D
sent2776 in O
sent2776 adults O
sent2776 with O
sent2776 cyanotic D
sent2776 congenital D
sent2776 heart D
sent2776 disease D
sent2777 Bolstering O
sent2777 Sisyphus O
sent2778 Use O
sent2778 of O
sent2778 public O
sent2778 performance O
sent2778 reports O
sent2778 : O
sent2778 a O
sent2778 survey O
sent2778 of O
sent2778 patients O
sent2778 undergoing O
sent2778 cardiac T
sent2778 surgery T
sent2779 Role O
sent2779 of O
sent2779 a O
sent2779 p53 O
sent2779 polymorphism O
sent2779 in O
sent2779 the O
sent2779 development O
sent2779 of O
sent2779 human D
sent2779 papillomavirus-associated D
sent2779 cancer D
sent2780 The O
sent2780 use O
sent2780 of O
sent2780 nurses O
sent2780 in O
sent2780 alternative O
sent2780 dispute O
sent2780 resolution O
sent2781 Re O
sent2781 : O
sent2781 Friday O
sent2781 afternoon O
sent2781 pulmonary T
sent2781 arteriography T
sent2781 ( T
sent2781 FAPA T
sent2781 ) T
sent2781 : O
sent2781 are O
sent2781 Fridays O
sent2781 good O
sent2781 for O
sent2781 your O
sent2781 health O
sent2781 ? O
sent2782 Hormone T
sent2782 replacement T
sent2782 therapy T
sent2782 and O
sent2782 breast D
sent2782 cancer D
sent2782 . O
sent2783 Physician O
sent2783 heal O
sent2783 thyself O
sent2783 : O
sent2783 are O
sent2783 antibiotics T
sent2783 the O
sent2783 cure O
sent2783 or O
sent2783 the O
sent2783 disease O
sent2783 ? O
sent2784 Primary D
sent2784 biliary D
sent2784 cirrhosis D
sent2785 Polymorphism O
sent2785 in O
sent2785 promoter O
sent2785 region O
sent2785 of O
sent2785 inducible O
sent2785 nitric O
sent2785 oxide O
sent2785 synthase O
sent2785 gene O
sent2785 and O
sent2785 protection O
sent2785 against O
sent2785 malaria D
sent2786 Ventilatory O
sent2786 responses O
sent2786 to O
sent2786 acute O
sent2786 and O
sent2786 sustained O
sent2786 hypoxia O
sent2786 during O
sent2786 isoflurane O
sent2786 anesthesia O
sent2787 Leprosy D
sent2787 type D
sent2787 1 D
sent2787 reaction O
sent2787 as O
sent2787 the O
sent2787 first O
sent2787 manifestation O
sent2787 of O
sent2787 borderline O
sent2787 lepromatous D
sent2787 leprosy D
sent2787 in O
sent2787 a O
sent2787 young O
sent2787 native O
sent2787 German O
sent2788 A O
sent2788 systematic O
sent2788 review O
sent2788 of O
sent2788 five O
sent2788 systemic T
sent2788 treatments T
sent2788 for O
sent2788 severe D
sent2788 psoriasis D
sent2789 Trisomy O
sent2789 10 O
sent2789 in O
sent2789 leukemia D
sent2790 Receptive O
sent2790 properties O
sent2790 of O
sent2790 primary O
sent2790 afferent O
sent2790 fibres O
sent2790 from O
sent2790 rabbit O
sent2790 pleura O
sent2790 , O
sent2790 in O
sent2790 vitro O
sent2791 Congenital D
sent2791 anomalies D
sent2791 of D
sent2791 tracheobronchial D
sent2791 branching D
sent2791 patterns D
sent2791 : O
sent2791 spiral O
sent2791 CT O
sent2791 aspects O
sent2791 in O
sent2791 adults O
sent2792 American O
sent2792 Heart O
sent2792 Association O
sent2792 urges O
sent2792 caution O
sent2792 on O
sent2792 new O
sent2792 diet O
sent2792 drug O
sent2793 Absence O
sent2793 of O
sent2793 renal O
sent2793 and O
sent2793 hepatic O
sent2793 toxicity O
sent2793 after O
sent2793 four O
sent2793 hours O
sent2793 of O
sent2793 1.25 O
sent2793 minimum O
sent2793 alveolar O
sent2793 anesthetic O
sent2793 concentration O
sent2793 sevoflurane O
sent2793 anesthesia O
sent2793 in O
sent2793 volunteers O
sent2794 Linear D
sent2794 lichen D
sent2794 planopilaris D
sent2794 of O
sent2794 the O
sent2794 face O
sent2795 Electrolyte O
sent2795 abnormalities O
sent2795 in O
sent2795 patients O
sent2795 with O
sent2795 chronic D
sent2795 renal D
sent2795 failure D
sent2795 receiving O
sent2795 parenteral O
sent2795 nutrition O
sent2796 Risk O
sent2796 factors O
sent2796 for O
sent2796 hemiretinal D
sent2796 vein D
sent2796 occlusion D
sent2796 : O
sent2796 comparison O
sent2796 with O
sent2796 risk O
sent2796 factors O
sent2796 for O
sent2796 central D
sent2796 and D
sent2796 branch D
sent2796 retinal D
sent2796 vein D
sent2796 occlusion D
sent2796 : O
sent2796 the O
sent2796 eye O
sent2796 disease O
sent2796 case-control O
sent2796 study O
sent2797 The O
sent2797 psychological O
sent2797 profiles O
sent2797 of O
sent2797 patients O
sent2797 with O
sent2797 whiplash-associated D
sent2797 headache D
sent2798 < O
sent2798 TO_SEE O
sent2798 > O
sent2798 Fatal O
sent2798 spontaneous O
sent2798 spinal O
sent2798 epidural O
sent2798 hematoma O
sent2798 following O
sent2798 thrombolysis O
sent2798 for O
sent2798 myocardial O
sent2798 infarction O
sent2799 Bifid O
sent2799 T O
sent2799 waves O
sent2799 induced O
sent2799 by O
sent2799 isoprenaline T
sent2799 in O
sent2799 a O
sent2799 patient O
sent2799 with O
sent2799 Brugada D
sent2799 syndrome D
sent2799 . O
sent2800 Quo O
sent2800 vadis O
sent2800 `` O
sent2800 suprema O
sent2800 lex O
sent2800 '' O
sent2800 ? O
sent2801 Death O
sent2801 in O
sent2801 springtime O
sent2802 Clinical T
sent2802 management T
sent2802 and O
sent2802 treatment O
sent2802 outcomes O
sent2802 of O
sent2802 Merkel D
sent2802 cell D
sent2802 carcinoma D
sent2803 Relatives O
sent2803 in O
sent2803 the O
sent2803 resuscitation O
sent2803 room O
sent2803 : O
sent2803 their O
sent2803 point O
sent2803 of O
sent2803 view O
sent2804 Large D
sent2804 airway D
sent2804 disease D
sent2804 associated O
sent2804 with O
sent2804 inflammatory D
sent2804 bowel D
sent2804 disease D
sent2805 Autonomy O
sent2805 in O
sent2805 the O
sent2805 face O
sent2805 of O
sent2805 a O
sent2805 devastating O
sent2805 diagnosis O
sent2806 Advanced O
sent2806 practice O
sent2806 nursing O
sent2806 : O
sent2806 is O
sent2806 the O
sent2806 physician O
sent2806 's O
sent2806 assistant O
sent2806 an O
sent2806 accident O
sent2806 of O
sent2806 history O
sent2806 or O
sent2806 a O
sent2806 failure O
sent2806 to O
sent2806 act O
sent2806 ? O
sent2807 Acute D
sent2807 obstructive D
sent2807 hydrocephalus D
sent2807 complicating O
sent2807 bacterial D
sent2807 meningitis D
sent2807 in O
sent2807 childhood O
sent2808 Subcutaneous O
sent2808 autologous O
sent2808 ovarian O
sent2808 transplantation O
sent2808 in O
sent2808 Wistar O
sent2808 rats O
sent2808 maintains O
sent2808 hormone O
sent2808 secretion O
sent2809 Teaching O
sent2809 irritable D
sent2809 bowel D
sent2809 syndrome D
sent2809 patients O
sent2809 to O
sent2809 care O
sent2809 for O
sent2809 themselves O
sent2810 Nonanesthetic O
sent2810 volatile O
sent2810 drugs O
sent2810 obey O
sent2810 the O
sent2810 Meyer-Overton O
sent2810 correlation O
sent2810 in O
sent2810 two O
sent2810 molecular O
sent2810 protein O
sent2810 site O
sent2810 models O
sent2811 Inhaled T
sent2811 sodium T
sent2811 cromoglycate T
sent2811 in O
sent2811 young O
sent2811 children O
sent2811 with O
sent2811 moderate O
sent2811 asthma D
sent2812 Directly O
sent2812 observed O
sent2812 therapy O
sent2812 and O
sent2812 treatment O
sent2812 completion O
sent2812 for O
sent2812 tuberculosis D
sent2812 in O
sent2812 the O
sent2812 United O
sent2812 States O
sent2812 : O
sent2812 is O
sent2812 universal O
sent2812 supervised O
sent2812 therapy O
sent2812 necessary O
sent2812 ? O
sent2813 Investigation O
sent2813 of O
sent2813 antibiotic T
sent2813 prophylaxis T
sent2813 usage O
sent2813 for O
sent2813 vascular O
sent2813 and O
sent2813 nonvascular O
sent2813 interventional O
sent2813 procedures O
sent2814 Effect O
sent2814 of O
sent2814 protein O
sent2814 kinase O
sent2814 C O
sent2814 inhibitors O
sent2814 on O
sent2814 cardioprotection O
sent2814 by O
sent2814 ischemic O
sent2814 preconditioning O
sent2814 depends O
sent2814 on O
sent2814 the O
sent2814 number O
sent2814 of O
sent2814 preconditioning O
sent2814 episodes O
sent2815 How O
sent2815 do O
sent2815 you O
sent2815 treat O
sent2815 refractory D
sent2815 pouchitis D
sent2815 and O
sent2815 when O
sent2815 do O
sent2815 you O
sent2815 decide O
sent2815 to O
sent2815 remove O
sent2815 the O
sent2815 pouch O
sent2815 ? O
sent2816 Filter O
sent2816 paper O
sent2816 blood O
sent2816 spot O
sent2816 assay O
sent2816 of O
sent2816 human O
sent2816 insulin-like O
sent2816 growth O
sent2816 factor O
sent2816 I O
sent2816 ( O
sent2816 IGF-I O
sent2816 ) O
sent2816 and O
sent2816 IGF-binding O
sent2816 protein-3 O
sent2816 and O
sent2816 preliminary O
sent2816 application O
sent2816 in O
sent2816 the O
sent2816 evaluation O
sent2816 of O
sent2816 growth O
sent2816 hormone O
sent2816 status O
sent2817 Effect O
sent2817 of O
sent2817 iodixanol D
sent2817 on O
sent2817 renal O
sent2817 function O
sent2817 immediately O
sent2817 after O
sent2817 abdominal T
sent2817 angiography T
sent2817 . O
sent2818 Clinical O
sent2818 comparison O
sent2818 with O
sent2818 iomeprol D
sent2818 and O
sent2818 ioxaglate D
sent2819 A O
sent2819 new O
sent2819 modified O
sent2819 technique O
sent2819 for O
sent2819 harvest O
sent2819 of O
sent2819 calcaneal O
sent2819 bone O
sent2819 grafts O
sent2819 in O
sent2819 surgery T
sent2819 on O
sent2819 the O
sent2819 foot O
sent2819 and O
sent2819 ankle O
sent2820 Is O
sent2820 prevaccination O
sent2820 screening O
sent2820 for O
sent2820 hepatitis D
sent2820 B D
sent2820 among O
sent2820 sexually O
sent2820 active O
sent2820 adolescents O
sent2820 cost-effective O
sent2820 ? O
sent2821 Epilepsy D
sent2821 -- O
sent2821 a O
sent2821 guide O
sent2821 to O
sent2821 medical O
sent2821 treatment O
sent2822 1 O
sent2822 : O
sent2822 Antiepileptic T
sent2822 drugs T
sent2823 Adolescent O
sent2823 pregnancy O
sent2823 and O
sent2823 sexual O
sent2823 abuse O
sent2824 Normoxic T
sent2824 cardiopulmonary T
sent2824 bypass T
sent2824 reduces O
sent2824 oxidative D
sent2824 myocardial D
sent2824 damage D
sent2824 and D
sent2824 nitric D
sent2824 oxide D
sent2824 during O
sent2824 cardiac O
sent2824 operations O
sent2824 in O
sent2824 the O
sent2824 adult O
sent2825 A O
sent2825 multidimensional O
sent2825 study O
sent2825 of O
sent2825 preference O
sent2825 judgements O
sent2825 for O
sent2825 excerpts O
sent2825 of O
sent2825 music O
sent2826 Extending O
sent2826 the O
sent2826 benefits O
sent2826 of O
sent2826 breast D
sent2826 cancer D
sent2826 screening O
sent2827 Still O
sent2827 hard O
sent2827 to O
sent2827 know O
sent2827 how O
sent2827 large O
sent2827 the O
sent2827 benefits O
sent2827 will O
sent2827 really O
sent2827 be O
sent2828 Rhabdomyolysis D
sent2828 and O
sent2828 carbon D
sent2828 monoxide D
sent2828 poisoning D
sent2829 Effect O
sent2829 of O
sent2829 dental T
sent2829 treatment T
sent2829 on O
sent2829 the O
sent2829 lung O
sent2829 function O
sent2829 of O
sent2829 children O
sent2829 with O
sent2829 asthma D
sent2829 . O
sent2830 conclusions O
sent2830 : O
sent2830 apc T
sent2830 is O
sent2830 effective O
sent2830 for O
sent2830 the O
sent2830 treatment O
sent2830 of O
sent2830 endoluminal D
sent2830 hemoptysis D
sent2830 and O
sent2830 airway D
sent2830 obstruction D
sent2831 induction T
sent2831 chemotherapy T
sent2831 ( T
sent2831 cisplatin T
sent2831 + T
sent2831 vinorelbine T
sent2831 ) T
sent2831 is O
sent2831 found O
sent2831 to O
sent2831 be O
sent2831 markedly O
sent2831 effective O
sent2831 for O
sent2831 squamous D
sent2831 cell D
sent2831 lung D
sent2831 carcinoma D
sent2831 with D
sent2831 sarcoidosis D
sent2831 -- O
sent2831 a O
sent2831 case O
sent2831 report O
sent2832 < O
sent2832 TO_SEE O
sent2832 > O
sent2832 in O
sent2832 conclusion O
sent2832 , O
sent2832 3d O
sent2832 computer-assisted O
sent2832 analysis O
sent2832 of O
sent2832 the O
sent2832 internal O
sent2832 structure O
sent2832 of O
sent2832 small O
sent2832 pulmonary O
sent2832 nodules O
sent2832 using O
sent2832 contrast-enhanced O
sent2832 dh-ct O
sent2832 was O
sent2832 found O
sent2832 to O
sent2832 be O
sent2832 effective O
sent2832 for O
sent2832 differentiating O
sent2832 between O
sent2832 benign O
sent2832 and O
sent2832 malignant O
sent2832 nodules O
sent2833 the O
sent2833 patient O
sent2833 was O
sent2833 a O
sent2833 62-year-old O
sent2833 man O
sent2833 with O
sent2833 squamous D
sent2833 cell D
sent2833 lung D
sent2833 cancer D
sent2833 , O
sent2833 which O
sent2833 was O
sent2833 first O
sent2833 successfully O
sent2833 treated O
sent2833 by O
sent2833 a O
sent2833 combination T
sent2833 of T
sent2833 radiation T
sent2833 therapy T
sent2833 and T
sent2833 chemotherapy T
sent2833 , O
sent2833 but O
sent2833 showed O
sent2833 local O
sent2833 recurrence O
sent2833 after O
sent2833 8 O
sent2833 months O
sent2834 the O
sent2834 combination T
sent2834 of T
sent2834 txt T
sent2834 , T
sent2834 gem T
sent2834 and T
sent2834 cddp T
sent2834 may O
sent2834 be O
sent2834 effective O
sent2834 for O
sent2834 recurrent D
sent2834 non-small-cell D
sent2834 lung D
sent2834 carcinoma D
sent2834 , O
sent2834 even O
sent2834 in O
sent2834 patients O
sent2834 that O
sent2834 have O
sent2834 failed O
sent2834 to O
sent2834 respond O
sent2834 to O
sent2834 more O
sent2834 than O
sent2834 one O
sent2834 chemotherapy O
sent2834 regimen O
sent2835 the O
sent2835 aim O
sent2835 of O
sent2835 the O
sent2835 current O
sent2835 study O
sent2835 was O
sent2835 to O
sent2835 compare O
sent2835 the O
sent2835 objective O
sent2835 response O
sent2835 and O
sent2835 survival O
sent2835 rates O
sent2835 of O
sent2835 patients O
sent2835 with O
sent2835 mrcc D
sent2835 treated O
sent2835 with O
sent2835 il-2 T
sent2835 administered O
sent2835 either O
sent2835 systemically O
sent2835 ( O
sent2835 syst O
sent2835 , O
sent2835 subcutaneously O
sent2835 ) O
sent2835 or O
sent2835 via O
sent2835 inhalation O
sent2835 ( O
sent2835 inh O
sent2835 ) O
sent2835 , O
sent2835 using O
sent2835 relatively O
sent2835 large O
sent2835 sample O
sent2835 sizes O
sent2835 to O
sent2835 afford O
sent2835 a O
sent2835 more O
sent2835 meaningful O
sent2835 comparison O
sent2836 conclusion O
sent2836 : O
sent2836 as O
sent2836 expected O
sent2836 , O
sent2836 the O
sent2836 type O
sent2836 of O
sent2836 chemotherapy T
sent2836 we O
sent2836 used O
sent2836 , O
sent2836 to O
sent2836 treat O
sent2836 non-seminomatous D
sent2836 germ-cell D
sent2836 tumors D
sent2836 proved O
sent2836 to O
sent2836 be O
sent2836 highly O
sent2836 effective O
sent2836 for O
sent2836 seminomatous D
sent2836 types D
sent2836 , O
sent2836 as O
sent2836 well O
sent2837 carboplatin T
sent2837 and T
sent2837 ifosfamide T
sent2837 performed O
sent2837 well O
sent2837 and O
sent2837 safe O
sent2837 , O
sent2837 in O
sent2837 the O
sent2837 treatment O
sent2837 of O
sent2837 non-bulky D
sent2837 metastatic D
sent2837 seminoma D
sent2838 these O
sent2838 results O
sent2838 suggested O
sent2838 that O
sent2838 the O
sent2838 sp1 T
sent2838 decoy T
sent2838 strategy T
sent2838 would O
sent2838 be O
sent2838 effective O
sent2838 for O
sent2838 regulating O
sent2838 tumor D
sent2838 growth D
sent2838 by O
sent2838 simultaneously O
sent2838 reducing O
sent2838 cancer O
sent2838 cell O
sent2838 ( O
sent2838 a O
sent2838 ) O
sent2838 angiogenic O
sent2838 growth O
sent2838 factor O
sent2838 expression O
sent2838 , O
sent2838 ( O
sent2838 b O
sent2838 ) O
sent2838 proliferation O
sent2838 , O
sent2838 and O
sent2838 ( O
sent2838 c O
sent2838 ) O
sent2838 invasiveness O
sent2839 considering O
sent2839 that O
sent2839 hamsters O
sent2839 had O
sent2839 a O
sent2839 lung O
sent2839 metastasis O
sent2839 rate O
sent2839 of O
sent2839 50 O
sent2839 % O
sent2839 before O
sent2839 mdp-lys O
sent2839 treatment O
sent2839 , O
sent2839 liposomal T
sent2839 mdp-lys T
sent2839 given O
sent2839 at O
sent2839 a O
sent2839 dose O
sent2839 of O
sent2839 20 O
sent2839 microg O
sent2839 twice/week O
sent2839 was O
sent2839 effective O
sent2839 for O
sent2839 inhibiting O
sent2839 lung D
sent2839 metastasis D
sent2839 at O
sent2839 a O
sent2839 far O
sent2839 lower O
sent2839 dose O
sent2839 of O
sent2839 mdp-lys O
sent2839 than O
sent2839 that O
sent2839 given O
sent2839 as O
sent2839 a O
sent2839 solution O
sent2839 ( O
sent2839 40 O
sent2839 microg O
sent2839 vs. O
sent2839 350 O
sent2839 microg O
sent2839 per O
sent2839 week O
sent2839 ) O
sent2840 we O
sent2840 have O
sent2840 documented O
sent2840 previously O
sent2840 that O
sent2840 adenovirus-mediated T
sent2840 interleukin T
sent2840 12 T
sent2840 ( T
sent2840 il-12 T
sent2840 ) T
sent2840 gene T
sent2840 therapy T
sent2840 is O
sent2840 effective O
sent2840 for O
sent2840 orthotopic D
sent2840 tumor D
sent2840 control O
sent2840 and O
sent2840 suppression O
sent2840 of O
sent2840 pre-established D
sent2840 metastases D
sent2840 in D
sent2840 a D
sent2840 preclinical D
sent2840 prostate D
sent2840 cancer D
sent2840 model D
sent2840 ( O
sent2840 y. O
sent2840 nasu O
sent2840 et O
sent2840 al O
sent2840 . O
sent2840 , O
sent2840 gene O
sent2840 ther O
sent2841 we O
sent2841 further O
sent2841 developed O
sent2841 a O
sent2841 vaccine O
sent2841 model O
sent2841 based O
sent2841 on O
sent2841 s.c.injection O
sent2841 of O
sent2841 infected O
sent2841 , O
sent2841 irradiated O
sent2841 rm-9 O
sent2841 cells O
sent2841 and O
sent2841 found O
sent2841 that O
sent2841 both O
sent2841 admil-12 T
sent2841 and T
sent2841 admil-12/b7 T
sent2841 are O
sent2841 effective O
sent2841 at O
sent2841 suppressing O
sent2841 the O
sent2841 development O
sent2841 and O
sent2841 growth O
sent2841 of O
sent2841 challenge D
sent2841 orthotopic D
sent2841 tumors D
sent2841 using O
sent2841 this O
sent2841 protocol O
sent2842 despite O
sent2842 the O
sent2842 marked O
sent2842 toxicity O
sent2842 of O
sent2842 the O
sent2842 initial O
sent2842 intensive T
sent2842 chemotherapy T
sent2842 , O
sent2842 the O
sent2842 treatments O
sent2842 are O
sent2842 tolerable O
sent2842 and O
sent2842 effective O
sent2842 in O
sent2842 the O
sent2842 control O
sent2842 of O
sent2842 extra-thoracic D
sent2842 micrometastases D
sent2842 , O
sent2842 whereas O
sent2842 they O
sent2842 are O
sent2842 less O
sent2842 effective O
sent2842 for O
sent2842 thoracic O
sent2842 primary O
sent2842 tumor O
sent2843 radiotherapy T
sent2843 is O
sent2843 effective O
sent2843 for O
sent2843 palliation O
sent2843 of O
sent2843 symptoms D
sent2843 associated D
sent2843 with D
sent2843 sblc D
sent2844 clinically O
sent2844 , O
sent2844 oral T
sent2844 administration T
sent2844 of T
sent2844 uft T
sent2844 has O
sent2844 proved O
sent2844 to O
sent2844 be O
sent2844 effective O
sent2844 as O
sent2844 an O
sent2844 adjuvant T
sent2844 therapy T
sent2844 after O
sent2844 surgery O
sent2844 for O
sent2844 some O
sent2844 malignant D
sent2844 tumors D
sent2844 such D
sent2844 as D
sent2844 non-small D
sent2844 cell D
sent2844 lung D
sent2844 cancer D
sent2845 moreover O
sent2845 , O
sent2845 uft T
sent2845 has O
sent2845 proved O
sent2845 to O
sent2845 be O
sent2845 effective O
sent2845 for O
sent2845 inoperable D
sent2845 advanced D
sent2845 malignancies D
sent2845 such D
sent2845 as D
sent2845 colorectal D
sent2845 cancer D
sent2845 , O
sent2845 especially O
sent2845 in O
sent2845 combination O
sent2845 with O
sent2845 leucovorin T
sent2845 or T
sent2845 cisplatin T
sent2846 a O
sent2846 phase O
sent2846 ii O
sent2846 study O
sent2846 of O
sent2846 fractionated O
sent2846 administration O
sent2846 of O
sent2846 irinotecan T
sent2846 ( T
sent2846 cpt-11 T
sent2846 ) T
sent2846 and T
sent2846 cisplatin T
sent2846 ( T
sent2846 cddp T
sent2846 ) T
sent2846 in O
sent2846 patients O
sent2846 with O
sent2846 non-small-cell D
sent2846 lung D
sent2846 cancer D
sent2846 ( D
sent2846 nsclc D
sent2846 ) D
sent2846 was O
sent2846 conducted O
sent2847 in O
sent2847 conclusion O
sent2847 , O
sent2847 fractionated O
sent2847 administration O
sent2847 of O
sent2847 cpt-11 T
sent2847 and T
sent2847 cddp T
sent2847 was O
sent2847 highly O
sent2847 effective O
sent2847 for O
sent2847 advanced D
sent2847 nsclc D
sent2847 with O
sent2847 manageable O
sent2847 toxicities O
sent2848 we O
sent2848 report O
sent2848 the O
sent2848 use O
sent2848 of O
sent2848 paclitaxel T
sent2848 in O
sent2848 the O
sent2848 successful O
sent2848 treatment O
sent2848 of O
sent2848 a O
sent2848 patient O
sent2848 with O
sent2848 recurrent D
sent2848 adenocarcinoma D
sent2848 of D
sent2848 the D
sent2848 cervix D
sent2849 weekly O
sent2849 paclitaxel T
sent2849 was O
sent2849 very O
sent2849 well O
sent2849 tolerated O
sent2849 , O
sent2849 yet O
sent2849 was O
sent2849 effective O
sent2849 for O
sent2849 recurrent D
sent2849 cervical D
sent2849 adenocarcinoma D
sent2850 conclusion O
sent2850 : O
sent2850 our O
sent2850 results O
sent2850 suggest O
sent2850 that O
sent2850 pseudoephedrine T
sent2850 plus T
sent2850 acetaminophen T
sent2850 is O
sent2850 effective O
sent2850 for O
sent2850 relief O
sent2850 of O
sent2850 symptoms D
sent2850 attributable D
sent2850 to D
sent2850 the D
sent2850 paranasal D
sent2850 sinuses D
sent2850 that O
sent2850 may O
sent2850 develop O
sent2850 early O
sent2850 in O
sent2850 the O
sent2850 course O
sent2850 of O
sent2850 a O
sent2850 cold O
sent2851 reviewer O
sent2851 's O
sent2851 conclusions O
sent2851 : O
sent2851 a O
sent2851 single O
sent2851 dose O
sent2851 of O
sent2851 nasal T
sent2851 decongestant T
sent2851 in O
sent2851 the O
sent2851 common O
sent2851 cold O
sent2851 is O
sent2851 moderately O
sent2851 effective O
sent2851 for O
sent2851 the O
sent2851 short O
sent2851 term O
sent2851 relief O
sent2851 of O
sent2851 congestion D
sent2851 in O
sent2851 adults O
sent2851 , O
sent2851 while O
sent2851 there O
sent2851 is O
sent2851 no O
sent2851 evidence O
sent2851 available O
sent2851 to O
sent2851 show O
sent2851 benefit O
sent2851 after O
sent2851 repeated O
sent2851 use O
sent2851 over O
sent2851 several O
sent2851 days O
sent2852 conclusions O
sent2852 : O
sent2852 members O
sent2852 of O
sent2852 an O
sent2852 ethnically O
sent2852 diverse O
sent2852 community O
sent2852 believe O
sent2852 antibiotics T
sent2852 are O
sent2852 effective O
sent2852 for O
sent2852 colds D
sent2852 , O
sent2852 are O
sent2852 very O
sent2852 likely O
sent2852 to O
sent2852 seek O
sent2852 care O
sent2852 for O
sent2852 colds O
sent2852 , O
sent2852 and O
sent2852 often O
sent2852 obtain O
sent2852 antibiotics O
sent2852 without O
sent2852 a O
sent2852 prescription O
sent2853 the O
sent2853 available O
sent2853 inactivated O
sent2853 vaccine T
sent2853 is O
sent2853 effective O
sent2853 for O
sent2853 preventing O
sent2853 influenza D
sent2853 and O
sent2853 the O
sent2853 serious O
sent2853 disease O
sent2853 and O
sent2853 death O
sent2853 that O
sent2853 can O
sent2853 accompany O
sent2853 it O
sent2854 < O
sent2854 TO_SEE O
sent2854 > O
sent2854 amantadine T
sent2854 , O
sent2854 rimantadine T
sent2854 , O
sent2854 and O
sent2854 the O
sent2854 newly O
sent2854 available O
sent2854 drugs O
sent2854 zanamivir T
sent2854 and O
sent2854 oseltamivir T
sent2854 are O
sent2854 effective O
sent2854 for O
sent2854 influenza D
sent2854 prevention D
sent2854 and D
sent2854 treatment D
sent2854 ( O
sent2854 the O
sent2854 former O
sent2854 two O
sent2854 for O
sent2854 influenza O
sent2854 a O
sent2854 only O
sent2854 ) O
sent2855 < O
sent2855 TO_SEE O
sent2855 > O
sent2855 the O
sent2855 availability O
sent2855 of O
sent2855 four O
sent2855 antiviral T
sent2855 agents T
sent2855 that O
sent2855 effectively O
sent2855 prevent O
sent2855 and O
sent2855 treat O
sent2855 influenza D
sent2855 provides O
sent2855 the O
sent2855 physician O
sent2855 with O
sent2855 considerable O
sent2855 flexibility O
sent2855 for O
sent2855 their O
sent2855 use O
sent2855 in O
sent2855 influenza O
sent2855 control O
sent2856 < O
sent2856 TO_SEE O
sent2856 > O
sent2856 thus O
sent2856 influenza D
sent2856 vaccination T
sent2856 is O
sent2856 effective O
sent2856 for O
sent2856 preventing O
sent2856 influenza D
sent2856 disease D
sent2856 in O
sent2856 persons O
sent2856 aged O
sent2856 65 O
sent2856 years O
sent2856 and O
sent2856 over O
sent2856 , O
sent2856 and O
sent2856 should O
sent2856 be O
sent2856 an O
sent2856 integral O
sent2856 part O
sent2856 of O
sent2856 the O
sent2856 care O
sent2856 of O
sent2856 this O
sent2856 population O
sent2856 residing O
sent2856 in O
sent2856 nursing O
sent2856 homes O
sent2857 intravenous T
sent2857 injection T
sent2857 of T
sent2857 pb2-as T
sent2857 , T
sent2857 as T
sent2857 a T
sent2857 complex T
sent2857 with T
sent2857 dmrie-c T
sent2857 , T
sent2857 a T
sent2857 cationic T
sent2857 liposome T
sent2857 , O
sent2857 was O
sent2857 most O
sent2857 effective O
sent2857 for O
sent2857 prolonging O
sent2857 the O
sent2857 mean O
sent2857 survival O
sent2857 time O
sent2857 in O
sent2857 days O
sent2857 ( O
sent2857 msds O
sent2857 ) O
sent2857 and O
sent2857 increasing O
sent2857 the O
sent2857 survival O
sent2857 rates O
sent2857 of O
sent2857 mice O
sent2857 infected O
sent2857 with O
sent2857 the O
sent2857 influenza D
sent2857 a D
sent2857 virus D
sent2858 background O
sent2858 and O
sent2858 objectives O
sent2858 : O
sent2858 thoracic T
sent2858 paravertebral T
sent2858 block T
sent2858 ( T
sent2858 tpvb T
sent2858 ) T
sent2858 is O
sent2858 a O
sent2858 unilateral O
sent2858 analgesic O
sent2858 technique O
sent2858 that O
sent2858 has O
sent2858 been O
sent2858 advocated O
sent2858 in O
sent2858 both O
sent2858 acute D
sent2858 and D
sent2858 chronic D
sent2858 thoracic D
sent2858 and D
sent2858 abdominal D
sent2858 pain D
sent2859 other T
sent2859 blocks T
sent2859 such T
sent2859 as T
sent2859 interpleural T
sent2859 and T
sent2859 epidural T
sent2859 can O
sent2859 be O
sent2859 effectively O
sent2859 used O
sent2859 in O
sent2859 pleuritic D
sent2859 pain D
sent2860 this O
sent2860 report O
sent2860 illustrates O
sent2860 that O
sent2860 tpvb T
sent2860 could O
sent2860 also O
sent2860 be O
sent2860 effective O
sent2860 for O
sent2860 this O
sent2860 kind O
sent2860 of O
sent2860 pain D
sent2861 conclusions O
sent2861 : O
sent2861 this O
sent2861 case O
sent2861 report O
sent2861 supports O
sent2861 the O
sent2861 notion O
sent2861 that O
sent2861 , O
sent2861 in O
sent2861 practice O
sent2861 , O
sent2861 the T
sent2861 paravertebral T
sent2861 block T
sent2861 could O
sent2861 be O
sent2861 an O
sent2861 effective O
sent2861 and O
sent2861 safe O
sent2861 alternative O
sent2861 to O
sent2861 relief O
sent2861 of O
sent2861 pleuritic D
sent2861 pain D
sent2862 conclusion O
sent2862 : O
sent2862 mr-guided T
sent2862 rfa T
sent2862 using T
sent2862 single T
sent2862 cooled T
sent2862 tip T
sent2862 electrodes T
sent2862 is O
sent2862 safe O
sent2862 and O
sent2862 technically O
sent2862 effective O
sent2862 for O
sent2862 treatment O
sent2862 of O
sent2862 hepatic D
sent2862 neoplasms D
sent2862 up O
sent2862 to O
sent2862 3 O
sent2862 cm O
sent2862 in O
sent2862 size O
sent2862 , O
sent2862 however O
sent2862 further O
sent2862 improvements O
sent2862 are O
sent2862 necessary O
sent2863 a O
sent2863 68-year-old O
sent2863 man O
sent2863 underwent O
sent2863 curative T
sent2863 pancreaticoduodenectomy T
sent2863 for O
sent2863 bile D
sent2863 duct D
sent2863 cancer D
sent2864 one O
sent2864 course O
sent2864 of O
sent2864 chronochemotherapy T
sent2864 was O
sent2864 effective O
sent2864 for O
sent2864 lymph D
sent2864 node D
sent2864 and D
sent2864 peritoneum D
sent2864 metastases D
sent2865 the O
sent2865 only O
sent2865 specific O
sent2865 antidote O
sent2865 for O
sent2865 dosage-dependent D
sent2865 hepatotoxicity D
sent2865 is O
sent2865 n-acetylcysteine T
sent2865 ( T
sent2865 and T
sent2865 some T
sent2865 other T
sent2865 sulfhydryl T
sent2865 donors T
sent2865 ) T
sent2865 , O
sent2865 which O
sent2865 is O
sent2865 highly O
sent2865 effective O
sent2865 for O
sent2865 the O
sent2865 prevention O
sent2865 of O
sent2865 significant O
sent2865 hepatotoxicity O
sent2865 after O
sent2865 acetaminophen O
sent2865 overdose O
sent2866 corticosteroids T
sent2866 can O
sent2866 be O
sent2866 considered O
sent2866 for O
sent2866 cases O
sent2866 of O
sent2866 drug-induced D
sent2866 hepatitis D
sent2866 , O
sent2866 especially O
sent2866 those O
sent2866 with O
sent2866 evidence O
sent2866 of O
sent2866 immune O
sent2866 hypersensitivity O
sent2866 , O
sent2866 if O
sent2866 no O
sent2866 improvement O
sent2866 is O
sent2866 seen O
sent2866 in O
sent2866 8 O
sent2866 to O
sent2866 12 O
sent2866 weeks O
sent2867 our O
sent2867 conclusion O
sent2867 was O
sent2867 that O
sent2867 the O
sent2867 covered-ems T
sent2867 can O
sent2867 be O
sent2867 effective O
sent2867 for O
sent2867 the O
sent2867 palliation O
sent2867 of O
sent2867 esophagorespiratory D
sent2867 fistulas D
sent2868 the O
sent2868 food O
sent2868 and O
sent2868 drug O
sent2868 administration O
sent2868 ( O
sent2868 fda O
sent2868 ) O
sent2868 recently O
sent2868 approved O
sent2868 the O
sent2868 first O
sent2868 protein-polysaccharide T
sent2868 conjugate T
sent2868 vaccine T
sent2868 to O
sent2868 prevent O
sent2868 invasive D
sent2868 pneumococcal D
sent2868 diseases D
sent2868 in O
sent2868 infants O
sent2868 and O
sent2868 toddlers O
sent2868 < O
sent2868 2 O
sent2868 years O
sent2868 of O
sent2868 age O
sent2869 this O
sent2869 conjugated T
sent2869 vaccine T
sent2869 against O
sent2869 pneumococcus D
sent2869 uses O
sent2869 the O
sent2869 same O
sent2869 technology O
sent2869 as O
sent2869 the O
sent2869 successful O
sent2869 vaccine T
sent2869 against O
sent2869 haemophilus D
sent2869 influenzae D
sent2869 type D
sent2869 b D
sent2870 the O
sent2870 most O
sent2870 recent O
sent2870 study O
sent2870 , O
sent2870 involving O
sent2870 over O
sent2870 37 O
sent2870 , O
sent2870 000 O
sent2870 young O
sent2870 children O
sent2870 , O
sent2870 also O
sent2870 evaluated O
sent2870 the O
sent2870 vaccine O
sent2870 's O
sent2870 efficacy O
sent2870 , O
sent2870 and O
sent2870 reported O
sent2870 that O
sent2870 the O
sent2870 vaccine T
sent2870 is O
sent2870 highly O
sent2870 effective O
sent2870 in O
sent2870 preventing O
sent2870 invasive D
sent2870 disease D
sent2870 and O
sent2870 has O
sent2870 had O
sent2870 an O
sent2870 impact O
sent2870 on O
sent2870 otitis D
sent2870 media D
sent2871 conclusions O
sent2871 : O
sent2871 the O
sent2871 heptavalent T
sent2871 pneumococcal T
sent2871 conjugate T
sent2871 vaccine T
sent2871 is O
sent2871 safe O
sent2871 and O
sent2871 highly O
sent2871 effective O
sent2871 in O
sent2871 preventing O
sent2871 pneumococcal D
sent2871 meningitis D
sent2871 and D
sent2871 bacteremic D
sent2871 pneumonia D
sent2871 in O
sent2871 young O
sent2871 children O
sent2871 < O
sent2871 2 O
sent2871 years O
sent2871 of O
sent2871 age O
sent2871 ; O
sent2871 it O
sent2871 is O
sent2871 less O
sent2871 effective O
sent2871 in O
sent2871 preventing O
sent2871 otitis O
sent2871 media O
sent2872 based O
sent2872 on O
sent2872 the O
sent2872 results O
sent2872 of O
sent2872 three O
sent2872 well-designed O
sent2872 studies O
sent2872 demonstrating O
sent2872 the O
sent2872 vaccine O
sent2872 's O
sent2872 safety O
sent2872 , O
sent2872 immunogenicity O
sent2872 , O
sent2872 and O
sent2872 efficacy O
sent2872 , O
sent2872 the O
sent2872 vaccine T
sent2872 is O
sent2872 safe O
sent2872 and O
sent2872 effective O
sent2872 for O
sent2872 active O
sent2872 immunization O
sent2872 of O
sent2872 children O
sent2872 < O
sent2872 2 O
sent2872 years O
sent2872 of O
sent2872 age O
sent2872 against O
sent2872 invasive D
sent2872 disease D
sent2872 caused D
sent2872 by D
sent2872 seven D
sent2872 streptococcus D
sent2872 pneumoniae D
sent2872 serotypes D
sent2872 included O
sent2872 in O
sent2872 the O
sent2872 vaccine O
sent2873 < O
sent2873 TO_SEE O
sent2873 > O
sent2873 i O
sent2873 concluded O
sent2873 that O
sent2873 6-month O
sent2873 regimen O
sent2873 containing O
sent2873 pyrazinamide T
sent2873 was O
sent2873 effective O
sent2873 for O
sent2873 the O
sent2873 patients O
sent2873 with O
sent2873 isoniazid-rifampicin D
sent2873 susceptible D
sent2873 tuberculosis D
sent2873 patients O
sent2873 except O
sent2873 the O
sent2873 patients O
sent2873 complicated O
sent2873 with O
sent2873 diabetes D
sent2873 mellitus D
sent2874 only O
sent2874 the O
sent2874 combination T
sent2874 of T
sent2874 a T
sent2874 cell T
sent2874 wall-active T
sent2874 antibiotic T
sent2874 to T
sent2874 which T
sent2874 the T
sent2874 enterococcus T
sent2874 is T
sent2874 susceptible T
sent2874 ( T
sent2874 ie T
sent2874 , T
sent2874 certain T
sent2874 beta-lactams T
sent2874 or T
sent2874 vancomycin T
sent2874 ) T
sent2874 plus T
sent2874 an T
sent2874 aminoglycoside T
sent2874 ( T
sent2874 ie T
sent2874 , T
sent2874 gentamicin T
sent2874 or T
sent2874 streptomycin T
sent2874 ) T
sent2874 is O
sent2874 bactericidal O
sent2874 , O
sent2874 and O
sent2874 is O
sent2874 required O
sent2874 for O
sent2874 cure O
sent2874 of O
sent2874 endocarditis D
sent2874 , D
sent2874 meningitis D
sent2874 and D
sent2874 probably D
sent2874 infection D
sent2874 in D
sent2874 neutropenic D
sent2874 patients D
sent2874 ; O
sent2874 bacteriostatic O
sent2874 activity O
sent2874 is O
sent2874 sufficient O
sent2874 to O
sent2874 treat O
sent2874 most O
sent2874 other O
sent2874 infections O
sent2875 two T
sent2875 triazole T
sent2875 antifungal T
sent2875 agents T
sent2875 , T
sent2875 fluconazole T
sent2875 and T
sent2875 itraconazole T
sent2875 , O
sent2875 were O
sent2875 introduced O
sent2875 over O
sent2875 a O
sent2875 decade O
sent2875 ago O
sent2875 and O
sent2875 since O
sent2875 then O
sent2875 have O
sent2875 been O
sent2875 used O
sent2875 extensively O
sent2875 for O
sent2875 the O
sent2875 prophylaxis O
sent2875 and O
sent2875 treatment O
sent2875 of O
sent2875 a O
sent2875 variety O
sent2875 of O
sent2875 fungal D
sent2875 infections D
sent2876 the O
sent2876 use O
sent2876 of O
sent2876 topical T
sent2876 corticosteroids T
sent2876 has O
sent2876 revolutionised O
sent2876 the O
sent2876 treatment O
sent2876 of O
sent2876 inflammatory D
sent2876 skin D
sent2876 diseases D
sent2877 in O
sent2877 particular O
sent2877 , O
sent2877 tacrolimus T
sent2877 and T
sent2877 ascomycin T
sent2877 derivatives T
sent2877 have O
sent2877 been O
sent2877 shown O
sent2877 to O
sent2877 be O
sent2877 effective O
sent2877 for O
sent2877 treating O
sent2877 atopic D
sent2877 dermatitism D
sent2877 with O
sent2877 a O
sent2877 surprising O
sent2877 lack O
sent2877 of O
sent2877 side O
sent2877 effects O
sent2878 cyclophosphamide T
sent2878 therapy T
sent2878 is O
sent2878 effective O
sent2878 for O
sent2878 bronchiolitis D
sent2878 obliterans D
sent2878 occurring D
sent2878 as D
sent2878 a D
sent2878 late D
sent2878 manifestation D
sent2878 of D
sent2878 lupus D
sent2878 erythematosus D
sent2878 ( O
sent2878 letter O
sent2878 ) O
sent2879 in O
sent2879 summary O
sent2879 , O
sent2879 gemifloxacin T
sent2879 was O
sent2879 found O
sent2879 to O
sent2879 be O
sent2879 well O
sent2879 tolerated O
sent2879 and O
sent2879 effective O
sent2879 for O
sent2879 the O
sent2879 treatment O
sent2879 of O
sent2879 aecb D
sent2879 , O
sent2879 suggesting O
sent2879 it O
sent2879 is O
sent2879 well O
sent2879 suited O
sent2879 for O
sent2879 empirical O
sent2879 treatment O
sent2879 of O
sent2879 this O
sent2879 common O
sent2879 respiratory O
sent2879 condition O
sent2879 in O
sent2879 the O
sent2879 current O
sent2879 clinical O
sent2879 environment O
sent2880 d-penicillamine T
sent2880 ( T
sent2880 2-amino-3-mercapto-3-methylbutanoic T
sent2880 acid T
sent2880 ) T
sent2880 , T
sent2880 a T
sent2880 well-known T
sent2880 heavy T
sent2880 metal T
sent2880 chelator T
sent2880 , O
sent2880 is O
sent2880 the O
sent2880 drug O
sent2880 of O
sent2880 choice O
sent2880 in O
sent2880 the O
sent2880 treatment O
sent2880 of O
sent2880 wilson D
sent2880 's D
sent2880 disease D
sent2880 and O
sent2880 is O
sent2880 also O
sent2880 effective O
sent2880 for O
sent2880 the O
sent2880 treatment O
sent2880 of O
sent2880 several D
sent2880 disorders D
sent2880 including D
sent2880 rheumatoid D
sent2880 arthritis D
sent2880 , D
sent2880 primary D
sent2880 biliary D
sent2880 cirrhosis D
sent2880 , D
sent2880 scleroderma D
sent2880 , D
sent2880 fibrotic D
sent2880 lung D
sent2880 diseases D
sent2880 and D
sent2880 progressive D
sent2880 systemic D
sent2880 sclerosis D
sent2881 stages O
sent2881 of O
sent2881 non-small D
sent2881 cell D
sent2881 lung D
sent2881 cancer D
sent2881 ( D
sent2881 nsclc D
sent2881 ) D
sent2881 that O
sent2881 are O
sent2881 potential O
sent2881 candidates O
sent2881 for O
sent2881 surgical T
sent2881 resection T
sent2881 have O
sent2881 been O
sent2881 treated O
sent2881 in O
sent2881 several O
sent2881 ways O
sent2881 : O
sent2881 surgery T
sent2881 alone O
sent2881 is O
sent2881 curative O
sent2881 in O
sent2881 only O
sent2881 two-thirds O
sent2881 of O
sent2881 cases O
sent2881 and O
sent2881 post-operative T
sent2881 radiotherapy T
sent2881 ( T
sent2881 rt T
sent2881 ) T
sent2881 provides O
sent2881 only O
sent2881 weak O
sent2881 control O
sent2881 of O
sent2881 advanced-stage O
sent2881 disease O
sent2882 among O
sent2882 these O
sent2882 , O
sent2882 the O
sent2882 gemcitabine/cisplatin T
sent2882 study O
sent2882 protocol O
sent2882 ( O
sent2882 gc O
sent2882 ) O
sent2882 , O
sent2882 set O
sent2882 up O
sent2882 in O
sent2882 a O
sent2882 phase O
sent2882 ii O
sent2882 study O
sent2882 for O
sent2882 patients O
sent2882 with O
sent2882 stage D
sent2882 iiia D
sent2882 n2 D
sent2882 nsclc D
sent2882 , O
sent2882 was O
sent2882 very O
sent2882 effective O
sent2882 ( O
sent2882 objective O
sent2882 response O
sent2882 ( O
sent2882 or O
sent2882 ) O
sent2882 : O
sent2882 70.2 O
sent2882 % O
sent2882 ; O
sent2882 median O
sent2882 survival O
sent2882 : O
sent2882 19 O
sent2882 months O
sent2882 ) O
sent2882 and O
sent2882 should O
sent2882 be O
sent2882 promising O
sent2882 for O
sent2882 stages O
sent2882 ib O
sent2882 and O
sent2882 ii O
sent2883 several O
sent2883 studies O
sent2883 have O
sent2883 suggested O
sent2883 that O
sent2883 non-small D
sent2883 cell D
sent2883 lung D
sent2883 cancer D
sent2883 ( D
sent2883 nsclc D
sent2883 ) D
sent2883 patients O
sent2883 whose O
sent2883 tumors O
sent2883 have O
sent2883 neuroendocrine O
sent2883 ( O
sent2883 ne O
sent2883 ) O
sent2883 features O
sent2883 may O
sent2883 be O
sent2883 more O
sent2883 responsive O
sent2883 to O
sent2883 chemotherapy T
sent2883 in O
sent2883 addition O
sent2883 , O
sent2883 increased O
sent2883 expression O
sent2883 of O
sent2883 p53 O
sent2883 and O
sent2883 her2 O
sent2883 may O
sent2883 confer O
sent2883 relative O
sent2883 chemotherapy O
sent2883 resistance O
sent2883 and O
sent2883 shortened O
sent2883 survival O
sent2884 the O
sent2884 cancer O
sent2884 and O
sent2884 leukemia O
sent2884 group O
sent2884 b O
sent2884 performed O
sent2884 a O
sent2884 series O
sent2884 of O
sent2884 studies O
sent2884 involving O
sent2884 sequential T
sent2884 chemotherapy T
sent2884 followed T
sent2884 by T
sent2884 radiation T
sent2884 for O
sent2884 patients O
sent2884 with O
sent2884 unresectable D
sent2884 stage D
sent2884 iii D
sent2884 nsclc D
sent2885 this O
sent2885 london O
sent2885 lung O
sent2885 cancer O
sent2885 group O
sent2885 trial O
sent2885 of O
sent2885 gemcitabine/carboplatin T
sent2885 may O
sent2885 define O
sent2885 an O
sent2885 active O
sent2885 , O
sent2885 safe O
sent2885 , O
sent2885 and O
sent2885 acceptable O
sent2885 treatment O
sent2885 for O
sent2885 patients O
sent2885 with O
sent2885 extensive-stage O
sent2885 and O
sent2885 poor-prognosis O
sent2885 small D
sent2885 cell D
sent2885 lung D
sent2885 cancer D
sent2886 gemcitabine T
sent2886 and T
sent2886 carboplatin T
sent2886 for O
sent2886 patients O
sent2886 with O
sent2886 advanced D
sent2886 non-small D
sent2886 cell D
sent2886 lung D
sent2886 cancer D
sent2887 an T
sent2887 aggressive T
sent2887 surgical T
sent2887 approach T
sent2887 is O
sent2887 justified O
sent2887 in O
sent2887 patients O
sent2887 with O
sent2887 mplc D
sent2887 and O
sent2887 offers O
sent2887 the O
sent2887 greatest O
sent2887 chance O
sent2887 for O
sent2887 long-term O
sent2887 survival O
sent2887 even O
sent2887 in O
sent2887 the O
sent2887 case O
sent2887 of O
sent2887 limited O
sent2887 resection O
sent2888 methods O
sent2888 and O
sent2888 materials O
sent2888 : O
sent2888 eleven O
sent2888 patients O
sent2888 with O
sent2888 small D
sent2888 cell D
sent2888 lung D
sent2888 cancer D
sent2888 ( D
sent2888 sclc D
sent2888 ) D
sent2888 , O
sent2888 who O
sent2888 had O
sent2888 presented O
sent2888 complete O
sent2888 response O
sent2888 of O
sent2888 disease O
sent2888 after O
sent2888 chemotherapy T
sent2888 and O
sent2888 radical T
sent2888 radiotherapy T
sent2888 in T
sent2888 the T
sent2888 lung T
sent2888 , O
sent2888 were O
sent2888 prescribed O
sent2888 to O
sent2888 receive O
sent2888 a O
sent2888 prophylacting O
sent2888 cranial O
sent2888 irradiation O
sent2888 ( O
sent2888 pci O
sent2888 ) O
sent2888 with O
sent2888 a O
sent2888 6 O
sent2888 mev O
sent2888 linear O
sent2888 accelerator O
sent2889 only O
sent2889 22 O
sent2889 patients O
sent2889 ( O
sent2889 10 O
sent2889 % O
sent2889 ) O
sent2889 were O
sent2889 alive O
sent2889 at O
sent2889 five O
sent2889 years O
sent2889 : O
sent2889 19 O
sent2889 patients O
sent2889 with O
sent2889 nsclc D
sent2889 who O
sent2889 had O
sent2889 got O
sent2889 surgical T
sent2889 treatment T
sent2889 , O
sent2889 one O
sent2889 patient O
sent2889 with O
sent2889 nsclc D
sent2889 ( D
sent2889 stage D
sent2889 iiib D
sent2889 ) D
sent2889 who O
sent2889 had O
sent2889 recieved O
sent2889 radiotherapy T
sent2889 , O
sent2889 and O
sent2889 two O
sent2889 patients O
sent2889 with O
sent2889 sclc D
sent2889 , D
sent2889 limited D
sent2889 disease D
sent2889 , O
sent2889 treated O
sent2889 with O
sent2889 chemo- T
sent2889 and T
sent2889 radiotherapy T
sent2890 < O
sent2890 TO_SEE O
sent2890 > O
sent2890 the O
sent2890 standard O
sent2890 care O
sent2890 for O
sent2890 patients O
sent2890 with O
sent2890 non-small-cell D
sent2890 lung D
sent2890 cancer D
sent2890 is O
sent2890 chemotherapy T
sent2890 of T
sent2890 supportive T
sent2890 care T
sent2890 , O
sent2890 with O
sent2890 surgery T
sent2890 being O
sent2890 reserved O
sent2890 for O
sent2890 palliation O
sent2890 of O
sent2890 symptoms O
sent2890 ; O
sent2890 however O
sent2890 , O
sent2890 there O
sent2890 is O
sent2890 a O
sent2890 small O
sent2890 group O
sent2890 of O
sent2890 patients O
sent2890 with O
sent2890 a O
sent2890 finite O
sent2890 number O
sent2890 of O
sent2890 extrathoracic D
sent2890 metastases D
sent2890 ( D
sent2890 oligometastases D
sent2890 ) D
sent2890 who O
sent2890 may O
sent2890 experience O
sent2890 improved O
sent2890 survival O
sent2890 by O
sent2890 resection T
sent2890 of T
sent2890 their T
sent2890 metastases T
sent2890 and T
sent2890 the T
sent2890 primary T
sent2890 site T
sent2890 , O
sent2890 with O
sent2890 or O
sent2890 without O
sent2890 systemic O
sent2890 treatment O
sent2891 five O
sent2891 new O
sent2891 agents O
sent2891 , O
sent2891 paclitaxel T
sent2891 , O
sent2891 docetaxel T
sent2891 , O
sent2891 vinorelbine T
sent2891 , O
sent2891 gemcitabine T
sent2891 and O
sent2891 irinotecan T
sent2891 , O
sent2891 have O
sent2891 been O
sent2891 introduced O
sent2891 for O
sent2891 the O
sent2891 treatment O
sent2891 of O
sent2891 nsclc D
sent2891 and O
sent2891 investigated O
sent2891 extensively O
sent2891 both O
sent2891 preclinically O
sent2891 and O
sent2891 clinically O
sent2892 whether O
sent2892 the O
sent2892 era O
sent2892 of O
sent2892 platinum-based T
sent2892 chemotherapy T
sent2892 in O
sent2892 the O
sent2892 treatment O
sent2892 of O
sent2892 nsclc D
sent2892 should O
sent2892 continue O
sent2892 or O
sent2892 not O
sent2892 must O
sent2892 be O
sent2892 determined O
sent2892 by O
sent2892 phase O
sent2892 iii O
sent2892 trials O
sent2892 , O
sent2892 evaluating O
sent2892 the O
sent2892 use O
sent2892 of O
sent2892 a O
sent2892 platinum O
sent2892 agent O
sent2892 with O
sent2892 one O
sent2892 of O
sent2892 the O
sent2892 new O
sent2892 agent O
sent2892 combinations O
sent2893 these O
sent2893 aggressive T
sent2893 chemotherapeutic T
sent2893 combinations T
sent2893 will O
sent2893 hopefully O
sent2893 improve O
sent2893 survival O
sent2893 and O
sent2893 quality O
sent2893 of O
sent2893 life O
sent2893 for O
sent2893 patients O
sent2893 with O
sent2893 advanced D
sent2893 nsclc D
sent2894 results O
sent2894 : O
sent2894 we O
sent2894 have O
sent2894 performed O
sent2894 60 O
sent2894 carinal T
sent2894 resections T
sent2894 for O
sent2894 bronchogenic D
sent2894 carcinoma D
sent2894 : O
sent2894 18 O
sent2894 isolated T
sent2894 carinal T
sent2894 resections T
sent2894 for O
sent2894 tumor D
sent2894 confined D
sent2894 to D
sent2894 the D
sent2894 carinal D
sent2894 or D
sent2894 proximal D
sent2894 main D
sent2894 stem D
sent2894 bronchus D
sent2894 ; O
sent2894 35 O
sent2894 carinal T
sent2894 pneumonectomies T
sent2894 ; O
sent2894 5 O
sent2894 carinal T
sent2894 plus T
sent2894 lobar T
sent2894 resections T
sent2894 , O
sent2894 and O
sent2894 2 O
sent2894 carinal T
sent2894 resections T
sent2894 for O
sent2894 stump D
sent2894 recurrence D
sent2894 after D
sent2894 prior D
sent2894 pneumonectomy D
sent2895 conclusions O
sent2895 : O
sent2895 this O
sent2895 constitutes O
sent2895 one O
sent2895 of O
sent2895 the O
sent2895 largest O
sent2895 single-institution O
sent2895 reports O
sent2895 on O
sent2895 carinal T
sent2895 resection T
sent2895 for O
sent2895 bronchogenic D
sent2895 carcinoma D
sent2895 involving D
sent2895 the D
sent2895 carina D
sent2896 extracorporeal T
sent2896 photopheresis T
sent2896 has O
sent2896 evolved O
sent2896 as O
sent2896 a O
sent2896 possible O
sent2896 therapy O
sent2896 for O
sent2896 patients O
sent2896 with O
sent2896 acute D
sent2896 nd D
sent2896 chronic D
sent2896 lung D
sent2896 allograft D
sent2896 rejection D
sent2897 methods O
sent2897 : O
sent2897 we O
sent2897 retrospectively O
sent2897 reviewed O
sent2897 14 O
sent2897 patients O
sent2897 diagnosed O
sent2897 with O
sent2897 bos D
sent2897 who O
sent2897 underwent O
sent2897 therapy T
sent2897 with T
sent2897 extracorporeal T
sent2897 photopheresis T
sent2898 in O
sent2898 three O
sent2898 patients O
sent2898 with O
sent2898 bos D
sent2898 and D
sent2898 concurrent D
sent2898 acute D
sent2898 rejection D
sent2898 , O
sent2898 therapy T
sent2898 with T
sent2898 extracorporeal T
sent2898 photopheresis T
sent2898 led O
sent2898 to O
sent2898 the O
sent2898 resolution O
sent2898 of O
sent2898 the O
sent2898 acute O
sent2898 rejection O
sent2898 episode O
sent2899 conclusion O
sent2899 : O
sent2899 extracorporeal T
sent2899 photopheresis T
sent2899 appears O
sent2899 to O
sent2899 be O
sent2899 a O
sent2899 promising O
sent2899 therapy O
sent2899 for O
sent2899 patients O
sent2899 with O
sent2899 early D
sent2899 bos D
sent2900 purpose O
sent2900 : O
sent2900 many O
sent2900 patients O
sent2900 with O
sent2900 locally D
sent2900 advanced D
sent2900 non-small-cell D
sent2900 lung D
sent2900 cancer D
sent2900 ( D
sent2900 la-nsclc D
sent2900 ) D
sent2900 are O
sent2900 eligible O
sent2900 for O
sent2900 combined-modality T
sent2900 therapy T
sent2900 ( T
sent2900 cmt T
sent2900 ; T
sent2900 chemotherapy T
sent2900 and T
sent2900 radiotherapy T
sent2900 ) T
sent2901 over O
sent2901 the O
sent2901 past O
sent2901 twenty O
sent2901 years O
sent2901 combination T
sent2901 chemotherapy T
sent2901 has O
sent2901 continued O
sent2901 to O
sent2901 produce O
sent2901 small O
sent2901 survival O
sent2901 gains O
sent2901 for O
sent2901 patients O
sent2901 with O
sent2901 sclc D
sent2902 < O
sent2902 TO_SEE O
sent2902 > O
sent2902 purpose O
sent2902 : O
sent2902 the O
sent2902 benefit O
sent2902 of O
sent2902 whole-lung T
sent2902 irradiation T
sent2902 ( T
sent2902 wli T
sent2902 ) T
sent2902 for O
sent2902 patients O
sent2902 who O
sent2902 have O
sent2902 pulmonary D
sent2902 metastases D
sent2902 ( D
sent2902 pm D
sent2902 ) D
sent2902 of D
sent2902 ewing D
sent2902 sarcoma D
sent2902 family D
sent2902 tumors D
sent2902 ( D
sent2902 esft D
sent2902 ) D
sent2902 is O
sent2902 unclear O
sent2903 extent O
sent2903 of O
sent2903 pulmonary O
sent2903 involvement O
sent2903 at O
sent2903 diagnosis O
sent2903 , O
sent2903 response O
sent2903 of O
sent2903 pm D
sent2903 after O
sent2903 induction T
sent2903 chemotherapy T
sent2903 , O
sent2903 local O
sent2903 treatment O
sent2903 of O
sent2903 pm O
sent2903 thereafter O
sent2903 , O
sent2903 and O
sent2903 clinical O
sent2903 outcome O
sent2903 were O
sent2903 recorded O
sent2904 conclusions O
sent2904 : O
sent2904 the O
sent2904 comparable O
sent2904 survival O
sent2904 of O
sent2904 patients O
sent2904 with O
sent2904 poor O
sent2904 and O
sent2904 good O
sent2904 response O
sent2904 of O
sent2904 pm D
sent2904 to O
sent2904 induction T
sent2904 chemotherapy T
sent2904 suggests O
sent2904 that O
sent2904 wli T
sent2904 may O
sent2904 benefit O
sent2904 poor O
sent2904 responders O
sent2905 objective O
sent2905 : O
sent2905 to O
sent2905 report O
sent2905 the O
sent2905 use O
sent2905 of O
sent2905 heparin T
sent2905 and O
sent2905 enoxaparin T
sent2905 for O
sent2905 radiation-induced D
sent2905 myelopathy D
sent2906 therefore O
sent2906 , O
sent2906 patients O
sent2906 with O
sent2906 radiation-induced D
sent2906 spinal D
sent2906 cord D
sent2906 injury D
sent2906 may O
sent2906 benefit O
sent2906 from O
sent2906 anticoagulant T
sent2906 therapy T
sent2907 conclusions O
sent2907 : O
sent2907 heparin T
sent2907 and/or T
sent2907 enoxaparin T
sent2907 may O
sent2907 be O
sent2907 considered O
sent2907 as O
sent2907 potential O
sent2907 treatments O
sent2907 for O
sent2907 patients O
sent2907 with O
sent2907 radiation-induced D
sent2907 myelopathy D
sent2908 < O
sent2908 TO_SEE O
sent2908 > O
sent2908 tracheal O
sent2908 stent O
sent2908 insertion O
sent2908 is O
sent2908 a O
sent2908 useful O
sent2908 method O
sent2908 for O
sent2908 patients O
sent2908 with O
sent2908 malignant O
sent2908 tracheal O
sent2908 stenosis O
sent2909 expandable T
sent2909 metal T
sent2909 stents T
sent2909 were O
sent2909 inserted O
sent2909 in O
sent2909 two O
sent2909 patients O
sent2909 with O
sent2909 severe D
sent2909 dyspnea D
sent2909 due D
sent2909 to D
sent2909 tracheal D
sent2909 stenosis D
sent2909 caused D
sent2909 by D
sent2909 lung D
sent2909 cancer D
sent2909 and D
sent2909 esophageal D
sent2909 cancer D
sent2910 thus O
sent2910 , O
sent2910 we O
sent2910 should O
sent2910 recognize O
sent2910 this O
sent2910 immanent O
sent2910 risk O
sent2910 and O
sent2910 perform O
sent2910 peri- T
sent2910 and T
sent2910 postoperative T
sent2910 management T
sent2910 for O
sent2910 patients O
sent2910 with O
sent2910 gh-producing D
sent2910 tumors D
sent2911 background O
sent2911 : O
sent2911 at O
sent2911 present O
sent2911 the O
sent2911 addition T
sent2911 of T
sent2911 thoracic T
sent2911 irradiation T
sent2911 to T
sent2911 combination T
sent2911 chemotherapy T
sent2911 is O
sent2911 a O
sent2911 standard O
sent2911 treatment O
sent2911 for O
sent2911 limited D
sent2911 staged D
sent2911 small D
sent2911 cell D
sent2911 lung D
sent2911 cancer D
sent2912 we O
sent2912 conducted O
sent2912 a O
sent2912 phase O
sent2912 ii O
sent2912 study O
sent2912 of O
sent2912 etoposide T
sent2912 ( T
sent2912 vp-16 T
sent2912 ) T
sent2912 -ifosfamide-cisplatin T
sent2912 ( T
sent2912 vip T
sent2912 ) T
sent2912 combination T
sent2912 chemotherapy T
sent2912 plus T
sent2912 early T
sent2912 concurrent T
sent2912 thoracic T
sent2912 irradiation T
sent2912 for O
sent2912 the O
sent2912 patients O
sent2912 with O
sent2912 previously O
sent2912 untreated D
sent2912 limited D
sent2912 small D
sent2912 cell D
sent2912 lung D
sent2912 cancer D
sent2912 in O
sent2912 order O
sent2912 to O
sent2912 assess O
sent2912 if O
sent2912 the O
sent2912 treatment O
sent2912 modality O
sent2912 could O
sent2912 improve O
sent2912 the O
sent2912 response O
sent2912 rate O
sent2912 and O
sent2912 the O
sent2912 toxicity O
sent2913 methods O
sent2913 : O
sent2913 forty-four O
sent2913 patients O
sent2913 with O
sent2913 limited D
sent2913 small D
sent2913 cell D
sent2913 lung D
sent2913 cancer D
sent2913 were O
sent2913 treated O
sent2913 with O
sent2913 etoposide-ifosfamide-cisplatin T
sent2913 and T
sent2913 concurrent T
sent2913 thoracic T
sent2913 irradiation T
sent2914 conclusion O
sent2914 : O
sent2914 vip T
sent2914 combination T
sent2914 chemotherapy T
sent2914 and T
sent2914 early T
sent2914 concurrent T
sent2914 thoracic T
sent2914 irradiation T
sent2914 for O
sent2914 patients O
sent2914 with O
sent2914 limited D
sent2914 stage D
sent2914 small D
sent2914 cell D
sent2914 lung D
sent2914 cancer D
sent2914 revealed O
sent2914 excellent O
sent2914 antitumor O
sent2914 response O
sent2914 with O
sent2914 tolerable O
sent2914 toxicity O
sent2915 in O
sent2915 this O
sent2915 study O
sent2915 we O
sent2915 analyzed O
sent2915 33 O
sent2915 cases O
sent2915 which O
sent2915 underwent O
sent2915 complete T
sent2915 surgical T
sent2915 resection T
sent2915 to O
sent2915 assess O
sent2915 the O
sent2915 role O
sent2915 of O
sent2915 surgery O
sent2915 in O
sent2915 the O
sent2915 treatment O
sent2915 of O
sent2915 patients O
sent2915 with O
sent2915 n D
sent2915 2 D
sent2915 nsclc D
sent2916 we O
sent2916 thereby O
sent2916 recommend O
sent2916 that O
sent2916 surgery T
sent2916 should O
sent2916 only O
sent2916 be O
sent2916 performed O
sent2916 for O
sent2916 those O
sent2916 n D
sent2916 2 D
sent2916 nsclc D
sent2916 patients O
sent2916 diagnosed O
sent2916 as O
sent2916 t O
sent2916 1 O
sent2916 or O
sent2916 t O
sent2916 2 O
sent2916 with O
sent2916 a O
sent2916 classification O
sent2916 of O
sent2916 p1 O
sent2916 or O
sent2916 less O
sent2917 inhaled T
sent2917 corticosteroid T
sent2917 therapy T
sent2917 is O
sent2917 recommended O
sent2917 for O
sent2917 patients O
sent2917 with O
sent2917 persistent D
sent2917 disease D
sent2917 , O
sent2917 and O
sent2917 careful O
sent2917 instruction O
sent2917 in O
sent2917 the O
sent2917 use O
sent2917 of O
sent2917 metered-dose O
sent2917 inhalers O
sent2917 is O
sent2917 particularly O
sent2917 important O
sent2917 for O
sent2917 the O
sent2917 elderly O
sent2918 background O
sent2918 : O
sent2918 the O
sent2918 role O
sent2918 of O
sent2918 surgical T
sent2918 staging T
sent2918 of O
sent2918 patients O
sent2918 with O
sent2918 non-small D
sent2918 cell D
sent2918 lung D
sent2918 cancer D
sent2918 ( D
sent2918 nsclc D
sent2918 ) D
sent2918 continues O
sent2918 to O
sent2918 evolve O
sent2919 < O
sent2919 TO_SEE O
sent2919 > O
sent2919 this O
sent2919 report O
sent2919 describes O
sent2919 our O
sent2919 findings O
sent2919 utilizing O
sent2919 routine O
sent2919 cervical O
sent2919 mediastinoscopy O
sent2919 in O
sent2919 the O
sent2919 evaluation O
sent2919 of O
sent2919 peripheral O
sent2919 t1 O
sent2919 ( O
sent2919 < O
sent2919 3 O
sent2919 cm O
sent2919 ) O
sent2919 lung O
sent2919 tumors O
sent2920 < O
sent2920 TO_SEE O
sent2920 > O
sent2920 mediastinoscopy O
sent2920 facilitates O
sent2920 identification O
sent2920 of O
sent2920 patients O
sent2920 with O
sent2920 regionally D
sent2920 advanced D
sent2920 disease D
sent2920 prior D
sent2920 to D
sent2920 resection D
sent2920 , O
sent2920 allowing O
sent2920 neoadjuvant T
sent2920 therapy T
sent2920 and O
sent2920 avoiding O
sent2920 unnecessary O
sent2920 resections O
sent2921 purpose O
sent2921 : O
sent2921 given O
sent2921 the O
sent2921 cisplatin-related O
sent2921 myelotoxicity O
sent2921 and O
sent2921 nonhematologic O
sent2921 toxicities O
sent2921 , O
sent2921 we O
sent2921 were O
sent2921 prompted O
sent2921 to O
sent2921 undertake O
sent2921 a O
sent2921 study O
sent2921 of O
sent2921 the O
sent2921 noncisplatin T
sent2921 combination T
sent2921 of T
sent2921 paclitaxel T
sent2921 plus T
sent2921 gemcitabine T
sent2921 to O
sent2921 evaluate O
sent2921 the O
sent2921 efficacy O
sent2921 , O
sent2921 tolerance O
sent2921 , O
sent2921 and O
sent2921 survival O
sent2921 of O
sent2921 this O
sent2921 combination O
sent2921 in O
sent2921 patients O
sent2921 with O
sent2921 locally D
sent2921 advanced D
sent2921 and D
sent2921 metastatic D
sent2921 non-small-cell D
sent2921 lung D
sent2921 cancer D
sent2921 ( D
sent2921 nsclc D
sent2921 ) D
sent2922 we O
sent2922 evaluated O
sent2922 the O
sent2922 role O
sent2922 of O
sent2922 systemic T
sent2922 chemotherapy T
sent2922 for O
sent2922 patients O
sent2922 with O
sent2922 malignant D
sent2922 pleural D
sent2922 effusions D
sent2922 from D
sent2922 nsclc D
sent2923 methods O
sent2923 : O
sent2923 we O
sent2923 analyzed O
sent2923 34 O
sent2923 patients O
sent2923 who O
sent2923 were O
sent2923 found O
sent2923 to O
sent2923 have O
sent2923 malignant D
sent2923 pleural D
sent2923 effusions D
sent2923 in O
sent2923 the O
sent2923 course O
sent2923 of O
sent2923 diagnosis O
sent2923 of O
sent2923 118 O
sent2923 patients O
sent2923 enrolled O
sent2923 in O
sent2923 three O
sent2923 consecutive O
sent2923 clinical O
sent2923 trials O
sent2923 on O
sent2923 advanced O
sent2923 nsclc D
sent2923 assessing O
sent2923 combination T
sent2923 chemotherapy T
sent2923 of T
sent2923 cisplatin T
sent2923 , T
sent2923 ifosfamide T
sent2923 , T
sent2923 and T
sent2923 irinotecan T
sent2923 with T
sent2923 recombinant T
sent2923 human T
sent2923 granulocyte T
sent2923 colony-stimulating T
sent2923 factor T
sent2923 support T
sent2924 conclusions O
sent2924 : O
sent2924 both O
sent2924 the O
sent2924 response O
sent2924 rate O
sent2924 and O
sent2924 survival O
sent2924 data O
sent2924 in O
sent2924 this O
sent2924 retrospective O
sent2924 study O
sent2924 suggest O
sent2924 a O
sent2924 high O
sent2924 degree O
sent2924 of O
sent2924 activity O
sent2924 of O
sent2924 this O
sent2924 combination T
sent2924 chemotherapy T
sent2924 in O
sent2924 patients O
sent2924 with O
sent2924 malignant D
sent2924 pleural D
sent2924 effusions D
sent2924 from D
sent2924 nsclc D
sent2925 in O
sent2925 contrast O
sent2925 , O
sent2925 the O
sent2925 introduction O
sent2925 and O
sent2925 improvement O
sent2925 of O
sent2925 chemotherapy T
sent2925 since O
sent2925 the O
sent2925 1970s O
sent2925 gave O
sent2925 rise O
sent2925 to O
sent2925 an O
sent2925 improvement O
sent2925 in O
sent2925 - O
sent2925 only O
sent2925 short-term O
sent2925 ( O
sent2925 < O
sent2925 2 O
sent2925 years O
sent2925 ) O
sent2925 - O
sent2925 survival O
sent2925 for O
sent2925 patients O
sent2925 with O
sent2925 small-cell D
sent2925 lung D
sent2925 cancer D
sent2926 between O
sent2926 july O
sent2926 1992 O
sent2926 and O
sent2926 december O
sent2926 1997 O
sent2926 , O
sent2926 1799 O
sent2926 patients O
sent2926 were O
sent2926 diagnosed O
sent2926 as O
sent2926 having O
sent2926 lung D
sent2926 cancer D
sent2926 in O
sent2926 our O
sent2926 hospital O
sent2926 and O
sent2926 926 O
sent2926 patients O
sent2926 received O
sent2926 chemotherapy T
sent2926 and/or T
sent2926 thoracic T
sent2926 radiotherapy T
sent2927 the O
sent2927 administration O
sent2927 of O
sent2927 mitomycin T
sent2927 c T
sent2927 in O
sent2927 addition O
sent2927 to O
sent2927 cisplatin-based T
sent2927 regimens T
sent2927 for O
sent2927 patients O
sent2927 with O
sent2927 lung D
sent2927 cancer D
sent2927 should O
sent2927 be O
sent2927 carefully O
sent2927 considered O
sent2928 570 O
sent2928 patients O
sent2928 with O
sent2928 osteosarcoma D
sent2928 of D
sent2928 the D
sent2928 extremities D
sent2928 were O
sent2928 treated O
sent2928 with O
sent2928 five O
sent2928 different O
sent2928 protocols O
sent2928 of O
sent2928 neoadjuvant T
sent2928 chemotherapy T
sent2928 at O
sent2928 rizzoli O
sent2928 institute O
sent2928 between O
sent2928 1983 O
sent2928 and O
sent2928 1995 O
sent2929 we O
sent2929 conclude O
sent2929 that O
sent2929 for O
sent2929 patients O
sent2929 with O
sent2929 osteosarcoma D
sent2929 of D
sent2929 the D
sent2929 extremities D
sent2929 treated O
sent2929 with O
sent2929 neoadjuvant T
sent2929 chemotherapy T
sent2929 : O
sent2929 ( O
sent2929 a O
sent2929 ) O
sent2929 the O
sent2929 pattern O
sent2929 of O
sent2929 systemic O
sent2929 relapse O
sent2929 changes O
sent2929 according O
sent2929 to O
sent2929 the O
sent2929 efficacy O
sent2929 of O
sent2929 the O
sent2929 protocol O
sent2929 of O
sent2929 chemotherapy O
sent2929 used O
sent2930 the O
sent2930 degree O
sent2930 of O
sent2930 healing O
sent2930 and O
sent2930 damage O
sent2930 of O
sent2930 the O
sent2930 bronchial O
sent2930 wall O
sent2930 after O
sent2930 photodynamic T
sent2930 therapy T
sent2930 , T
sent2930 nd-yag T
sent2930 laser T
sent2930 and T
sent2930 electrocautery T
sent2930 for O
sent2930 intraluminal D
sent2930 early-stage D
sent2930 cancer D
sent2930 have O
sent2930 been O
sent2930 analysed O
sent2931 to O
sent2931 examine O
sent2931 whether O
sent2931 efficacy O
sent2931 of O
sent2931 postoperative O
sent2931 oral O
sent2931 administration O
sent2931 of O
sent2931 uft T
sent2931 , T
sent2931 a T
sent2931 5-fluorouracil T
sent2931 derivative T
sent2931 chemotherapeutic T
sent2931 agent T
sent2931 , O
sent2931 may O
sent2931 be O
sent2931 influenced O
sent2931 by O
sent2931 incidence O
sent2931 of O
sent2931 apoptosis O
sent2931 ( O
sent2931 apoptosis O
sent2931 index O
sent2931 ) O
sent2931 or O
sent2931 apoptosis-related O
sent2931 gene O
sent2931 status O
sent2931 ( O
sent2931 p53 O
sent2931 and O
sent2931 bcl-2 O
sent2931 ) O
sent2931 of O
sent2931 the O
sent2931 tumour O
sent2931 , O
sent2931 a O
sent2931 total O
sent2931 of O
sent2931 162 O
sent2931 patients O
sent2931 with O
sent2931 pathologic D
sent2931 stage D
sent2931 i D
sent2931 non-small D
sent2931 cell D
sent2931 lung D
sent2931 cancer D
sent2931 were O
sent2931 retrospectively O
sent2931 reviewed O
sent2932 objectives O
sent2932 : O
sent2932 the O
sent2932 purpose O
sent2932 of O
sent2932 this O
sent2932 study O
sent2932 is O
sent2932 to O
sent2932 review O
sent2932 our O
sent2932 experience O
sent2932 with O
sent2932 the O
sent2932 spectrum O
sent2932 of O
sent2932 neuroendocrine D
sent2932 neoplasms D
sent2932 of D
sent2932 the D
sent2932 lung D
sent2932 with O
sent2932 emphasis O
sent2932 on O
sent2932 the O
sent2932 histopathologic O
sent2932 classification O
sent2932 and O
sent2932 surgical T
sent2932 therapy T
sent2932 of O
sent2932 each O
sent2932 class O
sent2932 of O
sent2932 neoplasm O
sent2933 patients O
sent2933 : O
sent2933 during O
sent2933 this O
sent2933 period O
sent2933 , O
sent2933 a O
sent2933 total O
sent2933 of O
sent2933 77 O
sent2933 patients O
sent2933 underwent O
sent2933 lung T
sent2933 resection T
sent2933 for O
sent2933 the O
sent2933 following O
sent2933 neuroendocrine D
sent2933 neoplasms D
sent2933 : O
sent2933 typical D
sent2933 carcinoid D
sent2933 ( D
sent2933 tc D
sent2933 ) D
sent2933 , O
sent2933 50 O
sent2933 patients O
sent2933 ; O
sent2933 atypical D
sent2933 carcinoid D
sent2933 ( D
sent2933 ac D
sent2933 ) D
sent2933 , O
sent2933 5 O
sent2933 patients O
sent2933 ; O
sent2933 large D
sent2933 cell D
sent2933 neuroendocrine D
sent2933 carcinoma D
sent2933 ( D
sent2933 lcnec D
sent2933 ) D
sent2933 , O
sent2933 9 O
sent2933 patients O
sent2933 ; O
sent2933 mixed D
sent2933 large-small D
sent2933 cell D
sent2933 neuroendocrine D
sent2933 carcinoma D
sent2933 ( D
sent2933 lsnec D
sent2933 ) D
sent2933 , O
sent2933 4 O
sent2933 patients O
sent2933 ; O
sent2933 or O
sent2933 small D
sent2933 cell D
sent2933 neuroendocrine D
sent2933 carcinoma D
sent2933 ( D
sent2933 scc D
sent2933 ) D
sent2933 , O
sent2933 9 O
sent2933 patients O
sent2934 despite O
sent2934 the O
sent2934 poor O
sent2934 overall O
sent2934 prognosis O
sent2934 in O
sent2934 high-grade O
sent2934 neuroendocrine D
sent2934 tumors D
sent2934 of D
sent2934 the D
sent2934 lung D
sent2934 , O
sent2934 surgery T
sent2934 remains O
sent2934 a O
sent2934 viable O
sent2934 adjunct O
sent2934 in O
sent2934 the O
sent2934 early O
sent2934 stages O
sent2934 of O
sent2934 this O
sent2934 disease O
sent2935 urpose O
sent2935 : O
sent2935 to O
sent2935 assess O
sent2935 results O
sent2935 with O
sent2935 twice-daily O
sent2935 high-dose O
sent2935 radiotherapy T
sent2935 ( T
sent2935 rt T
sent2935 ) T
sent2935 for O
sent2935 non-small-cell D
sent2935 lung D
sent2935 cancer D
sent2935 ( D
sent2935 nsclc D
sent2935 ) D
sent2936 is O
sent2936 prolonged O
sent2936 survival O
sent2936 possible O
sent2936 for O
sent2936 patients O
sent2936 with O
sent2936 supraclavicular D
sent2936 node D
sent2936 metastases D
sent2936 in D
sent2936 nsclc D
sent2936 treated O
sent2936 with O
sent2936 chemoradiotherapy T
sent2936 ? O
sent2936 ijrobp O
sent2936 1999 O
sent2936 ; O
sent2936 44 O
sent2936 ( O
sent2936 4 O
sent2936 ) O
sent2936 : O
sent2936 847-853 O
sent2937 we O
sent2937 aimed O
sent2937 to O
sent2937 investigate O
sent2937 whether O
sent2937 biological O
sent2937 factors O
sent2937 related O
sent2937 to O
sent2937 radiosensitivity O
sent2937 and O
sent2937 chemosensitivity O
sent2937 have O
sent2937 prognostic O
sent2937 significance O
sent2937 in O
sent2937 non-small-cell-lung-cancer D
sent2937 ( D
sent2937 nsclc D
sent2937 ) D
sent2937 patients O
sent2937 treated O
sent2937 with O
sent2937 daily O
sent2937 low O
sent2937 doses O
sent2937 of O
sent2937 cisplatin T
sent2937 and T
sent2937 radiotherapy T
sent2938 we O
sent2938 treated O
sent2938 27 O
sent2938 nsclcm D
sent2938 patients O
sent2938 with O
sent2938 concomitant O
sent2938 daily O
sent2938 low-dose O
sent2938 cisplatin T
sent2938 and T
sent2938 radiotherapy T
sent2938 between O
sent2938 1993 O
sent2938 and O
sent2938 1995 O
sent2939 background O
sent2939 : O
sent2939 we O
sent2939 examined O
sent2939 the O
sent2939 complications O
sent2939 and O
sent2939 outcomes O
sent2939 of O
sent2939 placing O
sent2939 stents T
sent2939 for O
sent2939 both O
sent2939 esophageal D
sent2939 and D
sent2939 tracheobronchial D
sent2939 stenoses D
sent2940 methods O
sent2940 : O
sent2940 we O
sent2940 placed O
sent2940 stents T
sent2940 for O
sent2940 both O
sent2940 esophageal D
sent2940 and D
sent2940 tracheobronchial D
sent2940 stenoses D
sent2940 in O
sent2940 8 O
sent2940 patients O
sent2940 ( O
sent2940 7 O
sent2940 with O
sent2940 esophageal O
sent2940 cancer O
sent2940 and O
sent2940 1 O
sent2940 with O
sent2940 lung O
sent2940 cancer O
sent2940 ) O
sent2941 covered O
sent2941 or O
sent2941 noncovered O
sent2941 metallic T
sent2941 stents T
sent2941 were O
sent2941 used O
sent2941 for O
sent2941 the O
sent2941 esophageal D
sent2941 stenoses D
sent2941 , O
sent2941 except O
sent2941 in O
sent2941 1 O
sent2941 patient O
sent2941 treated O
sent2941 with O
sent2941 a O
sent2941 silicone O
sent2941 stent O
sent2942 silicone T
sent2942 stents T
sent2942 were O
sent2942 used O
sent2942 for O
sent2942 the O
sent2942 tracheobronchial D
sent2942 stenoses D
sent2943 results O
sent2943 : O
sent2943 all O
sent2943 patients O
sent2943 experienced O
sent2943 improvement O
sent2943 of O
sent2943 grades O
sent2943 of O
sent2943 both O
sent2943 dysphagia D
sent2943 and D
sent2943 respiratory D
sent2943 symptoms D
sent2943 after O
sent2943 stent T
sent2943 therapy T
sent2944 conclusions O
sent2944 : O
sent2944 for O
sent2944 patients O
sent2944 with O
sent2944 both O
sent2944 esophageal D
sent2944 and D
sent2944 tracheobronchial D
sent2944 stenoses D
sent2944 , O
sent2944 a O
sent2944 stent T
sent2944 should O
sent2944 be O
sent2944 introduced O
sent2944 into O
sent2944 the O
sent2944 tracheobronchus O
sent2944 first O
sent2945 because O
sent2945 placement O
sent2945 of O
sent2945 stents O
sent2945 in O
sent2945 both O
sent2945 the O
sent2945 esophagus O
sent2945 and O
sent2945 tracheobronchus O
sent2945 has O
sent2945 a O
sent2945 high O
sent2945 risk O
sent2945 of O
sent2945 enlargement O
sent2945 of O
sent2945 the O
sent2945 fistula O
sent2945 , O
sent2945 a O
sent2945 covered T
sent2945 metallic T
sent2945 stent T
sent2945 is O
sent2945 preferable O
sent2945 for O
sent2945 esophageal D
sent2945 cancer D
sent2945 involving D
sent2945 the D
sent2945 tracheobronchus D
sent2946 a O
sent2946 retrospective O
sent2946 immunohistochemical O
sent2946 study O
sent2946 was O
sent2946 performed O
sent2946 on O
sent2946 material O
sent2946 from O
sent2946 patients O
sent2946 who O
sent2946 were O
sent2946 newly O
sent2946 diagnosed O
sent2946 with O
sent2946 osteogenic D
sent2946 sarcoma D
sent2946 who O
sent2946 were O
sent2946 treated O
sent2946 according O
sent2946 to O
sent2946 the O
sent2946 t12 T
sent2946 protocol T
sent2946 from O
sent2946 the O
sent2946 authors O
sent2946 ' O
sent2946 institution O
sent2946 between O
sent2946 1986 O
sent2946 to O
sent2946 1993 O
sent2947 these O
sent2947 data O
sent2947 suggest O
sent2947 that O
sent2947 her2/erbb-2 O
sent2947 should O
sent2947 be O
sent2947 evaluated O
sent2947 prospectively O
sent2947 as O
sent2947 a O
sent2947 prognostic O
sent2947 indicator O
sent2947 and O
sent2947 clinical O
sent2947 trials O
sent2947 using O
sent2947 antibodies T
sent2947 that O
sent2947 target O
sent2947 this O
sent2947 receptor O
sent2947 should O
sent2947 be O
sent2947 considered O
sent2947 for O
sent2947 the O
sent2947 treatment O
sent2947 of O
sent2947 patients O
sent2947 with O
sent2947 osteogenic D
sent2947 sarcoma D
sent2948 objective O
sent2948 : O
sent2948 to O
sent2948 examine O
sent2948 the O
sent2948 effectiveness O
sent2948 of O
sent2948 ninjin T
sent2948 yoei T
sent2948 to T
sent2948 ( T
sent2948 nyt T
sent2948 ; T
sent2948 ren-shen-yang-rong-tang T
sent2948 in T
sent2948 chinese T
sent2948 medicine T
sent2948 ; T
sent2948 kotaro T
sent2948 pharmaceutical T
sent2948 co. T
sent2948 , T
sent2948 ltd. T
sent2948 , T
sent2948 osaka T
sent2948 , T
sent2948 japan T
sent2948 ) T
sent2948 , T
sent2948 one T
sent2948 of T
sent2948 the T
sent2948 traditional T
sent2948 herbal T
sent2948 medicines T
sent2948 , O
sent2948 against O
sent2948 lung D
sent2948 carcinoma D
sent2949 setting O
sent2949 : O
sent2949 the O
sent2949 nursing O
sent2949 center O
sent2949 himawari O
sent2949 design O
sent2949 , O
sent2949 patient O
sent2949 , O
sent2949 and O
sent2949 preparation O
sent2949 : O
sent2949 the O
sent2949 regular O
sent2949 dosage O
sent2949 of O
sent2949 nyt T
sent2949 ( O
sent2949 15 O
sent2949 g/d O
sent2949 ) O
sent2949 was O
sent2949 prescribed O
sent2949 for O
sent2949 7 O
sent2949 weeks O
sent2949 to O
sent2949 one O
sent2949 elderly O
sent2949 patient O
sent2949 with O
sent2949 lung D
sent2949 carcinoma D
sent2950 conclusion O
sent2950 : O
sent2950 nyt T
sent2950 has O
sent2950 a O
sent2950 positive O
sent2950 effect O
sent2950 on O
sent2950 life O
sent2950 expectancy O
sent2950 for O
sent2950 patients O
sent2950 with O
sent2950 malignancy D
sent2951 background O
sent2951 : O
sent2951 the O
sent2951 costs O
sent2951 of O
sent2951 videothoracoscopic T
sent2951 procedures T
sent2951 for O
sent2951 patients O
sent2951 with O
sent2951 lung D
sent2951 carcinoma D
sent2951 were O
sent2951 compared O
sent2951 with O
sent2951 those O
sent2951 of O
sent2951 patients O
sent2951 who O
sent2951 underwent O
sent2951 open T
sent2951 thoracotomy T
sent2951 in O
sent2951 japan O
sent2952 methods O
sent2952 : O
sent2952 the O
sent2952 cost O
sent2952 of O
sent2952 surgical T
sent2952 treatment T
sent2952 in O
sent2952 1997 O
sent2952 and O
sent2952 1998 O
sent2952 for O
sent2952 patients O
sent2952 with O
sent2952 resectable D
sent2952 primary D
sent2952 or D
sent2952 metastatic D
sent2952 lung D
sent2952 carcinoma D
sent2952 was O
sent2952 analyzed O
sent2952 from O
sent2952 itemized O
sent2952 statements O
sent2952 of O
sent2952 hospital O
sent2952 charges O
sent2953 for O
sent2953 patients O
sent2953 with O
sent2953 lung D
sent2953 carcinoma D
sent2953 who O
sent2953 are O
sent2953 in O
sent2953 relatively O
sent2953 poor O
sent2953 health O
sent2953 , O
sent2953 the O
sent2953 authors O
sent2953 chose O
sent2953 videothoracoscopic T
sent2953 lobectomy T
sent2953 or T
sent2953 partial T
sent2953 resection T
sent2953 of T
sent2953 the T
sent2953 lung T
sent2953 instead O
sent2953 of O
sent2953 an O
sent2953 open O
sent2953 thoracotomy O
sent2954 for O
sent2954 patients O
sent2954 with O
sent2954 solitary D
sent2954 pulmonary D
sent2954 metastasis D
sent2954 , O
sent2954 the O
sent2954 authors O
sent2954 routinely O
sent2954 performed O
sent2954 thoracoscopic T
sent2954 partial T
sent2954 resection T
sent2954 of T
sent2954 the T
sent2954 lung T
sent2955 background O
sent2955 : O
sent2955 curative T
sent2955 therapy T
sent2955 is O
sent2955 available O
sent2955 for O
sent2955 patients O
sent2955 with O
sent2955 stage D
sent2955 0 D
sent2955 lung D
sent2955 carcinoma D
sent2955 , O
sent2955 with O
sent2955 a O
sent2955 > O
sent2955 90 O
sent2955 % O
sent2955 5-year O
sent2955 survival O
sent2955 rate O
sent2956 promising O
sent2956 chemopreventive T
sent2956 agents T
sent2956 also O
sent2956 are O
sent2956 under O
sent2956 investigation O
sent2956 currently O
sent2956 to O
sent2956 reduce O
sent2956 the O
sent2956 risk O
sent2956 of O
sent2956 lung D
sent2956 carcinoma D
sent2956 in O
sent2956 high O
sent2956 risk O
sent2956 populations O
sent2957 object O
sent2957 : O
sent2957 the O
sent2957 purpose O
sent2957 of O
sent2957 this O
sent2957 retrospective O
sent2957 study O
sent2957 was O
sent2957 to O
sent2957 compare O
sent2957 the O
sent2957 effectiveness O
sent2957 of O
sent2957 gamma T
sent2957 knife T
sent2957 radiosurgery T
sent2957 ( T
sent2957 gks T
sent2957 ) T
sent2957 for O
sent2957 multiple D
sent2957 cerebral D
sent2957 metastases D
sent2957 with O
sent2957 that O
sent2957 of O
sent2957 whole-brain T
sent2957 radiation T
sent2957 therapy T
sent2957 ( T
sent2957 wbrt T
sent2957 ) T
sent2958 in O
sent2958 the O
sent2958 gks O
sent2958 group O
sent2958 , O
sent2958 large O
sent2958 lesions O
sent2958 ( O
sent2958 > O
sent2958 30 O
sent2958 mm O
sent2958 ) O
sent2958 were O
sent2958 removed O
sent2958 surgically O
sent2958 and O
sent2958 all O
sent2958 other O
sent2958 small D
sent2958 lesions D
sent2958 ( O
sent2958 < O
sent2958 or O
sent2958 = O
sent2958 30 O
sent2958 mm O
sent2958 ) O
sent2958 were O
sent2958 treated O
sent2958 by O
sent2958 gks T
sent2959 new O
sent2959 distant D
sent2959 lesions D
sent2959 were O
sent2959 treated O
sent2959 by O
sent2959 repeated O
sent2959 gks T
sent2959 without O
sent2959 prophylactic O
sent2959 wbrt O
sent2960 conclusions O
sent2960 : O
sent2960 gamma T
sent2960 knife T
sent2960 radiosurgery T
sent2960 without O
sent2960 prophylactic O
sent2960 wbrt O
sent2960 could O
sent2960 be O
sent2960 a O
sent2960 primary O
sent2960 choice O
sent2960 of O
sent2960 treatment O
sent2960 for O
sent2960 patients O
sent2960 with O
sent2960 as O
sent2960 many O
sent2960 as O
sent2960 10 O
sent2960 cerebral D
sent2960 metastases D
sent2960 from D
sent2960 nonsmall D
sent2960 cell D
sent2960 cancer D
sent2961 the O
sent2961 notable O
sent2961 exception O
sent2961 has O
sent2961 been O
sent2961 docetaxel T
sent2961 , O
sent2961 which O
sent2961 has O
sent2961 been O
sent2961 extensively O
sent2961 studied O
sent2961 as O
sent2961 a O
sent2961 second-line O
sent2961 therapy O
sent2961 for O
sent2961 nsclc D
sent2962 object O
sent2962 : O
sent2962 the O
sent2962 purpose O
sent2962 of O
sent2962 this O
sent2962 retrospective O
sent2962 study O
sent2962 was O
sent2962 to O
sent2962 compare O
sent2962 the O
sent2962 effectiveness O
sent2962 of O
sent2962 gamma T
sent2962 knife T
sent2962 radiosurgery T
sent2962 ( T
sent2962 gks T
sent2962 ) T
sent2962 for O
sent2962 multiple D
sent2962 cerebral D
sent2962 metastases D
sent2962 with O
sent2962 that O
sent2962 of O
sent2962 whole-brain T
sent2962 radiation T
sent2962 therapy T
sent2962 ( T
sent2962 wbrt T
sent2962 ) T
sent2963 patients O
sent2963 with O
sent2963 a O
sent2963 single D
sent2963 non-sclc D
sent2963 , D
sent2963 breast D
sent2963 , D
sent2963 melanoma D
sent2963 , D
sent2963 renal D
sent2963 cell D
sent2963 , D
sent2963 and D
sent2963 ovarian D
sent2963 carcinoma D
sent2963 brain D
sent2963 metastasis D
sent2963 have O
sent2963 the O
sent2963 best O
sent2963 chance O
sent2963 for O
sent2963 long-term O
sent2963 survival O
sent2963 if O
sent2963 treated O
sent2963 with O
sent2963 surgical T
sent2963 resection T
sent2963 and T
sent2963 wbrt T
sent2964 objective O
sent2964 : O
sent2964 careful O
sent2964 patient O
sent2964 selection O
sent2964 is O
sent2964 vital O
sent2964 when O
sent2964 video-assisted T
sent2964 thoracoscopic T
sent2964 surgical T
sent2964 ( T
sent2964 vats T
sent2964 ) T
sent2964 therapeutic T
sent2964 pulmonary T
sent2964 metastasectomy T
sent2964 of O
sent2964 colorectal D
sent2964 carcinoma D
sent2964 is O
sent2964 considered O
sent2965 we O
sent2965 reviewed O
sent2965 our O
sent2965 vats O
sent2965 experience O
sent2965 for O
sent2965 therapeutic T
sent2965 metastasectomy T
sent2965 of O
sent2965 peripheral D
sent2965 colorectal D
sent2965 pulmonary D
sent2965 metastases D
sent2966 methods O
sent2966 : O
sent2966 over O
sent2966 90 O
sent2966 months O
sent2966 , O
sent2966 therapeutic T
sent2966 vats T
sent2966 metastasectomy T
sent2966 was O
sent2966 accomplished O
sent2966 upon O
sent2966 80 O
sent2966 patients O
sent2966 with O
sent2966 colorectal D
sent2966 metastases D
sent2967 conclusions O
sent2967 : O
sent2967 therapeutic T
sent2967 vats T
sent2967 resection T
sent2967 of O
sent2967 colorectal D
sent2967 metastases D
sent2967 appears O
sent2967 efficacious O
sent2968 objectives O
sent2968 : O
sent2968 to O
sent2968 review O
sent2968 the O
sent2968 spectrum O
sent2968 of O
sent2968 presentation O
sent2968 and O
sent2968 the O
sent2968 surgical T
sent2968 management T
sent2968 of O
sent2968 non D
sent2968 small D
sent2968 cell D
sent2968 lung D
sent2968 cancer D
sent2968 ( D
sent2968 nsclc D
sent2968 ) D
sent2968 and O
sent2968 the O
sent2968 role O
sent2968 of O
sent2968 various O
sent2968 diagnostic O
sent2968 modalities O
sent2968 in O
sent2968 predicting O
sent2968 the O
sent2968 post-operative O
sent2968 stage O
sent2968 and O
sent2968 the O
sent2968 correlation O
sent2968 of O
sent2968 the O
sent2968 post-operative O
sent2968 stage O
sent2968 with O
sent2968 the O
sent2968 chances O
sent2968 of O
sent2968 recurrence O
sent2969 patients O
sent2969 with O
sent2969 limited-stage D
sent2969 small-cell D
sent2969 carcinoma D
sent2969 of D
sent2969 the D
sent2969 lung D
sent2969 are O
sent2969 treated O
sent2969 with O
sent2969 combined-modality T
sent2969 therapy T
sent2969 with O
sent2969 the O
sent2969 intent O
sent2969 to O
sent2969 cure O
sent2970 in O
sent2970 the O
sent2970 past O
sent2970 several O
sent2970 years O
sent2970 , O
sent2970 new T
sent2970 chemotherapeutic T
sent2970 agents T
sent2970 , T
sent2970 including T
sent2970 the T
sent2970 taxanes T
sent2970 and T
sent2970 the T
sent2970 topoisomerase T
sent2970 i T
sent2970 inhibitors T
sent2970 , O
sent2970 have O
sent2970 demonstrated O
sent2970 substantial O
sent2970 activity O
sent2970 against O
sent2970 small-cell D
sent2970 carcinoma D
sent2971 we O
sent2971 evaluated O
sent2971 the O
sent2971 role O
sent2971 of O
sent2971 chemotherapy T
sent2971 for O
sent2971 patients O
sent2971 with O
sent2971 brain D
sent2971 metastases D
sent2971 from D
sent2971 nsclc D
sent2972 methods O
sent2972 : O
sent2972 we O
sent2972 analyzed O
sent2972 30 O
sent2972 patients O
sent2972 who O
sent2972 were O
sent2972 discovered O
sent2972 to O
sent2972 have O
sent2972 brain O
sent2972 metastases O
sent2972 during O
sent2972 the O
sent2972 diagnosis O
sent2972 of O
sent2972 121 O
sent2972 patients O
sent2972 enrolled O
sent2972 in O
sent2972 three O
sent2972 consecutive O
sent2972 clinical O
sent2972 trials O
sent2972 on O
sent2972 advanced D
sent2972 nsclc D
sent2972 assessing O
sent2972 combination T
sent2972 chemotherapy T
sent2972 of T
sent2972 cisplatin T
sent2972 , T
sent2972 ifosfamide T
sent2972 and T
sent2972 irinotecan T
sent2972 with T
sent2972 rhg-csf T
sent2972 support T
sent2973 conclusions O
sent2973 : O
sent2973 both O
sent2973 the O
sent2973 response O
sent2973 rate O
sent2973 and O
sent2973 survival O
sent2973 data O
sent2973 in O
sent2973 this O
sent2973 retrospective O
sent2973 study O
sent2973 suggest O
sent2973 a O
sent2973 high O
sent2973 degree O
sent2973 of O
sent2973 activity O
sent2973 of O
sent2973 this O
sent2973 combination T
sent2973 chemotherapy T
sent2973 in O
sent2973 patients O
sent2973 with O
sent2973 brain D
sent2973 metastases D
sent2973 from D
sent2973 nsclc D
sent2974 the O
sent2974 aim O
sent2974 of O
sent2974 this O
sent2974 study O
sent2974 was O
sent2974 the O
sent2974 evaluation O
sent2974 of O
sent2974 both O
sent2974 the O
sent2974 antitumour O
sent2974 activity O
sent2974 and O
sent2974 toxicity O
sent2974 of O
sent2974 an O
sent2974 immunochemotherapeutic T
sent2974 regimen T
sent2974 consisting T
sent2974 of T
sent2974 interferon-alpha2b T
sent2974 and T
sent2974 interleukin-2 T
sent2974 in T
sent2974 combination T
sent2974 with T
sent2974 fotemustine T
sent2974 for O
sent2974 patients O
sent2974 with O
sent2974 metastatic D
sent2974 melanoma D
sent2975 to O
sent2975 explore O
sent2975 the O
sent2975 induction O
sent2975 of O
sent2975 chemotherapy T
sent2975 ( T
sent2975 ct T
sent2975 ) T
sent2975 dna O
sent2975 damage O
sent2975 and O
sent2975 its O
sent2975 correlation O
sent2975 with O
sent2975 tumor O
sent2975 response O
sent2975 and O
sent2975 patient O
sent2975 survival O
sent2975 , O
sent2975 we O
sent2975 undertook O
sent2975 the O
sent2975 present O
sent2975 study O
sent2975 in O
sent2975 20 O
sent2975 small D
sent2975 cell D
sent2975 lung D
sent2975 cancer D
sent2975 ( D
sent2975 sclc D
sent2975 ) D
sent2975 patients O
sent2976 in O
sent2976 patients O
sent2976 with O
sent2976 metastatic D
sent2976 colorectal D
sent2976 cancer D
sent2976 , O
sent2976 intravenous T
sent2976 oxaliplatin T
sent2976 has O
sent2976 been O
sent2976 trialled O
sent2976 as O
sent2976 a O
sent2976 monotherapy O
sent2976 and O
sent2976 in O
sent2976 combination O
sent2976 with O
sent2976 other O
sent2976 agents O
sent2977 neoadjuvant T
sent2977 therapy T
sent2977 with T
sent2977 oxaliplatin/fluorouracil/folinic T
sent2977 acid T
sent2977 has O
sent2977 proven O
sent2977 beneficial O
sent2977 in O
sent2977 enabling O
sent2977 surgical O
sent2977 removal O
sent2977 of O
sent2977 previously O
sent2977 unresectable D
sent2977 liver D
sent2977 metastases D
sent2978 in O
sent2978 2 O
sent2978 studies O
sent2978 , O
sent2978 surgery T
sent2978 with O
sent2978 curative O
sent2978 intent O
sent2978 was O
sent2978 performed O
sent2978 in O
sent2978 16 O
sent2978 and O
sent2978 51 O
sent2978 % O
sent2978 of O
sent2978 patients O
sent2978 with O
sent2978 initially O
sent2978 unresectable D
sent2978 liver D
sent2978 metastases D
sent2978 following O
sent2978 oxaliplatin/fluorouracil/folinic T
sent2978 acid T
sent2978 therapy T
sent2978 ; O
sent2978 the O
sent2978 5-year O
sent2978 survival O
sent2978 rates O
sent2978 were O
sent2978 40 O
sent2978 and O
sent2978 50 O
sent2978 % O
sent2978 , O
sent2978 respectively O
sent2979 in O
sent2979 patients O
sent2979 with O
sent2979 advanced D
sent2979 ovarian D
sent2979 cancer D
sent2979 , O
sent2979 first-line O
sent2979 therapy O
sent2979 with O
sent2979 oxaliplatin/cyclophosphamide T
sent2979 achieved O
sent2979 an O
sent2979 objective O
sent2979 response O
sent2979 rate O
sent2979 which O
sent2979 did O
sent2979 not O
sent2979 differ O
sent2979 significantly O
sent2979 from O
sent2979 that O
sent2979 of O
sent2979 cisplatin/cyclophosphamide T
sent2979 ( O
sent2979 33 O
sent2979 vs O
sent2979 42 O
sent2979 % O
sent2979 ) O
sent2980 in O
sent2980 addition O
sent2980 , O
sent2980 oxaliplatin T
sent2980 has O
sent2980 shown O
sent2980 efficacy O
sent2980 in O
sent2980 patients O
sent2980 with O
sent2980 platinum-pretreated D
sent2980 ovarian D
sent2980 cancer D
sent2980 and O
sent2980 achieved O
sent2980 objective O
sent2980 response O
sent2980 rates O
sent2980 similar O
sent2980 to O
sent2980 paclitaxel O
sent2980 in O
sent2980 this O
sent2980 setting O
sent2980 ( O
sent2980 16 O
sent2980 vs O
sent2980 17 O
sent2980 % O
sent2980 ) O
sent2981 promising O
sent2981 results O
sent2981 have O
sent2981 also O
sent2981 been O
sent2981 found O
sent2981 with O
sent2981 oxaliplatin T
sent2981 in O
sent2981 patients O
sent2981 with O
sent2981 non-hodgkin D
sent2981 's D
sent2981 lymphoma D
sent2981 , D
sent2981 breast D
sent2981 cancer D
sent2981 , D
sent2981 mesothelioma D
sent2981 and D
sent2981 non-small D
sent2981 cell D
sent2981 lung D
sent2981 cancer D
sent2982 conclusion O
sent2982 : O
sent2982 oxaliplatin T
sent2982 in T
sent2982 combination T
sent2982 with T
sent2982 fluorouracil/folinic T
sent2982 acid T
sent2982 is O
sent2982 an O
sent2982 effective O
sent2982 treatment O
sent2982 option O
sent2982 for O
sent2982 patients O
sent2982 with O
sent2982 metastatic D
sent2982 colorectal D
sent2982 cancer D
sent2982 , O
sent2982 both O
sent2982 as O
sent2982 a O
sent2982 first-line O
sent2982 therapy O
sent2982 and O
sent2982 in O
sent2982 patients O
sent2982 refractory O
sent2982 to O
sent2982 previous O
sent2982 chemotherapy O
sent2983 additional O
sent2983 clinical O
sent2983 investigation O
sent2983 of O
sent2983 oxaliplatin T
sent2983 in O
sent2983 patients O
sent2983 with O
sent2983 other O
sent2983 cancers D
sent2983 is O
sent2983 warranted O
sent2983 given O
sent2983 the O
sent2983 promising O
sent2983 results O
sent2983 achieved O
sent2983 in O
sent2983 early O
sent2983 trials O
sent2983 , O
sent2983 most O
sent2983 notably O
sent2983 in O
sent2983 patients O
sent2983 with O
sent2983 platinum-pretreated O
sent2983 ovarian O
sent2983 cancer O
sent2984 combined T
sent2984 modality T
sent2984 treatment T
sent2984 has O
sent2984 'come O
sent2984 out O
sent2984 of O
sent2984 age O
sent2984 ' O
sent2984 and O
sent2984 increasingly O
sent2984 represents O
sent2984 standard O
sent2984 of O
sent2984 care O
sent2984 for O
sent2984 a O
sent2984 rapidly O
sent2984 growing O
sent2984 number O
sent2984 of O
sent2984 patients O
sent2984 in O
sent2984 locally O
sent2984 advanced O
sent2984 stages O
sent2984 of O
sent2984 nsclc D
sent2985 the O
sent2985 current O
sent2985 study O
sent2985 was O
sent2985 designed O
sent2985 to O
sent2985 assess O
sent2985 the O
sent2985 prognostic O
sent2985 value O
sent2985 of O
sent2985 immunomorphologic O
sent2985 changes O
sent2985 in O
sent2985 locoregional O
sent2985 lymph O
sent2985 nodes O
sent2985 and O
sent2985 lymphocytic O
sent2985 infiltration O
sent2985 of O
sent2985 primary O
sent2985 tumor O
sent2985 ( O
sent2985 li O
sent2985 ) O
sent2985 in O
sent2985 patients O
sent2985 who O
sent2985 undergo O
sent2985 resection T
sent2985 for O
sent2985 bronchogenic D
sent2985 carcinoma D
sent2986 conclusions O
sent2986 : O
sent2986 lymph O
sent2986 node O
sent2986 immunoreactivity O
sent2986 and O
sent2986 li O
sent2986 significantly O
sent2986 influence O
sent2986 long O
sent2986 term O
sent2986 survival O
sent2986 after O
sent2986 curative T
sent2986 surgery T
sent2986 for O
sent2986 patients O
sent2986 with O
sent2986 carcinoma D
sent2986 of D
sent2986 the D
sent2986 lung D
sent2986 and O
sent2986 may O
sent2986 be O
sent2986 useful O
sent2986 in O
sent2986 stratifying O
sent2986 patients O
sent2986 for O
sent2986 prospective O
sent2986 trials O
sent2986 of O
sent2986 adjuvant O
sent2986 treatment O
sent2986 , O
sent2986 including O
sent2986 immunotherapy O
sent2987 the O
sent2987 drug O
sent2987 is O
sent2987 currently O
sent2987 in O
sent2987 phase O
sent2987 iii O
sent2987 clinical O
sent2987 trials O
sent2987 for O
sent2987 patients O
sent2987 with O
sent2987 non-small D
sent2987 cell D
sent2987 lung D
sent2987 cancer D
sent2987 in O
sent2987 combination O
sent2987 with O
sent2987 paclitaxel T
sent2987 and T
sent2987 carboplatin T
sent2987 , O
sent2987 as O
sent2987 well O
sent2987 as O
sent2987 in O
sent2987 advanced D
sent2987 hormone D
sent2987 refractory D
sent2987 prostate D
sent2987 cancer D
sent2987 in O
sent2987 combination O
sent2987 with O
sent2987 mitoxantrone T
sent2988 standard O
sent2988 treatment O
sent2988 of O
sent2988 sclc D
sent2988 consists O
sent2988 of O
sent2988 platinum-based T
sent2988 combination T
sent2988 chemotherapy T
sent2988 , O
sent2988 with O
sent2988 thoracic O
sent2988 irradiation O
sent2988 added O
sent2988 for O
sent2988 patients O
sent2988 with O
sent2988 limited-stage O
sent2988 disease O
sent2989 several O
sent2989 newer O
sent2989 chemotherapeutic T
sent2989 drugs T
sent2989 have O
sent2989 recently O
sent2989 been O
sent2989 shown O
sent2989 to O
sent2989 have O
sent2989 significant O
sent2989 activity O
sent2989 in O
sent2989 patients O
sent2989 with O
sent2989 untreated D
sent2989 or D
sent2989 relapsed D
sent2989 sclc D
sent2990 we O
sent2990 recently O
sent2990 performed O
sent2990 completion T
sent2990 pneumonectomy T
sent2990 of T
sent2990 the T
sent2990 left T
sent2990 lung T
sent2990 in O
sent2990 a O
sent2990 70-year-old O
sent2990 man O
sent2990 with O
sent2990 hemophilia O
sent2990 a O
sent2990 , O
sent2990 for O
sent2990 squamous D
sent2990 cell D
sent2990 carcinoma D
sent2990 in O
sent2990 the O
sent2990 residual O
sent2990 left O
sent2990 lung O
sent2991 objective O
sent2991 : O
sent2991 several O
sent2991 reports O
sent2991 emphasize O
sent2991 the O
sent2991 importance O
sent2991 of O
sent2991 en-bloc T
sent2991 resection T
sent2991 as O
sent2991 the O
sent2991 optimal O
sent2991 surgical O
sent2991 treatment O
sent2991 of O
sent2991 lung D
sent2991 cancer D
sent2991 with O
sent2991 chest O
sent2991 wall O
sent2991 invasion O
sent2992 methods O
sent2992 : O
sent2992 between O
sent2992 1981 O
sent2992 and O
sent2992 1998 O
sent2992 , O
sent2992 100 O
sent2992 patients O
sent2992 ( O
sent2992 90 O
sent2992 male O
sent2992 ; O
sent2992 ten O
sent2992 female O
sent2992 ) O
sent2992 , O
sent2992 with O
sent2992 a O
sent2992 median O
sent2992 age O
sent2992 of O
sent2992 60 O
sent2992 years O
sent2992 ( O
sent2992 36-84 O
sent2992 ) O
sent2992 , O
sent2992 underwent O
sent2992 radical T
sent2992 en-bloc T
sent2992 resection T
sent2992 of O
sent2992 non-small D
sent2992 cell D
sent2992 lung D
sent2992 cancer D
sent2992 ( D
sent2992 nsclc D
sent2992 ) D
sent2992 with O
sent2992 chest O
sent2992 wall O
sent2992 involvement O
sent2993 over O
sent2993 the O
sent2993 past O
sent2993 17 O
sent2993 years O
sent2993 ( O
sent2993 1981 O
sent2993 to O
sent2993 1997 O
sent2993 ) O
sent2993 , O
sent2993 29 O
sent2993 patients O
sent2993 underwent O
sent2993 complete T
sent2993 pulmonary T
sent2993 resection T
sent2993 for O
sent2993 primary D
sent2993 lung D
sent2993 cancer D
sent2993 accompanied O
sent2993 by O
sent2993 satellite O
sent2993 nodules O
sent2993 in O
sent2993 the O
sent2993 same O
sent2993 lobe O
sent2993 as O
sent2993 the O
sent2993 primary O
sent2994 of O
sent2994 1 O
sent2994 , O
sent2994 042 O
sent2994 patients O
sent2994 with O
sent2994 primary D
sent2994 lung D
sent2994 cancer D
sent2994 who O
sent2994 underwent O
sent2994 resection T
sent2994 from O
sent2994 1982 O
sent2994 to O
sent2994 1995 O
sent2994 , O
sent2994 549 O
sent2994 patients O
sent2994 with O
sent2994 adenocarcinoma O
sent2994 ( O
sent2994 ad O
sent2994 ) O
sent2994 and O
sent2994 363 O
sent2994 with O
sent2994 squamous O
sent2994 cell O
sent2994 carcinoma O
sent2994 ( O
sent2994 sq O
sent2994 ) O
sent2994 were O
sent2994 included O
sent2994 in O
sent2994 this O
sent2994 study O
sent2995 for O
sent2995 small D
sent2995 cell D
sent2995 lung D
sent2995 cancer D
sent2995 ( D
sent2995 sclc D
sent2995 ) D
sent2995 , O
sent2995 which O
sent2995 accounts O
sent2995 for O
sent2995 approximately O
sent2995 20 O
sent2995 % O
sent2995 of O
sent2995 cases O
sent2995 of O
sent2995 lung O
sent2995 cancer O
sent2995 , O
sent2995 the O
sent2995 primary O
sent2995 treatment O
sent2995 is O
sent2995 chemotherapy T
sent2995 and O
sent2995 in O
sent2995 the O
sent2995 majority O
sent2995 of O
sent2995 cases O
sent2995 the O
sent2995 primary O
sent2995 aim O
sent2995 is O
sent2995 to O
sent2995 control O
sent2995 the O
sent2995 disease O
sent2995 which O
sent2995 generally O
sent2995 would O
sent2995 have O
sent2995 spread O
sent2995 beyond O
sent2995 the O
sent2995 lungs O
sent2995 at O
sent2995 the O
sent2995 time O
sent2995 of O
sent2995 presentation O
sent2996 a O
sent2996 growing O
sent2996 body O
sent2996 of O
sent2996 evidence O
sent2996 suggests O
sent2996 that O
sent2996 postoperative T
sent2996 irradiation T
sent2996 for O
sent2996 non-small D
sent2996 cell D
sent2996 lung D
sent2996 cancer D
sent2996 may O
sent2996 cause O
sent2996 life-threatening O
sent2996 toxicity O
sent2996 and O
sent2996 , O
sent2996 when O
sent2996 the O
sent2996 risk O
sent2996 of O
sent2996 local-regional O
sent2996 recurrence O
sent2996 is O
sent2996 low O
sent2996 , O
sent2996 the O
sent2996 toxicity O
sent2996 of O
sent2996 irradiation O
sent2996 may O
sent2996 outweight O
sent2996 the O
sent2996 benefit O
sent2997 as O
sent2997 a O
sent2997 best-case O
sent2997 scenario O
sent2997 , O
sent2997 postoperative T
sent2997 irradiation T
sent2997 may O
sent2997 improve O
sent2997 the O
sent2997 chance O
sent2997 for O
sent2997 long-term O
sent2997 survival O
sent2997 in O
sent2997 patients O
sent2997 with O
sent2997 n2 D
sent2997 tumors D
sent2998 for O
sent2998 patients O
sent2998 with O
sent2998 stage D
sent2998 i D
sent2998 or D
sent2998 ii D
sent2998 non-small D
sent2998 cell D
sent2998 lung D
sent2998 cancer D
sent2998 ( D
sent2998 nsclc D
sent2998 ) D
sent2998 , O
sent2998 surgical T
sent2998 resection T
sent2998 is O
sent2998 considered O
sent2998 the O
sent2998 standard O
sent2998 of O
sent2998 care O
sent2999 efforts O
sent2999 at O
sent2999 improving O
sent2999 survival O
sent2999 for O
sent2999 early-stage D
sent2999 nsclc D
sent2999 patients O
sent2999 have O
sent2999 focused O
sent2999 on O
sent2999 the O
sent2999 use O
sent2999 of O
sent2999 chemotherapy T
sent2999 administered O
sent2999 postoperatively O
sent2999 ( O
sent2999 adjuvant O
sent2999 ) O
sent2999 or O
sent2999 preoperatively O
sent2999 ( O
sent2999 neoadjuvant O
sent2999 or O
sent2999 induction O
sent2999 ) O
sent2999 to O
sent2999 eradicate O
sent2999 micrometastatic D
sent2999 disease D
sent3000 chemotherapy T
sent3000 administered O
sent3000 before O
sent3000 surgery O
sent3000 or O
sent3000 definitive O
sent3000 irradiation O
sent3000 has O
sent3000 improved O
sent3000 survival O
sent3000 rates O
sent3000 in O
sent3000 patients O
sent3000 with O
sent3000 stage D
sent3000 iii D
sent3000 nsclc D
sent3001 patients O
sent3001 : O
sent3001 patients O
sent3001 with O
sent3001 a O
sent3001 single O
sent3001 ( O
sent3001 n O
sent3001 = O
sent3001 2 O
sent3001 , O
sent3001 764 O
sent3001 ) O
sent3001 and O
sent3001 synchronous O
sent3001 nsclc D
sent3001 ( O
sent3001 n O
sent3001 = O
sent3001 85 O
sent3001 ) O
sent3001 who O
sent3001 underwent O
sent3001 pulmonary T
sent3001 resection T
sent3002 background O
sent3002 : O
sent3002 prophylactic T
sent3002 cranial T
sent3002 irradiation T
sent3002 halves O
sent3002 the O
sent3002 rate O
sent3002 of O
sent3002 brain O
sent3002 metastases O
sent3002 in O
sent3002 patients O
sent3002 with O
sent3002 small D
sent3002 cell D
sent3002 lung D
sent3002 cancer D
sent3003 objectives O
sent3003 : O
sent3003 this O
sent3003 study O
sent3003 aims O
sent3003 to O
sent3003 test O
sent3003 whether O
sent3003 prophylactic T
sent3003 cranial T
sent3003 irradiation T
sent3003 prolongs O
sent3003 survival O
sent3003 of O
sent3003 patients O
sent3003 with O
sent3003 small D
sent3003 cell D
sent3003 lung D
sent3003 cancer D
sent3003 in O
sent3003 complete O
sent3003 remission O
sent3004 reviewer O
sent3004 's O
sent3004 conclusions O
sent3004 : O
sent3004 prophylactic T
sent3004 cranial T
sent3004 irradiation T
sent3004 significantly O
sent3004 improves O
sent3004 survival O
sent3004 and O
sent3004 disease-free O
sent3004 survival O
sent3004 for O
sent3004 patients O
sent3004 with O
sent3004 small D
sent3004 cell D
sent3004 lung D
sent3004 cancer D
sent3004 in O
sent3004 complete O
sent3004 remission O
sent3005 methods O
sent3005 : O
sent3005 non-small D
sent3005 cell D
sent3005 lung D
sent3005 cancer D
sent3005 cells O
sent3005 were O
sent3005 treated O
sent3005 with O
sent3005 gemcitabine T
sent3005 , O
sent3005 harvested O
sent3005 , O
sent3005 and O
sent3005 nuclear O
sent3005 extracts O
sent3005 analyzed O
sent3005 for O
sent3005 nf-kappab O
sent3005 dna O
sent3005 binding O
sent3005 by O
sent3005 electrophoretic O
sent3005 mobility O
sent3005 shift O
sent3005 assays O
sent3006 novel O
sent3006 treatment O
sent3006 strategies O
sent3006 for O
sent3006 patients O
sent3006 with O
sent3006 advanced D
sent3006 nsclc D
sent3006 may O
sent3006 involve O
sent3006 chemotherapy T
sent3006 combined O
sent3006 with O
sent3006 inhibition O
sent3006 of O
sent3006 nf-kappab-dependent O
sent3006 cell-survival O
sent3006 pathways O
sent3007 combination T
sent3007 chemotherapy T
sent3007 is O
sent3007 the O
sent3007 cornerstone O
sent3007 of O
sent3007 treatment O
sent3007 that O
sent3007 confers O
sent3007 a O
sent3007 meaningful O
sent3007 survival O
sent3007 benefit O
sent3007 for O
sent3007 patients O
sent3007 with O
sent3007 small-cell D
sent3007 lung D
sent3007 cancer D
sent3008 in O
sent3008 single-agent O
sent3008 phase O
sent3008 ii O
sent3008 studies O
sent3008 , O
sent3008 irinotecan T
sent3008 yielded O
sent3008 response O
sent3008 rates O
sent3008 between O
sent3008 16 O
sent3008 % O
sent3008 and O
sent3008 47 O
sent3008 % O
sent3008 in O
sent3008 patients O
sent3008 with O
sent3008 previously O
sent3008 treated O
sent3008 small-cell D
sent3008 lung D
sent3008 cancer D
sent3009 a O
sent3009 phase O
sent3009 ii O
sent3009 study O
sent3009 of O
sent3009 irinotecan T
sent3009 in T
sent3009 combination T
sent3009 with T
sent3009 cisplatin T
sent3009 ( T
sent3009 platinol T
sent3009 ) T
sent3009 resulted O
sent3009 in O
sent3009 a O
sent3009 response O
sent3009 rate O
sent3009 of O
sent3009 86 O
sent3009 % O
sent3009 and O
sent3009 a O
sent3009 median O
sent3009 survival O
sent3009 of O
sent3009 13.0 O
sent3009 months O
sent3009 in O
sent3009 patients O
sent3009 with O
sent3009 extensive-disease D
sent3009 small-cell D
sent3009 lung D
sent3009 cancer D
sent3010 based O
sent3010 on O
sent3010 these O
sent3010 results O
sent3010 , O
sent3010 the O
sent3010 irinotecan T
sent3010 and T
sent3010 cisplatin T
sent3010 combination T
sent3010 is O
sent3010 a O
sent3010 new O
sent3010 standard O
sent3010 regimen O
sent3010 in O
sent3010 the O
sent3010 treatment O
sent3010 of O
sent3010 extensive-disease D
sent3010 small-cell D
sent3010 lung D
sent3010 cancer D
sent3011 background O
sent3011 : O
sent3011 both O
sent3011 gemcitabine T
sent3011 and T
sent3011 etoposide T
sent3011 are O
sent3011 active O
sent3011 in O
sent3011 the O
sent3011 treatment O
sent3011 of O
sent3011 small-cell D
sent3011 lung D
sent3011 cancer D
sent3011 ( D
sent3011 sclc D
sent3011 ) D
sent3011 , O
sent3011 and O
sent3011 are O
sent3011 characterised O
sent3011 by O
sent3011 mild O
sent3011 toxicity O
sent3011 profiles O
sent3012 patients O
sent3012 and O
sent3012 methods O
sent3012 : O
sent3012 forty-two O
sent3012 chemo-naive O
sent3012 extensive O
sent3012 disease O
sent3012 sclc D
sent3012 patients O
sent3012 were O
sent3012 enrolled O
sent3012 to O
sent3012 receive O
sent3012 gemcitabine T
sent3012 1000 O
sent3012 mg/m2 O
sent3012 , O
sent3012 days O
sent3012 1 O
sent3012 , O
sent3012 8 O
sent3012 and O
sent3012 15 O
sent3012 , O
sent3012 and O
sent3012 etoposide T
sent3012 80 O
sent3012 mg/m2 O
sent3012 , O
sent3012 days O
sent3012 8 O
sent3012 , O
sent3012 9 O
sent3012 and O
sent3012 10 O
sent3012 of O
sent3012 a O
sent3012 28-day O
sent3012 cycle O
sent3013 background O
sent3013 : O
sent3013 to O
sent3013 find O
sent3013 the O
sent3013 maximum O
sent3013 tolerated O
sent3013 dose O
sent3013 for O
sent3013 ifosfamide T
sent3013 in T
sent3013 combination T
sent3013 with T
sent3013 paclitaxel T
sent3013 and T
sent3013 carboplatin T
sent3013 in O
sent3013 small-cell D
sent3013 lung D
sent3013 cancer D
sent3013 patients O
sent3013 ( O
sent3013 sclc O
sent3013 ) O
sent3013 , O
sent3013 who O
sent3013 are O
sent3013 resistant O
sent3013 to O
sent3013 cyclophosphamide O
sent3013 , O
sent3013 doxorubicin O
sent3013 and O
sent3013 etoposide O
sent3013 ( O
sent3013 cde O
sent3013 ) O
sent3014 conclusions O
sent3014 : O
sent3014 the O
sent3014 maximum O
sent3014 tolerated O
sent3014 dose O
sent3014 of O
sent3014 this O
sent3014 combination O
sent3014 for O
sent3014 patients O
sent3014 with O
sent3014 resistant D
sent3014 sclc D
sent3014 is O
sent3014 ifosfamide T
sent3014 2000 O
sent3014 mg/m2 O
sent3014 in O
sent3014 combination O
sent3014 with O
sent3014 paclitaxel T
sent3014 175 O
sent3014 mg/m2 O
sent3014 and O
sent3014 carboplatin T
sent3014 auc O
sent3014 6 O
sent3014 mg/ml O
sent3014 min O
sent3014 administered O
sent3014 on O
sent3014 the O
sent3014 first O
sent3014 day O
sent3014 of O
sent3014 a O
sent3014 21-day O
sent3014 cycle O
sent3015 many O
sent3015 endobronchial T
sent3015 treatment T
sent3015 modalities T
sent3015 are O
sent3015 available O
sent3015 to O
sent3015 supplement O
sent3015 traditional O
sent3015 therapies O
sent3015 for O
sent3015 advanced D
sent3015 lung D
sent3015 cancer D
sent3016 methods O
sent3016 : O
sent3016 the O
sent3016 author O
sent3016 reviews O
sent3016 the O
sent3016 use O
sent3016 of O
sent3016 several O
sent3016 endobronchial T
sent3016 treatment T
sent3016 modalities T
sent3016 that T
sent3016 can T
sent3016 augment T
sent3016 standard T
sent3016 antitumor T
sent3016 therapies T
sent3016 for O
sent3016 advanced O
sent3016 lung D
sent3016 cancer D
sent3016 , O
sent3016 including O
sent3016 rigid O
sent3016 and O
sent3016 flexible O
sent3016 bronchoscopy O
sent3016 , O
sent3016 laser O
sent3016 therapy O
sent3016 , O
sent3016 endobronchial O
sent3016 prosthesis O
sent3016 , O
sent3016 and O
sent3016 photodynamic O
sent3016 therapy O
sent3017 conclusions O
sent3017 : O
sent3017 endobronchial T
sent3017 interventions T
sent3017 are O
sent3017 important O
sent3017 adjuncts O
sent3017 in O
sent3017 the O
sent3017 multimodality O
sent3017 management O
sent3017 of O
sent3017 lung D
sent3017 cancer D
sent3017 and O
sent3017 should O
sent3017 become O
sent3017 standard O
sent3017 considerations O
sent3017 in O
sent3017 the O
sent3017 management O
sent3017 of O
sent3017 patients O
sent3017 with O
sent3017 advanced O
sent3017 lung O
sent3017 cancer O
sent3018 standard O
sent3018 operations O
sent3018 for O
sent3018 lung D
sent3018 cancer D
sent3018 patients O
sent3018 are O
sent3018 generally O
sent3018 accepted O
sent3018 as O
sent3018 performing O
sent3018 lobectomy T
sent3018 or T
sent3018 pneumonectomy T
sent3018 on O
sent3018 the O
sent3018 tumor O
sent3018 baring O
sent3018 lung O
sent3018 and O
sent3018 ipsilateral O
sent3018 hilar O
sent3018 and O
sent3018 mediastinal O
sent3018 lymphadenectomy O
sent3018 including O
sent3018 subcarinal O
sent3018 lymph O
sent3018 nodes O
sent3019 small D
sent3019 cell D
sent3019 lung D
sent3019 cancer D
sent3019 is O
sent3019 a O
sent3019 frequently O
sent3019 relapsing O
sent3019 tumor O
sent3019 despite O
sent3019 a O
sent3019 high O
sent3019 rate O
sent3019 of O
sent3019 response O
sent3019 after O
sent3019 first-line O
sent3019 chemotherapy T
sent3020 for O
sent3020 symptomatic D
sent3020 metastases D
sent3020 in D
sent3020 bone D
sent3020 or D
sent3020 brain D
sent3020 , O
sent3020 radiotherapy T
sent3020 usually O
sent3020 gives O
sent3020 temporary O
sent3020 palliation O
sent3021 for O
sent3021 intrathoracic D
sent3021 relapse D
sent3021 and D
sent3021 severe D
sent3021 obstruction D
sent3021 of D
sent3021 main D
sent3021 bronchus D
sent3021 and/or D
sent3021 superior D
sent3021 caval D
sent3021 vein D
sent3021 , O
sent3021 radiotherapy T
sent3021 is O
sent3021 a O
sent3021 possibility O
sent3021 if O
sent3021 not O
sent3021 given O
sent3021 as O
sent3021 part O
sent3021 of O
sent3021 first-line O
sent3021 treatment O
sent3022 tumor T
sent3022 vaccines T
sent3022 against O
sent3022 gangliosides O
sent3022 that O
sent3022 are O
sent3022 expressed O
sent3022 on O
sent3022 almost O
sent3022 all O
sent3022 human O
sent3022 sclc D
sent3022 cells O
sent3022 have O
sent3022 been O
sent3022 recently O
sent3022 developed O
sent3023 an O
sent3023 anti-idiotypic T
sent3023 monoclonal T
sent3023 antibody T
sent3023 against O
sent3023 the O
sent3023 gd3 O
sent3023 ganglioside O
sent3023 , O
sent3023 bec-2 O
sent3023 , O
sent3023 is O
sent3023 being O
sent3023 evaluated O
sent3023 after O
sent3023 chemotherapy O
sent3023 in O
sent3023 sclc D
sent3023 patients O
sent3023 in O
sent3023 a O
sent3023 european O
sent3023 study O
sent3024 the O
sent3024 matrix T
sent3024 metalloproteinase T
sent3024 inhibitors T
sent3024 marimastat T
sent3024 and T
sent3024 bms-275291 T
sent3024 are O
sent3024 under O
sent3024 evaluation O
sent3024 in O
sent3024 sclc D
sent3025 we O
sent3025 attempted O
sent3025 a O
sent3025 new O
sent3025 regimen O
sent3025 of O
sent3025 intermittent O
sent3025 administration O
sent3025 of O
sent3025 5-fu T
sent3025 and T
sent3025 low-dose T
sent3025 isovorin T
sent3025 ( T
sent3025 f.i T
sent3025 ) T
sent3025 to O
sent3025 four O
sent3025 patients O
sent3025 with O
sent3025 advanced O
sent3025 and O
sent3025 recurrent O
sent3025 colon D
sent3025 cancer D
sent3026 purpose/objectives O
sent3026 : O
sent3026 to O
sent3026 describe O
sent3026 the O
sent3026 relationship O
sent3026 between O
sent3026 fatigue O
sent3026 and O
sent3026 nutritional O
sent3026 status O
sent3026 in O
sent3026 patients O
sent3026 receiving O
sent3026 radiation T
sent3026 therapy T
sent3026 for O
sent3026 lung D
sent3026 cancer D
sent3027 sample O
sent3027 : O
sent3027 45 O
sent3027 adults O
sent3027 with O
sent3027 primary O
sent3027 cancer D
sent3027 of D
sent3027 the D
sent3027 lung D
sent3027 receiving O
sent3027 < O
sent3027 outpatient O
sent3027 primary O
sent3027 or O
sent3027 adjuvant O
sent3027 radiation T
sent3027 therapy T
sent3028 we O
sent3028 present O
sent3028 the O
sent3028 case O
sent3028 of O
sent3028 a O
sent3028 patient O
sent3028 with O
sent3028 metastatic D
sent3028 transitional D
sent3028 cell D
sent3028 carcinoma D
sent3028 of D
sent3028 the D
sent3028 bladder D
sent3028 and D
sent3028 renal D
sent3028 failure D
sent3028 who O
sent3028 underwent O
sent3028 successful O
sent3028 systemic T
sent3028 chemotherapy T
sent3028 with T
sent3028 paclitaxel T
sent3028 and T
sent3028 carboplatin T
sent3029 background O
sent3029 : O
sent3029 the O
sent3029 objective O
sent3029 of O
sent3029 this O
sent3029 phase O
sent3029 ii O
sent3029 study O
sent3029 was O
sent3029 to O
sent3029 evaluate O
sent3029 the O
sent3029 concept O
sent3029 of O
sent3029 sequential T
sent3029 chemotherapy T
sent3029 in O
sent3029 the O
sent3029 treatment O
sent3029 of O
sent3029 patients O
sent3029 with O
sent3029 advanced D
sent3029 nonsmall D
sent3029 cell D
sent3029 lung D
sent3029 carcinoma D
sent3029 ( D
sent3029 nsclc D
sent3029 ) D
sent3029 by O
sent3029 the O
sent3029 administration O
sent3029 of O
sent3029 carboplatin T
sent3029 plus T
sent3029 gemcitabine T
sent3029 followed T
sent3029 by T
sent3029 of T
sent3029 paclitaxel T
sent3030 conclusions O
sent3030 : O
sent3030 this O
sent3030 study O
sent3030 is O
sent3030 the O
sent3030 first O
sent3030 to O
sent3030 evaluate O
sent3030 planned T
sent3030 sequential T
sent3030 chemotherapy T
sent3030 in O
sent3030 patients O
sent3030 with O
sent3030 nsclc D
sent3031 patients O
sent3031 who O
sent3031 benefit O
sent3031 from O
sent3031 a O
sent3031 surgical T
sent3031 resection T
sent3031 for O
sent3031 non-small-cell D
sent3031 lung D
sent3031 cancer D
sent3031 with O
sent3031 aneuploid O
sent3031 dna O
sent3031 content O
sent3031 prove O
sent3031 to O
sent3031 have O
sent3031 a O
sent3031 higher O
sent3031 risk O
sent3031 of O
sent3031 death O
sent3032 purpose O
sent3032 : O
sent3032 this O
sent3032 randomized O
sent3032 trial O
sent3032 was O
sent3032 designed O
sent3032 to O
sent3032 determine O
sent3032 whether O
sent3032 paclitaxel T
sent3032 plus T
sent3032 carboplatin T
sent3032 ( T
sent3032 pc T
sent3032 ) T
sent3032 offered O
sent3032 a O
sent3032 survival O
sent3032 advantage O
sent3032 over O
sent3032 vinorelbine T
sent3032 plus T
sent3032 cisplatin T
sent3032 ( T
sent3032 vc T
sent3032 ) T
sent3032 for O
sent3032 patients O
sent3032 with O
sent3032 advanced D
sent3032 non D
sent3032 -- D
sent3032 small-cell D
sent3032 lung D
sent3032 cancer D
sent3033 conclusion O
sent3033 : O
sent3033 pc T
sent3033 is O
sent3033 equally O
sent3033 efficacious O
sent3033 as O
sent3033 vc T
sent3033 for O
sent3033 the O
sent3033 treatment O
sent3033 of O
sent3033 advanced D
sent3033 non D
sent3033 -- D
sent3033 small-cell D
sent3033 lung D
sent3033 cancer D
sent3034 purpose O
sent3034 : O
sent3034 a O
sent3034 prospective O
sent3034 randomized O
sent3034 trial O
sent3034 in O
sent3034 small-cell O
sent3034 lung O
sent3034 cancer O
sent3034 ( O
sent3034 sclc O
sent3034 ) O
sent3034 was O
sent3034 performed O
sent3034 to O
sent3034 determine O
sent3034 if O
sent3034 intensification O
sent3034 of O
sent3034 the O
sent3034 platinum O
sent3034 dose O
sent3034 by O
sent3034 giving O
sent3034 cisplatin T
sent3034 and T
sent3034 carboplatin T
sent3034 in O
sent3034 combination O
sent3034 to O
sent3034 patients O
sent3034 with O
sent3034 sclc D
sent3034 yields O
sent3034 higher O
sent3034 response O
sent3034 rates O
sent3034 and O
sent3034 survival O
sent3034 , O
sent3034 than O
sent3034 carboplatin T
sent3034 alone T
sent3034 in T
sent3034 a T
sent3034 combination T
sent3034 chemotherapy T
sent3034 regimen T
sent3035 conclusions O
sent3035 : O
sent3035 the O
sent3035 intensification T
sent3035 of T
sent3035 platinum T
sent3035 dose T
sent3035 ( T
sent3035 cisplatin T
sent3035 plus T
sent3035 carboplatin T
sent3035 ) T
sent3035 in T
sent3035 combination T
sent3035 chemotherapy T
sent3035 significantly O
sent3035 increased O
sent3035 the O
sent3035 complete O
sent3035 response O
sent3035 rate O
sent3035 , O
sent3035 overall O
sent3035 survival O
sent3035 and O
sent3035 number O
sent3035 of O
sent3035 two-year O
sent3035 survivors O
sent3035 among O
sent3035 sclc D
sent3035 patients O
sent3035 with O
sent3035 limited O
sent3035 disease O
sent3035 compared O
sent3035 to O
sent3035 combination T
sent3035 therapy T
sent3035 with T
sent3035 carboplatin T
sent3035 alone T
sent3035 , O
sent3035 suggesting O
sent3035 that O
sent3035 a O
sent3035 more O
sent3035 aggressive O
sent3035 treatment O
sent3035 to O
sent3035 this O
sent3035 category O
sent3035 of O
sent3035 patients O
sent3035 is O
sent3035 worthwhile O
sent3035 , O
sent3035 while O
sent3035 no O
sent3035 difference O
sent3035 in O
sent3035 treatment O
sent3035 outcome O
sent3035 was O
sent3035 observed O
sent3035 for O
sent3035 patients O
sent3035 with O
sent3035 extensive O
sent3035 disease O
sent3036 the O
sent3036 aim O
sent3036 of O
sent3036 this O
sent3036 study O
sent3036 was O
sent3036 to O
sent3036 investigate O
sent3036 the O
sent3036 relationships O
sent3036 among O
sent3036 technetium-99m O
sent3036 tetrofosmin O
sent3036 ( O
sent3036 tc-tf O
sent3036 ) O
sent3036 accumulation O
sent3036 in O
sent3036 untreated O
sent3036 small O
sent3036 cell O
sent3036 lung O
sent3036 cancer O
sent3036 ( O
sent3036 sclc O
sent3036 ) O
sent3036 , O
sent3036 the O
sent3036 expression O
sent3036 of O
sent3036 p-glycoprotein O
sent3036 ( O
sent3036 pgp O
sent3036 ) O
sent3036 and O
sent3036 multidrug O
sent3036 resistance O
sent3036 related O
sent3036 protein-1 O
sent3036 ( O
sent3036 mrp1 O
sent3036 ) O
sent3036 , O
sent3036 and O
sent3036 the O
sent3036 response O
sent3036 to O
sent3036 chemotherapy T
sent3036 in O
sent3036 patients O
sent3036 with O
sent3036 untreated D
sent3036 sclc D
sent3037 tc-tf O
sent3037 chest O
sent3037 scintigraphy O
sent3037 correlated O
sent3037 well O
sent3037 with O
sent3037 pgp O
sent3037 or O
sent3037 mrp1 O
sent3037 expression O
sent3037 and O
sent3037 accurately O
sent3037 predicted O
sent3037 the O
sent3037 response O
sent3037 to O
sent3037 chemotherapy T
sent3037 in O
sent3037 patients O
sent3037 with O
sent3037 sclc D
sent3038 exploratory T
sent3038 interventions T
sent3038 , T
sent3038 partial T
sent3038 tumor T
sent3038 resections T
sent3038 and T
sent3038 lung T
sent3038 resections T
sent3038 for O
sent3038 metastasis D
sent3038 were O
sent3038 more O
sent3038 frequently O
sent3038 performed O
sent3038 in O
sent3038 young O
sent3038 patients O
sent3038 than O
sent3038 in O
sent3038 older O
sent3038 patients O
sent3039 in O
sent3039 the O
sent3039 present O
sent3039 report O
sent3039 , O
sent3039 we O
sent3039 reviewed O
sent3039 articles O
sent3039 on O
sent3039 pulmonary T
sent3039 angiography T
sent3039 for O
sent3039 patients O
sent3039 with O
sent3039 pulmonary D
sent3039 hypertension D
sent3040 prophylactic T
sent3040 cranial T
sent3040 irradiation T
sent3040 ( T
sent3040 pci T
sent3040 ) T
sent3040 has O
sent3040 been O
sent3040 demonstrated O
sent3040 to O
sent3040 significantly O
sent3040 reduce O
sent3040 the O
sent3040 incidence O
sent3040 of O
sent3040 brain O
sent3040 relapse O
sent3040 from O
sent3040 limited D
sent3040 disease D
sent3040 small-cell D
sent3040 lung D
sent3040 cancer D
sent3040 ( D
sent3040 ld D
sent3040 sclc D
sent3040 ) D
sent3040 , O
sent3040 but O
sent3040 concerns O
sent3040 about O
sent3040 neurologic O
sent3040 toxicity O
sent3040 remain O
sent3041 thus O
sent3041 , O
sent3041 twice-daily O
sent3041 pci T
sent3041 should O
sent3041 be O
sent3041 considered O
sent3041 for O
sent3041 patients O
sent3041 with O
sent3041 ld D
sent3041 sclc D
sent3041 who O
sent3041 achieve O
sent3041 a O
sent3041 complete O
sent3041 response O
sent3041 to O
sent3041 chemoirradiation O
sent3042 animal O
sent3042 studies O
sent3042 suggest O
sent3042 that O
sent3042 the O
sent3042 kidney O
sent3042 is O
sent3042 involved O
sent3042 in O
sent3042 the O
sent3042 elimination O
sent3042 of O
sent3042 recombinant T
sent3042 human T
sent3042 granulocyte T
sent3042 colony-stimulating T
sent3042 factor T
sent3042 ( T
sent3042 rhg-csf T
sent3042 ) T
sent3042 , O
sent3042 which O
sent3042 is O
sent3042 used O
sent3042 for O
sent3042 patients O
sent3042 with O
sent3042 neutropenia D
sent3042 during O
sent3042 cancer D
sent3042 chemotherapy T
sent3043 amifostine T
sent3043 ( T
sent3043 wr-2721 T
sent3043 ) T
sent3043 is O
sent3043 a O
sent3043 cytoprotective O
sent3043 agent O
sent3043 that O
sent3043 protects O
sent3043 a O
sent3043 broad O
sent3043 range O
sent3043 of O
sent3043 normal O
sent3043 tissues O
sent3043 from O
sent3043 the O
sent3043 toxic D
sent3043 effects D
sent3043 of D
sent3043 chemotherapy D
sent3043 and D
sent3043 radiotherapy D
sent3043 without O
sent3043 attenuating O
sent3043 tumour O
sent3043 response O
sent3044 in O
sent3044 a O
sent3044 pivotal O
sent3044 phase O
sent3044 iii O
sent3044 trial O
sent3044 , O
sent3044 242 O
sent3044 patients O
sent3044 with O
sent3044 advanced D
sent3044 ovarian D
sent3044 cancer D
sent3044 were O
sent3044 randomised O
sent3044 to O
sent3044 receive O
sent3044 treatment O
sent3044 with O
sent3044 cisplatin T
sent3044 100 O
sent3044 mg/m2 O
sent3044 and O
sent3044 cyclophosphamide T
sent3044 1000 O
sent3044 mg/m2 O
sent3044 every O
sent3044 3 O
sent3044 weeks O
sent3044 with O
sent3044 or O
sent3044 without O
sent3044 pretreatment O
sent3044 with O
sent3044 intravenous O
sent3044 amifostine O
sent3044 910 O
sent3044 mg/m2 O
sent3045 over O
sent3045 6 O
sent3045 cycles O
sent3045 of O
sent3045 therapy O
sent3045 , O
sent3045 amifostine T
sent3045 significantly O
sent3045 reduced O
sent3045 haematological D
sent3045 , D
sent3045 renal D
sent3045 and D
sent3045 neurological D
sent3045 toxicities D
sent3045 : O
sent3045 treatment O
sent3045 delays O
sent3045 , O
sent3045 treatment O
sent3045 discontinuation O
sent3045 and O
sent3045 days O
sent3045 in O
sent3045 hospital O
sent3045 related O
sent3045 to O
sent3045 these O
sent3045 adverse O
sent3045 events O
sent3045 were O
sent3045 also O
sent3045 significantly O
sent3045 reduced O
sent3045 in O
sent3045 patients O
sent3045 receiving O
sent3045 amifostine O
sent3045 versus O
sent3045 patients O
sent3045 receiving O
sent3045 chemotherapy O
sent3045 alone O
sent3046 < O
sent3046 TO_SEE O
sent3046 > O
sent3046 in O
sent3046 another O
sent3046 randomised O
sent3046 phase O
sent3046 iii O
sent3046 trial O
sent3046 in O
sent3046 303 O
sent3046 patients O
sent3046 with O
sent3046 head D
sent3046 and D
sent3046 neck D
sent3046 cancer D
sent3046 undergoing O
sent3046 irradiation T
sent3046 therapy T
sent3046 ( O
sent3046 total O
sent3046 dose O
sent3046 50 O
sent3046 to O
sent3046 70gy O
sent3046 ) O
sent3046 , O
sent3046 pretreatment O
sent3046 with O
sent3046 intravenous O
sent3046 amifostine T
sent3046 200 O
sent3046 mg/m2 O
sent3046 significantly O
sent3046 reduced O
sent3046 the O
sent3046 incidence O
sent3046 of O
sent3046 acute O
sent3046 and O
sent3046 late O
sent3046 grade O
sent3046 > O
sent3046 or O
sent3046 =2 O
sent3046 xerostomia D
sent3047 amifostine T
sent3047 ( O
sent3047 340 O
sent3047 mg/m2 O
sent3047 ) O
sent3047 also O
sent3047 provided O
sent3047 significant O
sent3047 protection O
sent3047 against O
sent3047 pneumonitis D
sent3047 and D
sent3047 oesophagitis D
sent3047 in O
sent3047 patients O
sent3047 with O
sent3047 lung D
sent3047 cancer D
sent3047 receiving O
sent3047 thoracic T
sent3047 irradiation T
sent3047 in O
sent3047 a O
sent3047 preliminary O
sent3047 report O
sent3047 from O
sent3047 a O
sent3047 phase O
sent3047 iii O
sent3047 trial O
sent3047 ( O
sent3047 n O
sent3047 = O
sent3047 144 O
sent3047 ) O
sent3048 amifostine T
sent3048 has O
sent3048 also O
sent3048 been O
sent3048 shown O
sent3048 to O
sent3048 stimulate O
sent3048 haematopoietic O
sent3048 stem O
sent3048 cells O
sent3048 and O
sent3048 has O
sent3048 been O
sent3048 investigated O
sent3048 as O
sent3048 a O
sent3048 therapy O
sent3048 for O
sent3048 patients O
sent3048 with O
sent3048 myelodysplastic D
sent3048 syndrome D
sent3048 in O
sent3048 number O
sent3048 of O
sent3048 small O
sent3048 preliminary O
sent3048 studies O
sent3049 < O
sent3049 TO_SEE O
sent3049 > O
sent3049 conclusion O
sent3049 : O
sent3049 the O
sent3049 results O
sent3049 of O
sent3049 phase O
sent3049 iii O
sent3049 trials O
sent3049 have O
sent3049 confirmed O
sent3049 the O
sent3049 safety O
sent3049 and O
sent3049 efficacy O
sent3049 of O
sent3049 amifostine T
sent3049 as O
sent3049 a O
sent3049 cytoprotectant O
sent3049 to O
sent3049 ameliorate O
sent3049 cisplatin-induced D
sent3049 cumulative D
sent3049 renal D
sent3049 toxicity D
sent3049 , O
sent3049 for O
sent3049 which O
sent3049 it O
sent3049 is O
sent3049 the O
sent3049 only O
sent3049 agent O
sent3049 proven O
sent3049 to O
sent3049 be O
sent3049 effective O
sent3049 , O
sent3049 and O
sent3049 neutropenia D
sent3049 in O
sent3049 patients O
sent3049 with O
sent3049 advanced O
sent3049 ovarian O
sent3049 cancer O
sent3049 , O
sent3049 and O
sent3049 to O
sent3049 reduce O
sent3049 xerostomia D
sent3049 in O
sent3049 patients O
sent3049 with O
sent3049 head D
sent3049 and D
sent3049 neck D
sent3049 cancer D
sent3049 receiving O
sent3049 irradiation T
sent3049 therapy T
sent3050 depending O
sent3050 on O
sent3050 the O
sent3050 outcome O
sent3050 of O
sent3050 numerous O
sent3050 ongoing O
sent3050 clinical O
sent3050 trials O
sent3050 , O
sent3050 amifostine T
sent3050 may O
sent3050 eventually O
sent3050 find O
sent3050 broader O
sent3050 clinical O
sent3050 applications O
sent3050 , O
sent3050 both O
sent3050 as O
sent3050 a O
sent3050 cytoprotectant O
sent3050 and O
sent3050 as O
sent3050 a O
sent3050 potential O
sent3050 therapy O
sent3050 in O
sent3050 myelodysplastic D
sent3050 syndrome D
sent3051 to O
sent3051 perform O
sent3051 a O
sent3051 curative O
sent3051 operation O
sent3051 for O
sent3051 the O
sent3051 lung D
sent3051 cancer D
sent3051 without O
sent3051 myocardial O
sent3051 infarction O
sent3051 , O
sent3051 minimally T
sent3051 invasive T
sent3051 direct T
sent3051 coronary T
sent3051 artery T
sent3051 bypass T
sent3051 and T
sent3051 left T
sent3051 lower T
sent3051 lobectomy T
sent3051 with T
sent3051 video-endoscopic T
sent3051 assistance T
sent3051 were O
sent3051 performed O
sent3051 simultaneously O
sent3052 A O
sent3052 review O
sent3052 of O
sent3052 the O
sent3052 fetal-maternal O
sent3052 carboxyhemoglobin O
sent3052 relationships O
sent3052 and O
sent3052 the O
sent3052 differences O
sent3052 in O
sent3052 fetal O
sent3052 oxyhemoglobin O
sent3052 physiology O
sent3052 are O
sent3052 used O
sent3052 to O
sent3052 explain O
sent3052 the O
sent3052 recommendation O
sent3052 that O
sent3052 pregnant O
sent3052 women O
sent3052 with O
sent3052 carbon D
sent3052 monoxide D
sent3052 poisoning D
sent3052 should O
sent3052 receive O
sent3052 100 O
sent3052 % O
sent3052 oxygen T
sent3052 therapy T
sent3052 for O
sent3052 up O
sent3052 to O
sent3052 five O
sent3052 times O
sent3052 longer O
sent3052 than O
sent3052 is O
sent3052 otherwise O
sent3052 necessary O
sent3053 The O
sent3053 authors O
sent3053 describe O
sent3053 the O
sent3053 case O
sent3053 of O
sent3053 a O
sent3053 child O
sent3053 with O
sent3053 status D
sent3053 epilepticus D
sent3053 in O
sent3053 whom O
sent3053 phenytoin T
sent3053 was O
sent3053 administered O
sent3053 via O
sent3053 the O
sent3053 intraosseous O
sent3053 route O
sent3053 , O
sent3053 and O
sent3053 seizure O
sent3053 resolution O
sent3053 and O
sent3053 therapeutic O
sent3053 serum O
sent3053 levels O
sent3053 were O
sent3053 achieved O
sent3054 A O
sent3054 patient O
sent3054 suffering O
sent3054 baclofen D
sent3054 overdose D
sent3054 successfully O
sent3054 treated O
sent3054 with O
sent3054 atropine T
sent3054 is O
sent3054 reported O
sent3055 Atropine T
sent3055 appears O
sent3055 to O
sent3055 be O
sent3055 useful O
sent3055 in O
sent3055 treating O
sent3055 cases O
sent3055 of O
sent3055 baclofen D
sent3055 overdose D
sent3055 complicated O
sent3055 by O
sent3055 bradycardia O
sent3055 and O
sent3055 hypotension O
sent3056 Therapeutic O
sent3056 effect O
sent3056 of O
sent3056 a O
sent3056 left T
sent3056 ventricular T
sent3056 assist T
sent3056 device T
sent3056 on O
sent3056 acute D
sent3056 myocardial D
sent3056 infarction D
sent3056 evaluated O
sent3056 by O
sent3056 magnetic O
sent3056 resonance O
sent3056 imaging O
sent3057 Continuous T
sent3057 arteriovenous T
sent3057 hemofiltration T
sent3057 for O
sent3057 the O
sent3057 treatment O
sent3057 of O
sent3057 anasarca D
sent3057 and D
sent3057 acute D
sent3057 renal D
sent3057 failure D
sent3057 in O
sent3057 severely O
sent3057 burned O
sent3057 patients O
sent3058 Continuous T
sent3058 renal T
sent3058 replacement T
sent3058 therapy T
sent3058 in O
sent3058 patients O
sent3058 with O
sent3058 acute D
sent3058 renal D
sent3058 dysfunction D
sent3058 undergoing O
sent3058 intraaortic O
sent3058 balloon O
sent3058 pump O
sent3058 and/or O
sent3058 left O
sent3058 ventricular O
sent3058 device O
sent3058 support O
sent3059 Continuous T
sent3059 arterio-venous T
sent3059 hemofiltration T
sent3059 in O
sent3059 a O
sent3059 wearable O
sent3059 device O
sent3059 to O
sent3059 treat O
sent3059 end-stage D
sent3059 renal D
sent3059 disease D
sent3060 The O
sent3060 effectiveness O
sent3060 of O
sent3060 neostigmine T
sent3060 0.07 T
sent3060 mg T
sent3060 kg-1 T
sent3060 and T
sent3060 edrophonium T
sent3060 0.8 O
sent3060 mg O
sent3060 kg-1 O
sent3060 as O
sent3060 antagonists O
sent3060 of O
sent3060 profound D
sent3060 neuromuscular D
sent3060 blockade D
sent3060 induced O
sent3060 by O
sent3060 vecuronium O
sent3060 0.1 O
sent3060 mg O
sent3060 kg-1 O
sent3060 or O
sent3060 atracurium O
sent3060 0.5 O
sent3060 mg O
sent3060 kg-1 O
sent3060 was O
sent3060 studied O
sent3060 in O
sent3060 59 O
sent3060 healthy O
sent3060 patients O
sent3061 Antagonism O
sent3061 of O
sent3061 atracurium-induced O
sent3061 neuromuscular D
sent3061 blockade D
sent3061 by O
sent3061 neostigmine T
sent3061 or T
sent3061 edrophonium T
sent3061 has O
sent3061 been O
sent3061 studied O
sent3061 using O
sent3061 the O
sent3061 tetanic O
sent3061 ( O
sent3061 50 O
sent3061 Hz O
sent3061 ) O
sent3061 and O
sent3061 train-of-four O
sent3061 ( O
sent3061 2 O
sent3061 Hz O
sent3061 ) O
sent3061 or O
sent3061 single O
sent3061 twitch O
sent3061 responses O
sent3061 of O
sent3061 the O
sent3061 adductor O
sent3061 pollicis O
sent3061 muscle O
sent3061 in O
sent3061 22 O
sent3061 anaesthetized O
sent3061 patients O
sent3062 Active T
sent3062 forms T
sent3062 of T
sent3062 vitamin T
sent3062 D3 T
sent3062 , T
sent3062 1 T
sent3062 alpha-hydroxyvitamin T
sent3062 D3 T
sent3062 and T
sent3062 1 T
sent3062 alpha T
sent3062 , T
sent3062 25-dihydroxyvitamin T
sent3062 D3 T
sent3062 , O
sent3062 were O
sent3062 administered O
sent3062 in O
sent3062 an O
sent3062 open-design O
sent3062 study O
sent3062 to O
sent3062 40 O
sent3062 patients O
sent3062 with O
sent3062 psoriasis D
sent3062 vulgaris D
sent3062 in O
sent3062 three O
sent3062 ways O
sent3062 : O
sent3062 to O
sent3062 17 O
sent3062 patients O
sent3062 1 O
sent3062 alpha-hydroxyvitamin O
sent3062 D3 O
sent3062 was O
sent3062 given O
sent3062 orally O
sent3062 at O
sent3062 a O
sent3062 dose O
sent3062 of O
sent3062 1.0 O
sent3062 micrograms/day O
sent3062 for O
sent3062 6 O
sent3062 months O
sent3062 , O
sent3062 to O
sent3062 four O
sent3062 patients O
sent3062 1 O
sent3062 alpha O
sent3062 , O
sent3062 25-dihydroxyvitamin O
sent3062 D3 O
sent3062 was O
sent3062 given O
sent3062 orally O
sent3062 at O
sent3062 a O
sent3062 dose O
sent3062 of O
sent3062 0.5 O
sent3062 microgram/day O
sent3062 for O
sent3062 6 O
sent3062 months O
sent3062 , O
sent3062 and O
sent3062 19 O
sent3062 patients O
sent3062 were O
sent3062 given O
sent3062 1 O
sent3062 alpha O
sent3062 , O
sent3062 25-dihydroxyvitamin O
sent3062 D3 O
sent3062 applied O
sent3062 topically O
sent3062 at O
sent3062 concentration O
sent3062 of O
sent3062 0.5 O
sent3062 microgram/g O
sent3062 of O
sent3062 base O
sent3062 for O
sent3062 8 O
sent3062 weeks O
sent3063 These O
sent3063 data O
sent3063 suggest O
sent3063 that O
sent3063 psoriasis D
sent3063 may O
sent3063 respond O
sent3063 to O
sent3063 active T
sent3063 metabolites T
sent3063 of T
sent3063 vitamin T
sent3063 D3 T
sent3063 and O
sent3063 that O
sent3063 abnormalities O
sent3063 in O
sent3063 vitamin O
sent3063 D O
sent3063 metabolism O
sent3063 or O
sent3063 in O
sent3063 responsiveness O
sent3063 of O
sent3063 the O
sent3063 skin O
sent3063 cells O
sent3063 to O
sent3063 active O
sent3063 metabolites O
sent3063 of O
sent3063 vitamin O
sent3063 D O
sent3063 may O
sent3063 be O
sent3063 involved O
sent3063 in O
sent3063 the O
sent3063 pathogenesis O
sent3063 of O
sent3063 this O
sent3063 skin O
sent3063 disease O
sent3064 Successful O
sent3064 treatment O
sent3064 of O
sent3064 psoriasis D
sent3064 with O
sent3064 topical O
sent3064 application O
sent3064 of O
sent3064 active T
sent3064 vitamin T
sent3064 D3 T
sent3064 analogue T
sent3064 , T
sent3064 1 T
sent3064 alpha T
sent3064 , T
sent3064 24-dihydroxycholecalciferol T
sent3065 We O
sent3065 suggest O
sent3065 that O
sent3065 1 T
sent3065 alpha T
sent3065 , T
sent3065 24 T
sent3065 ( T
sent3065 OH T
sent3065 ) T
sent3065 2D3 T
sent3065 merits O
sent3065 further O
sent3065 investigation O
sent3065 as O
sent3065 a O
sent3065 potentially O
sent3065 useful O
sent3065 topical O
sent3065 therapy O
sent3065 for O
sent3065 psoriasis D
sent3066 When O
sent3066 indomethacin T
sent3066 was O
sent3066 applied O
sent3066 immediately O
sent3066 after O
sent3066 irradiation O
sent3066 , O
sent3066 UVR O
sent3066 ( O
sent3066 ultraviolet O
sent3066 radiation O
sent3066 ) O
sent3066 dose-dependent O
sent3066 suppression O
sent3066 of O
sent3066 erythema D
sent3066 was O
sent3066 demonstrated O
sent3066 for O
sent3066 both O
sent3066 wavelengths O
sent3066 until O
sent3066 36 O
sent3066 h O
sent3066 after O
sent3066 irradiation O
sent3066 when O
sent3066 both O
sent3066 indomethacin O
sent3066 and O
sent3066 control O
sent3066 gel O
sent3066 base-treated O
sent3066 sites O
sent3066 were O
sent3066 equally O
sent3066 erythematous O
sent3067 Suppression O
sent3067 of O
sent3067 erythema D
sent3067 also O
sent3067 occurred O
sent3067 when O
sent3067 application O
sent3067 of O
sent3067 indomethacin T
sent3067 was O
sent3067 delayed O
sent3067 until O
sent3067 24 O
sent3067 h O
sent3067 after O
sent3067 irradiation O
sent3067 , O
sent3067 showing O
sent3067 that O
sent3067 for O
sent3067 both O
sent3067 wavelengths O
sent3067 prostaglandin O
sent3067 synthesis O
sent3067 remains O
sent3067 increased O
sent3067 throughout O
sent3067 this O
sent3067 period O
sent3068 There O
sent3068 was O
sent3068 one O
sent3068 retinal O
sent3068 dialysis O
sent3068 , O
sent3068 and O
sent3068 one O
sent3068 lens D
sent3068 dislocation D
sent3068 requiring O
sent3068 extraction T
sent3069 Rates O
sent3069 of O
sent3069 superoxide O
sent3069 ( O
sent3069 SA O
sent3069 ) O
sent3069 generation O
sent3069 by O
sent3069 blood O
sent3069 monocytes O
sent3069 stimulated O
sent3069 ex O
sent3069 vivo O
sent3069 were O
sent3069 studied O
sent3069 before O
sent3069 and O
sent3069 during O
sent3069 corticosteroid T
sent3069 treatment O
sent3069 of O
sent3069 rheumatoid D
sent3069 arthritis D
sent3069 ( D
sent3069 RA D
sent3069 ) D
sent3069 patients O
sent3069 , O
sent3069 in O
sent3069 control O
sent3069 patients O
sent3069 and O
sent3069 in O
sent3069 healthy O
sent3069 controls O
sent3070 Significant O
sent3070 inhibition O
sent3070 of O
sent3070 monocyte O
sent3070 SA O
sent3070 output O
sent3070 stimulated O
sent3070 with O
sent3070 IgG-treated O
sent3070 zymosan O
sent3070 ( O
sent3070 ITZ O
sent3070 ) O
sent3070 and O
sent3070 fluoride O
sent3070 ion O
sent3070 ( O
sent3070 F O
sent3070 ) O
sent3070 , O
sent3070 but O
sent3070 not O
sent3070 serum-treated O
sent3070 zymosan O
sent3070 ( O
sent3070 STZ O
sent3070 ) O
sent3070 was O
sent3070 demonstrated O
sent3070 following O
sent3070 steroid T
sent3070 therapy T
sent3070 in O
sent3070 RA D
sent3071 Methotrexate T
sent3071 ( T
sent3071 MTX T
sent3071 ) T
sent3071 appears O
sent3071 to O
sent3071 be O
sent3071 useful O
sent3071 in O
sent3071 patients O
sent3071 with O
sent3071 rheumatoid D
sent3071 arthritis D
sent3071 ( D
sent3071 RA D
sent3071 ) D
sent3071 refractory O
sent3071 to O
sent3071 other O
sent3071 drugs O
sent3071 but O
sent3071 its O
sent3071 long-term O
sent3071 toxicity O
sent3071 and O
sent3071 efficacy O
sent3071 are O
sent3071 uncertain O
sent3072 MTX T
sent3072 in O
sent3072 a O
sent3072 low-dose O
sent3072 regimen O
sent3072 is O
sent3072 useful O
sent3072 in O
sent3072 refractory D
sent3072 RA D
sent3072 and O
sent3072 superior O
sent3072 to O
sent3072 low-dose O
sent3072 purine O
sent3072 analogues O
sent3073 Twelve O
sent3073 patients O
sent3073 with O
sent3073 intractable D
sent3073 rheumatoid D
sent3073 arthritis D
sent3073 were O
sent3073 treated O
sent3073 with O
sent3073 antilymphocyte T
sent3073 globulin T
sent3073 ( T
sent3073 ALG T
sent3073 ) T
sent3073 , T
sent3073 prednisolone T
sent3073 and T
sent3073 a T
sent3073 cytotoxic T
sent3073 agent T
sent3073 , T
sent3073 usually T
sent3073 azathioprine T
sent3073 , O
sent3073 and O
sent3073 were O
sent3073 followed O
sent3073 for O
sent3073 1 O
sent3073 year O
sent3074 Rigid T
sent3074 ureteroscopy T
sent3074 for O
sent3074 the O
sent3074 treatment O
sent3074 of O
sent3074 ureteric D
sent3074 calculi D
sent3074 : O
sent3074 experience O
sent3074 in O
sent3074 120 O
sent3074 cases O
sent3075 Over O
sent3075 a O
sent3075 1-year O
sent3075 period O
sent3075 , O
sent3075 rigid T
sent3075 ureteroscopy T
sent3075 has O
sent3075 been O
sent3075 used O
sent3075 to O
sent3075 retrieve O
sent3075 ureteric D
sent3075 calculi D
sent3075 in O
sent3075 120 O
sent3075 patients O
sent3076 Eleven O
sent3076 patients O
sent3076 with O
sent3076 vesicoureteric D
sent3076 reflux D
sent3076 secondary O
sent3076 to O
sent3076 neuropathic O
sent3076 bladder O
sent3076 were O
sent3076 treated O
sent3076 by O
sent3076 endoscopic T
sent3076 injection T
sent3076 of T
sent3076 pyrolised T
sent3076 polytetrafluoroethylene T
sent3076 ( T
sent3076 Polytef T
sent3076 ) T
sent3076 paste T
sent3077 Two O
sent3077 hundred O
sent3077 and O
sent3077 seventy-seven O
sent3077 patients O
sent3077 with O
sent3077 advanced D
sent3077 prostatic D
sent3077 cancer D
sent3077 were O
sent3077 treated O
sent3077 by O
sent3077 either O
sent3077 orchiectomy T
sent3077 or T
sent3077 oestrogen T
sent3078 Use O
sent3078 of O
sent3078 scarred O
sent3078 flaps O
sent3078 and O
sent3078 secondary O
sent3078 flaps O
sent3078 for O
sent3078 reconstructive T
sent3078 surgery T
sent3078 of O
sent3078 extensive D
sent3078 burns D
sent3079 A O
sent3079 patient O
sent3079 with O
sent3079 a O
sent3079 vesico-enteric D
sent3079 fistula D
sent3079 was O
sent3079 successfully O
sent3079 treated O
sent3079 with O
sent3079 resection T
sent3079 of T
sent3079 the T
sent3079 small T
sent3079 intestine T
sent3079 and T
sent3079 dome T
sent3079 of T
sent3079 the T
sent3079 bladder T
sent3079 and T
sent3079 drainage T
sent3079 of T
sent3079 the T
sent3079 intervening T
sent3079 abscess T
sent3080 Supramaximal T
sent3080 horizontal T
sent3080 rectus T
sent3080 surgery T
sent3080 in O
sent3080 the O
sent3080 management O
sent3080 of O
sent3080 third D
sent3080 and D
sent3080 sixth D
sent3080 nerve D
sent3080 palsy D
sent3081 Supramaximal T
sent3081 medial T
sent3081 and T
sent3081 lateral T
sent3081 rectus T
sent3081 surgery T
sent3081 was O
sent3081 performed O
sent3081 to O
sent3081 correct O
sent3081 horizontal D
sent3081 deviations D
sent3081 in D
sent3081 seven D
sent3081 cases D
sent3081 of D
sent3081 sixth D
sent3081 nerve D
sent3081 palsy D
sent3081 and D
sent3081 three D
sent3081 cases D
sent3081 of D
sent3081 third D
sent3081 nerve D
sent3081 palsy D
sent3081 , O
sent3081 with O
sent3081 satisfactory O
sent3081 results O
sent3081 in O
sent3081 most O
sent3081 cases O
sent3082 Steroid T
sent3082 therapy T
sent3082 was O
sent3082 also O
sent3082 used O
sent3082 in O
sent3082 two O
sent3082 patients O
sent3082 with O
sent3082 NSAID-induced D
sent3082 proteinuria D
sent3083 Recombinant T
sent3083 leukocyte T
sent3083 A T
sent3083 interferon T
sent3083 ( T
sent3083 rIFN-alpha T
sent3083 A T
sent3083 ) T
sent3083 in O
sent3083 the O
sent3083 treatment O
sent3083 of O
sent3083 disseminated D
sent3083 malignant D
sent3083 melanoma D
sent3084 Ninety-six O
sent3084 patients O
sent3084 with O
sent3084 disseminated D
sent3084 malignant D
sent3084 melanoma D
sent3084 received O
sent3084 thrice O
sent3084 weekly O
sent3084 intramuscular O
sent3084 injections O
sent3084 of O
sent3084 leukocyte T
sent3084 A T
sent3084 recombinant T
sent3084 interferon T
sent3084 ( T
sent3084 rIFN-alpha T
sent3084 A T
sent3084 , T
sent3084 Roferon-A T
sent3084 , T
sent3084 Hoffmann T
sent3084 La T
sent3084 Roche T
sent3084 ) T
sent3084 at O
sent3084 doses O
sent3084 of O
sent3084 12 O
sent3084 X O
sent3084 10 O
sent3084 ( O
sent3084 6 O
sent3084 ) O
sent3084 U/m2 O
sent3084 or O
sent3084 50 O
sent3084 X O
sent3084 10 O
sent3084 ( O
sent3084 6 O
sent3084 ) O
sent3084 U/m2 O
sent3084 with O
sent3084 or O
sent3084 without O
sent3084 cimetidine O
sent3084 as O
sent3084 an O
sent3084 immunorestorative O
sent3084 agent O
sent3085 As O
sent3085 noted O
sent3085 previously O
sent3085 , O
sent3085 using O
sent3085 chemotherapy O
sent3085 , O
sent3085 a O
sent3085 small O
sent3085 proportion O
sent3085 of O
sent3085 patients O
sent3085 with O
sent3085 advanced D
sent3085 malignant D
sent3085 melanoma D
sent3085 , O
sent3085 despite O
sent3085 prior O
sent3085 therapy O
sent3085 , O
sent3085 may O
sent3085 achieve O
sent3085 prolonged O
sent3085 objective O
sent3085 regression O
sent3085 with O
sent3085 rIFN-alpha T
sent3085 A T
sent3086 Clinical O
sent3086 course O
sent3086 of O
sent3086 breast O
sent3086 cancer O
sent3086 patients O
sent3086 with O
sent3086 osseous D
sent3086 metastasis D
sent3086 treated O
sent3086 with O
sent3086 combination T
sent3086 chemotherapy T
sent3087 Between O
sent3087 July O
sent3087 1973 O
sent3087 and O
sent3087 December O
sent3087 1979 O
sent3087 , O
sent3087 1171 O
sent3087 patients O
sent3087 with O
sent3087 metastatic D
sent3087 breast D
sent3087 cancer D
sent3087 were O
sent3087 treated O
sent3087 with O
sent3087 doxorubicin-containing T
sent3087 chemotherapy T
sent3088 Two O
sent3088 patients O
sent3088 with O
sent3088 metastatic D
sent3088 dysgerminoma D
sent3088 of D
sent3088 the D
sent3088 ovary D
sent3088 were O
sent3088 treated O
sent3088 with O
sent3088 a T
sent3088 combination T
sent3088 of T
sent3088 etoposide T
sent3088 , T
sent3088 bleomycin T
sent3088 , T
sent3088 and T
sent3088 cisplatin T
sent3088 at O
sent3088 The O
sent3088 University O
sent3088 of O
sent3088 Texas O
sent3088 M.D O
sent3089 Chemotherapy T
sent3089 may O
sent3089 be O
sent3089 an O
sent3089 alternative O
sent3089 to O
sent3089 radiotherapy O
sent3089 for O
sent3089 the O
sent3089 treatment O
sent3089 of O
sent3089 metastatic D
sent3089 dysgerminoma D
sent3089 and O
sent3089 should O
sent3089 also O
sent3089 be O
sent3089 considered O
sent3089 for O
sent3089 selected O
sent3089 patients O
sent3089 with O
sent3089 Stage O
sent3089 I O
sent3089 disease O
sent3090 Long-term O
sent3090 survival O
sent3090 and O
sent3090 morbidity O
sent3090 in O
sent3090 patients O
sent3090 with O
sent3090 metastatic D
sent3090 malignant D
sent3090 germ D
sent3090 cell D
sent3090 tumors D
sent3090 treated O
sent3090 with O
sent3090 cisplatin-based T
sent3090 combination T
sent3090 chemotherapy T
sent3091 Treatment O
sent3091 of O
sent3091 advanced D
sent3091 stage D
sent3091 mycosis D
sent3091 fungoides D
sent3091 with O
sent3091 bleomycin T
sent3091 , T
sent3091 doxorubicin T
sent3091 , T
sent3091 and T
sent3091 methotrexate T
sent3091 with T
sent3091 topical T
sent3091 nitrogen T
sent3091 mustard T
sent3091 ( T
sent3091 BAM-M T
sent3091 ) T
sent3092 Ten O
sent3092 patients O
sent3092 with O
sent3092 advanced D
sent3092 stage D
sent3092 ( D
sent3092 TNM D
sent3092 IIB-IVB D
sent3092 ) D
sent3092 mycosis D
sent3092 fungoides D
sent3092 were O
sent3092 treated O
sent3092 with O
sent3092 a O
sent3092 combination T
sent3092 chemotherapy T
sent3092 program T
sent3092 consisting T
sent3092 of T
sent3092 bleomycin T
sent3092 and T
sent3092 methotrexate T
sent3092 weekly T
sent3092 , T
sent3092 doxorubicin T
sent3092 every T
sent3092 3 T
sent3092 weeks T
sent3092 , T
sent3092 and T
sent3092 topical T
sent3092 nitrogen T
sent3092 mustard T
sent3092 daily T
sent3092 ( T
sent3092 BAM-M T
sent3092 ) T
sent3093 Three O
sent3093 patients O
sent3093 in O
sent3093 whom O
sent3093 splenomegaly D
sent3093 was O
sent3093 detected O
sent3093 during O
sent3093 their O
sent3093 staging O
sent3093 evaluation O
sent3093 underwent O
sent3093 splenectomy T
sent3094 This O
sent3094 study O
sent3094 indicates O
sent3094 that O
sent3094 BAM-M T
sent3094 is O
sent3094 effective O
sent3094 therapy O
sent3094 for O
sent3094 advanced D
sent3094 stage D
sent3094 mycosis D
sent3094 fungoides D
sent3094 and O
sent3094 suggests O
sent3094 that O
sent3094 the O
sent3094 therapeutic O
sent3094 role O
sent3094 of O
sent3094 splenectomy O
sent3094 should O
sent3094 be O
sent3094 evaluated O
sent3094 further O
sent3095 Only O
sent3095 patients O
sent3095 whose O
sent3095 primary D
sent3095 head D
sent3095 and D
sent3095 neck D
sent3095 tumor D
sent3095 shows O
sent3095 a O
sent3095 response O
sent3095 to O
sent3095 systemic O
sent3095 therapy O
sent3095 undergo O
sent3095 Ommaya T
sent3095 placement T
sent3096 Additional O
sent3096 chemotherapy T
sent3096 may O
sent3096 thus O
sent3096 have O
sent3096 eradicated O
sent3096 these O
sent3096 micrometastases D
sent3096 in O
sent3096 the O
sent3096 older O
sent3096 children O
sent3096 , O
sent3096 since O
sent3096 the O
sent3096 age O
sent3096 influence O
sent3096 on O
sent3096 Stage O
sent3096 II O
sent3096 disease O
sent3096 disappeared O
sent3096 when O
sent3096 multimodal O
sent3096 treatment O
sent3096 was O
sent3096 given O
sent3096 in O
sent3096 this O
sent3096 study O
sent3097 Traditional O
sent3097 therapy O
sent3097 for O
sent3097 malignant D
sent3097 pleural D
sent3097 effusions D
sent3097 includes O
sent3097 thoracentesis T
sent3097 or T
sent3097 tube T
sent3097 drainage T
sent3097 with O
sent3097 instillation O
sent3097 of O
sent3097 irritants O
sent3097 to O
sent3097 achieve O
sent3097 pleurodesis O
sent3098 We O
sent3098 feel O
sent3098 that O
sent3098 pleuroperitoneal T
sent3098 shunting T
sent3098 is O
sent3098 a O
sent3098 valid O
sent3098 new O
sent3098 method O
sent3098 for O
sent3098 treatment O
sent3098 of O
sent3098 malignant D
sent3098 pleural D
sent3098 effusions D
sent3098 which O
sent3098 can O
sent3098 effectively O
sent3098 palliate O
sent3098 respiratory O
sent3098 symptoms O
sent3098 with O
sent3098 low O
sent3098 morbidity O
sent3099 When O
sent3099 right D
sent3099 ventricular D
sent3099 failure D
sent3099 prohibits O
sent3099 separation O
sent3099 from O
sent3099 cardiopulmonary O
sent3099 bypass O
sent3099 , O
sent3099 standard T
sent3099 methods T
sent3099 of T
sent3099 increasing T
sent3099 pulmonary T
sent3099 blood T
sent3099 flow T
sent3099 should O
sent3099 be O
sent3099 employed O
sent3099 , O
sent3099 including O
sent3099 correction O
sent3099 of O
sent3099 hypoxia O
sent3099 and O
sent3099 acidosis O
sent3099 , O
sent3099 volume O
sent3099 loading O
sent3099 , O
sent3099 and O
sent3099 inotropic O
sent3099 support O
sent3099 of O
sent3099 the O
sent3099 right O
sent3099 ventricle O
sent3100 For O
sent3100 refractory D
sent3100 right D
sent3100 ventricular D
sent3100 failure D
sent3100 following O
sent3100 the O
sent3100 surgical O
sent3100 repair O
sent3100 of O
sent3100 congenital O
sent3100 cardiac O
sent3100 defects O
sent3100 in O
sent3100 which O
sent3100 the O
sent3100 placement O
sent3100 of O
sent3100 right O
sent3100 atrial O
sent3100 and O
sent3100 pulmonary O
sent3100 artery O
sent3100 cannulae O
sent3100 is O
sent3100 not O
sent3100 technically O
sent3100 feasible O
sent3100 , O
sent3100 use T
sent3100 of T
sent3100 high-frequency T
sent3100 high-volume T
sent3100 ventilation T
sent3100 appears O
sent3100 to O
sent3100 be O
sent3100 quite O
sent3100 promising O
sent3101 Current O
sent3101 results O
sent3101 suggest O
sent3101 that O
sent3101 RHBP T
sent3101 remains O
sent3101 the O
sent3101 gold O
sent3101 standard O
sent3101 for O
sent3101 severe D
sent3101 RV D
sent3101 failure D
sent3101 , O
sent3101 but O
sent3101 further O
sent3101 clinical O
sent3101 experience O
sent3101 with O
sent3101 PABC O
sent3101 may O
sent3101 more O
sent3101 clearly O
sent3101 define O
sent3101 its O
sent3101 role O
sent3101 in O
sent3101 the O
sent3101 management O
sent3101 of O
sent3101 RV O
sent3101 failure O
sent3102 Guiding O
sent3102 surgical T
sent3102 therapy T
sent3102 of O
sent3102 ventricular D
sent3102 tachycardia D
sent3102 by O
sent3102 preoperative O
sent3102 endocardial O
sent3102 catheter O
sent3102 mapping O
sent3102 necessitates O
sent3102 improvement O
sent3102 of O
sent3102 the O
sent3102 accuracy O
sent3102 of O
sent3102 localization O
sent3102 of O
sent3102 the O
sent3102 arrhythmogenic O
sent3102 site O
sent3103 However O
sent3103 , O
sent3103 the O
sent3103 results O
sent3103 of O
sent3103 this O
sent3103 study O
sent3103 indicate O
sent3103 that O
sent3103 procainamide T
sent3103 may O
sent3103 be O
sent3103 effective O
sent3103 in O
sent3103 suppressing O
sent3103 the O
sent3103 induction O
sent3103 of O
sent3103 sustained O
sent3103 ventricular D
sent3103 tachycardia D
sent3103 at O
sent3103 a O
sent3103 relatively O
sent3103 low O
sent3103 plasma O
sent3103 concentration O
sent3103 , O
sent3103 but O
sent3103 not O
sent3103 at O
sent3103 a O
sent3103 higher O
sent3103 plasma O
sent3103 concentration O
sent3104 Coronary T
sent3104 angioplasty T
sent3104 for O
sent3104 early D
sent3104 postinfarction D
sent3104 unstable D
sent3104 angina D
sent3105 Coronary T
sent3105 angioplasty T
sent3105 was O
sent3105 performed O
sent3105 in O
sent3105 53 O
sent3105 patients O
sent3105 in O
sent3105 whom O
sent3105 unstable D
sent3105 angina D
sent3105 had O
sent3105 reoccurred O
sent3105 after O
sent3105 48 O
sent3105 hr O
sent3105 and O
sent3105 within O
sent3105 30 O
sent3105 days O
sent3105 after O
sent3105 sustained O
sent3105 myocardial O
sent3105 infarction O
sent3106 At O
sent3106 6 O
sent3106 months O
sent3106 follow-up O
sent3106 26 O
sent3106 % O
sent3106 ( O
sent3106 14/53 O
sent3106 ) O
sent3106 of O
sent3106 all O
sent3106 the O
sent3106 patients O
sent3106 who O
sent3106 underwent O
sent3106 angioplasty T
sent3106 had O
sent3106 recurrence O
sent3106 of O
sent3106 angina D
sent3106 , O
sent3106 which O
sent3106 was O
sent3106 successfully O
sent3106 treated O
sent3106 with O
sent3106 repeat T
sent3106 angioplasty T
sent3106 , T
sent3106 bypass T
sent3106 surgery T
sent3106 , T
sent3106 or T
sent3106 medical T
sent3106 therapy T
sent3107 Coronary D
sent3107 dissection D
sent3107 and D
sent3107 total D
sent3107 coronary D
sent3107 occlusion D
sent3107 leading O
sent3107 to O
sent3107 emergency T
sent3107 coronary T
sent3107 surgery T
sent3107 are O
sent3107 the O
sent3107 most O
sent3107 frequent O
sent3107 complications O
sent3107 of O
sent3107 percutaneous O
sent3107 transluminal O
sent3107 coronary O
sent3107 angioplasty O
sent3107 ( O
sent3107 PTCA O
sent3107 ) O
sent3107 and O
sent3107 their O
sent3107 occurrence O
sent3107 usually O
sent3107 is O
sent3107 unpredictable O
sent3108 Effect O
sent3108 of O
sent3108 zanamivir T
sent3108 on O
sent3108 duration O
sent3108 and O
sent3108 resolution O
sent3108 of O
sent3108 influenza D
sent3108 symptoms O
sent3109 A O
sent3109 comparison O
sent3109 of O
sent3109 a O
sent3109 five-day O
sent3109 regimen O
sent3109 of O
sent3109 cefdinir T
sent3109 with O
sent3109 a O
sent3109 seven-day O
sent3109 regimen O
sent3109 of O
sent3109 loracarbef T
sent3109 for O
sent3109 the O
sent3109 treatment O
sent3109 of O
sent3109 acute O
sent3109 exacerbations O
sent3109 of O
sent3109 chronic D
sent3109 bronchitis D
sent3110 Initial O
sent3110 empiric O
sent3110 therapy O
sent3110 for O
sent3110 community-acquired O
sent3110 bacterial D
sent3110 meningitis D
sent3110 should O
sent3110 be O
sent3110 based O
sent3110 on O
sent3110 the O
sent3110 possibility O
sent3110 that O
sent3110 penicillin-resistant O
sent3110 pneumococci O
sent3110 may O
sent3110 be O
sent3110 the O
sent3110 etiologic O
sent3110 organisms O
sent3110 and O
sent3110 , O
sent3110 hence O
sent3110 , O
sent3110 should O
sent3110 include O
sent3110 a O
sent3110 combination O
sent3110 of O
sent3110 third-generation O
sent3110 cephalosporin T
sent3110 ( T
sent3110 cefotaxime T
sent3110 or T
sent3110 ceftriaxone T
sent3110 ) T
sent3110 and T
sent3110 vancomycin T
sent3111 Ampicillin T
sent3111 should O
sent3111 be O
sent3111 included O
sent3111 if O
sent3111 the O
sent3111 patient O
sent3111 has O
sent3111 predisposing O
sent3111 factors O
sent3111 that O
sent3111 are O
sent3111 associated O
sent3111 with O
sent3111 a O
sent3111 risk O
sent3111 for O
sent3111 infection D
sent3111 with D
sent3111 Listeria D
sent3111 monocytogenes D
sent3112 Results O
sent3112 of O
sent3112 clinical O
sent3112 trials O
sent3112 and O
sent3112 meta-analysis O
sent3112 suggest O
sent3112 that O
sent3112 dexamethasone T
sent3112 therapy T
sent3112 improves O
sent3112 the O
sent3112 outcome O
sent3112 for O
sent3112 patients O
sent3112 with O
sent3112 bacterial D
sent3112 meningitis D
sent3113 Placebo-controlled O
sent3113 trials O
sent3113 have O
sent3113 shown O
sent3113 that O
sent3113 vitamin T
sent3113 C T
sent3113 supplementation O
sent3113 decreases O
sent3113 the O
sent3113 duration O
sent3113 and O
sent3113 severity O
sent3113 of O
sent3113 common D
sent3113 cold D
sent3113 infections D
sent3114 Since O
sent3114 few O
sent3114 trials O
sent3114 have O
sent3114 examined O
sent3114 the O
sent3114 effects O
sent3114 of O
sent3114 therapeutic O
sent3114 supplementation O
sent3114 and O
sent3114 their O
sent3114 results O
sent3114 have O
sent3114 been O
sent3114 variable O
sent3114 , O
sent3114 further O
sent3114 therapeutic O
sent3114 trials O
sent3114 are O
sent3114 required O
sent3114 to O
sent3114 examine O
sent3114 the O
sent3114 role O
sent3114 of O
sent3114 vitamin T
sent3114 C T
sent3114 in O
sent3114 the O
sent3114 treatment O
sent3114 of O
sent3114 colds D
sent3115 < O
sent3115 TO_SEE O
sent3115 > O
sent3115 Progressive D
sent3115 multifocal D
sent3115 leukoencephalopathy D
sent3115 following O
sent3115 oral T
sent3115 fludarabine T
sent3115 treatment O
sent3115 of O
sent3115 chronic D
sent3115 lymphocytic D
sent3115 leukemia D
sent3116 < O
sent3116 TO_SEE O
sent3116 > O
sent3116 PURPOSE O
sent3116 : O
sent3116 To O
sent3116 review O
sent3116 reported O
sent3116 inflammatory D
sent3116 reactions D
sent3116 occurring O
sent3116 after O
sent3116 initiation O
sent3116 of O
sent3116 highly O
sent3116 active O
sent3116 antiretroviral T
sent3116 therapy T
sent3116 ( T
sent3116 HAART T
sent3116 ) T
sent3116 in O
sent3116 persons O
sent3116 infected O
sent3116 with O
sent3116 HIV-1 D
sent3116 and O
sent3116 to O
sent3116 explore O
sent3116 the O
sent3116 mechanisms O
sent3116 leading O
sent3116 to O
sent3116 these O
sent3116 reactions O
sent3117 Levofloxacin T
sent3117 versus T
sent3117 intravenous T
sent3117 ceftriaxone T
sent3117 and T
sent3117 amoxicillin/clavulanate T
sent3117 in O
sent3117 the O
sent3117 treatment O
sent3117 of O
sent3117 community-acquired O
sent3117 pneumonia D
sent3117 that O
sent3117 require O
sent3117 hospitalization O
sent3118 Overall O
sent3118 1 O
sent3118 year O
sent3118 survival O
sent3118 ( O
sent3118 operative O
sent3118 deaths O
sent3118 excluded O
sent3118 ) O
sent3118 was O
sent3118 68 O
sent3118 % O
sent3118 after O
sent3118 tumor D
sent3118 resection T
sent3118 compared O
sent3118 to O
sent3118 31 O
sent3118 % O
sent3118 after O
sent3118 palliative O
sent3118 surgery O
sent3118 ( O
sent3118 P O
sent3118 < O
sent3118 0.001 O
sent3118 ) O
sent3119 The O
sent3119 results O
sent3119 of O
sent3119 this O
sent3119 study O
sent3119 show O
sent3119 that O
sent3119 resection T
sent3119 of O
sent3119 extrahepatic D
sent3119 bile D
sent3119 duct D
sent3119 carcinomas D
sent3119 , O
sent3119 particularly O
sent3119 in O
sent3119 an O
sent3119 upper-third O
sent3119 localization O
sent3119 , O
sent3119 is O
sent3119 often O
sent3119 associated O
sent3119 with O
sent3119 worthwhile O
sent3119 long-term O
sent3119 survival O
sent3120 Background O
sent3120 : O
sent3120 N-acetylcysteine T
sent3120 ( T
sent3120 NAC T
sent3120 ) T
sent3120 and T
sent3120 ambroxol T
sent3120 ( T
sent3120 AMB T
sent3120 ) T
sent3120 have O
sent3120 recently O
sent3120 been O
sent3120 proposed O
sent3120 as O
sent3120 possible O
sent3120 therapeutic O
sent3120 agents O
sent3120 in O
sent3120 the O
sent3120 treatment O
sent3120 of O
sent3120 pulmonary D
sent3120 disorders D
sent3121 < O
sent3121 TO_SEE O
sent3121 > O
sent3121 Postoperative O
sent3121 alkaline D
sent3121 reflux D
sent3121 after O
sent3121 total T
sent3121 gastrectomy T
sent3121 for O
sent3121 stomach D
sent3121 cancer D
sent3122 Antimicrobial T
sent3122 therapy T
sent3122 for O
sent3122 respiratory D
sent3122 disease D
sent3123 Corticosteroids T
sent3123 for O
sent3123 the O
sent3123 treatment O
sent3123 of O
sent3123 croup D
sent3124 < O
sent3124 TO_SEE O
sent3124 > O
sent3124 BACKGROUND O
sent3124 : O
sent3124 In O
sent3124 the O
sent3124 present O
sent3124 study O
sent3124 we O
sent3124 investigated O
sent3124 the O
sent3124 efficacy O
sent3124 and O
sent3124 tolerability O
sent3124 of O
sent3124 i.m T
sent3124 . T
sent3124 octreotide T
sent3124 acetate T
sent3124 ( T
sent3124 octreotide T
sent3124 LAR T
sent3124 ) T
sent3124 in O
sent3124 patients O
sent3124 with O
sent3124 metastatic D
sent3124 neuroendocrine D
sent3124 tumors D
sent3124 ( D
sent3124 NETs D
sent3124 ) D
sent3124 previously O
sent3124 treated O
sent3124 and O
sent3124 failed O
sent3124 on O
sent3124 i.m T
sent3124 . T
sent3124 lanreotide T
sent3125 The O
sent3125 PR O
sent3125 was O
sent3125 observed O
sent3125 in O
sent3125 one O
sent3125 patient O
sent3125 with O
sent3125 non-functioning D
sent3125 endocrine D
sent3125 pancreatic D
sent3125 tumor D
sent3125 with D
sent3125 progressive D
sent3125 liver D
sent3125 and D
sent3125 lymph D
sent3125 node D
sent3125 metastases D
sent3125 after O
sent3125 16 O
sent3125 months O
sent3125 of O
sent3125 i.m T
sent3125 . T
sent3125 lanreotide T
sent3125 therapy T
sent3126 CONCLUSIONS O
sent3126 : O
sent3126 Octreotide T
sent3126 LAR T
sent3126 20 O
sent3126 mg O
sent3126 shows O
sent3126 significant O
sent3126 efficacy O
sent3126 in O
sent3126 terms O
sent3126 of O
sent3126 objective O
sent3126 response O
sent3126 rate O
sent3126 ( O
sent3126 PR O
sent3126 + O
sent3126 SD O
sent3126 ) O
sent3126 , O
sent3126 biochemical O
sent3126 and O
sent3126 symptomatic O
sent3126 control O
sent3126 in O
sent3126 patients O
sent3126 with O
sent3126 metastatic D
sent3126 NETs D
sent3126 of O
sent3126 the O
sent3126 GEP O
sent3126 system O
sent3126 pretreated O
sent3126 and O
sent3126 progressing O
sent3126 on O
sent3126 slow O
sent3126 release O
sent3126 lanreotide O
sent3127 Inchinko-to T
sent3127 ( T
sent3127 TJ-135 T
sent3127 ) T
sent3127 is O
sent3127 a O
sent3127 herbal O
sent3127 medicine O
sent3127 consisting O
sent3127 of O
sent3127 three O
sent3127 kinds O
sent3127 of O
sent3127 crude O
sent3127 drugs O
sent3127 , O
sent3127 and O
sent3127 in O
sent3127 Japan O
sent3127 it O
sent3127 is O
sent3127 administered O
sent3127 mainly O
sent3127 to O
sent3127 patients O
sent3127 with O
sent3127 cholestasis D
sent3128 The O
sent3128 present O
sent3128 study O
sent3128 evaluated O
sent3128 the O
sent3128 effects O
sent3128 of O
sent3128 TJ-135 T
sent3128 on O
sent3128 concanavalin D
sent3128 A D
sent3128 ( D
sent3128 con D
sent3128 A D
sent3128 ) D
sent3128 -induced D
sent3128 hepatitis D
sent3128 in O
sent3128 mice O
sent3128 in O
sent3128 vivo O
sent3128 and O
sent3128 con O
sent3128 A-induced O
sent3128 cytokine O
sent3128 production O
sent3128 in O
sent3128 vitro O
sent3129 These O
sent3129 results O
sent3129 suggest O
sent3129 that O
sent3129 con D
sent3129 A-induced D
sent3129 hepatitis D
sent3129 was O
sent3129 ameliorated O
sent3129 by O
sent3129 pretreatment O
sent3129 with O
sent3129 TJ-135 T
sent3130 Therefore O
sent3130 administration O
sent3130 of O
sent3130 TJ-135 T
sent3130 may O
sent3130 be O
sent3130 useful O
sent3130 in O
sent3130 patients O
sent3130 with O
sent3130 severe O
sent3130 acute O
sent3130 hepatitis D
sent3130 accompanying D
sent3130 cholestasis D
sent3130 or O
sent3130 in O
sent3130 those O
sent3130 with O
sent3130 autoimmune D
sent3130 hepatitis D
sent3131 Zinc T
sent3131 lozenges T
sent3131 -- O
sent3131 a O
sent3131 cure O
sent3131 for O
sent3131 common D
sent3131 colds D
sent3131 ? O
sent3132 T-helper T
sent3132 type T
sent3132 2 T
sent3132 cell-directed T
sent3132 therapy T
sent3132 for O
sent3132 asthma D
sent3133 Effects O
sent3133 of O
sent3133 the O
sent3133 Japanese T
sent3133 herbal T
sent3133 medicine T
sent3133 'Inchinko-to T
sent3133 ' T
sent3133 ( T
sent3133 TJ-135 T
sent3133 ) T
sent3133 on O
sent3133 concanavalin D
sent3133 A-induced D
sent3133 hepatitis D
sent3133 in O
sent3133 mice O
sent3134 Presumed O
sent3134 cavernomas O
sent3134 have O
sent3134 been O
sent3134 documented O
sent3134 following O
sent3134 radiation T
sent3134 for O
sent3134 malignancy D
sent3134 ( O
sent3134 5-6 O
sent3134 ) O
sent3134 , O
sent3134 and O
sent3134 sterotactic O
sent3134 cerebral O
sent3134 biopsy O
sent3134 ( O
sent3134 7 O
sent3134 ) O
sent3135 Surgical T
sent3135 management T
sent3135 of O
sent3135 syringomyelia D
sent3135 associated D
sent3135 with D
sent3135 spinal D
sent3135 adhesive D
sent3135 arachnoiditis D
sent3136 Discontinuation O
sent3136 of O
sent3136 secondary O
sent3136 prophylaxis O
sent3136 for O
sent3136 cryptococcal D
sent3136 meningitis D
sent3136 in O
sent3136 HIV-infected O
sent3136 patients O
sent3136 responding O
sent3136 to O
sent3136 highly O
sent3136 active O
sent3136 antiretroviral T
sent3136 therapy T
sent3137 Hepatectomy T
sent3137 for O
sent3137 cholangiocarcinoma D
sent3137 complicated O
sent3137 with O
sent3137 right O
sent3137 umbilical O
sent3137 portion O
sent3137 : O
sent3137 anomalous O
sent3137 configuration O
sent3137 of O
sent3137 the O
sent3137 intrahepatic O
sent3137 biliary O
sent3137 tree O
sent3138 Traditionally O
sent3138 , O
sent3138 the O
sent3138 therapy O
sent3138 of O
sent3138 symptomatic D
sent3138 bronchiectasis D
sent3138 is O
sent3138 based O
sent3138 on O
sent3138 antibiotics T
sent3138 , T
sent3138 antibronchoobstructive T
sent3138 medication T
sent3138 , T
sent3138 and T
sent3138 chest T
sent3138 physical T
sent3138 therapy T
sent3139 Bilateral T
sent3139 lung T
sent3139 transplantation T
sent3139 should O
sent3139 be O
sent3139 considered O
sent3139 in O
sent3139 younger O
sent3139 patients O
sent3139 with O
sent3139 severe O
sent3139 , O
sent3139 generalized O
sent3139 bronchiectasis D
sent3139 and D
sent3139 respiratory D
sent3139 failure D
sent3140 Prospective O
sent3140 , O
sent3140 randomized O
sent3140 , O
sent3140 largescale O
sent3140 trials O
sent3140 supporting O
sent3140 any O
sent3140 of O
sent3140 the O
sent3140 different O
sent3140 treatment O
sent3140 strategies O
sent3140 are O
sent3140 not O
sent3140 available O
sent3140 , O
sent3140 but O
sent3140 antibiotics T
sent3140 and T
sent3140 surgery T
sent3140 probably O
sent3140 have O
sent3140 improved O
sent3140 the O
sent3140 long-term O
sent3140 outcome O
sent3140 of O
sent3140 many O
sent3140 patients O
sent3140 with O
sent3140 bronchiectasis D
sent3141 OBJECTIVES O
sent3141 : O
sent3141 Interest O
sent3141 in O
sent3141 zinc T
sent3141 as O
sent3141 a O
sent3141 treatment O
sent3141 for O
sent3141 the O
sent3141 common D
sent3141 cold D
sent3141 has O
sent3141 grown O
sent3141 following O
sent3141 the O
sent3141 recent O
sent3141 publication O
sent3141 of O
sent3141 several O
sent3141 controlled O
sent3141 trials O
sent3142 The O
sent3142 objective O
sent3142 of O
sent3142 this O
sent3142 review O
sent3142 was O
sent3142 to O
sent3142 assess O
sent3142 the O
sent3142 effects O
sent3142 of O
sent3142 zinc T
sent3142 lozenges T
sent3142 for O
sent3142 cold D
sent3142 symptoms D
sent3143 Results O
sent3143 from O
sent3143 two O
sent3143 trials O
sent3143 ( O
sent3143 04 O
sent3143 - O
sent3143 Mossad O
sent3143 ; O
sent3143 08 O
sent3143 - O
sent3143 Smith O
sent3143 ) O
sent3143 suggested O
sent3143 zinc T
sent3143 lozenges T
sent3143 reduced O
sent3143 the O
sent3143 severity O
sent3143 and O
sent3143 duration O
sent3143 of O
sent3143 cold D
sent3143 symptoms D
sent3144 Given O
sent3144 the O
sent3144 potential O
sent3144 for O
sent3144 treatment O
sent3144 to O
sent3144 produce O
sent3144 side O
sent3144 effects O
sent3144 , O
sent3144 the O
sent3144 use O
sent3144 of O
sent3144 zinc T
sent3144 lozenges T
sent3144 to O
sent3144 treat O
sent3144 cold D
sent3144 symptoms D
sent3144 deserves O
sent3144 further O
sent3144 study O
sent3145 Randomized O
sent3145 trial O
sent3145 of O
sent3145 interferon-alpha T
sent3145 plus T
sent3145 ursodeoxycholic T
sent3145 acid T
sent3145 versus O
sent3145 interferon T
sent3145 plus T
sent3145 placebo T
sent3145 in O
sent3145 patients O
sent3145 with O
sent3145 chronic D
sent3145 hepatitis D
sent3145 C D
sent3145 resistant D
sent3145 to D
sent3145 interferon D
sent3146 We O
sent3146 describe O
sent3146 a O
sent3146 rare O
sent3146 case O
sent3146 of O
sent3146 spontaneous D
sent3146 rupture D
sent3146 of D
sent3146 a D
sent3146 hepatic D
sent3146 metastasis D
sent3146 from D
sent3146 renal D
sent3146 cell D
sent3146 carcinoma D
sent3146 that O
sent3146 was O
sent3146 treated O
sent3146 successfully O
sent3146 by O
sent3146 hepatic T
sent3146 arterial T
sent3146 embolization T
sent3147 A O
sent3147 65-year-old O
sent3147 woman O
sent3147 , O
sent3147 who O
sent3147 had O
sent3147 been O
sent3147 undergoing O
sent3147 immunotherapy T
sent3147 for O
sent3147 inoperably D
sent3147 disseminated D
sent3147 renal D
sent3147 carcinoma D
sent3147 and D
sent3147 lung D
sent3147 metastases D
sent3147 , O
sent3147 presented O
sent3147 with O
sent3147 severe O
sent3147 abdominal O
sent3147 pain O
sent3147 in O
sent3147 a O
sent3147 state O
sent3147 of O
sent3147 hypovolemic O
sent3147 shock O
sent3148 Although O
sent3148 hepatic O
sent3148 rupture O
sent3148 due O
sent3148 to O
sent3148 metastatic O
sent3148 cancer O
sent3148 is O
sent3148 extremely O
sent3148 rare O
sent3148 , O
sent3148 transcatheter T
sent3148 arterial T
sent3148 embolization T
sent3148 ( T
sent3148 TAE T
sent3148 ) T
sent3148 is O
sent3148 an O
sent3148 appropriate O
sent3148 and O
sent3148 useful O
sent3148 treatment O
sent3148 for O
sent3148 massive D
sent3148 hemorrhage D
sent3148 caused D
sent3148 by D
sent3148 spontaneous D
sent3148 rupture D
sent3148 of D
sent3148 liver D
sent3148 metastasis D
sent3149 Patients O
sent3149 with O
sent3149 classical O
sent3149 symptoms O
sent3149 such O
sent3149 as O
sent3149 heartburn D
sent3149 and D
sent3149 regurgitation D
sent3149 may O
sent3149 be O
sent3149 treated O
sent3149 pharmaceutically T
sent3149 combined T
sent3149 with T
sent3149 life T
sent3149 style T
sent3149 counselling T
sent3150 Surgical T
sent3150 treatment T
sent3150 is O
sent3150 a O
sent3150 good O
sent3150 alternative O
sent3150 for O
sent3150 patients O
sent3150 with O
sent3150 persistent D
sent3150 severe D
sent3150 regurgitation D
sent3150 during O
sent3150 medical O
sent3150 therapy O
sent3150 and O
sent3150 for O
sent3150 young O
sent3150 patients O
sent3150 who O
sent3150 prefer O
sent3150 surgery O
sent3150 to O
sent3150 lifelong O
sent3150 medication O
sent3151 The O
sent3151 surgical T
sent3151 treatment T
sent3151 of O
sent3151 lung D
sent3151 lacerations D
sent3151 and D
sent3151 major D
sent3151 bronchial D
sent3151 disruptions D
sent3151 caused O
sent3151 by O
sent3151 blunt O
sent3151 thoracic O
sent3151 trauma O
sent3152 BACKGROUND O
sent3152 : O
sent3152 An O
sent3152 increasing O
sent3152 number O
sent3152 of O
sent3152 reports O
sent3152 indicate O
sent3152 symptomatic O
sent3152 relief O
sent3152 of O
sent3152 biliary O
sent3152 colic O
sent3152 symptoms O
sent3152 after O
sent3152 cholecystectomy T
sent3152 for O
sent3152 biliary D
sent3152 dyskinesia D
sent3153 Despite O
sent3153 this O
sent3153 , O
sent3153 cholecystectomy T
sent3153 as O
sent3153 a O
sent3153 treatment O
sent3153 for O
sent3153 biliary D
sent3153 dyskinesia D
sent3153 remains O
sent3153 controversial O
sent3154 Our O
sent3154 aim O
sent3154 was O
sent3154 to O
sent3154 determine O
sent3154 efficacy O
sent3154 of O
sent3154 cholecystectomy T
sent3154 in O
sent3154 alleviating O
sent3154 biliary D
sent3154 dyskinesia D
sent3154 symptoms D
sent3154 and O
sent3154 the O
sent3154 correlation O
sent3154 with O
sent3154 histologic O
sent3154 findings O
sent3155 CONCLUSIONS O
sent3155 : O
sent3155 Biliary D
sent3155 dyskinesia D
sent3155 patients O
sent3155 who O
sent3155 underwent O
sent3155 cholecystectomy T
sent3155 had O
sent3155 significantly O
sent3155 greater O
sent3155 symptom O
sent3155 improvement O
sent3155 compared O
sent3155 with O
sent3155 nonsurgical O
sent3155 patients O
sent3156 Cholecystectomy T
sent3156 should O
sent3156 be O
sent3156 a O
sent3156 first-line O
sent3156 therapy O
sent3156 for O
sent3156 biliary D
sent3156 dyskinesia D
sent3156 patients O
sent3157 Transbronchial O
sent3157 biopsy O
sent3157 revealed O
sent3157 inflammatory D
sent3157 nonspecific D
sent3157 alveolar D
sent3157 lesions D
sent3157 suggestive D
sent3157 of D
sent3157 bronchiolitis D
sent3157 obliterans D
sent3157 organizing D
sent3157 pneumonia D
sent3157 , O
sent3157 which O
sent3157 responded O
sent3157 well O
sent3157 clinically O
sent3157 and O
sent3157 radiologically O
sent3157 to O
sent3157 oral T
sent3157 corticosteroids T
sent3158 Novel O
sent3158 treatment O
sent3158 strategies O
sent3158 for O
sent3158 patients O
sent3158 with O
sent3158 advanced D
sent3158 NSCLC D
sent3158 may O
sent3158 involve O
sent3158 chemotherapy T
sent3158 combined O
sent3158 with O
sent3158 inhibition O
sent3158 of O
sent3158 NF-kappaB-dependent O
sent3158 cell-survival O
sent3158 pathways O
sent3159 Effectiveness O
sent3159 of O
sent3159 pseudoephedrine T
sent3159 plus T
sent3159 acetaminophen T
sent3159 for O
sent3159 treatment O
sent3159 of O
sent3159 symptoms O
sent3159 attributed O
sent3159 to O
sent3159 the O
sent3159 paranasal O
sent3159 sinuses O
sent3159 associated O
sent3159 with O
sent3159 the O
sent3159 common D
sent3159 cold D
sent3160 OBJECTIVE O
sent3160 : O
sent3160 This O
sent3160 retrospective O
sent3160 study O
sent3160 was O
sent3160 designed O
sent3160 to O
sent3160 confirm O
sent3160 that O
sent3160 aggressive T
sent3160 pulmonary T
sent3160 resection T
sent3160 can O
sent3160 provide O
sent3160 effective O
sent3160 long-term O
sent3160 palliation O
sent3160 of O
sent3160 disease O
sent3160 for O
sent3160 patients O
sent3160 with O
sent3160 pulmonary D
sent3160 aspergilloma D
sent3161 METHODS O
sent3161 AND O
sent3161 RESULTS O
sent3161 : O
sent3161 From O
sent3161 1959 O
sent3161 to O
sent3161 1998 O
sent3161 , O
sent3161 84 O
sent3161 patients O
sent3161 underwent O
sent3161 a O
sent3161 total O
sent3161 of O
sent3161 90 O
sent3161 operations T
sent3161 for O
sent3161 treatment O
sent3161 of O
sent3161 pulmonary D
sent3161 aspergilloma D
sent3161 in O
sent3161 the O
sent3161 Marie-Lannelongue O
sent3161 Hospital O
sent3162 The O
sent3162 lesion D
sent3162 was O
sent3162 resected O
sent3162 by O
sent3162 video-assisted T
sent3162 thoracoscopic T
sent3162 surgery T
sent3162 because O
sent3162 it O
sent3162 was O
sent3162 suspected O
sent3162 of O
sent3162 being O
sent3162 a O
sent3162 lung O
sent3162 abscess O
sent3162 that O
sent3162 had O
sent3162 caused O
sent3162 repeated O
sent3162 episodes O
sent3162 of O
sent3162 inflammation O
sent3163 In O
sent3163 this O
sent3163 study O
sent3163 , O
sent3163 we O
sent3163 investigated O
sent3163 the O
sent3163 expression O
sent3163 and O
sent3163 therapeutic O
sent3163 potential O
sent3163 of O
sent3163 TRAIL T
sent3163 in O
sent3163 cholangiocarcinoma D
sent3163 , O
sent3163 one O
sent3163 of O
sent3163 the O
sent3163 most O
sent3163 devastating O
sent3163 human O
sent3163 hepatic O
sent3163 malignancies O
sent3164 Finally O
sent3164 , O
sent3164 in O
sent3164 vivo O
sent3164 administration O
sent3164 of O
sent3164 recombinant O
sent3164 TRAIL T
sent3164 substantially O
sent3164 inhibited O
sent3164 subcutaneous O
sent3164 tumor O
sent3164 growth O
sent3164 of O
sent3164 human O
sent3164 cholangiocarcinoma D
sent3164 cells O
sent3165 Induction O
sent3165 of O
sent3165 apoptosis O
sent3165 in O
sent3165 tumor O
sent3165 cells O
sent3165 is O
sent3165 possible O
sent3165 with O
sent3165 a O
sent3165 biologically O
sent3165 active O
sent3165 TRAIL T
sent3165 , O
sent3165 and O
sent3165 suggests O
sent3165 that O
sent3165 this O
sent3165 cytokine O
sent3165 is O
sent3165 a O
sent3165 promising O
sent3165 antitumor O
sent3165 agent O
sent3165 against O
sent3165 human D
sent3165 cholangiocarcinoma D
sent3166 Interferon T
sent3166 plays O
sent3166 a O
sent3166 critical O
sent3166 role O
sent3166 in O
sent3166 the O
sent3166 host O
sent3166 's O
sent3166 natural O
sent3166 defense O
sent3166 against O
sent3166 viral D
sent3166 infections D
sent3166 and O
sent3166 in O
sent3166 their O
sent3166 treatment O
sent3167 This O
sent3167 study O
sent3167 investigated O
sent3167 whether O
sent3167 intensive O
sent3167 chemotherapy T
sent3167 might O
sent3167 have O
sent3167 a O
sent3167 positive O
sent3167 effect O
sent3167 on O
sent3167 asthma D
sent3167 in O
sent3167 these O
sent3167 special O
sent3167 cases O
sent3167 and O
sent3167 whether O
sent3167 asthma O
sent3167 generally O
sent3167 relapses O
sent3167 after O
sent3167 completion O
sent3167 of O
sent3167 chemotherapy O
sent3168 The O
sent3168 authors O
sent3168 monitored O
sent3168 clinical O
sent3168 outcome O
sent3168 and O
sent3168 lung O
sent3168 function O
sent3168 of O
sent3168 43 O
sent3168 children O
sent3168 with O
sent3168 acute D
sent3168 lymphoblastic D
sent3168 leukemia D
sent3168 and D
sent3168 non-Hodgkin D
sent3168 lymphoma D
sent3168 who O
sent3168 received O
sent3168 chemotherapy T
sent3168 at O
sent3168 the O
sent3168 University O
sent3168 Children O
sent3168 's O
sent3168 Hospital O
sent3168 of O
sent3168 Greifswald O
sent3168 between O
sent3168 1993 O
sent3168 and O
sent3168 1998 O
sent3169 She O
sent3169 was O
sent3169 diagnosed O
sent3169 as O
sent3169 miliary D
sent3169 tuberculosis D
sent3169 and O
sent3169 treated O
sent3169 with O
sent3169 antituberculous T
sent3169 drugs T
sent3170 The O
sent3170 hemorrhage D
sent3170 was O
sent3170 successfully O
sent3170 stopped O
sent3170 by O
sent3170 microcoil T
sent3170 embolization T
sent3171 Immunomodulatory O
sent3171 effects O
sent3171 of O
sent3171 acupuncture T
sent3171 in O
sent3171 the O
sent3171 treatment O
sent3171 of O
sent3171 allergic D
sent3171 asthma D
sent3171 : O
sent3171 a O
sent3171 randomized O
sent3171 controlled O
sent3171 study O
sent3172 An O
sent3172 open-label O
sent3172 study O
sent3172 of O
sent3172 lamivudine T
sent3172 for O
sent3172 chronic D
sent3172 hepatitis D
sent3172 B D
sent3172 in O
sent3172 six O
sent3172 patients O
sent3172 with O
sent3172 chronic O
sent3172 renal O
sent3172 failure O
sent3172 before O
sent3172 and O
sent3172 after O
sent3172 kidney O
sent3172 transplantation O
sent3173 CONCLUSION O
sent3173 : O
sent3173 The O
sent3173 WDTA O
sent3173 is O
sent3173 an O
sent3173 intrinsically O
sent3173 motivating O
sent3173 educational O
sent3173 program O
sent3173 that O
sent3173 has O
sent3173 the O
sent3173 ability O
sent3173 to O
sent3173 effect O
sent3173 determinants O
sent3173 of O
sent3173 asthma D
sent3173 self-management T
sent3173 behavior O
sent3173 in O
sent3173 9- O
sent3173 to O
sent3173 13-year-old O
sent3173 children O
sent3173 with O
sent3173 asthma O
sent3174 Usefulness O
sent3174 of O
sent3174 percutaneous T
sent3174 transhepatic T
sent3174 biliary T
sent3174 drainage T
sent3174 in O
sent3174 patients O
sent3174 with O
sent3174 surgical D
sent3174 jaundice D
sent3174 -- O
sent3174 a O
sent3174 prospective O
sent3174 randomised O
sent3174 study O
sent3175 Neutralization O
sent3175 of O
sent3175 hepatitis D
sent3175 A D
sent3175 virus D
sent3175 ( D
sent3175 HAV D
sent3175 ) D
sent3175 by O
sent3175 an O
sent3175 immunoadhesin T
sent3175 containing T
sent3175 the T
sent3175 cysteine-rich T
sent3175 region T
sent3175 of T
sent3175 HAV T
sent3175 cellular T
sent3175 receptor-1 T
sent3176 To O
sent3176 ascertain O
sent3176 the O
sent3176 results O
sent3176 of O
sent3176 standard T
sent3176 ABVD T
sent3176 chemotherapy T
sent3176 ( T
sent3176 doxorubicin T
sent3176 , T
sent3176 bleomycin T
sent3176 , T
sent3176 vinblastine T
sent3176 , T
sent3176 dacarbazine T
sent3176 ) T
sent3176 in O
sent3176 HIV-infected O
sent3176 patients O
sent3176 with O
sent3176 newly D
sent3176 diagnosed D
sent3176 Hodgkin D
sent3176 's D
sent3176 disease D
sent3176 ( D
sent3176 HD D
sent3176 ) D
sent3176 , O
sent3176 a O
sent3176 nonrandomized O
sent3176 , O
sent3176 prospective O
sent3176 , O
sent3176 multiinstitutional O
sent3176 clinical O
sent3176 trial O
sent3176 was O
sent3176 conducted O
sent3176 by O
sent3176 the O
sent3176 AIDS O
sent3176 Clinical O
sent3176 Trials O
sent3176 Group O
sent3176 ( O
sent3176 ACTG O
sent3176 ) O
sent3176 , O
sent3176 in O
sent3176 HIV-infected O
sent3176 patients O
sent3176 with O
sent3176 Hodgkin O
sent3176 's O
sent3176 disease O
sent3177 The O
sent3177 effectiveness O
sent3177 of O
sent3177 glucocorticoids T
sent3177 in O
sent3177 treating O
sent3177 croup D
sent3177 : O
sent3177 meta-analysis O
sent3177 ( O
sent3177 see O
sent3177 comments O
sent3177 ) O
sent3178 PURPOSE O
sent3178 : O
sent3178 Inhaled O
sent3178 corticosteroids T
sent3178 have O
sent3178 beneficial O
sent3178 effects O
sent3178 on O
sent3178 pulmonary O
sent3178 function O
sent3178 and O
sent3178 inflammation O
sent3178 in O
sent3178 patients O
sent3178 with O
sent3178 asthma D
sent3178 , O
sent3178 but O
sent3178 they O
sent3178 also O
sent3178 cause O
sent3178 systemic O
sent3178 adverse O
sent3178 effects O
sent3178 , O
sent3178 such O
sent3178 as O
sent3178 adrenal O
sent3178 suppression O
sent3179 Second O
sent3179 , O
sent3179 children O
sent3179 in O
sent3179 the O
sent3179 first O
sent3179 year O
sent3179 of O
sent3179 life O
sent3179 are O
sent3179 at O
sent3179 highest O
sent3179 risk O
sent3179 of O
sent3179 progression O
sent3179 and O
sent3179 should O
sent3179 be O
sent3179 treated O
sent3179 with O
sent3179 trimethoprim-sulfamethoxazole T
sent3179 to O
sent3179 prevent O
sent3179 Pneumocystis D
sent3179 carinii D
sent3179 pneumonia D
sent3179 , O
sent3179 and O
sent3179 targeted O
sent3179 for O
sent3179 receiving O
sent3179 antiretrovirals O
sent3180 Effectiveness O
sent3180 of O
sent3180 casein T
sent3180 hydrolysate T
sent3180 feedings O
sent3180 in O
sent3180 infants O
sent3180 with O
sent3180 colic D
sent3180 ( O
sent3180 see O
sent3180 comments O
sent3180 ) O
sent3181 We O
sent3181 conclude O
sent3181 that O
sent3181 antimicrobial/ T
sent3181 antituberculous T
sent3181 agents T
sent3181 have O
sent3181 only O
sent3181 a O
sent3181 minor O
sent3181 short-term O
sent3181 effect O
sent3181 in O
sent3181 long-lasting O
sent3181 CGM D
sent3181 of O
sent3181 undetermined O
sent3181 cause O
sent3182 The O
sent3182 patient O
sent3182 had O
sent3182 previously O
sent3182 been O
sent3182 immunized O
sent3182 with O
sent3182 two O
sent3182 doses O
sent3182 of O
sent3182 Hib D
sent3182 conjugate O
sent3182 vaccine T
sent3182 ( O
sent3182 PRP-T O
sent3182 ) O
sent3183 Thus O
sent3183 , O
sent3183 s-ECP O
sent3183 appears O
sent3183 to O
sent3183 be O
sent3183 a O
sent3183 useful O
sent3183 marker O
sent3183 for O
sent3183 determining O
sent3183 when O
sent3183 a O
sent3183 step-down O
sent3183 in O
sent3183 iBDP T
sent3183 therapy T
sent3183 is O
sent3183 indicated O
sent3183 , O
sent3183 and O
sent3183 thus O
sent3183 may O
sent3183 contribute O
sent3183 to O
sent3183 successful O
sent3183 long-term O
sent3183 management O
sent3183 of O
sent3183 chronic D
sent3183 asthma D
sent3184 Twinrix T
sent3184 ( O
sent3184 SmithKline O
sent3184 Beecham O
sent3184 Biologicals O
sent3184 ) O
sent3184 is O
sent3184 a O
sent3184 combined O
sent3184 hepatitis D
sent3184 A D
sent3184 and D
sent3184 B D
sent3184 vaccine T
sent3184 licensed O
sent3184 with O
sent3184 a O
sent3184 three-dose O
sent3184 schedule O
sent3185 A O
sent3185 two-dose O
sent3185 combined O
sent3185 hepatitis D
sent3185 A D
sent3185 and D
sent3185 B D
sent3185 vaccine T
sent3185 would O
sent3185 facilitate O
sent3185 immunisation O
sent3185 programs O
sent3186 Therefore O
sent3186 , O
sent3186 it O
sent3186 can O
sent3186 be O
sent3186 concluded O
sent3186 that O
sent3186 with O
sent3186 two O
sent3186 injections O
sent3186 of O
sent3186 the O
sent3186 high-dose O
sent3186 hepatitis D
sent3186 A D
sent3186 and D
sent3186 B D
sent3186 vaccine T
sent3186 , O
sent3186 6 O
sent3186 months O
sent3186 apart O
sent3186 , O
sent3186 a O
sent3186 similar O
sent3186 immune O
sent3186 response O
sent3186 can O
sent3186 be O
sent3186 obtained O
sent3186 as O
sent3186 induced O
sent3186 with O
sent3186 three O
sent3186 doses O
sent3186 of O
sent3186 Twinrix T
sent3186 at O
sent3186 months O
sent3186 0 O
sent3186 , O
sent3186 1 O
sent3186 and O
sent3186 6 O
sent3187 AIM O
sent3187 : O
sent3187 To O
sent3187 assess O
sent3187 the O
sent3187 impact O
sent3187 on O
sent3187 community-based O
sent3187 pediatricians O
sent3187 of O
sent3187 the O
sent3187 conclusions O
sent3187 of O
sent3187 the O
sent3187 10th O
sent3187 Conference O
sent3187 de O
sent3187 Consensus O
sent3187 en O
sent3187 Therapeutique O
sent3187 Anti-Infectieuse O
sent3187 ( O
sent3187 CCTAI O
sent3187 ) O
sent3187 on O
sent3187 the O
sent3187 antibiotic T
sent3187 treatment T
sent3187 in O
sent3187 acute D
sent3187 nasopharyngitis D
sent3187 ( D
sent3187 ANP D
sent3187 ) D
sent3188 CONCLUSIONS O
sent3188 : O
sent3188 These O
sent3188 data O
sent3188 , O
sent3188 the O
sent3188 first O
sent3188 evidence O
sent3188 that O
sent3188 chronic O
sent3188 stress O
sent3188 can O
sent3188 inhibit O
sent3188 the O
sent3188 stability O
sent3188 of O
sent3188 the O
sent3188 IgG O
sent3188 antibody O
sent3188 response O
sent3188 to O
sent3188 a O
sent3188 bacterial T
sent3188 vaccine T
sent3188 for O
sent3188 pneumonia D
sent3188 , O
sent3188 provide O
sent3188 additional O
sent3188 evidence O
sent3188 of O
sent3188 health O
sent3188 risks O
sent3188 associated O
sent3188 with O
sent3188 dementia O
sent3188 caregiving O
sent3189 We O
sent3189 assessed O
sent3189 the O
sent3189 prevalence O
sent3189 of O
sent3189 head O
sent3189 louse O
sent3189 infestation O
sent3189 and O
sent3189 the O
sent3189 effectiveness O
sent3189 of O
sent3189 1 T
sent3189 % T
sent3189 permethrin T
sent3189 against O
sent3189 head D
sent3189 lice D
sent3189 in O
sent3189 Kosovar O
sent3189 refugees O
sent3190 Refugees O
sent3190 with O
sent3190 crawling D
sent3190 lice D
sent3190 were O
sent3190 treated O
sent3190 with O
sent3190 a O
sent3190 pediculicide T
sent3190 containing T
sent3190 1 T
sent3190 % T
sent3190 permethrin T
sent3191 We O
sent3191 conclude O
sent3191 that O
sent3191 1 T
sent3191 % T
sent3191 permethrin T
sent3191 treatment T
sent3191 was O
sent3191 effective O
sent3191 in O
sent3191 louse D
sent3191 control O
sent3191 in O
sent3191 this O
sent3191 refugee O
sent3191 population O
sent3192 Antibiotics T
sent3192 for O
sent3192 Salmonella D
sent3192 meningitis D
sent3192 in O
sent3192 children O
sent3193 Four O
sent3193 patients O
sent3193 developed O
sent3193 mild O
sent3193 pancreatitis D
sent3193 , O
sent3193 one O
sent3193 had O
sent3193 moderate O
sent3193 pancreatitis D
sent3193 and O
sent3193 one O
sent3193 had O
sent3193 leak O
sent3193 of O
sent3193 contrast O
sent3193 , O
sent3193 which O
sent3193 was O
sent3193 treated O
sent3193 by O
sent3193 administration T
sent3193 of T
sent3193 clear T
sent3193 fluids T
sent3193 orally O
sent3193 for O
sent3193 one O
sent3193 day O
sent3194 We O
sent3194 treated O
sent3194 two O
sent3194 children O
sent3194 with O
sent3194 influenza-associated D
sent3194 acute D
sent3194 encephalopathy D
sent3194 by O
sent3194 a O
sent3194 combination T
sent3194 of T
sent3194 mild T
sent3194 hypothermia T
sent3194 and T
sent3194 steroid T
sent3194 pulse T
sent3194 therapy T
sent3195 Successful O
sent3195 treatment O
sent3195 of O
sent3195 anaerobic D
sent3195 pleuropulmonary D
sent3195 infections D
sent3195 requires O
sent3195 a O
sent3195 combination T
sent3195 of T
sent3195 antibiotic T
sent3195 therapy T
sent3195 and T
sent3195 surgical T
sent3195 interventions T
sent3196 Treatment O
sent3196 of O
sent3196 spontaneous D
sent3196 carotid-cavernous D
sent3196 fistula D
sent3196 in D
sent3196 Ehlers-Danlos D
sent3196 syndrome D
sent3196 by O
sent3196 transvenous T
sent3196 occlusion T
sent3196 with T
sent3196 Guglielmi T
sent3196 detachable T
sent3196 coils T
sent3197 PURPOSE O
sent3197 : O
sent3197 Macrolide T
sent3197 antibiotics T
sent3197 are O
sent3197 frequently O
sent3197 prescribed O
sent3197 to O
sent3197 patients O
sent3197 with O
sent3197 symptoms D
sent3197 of D
sent3197 a D
sent3197 common D
sent3197 cold D
sent3198 Because O
sent3198 the O
sent3198 symptoms O
sent3198 of O
sent3198 rhinovirus O
sent3198 colds O
sent3198 are O
sent3198 attributed O
sent3198 to O
sent3198 the O
sent3198 inflammatory O
sent3198 response O
sent3198 to O
sent3198 infection O
sent3198 , O
sent3198 we O
sent3198 studied O
sent3198 the O
sent3198 effects O
sent3198 of O
sent3198 treatment O
sent3198 with O
sent3198 clarithromycin T
sent3198 on O
sent3198 the O
sent3198 symptomatic O
sent3198 and O
sent3198 inflammatory O
sent3198 response O
sent3198 to O
sent3198 nasal O
sent3198 inoculation O
sent3198 with O
sent3198 rhinovirus D
sent3199 Therapeutic T
sent3199 pneumothorax T
sent3199 ( T
sent3199 TP T
sent3199 ) T
sent3199 proved O
sent3199 its O
sent3199 efficacy O
sent3199 in O
sent3199 pre-antibiotic O
sent3199 era O
sent3199 , O
sent3199 so O
sent3199 one O
sent3199 can O
sent3199 assume O
sent3199 that O
sent3199 it O
sent3199 can O
sent3199 be O
sent3199 applied O
sent3199 with O
sent3199 the O
sent3199 same O
sent3199 success O
sent3199 in O
sent3199 multidrug D
sent3199 resistant D
sent3199 TB D
sent3200 In O
sent3200 conclusion O
sent3200 , O
sent3200 in O
sent3200 some O
sent3200 cases O
sent3200 of O
sent3200 MDR D
sent3200 TB D
sent3200 , O
sent3200 the O
sent3200 TP T
sent3200 ( O
sent3200 if O
sent3200 there O
sent3200 are O
sent3200 no O
sent3200 pleural O
sent3200 adherences O
sent3200 ) O
sent3200 may O
sent3200 lead O
sent3200 to O
sent3200 good O
sent3200 results O
sent3201 Acupuncture T
sent3201 treatment O
sent3201 of O
sent3201 common D
sent3201 cold D
sent3202 CONCLUSIONS O
sent3202 : O
sent3202 These O
sent3202 data O
sent3202 , O
sent3202 the O
sent3202 first O
sent3202 evidence O
sent3202 that O
sent3202 chronic O
sent3202 stress O
sent3202 can O
sent3202 inhibit O
sent3202 the O
sent3202 stability O
sent3202 of O
sent3202 the O
sent3202 IgG O
sent3202 antibody O
sent3202 response O
sent3202 to O
sent3202 a O
sent3202 bacterial T
sent3202 vaccine T
sent3202 for O
sent3202 pneumonia D
sent3202 , O
sent3202 provide O
sent3202 additional O
sent3202 evidence O
sent3202 of O
sent3202 health O
sent3202 risks O
sent3202 associated O
sent3202 with O
sent3202 dementia O
sent3202 caregiving O
sent3203 When O
sent3203 bleeding D
sent3203 is O
sent3203 stopped O
sent3203 via O
sent3203 surgical T
sent3203 or T
sent3203 radiological T
sent3203 methods T
sent3203 , O
sent3203 the O
sent3203 clinical O
sent3203 course O
sent3203 of O
sent3203 hemobilia-associated O
sent3203 pancreatitis O
sent3203 appears O
sent3203 to O
sent3203 be O
sent3203 benign O
sent3204 A O
sent3204 case O
sent3204 of O
sent3204 biliary D
sent3204 stenosis D
sent3204 in O
sent3204 polycystic O
sent3204 liver O
sent3204 improved O
sent3204 by O
sent3204 injection T
sent3204 of T
sent3204 minocycline T
sent3204 hydrochloride T
sent3204 to O
sent3204 a O
sent3204 hepatic O
sent3204 cyst O
sent3205 The O
sent3205 ruptured D
sent3205 horn D
sent3205 was O
sent3205 excised O
sent3205 by O
sent3205 laparotomy T
sent3206 Therapy O
sent3206 designed O
sent3206 to O
sent3206 control O
sent3206 the O
sent3206 efferent D
sent3206 phase D
sent3206 of D
sent3206 established D
sent3206 asthma D
sent3206 by O
sent3206 augmenting T
sent3206 down-regulatory T
sent3206 Th1 T
sent3206 counterbalancing T
sent3206 mechanisms T
sent3206 should O
sent3206 be O
sent3206 effective O
sent3207 All O
sent3207 children O
sent3207 with O
sent3207 croup D
sent3207 symptoms O
sent3207 who O
sent3207 demonstrate O
sent3207 increased O
sent3207 work O
sent3207 of O
sent3207 breathing O
sent3207 in O
sent3207 the O
sent3207 clinics O
sent3207 or O
sent3207 emergency O
sent3207 departments O
sent3207 should O
sent3207 be O
sent3207 treated O
sent3207 with O
sent3207 glucocorticoids T
sent3208 Increasing O
sent3208 resistance O
sent3208 among O
sent3208 the O
sent3208 common D
sent3208 respiratory D
sent3208 pathogens D
sent3208 has O
sent3208 encouraged O
sent3208 assessment O
sent3208 of O
sent3208 alternative O
sent3208 agents O
sent3208 , O
sent3208 for O
sent3208 example O
sent3208 , O
sent3208 levofloxacin T
sent3209 Unlike O
sent3209 earlier O
sent3209 quinolones O
sent3209 , O
sent3209 levofloxacin T
sent3209 has O
sent3209 excellent O
sent3209 activity O
sent3209 against O
sent3209 Streptococcus D
sent3209 pneumoniae D
sent3209 , O
sent3209 including O
sent3209 strains O
sent3209 resistant O
sent3209 to O
sent3209 penicillin O
sent3210 Clinical O
sent3210 trials O
sent3210 show O
sent3210 levofloxacin T
sent3210 to O
sent3210 be O
sent3210 as O
sent3210 effective O
sent3210 as O
sent3210 cephalosporins O
sent3210 in O
sent3210 acute O
sent3210 exacerbation O
sent3210 of O
sent3210 chronic D
sent3210 bronchitis D
sent3210 and O
sent3210 as O
sent3210 effective O
sent3210 as O
sent3210 co-amoxiclav O
sent3210 , O
sent3210 cephalosporins O
sent3210 or O
sent3210 amoxycillin O
sent3210 in O
sent3210 community-acquired D
sent3210 pneumonia D
sent3211 Additionally O
sent3211 , O
sent3211 epidemiologic O
sent3211 evidence O
sent3211 of O
sent3211 a O
sent3211 marked O
sent3211 decline O
sent3211 in O
sent3211 new O
sent3211 KS D
sent3211 since O
sent3211 the O
sent3211 widespread O
sent3211 use O
sent3211 of O
sent3211 highly T
sent3211 active T
sent3211 antiretroviral T
sent3211 therapy T
sent3211 ( T
sent3211 HAART T
sent3211 ) T
sent3211 advocates O
sent3211 its O
sent3211 use O
sent3212 A O
sent3212 field O
sent3212 study O
sent3212 was O
sent3212 carried O
sent3212 out O
sent3212 to O
sent3212 evaluate O
sent3212 the O
sent3212 effect O
sent3212 of O
sent3212 vaccination T
sent3212 against O
sent3212 swine D
sent3212 enzootic D
sent3212 pneumonia D
sent3212 in O
sent3212 different O
sent3212 production O
sent3212 systems O
sent3212 ( O
sent3212 closed O
sent3212 or O
sent3212 one-site O
sent3212 , O
sent3212 and O
sent3212 open O
sent3212 , O
sent3212 two- O
sent3212 or O
sent3212 three-site O
sent3212 , O
sent3212 systems O
sent3212 ) O
sent3213 Humoral O
sent3213 immune O
sent3213 response O
sent3213 after O
sent3213 vaccination T
sent3213 against O
sent3213 influenza D
sent3213 in O
sent3213 patients O
sent3213 with O
sent3213 breast O
sent3213 cancer O
sent3214 Gingyo-san T
sent3214 and O
sent3214 its O
sent3214 components O
sent3214 were O
sent3214 administered O
sent3214 orally O
sent3214 to O
sent3214 mice O
sent3214 1 O
sent3214 day O
sent3214 before O
sent3214 , O
sent3214 then O
sent3214 1 O
sent3214 and O
sent3214 4 O
sent3214 days O
sent3214 after O
sent3214 the O
sent3214 inhalation O
sent3214 of O
sent3214 a O
sent3214 mouse-adopted D
sent3214 strain D
sent3214 of D
sent3214 influenza D
sent3214 A2 D
sent3214 ( D
sent3214 H2N2 D
sent3214 ) D
sent3214 virus D
sent3215 From O
sent3215 these O
sent3215 results O
sent3215 Gingyo-san T
sent3215 was O
sent3215 shown O
sent3215 to O
sent3215 be O
sent3215 an O
sent3215 antiviral O
sent3215 agent O
sent3215 in O
sent3215 mice O
sent3215 infected O
sent3215 with O
sent3215 a O
sent3215 lethal O
sent3215 amount O
sent3215 of O
sent3215 a O
sent3215 mouse-adopted D
sent3215 strain D
sent3215 of D
sent3215 influenza D
sent3215 A2 D
sent3215 virus D
sent3216 The O
sent3216 purpose O
sent3216 of O
sent3216 the O
sent3216 present O
sent3216 study O
sent3216 was O
sent3216 to O
sent3216 analyze O
sent3216 the O
sent3216 association O
sent3216 of O
sent3216 recurrent O
sent3216 abdominal O
sent3216 pain O
sent3216 and O
sent3216 H. O
sent3216 pylori O
sent3216 infection O
sent3216 in O
sent3216 children O
sent3216 and O
sent3216 to O
sent3216 evaluate O
sent3216 the O
sent3216 efficacy O
sent3216 of O
sent3216 antimicrobial T
sent3216 treatment T
sent3216 in O
sent3216 patients O
sent3216 with O
sent3216 evidence O
sent3216 of O
sent3216 infection D
sent3217 Patients O
sent3217 with O
sent3217 evidence O
sent3217 of O
sent3217 infection D
sent3217 with D
sent3217 H. D
sent3217 pylori D
sent3217 were O
sent3217 treated O
sent3217 with O
sent3217 a O
sent3217 combination T
sent3217 of T
sent3217 omeprazole T
sent3217 , T
sent3217 amoxicillin T
sent3217 , T
sent3217 and T
sent3217 clarithromycin T
sent3218 Treatment O
sent3218 with O
sent3218 omeprazole T
sent3218 , T
sent3218 amoxicillin T
sent3218 , T
sent3218 and T
sent3218 clarithromycin T
sent3218 resulted O
sent3218 in O
sent3218 eradication O
sent3218 of O
sent3218 the O
sent3218 infection D
sent3218 in O
sent3218 all O
sent3218 and O
sent3218 in O
sent3218 resolution O
sent3218 of O
sent3218 the O
sent3218 clinical O
sent3218 symptoms O
sent3218 in O
sent3218 15 O
sent3218 ( O
sent3218 80 O
sent3218 % O
sent3218 ) O
sent3218 of O
sent3218 19 O
sent3218 patients O
sent3218 who O
sent3218 had O
sent3218 a O
sent3218 follow-up O
sent3218 examination O
sent3219 A O
sent3219 combined T
sent3219 therapy T
sent3219 results O
sent3219 in O
sent3219 eradication O
sent3219 of O
sent3219 the O
sent3219 bacterium D
sent3219 and O
sent3219 in O
sent3219 improvement O
sent3219 of O
sent3219 the O
sent3219 clinical O
sent3219 symptoms O
sent3219 in O
sent3219 a O
sent3219 significant O
sent3219 majority O
sent3219 of O
sent3219 the O
sent3219 patients O
sent3220 In O
sent3220 certain O
sent3220 clinical O
sent3220 settings O
sent3220 , O
sent3220 interventional T
sent3220 radiologic T
sent3220 procedures T
sent3220 have O
sent3220 become O
sent3220 an O
sent3220 important O
sent3220 alternative O
sent3220 to O
sent3220 surgery O
sent3220 in O
sent3220 the O
sent3220 treatment O
sent3220 of O
sent3220 gallstones D
sent3220 and O
sent3220 their O
sent3220 complications O
sent3220 ; O
sent3220 techniques O
sent3220 include O
sent3220 percutaneous T
sent3220 cholecystostomy T
sent3220 and T
sent3220 gallstone T
sent3220 removal T
sent3221 BACKGROUND O
sent3221 : O
sent3221 The O
sent3221 administration O
sent3221 of O
sent3221 salbutamol T
sent3221 is O
sent3221 permitted O
sent3221 only O
sent3221 by O
sent3221 inhalation O
sent3221 by O
sent3221 the O
sent3221 International O
sent3221 Olympic O
sent3221 Committee O
sent3221 ( O
sent3221 IOC O
sent3221 ) O
sent3221 for O
sent3221 the O
sent3221 management O
sent3221 of O
sent3221 asthma D
sent3221 and D
sent3221 exercise-induced D
sent3221 asthma D
sent3221 in O
sent3221 athletes O
sent3222 Urine O
sent3222 was O
sent3222 also O
sent3222 obtained O
sent3222 from O
sent3222 subjects O
sent3222 who O
sent3222 had O
sent3222 received O
sent3222 the O
sent3222 maximum O
sent3222 dosage O
sent3222 of O
sent3222 inhaled O
sent3222 salbutamol T
sent3222 advisable O
sent3222 for O
sent3222 competing O
sent3222 athletes O
sent3222 to O
sent3222 provide O
sent3222 protection O
sent3222 from O
sent3222 exercise-induced O
sent3222 asthma O
sent3222 and O
sent3222 treatment O
sent3222 of O
sent3222 asthma D
sent3222 ( O
sent3222 1600 O
sent3222 microg O
sent3222 in O
sent3222 24 O
sent3222 h O
sent3222 , O
sent3222 800 O
sent3222 microg O
sent3222 being O
sent3222 in O
sent3222 the O
sent3222 last O
sent3222 4 O
sent3222 h O
sent3222 ) O
sent3223 Antimicrobials T
sent3223 were O
sent3223 prescribed O
sent3223 to O
sent3223 175 O
sent3223 ( O
sent3223 83.73 O
sent3223 per O
sent3223 cent O
sent3223 ) O
sent3223 patients O
sent3223 with O
sent3223 common D
sent3223 cold D
sent3223 and O
sent3223 78 O
sent3223 ( O
sent3223 82.11 O
sent3223 per O
sent3223 cent O
sent3223 ) O
sent3223 patients O
sent3223 with O
sent3223 diarrhea D
sent3224 OBJECTIVE O
sent3224 : O
sent3224 to O
sent3224 evaluate O
sent3224 the O
sent3224 possible O
sent3224 existence O
sent3224 of O
sent3224 the O
sent3224 so-called O
sent3224 < O
sent3224 Roux-en-Y O
sent3224 syndrome O
sent3224 > O
sent3224 in O
sent3224 a O
sent3224 group O
sent3224 of O
sent3224 21 O
sent3224 patients O
sent3224 who O
sent3224 underwent O
sent3224 surgery T
sent3224 to O
sent3224 correct O
sent3224 postoperative D
sent3224 alkaline D
sent3224 reflux D
sent3224 gastritis D
sent3225 All O
sent3225 had O
sent3225 undergone O
sent3225 Billroth T
sent3225 II T
sent3225 subtotal T
sent3225 gastrectomy T
sent3225 ( O
sent3225 20 O
sent3225 for O
sent3225 ulcer D
sent3225 and O
sent3225 1 O
sent3225 for O
sent3225 gastric D
sent3225 cancer D
sent3225 ) O
sent3226 CONCLUSIONS O
sent3226 : O
sent3226 we O
sent3226 found O
sent3226 no O
sent3226 evidence O
sent3226 of O
sent3226 disturbances O
sent3226 in O
sent3226 gastric O
sent3226 remnant O
sent3226 emptying O
sent3226 after O
sent3226 Roux-en-Y T
sent3226 gastrojejunostomy T
sent3226 to O
sent3226 treat O
sent3226 postoperative D
sent3226 alkaline D
sent3226 gastric D
sent3226 reflux D
sent3227 BACKGROUND O
sent3227 : O
sent3227 Drainage O
sent3227 methods O
sent3227 for O
sent3227 the O
sent3227 gastric O
sent3227 conduit O
sent3227 after O
sent3227 esophagectomy T
sent3227 for O
sent3227 carcinoma D
sent3227 have O
sent3227 been O
sent3227 controversial O
sent3228 CONCLUSIONS O
sent3228 : O
sent3228 This O
sent3228 study O
sent3228 indicates O
sent3228 that O
sent3228 the O
sent3228 use O
sent3228 of O
sent3228 a O
sent3228 computerized O
sent3228 physician O
sent3228 reminder O
sent3228 and O
sent3228 a O
sent3228 mailed O
sent3228 patient O
sent3228 reminder O
sent3228 had O
sent3228 a O
sent3228 positive O
sent3228 impact O
sent3228 on O
sent3228 influenza D
sent3228 immunizations T
sent3228 for O
sent3228 older O
sent3228 adults O
sent3228 in O
sent3228 a O
sent3228 large O
sent3228 family O
sent3228 practice O
sent3228 office O
sent3229 Contemporary O
sent3229 asthma O
sent3229 management O
sent3229 guidelines O
sent3229 list O
sent3229 inhaled T
sent3229 corticosteroids T
sent3229 as O
sent3229 the O
sent3229 preferred O
sent3229 controller O
sent3229 medication O
sent3229 for O
sent3229 patients O
sent3229 with O
sent3229 persistent D
sent3229 asthma D
sent3230 Fluticasone T
sent3230 propionate T
sent3230 is O
sent3230 one O
sent3230 of O
sent3230 several O
sent3230 inhaled O
sent3230 corticosteroids O
sent3230 used O
sent3230 for O
sent3230 the O
sent3230 treatment O
sent3230 of O
sent3230 asthma D
sent3231 A O
sent3231 series O
sent3231 of O
sent3231 comparative O
sent3231 analyses O
sent3231 show O
sent3231 that O
sent3231 inhaled T
sent3231 fluticasone T
sent3231 propionate T
sent3231 is O
sent3231 more O
sent3231 cost O
sent3231 effective O
sent3231 than O
sent3231 oral O
sent3231 zafirlukast O
sent3231 and O
sent3231 triamcinolone O
sent3231 acetonide O
sent3231 and O
sent3231 slightly O
sent3231 more O
sent3231 cost O
sent3231 effective O
sent3231 than O
sent3231 flunisolide O
sent3231 in O
sent3231 adult O
sent3231 patients O
sent3231 with O
sent3231 asthma D
sent3232 Quality-of-life O
sent3232 assessments O
sent3232 in O
sent3232 patients O
sent3232 with O
sent3232 mild O
sent3232 to O
sent3232 moderate O
sent3232 disease O
sent3232 show O
sent3232 that O
sent3232 inhaled T
sent3232 fluticasone T
sent3232 propionate T
sent3232 achieved O
sent3232 improvements O
sent3232 which O
sent3232 were O
sent3232 deemed O
sent3232 to O
sent3232 be O
sent3232 clinically O
sent3232 meaningful O
sent3232 in O
sent3232 patients O
sent3232 with O
sent3232 mild O
sent3232 to O
sent3232 moderate O
sent3232 asthma D
sent3232 ; O
sent3232 these O
sent3232 changes O
sent3232 were O
sent3232 significantly O
sent3232 greater O
sent3232 than O
sent3232 those O
sent3232 achieved O
sent3232 with O
sent3232 oral O
sent3232 zafirlukast O
sent3232 , O
sent3232 inhaled O
sent3232 triamcinolone O
sent3232 acetonide O
sent3232 or O
sent3232 placebo O
sent3233 CONCLUSIONS O
sent3233 : O
sent3233 In O
sent3233 addition O
sent3233 to O
sent3233 the O
sent3233 considerable O
sent3233 body O
sent3233 of O
sent3233 clinical O
sent3233 evidence O
sent3233 supporting O
sent3233 the O
sent3233 use O
sent3233 of O
sent3233 inhaled T
sent3233 fluticasone T
sent3233 propionate T
sent3233 in O
sent3233 patients O
sent3233 with O
sent3233 asthma D
sent3233 , O
sent3233 accumulating O
sent3233 short O
sent3233 term O
sent3233 cost-effectiveness O
sent3233 data O
sent3233 also O
sent3233 suggest O
sent3233 that O
sent3233 this O
sent3233 agent O
sent3233 can O
sent3233 be O
sent3233 administered O
sent3233 for O
sent3233 a O
sent3233 similar O
sent3233 or O
sent3233 lower O
sent3233 cost O
sent3233 per O
sent3233 outcome O
sent3233 than O
sent3233 other O
sent3233 inhaled O
sent3233 corticosteroids O
sent3233 or O
sent3233 oral O
sent3233 zafirlukast O
sent3234 Importantly O
sent3234 , O
sent3234 the O
sent3234 clinical O
sent3234 benefits O
sent3234 offered O
sent3234 by O
sent3234 fluticasone T
sent3234 propionate T
sent3234 in O
sent3234 patients O
sent3234 with O
sent3234 persistent D
sent3234 asthma D
sent3234 are O
sent3234 accompanied O
sent3234 by O
sent3234 clinically O
sent3234 significant O
sent3234 improvements O
sent3234 in O
sent3234 quality O
sent3234 of O
sent3234 life O
sent3235 OBJECTIVE O
sent3235 : O
sent3235 To O
sent3235 describe O
sent3235 the O
sent3235 effect O
sent3235 of O
sent3235 influenza D
sent3235 vaccination T
sent3235 on O
sent3235 long-term O
sent3235 change O
sent3235 in O
sent3235 CD4 O
sent3235 count O
sent3235 and O
sent3235 HIV O
sent3235 RNA O
sent3235 level O
sent3235 , O
sent3235 and O
sent3235 on O
sent3235 progression O
sent3235 to O
sent3235 AIDS O
sent3235 or O
sent3235 death O
sent3236 Combination T
sent3236 therapy T
sent3236 with T
sent3236 interferon-alpha T
sent3236 ( T
sent3236 IFN T
sent3236 alpha T
sent3236 ) T
sent3236 plus T
sent3236 Ribavirin T
sent3236 has O
sent3236 been O
sent3236 shown O
sent3236 to O
sent3236 improve O
sent3236 the O
sent3236 response O
sent3236 rate O
sent3236 in O
sent3236 patients O
sent3236 with O
sent3236 chronic D
sent3236 hepatitis D
sent3236 C D
sent3236 as O
sent3236 compared O
sent3236 to O
sent3236 IFN O
sent3236 alpha O
sent3236 alone O
sent3237 To O
sent3237 prove O
sent3237 , O
sent3237 whether O
sent3237 Ribavirin T
sent3237 has O
sent3237 any O
sent3237 additional O
sent3237 effect O
sent3237 on O
sent3237 the O
sent3237 decline O
sent3237 of O
sent3237 hepatitis D
sent3237 C D
sent3237 viremia D
sent3237 during O
sent3237 the O
sent3237 first O
sent3237 weeks O
sent3237 of O
sent3237 treatment O
sent3237 patients O
sent3237 with O
sent3237 and O
sent3237 without O
sent3237 combination O
sent3237 therapy O
sent3237 were O
sent3237 compared O
sent3238 In O
sent3238 patients O
sent3238 with O
sent3238 combination T
sent3238 therapy T
sent3238 , O
sent3238 a O
sent3238 further O
sent3238 reduction O
sent3238 of O
sent3238 viremia D
sent3238 level O
sent3238 could O
sent3238 be O
sent3238 observed O
sent3238 , O
sent3238 whereas O
sent3238 viremia O
sent3238 levels O
sent3238 in O
sent3238 patients O
sent3238 with O
sent3238 IFN O
sent3238 alpha O
sent3238 alone O
sent3238 slightly O
sent3238 increased O
sent3239 Ribavirin T
sent3239 in T
sent3239 combination T
sent3239 with T
sent3239 IFN T
sent3239 alpha T
sent3239 exerts O
sent3239 an O
sent3239 additional O
sent3239 anti-viral/immunmodulatory O
sent3239 effect O
sent3239 which O
sent3239 manifests O
sent3239 itself O
sent3239 in O
sent3239 phase O
sent3239 2 O
sent3239 of O
sent3239 hepatitis D
sent3239 C D
sent3239 viremia D
sent3239 decline O
sent3240 Surgical T
sent3240 clearance T
sent3240 of O
sent3240 CBD D
sent3240 stones D
sent3240 was O
sent3240 achieved O
sent3240 in O
sent3240 58 O
sent3240 patients O
sent3240 ( O
sent3240 93.5 O
sent3240 % O
sent3240 ; O
sent3240 group O
sent3240 Ia O
sent3240 ) O
sent3241 Use O
sent3241 of O
sent3241 ES T
sent3241 to O
sent3241 treat O
sent3241 CBD D
sent3241 stones D
sent3241 on O
sent3241 a O
sent3241 routine O
sent3241 basis O
sent3241 was O
sent3241 therefore O
sent3241 not O
sent3241 found O
sent3241 to O
sent3241 be O
sent3241 any O
sent3241 better O
sent3241 than O
sent3241 one-time O
sent3241 surgical O
sent3241 exploration O
sent3242 Effect O
sent3242 of O
sent3242 cholecystectomy T
sent3242 on O
sent3242 gastroesophageal D
sent3242 and D
sent3242 duodenogastric D
sent3242 reflux D
sent3243 It O
sent3243 is O
sent3243 suggested O
sent3243 that O
sent3243 damaged D
sent3243 mucosal D
sent3243 tissues D
sent3243 with O
sent3243 AHF T
sent3243 can O
sent3243 be O
sent3243 effectively O
sent3243 compensated O
sent3243 by O
sent3243 enhanced O
sent3243 regeneration O
sent3243 response O
sent3243 due O
sent3243 to O
sent3243 an O
sent3243 adequately O
sent3243 high O
sent3243 dose O
sent3243 intensity O
sent3243 , O
sent3243 suggesting O
sent3243 a O
sent3243 possible O
sent3243 tolerability O
sent3243 advantage O
sent3243 for O
sent3243 AHF O
sent3244 Minimally O
sent3244 invasive O
sent3244 treatment O
sent3244 of O
sent3244 abscesses D
sent3244 by O
sent3244 CT-controlled T
sent3244 drainage T
sent3244 with T
sent3244 a T
sent3244 basket T
sent3244 catheter T
sent3244 system T
sent3245 PL T
sent3245 granule T
sent3245 is O
sent3245 one O
sent3245 of O
sent3245 the O
sent3245 most O
sent3245 common O
sent3245 forms O
sent3245 of O
sent3245 composite O
sent3245 medicine O
sent3245 for O
sent3245 colds D
sent3245 in O
sent3245 Japan O
sent3245 , O
sent3245 including O
sent3245 acetaminophen O
sent3246 A O
sent3246 72-year O
sent3246 old O
sent3246 man O
sent3246 who O
sent3246 had O
sent3246 been O
sent3246 prescribed O
sent3246 amiodarone T
sent3246 for O
sent3246 more O
sent3246 than O
sent3246 one O
sent3246 year O
sent3246 before O
sent3246 for O
sent3246 arrhythmogenic D
sent3246 right D
sent3246 ventricular D
sent3246 dystrophy D
sent3246 , O
sent3246 repeatedly O
sent3246 took O
sent3246 PL O
sent3246 granules O
sent3246 at O
sent3246 one-week O
sent3246 intervals O
sent3246 because O
sent3246 of O
sent3246 sneezing O
sent3246 and O
sent3246 fever O
sent3247 He O
sent3247 needed O
sent3247 mechanical T
sent3247 ventilation T
sent3247 for O
sent3247 severe D
sent3247 hypoxemia D
sent3247 , O
sent3247 but O
sent3247 recovered O
sent3247 with O
sent3247 glucocorticoid T
sent3247 pulse T
sent3247 therapy T
sent3248 In O
sent3248 a O
sent3248 follow-up O
sent3248 study O
sent3248 operative O
sent3248 risk O
sent3248 , O
sent3248 postoperative O
sent3248 functional O
sent3248 disorders O
sent3248 and O
sent3248 incidence O
sent3248 of O
sent3248 anastomotic O
sent3248 ( O
sent3248 recurrent O
sent3248 ) O
sent3248 ulcer O
sent3248 after O
sent3248 partial T
sent3248 gastrectomy T
sent3248 with T
sent3248 Roux-en-Y T
sent3248 gastrojejunostomy T
sent3248 for O
sent3248 gastroduodenal D
sent3248 ulcer D
sent3248 were O
sent3248 evaluated O
sent3248 in O
sent3248 52 O
sent3248 patients O
sent3249 < O
sent3249 TO_SEE O
sent3249 > O
sent3249 With O
sent3249 regard O
sent3249 to O
sent3249 the O
sent3249 high O
sent3249 rate O
sent3249 of O
sent3249 recurrent D
sent3249 ulcer D
sent3249 Roux-en-Y T
sent3249 reconstruction T
sent3249 after O
sent3249 partial T
sent3249 gastrectomy T
sent3249 for O
sent3249 primary D
sent3249 ulcer D
sent3249 surgery D
sent3249 should O
sent3249 be O
sent3249 avoided O
sent3249 and O
sent3249 reconstruction O
sent3249 procedures O
sent3249 preferred O
sent3249 , O
sent3249 which O
sent3249 guarantee O
sent3249 duodenogastric O
sent3249 reflux O
sent3250 OBJECTIVE O
sent3250 : O
sent3250 The O
sent3250 aim O
sent3250 of O
sent3250 these O
sent3250 studies O
sent3250 was O
sent3250 to O
sent3250 compare O
sent3250 the O
sent3250 pharmacokinetics O
sent3250 of O
sent3250 inhaled T
sent3250 fluticasone T
sent3250 propionate T
sent3250 ( T
sent3250 FP T
sent3250 ) T
sent3250 after O
sent3250 repeated O
sent3250 administration O
sent3250 via O
sent3250 the O
sent3250 Diskus O
sent3250 or O
sent3250 Diskhaler O
sent3250 dry O
sent3250 powder O
sent3250 inhalers O
sent3250 ( O
sent3250 DPIs O
sent3250 ) O
sent3250 to O
sent3250 patients O
sent3250 with O
sent3250 mild-to-moderate D
sent3250 asthma D
sent3251 CONCLUSION O
sent3251 : O
sent3251 In O
sent3251 patients O
sent3251 with O
sent3251 asthma D
sent3251 receiving O
sent3251 repeated T
sent3251 inhaled T
sent3251 doses T
sent3251 of T
sent3251 FP T
sent3251 , O
sent3251 the O
sent3251 systemic O
sent3251 exposure O
sent3251 ( O
sent3251 AUC O
sent3251 ) O
sent3251 after O
sent3251 inhalation O
sent3251 from O
sent3251 the O
sent3251 Diskus O
sent3251 was O
sent3251 similar O
sent3251 to O
sent3251 that O
sent3251 from O
sent3251 the O
sent3251 Diskhaler O
sent3251 , O
sent3251 with O
sent3251 no O
sent3251 difference O
sent3251 between O
sent3251 the O
sent3251 DPIs O
sent3251 in O
sent3251 the O
sent3251 effects O
sent3251 on O
sent3251 cortisol O
sent3251 suppression O
sent3252 DATA O
sent3252 SYNTHESIS O
sent3252 : O
sent3252 Recently O
sent3252 , O
sent3252 an O
sent3252 expert O
sent3252 panel O
sent3252 of O
sent3252 the O
sent3252 Centers O
sent3252 for O
sent3252 Disease O
sent3252 Control O
sent3252 and O
sent3252 Prevention O
sent3252 recommended O
sent3252 use O
sent3252 of O
sent3252 only O
sent3252 three O
sent3252 of O
sent3252 16 O
sent3252 systemic T
sent3252 antibiotics T
sent3252 approved O
sent3252 by O
sent3252 the O
sent3252 Food O
sent3252 and O
sent3252 Drug O
sent3252 Administration O
sent3252 for O
sent3252 treatment O
sent3252 of O
sent3252 AOM D
sent3252 : O
sent3252 amoxicillin T
sent3252 , T
sent3252 cefuroxime T
sent3252 axetil T
sent3252 , T
sent3252 and T
sent3252 ceftriaxone T
sent3253 A O
sent3253 three-step O
sent3253 treatment O
sent3253 algorithm O
sent3253 for O
sent3253 refractory D
sent3253 AOM D
sent3253 that O
sent3253 employs O
sent3253 amoxicillin T
sent3253 , T
sent3253 trimethoprim/sulfamethoxazole T
sent3253 ( T
sent3253 TMP/SMX T
sent3253 ) T
sent3253 , T
sent3253 or T
sent3253 high-dose T
sent3253 amoxicillin/clavulanate T
sent3253 ( T
sent3253 depending T
sent3253 on T
sent3253 the T
sent3253 prior T
sent3253 dose T
sent3253 of T
sent3253 and T
sent3253 adherence T
sent3253 to T
sent3253 amoxicillin T
sent3253 therapy T
sent3253 ) T
sent3253 , T
sent3253 and T
sent3253 ceftriaxone T
sent3253 or T
sent3253 tympanocentesis T
sent3253 at O
sent3253 steps O
sent3253 1 O
sent3253 , O
sent3253 2 O
sent3253 , O
sent3253 and O
sent3253 3 O
sent3253 , O
sent3253 respectively O
sent3253 , O
sent3253 appears O
sent3253 rational O
sent3253 and O
sent3253 cost-effective O
sent3254 CONCLUSIONS O
sent3254 : O
sent3254 Amoxicillin T
sent3254 remains O
sent3254 the O
sent3254 antibiotic O
sent3254 of O
sent3254 choice O
sent3254 for O
sent3254 initial O
sent3254 empiric O
sent3254 treatment O
sent3254 of O
sent3254 AOM D
sent3254 , O
sent3254 although O
sent3254 the O
sent3254 traditional O
sent3254 dosage O
sent3254 should O
sent3254 be O
sent3254 increased O
sent3254 in O
sent3254 patients O
sent3254 at O
sent3254 risk O
sent3254 for O
sent3254 drug-resistant O
sent3254 S. O
sent3254 pneumoniae O
sent3255 We O
sent3255 support O
sent3255 the O
sent3255 use O
sent3255 of O
sent3255 conjugate T
sent3255 pneumococcal T
sent3255 vaccine T
sent3255 per O
sent3255 guidelines O
sent3255 for O
sent3255 prevention O
sent3255 of O
sent3255 Raom D
sent3255 from O
sent3255 the O
sent3255 Advisory O
sent3255 Committee O
sent3255 on O
sent3255 Immunization O
sent3255 Practice O
sent3255 of O
sent3255 the O
sent3255 Centers O
sent3255 for O
sent3255 Disease O
sent3255 Control O
sent3255 and O
sent3255 Prevention O
sent3255 , O
sent3255 with O
sent3255 consideration O
sent3255 given O
sent3255 to O
sent3255 influenza D
sent3255 vaccine T
sent3255 for O
sent3255 cases O
sent3255 of O
sent3255 rAOM O
sent3255 that O
sent3255 historically O
sent3255 worsen O
sent3255 during O
sent3255 the O
sent3255 flu O
sent3255 season O
sent3256 This O
sent3256 model O
sent3256 can O
sent3256 be O
sent3256 used O
sent3256 to O
sent3256 test O
sent3256 the O
sent3256 safety O
sent3256 and O
sent3256 efficacy O
sent3256 of O
sent3256 liver-assist T
sent3256 devices T
sent3256 aimed O
sent3256 at O
sent3256 temporizing O
sent3256 the O
sent3256 detoxification O
sent3256 functions O
sent3256 of O
sent3256 the O
sent3256 failing D
sent3256 liver D
sent3257 Recent O
sent3257 major O
sent3257 epidemiologic O
sent3257 trends O
sent3257 in O
sent3257 bacterial O
sent3257 meningitis O
sent3257 include O
sent3257 a O
sent3257 dramatic O
sent3257 decline O
sent3257 in O
sent3257 the O
sent3257 incidence O
sent3257 of O
sent3257 Haemophilus D
sent3257 influenzae D
sent3257 meningitis D
sent3257 since O
sent3257 the O
sent3257 introduction O
sent3257 of O
sent3257 the O
sent3257 protein-conjugated T
sent3257 H. T
sent3257 influenzae T
sent3257 vaccines T
sent3257 , O
sent3257 and O
sent3257 a O
sent3257 worldwide O
sent3257 increase O
sent3257 in O
sent3257 infections O
sent3257 with O
sent3257 antibiotic-resistant O
sent3257 strains O
sent3257 of O
sent3257 bacterial O
sent3257 pathogens O
sent3258 dverse O
sent3258 outcomes O
sent3258 and O
sent3258 opioid T
sent3258 analgesic T
sent3258 administration T
sent3258 in O
sent3258 acute D
sent3258 abdominal D
sent3258 pain D
sent3259 We O
sent3259 examined O
sent3259 the O
sent3259 remnant O
sent3259 stomach O
sent3259 for O
sent3259 H. O
sent3259 pylori O
sent3259 infection O
sent3259 after O
sent3259 gastrectomy T
sent3259 for O
sent3259 gastric D
sent3259 cancer D
sent3259 or D
sent3259 peptic D
sent3259 ulcer D
sent3259 between O
sent3259 October O
sent3259 1992 O
sent3259 and O
sent3259 July O
sent3259 1997 O
sent3260 The O
sent3260 recent O
sent3260 introduction O
sent3260 of O
sent3260 ribavirin T
sent3260 , O
sent3260 given O
sent3260 in O
sent3260 combination O
sent3260 , O
sent3260 has O
sent3260 led O
sent3260 to O
sent3260 a O
sent3260 re-appraisal O
sent3260 of O
sent3260 the O
sent3260 management O
sent3260 of O
sent3260 chronic D
sent3260 hepatitis D
sent3260 C D
sent3261 The O
sent3261 current O
sent3261 report O
sent3261 considers O
sent3261 the O
sent3261 additional O
sent3261 benefit O
sent3261 of O
sent3261 combination T
sent3261 therapy T
sent3261 ( T
sent3261 interferon T
sent3261 alfa T
sent3261 and T
sent3261 ribavirin T
sent3261 ) T
sent3261 compared O
sent3261 with O
sent3261 monotherapy O
sent3261 ( O
sent3261 interferon O
sent3261 alfa O
sent3261 alone O
sent3261 ) O
sent3261 for O
sent3261 the O
sent3261 treatment O
sent3261 of O
sent3261 patients O
sent3261 with O
sent3261 chronic D
sent3261 hepatitis D
sent3261 C D
sent3262 OBJECTIVE O
sent3262 : O
sent3262 To O
sent3262 review O
sent3262 the O
sent3262 clinical O
sent3262 effectiveness O
sent3262 and O
sent3262 cost-effectiveness O
sent3262 of O
sent3262 combination T
sent3262 therapy T
sent3262 with T
sent3262 interferon T
sent3262 alfa T
sent3262 and T
sent3262 ribavirin T
sent3262 in O
sent3262 patients O
sent3262 with O
sent3262 chronic D
sent3262 hepatitis D
sent3262 C D
sent3263 Sida T
sent3263 cordifolia T
sent3263 L. T
sent3263 ( T
sent3263 Malvaceae T
sent3263 ) T
sent3263 is O
sent3263 used O
sent3263 in O
sent3263 folk O
sent3263 medicine O
sent3263 for O
sent3263 the O
sent3263 treatment O
sent3263 of O
sent3263 inflammation D
sent3263 of D
sent3263 the D
sent3263 oral D
sent3263 mucosa D
sent3263 , D
sent3263 blenorrhea D
sent3263 , D
sent3263 asthmatic D
sent3263 bronchitis D
sent3263 and D
sent3263 nasal D
sent3263 congestion D
sent3264 Double-blind O
sent3264 placebo-controlled O
sent3264 trial O
sent3264 of O
sent3264 Mycobacterium T
sent3264 vaccae T
sent3264 immunotherapy T
sent3264 for O
sent3264 tuberculosis D
sent3264 in O
sent3264 KwaZulu O
sent3264 , O
sent3264 South O
sent3264 Africa O
sent3264 , O
sent3264 1991-97 O
sent3265 OBJECTIVE O
sent3265 : O
sent3265 To O
sent3265 evaluate O
sent3265 the O
sent3265 efficacy O
sent3265 of O
sent3265 oral T
sent3265 tacrolimus T
sent3265 as O
sent3265 an O
sent3265 induction O
sent3265 agent O
sent3265 in O
sent3265 steroid-refractory D
sent3265 severe D
sent3265 colitis D
sent3265 .Study O
sent3265 design O
sent3265 : O
sent3265 Open-label O
sent3265 , O
sent3265 multicenter O
sent3265 trial O
sent3265 of O
sent3265 oral O
sent3265 tacrolimus O
sent3265 in O
sent3265 patients O
sent3265 with O
sent3265 severe O
sent3265 colitis O
sent3266 CONCLUSION O
sent3266 : O
sent3266 Although O
sent3266 tacrolimus T
sent3266 is O
sent3266 effective O
sent3266 induction O
sent3266 therapy O
sent3266 for O
sent3266 severe D
sent3266 ulcerative D
sent3266 or D
sent3266 Crohn D
sent3266 's D
sent3266 colitis D
sent3266 , O
sent3266 fewer O
sent3266 than O
sent3266 50 O
sent3266 % O
sent3266 of O
sent3266 patients O
sent3266 treated O
sent3266 will O
sent3266 successfully O
sent3266 achieve O
sent3266 a O
sent3266 long-term O
sent3266 remission O
sent3267 Cytomegalovirus D
sent3267 ( D
sent3267 CMV D
sent3267 ) D
sent3267 infection D
sent3267 was O
sent3267 one O
sent3267 of O
sent3267 the O
sent3267 most O
sent3267 common O
sent3267 opportunistic O
sent3267 infections O
sent3267 in O
sent3267 AIDS O
sent3267 patients O
sent3267 , O
sent3267 leading O
sent3267 to O
sent3267 blindness O
sent3267 or O
sent3267 life-threatening O
sent3267 disease O
sent3267 in O
sent3267 about O
sent3267 40 O
sent3267 % O
sent3267 of O
sent3267 patients O
sent3267 in O
sent3267 the O
sent3267 later O
sent3267 stages O
sent3267 of O
sent3267 AIDS O
sent3267 before O
sent3267 highly T
sent3267 active T
sent3267 antiretroviral T
sent3267 therapy T
sent3267 ( T
sent3267 HAART T
sent3267 ) T
sent3268 New T
sent3268 vaccines T
sent3268 are O
sent3268 under O
sent3268 study O
sent3268 to O
sent3268 further O
sent3268 control O
sent3268 bacterial D
sent3268 meningitis D
sent3269 The O
sent3269 study O
sent3269 involved O
sent3269 117 O
sent3269 infants O
sent3269 ( O
sent3269 mean O
sent3269 age O
sent3269 2.6 O
sent3269 months O
sent3269 ) O
sent3269 , O
sent3269 who O
sent3269 needed O
sent3269 hospital T
sent3269 treatment T
sent3269 because O
sent3269 of O
sent3269 RSV D
sent3269 bronchiolitis D
sent3270 According O
sent3270 to O
sent3270 the O
sent3270 present O
sent3270 study O
sent3270 it O
sent3270 seems O
sent3270 that O
sent3270 inhaled T
sent3270 corticosteroid T
sent3270 treatment T
sent3270 during O
sent3270 and O
sent3270 after O
sent3270 the O
sent3270 acute O
sent3270 phase O
sent3270 of O
sent3270 infant D
sent3270 RSV D
sent3270 bronchiolitis D
sent3270 may O
sent3270 have O
sent3270 a O
sent3270 beneficial O
sent3270 effect O
sent3270 on O
sent3270 subsequent O
sent3270 bronchial O
sent3270 wheezing O
sent3270 tendency O
sent3271 OBJECTIVE O
sent3271 : O
sent3271 This O
sent3271 study O
sent3271 was O
sent3271 designed O
sent3271 to O
sent3271 evaluate O
sent3271 the O
sent3271 safety O
sent3271 and O
sent3271 estimate O
sent3271 the O
sent3271 efficacy O
sent3271 of O
sent3271 oral T
sent3271 budesonide T
sent3271 in O
sent3271 patients O
sent3271 with O
sent3271 primary D
sent3271 sclerosing D
sent3271 cholangitis D
sent3271 ( D
sent3271 PSC D
sent3271 ) D
sent3272 Combined T
sent3272 interferon T
sent3272 and T
sent3272 lamivudine T
sent3272 therapy T
sent3272 : O
sent3272 is O
sent3272 this O
sent3272 the O
sent3272 treatment O
sent3272 of O
sent3272 choice O
sent3272 for O
sent3272 patients O
sent3272 with O
sent3272 chronic D
sent3272 hepatitis D
sent3272 B D
sent3272 virus D
sent3272 infection D
sent3272 ? O
sent3273 She O
sent3273 had O
sent3273 been O
sent3273 taking O
sent3273 amitriptyline T
sent3273 75 O
sent3273 mg O
sent3273 at O
sent3273 night O
sent3273 for O
sent3273 depression D
sent3273 for O
sent3273 four O
sent3273 months O
sent3273 before O
sent3273 her O
sent3273 admission O
sent3274 Side O
sent3274 effects O
sent3274 from O
sent3274 influenza D
sent3274 vaccination T
sent3274 : O
sent3274 differences O
sent3274 between O
sent3274 returned O
sent3274 and O
sent3274 random O
sent3274 surveys O
sent3275 OBJECTIVE O
sent3275 : O
sent3275 To O
sent3275 study O
sent3275 the O
sent3275 relationship O
sent3275 between O
sent3275 interleukin-2 O
sent3275 ( O
sent3275 IL-2 O
sent3275 ) O
sent3275 , O
sent3275 soluble O
sent3275 interleukin-2 O
sent3275 receptor O
sent3275 ( O
sent3275 sIL-2R O
sent3275 ) O
sent3275 and O
sent3275 the O
sent3275 non-and-hypo-responsiveness O
sent3275 to O
sent3275 hepatitis D
sent3275 B D
sent3275 vaccine T
sent3276 We O
sent3276 assessed O
sent3276 the O
sent3276 effects O
sent3276 of O
sent3276 early T
sent3276 replacement T
sent3276 therapy T
sent3276 with T
sent3276 protein-C T
sent3276 concentrate T
sent3276 together T
sent3276 with T
sent3276 continuous T
sent3276 veno-venous T
sent3276 haemodiafiltration T
sent3276 and O
sent3276 conventional O
sent3276 treatment O
sent3276 in O
sent3276 meningococcaemia D
sent3277 The O
sent3277 purpose O
sent3277 of O
sent3277 this O
sent3277 study O
sent3277 was O
sent3277 to O
sent3277 determine O
sent3277 if O
sent3277 topical T
sent3277 DL-alpha-tocopherol T
sent3277 ( T
sent3277 vitamin T
sent3277 E T
sent3277 ) T
sent3277 could O
sent3277 reduce O
sent3277 ultraviolet-induced D
sent3277 damage D
sent3277 to D
sent3277 the D
sent3277 epidermis D
sent3278 We O
sent3278 observed O
sent3278 the O
sent3278 effects O
sent3278 of O
sent3278 cisapride T
sent3278 in O
sent3278 the O
sent3278 management O
sent3278 of O
sent3278 idiopathic D
sent3278 constipation D
sent3278 in O
sent3278 children O
sent3279 METHODS O
sent3279 : O
sent3279 Thirty-seven O
sent3279 children O
sent3279 with O
sent3279 a O
sent3279 history O
sent3279 of O
sent3279 constipation D
sent3279 ( O
sent3279 i.e O
sent3279 . O
sent3279 , O
sent3279 pain O
sent3279 and O
sent3279 difficulty O
sent3279 or O
sent3279 delay O
sent3279 in O
sent3279 defecation O
sent3279 for O
sent3279 > O
sent3279 3 O
sent3279 months O
sent3279 ) O
sent3279 were O
sent3279 recruited O
sent3279 and O
sent3279 randomly O
sent3279 assigned O
sent3279 to O
sent3279 8 O
sent3279 weeks O
sent3279 of O
sent3279 treatment O
sent3279 with O
sent3279 either O
sent3279 cisapride T
sent3279 , O
sent3279 0.2 O
sent3279 mg/kg O
sent3279 three O
sent3279 times O
sent3279 daily O
sent3279 , O
sent3279 or O
sent3279 matching O
sent3279 placebo O
sent3279 after O
sent3279 a O
sent3279 2-week O
sent3279 run-in O
sent3279 period O
sent3279 in O
sent3279 a O
sent3279 double-blind O
sent3279 , O
sent3279 parallel-group O
sent3279 study O
sent3279 design O
sent3280 Patient O
sent3280 1 O
sent3280 demonstrated O
sent3280 dramatic O
sent3280 clearing O
sent3280 of O
sent3280 his O
sent3280 MCV D
sent3280 lesions D
sent3280 when O
sent3280 intravenous T
sent3280 cidofovir T
sent3280 therapy T
sent3280 was O
sent3280 started O
sent3280 for O
sent3280 his O
sent3280 treatment-resistant D
sent3280 bilateral D
sent3280 CMV D
sent3280 retinitis D
sent3280 and O
sent3280 because O
sent3280 of O
sent3280 cidofovir T
sent3280 's T
sent3280 possible O
sent3280 activity O
sent3280 against O
sent3280 MCV D
sent3281 In O
sent3281 case O
sent3281 2 O
sent3281 , O
sent3281 cidofovir T
sent3281 was O
sent3281 compounded O
sent3281 as O
sent3281 a O
sent3281 3 O
sent3281 % O
sent3281 cream O
sent3281 in O
sent3281 a O
sent3281 combination O
sent3281 vehicle O
sent3281 ( O
sent3281 Dermovan O
sent3281 ) O
sent3281 for O
sent3281 extensive O
sent3281 facial O
sent3281 involvement O
sent3281 , O
sent3281 and O
sent3281 complete O
sent3281 resolution O
sent3281 of O
sent3281 MCV D
sent3281 was O
sent3281 seen O
sent3281 after O
sent3281 1 O
sent3281 month O
sent3281 of O
sent3281 therapy O
sent3282 In O
sent3282 case O
sent3282 3 O
sent3282 , O
sent3282 intravenous T
sent3282 cidofovir T
sent3282 therapy T
sent3282 was O
sent3282 started O
sent3282 both O
sent3282 for O
sent3282 CMV D
sent3282 retinitis D
sent3282 and O
sent3282 in O
sent3282 an O
sent3282 attempt O
sent3282 to O
sent3282 clear O
sent3282 90 O
sent3282 % O
sent3282 facial O
sent3282 MCV D
sent3282 involvement O
sent3282 ; O
sent3282 after O
sent3282 1 O
sent3282 month O
sent3282 of O
sent3282 treatment O
sent3282 , O
sent3282 all O
sent3282 clinical O
sent3282 evidence O
sent3282 of O
sent3282 MCV D
sent3282 had O
sent3282 resolved O
sent3283 CONCLUSIONS O
sent3283 : O
sent3283 Cidofovir T
sent3283 , O
sent3283 a O
sent3283 nucleotide O
sent3283 analog O
sent3283 of O
sent3283 deoxycytidine O
sent3283 monophosphate O
sent3283 , O
sent3283 appears O
sent3283 to O
sent3283 have O
sent3283 contributed O
sent3283 to O
sent3283 clearing O
sent3283 of O
sent3283 advanced D
sent3283 MCV D
sent3283 lesions D
sent3283 in O
sent3283 these O
sent3283 3 O
sent3283 patients O
sent3283 , O
sent3283 thus O
sent3283 providing O
sent3283 suggestive O
sent3283 evidence O
sent3283 of O
sent3283 clinical O
sent3283 activity O
sent3283 against O
sent3283 MCV D
sent3284 Controlled O
sent3284 trials O
sent3284 of O
sent3284 cidofovir T
sent3284 therapy T
sent3284 for O
sent3284 MCV D
sent3284 in O
sent3284 persons O
sent3284 infected O
sent3284 with O
sent3284 human O
sent3284 immunodeficiency O
sent3284 virus O
sent3284 are O
sent3284 warranted O
sent3285 OBJECTIVE O
sent3285 : O
sent3285 This O
sent3285 study O
sent3285 aimed O
sent3285 to O
sent3285 determine O
sent3285 the O
sent3285 effect O
sent3285 of O
sent3285 external T
sent3285 beam T
sent3285 radiation T
sent3285 therapy T
sent3285 on O
sent3285 choroidal D
sent3285 neovascularization D
sent3285 ( D
sent3285 CNV D
sent3285 ) D
sent3285 secondary O
sent3285 to O
sent3285 age-related D
sent3285 macular D
sent3285 degeneration D
sent3285 ( D
sent3285 AMD D
sent3285 ) D
sent3286 Thrombolytic T
sent3286 therapy T
sent3286 has O
sent3286 been O
sent3286 accepted O
sent3286 in O
sent3286 the O
sent3286 treatment O
sent3286 of O
sent3286 acute D
sent3286 myocardial D
sent3286 infarction D
sent3287 A O
sent3287 bolus O
sent3287 infusion O
sent3287 of O
sent3287 tissue T
sent3287 plasminogen T
sent3287 activator T
sent3287 was O
sent3287 administered O
sent3287 during O
sent3287 CPR T
sent3287 in O
sent3287 refractory D
sent3287 ventricular D
sent3287 fibrillation D
sent3287 ( O
sent3287 two O
sent3287 cases O
sent3287 ) O
sent3287 and O
sent3287 pulseless D
sent3287 ventricular D
sent3287 tachycardia D
sent3287 ( O
sent3287 one O
sent3287 case O
sent3287 ) O
sent3288 We O
sent3288 conclude O
sent3288 that O
sent3288 bolus T
sent3288 thrombolytic T
sent3288 infusions T
sent3288 during O
sent3288 CPR D
sent3288 may O
sent3288 facilitate O
sent3288 spontaneous O
sent3288 return O
sent3288 of O
sent3288 circulation O
sent3288 in O
sent3288 select O
sent3288 patients O
sent3288 with O
sent3288 confirmed D
sent3288 acute D
sent3288 myocardial D
sent3288 infarction D
sent3288 , O
sent3288 witnessed O
sent3288 cardiac D
sent3288 arrest D
sent3288 in O
sent3288 the O
sent3288 ED O
sent3288 , O
sent3288 and O
sent3288 refractory D
sent3288 ventricular D
sent3288 fibrillation D
sent3288 or O
sent3288 tachycardia D
sent3289 < O
sent3289 TO_SEE O
sent3289 > O
sent3289 CASE O
sent3289 SUMMARY O
sent3289 : O
sent3289 A O
sent3289 92-year O
sent3289 old O
sent3289 white O
sent3289 woman O
sent3289 who O
sent3289 was O
sent3289 receiving O
sent3289 venlafaxine T
sent3289 for O
sent3289 management O
sent3289 of O
sent3289 depression D
sent3289 was O
sent3289 found O
sent3289 to O
sent3289 have O
sent3289 hyponatremia O
sent3290 Touch O
sent3290 sensibility O
sent3290 was O
sent3290 assessed O
sent3290 with O
sent3290 von O
sent3290 Frey O
sent3290 's O
sent3290 monofilaments O
sent3290 in O
sent3290 the O
sent3290 breasts O
sent3290 of O
sent3290 10 O
sent3290 healthy O
sent3290 women O
sent3290 ( O
sent3290 controls O
sent3290 ) O
sent3290 and O
sent3290 of O
sent3290 80 O
sent3290 women O
sent3290 with O
sent3290 breast D
sent3290 cancer D
sent3290 who O
sent3290 at O
sent3290 least O
sent3290 1 O
sent3290 year O
sent3290 previously O
sent3290 had O
sent3290 undergone O
sent3290 subcutaneous T
sent3290 mastectomy T
sent3290 and O
sent3290 immediate O
sent3290 reconstruction O
sent3290 with O
sent3290 a O
sent3290 prosthesis O
sent3291 Although O
sent3291 improved O
sent3291 glycemic T
sent3291 control T
sent3291 , O
sent3291 maintenance O
sent3291 of O
sent3291 normal O
sent3291 blood O
sent3291 pressure O
sent3291 , O
sent3291 and O
sent3291 use O
sent3291 of O
sent3291 angiotensin-converting T
sent3291 enzyme T
sent3291 inhibitors T
sent3291 are O
sent3291 important O
sent3291 strategies O
sent3291 to O
sent3291 avoid O
sent3291 developing O
sent3291 microalbuminuria D
sent3291 , O
sent3291 dietary O
sent3291 macronutrient O
sent3291 intake O
sent3291 may O
sent3291 also O
sent3291 play O
sent3291 a O
sent3291 role O
sent3292 Local O
sent3292 injection O
sent3292 of O
sent3292 corticosteroids T
sent3292 into O
sent3292 refractory O
sent3292 esophageal O
sent3292 strictures O
sent3292 to O
sent3292 decrease O
sent3292 the O
sent3292 restenosis D
sent3292 rate O
sent3292 has O
sent3292 been O
sent3292 reported O
sent3293 We O
sent3293 systematically O
sent3293 reviewed O
sent3293 the O
sent3293 evidence O
sent3293 concerning O
sent3293 the O
sent3293 ability O
sent3293 of O
sent3293 five O
sent3293 systemic T
sent3293 treatments T
sent3293 to O
sent3293 induce O
sent3293 remission O
sent3293 in O
sent3293 patients O
sent3293 with O
sent3293 severe D
sent3293 psoriasis D
sent3293 : O
sent3293 ultraviolet T
sent3293 B T
sent3293 ( T
sent3293 UVB T
sent3293 ) T
sent3293 , O
sent3293 photochemotherapy T
sent3293 ( T
sent3293 PUVA T
sent3293 ) T
sent3293 , O
sent3293 methotrexate T
sent3293 ( T
sent3293 MTX T
sent3293 ) T
sent3293 , O
sent3293 retinoids T
sent3293 ( T
sent3293 RET T
sent3293 ) T
sent3293 and O
sent3293 cyclosporin T
sent3293 A T
sent3293 ( T
sent3293 CYA T
sent3293 ) T
sent3294 Consequently O
sent3294 , O
sent3294 parenteral T
sent3294 nutrition T
sent3294 ( T
sent3294 PN T
sent3294 ) T
sent3294 solutions T
sent3294 used O
sent3294 to O
sent3294 treat O
sent3294 malnourished O
sent3294 patients O
sent3294 with O
sent3294 chronic D
sent3294 renal D
sent3294 failure D
sent3294 usually O
sent3294 are O
sent3294 prepared O
sent3294 with O
sent3294 little O
sent3294 supplementation O
sent3294 of O
sent3294 these O
sent3294 cations O
sent3295 < O
sent3295 TO_SEE O
sent3295 > O
sent3295 CONCLUSIONS O
sent3295 : O
sent3295 Malnourished O
sent3295 patients O
sent3295 with O
sent3295 chronic D
sent3295 renal D
sent3295 failure D
sent3295 receiving O
sent3295 PN T
sent3295 are O
sent3295 at O
sent3295 risk O
sent3295 of O
sent3295 developing O
sent3295 electrolyte D
sent3295 abnormalities D
sent3295 , O
sent3295 particularly O
sent3295 hypophosphatemia D
sent3296 PURPOSE O
sent3296 : O
sent3296 We O
sent3296 report O
sent3296 a O
sent3296 multicenter O
sent3296 experience O
sent3296 using O
sent3296 tubularized T
sent3296 incised T
sent3296 plate T
sent3296 urethroplastym T
sent3296 for O
sent3296 proximal D
sent3296 hypospadias D
sent3297 MATERIALS O
sent3297 AND O
sent3297 METHODS O
sent3297 : O
sent3297 From O
sent3297 August O
sent3297 1993 O
sent3297 to O
sent3297 December O
sent3297 1996 O
sent3297 tubularized T
sent3297 incised T
sent3297 plate T
sent3297 urethroplasty T
sent3297 was O
sent3297 performed O
sent3297 in O
sent3297 27 O
sent3297 boys O
sent3297 6 O
sent3297 months O
sent3297 to O
sent3297 3 O
sent3297 years O
sent3297 old O
sent3297 with O
sent3297 mid D
sent3297 shaft D
sent3297 and D
sent3297 penoscrotal D
sent3297 hypospadias D
sent3298 RESULTS O
sent3298 : O
sent3298 Tubularized T
sent3298 incised T
sent3298 plate T
sent3298 surgery T
sent3298 created O
sent3298 a O
sent3298 functional O
sent3298 neourethra O
sent3298 even O
sent3298 in O
sent3298 penoscrotal D
sent3298 hypospadias D
sent3299 CONCLUSIONS O
sent3299 : O
sent3299 Tubularized T
sent3299 incised T
sent3299 plate T
sent3299 urethroplasty T
sent3299 is O
sent3299 a O
sent3299 versatile O
sent3299 operation O
sent3299 that O
sent3299 corrects O
sent3299 proximal D
sent3299 hypospadias D
sent3299 defects D
sent3299 with O
sent3299 few O
sent3299 complications O
sent3299 and O
sent3299 superior O
sent3299 cosmetic O
sent3299 results O
sent3300 Aortocoronary T
sent3300 bypass T
sent3300 grafting T
sent3300 is O
sent3300 an O
sent3300 accepted O
sent3300 procedure O
sent3300 for O
sent3300 ischemic D
sent3300 heart D
sent3300 disease D
sent3301 Immunotherapy T
sent3301 of O
sent3301 mice O
sent3301 with O
sent3301 preexisting O
sent3301 cancers D
sent3301 with O
sent3301 heat T
sent3301 shock T
sent3301 protein T
sent3301 preparations T
sent3301 derived T
sent3301 from T
sent3301 autologous T
sent3301 cancer T
sent3301 resulted O
sent3301 in O
sent3301 retarded O
sent3301 progression O
sent3301 of O
sent3301 the O
sent3301 primary O
sent3301 cancer D
sent3301 , O
sent3301 a O
sent3301 reduced O
sent3301 metastatic O
sent3301 load O
sent3301 , O
sent3301 and O
sent3301 prolongation O
sent3301 of O
sent3301 life-span O
sent3302 < O
sent3302 TO_SEE O
sent3302 > O
sent3302 Intrapleural T
sent3302 injection T
sent3302 of T
sent3302 irradiated T
sent3302 LLC-IL2 T
sent3302 cured O
sent3302 pre-existing D
sent3302 lung D
sent3302 LLC D
sent3302 tumors D
sent3302 and O
sent3302 extended O
sent3302 the O
sent3302 survival O
sent3302 of O
sent3302 the O
sent3302 mice O
sent3302 but O
sent3302 did O
sent3302 not O
sent3302 affect O
sent3302 survival O
sent3302 of O
sent3302 mice O
sent3302 with O
sent3302 pre-existing O
sent3302 peritoneal D
sent3302 tumors D
sent3302 nor O
sent3302 did O
sent3302 it O
sent3302 affect O
sent3302 the O
sent3302 growth O
sent3302 of O
sent3302 s.c. D
sent3302 tumors D
sent3303 < O
sent3303 TO_SEE O
sent3303 > O
sent3303 Intraperitoneal T
sent3303 injection T
sent3303 of T
sent3303 irradiated T
sent3303 LLC-IL2 T
sent3303 cured O
sent3303 pre-existing D
sent3303 LLC D
sent3303 peritoneal D
sent3303 tumors D
sent3303 and O
sent3303 extended O
sent3303 the O
sent3303 survival O
sent3303 of O
sent3303 the O
sent3303 mice O
sent3303 but O
sent3303 did O
sent3303 not O
sent3303 affect O
sent3303 survival O
sent3303 of O
sent3303 mice O
sent3303 bearing O
sent3303 lung D
sent3303 tumors D
sent3303 nor O
sent3303 did O
sent3303 it O
sent3303 affect O
sent3303 the O
sent3303 growth O
sent3303 of O
sent3303 s.c. D
sent3303 tumors D
sent3304 Subcutaneous T
sent3304 injection T
sent3304 of T
sent3304 irradiated T
sent3304 LLC-IL2 T
sent3304 did O
sent3304 not O
sent3304 affect O
sent3304 the O
sent3304 growth O
sent3304 of O
sent3304 preexisting O
sent3304 s.c. D
sent3304 tumors D
sent3304 and O
sent3304 also O
sent3304 did O
sent3304 not O
sent3304 improve O
sent3304 survival O
sent3304 of O
sent3304 mice O
sent3304 bearing O
sent3304 the O
sent3304 lung D
sent3304 or D
sent3304 peritoneal D
sent3304 tumors D
sent3305 We O
sent3305 describe O
sent3305 such O
sent3305 an O
sent3305 event O
sent3305 in O
sent3305 a O
sent3305 man O
sent3305 who O
sent3305 underwent O
sent3305 allogeneic T
sent3305 BMT T
sent3305 for O
sent3305 APL D
sent3305 in O
sent3305 second O
sent3305 relapse O
sent3305 and O
sent3305 4 O
sent3305 years O
sent3305 later O
sent3305 presented O
sent3305 with O
sent3305 testicular O
sent3305 relapse O
sent3306 Olanzapine T
sent3306 is O
sent3306 an O
sent3306 atypical O
sent3306 antipsychotic O
sent3306 effective O
sent3306 in O
sent3306 the O
sent3306 treatment O
sent3306 of O
sent3306 schizophrenic D
sent3306 patients D
sent3307 After O
sent3307 a O
sent3307 2- O
sent3307 to O
sent3307 9-day O
sent3307 placebo O
sent3307 lead-in O
sent3307 , O
sent3307 79 O
sent3307 inpatients O
sent3307 with O
sent3307 schizophrenia D
sent3307 according O
sent3307 to O
sent3307 DSM-III-R O
sent3307 criteria O
sent3307 were O
sent3307 placed O
sent3307 on O
sent3307 an O
sent3307 olanzapine T
sent3307 dosage O
sent3307 of O
sent3307 10 O
sent3307 mg/day O
sent3307 or O
sent3307 1 O
sent3307 mg/day O
sent3307 for O
sent3307 up O
sent3307 to O
sent3307 6 O
sent3307 weeks O
sent3308 Fludarabine T
sent3308 and O
sent3308 ara-C T
sent3308 successfully O
sent3308 eradicated O
sent3308 bone D
sent3308 marrow D
sent3308 disease D
sent3308 in O
sent3308 16 O
sent3308 of O
sent3308 27 O
sent3308 patients O
sent3308 ( O
sent3308 59 O
sent3308 % O
sent3308 ) O
sent3308 , O
sent3308 23 O
sent3308 patients O
sent3308 of O
sent3308 which O
sent3308 had O
sent3308 been O
sent3308 treated O
sent3308 previously O
sent3308 with O
sent3308 high-dose O
sent3308 ara-C T
sent3309 These O
sent3309 results O
sent3309 verified O
sent3309 the O
sent3309 synergistic O
sent3309 effect O
sent3309 fludarabine T
sent3309 exhibited O
sent3309 in O
sent3309 augmenting O
sent3309 ara-CTP T
sent3309 concentrations O
sent3309 in O
sent3309 patients O
sent3309 ' O
sent3309 leukemic O
sent3309 blasts O
sent3309 , O
sent3309 thus O
sent3309 improving O
sent3309 the O
sent3309 clinical O
sent3309 response O
sent3309 in O
sent3309 relapsed D
sent3309 pediatric D
sent3309 leukemias D
sent3310 BACKGROUND O
sent3310 : O
sent3310 The O
sent3310 growing O
sent3310 use O
sent3310 of O
sent3310 heparin T
sent3310 in O
sent3310 acute D
sent3310 thrombotic D
sent3310 disorders D
sent3310 , O
sent3310 coupled O
sent3310 with O
sent3310 the O
sent3310 availability O
sent3310 of O
sent3310 many O
sent3310 new O
sent3310 antithrombotic T
sent3310 agents T
sent3310 , O
sent3310 emphasizes O
sent3310 the O
sent3310 need O
sent3310 for O
sent3310 adequate O
sent3310 characterization O
sent3310 of O
sent3310 the O
sent3310 platelet O
sent3310 effects O
sent3310 of O
sent3310 the O
sent3310 various O
sent3310 anticoagulants T
sent3311 METHODS O
sent3311 AND O
sent3311 RESULTS O
sent3311 : O
sent3311 Platelet O
sent3311 P-selectin O
sent3311 ( O
sent3311 CD62 O
sent3311 ) O
sent3311 and O
sent3311 activated O
sent3311 GP O
sent3311 IIb/IIIa O
sent3311 ( O
sent3311 PAC-1 O
sent3311 ) O
sent3311 expression O
sent3311 on O
sent3311 platelet O
sent3311 membrane O
sent3311 was O
sent3311 quantified O
sent3311 in O
sent3311 whole O
sent3311 blood O
sent3311 as O
sent3311 well O
sent3311 as O
sent3311 platelet O
sent3311 aggregation O
sent3311 in O
sent3311 platelet-rich O
sent3311 plasma O
sent3311 in O
sent3311 43 O
sent3311 patients O
sent3311 with O
sent3311 unstable D
sent3311 angina D
sent3311 before O
sent3311 and O
sent3311 during O
sent3311 treatment O
sent3311 with O
sent3311 UFH T
sent3311 or O
sent3311 enoxaparin T
sent3312 PURPOSE O
sent3312 : O
sent3312 We O
sent3312 review O
sent3312 our O
sent3312 initial O
sent3312 experience O
sent3312 with O
sent3312 direct T
sent3312 percutaneous T
sent3312 transluminal T
sent3312 angioplasty T
sent3312 ( T
sent3312 PTA T
sent3312 ) T
sent3312 as O
sent3312 a O
sent3312 reperfusion T
sent3312 treatment T
sent3312 for O
sent3312 acute D
sent3312 occlusion D
sent3312 of D
sent3312 the D
sent3312 middle D
sent3312 cerebral D
sent3312 artery D
sent3313 < O
sent3313 TO_SEE O
sent3313 > O
sent3313 CONCLUSION O
sent3313 : O
sent3313 Direct O
sent3313 PTA O
sent3313 may O
sent3313 be O
sent3313 performed O
sent3313 safely O
sent3313 as O
sent3313 an O
sent3313 alternative O
sent3313 to O
sent3313 thrombolytic O
sent3313 therapy O
sent3313 in O
sent3313 patients O
sent3313 with O
sent3313 acute O
sent3313 occlusion O
sent3313 of O
sent3313 the O
sent3313 middle O
sent3313 cerebral O
sent3313 artery O
sent3313 when O
sent3313 early O
sent3313 CT O
sent3313 findings O
sent3313 and/or O
sent3313 lenticulostriate O
sent3313 artery O
sent3313 involvement O
sent3313 are O
sent3313 present O
sent3313 or O
sent3313 when O
sent3313 superselective O
sent3313 local O
sent3313 angiography O
sent3313 shows O
sent3313 the O
sent3313 presence O
sent3313 of O
sent3313 a O
sent3313 large O
sent3313 embolus O
sent3313 or O
sent3313 high-grade O
sent3313 stenosis O
sent3314 Women O
sent3314 randomised O
sent3314 to O
sent3314 screen-and-treat O
sent3314 received O
sent3314 appropriate O
sent3314 antibiotics T
sent3314 only O
sent3314 if O
sent3314 screening O
sent3314 proved O
sent3314 positive O
sent3314 for O
sent3314 one O
sent3314 or O
sent3314 more O
sent3314 infection D
sent3315 < O
sent3315 TO_SEE O
sent3315 > O
sent3315 A O
sent3315 71-year-old O
sent3315 woman O
sent3315 with O
sent3315 autoimmune O
sent3315 hemolytic O
sent3315 anemia O
sent3315 underwent O
sent3315 an O
sent3315 emergency O
sent3315 endocardial T
sent3315 patch T
sent3315 repair T
sent3315 for O
sent3315 ventricular D
sent3315 septal D
sent3315 perforation D
sent3315 after O
sent3315 acute O
sent3315 myocardial O
sent3315 infarction O
sent3316 Use O
sent3316 of O
sent3316 washed T
sent3316 red T
sent3316 blood T
sent3316 cells T
sent3316 was O
sent3316 effective O
sent3316 in O
sent3316 averting O
sent3316 hemolytic D
sent3316 crisis D
sent3316 throughout O
sent3316 perioperative O
sent3316 period O
sent3317 Therefore O
sent3317 , O
sent3317 prudent O
sent3317 management O
sent3317 and O
sent3317 use O
sent3317 of O
sent3317 washed T
sent3317 red T
sent3317 blood T
sent3317 cells T
sent3317 transfusion T
sent3317 would O
sent3317 prevent O
sent3317 hemolytic D
sent3317 aggravation D
sent3317 even O
sent3317 in O
sent3317 open O
sent3317 heart O
sent3317 surgery O
sent3318 < O
sent3318 TO_SEE O
sent3318 > O
sent3318 We O
sent3318 report O
sent3318 a O
sent3318 case O
sent3318 of O
sent3318 a O
sent3318 29-year-old O
sent3318 male O
sent3318 chronic O
sent3318 HBV O
sent3318 carrier O
sent3318 who O
sent3318 developed O
sent3318 fulminant D
sent3318 reactivated D
sent3318 HBV D
sent3318 infection D
sent3318 following O
sent3318 intensive O
sent3318 chemotherapy T
sent3318 for O
sent3318 stage D
sent3318 IVB D
sent3318 large D
sent3318 cell D
sent3318 B-cell D
sent3318 non-Hodgkin D
sent3318 's D
sent3318 lymphoma D
sent3318 associated O
sent3318 with O
sent3318 extensive O
sent3318 central O
sent3318 nervous O
sent3318 system O
sent3318 and O
sent3318 bone O
sent3318 marrow O
sent3318 involvement O
sent3319 We O
sent3319 advise O
sent3319 that O
sent3319 lamivudine T
sent3319 should O
sent3319 be O
sent3319 considered O
sent3319 during O
sent3319 intensive O
sent3319 chemotherapy T
sent3319 treatment T
sent3319 of O
sent3319 chronic O
sent3319 carriers O
sent3319 of O
sent3319 HBV D
sent3320 OBJECTIVES O
sent3320 : O
sent3320 The O
sent3320 purpose O
sent3320 of O
sent3320 this O
sent3320 analysis O
sent3320 was O
sent3320 to O
sent3320 determine O
sent3320 the O
sent3320 influence O
sent3320 of O
sent3320 an O
sent3320 additional O
sent3320 treatment O
sent3320 delay O
sent3320 inherent O
sent3320 in O
sent3320 transfer O
sent3320 to O
sent3320 an O
sent3320 angioplasty O
sent3320 center O
sent3320 for O
sent3320 primary T
sent3320 angioplasty T
sent3320 of O
sent3320 patients O
sent3320 with O
sent3320 acute D
sent3320 myocardial D
sent3320 infarction D
sent3320 who O
sent3320 are O
sent3320 first O
sent3320 admitted O
sent3320 to O
sent3320 hospitals O
sent3320 without O
sent3320 angioplasty O
sent3320 facilities O
sent3321 BACKGROUND O
sent3321 : O
sent3321 Several O
sent3321 randomized O
sent3321 trials O
sent3321 have O
sent3321 demonstrated O
sent3321 the O
sent3321 benefits O
sent3321 of O
sent3321 primary T
sent3321 angioplasty T
sent3321 in O
sent3321 acute D
sent3321 myocardial D
sent3321 infarction D
sent3322 We O
sent3322 report O
sent3322 the O
sent3322 first O
sent3322 case O
sent3322 ( O
sent3322 to O
sent3322 our O
sent3322 knowledge O
sent3322 ) O
sent3322 of O
sent3322 an O
sent3322 endoscopic T
sent3322 removal T
sent3322 of O
sent3322 a O
sent3322 forehead D
sent3322 soft D
sent3322 tissue D
sent3322 mass D
sent3323 As O
sent3323 the O
sent3323 overview O
sent3323 shows O
sent3323 , O
sent3323 both O
sent3323 groups O
sent3323 of O
sent3323 substances O
sent3323 are O
sent3323 useful O
sent3323 for O
sent3323 individualized O
sent3323 treatment O
sent3323 of O
sent3323 benign D
sent3323 prostatic D
sent3323 hyperplasia D
sent3323 ( D
sent3323 BPH D
sent3323 ) D
sent3323 , O
sent3323 provided O
sent3323 that O
sent3323 conservative O
sent3323 pharmacological T
sent3323 treatment T
sent3323 of O
sent3323 BPH D
sent3323 is O
sent3323 basically O
sent3323 accepted O
sent3323 and O
sent3323 that O
sent3323 the O
sent3323 patients O
sent3323 ' O
sent3323 quality O
sent3323 of O
sent3323 life O
sent3323 is O
sent3323 also O
sent3323 considered O
sent3324 The O
sent3324 results O
sent3324 of O
sent3324 several O
sent3324 clinical O
sent3324 investigations O
sent3324 showed O
sent3324 the O
sent3324 efficacy O
sent3324 and O
sent3324 safety O
sent3324 of O
sent3324 artichoke T
sent3324 extracts T
sent3324 ( T
sent3324 Cynara T
sent3324 scolymus T
sent3324 L. T
sent3324 ) T
sent3324 in O
sent3324 the O
sent3324 treatment O
sent3324 of O
sent3324 hepato-biliary D
sent3324 dysfunction D
sent3324 and D
sent3324 digestive D
sent3324 complaints D
sent3324 , O
sent3324 such O
sent3324 as O
sent3324 sensation O
sent3324 of O
sent3324 fullness O
sent3324 , O
sent3324 loss D
sent3324 of D
sent3324 appetite D
sent3324 , O
sent3324 nausea D
sent3324 and O
sent3324 abdominal D
sent3324 pain D
sent3325 Besides O
sent3325 the O
sent3325 well-known O
sent3325 nonsteroidal T
sent3325 antiinflammatory T
sent3325 drugs T
sent3325 ( T
sent3325 NSAID T
sent3325 ) T
sent3325 for O
sent3325 the O
sent3325 treatment O
sent3325 of O
sent3325 rheumatic D
sent3325 pain D
sent3325 herbal T
sent3325 medicine T
sent3325 can O
sent3325 also O
sent3325 be O
sent3325 applied O
sent3325 successfully O
sent3326 Extracts O
sent3326 of O
sent3326 the O
sent3326 secondary O
sent3326 tubers O
sent3326 of O
sent3326 Devil T
sent3326 's T
sent3326 Claw T
sent3326 ( T
sent3326 Harpagophytum T
sent3326 procumbens T
sent3326 ) T
sent3326 are O
sent3326 recommended O
sent3326 for O
sent3326 the O
sent3326 supportive O
sent3326 treatment O
sent3326 of O
sent3326 degenerative D
sent3326 painful D
sent3326 rheumatism D
sent3327 High-dose T
sent3327 intravenous T
sent3327 immunoglobulin T
sent3327 ( T
sent3327 hdIVIg T
sent3327 ) T
sent3327 is O
sent3327 increasingly O
sent3327 used O
sent3327 to O
sent3327 treat O
sent3327 a O
sent3327 range O
sent3327 of O
sent3327 inflammatory D
sent3327 and D
sent3327 autoimmune D
sent3327 diseases D
sent3328 The O
sent3328 current O
sent3328 dermatological O
sent3328 uses O
sent3328 of O
sent3328 hdIVIg T
sent3328 include O
sent3328 the O
sent3328 treatment O
sent3328 of O
sent3328 dermatomyositis D
sent3328 and O
sent3328 the O
sent3328 autoimmune D
sent3328 bullous D
sent3328 disorders D
sent3328 , O
sent3328 epidermolysis D
sent3328 bullosa D
sent3328 acquisita D
sent3328 , O
sent3328 pemphigoid D
sent3328 , O
sent3328 and O
sent3328 pemphigus D
sent3329 Unfortunately O
sent3329 , O
sent3329 current O
sent3329 dermatological O
sent3329 uses O
sent3329 of O
sent3329 hdIVIg O
sent3329 have O
sent3329 been O
sent3329 limited O
sent3329 to O
sent3329 either O
sent3329 uncontrolled O
sent3329 trials O
sent3329 or O
sent3329 anecdotal O
sent3329 case O
sent3329 reports O
sent3329 , O
sent3329 except O
sent3329 for O
sent3329 a O
sent3329 single O
sent3329 controlled O
sent3329 trial O
sent3329 of O
sent3329 hdIVIg T
sent3329 as O
sent3329 adjunctive O
sent3329 therapy O
sent3329 in O
sent3329 patients O
sent3329 with O
sent3329 dermatomyositis D
sent3329 , O
sent3329 which O
sent3329 documented O
sent3329 a O
sent3329 significant O
sent3329 benefit O
sent3330 We O
sent3330 describe O
sent3330 a O
sent3330 technique O
sent3330 that O
sent3330 enables O
sent3330 the O
sent3330 autologous T
sent3330 repair T
sent3330 of O
sent3330 large D
sent3330 midline D
sent3330 incisional D
sent3330 hernias D
sent3330 by O
sent3330 restoring O
sent3330 the O
sent3330 functional O
sent3330 musculoaponeurotic O
sent3330 support O
sent3330 of O
sent3330 the O
sent3330 abdominal O
sent3330 wall O
sent3331 OBJECTIVE O
sent3331 AND O
sent3331 IMPORTANCE O
sent3331 : O
sent3331 The O
sent3331 use O
sent3331 of O
sent3331 chronic T
sent3331 intrathecal T
sent3331 morphine T
sent3331 for O
sent3331 the O
sent3331 treatment O
sent3331 of O
sent3331 intractable D
sent3331 , D
sent3331 nonmalignant D
sent3331 pain D
sent3331 is O
sent3331 becoming O
sent3331 more O
sent3331 prevalent O
sent3332 METHODS O
sent3332 : O
sent3332 During O
sent3332 a O
sent3332 19-month O
sent3332 period O
sent3332 , O
sent3332 seven O
sent3332 children O
sent3332 with O
sent3332 empyema D
sent3332 underwent O
sent3332 thoracoscopy T
sent3333 < O
sent3333 TO_SEE O
sent3333 > O
sent3333 We O
sent3333 describe O
sent3333 a O
sent3333 patient O
sent3333 with O
sent3333 left D
sent3333 cardiac D
sent3333 herniation D
sent3333 presenting O
sent3333 after O
sent3333 intrapericardial T
sent3333 pulmonectomy T
sent3333 for O
sent3333 primary D
sent3333 lung D
sent3333 cancer D
sent3334 The O
sent3334 growing O
sent3334 use O
sent3334 of O
sent3334 automated T
sent3334 night-time T
sent3334 dialysis T
sent3334 ( T
sent3334 APD T
sent3334 ) T
sent3334 in O
sent3334 peritoneal D
sent3334 dialysis D
sent3334 over O
sent3334 the O
sent3334 last O
sent3334 few O
sent3334 years O
sent3334 shows O
sent3334 that O
sent3334 this O
sent3334 method O
sent3334 represents O
sent3334 a O
sent3334 valid O
sent3334 alternative O
sent3334 to O
sent3334 continuous T
sent3334 ambulatory T
sent3334 peritoneal T
sent3334 dialysis T
sent3334 ( T
sent3334 CAPD T
sent3334 ) T
sent3335 La O
sent3335 Serna O
sent3335 et O
sent3335 al O
sent3335 . O
sent3335 ( O
sent3335 Lancet O
sent3335 1987 O
sent3335 ; O
sent3335 26 O
sent3335 : O
sent3335 1517 O
sent3335 ) O
sent3335 were O
sent3335 the O
sent3335 first O
sent3335 to O
sent3335 treat O
sent3335 adults O
sent3335 with O
sent3335 recurrent D
sent3335 pericarditis D
sent3335 with O
sent3335 colchicine T
sent3335 , O
sent3335 and O
sent3335 were O
sent3335 followed O
sent3335 by O
sent3335 other O
sent3335 authors O
sent3336 While O
sent3336 these O
sent3336 findings O
sent3336 are O
sent3336 observed O
sent3336 for O
sent3336 all O
sent3336 classes O
sent3336 of O
sent3336 oral O
sent3336 drugs O
sent3336 , O
sent3336 the O
sent3336 issue O
sent3336 is O
sent3336 especially O
sent3336 critical O
sent3336 for O
sent3336 cancer D
sent3336 chemotherapy T
sent3336 , O
sent3336 in O
sent3336 which O
sent3336 a O
sent3336 narrow O
sent3336 therapeutic O
sent3336 index O
sent3336 is O
sent3336 frequently O
sent3336 observed O
sent3337 Treatment O
sent3337 for O
sent3337 low-grade D
sent3337 NHL D
sent3337 during O
sent3337 the O
sent3337 past O
sent3337 30 O
sent3337 yr O
sent3337 has O
sent3337 consisted O
sent3337 of O
sent3337 high-dose T
sent3337 radiation T
sent3337 and O
sent3337 cytotoxic T
sent3337 agents T
sent3337 , O
sent3337 administered O
sent3337 alone O
sent3337 or O
sent3337 in O
sent3337 combination O
sent3337 , O
sent3337 and O
sent3337 high-dose T
sent3337 therapy T
sent3337 with T
sent3337 stem T
sent3337 cell T
sent3337 transplant T
sent3338 However O
sent3338 , O
sent3338 recent O
sent3338 clinical O
sent3338 use O
sent3338 of O
sent3338 monoclonal T
sent3338 antibodies T
sent3338 ( T
sent3338 mAbs T
sent3338 ) T
sent3338 in O
sent3338 patients O
sent3338 with O
sent3338 low-grade D
sent3338 or D
sent3338 transformed D
sent3338 low-grade D
sent3338 NHL D
sent3338 has O
sent3338 resulted O
sent3338 in O
sent3338 less O
sent3338 toxicity O
sent3338 than O
sent3338 conventional O
sent3338 treatments O
sent3338 , O
sent3338 as O
sent3338 well O
sent3338 as O
sent3338 response O
sent3338 rates O
sent3338 that O
sent3338 are O
sent3338 comparable O
sent3338 or O
sent3338 superior O
sent3338 to O
sent3338 those O
sent3338 achieved O
sent3338 with O
sent3338 chemotherapy T
sent3339 Therefore O
sent3339 , O
sent3339 interest O
sent3339 is O
sent3339 growing O
sent3339 in O
sent3339 mAbs T
sent3339 as O
sent3339 therapeutic O
sent3339 alternatives O
sent3339 for O
sent3339 patients O
sent3339 with O
sent3339 low-grade D
sent3339 NHL D
sent3339 and O
sent3339 those O
sent3339 with O
sent3339 transformed O
sent3339 histology O
sent3340 CONCLUSION O
sent3340 : O
sent3340 The O
sent3340 treatment O
sent3340 paradigm O
sent3340 for O
sent3340 NHL D
sent3340 is O
sent3340 expected O
sent3340 to O
sent3340 change O
sent3340 over O
sent3340 the O
sent3340 next O
sent3340 few O
sent3340 years O
sent3340 to O
sent3340 include O
sent3340 radiolabeled T
sent3340 mAbs T
sent3340 , O
sent3340 administered O
sent3340 alone O
sent3340 or O
sent3340 in O
sent3340 combination O
sent3340 with O
sent3340 cytotoxic T
sent3340 agents T
sent3341 RESULTS O
sent3341 : O
sent3341 Clinical O
sent3341 trials O
sent3341 of O
sent3341 UFT T
sent3341 published O
sent3341 in O
sent3341 the O
sent3341 Western O
sent3341 world O
sent3341 have O
sent3341 included O
sent3341 581 O
sent3341 patients O
sent3341 with O
sent3341 colorectal D
sent3341 cancer D
sent3342 The O
sent3342 activity O
sent3342 of O
sent3342 oral T
sent3342 UFT T
sent3342 in O
sent3342 large-bowel D
sent3342 cancer D
sent3342 when O
sent3342 administered O
sent3342 with O
sent3342 oral T
sent3342 LV T
sent3342 ( O
sent3342 approximately O
sent3342 50 O
sent3342 mg/dose O
sent3342 ) O
sent3342 has O
sent3342 resulted O
sent3342 in O
sent3342 objective O
sent3342 response O
sent3342 rates O
sent3342 of O
sent3342 approximately O
sent3342 40 O
sent3342 % O
sent3343 CONCLUSION O
sent3343 : O
sent3343 UFT T
sent3343 is O
sent3343 a O
sent3343 fluoropyrimidine T
sent3343 active O
sent3343 in O
sent3343 colorectal D
sent3343 cancer D
sent3344 BACKGROUND O
sent3344 : O
sent3344 Adrenalectomy T
sent3344 is O
sent3344 the O
sent3344 current O
sent3344 treatment O
sent3344 for O
sent3344 phaeochromocytoma D
sent3345 CONCLUSION O
sent3345 : O
sent3345 Adrenal-sparing T
sent3345 surgery T
sent3345 is O
sent3345 safe O
sent3345 and O
sent3345 effective O
sent3345 , O
sent3345 and O
sent3345 may O
sent3345 become O
sent3345 the O
sent3345 treatment O
sent3345 of O
sent3345 choice O
sent3345 in O
sent3345 patients O
sent3345 with O
sent3345 hereditary D
sent3345 phaeochromocytoma D
sent3346 < O
sent3346 TO_SEE O
sent3346 > O
sent3346 PURPOSE O
sent3346 : O
sent3346 The O
sent3346 purposes O
sent3346 of O
sent3346 this O
sent3346 descriptive O
sent3346 , O
sent3346 longitudinal O
sent3346 study O
sent3346 were O
sent3346 to O
sent3346 evaluate O
sent3346 the O
sent3346 MacDibbs O
sent3346 Mouth O
sent3346 Assessment O
sent3346 instrument O
sent3346 for O
sent3346 the O
sent3346 assessment O
sent3346 of O
sent3346 mucositis O
sent3346 in O
sent3346 the O
sent3346 radiation T
sent3346 therapy T
sent3346 patient O
sent3346 being O
sent3346 treated O
sent3346 for O
sent3346 head D
sent3346 and D
sent3346 neck D
sent3346 cancer D
sent3346 and O
sent3346 to O
sent3346 describe O
sent3346 the O
sent3346 course O
sent3346 of O
sent3346 radiation-induced D
sent3346 mucositis D
sent3346 in O
sent3346 these O
sent3346 patients O
sent3347 < O
sent3347 TO_SEE O
sent3347 > O
sent3347 As O
sent3347 concomitant D
sent3347 thrombocytosis D
sent3347 persisted O
sent3347 despite O
sent3347 treatment O
sent3347 with O
sent3347 hydroxyurea T
sent3347 , O
sent3347 the O
sent3347 new O
sent3347 megakaryocyte T
sent3347 inhibitor T
sent3347 anagrelide T
sent3347 ( T
sent3347 Agrelin T
sent3347 ) T
sent3347 was O
sent3347 administered O
sent3347 and O
sent3347 led O
sent3347 to O
sent3347 normalization O
sent3347 of O
sent3347 the O
sent3347 platelet O
sent3347 count O
sent3347 within O
sent3347 11 O
sent3347 days O
sent3348 Background O
sent3348 : O
sent3348 Troglitazone T
sent3348 is O
sent3348 a O
sent3348 new O
sent3348 drug O
sent3348 for O
sent3348 the O
sent3348 treatment O
sent3348 of O
sent3348 type D
sent3348 2 D
sent3348 diabetes D
sent3349 < O
sent3349 TO_SEE O
sent3349 > O
sent3349 For O
sent3349 a O
sent3349 subset O
sent3349 of O
sent3349 patients O
sent3349 with O
sent3349 Kaposi D
sent3349 's D
sent3349 sarcoma D
sent3349 who O
sent3349 were O
sent3349 treated O
sent3349 with O
sent3349 recombinant T
sent3349 interferon T
sent3349 alfa-2a T
sent3349 , O
sent3349 the O
sent3349 disease O
sent3349 is O
sent3349 in O
sent3349 complete O
sent3349 remission O
sent3349 , O
sent3349 without O
sent3349 opportunistic D
sent3349 infection D
sent3349 , O
sent3349 and O
sent3349 they O
sent3349 appear O
sent3349 to O
sent3349 be O
sent3349 culture-negative O
sent3349 for O
sent3349 the O
sent3349 etiologic O
sent3349 retrovirus O
sent3349 that O
sent3349 causes O
sent3349 their O
sent3349 immune D
sent3349 deficiency D
sent3350 Interferon T
sent3350 alfa-2a T
sent3350 appears O
sent3350 to O
sent3350 have O
sent3350 antineoplastic O
sent3350 efficacy O
sent3350 , O
sent3350 ( O
sent3350 and O
sent3350 may O
sent3350 have O
sent3350 antiretroviral O
sent3350 efficacy O
sent3350 as O
sent3350 well O
sent3350 ) O
sent3350 in O
sent3350 this O
sent3350 epidemic O
sent3350 neoplasm D
sent3351 In O
sent3351 three O
sent3351 consecutive O
sent3351 Phase O
sent3351 II O
sent3351 trials O
sent3351 of O
sent3351 recombinant T
sent3351 interferon T
sent3351 alfa-2a T
sent3351 ( O
sent3351 rIFN O
sent3351 alfa-2a O
sent3351 ; O
sent3351 Roferon-A O
sent3351 Hoffmann-La O
sent3351 Roche O
sent3351 , O
sent3351 Nutley O
sent3351 , O
sent3351 NJ O
sent3351 ) O
sent3351 involving O
sent3351 96 O
sent3351 patients O
sent3351 with O
sent3351 advanced D
sent3351 malignant D
sent3351 melanoma D
sent3351 , O
sent3351 an O
sent3351 overall O
sent3351 response O
sent3351 rate O
sent3351 of O
sent3351 22 O
sent3351 % O
sent3351 was O
sent3351 observed O
sent3352 As O
sent3352 single O
sent3352 agent O
sent3352 therapy O
sent3352 in O
sent3352 malignant D
sent3352 melanoma D
sent3352 , O
sent3352 interferon T
sent3352 alfa-2a T
sent3352 was O
sent3352 only O
sent3352 marginally O
sent3352 useful O
sent3352 in O
sent3352 most O
sent3352 patients O
sent3353 Studies O
sent3353 with O
sent3353 various O
sent3353 interferon T
sent3353 alpha T
sent3353 preparations T
sent3353 , O
sent3353 including O
sent3353 interferons T
sent3353 induced O
sent3353 in O
sent3353 human O
sent3353 leukocytes O
sent3353 , O
sent3353 interferon T
sent3353 alfa-N1 T
sent3353 , O
sent3353 interferon T
sent3353 alfa-2a T
sent3353 , O
sent3353 and O
sent3353 interferon T
sent3353 alfa-2b T
sent3353 , O
sent3353 have O
sent3353 all O
sent3353 provided O
sent3353 evidence O
sent3353 for O
sent3353 modest O
sent3353 but O
sent3353 reproducible O
sent3353 antitumor O
sent3353 activity O
sent3353 in O
sent3353 advanced D
sent3353 renal D
sent3353 cell D
sent3353 carcinoma D
sent3354 Preliminary O
sent3354 evidence O
sent3354 suggests O
sent3354 that O
sent3354 interferons T
sent3354 beta T
sent3354 and T
sent3354 gamma T
sent3354 may O
sent3354 also O
sent3354 induce O
sent3354 regression O
sent3354 of O
sent3354 metastatic D
sent3354 renal D
sent3354 cell D
sent3354 carcinoma D
sent3355 The O
sent3355 rationale O
sent3355 for O
sent3355 antileukemic T
sent3355 therapy T
sent3355 in O
sent3355 hairy D
sent3355 cell D
sent3355 leukemia D
sent3355 is O
sent3355 to O
sent3355 reduce O
sent3355 the O
sent3355 significant O
sent3355 risk O
sent3355 of O
sent3355 infection O
sent3355 and O
sent3355 other O
sent3355 potential O
sent3355 serious O
sent3355 complications O
sent3356 Splenectomy T
sent3356 presumably O
sent3356 alleviates O
sent3356 the O
sent3356 pancytopenic O
sent3356 effect O
sent3356 of O
sent3356 hypersplenism D
sent3356 by O
sent3356 removing O
sent3356 the O
sent3356 preferred O
sent3356 site O
sent3356 of O
sent3356 leukemic O
sent3356 cell O
sent3356 proliferation O
sent3357 Recombinant O
sent3357 and O
sent3357 natural O
sent3357 forms O
sent3357 of O
sent3357 interferon T
sent3357 alpha T
sent3357 have O
sent3357 been O
sent3357 shown O
sent3357 to O
sent3357 bring O
sent3357 about O
sent3357 tumor O
sent3357 regressions O
sent3357 in O
sent3357 patients O
sent3357 with O
sent3357 low-grade D
sent3357 non-Hodgkin D
sent3357 's D
sent3357 lymphoma D
sent3358 Current O
sent3358 studies O
sent3358 using O
sent3358 interferon T
sent3358 in O
sent3358 patients O
sent3358 with O
sent3358 low-grade D
sent3358 non-Hodgkin D
sent3358 's D
sent3358 lymphomas D
sent3358 are O
sent3358 evaluating O
sent3358 lower O
sent3358 , O
sent3358 and O
sent3358 perhaps O
sent3358 better O
sent3358 tolerated O
sent3358 doses O
sent3358 of O
sent3358 interferon T
sent3359 This O
sent3359 approach O
sent3359 is O
sent3359 being O
sent3359 extended O
sent3359 to O
sent3359 the O
sent3359 clinic O
sent3359 , O
sent3359 and O
sent3359 trials O
sent3359 are O
sent3359 now O
sent3359 underway O
sent3359 evaluating O
sent3359 combinations O
sent3359 of O
sent3359 interferon T
sent3359 and O
sent3359 various O
sent3359 cytotoxic T
sent3359 drugs T
sent3359 known O
sent3359 from O
sent3359 previous O
sent3359 studies O
sent3359 to O
sent3359 be O
sent3359 active O
sent3359 in O
sent3359 patients O
sent3359 with O
sent3359 low-grade D
sent3359 non-Hodgkin D
sent3359 's D
sent3359 lymphomas D
sent3360 While O
sent3360 the O
sent3360 demonstrated O
sent3360 antiviral O
sent3360 , O
sent3360 antiproliferative O
sent3360 , O
sent3360 and O
sent3360 immunomodulatory O
sent3360 properties O
sent3360 of O
sent3360 interferons T
sent3360 have O
sent3360 led O
sent3360 to O
sent3360 a O
sent3360 number O
sent3360 of O
sent3360 theories O
sent3360 regarding O
sent3360 their O
sent3360 potential O
sent3360 use O
sent3360 in O
sent3360 treating O
sent3360 individuals O
sent3360 with O
sent3360 chronic D
sent3360 myelogenous D
sent3360 leukemia D
sent3360 ( D
sent3360 CML D
sent3360 ) D
sent3360 , O
sent3360 their O
sent3360 limited O
sent3360 availability O
sent3360 has O
sent3360 prevented O
sent3360 thorough O
sent3360 clinical O
sent3360 investigation O
sent3361 The O
sent3361 data O
sent3361 resulting O
sent3361 from O
sent3361 these O
sent3361 clinical O
sent3361 trials O
sent3361 indicate O
sent3361 that O
sent3361 interferon T
sent3361 alfa-2a T
sent3361 is O
sent3361 effective O
sent3361 in O
sent3361 inducing O
sent3361 hematologic O
sent3361 remissions O
sent3361 in O
sent3361 the O
sent3361 majority O
sent3361 of O
sent3361 minimally O
sent3361 treated O
sent3361 , O
sent3361 benign-phase D
sent3361 CML D
sent3361 , O
sent3361 Ph1-positive O
sent3361 patients O
sent3362 More O
sent3362 than O
sent3362 1600 O
sent3362 patients O
sent3362 with O
sent3362 neoplastic D
sent3362 disorders D
sent3362 have O
sent3362 received O
sent3362 recombinant T
sent3362 human T
sent3362 interferon T
sent3362 alfa-2a T
sent3362 ( T
sent3362 Roferon-A T
sent3362 , T
sent3362 Hoffmann-La T
sent3362 Roche T
sent3362 , T
sent3362 Nutley T
sent3362 , T
sent3362 NJ T
sent3362 ) T
sent3362 as O
sent3362 part O
sent3362 of O
sent3362 ongoing O
sent3362 or O
sent3362 completed O
sent3362 clinical O
sent3362 trials O
sent3363 PURPOSE O
sent3363 : O
sent3363 A O
sent3363 phase O
sent3363 I/II O
sent3363 trial O
sent3363 of O
sent3363 docetaxel T
sent3363 , O
sent3363 cisplatin T
sent3363 , O
sent3363 fluorouracil T
sent3363 ( T
sent3363 5-FU T
sent3363 ) T
sent3363 , O
sent3363 and O
sent3363 leucovorin T
sent3363 ( T
sent3363 TPFL5 T
sent3363 ) T
sent3363 induction T
sent3363 chemotherapy T
sent3363 for O
sent3363 patients O
sent3363 with O
sent3363 locally D
sent3363 advanced D
sent3363 squamous D
sent3363 cell D
sent3363 carcinoma D
sent3363 of D
sent3363 the D
sent3363 head D
sent3363 and D
sent3363 neck D
sent3363 ( D
sent3363 SCCHN D
sent3363 ) D
sent3364 PATIENTS O
sent3364 AND O
sent3364 METHODS O
sent3364 : O
sent3364 Twenty-three O
sent3364 previously O
sent3364 untreated O
sent3364 patients O
sent3364 with O
sent3364 stage D
sent3364 III D
sent3364 or D
sent3364 IV D
sent3364 SCCHN D
sent3364 and O
sent3364 Eastern O
sent3364 Cooperative O
sent3364 Oncology O
sent3364 Group O
sent3364 functional O
sent3364 status O
sent3364 less O
sent3364 than O
sent3364 or O
sent3364 equal O
sent3364 to O
sent3364 2 O
sent3364 were O
sent3364 treated O
sent3364 with O
sent3364 TPFL5 T
sent3365 Intrathecal T
sent3365 sufentanil T
sent3365 provides O
sent3365 approximately O
sent3365 2 O
sent3365 h O
sent3365 of O
sent3365 excellent O
sent3365 labor D
sent3365 analgesia O
sent3365 with O
sent3365 minimal O
sent3365 motor O
sent3365 blockade O
sent3366 OBJECTIVE O
sent3366 : O
sent3366 We O
sent3366 report O
sent3366 the O
sent3366 results O
sent3366 of O
sent3366 a O
sent3366 double-blind O
sent3366 , O
sent3366 double-dummy O
sent3366 , O
sent3366 active-control O
sent3366 study O
sent3366 designed O
sent3366 to O
sent3366 evaluate O
sent3366 the O
sent3366 efficacy O
sent3366 and O
sent3366 safety O
sent3366 of O
sent3366 lamotrigine T
sent3366 ( T
sent3366 LTG T
sent3366 ) T
sent3366 administered O
sent3366 as O
sent3366 monotherapy O
sent3366 to O
sent3366 adult O
sent3366 outpatients O
sent3366 with O
sent3366 partial D
sent3366 seizures D
sent3367 BACKGROUND O
sent3367 : O
sent3367 The O
sent3367 effectiveness O
sent3367 of O
sent3367 LTG T
sent3367 as O
sent3367 add-on O
sent3367 therapy O
sent3367 for O
sent3367 partial D
sent3367 seizures D
sent3367 in O
sent3367 adults O
sent3367 has O
sent3367 previously O
sent3367 been O
sent3367 established O
sent3368 CONCLUSIONS O
sent3368 : O
sent3368 We O
sent3368 conclude O
sent3368 that O
sent3368 LTG T
sent3368 is O
sent3368 effective O
sent3368 and O
sent3368 well O
sent3368 tolerated O
sent3368 when O
sent3368 administered O
sent3368 as O
sent3368 monotherapy O
sent3368 in O
sent3368 adult O
sent3368 patients O
sent3368 with O
sent3368 partial D
sent3368 seizures D
sent3369 BACKGROUND O
sent3369 : O
sent3369 Omega3 O
sent3369 fatty O
sent3369 acids O
sent3369 may O
sent3369 inhibit O
sent3369 neuronal O
sent3369 signal O
sent3369 transduction O
sent3369 pathways O
sent3369 in O
sent3369 a O
sent3369 manner O
sent3369 similar O
sent3369 to O
sent3369 that O
sent3369 of O
sent3369 lithium T
sent3369 carbonate T
sent3369 and O
sent3369 valproate T
sent3369 , O
sent3369 2 O
sent3369 effective O
sent3369 treatments O
sent3369 for O
sent3369 bipolar D
sent3369 disorder D
sent3370 The O
sent3370 present O
sent3370 study O
sent3370 was O
sent3370 performed O
sent3370 to O
sent3370 examine O
sent3370 whether O
sent3370 omega3 T
sent3370 fatty T
sent3370 acids T
sent3370 also O
sent3370 exhibit O
sent3370 mood-stabilizing O
sent3370 properties O
sent3370 in O
sent3370 bipolar D
sent3370 disorder D
sent3371 CONCLUSION O
sent3371 : O
sent3371 Omega3 T
sent3371 fatty T
sent3371 acids T
sent3371 were O
sent3371 well O
sent3371 tolerated O
sent3371 and O
sent3371 improved O
sent3371 the O
sent3371 short-term O
sent3371 course O
sent3371 of O
sent3371 illness O
sent3371 in O
sent3371 this O
sent3371 preliminary O
sent3371 study O
sent3371 of O
sent3371 patients O
sent3371 with O
sent3371 bipolar D
sent3371 disorder D
sent3372 Several O
sent3372 large-scale O
sent3372 trials O
sent3372 have O
sent3372 firmly O
sent3372 established O
sent3372 the O
sent3372 effectiveness O
sent3372 of O
sent3372 thrombolytic T
sent3372 therapy T
sent3372 , O
sent3372 beta T
sent3372 blockers T
sent3372 , O
sent3372 and O
sent3372 aspirin T
sent3372 in O
sent3372 the O
sent3372 treatment O
sent3372 of O
sent3372 AMI D
sent3373 < O
sent3373 TO_SEE O
sent3373 > O
sent3373 While O
sent3373 diastolic D
sent3373 left D
sent3373 ventricular D
sent3373 ( D
sent3373 LV D
sent3373 ) D
sent3373 dysfunction D
sent3373 is O
sent3373 frequent O
sent3373 and O
sent3373 associated O
sent3373 with O
sent3373 cardiovascular D
sent3373 complications D
sent3373 in O
sent3373 end-stage D
sent3373 renal D
sent3373 disease D
sent3373 treated O
sent3373 with O
sent3373 dialysis T
sent3373 , O
sent3373 controversial O
sent3373 information O
sent3373 exists O
sent3373 on O
sent3373 diastolic O
sent3373 LV O
sent3373 function O
sent3373 after O
sent3373 renal O
sent3373 transplantation O
sent3374 METHODS O
sent3374 : O
sent3374 Fluvastatin T
sent3374 40 O
sent3374 mg O
sent3374 daily O
sent3374 was O
sent3374 administered O
sent3374 to O
sent3374 25 O
sent3374 patients O
sent3374 with O
sent3374 hypercholesterolaemia D
sent3374 for O
sent3374 up O
sent3374 to O
sent3374 24 O
sent3374 weeks O
sent3375 The O
sent3375 inhibitory O
sent3375 effect O
sent3375 of O
sent3375 n-3 T
sent3375 polyunsaturated T
sent3375 fatty T
sent3375 acids T
sent3375 on O
sent3375 human D
sent3375 colorectal D
sent3375 cancer D
sent3375 has O
sent3375 been O
sent3375 speculated O
sent3375 on O
sent3375 from O
sent3375 epidemiological O
sent3375 data O
sent3375 and O
sent3375 animal O
sent3375 studies O
sent3376 We O
sent3376 conducted O
sent3376 a O
sent3376 long-term O
sent3376 trial O
sent3376 of O
sent3376 docosahexanoic T
sent3376 acid T
sent3376 ( T
sent3376 DHA T
sent3376 ) T
sent3376 -concentrated T
sent3376 fish T
sent3376 oil T
sent3376 capsules T
sent3376 for O
sent3376 patients O
sent3376 in O
sent3376 a O
sent3376 high-risk O
sent3376 group O
sent3376 for O
sent3376 colorectal D
sent3376 cancer D
sent3377 Three O
sent3377 patients O
sent3377 with O
sent3377 FAP D
sent3377 and O
sent3377 two O
sent3377 patients O
sent3377 with O
sent3377 multiple O
sent3377 ( O
sent3377 more O
sent3377 than O
sent3377 30 O
sent3377 ) O
sent3377 colorectal D
sent3377 polyps D
sent3377 were O
sent3377 administered O
sent3377 DHA-concentrated T
sent3377 fish T
sent3377 oil T
sent3377 capsules_Hlk427554600 T
sent3377 ( T
sent3377 2.2 T
sent3377 g T
sent3377 of T
sent3377 DHA T
sent3377 and T
sent3377 0.6 T
sent3377 g T
sent3377 of T
sent3377 eicosapentanoic T
sent3377 acid T
sent3377 ( T
sent3377 EPA T
sent3377 ) T
sent3377 per T
sent3377 day T
sent3377 ) T
sent3377 for O
sent3377 one O
sent3377 or O
sent3377 two O
sent3377 years O
sent3378 This O
sent3378 article O
sent3378 reviews O
sent3378 current O
sent3378 trends O
sent3378 in O
sent3378 management O
sent3378 of O
sent3378 esophageal D
sent3378 achalasia D
sent3378 , O
sent3378 highlighting O
sent3378 short-term O
sent3378 outcome O
sent3378 and O
sent3378 cost O
sent3378 comparisons O
sent3378 of O
sent3378 three O
sent3378 treatments O
sent3378 : O
sent3378 botulinum T
sent3378 toxin T
sent3378 injection T
sent3378 , O
sent3378 pneumatic T
sent3378 dilation T
sent3378 , O
sent3378 and O
sent3378 laparoscopic T
sent3378 myotomy T
sent3379 The O
sent3379 clinical O
sent3379 application O
sent3379 of O
sent3379 therapeutic T
sent3379 hysteroscopy T
sent3379 , O
sent3379 mainly O
sent3379 in O
sent3379 the O
sent3379 field O
sent3379 of O
sent3379 the O
sent3379 treatment O
sent3379 of O
sent3379 abnormal D
sent3379 uterine D
sent3379 bleeding D
sent3379 , O
sent3379 started O
sent3379 in O
sent3379 the O
sent3379 1980s O
sent3380 < O
sent3380 TO_SEE O
sent3380 > O
sent3380 In O
sent3380 this O
sent3380 article O
sent3380 , O
sent3380 evidence O
sent3380 of O
sent3380 effectiveness O
sent3380 and O
sent3380 cost-effectiveness O
sent3380 of O
sent3380 the O
sent3380 following O
sent3380 procedures O
sent3380 is O
sent3380 reviewed O
sent3380 : O
sent3380 ( O
sent3380 1 O
sent3380 ) O
sent3380 laser T
sent3380 treatment T
sent3380 of O
sent3380 bladder D
sent3380 tumors D
sent3380 ; O
sent3380 ( O
sent3380 2 O
sent3380 ) O
sent3380 extracorporeal O
sent3380 shock-wave O
sent3380 lithotripsy O
sent3380 and O
sent3380 percutaneous O
sent3380 nephrolithotomy O
sent3380 ; O
sent3380 ( O
sent3380 3 O
sent3380 ) O
sent3380 laparoscopic T
sent3380 treatment T
sent3380 of O
sent3380 endometriosis D
sent3380 ; O
sent3380 ( O
sent3380 4 O
sent3380 ) O
sent3380 laparoscopic T
sent3380 removal T
sent3380 of O
sent3380 ovarian D
sent3380 cysts D
sent3380 ; O
sent3380 ( O
sent3380 5 O
sent3380 ) O
sent3380 laparoscopic O
sent3380 cholecystectomy O
sent3380 ; O
sent3380 ( O
sent3380 6 O
sent3380 ) O
sent3380 laparoscopic O
sent3380 appendectomy O
sent3380 ; O
sent3380 ( O
sent3380 7 O
sent3380 ) O
sent3380 catheter T
sent3380 treatment T
sent3380 of O
sent3380 coronary D
sent3380 artery D
sent3380 disease D
sent3380 ; O
sent3380 ( O
sent3380 8 O
sent3380 ) O
sent3380 palliation O
sent3380 of O
sent3380 colon O
sent3380 cancer O
sent3380 by O
sent3380 endoscopic O
sent3380 intervention O
sent3380 ; O
sent3380 ( O
sent3380 9 O
sent3380 ) O
sent3380 treatment O
sent3380 of O
sent3380 upper D
sent3380 gastrointestinal D
sent3380 ( D
sent3380 UGI D
sent3380 ) D
sent3380 bleeding D
sent3380 by O
sent3380 endoscopic T
sent3380 intervention T
sent3380 ; O
sent3380 and O
sent3380 ( O
sent3380 10 O
sent3380 ) O
sent3380 arthroscopic O
sent3380 knee O
sent3380 surgery O
sent3381 Gene T
sent3381 therapy T
sent3381 of O
sent3381 malignant D
sent3381 brain D
sent3381 tumors D
sent3382 Treatment O
sent3382 of O
sent3382 irritable D
sent3382 bowel D
sent3382 syndrome D
sent3382 with O
sent3382 Chinese T
sent3382 herbal T
sent3382 medicine T
sent3382 : O
sent3382 a O
sent3382 randomized O
sent3382 controlled O
sent3382 trial O
sent3383 Randomised O
sent3383 trial O
sent3383 of O
sent3383 interferon T
sent3383 alpha2b T
sent3383 plus T
sent3383 ribavirin T
sent3383 for O
sent3383 48 O
sent3383 weeks O
sent3383 or O
sent3383 for O
sent3383 24 O
sent3383 weeks O
sent3383 versus O
sent3383 interferon T
sent3383 alpha2b T
sent3383 plus T
sent3383 placebo T
sent3383 for O
sent3383 48 O
sent3383 weeks O
sent3383 for O
sent3383 treatment O
sent3383 of O
sent3383 chronic D
sent3383 infection D
sent3383 with D
sent3383 hepatitis D
sent3383 C D
sent3383 virus D
sent3384 Low-molecular-weight T
sent3384 heparin T
sent3384 for O
sent3384 immediate O
sent3384 management O
sent3384 of O
sent3384 thromboembolic D
sent3384 disease D
sent3384 in O
sent3384 pregnancy O
sent3385 Tubularized T
sent3385 incised T
sent3385 plate T
sent3385 hypospadias T
sent3385 repair T
sent3385 for O
sent3385 proximal D
sent3385 hypospadias D
sent3386 Comparison O
sent3386 of O
sent3386 radical T
sent3386 prostatectomy T
sent3386 and O
sent3386 iodine T
sent3386 125 T
sent3386 interstitial T
sent3386 radiotherapy T
sent3386 for O
sent3386 the O
sent3386 treatment O
sent3386 of O
sent3386 clinically D
sent3386 localized D
sent3386 prostate D
sent3386 cancer D
sent3386 : O
sent3386 a O
sent3386 7-year O
sent3386 biochemical O
sent3386 ( O
sent3386 PSA O
sent3386 ) O
sent3386 progression O
sent3386 analysis O
sent3387 The O
sent3387 effectiveness O
sent3387 of O
sent3387 acupuncture T
sent3387 in O
sent3387 treating O
sent3387 acute D
sent3387 dental D
sent3387 pain D
sent3387 : O
sent3387 a O
sent3387 systematic O
sent3387 review O
sent3388 Correction O
sent3388 of O
sent3388 cardiac D
sent3388 defects D
sent3388 through O
sent3388 a O
sent3388 right T
sent3388 thoracotomy T
sent3388 in O
sent3388 children O
sent3389 New O
sent3389 technique O
sent3389 for O
sent3389 mesh T
sent3389 repair T
sent3389 of O
sent3389 paracolostomy D
sent3389 hernias D
sent3390 Immunotherapy T
sent3390 of O
sent3390 tumors D
sent3390 with O
sent3390 autologous T
sent3390 tumor-derived T
sent3390 heat T
sent3390 shock T
sent3390 protein T
sent3390 preparations T
sent3391 Comprehensive T
sent3391 modified T
sent3391 diet T
sent3391 simplifies O
sent3391 nutrition T
sent3391 management T
sent3391 of O
sent3391 adults O
sent3391 with O
sent3391 short-bowel D
sent3391 syndrome D
sent3392 Extended O
sent3392 use O
sent3392 of O
sent3392 glatiramer T
sent3392 acetate T
sent3392 ( T
sent3392 Copaxone T
sent3392 ) T
sent3392 is O
sent3392 well O
sent3392 tolerated O
sent3392 and O
sent3392 maintains O
sent3392 its O
sent3392 clinical O
sent3392 effect O
sent3392 on O
sent3392 multiple D
sent3392 sclerosis D
sent3392 relapse O
sent3392 rate O
sent3392 and O
sent3392 degree O
sent3392 of O
sent3392 disability O
sent3393 European O
sent3393 register O
sent3393 of O
sent3393 patients O
sent3393 with O
sent3393 sickle D
sent3393 cell D
sent3393 disease D
sent3393 treated O
sent3393 with O
sent3393 hydroxyurea T
sent3393 is O
sent3393 being O
sent3393 set O
sent3393 up O
sent3394 Understanding O
sent3394 the O
sent3394 culture O
sent3394 of O
sent3394 prescribing O
sent3394 : O
sent3394 qualitative O
sent3394 study O
sent3394 of O
sent3394 general O
sent3394 practitioners O
sent3394 ' O
sent3394 and O
sent3394 patients O
sent3394 ' O
sent3394 perceptions O
sent3394 of O
sent3394 antibiotics T
sent3394 for O
sent3394 sore D
sent3394 throats D
sent3395 Steroid T
sent3395 delivery T
sent3395 in O
sent3395 croup D
sent3396 Haematoma T
sent3396 block T
sent3396 versus O
sent3396 intravenous T
sent3396 regional T
sent3396 anaesthesia T
sent3396 in O
sent3396 Colles D
sent3396 ' D
sent3396 fractures D
sent3397 Direct T
sent3397 percutaneous T
sent3397 transluminal T
sent3397 angioplasty T
sent3397 for O
sent3397 acute D
sent3397 middle D
sent3397 cerebral D
sent3397 artery D
sent3397 occlusion D
sent3398 Magnesium T
sent3398 sulphate T
sent3398 for O
sent3398 the O
sent3398 control O
sent3398 of O
sent3398 spasms D
sent3398 in D
sent3398 severe D
sent3398 tetanus D
sent3399 Protective O
sent3399 effect O
sent3399 of O
sent3399 pralidoxime T
sent3399 on O
sent3399 muscle D
sent3399 fiber D
sent3399 necrosis D
sent3399 induced O
sent3399 by O
sent3399 organophosphate O
sent3399 compounds O
sent3400 Assessment O
sent3400 of O
sent3400 atrioventricular T
sent3400 junction T
sent3400 ablation T
sent3400 and T
sent3400 VVIR T
sent3400 pacemaker T
sent3400 versus O
sent3400 pharmacological T
sent3400 treatment T
sent3400 in O
sent3400 patients O
sent3400 with O
sent3400 heart D
sent3400 failure D
sent3400 and D
sent3400 chronic D
sent3400 atrial D
sent3400 fibrillation D
sent3400 : O
sent3400 a O
sent3400 randomized O
sent3400 , O
sent3400 controlled O
sent3400 study O
sent3401 Statins T
sent3401 for O
sent3401 prevention O
sent3401 of O
sent3401 stroke D
sent3402 Repair O
sent3402 of O
sent3402 ventral D
sent3402 hernias D
sent3402 with O
sent3402 expanded T
sent3402 polytetrafluoroethylene T
sent3402 patch T
sent3403 Spinal T
sent3403 manipulation T
sent3403 in O
sent3403 the O
sent3403 treatment O
sent3403 of O
sent3403 episodic D
sent3403 tension-type D
sent3403 headache D
sent3403 : O
sent3403 a O
sent3403 randomized O
sent3403 controlled O
sent3403 trial O
sent3404 Successful O
sent3404 treatment O
sent3404 with O
sent3404 lamivudine T
sent3404 for O
sent3404 fulminant D
sent3404 reactivated D
sent3404 hepatitis D
sent3404 B D
sent3404 infectioN D
sent3404 following O
sent3404 intensive T
sent3404 therapy T
sent3404 for O
sent3404 high-grade D
sent3404 non-Hodgkin D
sent3404 's D
sent3404 lymphoma D
sent3405 Influence O
sent3405 of O
sent3405 treatment O
sent3405 delay O
sent3405 on O
sent3405 infarct O
sent3405 size O
sent3405 and O
sent3405 clinical O
sent3405 outcome O
sent3405 in O
sent3405 patients O
sent3405 with O
sent3405 acute D
sent3405 myocardial D
sent3405 infarction D
sent3405 treated O
sent3405 with O
sent3405 primary T
sent3405 angioplasty T
sent3406 Should O
sent3406 patients O
sent3406 with O
sent3406 advanced D
sent3406 sarcomas D
sent3406 be O
sent3406 treated O
sent3406 with O
sent3406 chemotherapy T
sent3406 ? O
sent3407 Plasma T
sent3407 exchange T
sent3407 and T
sent3407 tacrolimus-mycophenolate T
sent3407 rescue T
sent3407 for O
sent3407 acute D
sent3407 humoral D
sent3407 rejection D
sent3407 in O
sent3407 kidney O
sent3407 transplantation O
sent3408 Hyperbaric T
sent3408 oxygen T
sent3408 therapy T
sent3408 for O
sent3408 children O
sent3408 with O
sent3408 cerebral D
sent3408 palsy D
sent3409 Endoscopic T
sent3409 excision T
sent3409 of O
sent3409 a D
sent3409 forehead D
sent3409 mass D
sent3410 Effect O
sent3410 of O
sent3410 photodynamic T
sent3410 therapy T
sent3410 in T
sent3410 combination T
sent3410 with T
sent3410 mitomycin T
sent3410 C T
sent3410 on O
sent3410 a O
sent3410 mitomycin-resistant D
sent3410 bladder D
sent3410 cancer D
sent3410 cell O
sent3410 line O
sent3411 Is O
sent3411 conservative T
sent3411 surgery T
sent3411 for O
sent3411 tubal D
sent3411 pregnancy D
sent3411 preferable O
sent3411 to O
sent3411 salpingectomy T
sent3411 ? O
sent3411 An O
sent3411 economic O
sent3411 analysis O
sent3412 Laparoscopic T
sent3412 cornuostomy T
sent3412 in O
sent3412 the O
sent3412 treatment O
sent3412 of O
sent3412 interstitial D
sent3412 pregnancy D
sent3412 with O
sent3412 subsequent O
sent3412 hysterosalpingography O
sent3413 Experimental O
sent3413 evaluation O
sent3413 of O
sent3413 the O
sent3413 use O
sent3413 of O
sent3413 recombinant T
sent3413 prourokinase T
sent3413 and O
sent3413 its O
sent3413 immobilized O
sent3413 forms O
sent3413 in O
sent3413 the O
sent3413 treatment O
sent3413 of O
sent3413 postoperative D
sent3413 fibrinoid D
sent3413 syndrome D
sent3413 in O
sent3413 ophthalmology O
sent3414 In O
sent3414 vitro O
sent3414 and O
sent3414 in O
sent3414 vivo O
sent3414 comparison O
sent3414 between O
sent3414 the O
sent3414 effects O
sent3414 of O
sent3414 treatment O
sent3414 with O
sent3414 adenosine T
sent3414 triphosphate T
sent3414 and O
sent3414 treatment O
sent3414 with O
sent3414 buthionine T
sent3414 sulfoximine T
sent3414 on O
sent3414 chemosensitization O
sent3414 and O
sent3414 tumour O
sent3414 growth O
sent3414 of O
sent3414 B16 D
sent3414 melanoma D
sent3415 Effects O
sent3415 of O
sent3415 transpupillary T
sent3415 thermotherapy T
sent3415 on O
sent3415 immunological O
sent3415 parameters O
sent3415 and O
sent3415 apoptosis O
sent3415 in O
sent3415 a O
sent3415 case O
sent3415 of O
sent3415 primary D
sent3415 uveal D
sent3415 melanoma D
sent3416 Is O
sent3416 there O
sent3416 a O
sent3416 rational O
sent3416 therapy O
sent3416 for O
sent3416 symptomatic O
sent3416 treatment O
sent3416 of O
sent3416 benign D
sent3416 prostatic D
sent3416 hyperplasia D
sent3416 with O
sent3416 phytogenic T
sent3416 drugs T
sent3416 ? O
sent3416 Illustrated O
sent3416 with O
sent3416 the O
sent3416 example O
sent3416 of O
sent3416 the O
sent3416 prostate O
sent3416 agent O
sent3416 from O
sent3416 Serenoa O
sent3416 repens O
sent3416 ( O
sent3416 Sabal O
sent3416 fructus O
sent3416 ) O
sent3417 Pharmacological O
sent3417 and O
sent3417 clinical O
sent3417 effectiveness O
sent3417 of O
sent3417 a O
sent3417 fixed T
sent3417 phytogenic T
sent3417 combination T
sent3417 trembling T
sent3417 poplar T
sent3417 ( T
sent3417 Populus T
sent3417 tremula T
sent3417 ) T
sent3417 , T
sent3417 true T
sent3417 goldenrod T
sent3417 ( T
sent3417 Solidago T
sent3417 virgaurea T
sent3417 ) T
sent3417 and T
sent3417 ash T
sent3417 ( T
sent3417 Fraxinus T
sent3417 excelsior T
sent3417 ) T
sent3417 in O
sent3417 mild D
sent3417 to D
sent3417 moderate D
sent3417 rheumatic D
sent3417 complaints D
sent3418 Therapy O
sent3418 of O
sent3418 degenerative D
sent3418 diseases D
sent3418 of D
sent3418 the D
sent3418 musculoskeletal D
sent3418 system D
sent3418 with O
sent3418 South T
sent3418 African T
sent3418 devil T
sent3418 's T
sent3418 claw T
sent3418 ( T
sent3418 Harpagophytum T
sent3418 procumbens T
sent3418 DC T
sent3418 ) T
sent3419 Treatment O
sent3419 strategy O
sent3419 for O
sent3419 mucin-producing D
sent3419 intrahepatic D
sent3419 cholangiocarcinoma D
sent3419 : O
sent3419 value O
sent3419 of O
sent3419 percutaneous T
sent3419 transhepatic T
sent3419 biliary T
sent3419 drainage T
sent3419 and O
sent3419 cholangioscopy T
sent3420 Strategy O
sent3420 for O
sent3420 surgical T
sent3420 management T
sent3420 of O
sent3420 ileocolonic D
sent3420 anastomotic D
sent3420 recurrence D
sent3420 in D
sent3420 Crohn D
sent3420 's D
sent3420 disease D
sent3421 Nerve-sparing T
sent3421 surgery T
sent3421 for O
sent3421 advanced D
sent3421 rectal D
sent3421 cancer D
sent3421 patients O
sent3421 : O
sent3421 special O
sent3421 reference O
sent3421 to O
sent3421 Dukes O
sent3421 C O
sent3421 patients O
sent3422 Prognostic O
sent3422 factors O
sent3422 in O
sent3422 patients O
sent3422 with O
sent3422 locally O
sent3422 advanced O
sent3422 rectal D
sent3422 adenocarcinoma D
sent3422 treated O
sent3422 with O
sent3422 preoperative T
sent3422 radiotherapy T
sent3422 and O
sent3422 surgery T
sent3423 Current O
sent3423 surgical T
sent3423 therapy T
sent3423 for O
sent3423 bronchiectasis D
sent3424 Thoracic T
sent3424 surgery T
sent3424 for O
sent3424 hydatid D
sent3424 disease D
sent3425 Surgical T
sent3425 treatment T
sent3425 of O
sent3425 postpneumonic D
sent3425 empyema D
sent3426 Thoracoscopic T
sent3426 surgery T
sent3426 for O
sent3426 pulmonary D
sent3426 tuberculosis D
sent3427 Thoracoscopic T
sent3427 surgery T
sent3427 for O
sent3427 spontaneous D
sent3427 pneumothorax D
sent3428 Surgery T
sent3428 for O
sent3428 chronic D
sent3428 thromboembolic D
sent3428 pulmonary D
sent3428 hypertension D
sent3429 Transabdominal T
sent3429 extensive T
sent3429 esophagogastric T
sent3429 devascularization T
sent3429 with T
sent3429 gastroesophageal T
sent3429 stapling T
sent3429 for O
sent3429 management O
sent3429 of O
sent3429 noncirrhotic D
sent3429 portal D
sent3429 hypertension D
sent3429 : O
sent3429 long-term O
sent3429 results O
sent3430 Surgical T
sent3430 treatment T
sent3430 for O
sent3430 lung D
sent3430 hydatid D
sent3430 disease D
sent3431 Sliding T
sent3431 door T
sent3431 technique T
sent3431 for O
sent3431 the O
sent3431 repair O
sent3431 of O
sent3431 midline D
sent3431 incisional D
sent3431 hernias D
sent3432 One-lung T
sent3432 ventilation T
sent3432 in O
sent3432 patients O
sent3432 with O
sent3432 difficult D
sent3432 airways D
sent3433 Thoracoscopy T
sent3433 for O
sent3433 empyema D
sent3433 in O
sent3433 children O
sent3434 Sex O
sent3434 differences O
sent3434 in O
sent3434 the O
sent3434 use O
sent3434 of O
sent3434 asthma D
sent3434 drugs T
sent3434 : O
sent3434 cross O
sent3434 sectional O
sent3434 study O
sent3435 Conventional T
sent3435 treatments T
sent3435 for O
sent3435 non-Hodgkin D
sent3435 's D
sent3435 lymphoma D
sent3435 : O
sent3435 the O
sent3435 need O
sent3435 for O
sent3435 new O
sent3435 therapies O
sent3436 Adrenal-sparing T
sent3436 surgery T
sent3436 for O
sent3436 phaeochromocytoma D
sent3437 Antiplatelet T
sent3437 therapy T
sent3437 in O
sent3437 acute D
sent3437 cerebral D
sent3437 ischemia D
sent3438 Laugier-Hunziker D
sent3438 syndrome D
sent3438 : O
sent3438 case O
sent3438 report O
sent3438 and O
sent3438 treatment O
sent3438 with O
sent3438 the O
sent3438 Q-switched T
sent3438 Nd-Yag T
sent3438 laser T
sent3439 Thoracoscopic T
sent3439 operation T
sent3439 for O
sent3439 secondary D
sent3439 pneumothorax D
sent3439 under O
sent3439 local O
sent3439 and O
sent3439 epidural O
sent3439 anesthesia O
sent3439 in O
sent3439 high-risk O
sent3439 patients O
sent3440 Troglitazone-induced D
sent3440 hepatic D
sent3440 failure D
sent3440 leading O
sent3440 to O
sent3440 liver T
sent3440 transplantation T
sent3441 A O
sent3441 modified O
sent3441 technique O
sent3441 of O
sent3441 tubeless O
sent3441 anaesthesia O
sent3441 for O
sent3441 microlaryngoscopy T
sent3441 and T
sent3441 bronchoscopy T
sent3441 in O
sent3441 young O
sent3441 children O
sent3441 with O
sent3441 stridor D
sent3442 A O
sent3442 randomized O
sent3442 trial O
sent3442 of O
sent3442 Lactobacillus T
sent3442 acidophilus T
sent3442 BG2FO4 T
sent3442 to O
sent3442 treat O
sent3442 lactose D
sent3442 intolerance D
sent3443 Treatment O
sent3443 of O
sent3443 idiopathic D
sent3443 thrombopenic D
sent3443 purpura D
sent3443 in O
sent3443 adolescents O
sent3443 by O
sent3443 intravenous T
sent3443 immunoglobulin T
sent3444 Azithromycin T
sent3444 therapy T
sent3444 for O
sent3444 scrub D
sent3444 typhus D
sent3444 during O
sent3444 pregnancy O
sent3445 Excimer T
sent3445 laser T
sent3445 assisted T
sent3445 in T
sent3445 situ T
sent3445 keratomileusis T
sent3445 for O
sent3445 hyperopia D
sent3446 Three O
sent3446 consecutive O
sent3446 phase O
sent3446 II O
sent3446 studies O
sent3446 of O
sent3446 recombinant T
sent3446 interferon T
sent3446 alfa-2a T
sent3446 in O
sent3446 advanced D
sent3446 malignant D
sent3446 melanoma D
sent3447 Interferon T
sent3447 treatment T
sent3447 of O
sent3447 renal D
sent3447 cell D
sent3447 carcinoma D
sent3448 Current O
sent3448 and O
sent3448 future O
sent3448 uses O
sent3448 of O
sent3448 recombinant T
sent3448 interferon T
sent3448 alpha T
sent3448 in O
sent3448 the O
sent3448 treatment O
sent3448 of O
sent3448 low-grade D
sent3448 non-Hodgkin D
sent3448 's D
sent3448 lymphoma D
sent3449 Antimicrobial T
sent3449 treatment T
sent3449 options O
sent3449 in O
sent3449 the O
sent3449 management O
sent3449 of O
sent3449 odontogenic D
sent3449 infections D
sent3450 Recombinant T
sent3450 glycoprotein T
sent3450 vaccine T
sent3450 for O
sent3450 the O
sent3450 prevention O
sent3450 of O
sent3450 genital D
sent3450 HSV-2 D
sent3450 infection D
sent3450 : O
sent3450 two O
sent3450 randomized O
sent3450 controlled O
sent3450 trials O
sent3451 Induction T
sent3451 chemotherapy T
sent3451 with T
sent3451 docetaxel T
sent3451 , T
sent3451 cisplatin T
sent3451 , T
sent3451 fluorouracil T
sent3451 , T
sent3451 and T
sent3451 leucovorin T
sent3451 for O
sent3451 squamous D
sent3451 cell D
sent3451 carcinoma D
sent3451 of O
sent3451 the O
sent3451 head O
sent3451 and O
sent3451 neck O
sent3451 : O
sent3451 a O
sent3451 phase O
sent3451 I/II O
sent3451 trial O
sent3452 Low-dose T
sent3452 steroids T
sent3452 reduce O
sent3452 flu-like D
sent3452 symptoms D
sent3452 at O
sent3452 the O
sent3452 initiation O
sent3452 of O
sent3452 IFNbeta-1b O
sent3452 in O
sent3452 relapsing-remitting O
sent3452 MS O
sent3453 Study O
sent3453 of O
sent3453 three O
sent3453 different O
sent3453 doses O
sent3453 of O
sent3453 epidural T
sent3453 neostigmine T
sent3453 coadministered T
sent3453 with T
sent3453 lidocaine T
sent3453 for O
sent3453 postoperative D
sent3453 analgesia D
sent3454 An O
sent3454 active-control O
sent3454 trial O
sent3454 of O
sent3454 lamotrigine T
sent3454 monotherapy T
sent3454 for O
sent3454 partial D
sent3454 seizures D
sent3455 < O
sent3455 TO_SEE O
sent3455 > O
sent3455 Safety O
sent3455 of O
sent3455 intrathecal T
sent3455 sodium T
sent3455 nitroprusside T
sent3455 for O
sent3455 the O
sent3455 treatment O
sent3455 and O
sent3455 prevention O
sent3455 of O
sent3455 refractory D
sent3455 cerebral D
sent3455 vasospasm D
sent3455 and D
sent3455 ischemia D
sent3455 in O
sent3455 humans O
sent3456 The O
sent3456 effect O
sent3456 of O
sent3456 heliox T
sent3456 in O
sent3456 acute D
sent3456 severe D
sent3456 asthma D
sent3456 : O
sent3456 a O
sent3456 randomized O
sent3456 controlled O
sent3456 trial O
sent3456 . O
sent3457 Long-term O
sent3457 survival O
sent3457 of O
sent3457 patients O
sent3457 with O
sent3457 unresectable D
sent3457 colorectal D
sent3457 cancer D
sent3457 liver D
sent3457 metastases D
sent3457 following O
sent3457 infusional T
sent3457 chemotherapy T
sent3457 with T
sent3457 5-fluorouracil T
sent3457 , T
sent3457 leucovorin T
sent3457 , T
sent3457 oxaliplatin T
sent3457 and T
sent3457 surgery T
sent3458 < O
sent3458 TO_SEE O
sent3458 > O
sent3458 Fatal D
sent3458 acute D
sent3458 haemolysis D
sent3458 in O
sent3458 an O
sent3458 AIDS D
sent3458 patient O
sent3458 treated O
sent3458 with O
sent3458 lindinavir T
sent3459 A O
sent3459 simplified O
sent3459 laparoscopic T
sent3459 technique T
sent3459 for T
sent3459 mesh T
sent3459 placement T
sent3459 in O
sent3459 ventral D
sent3459 hernia D
sent3459 repair O
sent3460 Pharmacological T
sent3460 management T
sent3460 of O
sent3460 acute D
sent3460 myocardial D
sent3460 infarction D
sent3461 Mesenteric D
sent3461 venous D
sent3461 thrombosis D
sent3461 : O
sent3461 successful O
sent3461 treatment O
sent3461 by O
sent3461 intraarterial T
sent3461 lytic T
sent3461 therapy T
sent3462 Gene T
sent3462 therapy T
sent3462 for O
sent3462 myocardial D
sent3462 angiogenesis D
sent3463 Dipyridamole T
sent3463 plus T
sent3463 aspirin T
sent3463 in O
sent3463 cerebrovascular D
sent3463 disease D
sent3464 What O
sent3464 is O
sent3464 the O
sent3464 real O
sent3464 role O
sent3464 of O
sent3464 CD40 O
sent3464 in O
sent3464 cancer D
sent3464 immunotherapy T
sent3464 ? O
sent3465 The O
sent3465 effects O
sent3465 of O
sent3465 oral T
sent3465 liarozole T
sent3465 on O
sent3465 epidermal O
sent3465 proliferation O
sent3465 and O
sent3465 differentiation O
sent3465 in O
sent3465 severe D
sent3465 plaque D
sent3465 psoriasis D
sent3465 are O
sent3465 comparable O
sent3465 with O
sent3465 those O
sent3465 of O
sent3465 acitretin T
sent3465 . O
sent3466 Safety O
sent3466 and O
sent3466 potential O
sent3466 effectiveness O
sent3466 of O
sent3466 daunorubicin-containing T
sent3466 liposomes T
sent3466 in O
sent3466 patients O
sent3466 with O
sent3466 advanced D
sent3466 recurrent D
sent3466 malignant D
sent3466 CNS D
sent3466 tumors D
sent3467 An O
sent3467 experimental O
sent3467 application O
sent3467 of O
sent3467 gene T
sent3467 therapy T
sent3467 for O
sent3467 human D
sent3467 retinoblastoma D
sent3468 Acid T
sent3468 suppression T
sent3468 therapy T
sent3468 in O
sent3468 Barrett D
sent3468 's D
sent3468 esophagus D
sent3468 : O
sent3468 the O
sent3468 importance O
sent3468 of O
sent3468 pH O
sent3468 monitoring O
sent3469 Surgical T
sent3469 approaches T
sent3469 to O
sent3469 pediatric D
sent3469 defecatory D
sent3469 disorders D
sent3470 Lutein T
sent3470 improves O
sent3470 visual O
sent3470 function O
sent3470 in O
sent3470 some O
sent3470 patients O
sent3470 with O
sent3470 retinal D
sent3470 degeneration D
sent3470 : O
sent3470 a O
sent3470 pilot O
sent3470 study O
sent3470 via O
sent3470 the O
sent3470 Internet O
sent3471 Drug O
sent3471 information O
sent3471 questions O
sent3471 and O
sent3471 answers O
sent3471 : O
sent3471 new O
sent3471 for O
sent3471 psoriasis D
sent3471 : O
sent3471 colchicine T
sent3472 IPPB T
sent3472 in O
sent3472 severe D
sent3472 pulmonary D
sent3472 emphysema D
sent3472 : O
sent3472 limited O
sent3472 applications O
sent3473 Long-term O
sent3473 mortality O
sent3473 in O
sent3473 patients O
sent3473 after O
sent3473 a O
sent3473 British O
sent3473 trial O
sent3473 of O
sent3473 anticoagulants T
sent3473 in O
sent3473 acute D
sent3473 myocardial D
sent3473 infarction D
sent3474 Our O
sent3474 results O
sent3474 in O
sent3474 the O
sent3474 surgical T
sent3474 treatment T
sent3474 of O
sent3474 habitual D
sent3474 shoulder D
sent3474 dislocation D
sent3474 with O
sent3474 special O
sent3474 reference O
sent3474 to O
sent3474 occupational O
sent3474 disability O
sent3475 Alkaline O
sent3475 phosphatase O
sent3475 in O
sent3475 neutrophil O
sent3475 leukocytes O
sent3475 of O
sent3475 patients O
sent3475 with O
sent3475 infectious D
sent3475 mononucleosis D
sent3475 and O
sent3475 the O
sent3475 effect O
sent3475 of O
sent3475 corticosteroid T
sent3475 therapy T
sent3476 Surgical T
sent3476 treatment T
sent3476 of O
sent3476 uterine D
sent3476 cervix D
sent3476 insufficiency D
sent3476 during O
sent3476 the O
sent3476 2d O
sent3476 trimester O
sent3476 of O
sent3476 pregnancy O
sent3477 Physiologic T
sent3477 treatment T
sent3477 of O
sent3477 depressive D
sent3477 reactions D
sent3477 : O
sent3477 a O
sent3477 pilot O
sent3477 study O
sent3478 The O
sent3478 use O
sent3478 of O
sent3478 quinidine T
sent3478 sulphate T
sent3478 for O
sent3478 the O
sent3478 treatment O
sent3478 of O
sent3478 atrial D
sent3478 fibrillation D
sent3478 in O
sent3478 twelve O
sent3478 horses O
sent3479 Synergism O
sent3479 in O
sent3479 the O
sent3479 chemotherapy T
sent3479 of O
sent3479 Eimeria D
sent3479 infections D
sent3479 of O
sent3479 chicks O
sent3480 Treatment O
sent3480 of O
sent3480 hydrocele D
sent3480 and D
sent3480 cysts D
sent3480 of D
sent3480 the D
sent3480 epididymis D
sent3480 with O
sent3480 sclerosing T
sent3480 injections T
sent3480 of T
sent3480 quinine T
sent3480 and T
sent3480 urea T
sent3480 chlorhydrolactate T
sent3480 in O
sent3480 a O
sent3480 30 O
sent3480 per O
sent3480 cent O
sent3480 solution O
sent3481 The O
sent3481 single-place T
sent3481 caisson T
sent3481 in O
sent3481 the O
sent3481 treatment O
sent3481 of O
sent3481 decompression D
sent3481 accidents D
sent3482 Blood O
sent3482 volume O
sent3482 measurements O
sent3482 in O
sent3482 burn D
sent3482 therapy T
sent3483 Phenylbutazone T
sent3483 and O
sent3483 acute D
sent3483 leukemia D
sent3483 . O
sent3484 The O
sent3484 place O
sent3484 of O
sent3484 surgery T
sent3484 in O
sent3484 hypertrophic D
sent3484 obstructive D
sent3484 cardiomyopathy D
sent3484 ( D
sent3484 idiopathic D
sent3484 hypertrophic D
sent3484 subaortic D
sent3484 stenosis D
sent3484 ) D
sent3485 The O
sent3485 treatment O
sent3485 of O
sent3485 autoimmune D
sent3485 hemolytic D
sent3485 anemia D
sent3485 with O
sent3485 heparin T
sent3486 Effects O
sent3486 of O
sent3486 clomiphene T
sent3486 citrate T
sent3486 on O
sent3486 endometrial D
sent3486 hyperplasia D
sent3486 in O
sent3486 the O
sent3486 premenopausal O
sent3486 female O
sent3487 Prolonged O
sent3487 use O
sent3487 of O
sent3487 methyldopa T
sent3487 in O
sent3487 severe D
sent3487 hypertension D
sent3487 in O
sent3487 pregnancy O
sent3488 The O
sent3488 effects O
sent3488 of O
sent3488 social O
sent3488 class O
sent3488 and O
sent3488 friends O
sent3488 ' O
sent3488 expectations O
sent3488 on O
sent3488 oral O
sent3488 polio D
sent3488 vaccination T
sent3488 participation O
sent3489 Glutathione O
sent3489 S-transferase O
sent3489 activity O
sent3489 in O
sent3489 epithelial D
sent3489 ovarian D
sent3489 cancer D
sent3489 : O
sent3489 association O
sent3489 with O
sent3489 response O
sent3489 to O
sent3489 chemotherapy T
sent3489 and O
sent3489 disease O
sent3489 outcome O
sent3490 Interferon-alpha-2b T
sent3490 in O
sent3490 the O
sent3490 management O
sent3490 of O
sent3490 patients O
sent3490 with O
sent3490 relapsed O
sent3490 and/or O
sent3490 refractory O
sent3490 Hodgkin D
sent3490 's D
sent3490 disease D
sent3491 < O
sent3491 TO_SEE O
sent3491 > O
sent3491 Frontal D
sent3491 dysfunction D
sent3491 blocks O
sent3491 the O
sent3491 therapeutic O
sent3491 effect O
sent3491 of O
sent3491 THA T
sent3491 on O
sent3491 attention O
sent3491 in O
sent3491 Alzheimer D
sent3491 's D
sent3491 disease D
sent3492 Effects O
sent3492 of O
sent3492 clomipramine T
sent3492 on O
sent3492 plasma O
sent3492 amino O
sent3492 acids O
sent3492 and O
sent3492 serotonergic O
sent3492 parameters O
sent3492 in O
sent3492 panic D
sent3492 disorder D
sent3492 and D
sent3492 depression D
sent3492 . O
sent3493 Thalidomide T
sent3493 for O
sent3493 aphthous D
sent3493 ulcers D
sent3493 in O
sent3493 HIV D
sent3493 infection D
sent3494 Aspirin T
sent3494 therapy T
sent3494 in O
sent3494 diabetes D
sent3494 mellitus D
sent3495 Combined T
sent3495 pancreas-/kidney T
sent3495 transplantation T
sent3495 as O
sent3495 a O
sent3495 standard O
sent3495 procedure O
sent3495 in O
sent3495 therapy O
sent3495 of O
sent3495 kidney D
sent3495 failure D
sent3495 in D
sent3495 type D
sent3495 I D
sent3495 diabetic D
sent3495 patients D
sent3496 Corticosteroid T
sent3496 injections T
sent3496 for O
sent3496 sciatica D
sent3497 Flutamide T
sent3497 plus T
sent3497 castration T
sent3497 in O
sent3497 patients O
sent3497 with O
sent3497 previously O
sent3497 untreated O
sent3497 prostate D
sent3497 cancer D
sent3498 The O
sent3498 immediate O
sent3498 effectiveness O
sent3498 of O
sent3498 electrical T
sent3498 nerve T
sent3498 stimulation T
sent3498 and O
sent3498 electrical T
sent3498 muscle T
sent3498 stimulation T
sent3498 on O
sent3498 myofascial D
sent3498 trigger D
sent3498 points D
sent3499 In O
sent3499 vitro O
sent3499 radiation-induced O
sent3499 apoptosis O
sent3499 and O
sent3499 tumour O
sent3499 response O
sent3499 to O
sent3499 radiotherapy T
sent3499 : O
sent3499 a O
sent3499 prospective O
sent3499 study O
sent3499 in O
sent3499 patients O
sent3499 with O
sent3499 non-Hodgkin D
sent3499 lymphomas D
sent3499 treated O
sent3499 by O
sent3499 low-dose T
sent3499 irradiation T
sent3500 Drug T
sent3500 therapy T
sent3500 for O
sent3500 coronary D
sent3500 heart D
sent3500 disease D
sent3500 : O
sent3500 the O
sent3500 Sheffield O
sent3500 table O
sent3501 Percutaneous T
sent3501 drainage T
sent3501 of O
sent3501 hydatid D
sent3501 cysts D
sent3502 Surgery T
sent3502 for O
sent3502 ectopia D
sent3502 lentis D
sent3503 < O
sent3503 TO_SEE O
sent3503 > O
sent3503 Antiplatelet T
sent3503 therapy T
sent3503 to O
sent3503 prevent O
sent3503 stroke D
sent3503 : O
sent3503 risk O
sent3503 of O
sent3503 brain D
sent3503 hemorrhage D
sent3503 and O
sent3503 efficacy O
sent3503 in O
sent3503 atrial T
sent3503 fibrillation T
sent3504 High-dose T
sent3504 chemotherapy T
sent3504 with T
sent3504 autologous T
sent3504 hematopoietic T
sent3504 stem-cell T
sent3504 support T
sent3504 for O
sent3504 breast D
sent3504 cancer D
sent3504 in O
sent3504 North O
sent3504 America O
sent3505 Is O
sent3505 concomitant T
sent3505 radiotherapy T
sent3505 and T
sent3505 chemotherapy T
sent3505 superior O
sent3505 to O
sent3505 optimal O
sent3505 radiotherapy T
sent3505 alone O
sent3505 in O
sent3505 anal D
sent3505 cancer D
sent3505 ? O
sent3506 Standard T
sent3506 versus T
sent3506 high-dose T
sent3506 therapy T
sent3506 in O
sent3506 10+ O
sent3506 breast D
sent3506 cancer D
sent3507 Anal O
sent3507 continence O
sent3507 after O
sent3507 surgery T
sent3507 for O
sent3507 rectal D
sent3507 prolapse D
sent3508 Aspirin T
sent3508 therapy T
sent3508 for O
sent3508 cardiovascular D
sent3508 disease D
sent3509 Dosing O
sent3509 of O
sent3509 amoxicillin/clavulanate T
sent3509 for O
sent3509 treatment O
sent3509 of O
sent3509 lower D
sent3509 respiratory D
sent3509 tract D
sent3509 infection D
sent3510 Pharmacoeconomic O
sent3510 analysis O
sent3510 of O
sent3510 ampicillin-sulbactam T
sent3510 versus O
sent3510 cefoxitin T
sent3510 in O
sent3510 the O
sent3510 treatment O
sent3510 of O
sent3510 intraabdominal D
sent3510 infections D
sent3511 New T
sent3511 therapies T
sent3511 for O
sent3511 severe D
sent3511 meningococcal D
sent3511 disease D
sent3512 Another O
sent3512 potential O
sent3512 use O
sent3512 of O
sent3512 troglitazone T
sent3512 in O
sent3512 noninsulin-dependent D
sent3512 diabetes D
sent3512 mellitus D
sent3513 < O
sent3513 TO_SEE O
sent3513 > O
sent3513 Jaw D
sent3513 clenching D
sent3513 following O
sent3513 Gamma T
sent3513 Knife T
sent3513 treatment T
sent3513 for O
sent3513 trigeminal D
sent3513 neuralgia D
sent3514 The O
sent3514 protective O
sent3514 effect O
sent3514 of O
sent3514 condoms T
sent3514 and O
sent3514 nonoxynol-9 T
sent3514 against O
sent3514 HIV D
sent3514 infection D
sent3515 Evaluation O
sent3515 of O
sent3515 adjuvant T
sent3515 psychological T
sent3515 therapy T
sent3515 in O
sent3515 patients O
sent3515 with O
sent3515 testicular D
sent3515 cancer D
sent3515 : O
sent3515 randomised O
sent3515 controlled O
sent3515 trial O
sent3516 The O
sent3516 effect O
sent3516 of O
sent3516 an O
sent3516 endothelin-receptor T
sent3516 antagonist T
sent3516 , T
sent3516 bosentan T
sent3516 , O
sent3516 on O
sent3516 blood O
sent3516 pressure O
sent3516 in O
sent3516 patients O
sent3516 with O
sent3516 essential D
sent3516 hypertension D
sent3516 . O
sent3517 Guidelines O
sent3517 for O
sent3517 the O
sent3517 use O
sent3517 of O
sent3517 antiretroviral T
sent3517 agents T
sent3517 in O
sent3517 HIV D
sent3517 -infected O
sent3517 adults O
sent3517 and O
sent3517 adolescents O
sent3518 Long-term O
sent3518 therapy O
sent3518 with O
sent3518 long-acting T
sent3518 octreotide T
sent3518 ( T
sent3518 Sandostatin-LAR T
sent3518 ) T
sent3518 for O
sent3518 the O
sent3518 management O
sent3518 of O
sent3518 acromegaly D
sent3519 Are O
sent3519 ABVD T
sent3519 and O
sent3519 MOPP/ABV T
sent3519 truly O
sent3519 equivalent O
sent3519 for O
sent3519 treating O
sent3519 Hodgkin D
sent3519 's D
sent3519 disease D
sent3519 at O
sent3519 advanced O
sent3519 stages O
sent3519 ? O
sent3520 Paclitaxel T
sent3520 for O
sent3520 the O
sent3520 treatment O
sent3520 of O
sent3520 lymphoma D
sent3521 Montelukast T
sent3521 , T
sent3521 a T
sent3521 leukotriene-receptor T
sent3521 antagonist T
sent3521 , T
sent3521 for O
sent3521 the O
sent3521 treatment O
sent3521 of O
sent3521 mild D
sent3521 asthma D
sent3521 and D
sent3521 exercise-induced D
sent3521 bronchoconstriction D
sent3522 Atypical O
sent3522 antipsychotic T
sent3522 agents T
sent3522 in O
sent3522 the O
sent3522 treatment O
sent3522 of O
sent3522 Schizophrenia D
sent3522 and D
sent3522 other D
sent3522 psychiatric D
sent3522 disorders D
sent3523 Percutaneous T
sent3523 transluminal T
sent3523 angioplasty T
sent3523 in O
sent3523 the O
sent3523 treatment O
sent3523 of O
sent3523 renovascular D
sent3523 hypertension D
sent3523 : O
sent3523 sequential O
sent3523 prospective O
sent3523 study O
sent3524 Esophageal T
sent3524 intubation T
sent3524 for O
sent3524 palliative O
sent3524 treatment O
sent3524 in O
sent3524 advanced D
sent3524 carcinoma D
sent3524 of D
sent3524 the D
sent3524 esophagus D
sent3524 and D
sent3524 cardia D
sent3525 Pathological O
sent3525 staging O
sent3525 and O
sent3525 biochemical O
sent3525 recurrence O
sent3525 after O
sent3525 neoadjuvant T
sent3525 androgen T
sent3525 deprivation T
sent3525 therapy T
sent3525 in O
sent3525 combination O
sent3525 with O
sent3525 radical T
sent3525 prostatectomy T
sent3525 in O
sent3525 clinically O
sent3525 localized O
sent3525 prostate D
sent3525 cancer D
sent3526 How O
sent3526 often O
sent3526 does O
sent3526 surgery T
sent3526 for O
sent3526 peptic D
sent3526 ulceration D
sent3526 eradicate O
sent3526 Helicobacter O
sent3526 pylori O
sent3526 ? O
sent3526 Systematic O
sent3526 review O
sent3526 of O
sent3526 36 O
sent3526 studies O
sent3527 A O
sent3527 comparison O
sent3527 of O
sent3527 noninvasive T
sent3527 positive-pressure T
sent3527 ventilation T
sent3527 and O
sent3527 conventional T
sent3527 mechanical T
sent3527 ventilation T
sent3527 in O
sent3527 patients O
sent3527 with O
sent3527 acute D
sent3527 respiratory D
sent3527 failure D
sent3528 Long-term O
sent3528 safety O
sent3528 and O
sent3528 effectiveness O
sent3528 of O
sent3528 iron-chelation T
sent3528 therapy T
sent3528 with T
sent3528 deferiprone T
sent3528 for O
sent3528 thalassemia D
sent3528 major D
sent3529 Positron O
sent3529 emission O
sent3529 tomography O
sent3529 in O
sent3529 assessing O
sent3529 response O
sent3529 to O
sent3529 neoadjuvant T
sent3529 chemotherapy T
sent3529 for O
sent3529 non-small-cell D
sent3529 lung D
sent3529 cancer D
sent3530 Reconstruction O
sent3530 of O
sent3530 thoracic O
sent3530 wall O
sent3530 defects O
sent3530 after O
sent3530 tumor D
sent3530 resection T
sent3530 using O
sent3530 a O
sent3530 polytetrafluoroethylene O
sent3530 soft O
sent3530 tissue O
sent3530 ( O
sent3530 Gore-Tex O
sent3530 ) O
sent3530 patch O
sent3531 A O
sent3531 comparison O
sent3531 of O
sent3531 rectal T
sent3531 diazepam T
sent3531 gel T
sent3531 and O
sent3531 placebo O
sent3531 for O
sent3531 acute D
sent3531 repetitive D
sent3531 seizures D
sent3532 Effect O
sent3532 of O
sent3532 long-term O
sent3532 salmeterol T
sent3532 treatment T
sent3532 on O
sent3532 exercise-induced D
sent3532 asthma D
sent3533 Randomized O
sent3533 trial O
sent3533 of O
sent3533 intensive T
sent3533 cyclophosphamide T
sent3533 , T
sent3533 epirubicin T
sent3533 , T
sent3533 and T
sent3533 fluorouracil T
sent3533 chemotherapy T
sent3533 compared O
sent3533 with O
sent3533 cyclophosphamide T
sent3533 , T
sent3533 methotrexate T
sent3533 , T
sent3533 and T
sent3533 fluorouracil T
sent3533 in O
sent3533 premenopausal O
sent3533 women O
sent3533 with O
sent3533 node-positive D
sent3533 breast D
sent3533 cancer D
sent3534 Acute O
sent3534 effect O
sent3534 of O
sent3534 lorazepam T
sent3534 on O
sent3534 respiratory O
sent3534 muscles O
sent3534 in O
sent3534 patients O
sent3534 with O
sent3534 chronic D
sent3534 obstructive D
sent3534 pulmonary D
sent3534 disease D
sent3535 Low-molecular-weight T
sent3535 heparins T
sent3535 in O
sent3535 the O
sent3535 treatment O
sent3535 of O
sent3535 venous D
sent3535 thromboembolism D
sent3536 5-year O
sent3536 outcome O
sent3536 of O
sent3536 surgical T
sent3536 resection T
sent3536 and O
sent3536 watchful O
sent3536 waiting O
sent3536 for O
sent3536 men O
sent3536 with O
sent3536 moderately O
sent3536 symptomatic O
sent3536 benign D
sent3536 prostatic D
sent3536 hyperplasia D
sent3536 : O
sent3536 a O
sent3536 Department O
sent3536 of O
sent3536 Veterans O
sent3536 Affairs O
sent3536 cooperative O
sent3536 study O
sent3537 For O
sent3537 how O
sent3537 long O
sent3537 should O
sent3537 antipsychotic T
sent3537 medication T
sent3537 be O
sent3537 continued O
sent3537 after O
sent3537 the O
sent3537 first O
sent3537 psychotic D
sent3537 episode D
sent3537 in D
sent3537 schizophrenics D
sent3537 ? O
sent3538 IDA-FLAG T
sent3538 ( T
sent3538 idarubicin T
sent3538 , T
sent3538 fludarabine T
sent3538 , T
sent3538 cytarabine T
sent3538 , T
sent3538 G-CSF T
sent3538 ) T
sent3538 , O
sent3538 an O
sent3538 effective O
sent3538 remission-induction T
sent3538 therapy T
sent3538 for O
sent3538 poor-prognosis D
sent3538 AML D
sent3538 of D
sent3538 childhood D
sent3538 prior O
sent3538 to O
sent3538 allogeneic O
sent3538 or O
sent3538 autologous O
sent3538 bone O
sent3538 marrow O
sent3538 transplantation O
sent3538 : O
sent3538 experiences O
sent3538 of O
sent3538 a O
sent3538 phase O
sent3538 II O
sent3538 trial O
sent3539 < O
sent3539 TO_SEE O
sent3539 > O
sent3539 Effects O
sent3539 of O
sent3539 anal T
sent3539 invasive T
sent3539 treatment T
sent3539 and O
sent3539 incontinence D
sent3539 on O
sent3539 mental O
sent3539 health O
sent3539 and O
sent3539 psychosocial O
sent3539 functioning O
sent3539 of O
sent3539 adolescents O
sent3539 with O
sent3539 Hirshsprung D
sent3539 's D
sent3539 disease D
sent3539 and O
sent3539 low O
sent3539 anorectal D
sent3539 anomalies D
sent3540 Single O
sent3540 or O
sent3540 double O
sent3540 lung T
sent3540 transplantation T
sent3540 for O
sent3540 pulmonary D
sent3540 hypertension D
sent3541 Interferon T
sent3541 beta T
sent3541 treatment T
sent3541 for O
sent3541 multiple D
sent3541 sclerosis D
sent3542 Ten-year O
sent3542 disease O
sent3542 free O
sent3542 survival O
sent3542 after O
sent3542 transperineal T
sent3542 sonography-guided T
sent3542 iodine-125 T
sent3542 brachytherapy T
sent3542 with O
sent3542 or O
sent3542 without O
sent3542 45-Gray T
sent3542 external T
sent3542 beam T
sent3542 irradiation T
sent3542 in O
sent3542 the O
sent3542 treatment O
sent3542 of O
sent3542 patients O
sent3542 with O
sent3542 clinically O
sent3542 localized O
sent3542 , O
sent3542 low O
sent3542 to O
sent3542 high O
sent3542 Gleason D
sent3542 grade D
sent3542 prostate D
sent3542 carcinoma D
sent3543 Partial O
sent3543 or O
sent3543 near O
sent3543 total O
sent3543 pancreatectomy T
sent3543 for O
sent3543 persistent D
sent3543 neonatal D
sent3543 hyperinsulinaemic D
sent3543 hypoglycaemia D
sent3543 : O
sent3543 the O
sent3543 pathologist O
sent3543 's O
sent3543 role O
sent3544 Radical T
sent3544 prostatectomy T
sent3544 for O
sent3544 prostate D
sent3544 cancer D
sent3544 : O
sent3544 the O
sent3544 perineal O
sent3544 approach O
sent3544 increases O
sent3544 the O
sent3544 risk O
sent3544 of O
sent3544 surgically O
sent3544 induced O
sent3544 positive O
sent3544 margins O
sent3544 and O
sent3544 capsular O
sent3544 incisions O
sent3545 Open T
sent3545 capsulorrhaphy T
sent3545 with T
sent3545 suture T
sent3545 anchors T
sent3545 for O
sent3545 recurrent D
sent3545 anterior D
sent3545 dislocation D
sent3545 of D
sent3545 the D
sent3545 shoulder D
sent3546 Intravenous T
sent3546 immunoglobulin T
sent3546 treatment T
sent3546 in O
sent3546 multiple D
sent3546 sclerosis D
sent3547 Randomised O
sent3547 trial O
sent3547 of O
sent3547 irinotecan T
sent3547 versus O
sent3547 fluorouracil T
sent3547 by O
sent3547 continuous O
sent3547 infusion O
sent3547 after O
sent3547 fluorouracil O
sent3547 failure O
sent3547 in O
sent3547 patients O
sent3547 with O
sent3547 metastatic D
sent3547 colorectal D
sent3547 cancer D
sent3548 The O
sent3548 effectiveness O
sent3548 of O
sent3548 intraocular T
sent3548 pressure T
sent3548 reduction T
sent3548 in O
sent3548 the O
sent3548 treatment O
sent3548 of O
sent3548 normal-tension D
sent3548 glaucoma D
sent3549 Perceived O
sent3549 contraindications O
sent3549 to O
sent3549 thrombolytic T
sent3549 treatment T
sent3549 in O
sent3549 acute D
sent3549 myocardial D
sent3549 infarction D
sent3550 Lignocaine T
sent3550 or O
sent3550 bupivacaine T
sent3550 for O
sent3550 digital D
sent3550 ring D
sent3550 block D
sent3551 Steroids T
sent3551 in O
sent3551 lateral D
sent3551 epicondylitis D
sent3552 Steroids T
sent3552 in O
sent3552 De D
sent3552 Quervain D
sent3552 's D
sent3552 tenosynovitis D
sent3553 Antibiotics T
sent3553 after O
sent3553 dog D
sent3553 bite D
sent3554 Immobilisation T
sent3554 after O
sent3554 first O
sent3554 anterior O
sent3554 shoulder D
sent3554 dislocation D
sent3555 Stereotactic T
sent3555 radiosurgery T
sent3555 for O
sent3555 acoustic D
sent3555 neuroma D
sent3555 : O
sent3555 a O
sent3555 Canadian O
sent3555 perspective O
sent3556 Anticytokine T
sent3556 therapy T
sent3556 -- O
sent3556 a O
sent3556 new O
sent3556 era O
sent3556 in O
sent3556 the O
sent3556 treatment O
sent3556 of O
sent3556 rheumatoid D
sent3556 arthritis D
sent3556 ? O
sent3557 Control O
sent3557 of O
sent3557 the O
sent3557 malignant D
sent3557 hyperpyrexic D
sent3557 syndrome D
sent3557 in O
sent3557 MHS O
sent3557 swine O
sent3557 by O
sent3557 dantrolene T
sent3557 sodium T
sent3558 Hematopoietic T
sent3558 stem-cell T
sent3558 transplantation T
sent3558 for O
sent3558 the O
sent3558 treatment O
sent3558 of O
sent3558 severe D
sent3558 combined D
sent3558 immunodeficiency D
sent3559 Low-dose T
sent3559 clozapine T
sent3559 for O
sent3559 the O
sent3559 treatment O
sent3559 of O
sent3559 drug-induced D
sent3559 psychosis D
sent3559 in D
sent3559 Parkinson D
sent3559 's D
sent3559 disease D
sent3560 Comparing O
sent3560 the O
sent3560 efficacy O
sent3560 and O
sent3560 safety O
sent3560 of O
sent3560 fluoxetine T
sent3560 and O
sent3560 venlafaxine T
sent3560 in O
sent3560 outpatient D
sent3560 depression D
sent3561 Cost-effectiveness O
sent3561 of O
sent3561 interferon T
sent3561 treatment T
sent3561 for O
sent3561 hepatitis D
sent3561 C D
sent3562 Hyperbaric T
sent3562 oxygen T
sent3562 therapy T
sent3562 for O
sent3562 children O
sent3562 with O
sent3562 cerebral D
sent3562 palsy D
sent3563 Peripheral T
sent3563 retinal T
sent3563 cryotherapy T
sent3563 for O
sent3563 postvitrectomy D
sent3563 diabetic D
sent3563 vitreous D
sent3563 hemorrhage D
sent3563 in O
sent3563 phakic O
sent3563 patients O
sent3564 Hyperbaric T
sent3564 or T
sent3564 normobaric T
sent3564 oxygen T
sent3564 for O
sent3564 acute D
sent3564 carbon D
sent3564 monoxide D
sent3564 poisoning D
sent3564 : O
sent3564 a O
sent3564 randomised O
sent3564 controlled O
sent3564 clinical O
sent3564 trial O
sent3565 Multicentre O
sent3565 clinical O
sent3565 evaluation O
sent3565 of O
sent3565 vigabatrin T
sent3565 ( T
sent3565 Sabril T
sent3565 ) T
sent3565 in O
sent3565 mild D
sent3565 to D
sent3565 moderate D
sent3565 partial D
sent3565 epilepsies D
sent3566 Matrix T
sent3566 metalloproteinase T
sent3566 inhibitors T
sent3566 in O
sent3566 the O
sent3566 treatment O
sent3566 of O
sent3566 cancer D
sent3567 High O
sent3567 dose O
sent3567 cyclophosphamide T
sent3567 with O
sent3567 carboplatin T
sent3567 : O
sent3567 a O
sent3567 tolerable O
sent3567 regimen O
sent3567 suitable O
sent3567 for O
sent3567 dose O
sent3567 intensification O
sent3567 in O
sent3567 children O
sent3567 with O
sent3567 solid D
sent3567 tumors D
sent3568 Microsurgical T
sent3568 treatment T
sent3568 of O
sent3568 supratentorial D
sent3568 cavernous D
sent3568 malformations D
sent3569 Microsurgical T
sent3569 treatment T
sent3569 of O
sent3569 infratentorial D
sent3569 malformations D
sent3570 Stereotactic T
sent3570 radiosurgery T
sent3570 for O
sent3570 management O
sent3570 of O
sent3570 deep D
sent3570 brain D
sent3570 cavernous D
sent3570 malformations D
sent3571 Interferon-antibodies T
sent3571 and O
sent3571 the O
sent3571 breakthrough O
sent3571 phenomenon O
sent3571 during O
sent3571 ribavirin/interferon-alpha T
sent3571 combination T
sent3571 therapy T
sent3571 and O
sent3571 interferon-alpha T
sent3571 monotherapy T
sent3571 of O
sent3571 patients O
sent3571 with O
sent3571 chronic D
sent3571 hepatitis D
sent3571 C D
sent3572 Treatment O
sent3572 of O
sent3572 Barrett D
sent3572 esophagus D
sent3572 with O
sent3572 argon T
sent3572 plasma T
sent3572 coagulation T
sent3572 with T
sent3572 acid T
sent3572 suppression T
sent3572 -- O
sent3572 a O
sent3572 prospective O
sent3572 study O
sent3573 Meta-analysis O
sent3573 of O
sent3573 typhoid D
sent3573 vaccine T
sent3573 efficacy O
sent3573 trials O
sent3573 showed O
sent3573 that O
sent3573 whole O
sent3573 cell O
sent3573 vaccines O
sent3573 are O
sent3573 more O
sent3573 effective O
sent3573 than O
sent3573 either O
sent3573 the O
sent3573 oral O
sent3573 , O
sent3573 attenuated O
sent3573 vaccine O
sent3573 or O
sent3573 the O
sent3573 Vi O
sent3573 polysaccharide O
sent3573 vaccine O
sent3574 Experimental O
sent3574 vaccination T
sent3574 against O
sent3574 Mycoplasma D
sent3574 agalactiae D
sent3574 using O
sent3574 different O
sent3574 inactivated O
sent3574 vaccines O
sent3575 A O
sent3575 randomized O
sent3575 , O
sent3575 controlled O
sent3575 study O
sent3575 in O
sent3575 adults O
sent3575 of O
sent3575 the O
sent3575 immunogenicity O
sent3575 of O
sent3575 a O
sent3575 novel O
sent3575 hepatitis D
sent3575 B D
sent3575 vaccine T
sent3575 containing O
sent3575 MF59 O
sent3575 adjuvant O
sent3576 Immunogenicity O
sent3576 of O
sent3576 three O
sent3576 Haemophilus D
sent3576 influenzae D
sent3576 type D
sent3576 b D
sent3576 protein O
sent3576 conjugate O
sent3576 vaccines T
sent3576 in O
sent3576 HIV O
sent3576 seropositive O
sent3576 adults O
sent3576 and O
sent3576 analysis O
sent3576 of O
sent3576 predictors O
sent3576 of O
sent3576 vaccine O
sent3576 response O
sent3577 Vaccination T
sent3577 against O
sent3577 Schistosoma D
sent3577 mansoni D
sent3577 infection D
sent3577 using O
sent3577 74 O
sent3577 kDa O
sent3577 Schistosoma O
sent3577 protein O
sent3577 antigen O
sent3578 Phase O
sent3578 1 O
sent3578 safety O
sent3578 and O
sent3578 immune O
sent3578 response O
sent3578 studies O
sent3578 of O
sent3578 a O
sent3578 DNA T
sent3578 vaccine T
sent3578 encoding O
sent3578 hepatitis D
sent3578 B D
sent3578 surface O
sent3578 antigen O
sent3578 delivered O
sent3578 by O
sent3578 a O
sent3578 gene O
sent3578 delivery O
sent3578 device O
sent3579 Protection O
sent3579 of O
sent3579 swine O
sent3579 from O
sent3579 foot-and-mouth D
sent3579 disease D
sent3579 with O
sent3579 one O
sent3579 dose O
sent3579 of O
sent3579 an O
sent3579 all-D T
sent3579 retro T
sent3579 peptide T
sent3580 Intranasal T
sent3580 immunization T
sent3580 with O
sent3580 Chlamydia D
sent3580 trachomatis D
sent3580 , D
sent3580 serovar D
sent3580 E D
sent3580 , O
sent3580 protects O
sent3580 from O
sent3580 a O
sent3580 subsequent O
sent3580 vaginal O
sent3580 challenge O
sent3580 with O
sent3580 the O
sent3580 homologous O
sent3580 serovar O
sent3581 Mutants O
sent3581 of O
sent3581 cholera O
sent3581 toxin O
sent3581 as O
sent3581 an O
sent3581 effective O
sent3581 and O
sent3581 safe O
sent3581 adjuvant O
sent3581 for O
sent3581 nasal D
sent3581 influenza D
sent3581 vaccine T
sent3582 Field O
sent3582 evaluation O
sent3582 of O
sent3582 the O
sent3582 clinical O
sent3582 effectiveness O
sent3582 of O
sent3582 vaccines T
sent3582 against O
sent3582 pertussis D
sent3582 , D
sent3582 measles D
sent3582 , D
sent3582 rubella D
sent3582 and D
sent3582 mumps D
sent3582 : O
sent3582 comments O
sent3583 Transmural T
sent3583 drainage T
sent3583 of O
sent3583 pancreatic D
sent3583 fluid D
sent3583 collections D
sent3583 without O
sent3583 electrocautery O
sent3583 using O
sent3583 the O
sent3583 Seldinger O
sent3583 technique O
sent3584 Echocardiography-guided T
sent3584 ethanol T
sent3584 septal T
sent3584 reduction T
sent3584 for O
sent3584 hypertrophic D
sent3584 obstructive D
sent3584 cardiomyopathy D
sent3585 Alterations O
sent3585 of O
sent3585 monocyte O
sent3585 function O
sent3585 in O
sent3585 patients O
sent3585 with O
sent3585 growth D
sent3585 hormone D
sent3585 ( D
sent3585 GH D
sent3585 ) D
sent3585 deficiency D
sent3585 : O
sent3585 effect O
sent3585 of O
sent3585 substitutive O
sent3585 GH T
sent3585 therapy T
sent3586 Comparison O
sent3586 of O
sent3586 the O
sent3586 effects O
sent3586 of O
sent3586 salmeterol T
sent3586 and O
sent3586 ipratropium T
sent3586 bromide T
sent3586 on O
sent3586 exercise O
sent3586 performance O
sent3586 and O
sent3586 breathlessness O
sent3586 in O
sent3586 patients O
sent3586 with O
sent3586 stable D
sent3586 chronic D
sent3586 obstructive D
sent3586 pulmonary D
sent3586 disease D
sent3586 . O
sent3587 < O
sent3587 TO_SEE O
sent3587 > O
sent3587 Safety O
sent3587 trial O
sent3587 with O
sent3587 the O
sent3587 5HT1B/1D T
sent3587 agonist T
sent3587 avitriptan T
sent3587 ( O
sent3587 BMS-180048 O
sent3587 ) O
sent3587 in O
sent3587 patients O
sent3587 with O
sent3587 migraine D
sent3587 who O
sent3587 have O
sent3587 experienced O
sent3587 pressure D
sent3587 , D
sent3587 tightness D
sent3587 , D
sent3587 and/or D
sent3587 pain D
sent3587 in O
sent3587 the O
sent3587 chest O
sent3587 , O
sent3587 neck O
sent3587 , O
sent3587 and/or O
sent3587 throat O
sent3587 following O
sent3587 sumatriptan T
sent3588 Double O
sent3588 blind O
sent3588 , O
sent3588 cluster O
sent3588 randomised O
sent3588 trial O
sent3588 of O
sent3588 low O
sent3588 dose O
sent3588 supplementation O
sent3588 with O
sent3588 vitamin T
sent3588 A T
sent3588 or O
sent3588 beta T
sent3588 carotene T
sent3588 on O
sent3588 mortality D
sent3588 related D
sent3588 to D
sent3588 pregnancy D
sent3588 in O
sent3588 Nepal O
sent3588 . O
sent3589 Medical T
sent3589 treatments T
sent3589 for O
sent3589 balding D
sent3589 in O
sent3589 men O
sent3590 Carbon D
sent3590 monoxide D
sent3590 poisoning D
sent3590 treated O
sent3590 with O
sent3590 hyperbaric T
sent3590 oxygen T
sent3590 : O
sent3590 metabolic O
sent3590 acidosis O
sent3590 as O
sent3590 a O
sent3590 predictor O
sent3590 of O
sent3590 treatment O
sent3590 requirements O
sent3591 Medication T
sent3591 received O
sent3591 by O
sent3591 patients O
sent3591 with O
sent3591 depression D
sent3591 following O
sent3591 the O
sent3591 acute O
sent3591 episode O
sent3591 : O
sent3591 adequacy O
sent3591 and O
sent3591 relation O
sent3591 to O
sent3591 outcome O
sent3592 < O
sent3592 TO_SEE O
sent3592 > O
sent3592 Reduced D
sent3592 bone D
sent3592 density D
sent3592 at O
sent3592 completion O
sent3592 of O
sent3592 chemotherapy T
sent3592 for O
sent3592 a O
sent3592 malignancy D
sent3593 < O
sent3593 TO_SEE O
sent3593 > O
sent3593 Surgical-site D
sent3593 complications D
sent3593 associated O
sent3593 with O
sent3593 a O
sent3593 morphine T
sent3593 nerve T
sent3593 paste T
sent3593 used O
sent3593 for O
sent3593 postoperative D
sent3593 pain D
sent3593 control D
sent3593 after D
sent3593 laminectomy D
sent3594 Splenectomy T
sent3594 during O
sent3594 pregnancy O
sent3594 : O
sent3594 an O
sent3594 option O
sent3594 in O
sent3594 the O
sent3594 treatment O
sent3594 of O
sent3594 autoimmune D
sent3594 thrombocytopenic D
sent3594 purpura D
sent3595 Melatonin T
sent3595 treatment T
sent3595 of O
sent3595 sleep-wake D
sent3595 cycle D
sent3595 disorders D
sent3595 in O
sent3595 children O
sent3595 and O
sent3595 adolescents O
sent3596 Randomized O
sent3596 phase O
sent3596 II O
sent3596 study O
sent3596 of O
sent3596 the O
sent3596 neurokinin T
sent3596 1 T
sent3596 receptor T
sent3596 antagonist T
sent3596 CJ-11 T
sent3596 , T
sent3596 974 T
sent3596 in O
sent3596 the O
sent3596 control O
sent3596 of O
sent3596 cisplatin-induced D
sent3596 emesis D
sent3597 Cataract D
sent3597 surgery T
sent3597 and O
sent3597 its O
sent3597 effect O
sent3597 on O
sent3597 intraocular O
sent3597 pressure O
sent3598 The O
sent3598 outcome O
sent3598 of O
sent3598 arthroscopic T
sent3598 treatment T
sent3598 of O
sent3598 temporomandibular D
sent3598 joint D
sent3598 arthropathy D
sent3599 Neostigmine T
sent3599 for O
sent3599 acute D
sent3599 colonic D
sent3599 pseudo-obstruction D
sent3600 New O
sent3600 vaccine T
sent3600 targets O
sent3600 childhood D
sent3600 pneumonia D
sent3601 A O
sent3601 comparison O
sent3601 of O
sent3601 botulinum T
sent3601 toxin T
sent3601 and O
sent3601 nitroglycerin T
sent3601 ointment T
sent3601 for O
sent3601 chronic D
sent3601 anal D
sent3601 fissure D
sent3602 < O
sent3602 TO_SEE O
sent3602 > O
sent3602 The O
sent3602 effect O
sent3602 of O
sent3602 bisoprolol T
sent3602 on O
sent3602 perioperative D
sent3602 mortality D
sent3602 and O
sent3602 myocardial D
sent3602 infarction D
sent3602 in O
sent3602 high-risk O
sent3602 patients O
sent3602 undergoing O
sent3602 vascular T
sent3602 surgery T
sent3603 Surgical T
sent3603 management T
sent3603 of O
sent3603 severe D
sent3603 secondary D
sent3603 peritonitis D
sent3604 Early T
sent3604 surgical T
sent3604 treatment T
sent3604 for O
sent3604 supratentorial D
sent3604 intracerebral D
sent3604 hemorrhage D
sent3604 : O
sent3604 a O
sent3604 randomized O
sent3604 feasibility O
sent3604 study O
sent3605 Evaluation O
sent3605 of O
sent3605 clomipramine T
sent3605 as O
sent3605 an O
sent3605 adjunct O
sent3605 to O
sent3605 behavioural T
sent3605 therapy T
sent3605 in O
sent3605 the O
sent3605 treatment O
sent3605 of O
sent3605 separation-related D
sent3605 problems D
sent3605 in O
sent3605 dogs O
sent3606 NICE O
sent3606 to O
sent3606 rule O
sent3606 on O
sent3606 influenza D
sent3606 flu D
sent3606 drug O
sent3606 zanamivir T
sent3607 < O
sent3607 TO_SEE O
sent3607 > O
sent3607 Longitudinal D
sent3607 melanonychia D
sent3607 associated O
sent3607 with O
sent3607 hydroxyurea T
sent3607 therapy T
sent3607 in O
sent3607 a O
sent3607 patient O
sent3607 with O
sent3607 essential D
sent3607 thrombocytosis D
sent3608 Biologic O
sent3608 markers O
sent3608 as O
sent3608 predictors O
sent3608 of O
sent3608 clinical O
sent3608 outcome O
sent3608 from O
sent3608 systemic T
sent3608 therapy T
sent3608 for O
sent3608 primary O
sent3608 operable O
sent3608 breast D
sent3608 cancer D
sent3609 Treatment O
sent3609 of O
sent3609 hypertension D
sent3609 with O
sent3609 ascorbic T
sent3609 acid T
sent3610 Postoperative D
sent3610 peritonitis D
sent3610 originating O
sent3610 from O
sent3610 the O
sent3610 duodenum O
sent3610 : O
sent3610 operative O
sent3610 management O
sent3610 by O
sent3610 intubation T
sent3610 and T
sent3610 continuous T
sent3610 intraluminal T
sent3610 irrigation T
sent3611 Efficacy O
sent3611 of O
sent3611 open-bite D
sent3611 treatment O
sent3611 with O
sent3611 the O
sent3611 Thera-spoon T
sent3612 < O
sent3612 TO_SEE O
sent3612 > O
sent3612 Pompholyx D
sent3612 ( D
sent3612 vesicular D
sent3612 eczema D
sent3612 ) D
sent3612 after O
sent3612 i.v T
sent3612 . T
sent3612 immunoglobulin T
sent3612 therapy T
sent3612 for O
sent3612 neurologic D
sent3612 disease D
sent3613 Mitomycin T
sent3613 , T
sent3613 ifosfamide T
sent3613 , T
sent3613 and T
sent3613 cisplatin T
sent3613 in O
sent3613 unresectable D
sent3613 non-small-cell D
sent3613 lung D
sent3613 cancer D
sent3613 : O
sent3613 effects O
sent3613 on O
sent3613 survival O
sent3613 and O
sent3613 quality O
sent3613 of O
sent3613 life O
sent3613 . O
sent3614 Hepatic O
sent3614 arterial O
sent3614 infusion O
sent3614 of O
sent3614 chemotherapy T
sent3614 after O
sent3614 resection T
sent3614 of O
sent3614 hepatic D
sent3614 metastases D
sent3614 from O
sent3614 colorectal D
sent3614 cancer D
sent3615 Waiting O
sent3615 for O
sent3615 the O
sent3615 definitive O
sent3615 trial O
sent3615 of O
sent3615 hepatic T
sent3615 arterial T
sent3615 chemotherapy T
sent3615 for O
sent3615 colorectal D
sent3615 cancer D
sent3616 Phase O
sent3616 III O
sent3616 randomized O
sent3616 study O
sent3616 of O
sent3616 cisplatin T
sent3616 versus O
sent3616 paclitaxel T
sent3616 versus O
sent3616 cisplatin T
sent3616 and T
sent3616 paclitaxel T
sent3616 in O
sent3616 patients O
sent3616 with O
sent3616 suboptimal O
sent3616 stage O
sent3616 III O
sent3616 or O
sent3616 IV O
sent3616 ovarian D
sent3616 cancer D
sent3616 : O
sent3616 a O
sent3616 gynecologic O
sent3616 oncology O
sent3616 group O
sent3616 study O
sent3617 Evidence O
sent3617 for O
sent3617 double O
sent3617 resistance O
sent3617 to O
sent3617 permethrin T
sent3617 and T
sent3617 malathion T
sent3617 in O
sent3617 head D
sent3617 lice D
sent3618 Urgent O
sent3618 colonoscopy T
sent3618 for O
sent3618 the O
sent3618 diagnosis O
sent3618 and O
sent3618 treatment O
sent3618 of O
sent3618 severe D
sent3618 diverticular D
sent3618 hemorrhage D
sent3619 Treatment O
sent3619 of O
sent3619 Parkinson D
sent3619 's D
sent3619 disease D
sent3619 should O
sent3619 begin O
sent3619 with O
sent3619 a O
sent3619 dopamine T
sent3619 agonist T
sent3620 < O
sent3620 TO_SEE O
sent3620 > O
sent3620 Ulceration D
sent3620 in O
sent3620 an O
sent3620 ileocolic D
sent3620 anastomosis D
sent3620 treated O
sent3620 with O
sent3620 ranitidin T
sent3621 Low-molecular-weight T
sent3621 heparin T
sent3621 vs O
sent3621 heparin T
sent3621 in O
sent3621 the O
sent3621 treatment O
sent3621 of O
sent3621 patients O
sent3621 with O
sent3621 pulmonary D
sent3621 embolism D
sent3622 Radiotherapy T
sent3622 in O
sent3622 breast-conserving T
sent3622 treatment T
sent3622 for O
sent3622 ductal D
sent3622 carcinoma D
sent3622 in O
sent3622 situ O
sent3622 : O
sent3622 first O
sent3622 results O
sent3622 of O
sent3622 the O
sent3622 EORTC O
sent3622 randomised O
sent3622 phase O
sent3622 III O
sent3622 trial O
sent3622 10853 O
sent3623 Methadone T
sent3623 maintenance T
sent3623 vs O
sent3623 180-day O
sent3623 psychosocially O
sent3623 enriched O
sent3623 detoxification T
sent3623 for O
sent3623 treatment O
sent3623 of O
sent3623 opioid D
sent3623 dependence D
sent3623 : O
sent3623 a O
sent3623 randomized O
sent3623 controlled O
sent3623 trial O
sent3624 Cryogen O
sent3624 spray O
sent3624 cooling O
sent3624 during O
sent3624 Nd T
sent3624 : T
sent3624 YAG T
sent3624 laser T
sent3624 treatment T
sent3624 of O
sent3624 hemangiomas D
sent3625 Effects O
sent3625 of O
sent3625 tolcapone T
sent3625 , T
sent3625 a T
sent3625 catechol-O-methyltransferase T
sent3625 inhibitor T
sent3625 , O
sent3625 on O
sent3625 motor O
sent3625 symptoms O
sent3625 and O
sent3625 pharmacokinetics O
sent3625 of O
sent3625 levodopa T
sent3625 in O
sent3625 patients O
sent3625 with O
sent3625 Parkinson D
sent3625 's D
sent3625 disease D
sent3625 . O
sent3626 Gene T
sent3626 therapy T
sent3626 for O
sent3626 cancer D
sent3627 Therapeutic O
sent3627 effects O
sent3627 of O
sent3627 LDL T
sent3627 apheresis T
sent3627 in O
sent3627 the O
sent3627 prevention O
sent3627 of O
sent3627 atherosclerosis D
sent3628 Dry T
sent3628 powdered T
sent3628 formoterol T
sent3628 , O
sent3628 twice O
sent3628 a O
sent3628 day O
sent3628 versus O
sent3628 aerosolized T
sent3628 salbutamol T
sent3628 , O
sent3628 four O
sent3628 times O
sent3628 a O
sent3628 day O
sent3628 , O
sent3628 in O
sent3628 patients O
sent3628 with O
sent3628 stable D
sent3628 asthma D
sent3629 Cell-based T
sent3629 vaccination T
sent3629 against O
sent3629 melanoma D
sent3629 -- O
sent3629 background O
sent3629 , O
sent3629 preliminary O
sent3629 results O
sent3629 , O
sent3629 and O
sent3629 perspective O
sent3630 Celecoxib T
sent3630 for O
sent3630 arthritis D
sent3631 Poliomyelitis D
sent3631 prevention O
sent3631 : O
sent3631 revised O
sent3631 recommendations O
sent3631 for O
sent3631 use O
sent3631 of O
sent3631 inactivated O
sent3631 and O
sent3631 live O
sent3631 oral O
sent3631 poliovirus D
sent3631 vaccines T
sent3632 Mesh O
sent3632 plug O
sent3632 repair O
sent3632 and O
sent3632 groin D
sent3632 hernia D
sent3632 surgery T
sent3633 Brimonidine T
sent3633 tartrate T
sent3633 0.2 O
sent3633 % O
sent3633 twice O
sent3633 daily O
sent3633 vs O
sent3633 timolol T
sent3633 0.5 O
sent3633 % O
sent3633 twice O
sent3633 daily O
sent3633 : O
sent3633 1-year O
sent3633 results O
sent3633 in O
sent3633 glaucoma D
sent3633 patients O
sent3634 Ticarcillin/clavulanate T
sent3634 versus O
sent3634 imipenem/cilistatin T
sent3634 for O
sent3634 the O
sent3634 treatment O
sent3634 of O
sent3634 infections D
sent3634 associated D
sent3634 with D
sent3634 gangrenous D
sent3634 and D
sent3634 perforated D
sent3634 appendicitis D
sent3635 Is O
sent3635 zero O
sent3635 dose O
sent3635 oral O
sent3635 polio D
sent3635 vaccine T
sent3635 effective O
sent3635 in O
sent3635 preterm O
sent3635 babies O
sent3635 ? O
sent3636 An O
sent3636 economic O
sent3636 analysis O
sent3636 of O
sent3636 different O
sent3636 strategies O
sent3636 of O
sent3636 immunization T
sent3636 against O
sent3636 hepatitis D
sent3636 A D
sent3636 virus D
sent3636 in O
sent3636 developed O
sent3636 countries O
sent3637 Issues O
sent3637 and O
sent3637 challenges O
sent3637 with O
sent3637 antithrombotic T
sent3637 therapy T
sent3637 in O
sent3637 diabetic O
sent3637 patients O
sent3637 with O
sent3637 acute D
sent3637 coronary D
sent3637 syndromes D
sent3638 Global O
sent3638 risk O
sent3638 assessment O
sent3638 for O
sent3638 lipid T
sent3638 therapy T
sent3638 to O
sent3638 prevent O
sent3638 coronary D
sent3638 heart D
sent3638 disease D
sent3639 The O
sent3639 role O
sent3639 of O
sent3639 fibric T
sent3639 acid T
sent3639 derivatives T
sent3639 in O
sent3639 the O
sent3639 secondary O
sent3639 prevention O
sent3639 of O
sent3639 coronary D
sent3639 heart D
sent3639 disease D
sent3640 Epoetin T
sent3640 : O
sent3640 a O
sent3640 pharmacoeconomic O
sent3640 review O
sent3640 of O
sent3640 its O
sent3640 use O
sent3640 in O
sent3640 chronic D
sent3640 renal D
sent3640 failure D
sent3640 and O
sent3640 its O
sent3640 effects O
sent3640 on O
sent3640 quality O
sent3640 of O
sent3640 life O
sent3641 Rationale O
sent3641 for O
sent3641 the O
sent3641 use O
sent3641 of O
sent3641 antiplatelet T
sent3641 drugs T
sent3641 in O
sent3641 patients O
sent3641 with O
sent3641 peripheral D
sent3641 vascular D
sent3641 disease D
sent3642 The O
sent3642 fluoroquinolones T
sent3642 for O
sent3642 urinary D
sent3642 tract D
sent3642 infections D
sent3642 : O
sent3642 a O
sent3642 review O
sent3643 Reduction O
sent3643 of O
sent3643 vasoreactivity D
sent3643 and O
sent3643 thrombogenicity D
sent3643 with O
sent3643 laser-thermal T
sent3643 angioplasty T
sent3643 : O
sent3643 comparison O
sent3643 with O
sent3643 balloon T
sent3643 angioplasty T
sent3644 Effects O
sent3644 of O
sent3644 ultrasound T
sent3644 energy T
sent3644 on O
sent3644 total D
sent3644 peripheral D
sent3644 artery D
sent3644 occlusions D
sent3644 : O
sent3644 initial O
sent3644 angiographic O
sent3644 and O
sent3644 angioscopic O
sent3644 results O
sent3644 . O
sent3645 High-dose T
sent3645 chemotherapy T
sent3645 with T
sent3645 autologous T
sent3645 stem-cell T
sent3645 support T
sent3645 for O
sent3645 epithelial D
sent3645 ovarian D
sent3645 cancer D
sent3646 Pelvic T
sent3646 floor T
sent3646 stimulation T
sent3646 in O
sent3646 the O
sent3646 treatment O
sent3646 of O
sent3646 adult D
sent3646 urinary D
sent3646 incontinence D
sent3647 Chronic T
sent3647 vagus T
sent3647 nerve T
sent3647 stimulation T
sent3647 for O
sent3647 treatment O
sent3647 of O
sent3647 seizures D
sent3648 `` T
sent3648 Tandem T
sent3648 '' T
sent3648 high-dose T
sent3648 chemoradiotherapy T
sent3648 with T
sent3648 autologous T
sent3648 stem-cell T
sent3648 support T
sent3648 in O
sent3648 the O
sent3648 treatment O
sent3648 of O
sent3648 newly O
sent3648 diagnosed O
sent3648 or O
sent3648 responsive O
sent3648 multiple D
sent3648 myeloma D
sent3649 Special O
sent3649 report O
sent3649 : O
sent3649 comparative O
sent3649 efficacy O
sent3649 of O
sent3649 different O
sent3649 types O
sent3649 of O
sent3649 pneumatic T
sent3649 compression T
sent3649 pumps T
sent3649 for O
sent3649 the O
sent3649 treatment O
sent3649 of O
sent3649 lymphedema D
sent3650 Special O
sent3650 report O
sent3650 : O
sent3650 pressure-reducing T
sent3650 support T
sent3650 surfaces T
sent3650 in O
sent3650 the O
sent3650 prevention O
sent3650 and O
sent3650 treatment O
sent3650 of O
sent3650 pressure D
sent3650 ulcers D
sent3650 : O
sent3650 group O
sent3650 1 O
sent3650 technologies O
sent3651 Intravenous T
sent3651 immune T
sent3651 globulin T
sent3651 for O
sent3651 recurrent D
sent3651 spontaneous D
sent3651 abortion D
sent3652 External T
sent3652 counterpulsation T
sent3652 for O
sent3652 treatment O
sent3652 of O
sent3652 chronic D
sent3652 stable D
sent3652 angina D
sent3652 pectoris D
sent3653 Intra-articular T
sent3653 hyaluronan T
sent3653 injections T
sent3653 for O
sent3653 treatment O
sent3653 of O
sent3653 osteoarthritis D
sent3653 of O
sent3653 the O
sent3653 knee O
sent3654 Pneumococcal D
sent3654 vaccine T
sent3654 : O
sent3654 a O
sent3654 second O
sent3654 look O
